

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51633 A2(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/47, C12N 5/10, 5/08, 1/21, C07K 16/18, G01N
33/68, C07K 19/00, C12N 15/11, A61K 38/17, C12Q 1/68

(21) International Application Number: PCT/US01/01574

(22) International Filing Date: 16 January 2001 (16.01.2001)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
09/483,672 14 January 2000 (14.01.2000) US(71) Applicant (for all designated States except US): **CORIXA CORPORATION** [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **XU, Jiangchun** [US/US]; 15805 S.E. 43rd Place, Bellevue, WA 98006 (US). **DILLON, Davin, C.** [US/US]; 18112 N.W. Montreux Drive, Issaquah, WA 98027 (US). **MITCHAM,****Jennifer, L.** [US/US]; 16677 N.E. 88th Street, Redmond, WA 98052 (US). **HARLOCKER, Susan, L.** [US/US]; 7522 13th Avenue W., Seattle, WA 98117 (US). **JIANG, Yuqiu** [CN/US]; 5001 South 232nd Street, Kent, WA 98032 (US). **REED, Steven, G.** [US/US]; 2843 122nd Place N.E., Bellevue, WA 98005 (US). **KALOS, Michael, D.** [US/US]; 8116 Dayton Ave. N., Seattle, WA 98103 (US). **FANGER, Gary, Richard** [US/US]; 15906 29th Drive S.E., Mill Creek, WA 98012 (US). **DAY, Craig, H.** [US/US]; 11501 Stone Ave. N., C122, Seattle, WA 98133 (US). **RETTTER, Marc, W.** [US/US]; 33402 N.E. 43rd Place, Carnation, WA 98104 (US). **STOLK, John, A.** [US/US]; 7436 Northeast 144th Place, Bothell, WA 98011 (US). **SKEIKY, Yasir, A.W.** [LB/US]; 15106 S.E. 47th Place, Bellevue, WA 98006 (US). **WANG, Aijun** [CN/US]; 3106 213th Place S.E., Issaquah, WA 98029 (US). **MEAGHER, Madeleine, Joy** [US/US]; 507 N.E. 71st, #1, Seattle, WA 98115 (US).(74) Agents: **POTTER, Jane, E.R.**; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 et al. (US).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER



(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

WO 01/51633 A2



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER

5 TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to therapy and diagnosis of cancer, such as prostate cancer. The invention is more specifically related to polypeptides, comprising at least a portion of a prostate-specific protein, and to polynucleotides encoding such polypeptides. Such polypeptides and polynucleotides
10 are useful in pharmaceutical compositions, *e.g.*, vaccines, and other compositions for the diagnosis and treatment of prostate cancer.

BACKGROUND OF THE INVENTION

Cancer is a significant health problem throughout the world. Although Cancer is a significant health problem throughout the world. Although advances have
15 been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention or treatment is currently available. Current therapies, which are generally based on a combination of chemotherapy or surgery and radiation, continue to prove inadequate in many patients.

Prostate cancer is the most common form of cancer among males, with
20 an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.

25 In spite of considerable research into therapies for the disease, prostate cancer remains difficult to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins - prostate specific antigen (PSA)

and prostatic acid phosphatase (PAP) - have limited therapeutic and diagnostic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with
5 prostate volume, and do not indicate the level of metastasis.

In spite of considerable research into therapies for these and other cancers, prostate cancer remains difficult to diagnose and treat effectively. Accordingly, there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

10 SUMMARY OF THE INVENTION

In one aspect, the present invention provides polynucleotide compositions comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524,
15 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382
20 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315,
25 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375,

381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, under moderately stringent conditions;

5 (e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

10 (f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

15 (g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

20 In one preferred embodiment, the polynucleotide compositions of the invention are expressed in at least about 20%, more preferably in at least about 30%, and most preferably in at least about 50% of prostate tissue samples tested, at a level that is at least about 2-fold, preferably at least about 5-fold, and most preferably at least about 10-fold higher than that for other normal tissues.

25 The present invention, in another aspect, provides polypeptide compositions comprising an amino acid sequence that is encoded by a polynucleotide sequence described above.

The present invention further provides polypeptide compositions comprising an amino acid sequence selected from the group consisting of sequences
30 recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383,

477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

In certain preferred embodiments, the polypeptides and/or
5 polynucleotides of the present invention are immunogenic, *i.e.*, they are capable of eliciting an immune response, particularly a humoral and/or cellular immune response, as further described herein.

The present invention further provides fragments, variants and/or derivatives of the disclosed polypeptide and/or polynucleotide sequences, wherein the
10 fragments, variants and/or derivatives preferably have a level of immunogenic activity of at least about 50%, preferably at least about 70% and more preferably at least about 90% of the level of immunogenic activity of a polypeptide sequence set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-
15 629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 or 789-791, or a polypeptide sequence encoded by a polynucleotide sequence set forth in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626,
20 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

The present invention further provides polynucleotides that encode a polypeptide described above, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

25 Within other aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

Within a related aspect of the present invention, pharmaceutical compositions, *e.g.*, vaccine compositions, are provided for prophylactic or therapeutic
30 applications. Such compositions generally comprise an immunogenic polypeptide or

polynucleotide of the invention and an immunostimulant, such as an adjuvant, together with a physiologically acceptable carrier.

The present invention further provides pharmaceutical compositions that comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to a polypeptide of the present invention, or a fragment thereof; and (b) a physiologically acceptable carrier.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) a pharmaceutically acceptable carrier or excipient. Illustrative antigen presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

Within related aspects, pharmaceutical compositions are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, e.g., vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. The fusions proteins may comprise multiple immunogenic polypeptides or portions/variants thereof, as described herein, and may further comprise one or more polypeptide segments for facilitating and/or enhancing the expression, purification and/or immunogenicity of the polypeptide(s).

Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a

patient a pharmaceutical composition as recited above. The patient may be afflicted with prostate cancer, in which case the methods provide treatment for the disease, or a patient considered to be at risk for such a disease may be treated prophylactically.

The present invention further provides, within other aspects, methods for
5 removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the polypeptide from the sample.

Within related aspects, methods are provided for inhibiting the
10 development of a cancer in a patient, comprising administering to a patient a biological sample treated as described above.

Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a
15 polynucleotide encoding such a polypeptide; and (iii) an antigen presenting cell that expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

Within further aspects, the present invention provides methods for
20 inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with one or more of: (i) a polypeptide
25 comprising at least an immunogenic portion of polypeptide disclosed herein; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount of the proliferated T cells, thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

Within further aspects, the present invention provides methods for determining the presence or absence of a cancer, preferably a prostate cancer, in a patient comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody.

The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide of the present invention, or a complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to an inventive polynucleotide, or a complement of such a polynucleotide.

In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide of the present invention; (b) detecting in the sample an amount of a polynucleotide that
5 hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b), and therefrom monitoring the progression of the cancer in the patient.

Within further aspects, the present invention provides antibodies, such as
10 monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All
15 references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

Figure 1 illustrates the ability of T cells to kill fibroblasts expressing the representative prostate-specific polypeptide P502S, as compared to control fibroblasts.
20 The percentage lysis is shown as a series of effector:target ratios, as indicated.

Figures 2A and 2B illustrate the ability of T cells to recognize cells expressing the representative prostate-specific polypeptide P502S. In each case, the number of γ -interferon spots is shown for different numbers of responders. In Figure 2A, data is presented for fibroblasts pulsed with the P2S-12 peptide, as compared to
25 fibroblasts pulsed with a control E75 peptide. In Figure 2B, data is presented for fibroblasts expressing P502S, as compared to fibroblasts expressing HER-2/*neu*.

Figure 3 represents a peptide competition binding assay showing that the P1S#10 peptide, derived from P501S, binds HLA-A2. Peptide P1S#10 inhibits HLA-A2 restricted presentation of fluM58 peptide to CTL clone D150M58 in TNF release

bioassay. D150M58 CTL is specific for the HLA-A2 binding influenza matrix peptide fluM58.

Figure 4 illustrates the ability of T cell lines generated from P1S#10 immunized mice to specifically lyse P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat A2Kb targets, as compared to EGFP-transduced Jurkat A2Kb. The percent lysis is shown as a series of effector to target ratios, as indicated.

Figure 5 illustrates the ability of a T cell clone to recognize and specifically lyse Jurkat A2Kb cells expressing the representative prostate-specific polypeptide P501S, thereby demonstrating that the P1S#10 peptide may be a naturally processed epitope of the P501S polypeptide.

Figures 6A and 6B are graphs illustrating the specificity of a CD8⁺ cell line (3A-1) for a representative prostate-specific antigen (P501S). Figure 6A shows the results of a ⁵¹Cr release assay. The percent specific lysis is shown as a series of effector:target ratios, as indicated. Figure 6B shows the production of interferon-gamma by 3A-1 cells stimulated with autologous B-LCL transduced with P501S, at varying effector:target ratios as indicated.

Figure 7 is a Western blot showing the expression of P501S in baculovirus.

Figure 8 illustrates the results of epitope mapping studies on P501S.

Figure 9 is a schematic representation of the P501S protein showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Figure 10 is a genomic map showing the location of the prostate genes P775P, P704P, B305D, P712P and P774P within the Cat Eye Syndrome region of chromosome 22q11.2.

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S.

SEQ ID NO: 1 is the determined cDNA sequence for F1-13

SEQ ID NO: 2 is the determined 3' cDNA sequence for F1-12

SEQ ID NO: 3 is the determined 5' cDNA sequence for F1-12

SEQ ID NO: 4 is the determined 3' cDNA sequence for F1-16
SEQ ID NO: 5 is the determined 3' cDNA sequence for H1-1
SEQ ID NO: 6 is the determined 3' cDNA sequence for H1-9
SEQ ID NO: 7 is the determined 3' cDNA sequence for H1-4
5 SEQ ID NO: 8 is the determined 3' cDNA sequence for J1-17
SEQ ID NO: 9 is the determined 5' cDNA sequence for J1-17
SEQ ID NO: 10 is the determined 3' cDNA sequence for L1-12
SEQ ID NO: 11 is the determined 5' cDNA sequence for L1-12
SEQ ID NO: 12 is the determined 3' cDNA sequence for N1-1862
10 SEQ ID NO: 13 is the determined 5' cDNA sequence for N1-1862
SEQ ID NO: 14 is the determined 3' cDNA sequence for J1-13
SEQ ID NO: 15 is the determined 5' cDNA sequence for J1-13
SEQ ID NO: 16 is the determined 3' cDNA sequence for J1-19
SEQ ID NO: 17 is the determined 5' cDNA sequence for J1-19
15 SEQ ID NO: 18 is the determined 3' cDNA sequence for J1-25
SEQ ID NO: 19 is the determined 5' cDNA sequence for J1-25
SEQ ID NO: 20 is the determined 5' cDNA sequence for J1-24
SEQ ID NO: 21 is the determined 3' cDNA sequence for J1-24
SEQ ID NO: 22 is the determined 5' cDNA sequence for K1-58
20 SEQ ID NO: 23 is the determined 3' cDNA sequence for K1-58
SEQ ID NO: 24 is the determined 5' cDNA sequence for K1-63
SEQ ID NO: 25 is the determined 3' cDNA sequence for K1-63
SEQ ID NO: 26 is the determined 5' cDNA sequence for L1-4
SEQ ID NO: 27 is the determined 3' cDNA sequence for L1-4
25 SEQ ID NO: 28 is the determined 5' cDNA sequence for L1-14
SEQ ID NO: 29 is the determined 3' cDNA sequence for L1-14
SEQ ID NO: 30 is the determined 3' cDNA sequence for J1-12
SEQ ID NO: 31 is the determined 3' cDNA sequence for J1-16
SEQ ID NO: 32 is the determined 3' cDNA sequence for J1-21
30 SEQ ID NO: 33 is the determined 3' cDNA sequence for K1-48

SEQ ID NO: 34 is the determined 3' cDNA sequence for K1-55
SEQ ID NO: 35 is the determined 3' cDNA sequence for L1-2
SEQ ID NO: 36 is the determined 3' cDNA sequence for L1-6
SEQ ID NO: 37 is the determined 3' cDNA sequence for N1-1858
5 SEQ ID NO: 38 is the determined 3' cDNA sequence for N1-1860
SEQ ID NO: 39 is the determined 3' cDNA sequence for N1-1861
SEQ ID NO: 40 is the determined 3' cDNA sequence for N1-1864
SEQ ID NO: 41 is the determined cDNA sequence for P5
SEQ ID NO: 42 is the determined cDNA sequence for P8
10 SEQ ID NO: 43 is the determined cDNA sequence for P9
SEQ ID NO: 44 is the determined cDNA sequence for P18
SEQ ID NO: 45 is the determined cDNA sequence for P20
SEQ ID NO: 46 is the determined cDNA sequence for P29
SEQ ID NO: 47 is the determined cDNA sequence for P30
15 SEQ ID NO: 48 is the determined cDNA sequence for P34
SEQ ID NO: 49 is the determined cDNA sequence for P36
SEQ ID NO: 50 is the determined cDNA sequence for P38
SEQ ID NO: 51 is the determined cDNA sequence for P39
SEQ ID NO: 52 is the determined cDNA sequence for P42
20 SEQ ID NO: 53 is the determined cDNA sequence for P47
SEQ ID NO: 54 is the determined cDNA sequence for P49
SEQ ID NO: 55 is the determined cDNA sequence for P50
SEQ ID NO: 56 is the determined cDNA sequence for P53
SEQ ID NO: 57 is the determined cDNA sequence for P55
25 SEQ ID NO: 58 is the determined cDNA sequence for P60
SEQ ID NO: 59 is the determined cDNA sequence for P64
SEQ ID NO: 60 is the determined cDNA sequence for P65
SEQ ID NO: 61 is the determined cDNA sequence for P73
SEQ ID NO: 62 is the determined cDNA sequence for P75
30 SEQ ID NO: 63 is the determined cDNA sequence for P76

SEQ ID NO: 64 is the determined cDNA sequence for P79

SEQ ID NO: 65 is the determined cDNA sequence for P84

SEQ ID NO: 66 is the determined cDNA sequence for P68

SEQ ID NO: 67 is the determined cDNA sequence for P80 (also referred

5 to as P704P)

SEQ ID NO: 68 is the determined cDNA sequence for P82

SEQ ID NO: 69 is the determined cDNA sequence for U1-3064

SEQ ID NO: 70 is the determined cDNA sequence for U1-3065

SEQ ID NO: 71 is the determined cDNA sequence for V1-3692

10 SEQ ID NO: 72 is the determined cDNA sequence for 1A-3905

SEQ ID NO: 73 is the determined cDNA sequence for V1-3686

SEQ ID NO: 74 is the determined cDNA sequence for R1-2330

SEQ ID NO: 75 is the determined cDNA sequence for 1B-3976

SEQ ID NO: 76 is the determined cDNA sequence for V1-3679

15 SEQ ID NO: 77 is the determined cDNA sequence for 1G-4736

SEQ ID NO: 78 is the determined cDNA sequence for 1G-4738

SEQ ID NO: 79 is the determined cDNA sequence for 1G-4741

SEQ ID NO: 80 is the determined cDNA sequence for 1G-4744

SEQ ID NO: 81 is the determined cDNA sequence for 1G-4734

20 SEQ ID NO: 82 is the determined cDNA sequence for 1H-4774

SEQ ID NO: 83 is the determined cDNA sequence for 1H-4781

SEQ ID NO: 84 is the determined cDNA sequence for 1H-4785

SEQ ID NO: 85 is the determined cDNA sequence for 1H-4787

SEQ ID NO: 86 is the determined cDNA sequence for 1H-4796

25 SEQ ID NO: 87 is the determined cDNA sequence for 1I-4807

SEQ ID NO: 88 is the determined cDNA sequence for 1I-4810

SEQ ID NO: 89 is the determined cDNA sequence for 1I-4811

SEQ ID NO: 90 is the determined cDNA sequence for 1J-4876

SEQ ID NO: 91 is the determined cDNA sequence for 1K-4884

30 SEQ ID NO: 92 is the determined cDNA sequence for 1K-4896

- SEQ ID NO: 93 is the determined cDNA sequence for 1G-4761
SEQ ID NO: 94 is the determined cDNA sequence for 1G-4762
SEQ ID NO: 95 is the determined cDNA sequence for 1H-4766
SEQ ID NO: 96 is the determined cDNA sequence for 1H-4770
5 SEQ ID NO: 97 is the determined cDNA sequence for 1H-4771
SEQ ID NO: 98 is the determined cDNA sequence for 1H-4772
SEQ ID NO: 99 is the determined cDNA sequence for 1D-4297
SEQ ID NO: 100 is the determined cDNA sequence for 1D-4309
SEQ ID NO: 101 is the determined cDNA sequence for 1D.1-4278
10 SEQ ID NO: 102 is the determined cDNA sequence for 1D-4288
SEQ ID NO: 103 is the determined cDNA sequence for 1D-4283
SEQ ID NO: 104 is the determined cDNA sequence for 1D-4304
SEQ ID NO: 105 is the determined cDNA sequence for 1D-4296
SEQ ID NO: 106 is the determined cDNA sequence for 1D-4280
15 SEQ ID NO: 107 is the determined full length cDNA sequence for F1-12
(also referred to as P504S)
SEQ ID NO: 108 is the predicted amino acid sequence for F1-12
SEQ ID NO: 109 is the determined full length cDNA sequence for J1-17
SEQ ID NO: 110 is the determined full length cDNA sequence for L1-12
20 (also referred to as P501S)
SEQ ID NO: 111 is the determined full length cDNA sequence for N1-
1862 (also referred to as P503S)
SEQ ID NO: 112 is the predicted amino acid sequence for J1-17
SEQ ID NO: 113 is the predicted amino acid sequence for L1-12 (also
25 referred to as P501S)
SEQ ID NO: 114 is the predicted amino acid sequence for N1-1862 (also
referred to as P503S)
SEQ ID NO: 115 is the determined cDNA sequence for P89
SEQ ID NO: 116 is the determined cDNA sequence for P90
30 SEQ ID NO: 117 is the determined cDNA sequence for P92

SEQ ID NO: 118 is the determined cDNA sequence for P95
SEQ ID NO: 119 is the determined cDNA sequence for P98
SEQ ID NO: 120 is the determined cDNA sequence for P102
SEQ ID NO: 121 is the determined cDNA sequence for P110
5 SEQ ID NO: 122 is the determined cDNA sequence for P111
SEQ ID NO: 123 is the determined cDNA sequence for P114
SEQ ID NO: 124 is the determined cDNA sequence for P115
SEQ ID NO: 125 is the determined cDNA sequence for P116
SEQ ID NO: 126 is the determined cDNA sequence for P124
10 SEQ ID NO: 127 is the determined cDNA sequence for P126
SEQ ID NO: 128 is the determined cDNA sequence for P130
SEQ ID NO: 129 is the determined cDNA sequence for P133
SEQ ID NO: 130 is the determined cDNA sequence for P138
SEQ ID NO: 131 is the determined cDNA sequence for P143
15 SEQ ID NO: 132 is the determined cDNA sequence for P151
SEQ ID NO: 133 is the determined cDNA sequence for P156
SEQ ID NO: 134 is the determined cDNA sequence for P157
SEQ ID NO: 135 is the determined cDNA sequence for P166
SEQ ID NO: 136 is the determined cDNA sequence for P176
20 SEQ ID NO: 137 is the determined cDNA sequence for P178
SEQ ID NO: 138 is the determined cDNA sequence for P179
SEQ ID NO: 139 is the determined cDNA sequence for P185
SEQ ID NO: 140 is the determined cDNA sequence for P192
SEQ ID NO: 141 is the determined cDNA sequence for P201
25 SEQ ID NO: 142 is the determined cDNA sequence for P204
SEQ ID NO: 143 is the determined cDNA sequence for P208
SEQ ID NO: 144 is the determined cDNA sequence for P211
SEQ ID NO: 145 is the determined cDNA sequence for P213
SEQ ID NO: 146 is the determined cDNA sequence for P219
30 SEQ ID NO: 147 is the determined cDNA sequence for P237

SEQ ID NO: 148 is the determined cDNA sequence for P239
SEQ ID NO: 149 is the determined cDNA sequence for P248
SEQ ID NO: 150 is the determined cDNA sequence for P251
SEQ ID NO: 151 is the determined cDNA sequence for P255
5 SEQ ID NO: 152 is the determined cDNA sequence for P256
SEQ ID NO: 153 is the determined cDNA sequence for P259
SEQ ID NO: 154 is the determined cDNA sequence for P260
SEQ ID NO: 155 is the determined cDNA sequence for P263
SEQ ID NO: 156 is the determined cDNA sequence for P264
10 SEQ ID NO: 157 is the determined cDNA sequence for P266
SEQ ID NO: 158 is the determined cDNA sequence for P270
SEQ ID NO: 159 is the determined cDNA sequence for P272
SEQ ID NO: 160 is the determined cDNA sequence for P278
SEQ ID NO: 161 is the determined cDNA sequence for P105
15 SEQ ID NO: 162 is the determined cDNA sequence for P107
SEQ ID NO: 163 is the determined cDNA sequence for P137
SEQ ID NO: 164 is the determined cDNA sequence for P194
SEQ ID NO: 165 is the determined cDNA sequence for P195
SEQ ID NO: 166 is the determined cDNA sequence for P196
20 SEQ ID NO: 167 is the determined cDNA sequence for P220
SEQ ID NO: 168 is the determined cDNA sequence for P234
SEQ ID NO: 169 is the determined cDNA sequence for P235
SEQ ID NO: 170 is the determined cDNA sequence for P243
SEQ ID NO: 171 is the determined cDNA sequence for P703P-DE1
25 SEQ ID NO: 172 is the predicted amino acid sequence for P703P-DE1
SEQ ID NO: 173 is the determined cDNA sequence for P703P-DE2
SEQ ID NO: 174 is the determined cDNA sequence for P703P-DE6
SEQ ID NO: 175 is the determined cDNA sequence for P703P-DE13
SEQ ID NO: 176 is the predicted amino acid sequence for P703P-DE13
30 SEQ ID NO: 177 is the determined cDNA sequence for P703P-DE14

SEQ ID NO: 178 is the predicted amino acid sequence for P703P-DE14

SEQ ID NO: 179 is the determined extended cDNA sequence for 1G-

4736

SEQ ID NO: 180 is the determined extended cDNA sequence for 1G-

5 4738

SEQ ID NO: 181 is the determined extended cDNA sequence for 1G-

4741

SEQ ID NO: 182 is the determined extended cDNA sequence for 1G-

4744

10

SEQ ID NO: 183 is the determined extended cDNA sequence for 1H-

4774

SEQ ID NO: 184 is the determined extended cDNA sequence for 1H-

4781

SEQ ID NO: 185 is the determined extended cDNA sequence for 1H-

15 4785

SEQ ID NO: 186 is the determined extended cDNA sequence for 1H-

4787

SEQ ID NO: 187 is the determined extended cDNA sequence for 1H-

4796

20

SEQ ID NO: 188 is the determined extended cDNA sequence for 1I-

4807

SEQ ID NO: 189 is the determined 3' cDNA sequence for 1I-4810

SEQ ID NO: 190 is the determined 3' cDNA sequence for 1I-4811

SEQ ID NO: 191 is the determined extended cDNA sequence for 1J-

25 4876

SEQ ID NO: 192 is the determined extended cDNA sequence for 1K-

4884

SEQ ID NO: 193 is the determined extended cDNA sequence for 1K-

4896

- SEQ ID NO: 194 is the determined extended cDNA sequence for 1G-
4761
- SEQ ID NO: 195 is the determined extended cDNA sequence for 1G-
4762
- 5 SEQ ID NO: 196 is the determined extended cDNA sequence for 1H-
4766
- SEQ ID NO: 197 is the determined 3' cDNA sequence for 1H-4770
SEQ ID NO: 198 is the determined 3' cDNA sequence for 1H-4771
SEQ ID NO: 199 is the determined extended cDNA sequence for 1H-
10 4772
- SEQ ID NO: 200 is the determined extended cDNA sequence for 1D-
4309
- SEQ ID NO: 201 is the determined extended cDNA sequence for 1D.1-
4278
- 15 SEQ ID NO: 202 is the determined extended cDNA sequence for 1D-
4288
- SEQ ID NO: 203 is the determined extended cDNA sequence for 1D-
4283
- SEQ ID NO: 204 is the determined extended cDNA sequence for 1D-
20 4304
- SEQ ID NO: 205 is the determined extended cDNA sequence for 1D-
4296
- SEQ ID NO: 206 is the determined extended cDNA sequence for 1D-
4280
- 25 SEQ ID NO: 207 is the determined cDNA sequence for 10-d8fwd
SEQ ID NO: 208 is the determined cDNA sequence for 10-H10con
SEQ ID NO: 209 is the determined cDNA sequence for 11-C8rev
SEQ ID NO: 210 is the determined cDNA sequence for 7.g6fwd
SEQ ID NO: 211 is the determined cDNA sequence for 7.g6rev
30 SEQ ID NO: 212 is the determined cDNA sequence for 8-b5fwd

SEQ ID NO: 213 is the determined cDNA sequence for 8-b5rev
SEQ ID NO: 214 is the determined cDNA sequence for 8-b6fwd
SEQ ID NO: 215 is the determined cDNA sequence for 8-b6 rev
SEQ ID NO: 216 is the determined cDNA sequence for 8-d4fwd
5 SEQ ID NO: 217 is the determined cDNA sequence for 8-d9rev
SEQ ID NO: 218 is the determined cDNA sequence for 8-g3fwd
SEQ ID NO: 219 is the determined cDNA sequence for 8-g3rev
SEQ ID NO: 220 is the determined cDNA sequence for 8-h11rev
SEQ ID NO: 221 is the determined cDNA sequence for g-f12fwd
10 SEQ ID NO: 222 is the determined cDNA sequence for g-f3rev
SEQ ID NO: 223 is the determined cDNA sequence for P509S
SEQ ID NO: 224 is the determined cDNA sequence for P510S
SEQ ID NO: 225 is the determined cDNA sequence for P703DE5
SEQ ID NO: 226 is the determined cDNA sequence for 9-A11
15 SEQ ID NO: 227 is the determined cDNA sequence for 8-C6
SEQ ID NO: 228 is the determined cDNA sequence for 8-H7
SEQ ID NO: 229 is the determined cDNA sequence for JPTPN13
SEQ ID NO: 230 is the determined cDNA sequence for JPTPN14
SEQ ID NO: 231 is the determined cDNA sequence for JPTPN23
20 SEQ ID NO: 232 is the determined cDNA sequence for JPTPN24
SEQ ID NO: 233 is the determined cDNA sequence for JPTPN25
SEQ ID NO: 234 is the determined cDNA sequence for JPTPN30
SEQ ID NO: 235 is the determined cDNA sequence for JPTPN34
SEQ ID NO: 236 is the determined cDNA sequence for PTPN35
25 SEQ ID NO: 237 is the determined cDNA sequence for JPTPN36
SEQ ID NO: 238 is the determined cDNA sequence for JPTPN38
SEQ ID NO: 239 is the determined cDNA sequence for JPTPN39
SEQ ID NO: 240 is the determined cDNA sequence for JPTPN40
SEQ ID NO: 241 is the determined cDNA sequence for JPTPN41
30 SEQ ID NO: 242 is the determined cDNA sequence for JPTPN42

SEQ ID NO: 243 is the determined cDNA sequence for JPTPN45
SEQ ID NO: 244 is the determined cDNA sequence for JPTPN46
SEQ ID NO: 245 is the determined cDNA sequence for JPTPN51
SEQ ID NO: 246 is the determined cDNA sequence for JPTPN56
5 SEQ ID NO: 247 is the determined cDNA sequence for PTPN64
SEQ ID NO: 248 is the determined cDNA sequence for JPTPN65
SEQ ID NO: 249 is the determined cDNA sequence for JPTPN67
SEQ ID NO: 250 is the determined cDNA sequence for JPTPN76
SEQ ID NO: 251 is the determined cDNA sequence for JPTPN84
10 SEQ ID NO: 252 is the determined cDNA sequence for JPTPN85
SEQ ID NO: 253 is the determined cDNA sequence for JPTPN86
SEQ ID NO: 254 is the determined cDNA sequence for JPTPN87
SEQ ID NO: 255 is the determined cDNA sequence for JPTPN88
SEQ ID NO: 256 is the determined cDNA sequence for JP1F1
15 SEQ ID NO: 257 is the determined cDNA sequence for JP1F2
SEQ ID NO: 258 is the determined cDNA sequence for JP1C2
SEQ ID NO: 259 is the determined cDNA sequence for JP1B1
SEQ ID NO: 260 is the determined cDNA sequence for JP1B2
SEQ ID NO: 261 is the determined cDNA sequence for JP1D3
20 SEQ ID NO: 262 is the determined cDNA sequence for JP1A4
SEQ ID NO: 263 is the determined cDNA sequence for JP1F5
SEQ ID NO: 264 is the determined cDNA sequence for JP1E6
SEQ ID NO: 265 is the determined cDNA sequence for JP1D6
SEQ ID NO: 266 is the determined cDNA sequence for JP1B5
25 SEQ ID NO: 267 is the determined cDNA sequence for JP1A6
SEQ ID NO: 268 is the determined cDNA sequence for JP1E8
SEQ ID NO: 269 is the determined cDNA sequence for JP1D7
SEQ ID NO: 270 is the determined cDNA sequence for JP1D9
SEQ ID NO: 271 is the determined cDNA sequence for JP1C10
30 SEQ ID NO: 272 is the determined cDNA sequence for JP1A9

SEQ ID NO: 273 is the determined cDNA sequence for JP1F12
SEQ ID NO: 274 is the determined cDNA sequence for JP1E12
SEQ ID NO: 275 is the determined cDNA sequence for JP1D11
SEQ ID NO: 276 is the determined cDNA sequence for JP1C11
5 SEQ ID NO: 277 is the determined cDNA sequence for JP1C12
SEQ ID NO: 278 is the determined cDNA sequence for JP1B12
SEQ ID NO: 279 is the determined cDNA sequence for JP1A12
SEQ ID NO: 280 is the determined cDNA sequence for JP8G2
SEQ ID NO: 281 is the determined cDNA sequence for JP8H1
10 SEQ ID NO: 282 is the determined cDNA sequence for JP8H2
SEQ ID NO: 283 is the determined cDNA sequence for JP8A3
SEQ ID NO: 284 is the determined cDNA sequence for JP8A4
SEQ ID NO: 285 is the determined cDNA sequence for JP8C3
SEQ ID NO: 286 is the determined cDNA sequence for JP8G4
15 SEQ ID NO: 287 is the determined cDNA sequence for JP8B6
SEQ ID NO: 288 is the determined cDNA sequence for JP8D6
SEQ ID NO: 289 is the determined cDNA sequence for JP8F5
SEQ ID NO: 290 is the determined cDNA sequence for JP8A8
SEQ ID NO: 291 is the determined cDNA sequence for JP8C7
20 SEQ ID NO: 292 is the determined cDNA sequence for JP8D7
SEQ ID NO: 293 is the determined cDNA sequence for P8D8
SEQ ID NO: 294 is the determined cDNA sequence for JP8E7
SEQ ID NO: 295 is the determined cDNA sequence for JP8F8
SEQ ID NO: 296 is the determined cDNA sequence for JP8G8
25 SEQ ID NO: 297 is the determined cDNA sequence for JP8B10
SEQ ID NO: 298 is the determined cDNA sequence for JP8C10
SEQ ID NO: 299 is the determined cDNA sequence for JP8E9
SEQ ID NO: 300 is the determined cDNA sequence for JP8E10
SEQ ID NO: 301 is the determined cDNA sequence for JP8F9
30 SEQ ID NO: 302 is the determined cDNA sequence for JP8H9

- SEQ ID NO: 303 is the determined cDNA sequence for JP8C12
SEQ ID NO: 304 is the determined cDNA sequence for JP8E11
SEQ ID NO: 305 is the determined cDNA sequence for JP8E12
SEQ ID NO: 306 is the amino acid sequence for the peptide PS2#12
5 SEQ ID NO: 307 is the determined cDNA sequence for P711P
SEQ ID NO: 308 is the determined cDNA sequence for P712P
SEQ ID NO: 309 is the determined cDNA sequence for CLONE23
SEQ ID NO: 310 is the determined cDNA sequence for P774P
SEQ ID NO: 311 is the determined cDNA sequence for P775P
10 SEQ ID NO: 312 is the determined cDNA sequence for P715P
SEQ ID NO: 313 is the determined cDNA sequence for P710P
SEQ ID NO: 314 is the determined cDNA sequence for P767P
SEQ ID NO: 315 is the determined cDNA sequence for P768P
SEQ ID NO: 316-325 are the determined cDNA sequences of previously
15 isolated genes
SEQ ID NO: 326 is the determined cDNA sequence for P703PDE5
SEQ ID NO: 327 is the predicted amino acid sequence for P703PDE5
SEQ ID NO: 328 is the determined cDNA sequence for P703P6.26
SEQ ID NO: 329 is the predicted amino acid sequence for P703P6.26
20 SEQ ID NO: 330 is the determined cDNA sequence for P703PX-23
SEQ ID NO: 331 is the predicted amino acid sequence for P703PX-23
SEQ ID NO: 332 is the determined full length cDNA sequence for
P509S
SEQ ID NO: 333 is the determined extended cDNA sequence for P707P
25 (also referred to as 11-C9)
SEQ ID NO: 334 is the determined cDNA sequence for P714P
SEQ ID NO: 335 is the determined cDNA sequence for P705P (also
referred to as 9-F3)
SEQ ID NO: 336 is the predicted amino acid sequence for P705P
30 SEQ ID NO: 337 is the amino acid sequence of the peptide P1S#10

- SEQ ID NO: 338 is the amino acid sequence of the peptide p5
- SEQ ID NO: 339 is the predicted amino acid sequence of P509S
- SEQ ID NO: 340 is the determined cDNA sequence for P778P
- SEQ ID NO: 341 is the determined cDNA sequence for P786P
- 5 SEQ ID NO: 342 is the determined cDNA sequence for P789P
- SEQ ID NO: 343 is the determined cDNA sequence for a clone showing
homology to Homo sapiens MM46 mRNA
- SEQ ID NO: 344 is the determined cDNA sequence for a clone showing
homology to Homo sapiens TNF-alpha stimulated ABC protein (ABC50) mRNA
- 10 SEQ ID NO: 345 is the determined cDNA sequence for a clone showing
homology to Homo sapiens mRNA for E-cadherin
- SEQ ID NO: 346 is the determined cDNA sequence for a clone showing
homology to Human nuclear-encoded mitochondrial serine hydroxymethyltransferase
(SHMT)
- 15 SEQ ID NO: 347 is the determined cDNA sequence for a clone showing
homology to Homo sapiens natural resistance-associated macrophage protein2
(NRAMP2)
- SEQ ID NO: 348 is the determined cDNA sequence for a clone showing
homology to Homo sapiens phosphoglucomutase-related protein (PGMRP)
- 20 SEQ ID NO: 349 is the determined cDNA sequence for a clone showing
homology to Human mRNA for proteosome subunit p40
- SEQ ID NO: 350 is the determined cDNA sequence for P777P
- SEQ ID NO: 351 is the determined cDNA sequence for P779P
- SEQ ID NO: 352 is the determined cDNA sequence for P790P
- 25 SEQ ID NO: 353 is the determined cDNA sequence for P784P
- SEQ ID NO: 354 is the determined cDNA sequence for P776P
- SEQ ID NO: 355 is the determined cDNA sequence for P780P
- SEQ ID NO: 356 is the determined cDNA sequence for P544S
- SEQ ID NO: 357 is the determined cDNA sequence for P745S
- 30 SEQ ID NO: 358 is the determined cDNA sequence for P782P

- SEQ ID NO: 359 is the determined cDNA sequence for P783P
SEQ ID NO: 360 is the determined cDNA sequence for unknown 17984
SEQ ID NO: 361 is the determined cDNA sequence for P787P
SEQ ID NO: 362 is the determined cDNA sequence for P788P
5 SEQ ID NO: 363 is the determined cDNA sequence for unknown 17994
SEQ ID NO: 364 is the determined cDNA sequence for P781P
SEQ ID NO: 365 is the determined cDNA sequence for P785P
SEQ ID NO: 366-375 are the determined cDNA sequences for splice
variants of B305D.
- 10 SEQ ID NO: 376 is the predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 366.
SEQ ID NO: 377 is the predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 372.
SEQ ID NO: 378 is the predicted amino acid sequence encoded by the
15 sequence of SEQ ID NO: 373.
SEQ ID NO: 379 is the predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 374.
SEQ ID NO: 380 is the predicted amino acid sequence encoded by the
sequence of SEQ ID NO: 375.
- 20 SEQ ID NO: 381 is the determined cDNA sequence for B716P.
SEQ ID NO: 382 is the determined full-length cDNA sequence for
P711P.
SEQ ID NO: 383 is the predicted amino acid sequence for P711P.
SEQ ID NO: 384 is the cDNA sequence for P1000C.
25 SEQ ID NO: 385 is the cDNA sequence for CGI-82.
SEQ ID NO: 386 is the cDNA sequence for 23320.
SEQ ID NO: 387 is the cDNA sequence for CGI-69.
SEQ ID NO: 388 is the cDNA sequence for L-iditol-2-dehydrogenase.
SEQ ID NO: 389 is the cDNA sequence for 23379.
30 SEQ ID NO: 390 is the cDNA sequence for 23381.

- SEQ ID NO:391 is the cDNA sequence for KIAA0122.
SEQ ID NO:392 is the cDNA sequence for 23399.
SEQ ID NO:393 is the cDNA sequence for a previously identified gene.
SEQ ID NO:394 is the cDNA sequence for HCLBP.
5 SEQ ID NO:395 is the cDNA sequence for transglutaminase.
SEQ ID NO:396 is the cDNA sequence for a previously identified gene.
SEQ ID NO:397 is the cDNA sequence for PAP.
SEQ ID NO:398 is the cDNA sequence for Ets transcription factor
PDEF.
10 SEQ ID NO:399 is the cDNA sequence for hTGR.
SEQ ID NO:400 is the cDNA sequence for KIAA0295.
SEQ ID NO:401 is the cDNA sequence for 22545.
SEQ ID NO:402 is the cDNA sequence for 22547.
SEQ ID NO:403 is the cDNA sequence for 22548.
15 SEQ ID NO:404 is the cDNA sequence for 22550.
SEQ ID NO:405 is the cDNA sequence for 22551.
SEQ ID NO:406 is the cDNA sequence for 22552.
SEQ ID NO:407 is the cDNA sequence for 22553 (also known as
P1020C).
20 SEQ ID NO:408 is the cDNA sequence for 22558.
SEQ ID NO:409 is the cDNA sequence for 22562.
SEQ ID NO:410 is the cDNA sequence for 22565.
SEQ ID NO:411 is the cDNA sequence for 22567.
SEQ ID NO:412 is the cDNA sequence for 22568.
25 SEQ ID NO:413 is the cDNA sequence for 22570.
SEQ ID NO:414 is the cDNA sequence for 22571.
SEQ ID NO:415 is the cDNA sequence for 22572.
SEQ ID NO:416 is the cDNA sequence for 22573.
SEQ ID NO:417 is the cDNA sequence for 22573.
30 SEQ ID NO:418 is the cDNA sequence for 22575.

SEQ ID NO:419 is the cDNA sequence for 22580.
SEQ ID NO:420 is the cDNA sequence for 22581.
SEQ ID NO:421 is the cDNA sequence for 22582.
SEQ ID NO:422 is the cDNA sequence for 22583.
5 SEQ ID NO:423 is the cDNA sequence for 22584.
SEQ ID NO:424 is the cDNA sequence for 22585.
SEQ ID NO:425 is the cDNA sequence for 22586.
SEQ ID NO:426 is the cDNA sequence for 22587.
SEQ ID NO:427 is the cDNA sequence for 22588.
10 SEQ ID NO:428 is the cDNA sequence for 22589.
SEQ ID NO:429 is the cDNA sequence for 22590.
SEQ ID NO:430 is the cDNA sequence for 22591.
SEQ ID NO:431 is the cDNA sequence for 22592.
SEQ ID NO:432 is the cDNA sequence for 22593.
15 SEQ ID NO:433 is the cDNA sequence for 22594.
SEQ ID NO:434 is the cDNA sequence for 22595.
SEQ ID NO:435 is the cDNA sequence for 22596.
SEQ ID NO:436 is the cDNA sequence for 22847.
SEQ ID NO:437 is the cDNA sequence for 22848.
20 SEQ ID NO:438 is the cDNA sequence for 22849.
SEQ ID NO:439 is the cDNA sequence for 22851.
SEQ ID NO:440 is the cDNA sequence for 22852.
SEQ ID NO:441 is the cDNA sequence for 22853.
SEQ ID NO:442 is the cDNA sequence for 22854.
25 SEQ ID NO:443 is the cDNA sequence for 22855.
SEQ ID NO:444 is the cDNA sequence for 22856.
SEQ ID NO:445 is the cDNA sequence for 22857.
SEQ ID NO:446 is the cDNA sequence for 23601.
SEQ ID NO:447 is the cDNA sequence for 23602.
30 SEQ ID NO:448 is the cDNA sequence for 23605.

- SEQ ID NO:449 is the cDNA sequence for 23606.
- SEQ ID NO:450 is the cDNA sequence for 23612.
- SEQ ID NO:451 is the cDNA sequence for 23614.
- SEQ ID NO:452 is the cDNA sequence for 23618.
- 5 SEQ ID NO:453 is the cDNA sequence for 23622.
- SEQ ID NO:454 is the cDNA sequence for folate hydrolase.
- SEQ ID NO:455 is the cDNA sequence for LIM protein.
- SEQ ID NO:456 is the cDNA sequence for a known gene.
- SEQ ID NO:457 is the cDNA sequence for a known gene.
- 10 SEQ ID NO:458 is the cDNA sequence for a previously identified gene.
- SEQ ID NO:459 is the cDNA sequence for 23045.
- SEQ ID NO:460 is the cDNA sequence for 23032.
- SEQ ID NO:461 is the cDNA sequence for clone 23054.
- SEQ ID NO:462-467 are cDNA sequences for known genes.
- 15 SEQ ID NO:468-471 are cDNA sequences for P710P.
- SEQ ID NO:472 is a cDNA sequence for P1001C.
- SEQ ID NO: 473 is the determined cDNA sequence for a first splice variant of P775P (referred to as 27505).
- SEQ ID NO: 474 is the determined cDNA sequence for a second splice variant of P775P (referred to as 19947).
- 20 SEQ ID NO: 475 is the determined cDNA sequence for a third splice variant of P775P (referred to as 19941).
- SEQ ID NO: 476 is the determined cDNA sequence for a fourth splice variant of P775P (referred to as 19937).
- 25 SEQ ID NO: 477 is a first predicted amino acid sequence encoded by the sequence of SEQ ID NO: 474.
- SEQ ID NO: 478 is a second predicted amino acid sequence encoded by the sequence of SEQ ID NO: 474.
- SEQ ID NO: 479 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: 475.
- 30

SEQ ID NO: 480 is a first predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 481 is a second predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

5 SEQ ID NO: 482 is a third predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

SEQ ID NO: 483 is a fourth predicted amino acid sequence encoded by the sequence of SEQ ID NO: 473.

10 SEQ ID NO: 484 is the first 30 amino acids of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 485 is the PCR primer AW025.

SEQ ID NO: 486 is the PCR primer AW003.

SEQ ID NO: 487 is the PCR primer AW027.

SEQ ID NO: 488 is the PCR primer AW026.

15 SEQ ID NO: 489-501 are peptides employed in epitope mapping studies.

SEQ ID NO: 502 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody 20D4.

SEQ ID NO: 503 is the determined cDNA sequence of the complementarity determining region for the anti-P503S monoclonal antibody JA1.

20 SEQ ID NO: 504 & 505 are peptides employed in epitope mapping studies.

SEQ ID NO: 506 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 8H2.

25 SEQ ID NO: 507 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 7H8.

SEQ ID NO: 508 is the determined cDNA sequence of the complementarity determining region for the anti-P703P monoclonal antibody 2D4.

SEQ ID NO: 509-522 are peptides employed in epitope mapping studies.

30 SEQ ID NO: 523 is a mature form of P703P used to raise antibodies against P703P.

- SEQ ID NO: 524 is the putative full-length cDNA sequence of P703P.
SEQ ID NO: 525 is the predicted amino acid sequence encoded by SEQ
ID NO: 524.
- SEQ ID NO: 526 is the full-length cDNA sequence for P790P.
- 5 SEQ ID NO: 527 is the predicted amino acid sequence for P790P.
- SEQ ID NO: 528 & 529 are PCR primers.
- SEQ ID NO: 530 is the cDNA sequence of a splice variant of SEQ ID
NO: 366.
- SEQ ID NO: 531 is the cDNA sequence of the open reading frame of
10 SEQ ID NO: 530.
- SEQ ID NO: 532 is the predicted amino acid encoded by the sequence of
SEQ ID NO: 531.
- SEQ ID NO: 533 is the DNA sequence of a putative ORF of P775P.
- SEQ ID NO: 534 is the predicted amino acid sequence encoded by SEQ
15 ID NO: 533.
- SEQ ID NO: 535 is a first full-length cDNA sequence for P510S.
- SEQ ID NO: 536 is a second full-length cDNA sequence for P510S.
- SEQ ID NO: 537 is the predicted amino acid sequence encoded by SEQ
ID NO: 535.
- 20 SEQ ID NO: 538 is the predicted amino acid sequence encoded by SEQ
ID NO: 536.
- SEQ ID NO: 539 is the peptide P501S-370.
- SEQ ID NO: 540 is the peptide P501S-376.
- SEQ ID NO: 541-551 are epitopes of P501S.
- 25 SEQ ID NO: 552 is an extended cDNA sequence for P712P.
- SEQ ID NO: 553-568 are the amino acid sequences encoded by
predicted open reading frames within SEQ ID NO: 552.
- SEQ ID NO: 569 is an extended cDNA sequence for P776P.
- SEQ ID NO: 570 is the determined cDNA sequence for a splice variant
30 of P776P referred to as contig 6.

SEQ ID NO: 571 is the determined cDNA sequence for a splice variant of P776P referred to as contig 7.

SEQ ID NO: 572 is the determined cDNA sequence for a splice variant of P776P referred to as contig 14.

5 SEQ ID NO: 573 is the amino acid sequence encoded by a first predicted ORF of SEQ ID NO: 570.

SEQ ID NO: 574 is the amino acid sequence encoded by a second predicted ORF of SEQ ID NO: 570.

10 SEQ ID NO: 575 is the amino acid sequence encoded by a predicted ORF of SEQ ID NO: 571.

SEQ ID NO: 576-586 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 569.

SEQ ID NO: 587 is a DNA consensus sequence of the sequences of P767P and P777P.

15 SEQ ID NO: 588-590 are amino acid sequences encoded by predicted ORFs of SEQ ID NO: 587.

SEQ ID NO: 591 is an extended cDNA sequence for P1020C.

SEQ ID NO: 592 is the predicted amino acid sequence encoded by the sequence of SEQ ID NO: P1020C.

20 SEQ ID NO: 593 is a splice variant of P775P referred to as 50748.

SEQ ID NO: 594 is a splice variant of P775P referred to as 50717.

SEQ ID NO: 595 is a splice variant of P775P referred to as 45985.

SEQ ID NO: 596 is a splice variant of P775P referred to as 38769.

SEQ ID NO: 597 is a splice variant of P775P referred to as 37922.

25 SEQ ID NO: 598 is a splice variant of P510S referred to as 49274.

SEQ ID NO: 599 is a splice variant of P510S referred to as 39487.

SEQ ID NO: 600 is a splice variant of P504S referred to as 5167.16.

SEQ ID NO: 601 is a splice variant of P504S referred to as 5167.1.

SEQ ID NO: 602 is a splice variant of P504S referred to as 5163.46.

30 SEQ ID NO: 603 is a splice variant of P504S referred to as 5163.42.

SEQ ID NO: 604 is a splice variant of P504S referred to as 5163.34.

SEQ ID NO: 605 is a splice variant of P504S referred to as 5163.17.

SEQ ID NO: 606 is a splice variant of P501S referred to as 10640.

SEQ ID NO: 607-615 are the sequences of PCR primers.

5 SEQ ID NO: 616 is the determined cDNA sequence of a fusion of P703P
and PSA.

SEQ ID NO: 617 is the amino acid sequence of the fusion of P703P and
PSA.

SEQ ID NO: 618 is the cDNA sequence of the gene DD3.

10 SEQ ID NO: 619 is an extended cDNA sequence for P714P.

SEQ ID NO: 620-622 are the cDNA sequences for splice variants of
P704P.

SEQ ID NO: 623 is the cDNA sequence of a splice variant of P553S
referred to as P553S-14.

15 SEQ ID NO: 624 is the cDNA sequence of a splice variant of P553S
referred to as P553S-12.

SEQ ID NO: 625 is the cDNA sequence of a splice variant of P553S
referred to as P553S-10.

20 SEQ ID NO: 626 is the cDNA sequence of a splice variant of P553S
referred to as P553S-6.

SEQ ID NO: 627 is the amino acid sequence encoded by SEQ ID NO:
626.

SEQ ID NO: 628 is a first amino acid sequence encoded by SEQ ID NO:
623.

25 SEQ ID NO: 629 is a second amino acid sequence encoded by SEQ ID
NO: 623.

SEQ ID NO: 630 is a first full-length cDNA sequence for prostate-
specific transglutaminase gene (also referred to herein as P558S).

30 SEQ ID NO: 631 is a second full-length cDNA sequence for prostate-
specific transglutaminase gene.

SEQ ID NO: 632 is the amino acid sequence encoded by the sequence of
SEQ ID NO: 630.

SEQ ID NO: 633 is the amino acid sequence encoded by the sequence of
SEQ ID NO: 631.

5 SEQ ID NO: 634 is the full-length cDNA sequence for P788P.

SEQ ID NO: 635 is the amino acid sequence encoded by SEQ ID NO:
634.

SEQ ID NO: 636 is the determined cDNA sequence for a polymorphic
variant of P788P.

10 SEQ ID NO: 637 is the amino acid sequence encoded by SEQ ID NO:
636.

SEQ ID NO: 638 is the amino acid sequence of peptide 4 from P703P.

SEQ ID NO: 639 is the cDNA sequence that encodes peptide 4 from
P703P.

15 SEQ ID NO: 640-655 are cDNA sequences encoding epitopes of P703P.

SEQ ID NO: 656-671 are the amino acid sequences of epitopes of
P703P.

SEQ ID NO: 672 and 673 are PCR primers.

20 SEQ ID NO: 674 is the cDNA sequence encoding an N-terminal portion
of P788P expressed in *E. coli*.

SEQ ID NO: 675 is the amino acid sequence of the N-terminal portion of
P788P expressed in *E. coli*.

SEQ ID NO: 676 is the amino acid sequence of the *M. tuberculosis*
antigen Ra12.

25 SEQ ID NO: 677 and 678 are PCR primers.

SEQ ID NO: 679 is the cDNA sequence for the Ra12-P510S-C
construct.

SEQ ID NO: 680 is the cDNA sequence for the P510S-C construct.

SEQ ID NO: 681 is the cDNA sequence for the P510S-E3 construct.

SEQ ID NO: 682 is the amino acid sequence for the Ra12-P510S-C construct.

SEQ ID NO: 683 is the amino acid sequence for the P510S-C construct.

SEQ ID NO: 684 is the amino acid sequence for the P510S-E3 construct.

5 SEQ ID NO: 685-690 are PCR primers.

SEQ ID NO: 691 is the cDNA sequence of the construct Ra12-P775P-ORF3.

SEQ ID NO: 692 is the amino acid sequence of the construct Ra12-P775P-ORF3.

10 SEQ ID NO: 693 and 694 are PCR primers.

SEQ ID NO: 695 is the determined amino acid sequence for a P703P His tag fusion protein.

SEQ ID NO: 696 is the determined cDNA sequence for a P703P His tag fusion protein.

15 SEQ ID NO: 697 and 698 are PCR primers.

SEQ ID NO: 699 is the determined amino acid sequence for a P705P His tag fusion protein.

SEQ ID NO: 700 is the determined cDNA sequence for a P705P His tag fusion protein.

20 SEQ ID NO: 701 and 702 are PCR primers.

SEQ ID NO: 703 is the determined amino acid sequence for a P711P His tag fusion protein.

SEQ ID NO: 704 is the determined cDNA sequence for a P711P His tag fusion protein.

25 SEQ ID NO: 705 is the amino acid sequence of the *M. tuberculosis* antigen Ra12.

SEQ ID NO: 706 and 707 are PCR primers.

SEQ ID NO: 708 is the determined cDNA sequence for the construct Ra12-P501S-E2.

SEQ ID NO: 709 is the determined amino acid sequence for the construct Ra12-P501S-E2.

SEQ ID NO: 710 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 711 is the DNA sequence encoding SEQ ID NO: 710.

5 SEQ ID NO: 712 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 713 is the DNA sequence encoding SEQ ID NO: 712.

SEQ ID NO: 714 is a peptide employed in epitope mapping studies.

SEQ ID NO: 715 is the amino acid sequence for an epitope of P501S.

SEQ ID NO: 716 is the DNA sequence encoding SEQ ID NO: 715.

10 SEQ ID NO: 717-719 are the amino acid sequences for CD4 epitopes of P501S.

SEQ ID NO: 720-722 are the DNA sequences encoding the sequences of SEQ ID NO: 717-719.

15 SEQ ID NO: 723-734 are the amino acid sequences for putative CTL epitopes of P703P.

SEQ ID NO: 735 is the full-length cDNA sequence for P789P.

SEQ ID NO: 736 is the amino acid sequence encoded by SEQ ID NO: 735.

20 SEQ ID NO: 737 is the determined full-length cDNA sequence for the splice variant of P776P referred to as contig 6.

SEQ ID NO: 738-739 are determined full-length cDNA sequences for the splice variant of P776P referred to as contig 7.

SEQ ID NO: 740-744 are amino acid sequences encoded by SEQ ID NO: 737.

25 SEQ ID NO: 745-750 are amino acid sequences encoded by the splice variant of P776P referred to as contig 7.

SEQ ID NO: 751 is the full-length cDNA sequence for human transmembrane protease serine 2.

30 SEQ ID NO: 752 is the amino acid sequence encoded by SEQ ID NO: 751.

SEQ ID NO: 753 is the cDNA sequence encoding the first 209 amino acids of human transmembrane protease serine 2.

SEQ ID NO: 754 is the first 209 amino acids of human transmembrane protease serine 2.

5 SEQ ID NO: 755 is the amino acid sequence of peptide 296-322 of P501S.

SEQ ID NO: 756-759 are PCR primers.

SEQ ID NO: 760 is the determined cDNA sequence of the Vb chain of a T cell receptor for the P501S-specific T cell clone 4E5.

10 SEQ ID NO: 761 is the determined cDNA sequence of the Va chain of a T cell receptor for the P501S-specific T cell clone 4E5.

SEQ ID NO: 762 is the amino acid sequence encoded by SEQ ID NO 760.

15 SEQ ID NO: 763 is the amino acid sequence encoded by SEQ ID NO 761.

SEQ ID NO: 764 is the full-length open reading frame for P768P including stop codon.

SEQ ID NO: 765 is the full-length open reading frame for P768P without stop codon.

20 SEQ ID NO: 766 is the amino acid sequence encoded by SEQ ID NO: 765.

SEQ ID NO: 767-772 are the amino acid sequences for predicted domains of P768P.

SEQ ID NO: 773 is the full-length cDNA sequence of P835P.

25 SEQ ID NO: 774 is the cDNA sequence of the previously identified clone FLJ13581.

SEQ ID NO: 775 is the cDNA sequence of the open reading frame for P835P with stop codon.

30 SEQ ID NO: 776 is the cDNA sequence of the open reading frame for P835P without stop codon.

SEQ ID NO: 777 is the full-length amino acid sequence for P835P.

SEQ ID NO: 778-785 are the amino acid sequences of extracellular and intracellular domains of P835P.

SEQ ID NO: 786 is the full-length cDNA sequence for P1000C.

5 SEQ ID NO: 787 is the cDNA sequence of the open reading frame for P1000C, including stop codon.

SEQ ID NO: 788 is the cDNA sequence of the open reading frame for P1000C, without stop codon.

SEQ ID NO: 789 is the full-length amino acid sequence for P1000C.

10 SEQ ID NO: 790 is amino acids 1-100 of SEQ ID NO: 789.

SEQ ID NO: 791 is amino acids 100-492 of SEQ ID NO: 789.

SEQ ID NO: 792 is the amino acid sequence of an α prepro-P501S recombinant protein.

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed generally to compositions and their use in the therapy and diagnosis of cancer, particularly prostate cancer. As described further below, illustrative compositions of the present invention include, but are not restricted to, polypeptides, particularly immunogenic polypeptides, polynucleotides encoding such
20 polypeptides, antibodies and other binding agents, antigen presenting cells (APCs) and immune system cells (*e.g.*, T cells).

The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of
25 the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, et al. Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Maniatis et al. Molecular Cloning: A Laboratory Manual (1982); DNA Cloning: A Practical Approach, vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., 1984); Nucleic Acid

Hybridization (B. Hames & S. Higgins, eds., 1985); Transcription and Translation (B. Hames & S. Higgins, eds., 1984); Animal Cell Culture (R. Freshney, ed., 1986); Perbal, A Practical Guide to Molecular Cloning (1984).

All publications, patents and patent applications cited herein, whether
5 supra or infra, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

Polypeptide Compositions

10 As used herein, the term "polypeptide" " is used in its conventional meaning, *i.e.*, as a sequence of amino acids. The polypeptides are not limited to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-
15 expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising epitopes, *i.e.*, antigenic
20 determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of evoking an immune response.

Particularly illustrative polypeptides of the present invention comprise those encoded by a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382
25 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, or a sequence that hybridizes under moderately stringent conditions, or, alternatively, under highly stringent conditions, to a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175,

177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788. In specific embodiments, the polypeptides of the invention
5 comprise amino acid sequences as set forth in any one of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791.

10 The polypeptides of the present invention are sometimes herein referred to as prostate-specific proteins or prostate-specific polypeptides, as an indication that their identification has been based at least in part upon their increased levels of expression in prostate tissue samples. Thus, a "prostate-specific polypeptide" or "prostate-specific protein," refers generally to a polypeptide sequence of the present
15 invention, or a polynucleotide sequence encoding such a polypeptide, that is expressed in a substantial proportion of prostate tissue samples, for example preferably greater than about 20%, more preferably greater than about 30%, and most preferably greater than about 50% or more of prostate tissue samples tested, at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in other
20 normal tissues, as determined using a representative assay provided herein. A prostate-specific polypeptide sequence of the invention, based upon its increased level of expression in tumor cells, has particular utility both as a diagnostic marker as well as a therapeutic target, as further described below.

In certain preferred embodiments, the polypeptides of the invention are
25 immunogenic, *i.e.*, they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with prostate cancer. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as those described in Harlow and Lane, *Antibodies: A Laboratory*
30 *Manual*, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a

polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

- 5 As would be recognized by the skilled artisan, immunogenic portions of the polypeptides disclosed herein are also encompassed by the present invention. An "immunogenic portion," as used herein, is a fragment of an immunogenic polypeptide of the invention that itself is immunologically reactive (*i.e.*, specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide.
- 10 Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they
- 15 specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques.

- In one preferred embodiment, an immunogenic portion of a polypeptide of the present invention is a portion that reacts with antisera and/or T-cells at a level that
- 20 is not substantially less than the reactivity of the full-length polypeptide (*e.g.*, in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that
- 25 have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, *e.g.*, having greater than about 100% or 150% or more immunogenic activity.

- In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain
- 30 has been deleted. Other illustrative immunogenic portions will contain a small N-

and/or C-terminal deletion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

In another embodiment, a polypeptide composition of the invention may also comprise one or more polypeptides that are immunologically reactive with T cells
5 and/or antibodies generated against a polypeptide of the invention, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.

In another embodiment of the invention, polypeptides are provided that comprise one or more polypeptides that are capable of eliciting T cells and/or antibodies
10 that are immunologically reactive with one or more polypeptides described herein, or one or more polypeptides encoded by contiguous nucleic acid sequences contained in the polynucleotide sequences disclosed herein, or immunogenic fragments or variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

15 The present invention, in another aspect, provides polypeptide fragments comprising at least about 5, 10, 15, 20, 25, 50, or 100 contiguous amino acids, or more, including all intermediate lengths, of a polypeptide composition set forth herein, such as those set forth in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568,
20 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791, or those encoded by a polynucleotide sequence set forth in a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591,
25 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

In another aspect, the present invention provides variants of the polypeptide compositions described herein. Polypeptide variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%,
30 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity

(determined as described below), along its length, to a polypeptide sequence set forth herein.

In one preferred embodiment, the polypeptide fragments and variants provided by the present invention are immunologically reactive with an antibody and/or
5 T-cell that reacts with a full-length polypeptide specifically set forth herein.

In another preferred embodiment, the polypeptide fragments and variants provided by the present invention exhibit a level of immunogenic activity of at least about 50%, preferably at least about 70%, and most preferably at least about 90% or more of that exhibited by a full-length polypeptide sequence specifically set forth
10 herein.

A polypeptide "variant," as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of
15 the above polypeptide sequences of the invention and evaluating their immunogenic activity as described herein using any of a number of techniques well known in the art.

For example, certain illustrative variants of the polypeptides of the invention include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other illustrative variants
20 include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

In many instances, a variant will contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide
25 chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, *e.g.*, with immunogenic characteristics. When it is
30 desired to alter the amino acid sequence of a polypeptide to create an equivalent, or

even an improved, immunogenic variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

TABLE 1

Amino Acids			Codons						
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its

hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5);
5 glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are
10 within ± 2 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of
15 its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine
20 (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2
25 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that
30 take various of the foregoing characteristics into consideration are well known to those

of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition, any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of
5 flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

10 Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values
15 include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a
20 preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

25 As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (*e.g.*, poly-His), or to enhance binding of the polypeptide to a solid support. For
30 example, a polypeptide may be conjugated to an immunoglobulin Fc region.

When comparing polypeptide sequences, two sequences are said to be "identical" if the sequence of amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

- Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics

Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

In one preferred approach, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Within other illustrative embodiments, a polypeptide may be a fusion polypeptide that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known

tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological
5 and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the polypeptide or to enable the polypeptide to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the polypeptide.

Fusion polypeptides may generally be prepared using standard
10 techniques, including chemical conjugation. Preferably, a fusion polypeptide is expressed as a recombinant polypeptide, allowing the production of increased levels, relative to a non-fused polypeptide, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one
15 polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion polypeptide that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and
20 second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a
25 secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as
30 linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al.,

Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to
5 separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and
10 transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

The fusion polypeptide can comprise a polypeptide as described herein together with an unrelated immunogenic protein, such as an immunogenic protein capable of eliciting a recall response. Examples of such proteins include tetanus,
15 tuberculosis and hepatitis proteins (*see, for example, Stoute et al. New Engl. J. Med.*, 336:86-91, 1997).

In one preferred embodiment, the immunological fusion partner is derived from a *Mycobacterium* sp., such as a *Mycobacterium tuberculosis*-derived Ra12 fragment. Ra12 compositions and methods for their use in enhancing the expression
20 and/or immunogenicity of heterologous polynucleotide/polypeptide sequences is described in U.S. Patent Application 60/158,585, the disclosure of which is incorporated herein by reference in its entirety. Briefly, Ra12 refers to a polynucleotide region that is a subsequence of a *Mycobacterium tuberculosis* MTB32A nucleic acid. MTB32A is a serine protease of 32 KD molecular weight encoded by a gene in virulent
25 and avirulent strains of *M. tuberculosis*. The nucleotide sequence and amino acid sequence of MTB32A have been described (for example, U.S. Patent Application 60/158,585; *see also, Skeiky et al., Infection and Immun.* (1999) 67:3998-4007, incorporated herein by reference). C-terminal fragments of the MTB32A coding sequence express at high levels and remain as a soluble polypeptides throughout the
30 purification process. Moreover, Ra12 may enhance the immunogenicity of heterologous

immunogenic polypeptides with which it is fused. One preferred Ra12 fusion polypeptide comprises a 14 KD C-terminal fragment corresponding to amino acid residues 192 to 323 of MTB32A. Other preferred Ra12 polynucleotides generally comprise at least about 15 consecutive nucleotides, at least about 30 nucleotides, at least
5 about 60 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, or at least about 300 nucleotides that encode a portion of a Ra12 polypeptide. Ra12 polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a Ra12 polypeptide or a portion thereof) or may comprise a variant of such a sequence. Ra12 polynucleotide variants may contain one or more substitutions,
10 additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not substantially diminished, relative to a fusion polypeptide comprising a native Ra12 polypeptide. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native Ra12 polypeptide or a
15 portion thereof.

Within other preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza B* (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (*e.g.*, the first N-terminal 100-110 amino
20 acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells.
25 Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is
30 derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine

amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been
5 exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion polypeptide. A repeat portion is found in the C-terminal region starting at
10 residue 178. A particularly preferred repeat portion incorporates residues 188-305.

Yet another illustrative embodiment involves fusion polypeptides, and the polynucleotides encoding them, wherein the fusion partner comprises a targeting signal capable of directing a polypeptide to the endosomal/lysosomal compartment, as described in U.S. Patent No. 5,633,234. An immunogenic polypeptide of the invention,
15 when fused with this targeting signal, will associate more efficiently with MHC class II molecules and thereby provide enhanced in vivo stimulation of CD4⁺ T-cells specific for the polypeptide.

Polypeptides of the invention are prepared using any of a variety of well known synthetic and/or recombinant techniques, the latter of which are further
20 described below. Polypeptides, portions and other variants generally less than about 150 amino acids can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. In one illustrative example, such polypeptides are synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a
25 growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

In general, polypeptide compositions (including fusion polypeptides) of
30 the invention are isolated. An "isolated" polypeptide is one that is removed from its

original environment. For example, a naturally-occurring protein or polypeptide is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are also purified, *e.g.*, are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99%
5 pure.

Polynucleotide Compositions

The present invention, in other aspects, provides polynucleotide compositions. The terms "DNA" and "polynucleotide" are used essentially interchangeably herein to refer to a DNA molecule that has been isolated free of total
10 genomic DNA of a particular species. "Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA molecule does not contain large portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA molecule as originally isolated, and does not exclude
15 genes or coding regions later added to the segment by the hand of man.

As will be understood by those skilled in the art, the polynucleotide compositions of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may
20 be naturally isolated, or modified synthetically by the hand of man.

As will be also recognized by the skilled artisan, polynucleotides of the invention may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules may include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-
25 to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a polypeptide/protein of the invention or a portion thereof) or may comprise a sequence that encodes a variant or derivative, preferably an immunogenic variant or derivative, of such a sequence.

5 Therefore, according to another aspect of the present invention, polynucleotide compositions are provided that comprise some or all of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655,
10 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, complements of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722,
15 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, and degenerate variants of a polynucleotide sequence set forth in any one of SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765,
20 773-776 and 786-788. In certain preferred embodiments, the polynucleotide sequences set forth herein encode immunogenic polypeptides, as described above.

 In other related embodiments, the present invention provides polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NOs: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-
25 335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a
30 polynucleotide sequence of this invention using the methods described herein, (*e.g.*,

BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

Typically, polynucleotide variants will contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenicity of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth herein). The term "variants" should also be understood to encompass homologous genes of xenogenic origin.

In additional embodiments, the present invention provides polynucleotide fragments comprising various lengths of contiguous stretches of sequence identical to, or complementary to, one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-60°C, 5 X SSC, overnight; followed by washing twice at 65°C for

20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable
5 highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, *e.g.*, to 60-65°C or 65-70°C.

In certain preferred embodiments, the polynucleotides described above, *e.g.*, polynucleotide variants, fragments and hybridizing sequences, encode polypeptides
10 that are immunologically cross-reactive with a polypeptide sequence specifically set forth herein. In other preferred embodiments, such polynucleotides encode polypeptides that have a level of immunogenic activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein.

15 The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment
20 of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated
25 to be useful in many implementations of this invention.

When comparing polynucleotide sequences, two sequences are said to be "identical" if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison
30 window to identify and compare local regions of sequence similarity. A "comparison

window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, preferably 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

- 5 Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships.
- 10 In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson,
- 15 E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

- Alternatively, optimal alignment of sequences for comparison may be
- 20 conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics
- 25 Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

- One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402
- 30 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST

2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for
5 nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments;
10 or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and
15 a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5
20 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the
25 reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal
30 homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides

that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions
5 and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Therefore, in another embodiment of the invention, a mutagenesis approach, such as site-specific mutagenesis, is employed for the preparation of
10 immunogenic variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence can be made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more
15 nucleotide sequence changes into the polynucleotide.

Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on
20 both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

In certain embodiments of the present invention, the inventors
25 contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the immunogenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA
30 molecule. In such embodiments, a primer comprising typically about 14 to about 25

nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

As used herein, the term "oligonucleotide directed mutagenesis procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable
5 signal, such as amplification. As used herein, the term "oligonucleotide directed mutagenesis procedure" is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known
10 rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

15 In another approach for the production of polypeptide variants of the present invention, recursive sequence recombination, as described in U.S. Patent No. 5,837,458, may be employed. In this approach, iterative cycles of recombination and screening or selection are performed to "evolve" individual polynucleotide variants of the invention having, for example, enhanced immunogenic activity.

20 In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15 contiguous nucleotides that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence
25 disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500, 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

The ability of such nucleic acid probes to specifically hybridize to a
30 sequence of interest will enable them to be of use in detecting the presence of

complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

Polynucleotide molecules having sequence regions consisting of
5 contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization probes for use in, *e.g.*, Southern and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in
10 various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger
15 contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

The use of a hybridization probe of about 15-25 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 15 bases in
20 length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

25 Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various

factors. For example, one may wish to employ primers from towards the termini of the total sequence.

Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCRTM technology of U. S. Patent 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to

destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

According to another embodiment of the present invention, 5 polynucleotide compositions comprising antisense oligonucleotides are provided. Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, provide a therapeutic approach by which a disease can be treated by inhibiting the synthesis of proteins that contribute to the disease. The efficacy of antisense oligonucleotides for inhibiting protein synthesis 10 is well established. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, 15 striatal GABA_A receptor and human EGF (Jaskulski *et al.*, Science. 1988 Jun 10;240(4858):1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989;1(4):225-32; Peris *et al.*, Brain Res Mol Brain Res. 1998 Jun 15;57(2):310-20; U. S. Patent 5,801,154; U.S. Patent 5,789,573; U. S. Patent 5,718,709 and U.S. Patent 5,610,288). Antisense constructs have also been described that inhibit and can be used to treat a 20 variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S. Patent 5,591,317 and U. S. Patent 5,783,683).

Therefore, in certain embodiments, the present invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a 25 complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In 30 each case, preferred compositions comprise a sequence region that is complementary,

and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein. Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence and determination of secondary structure, T_m ,
5 binding energy, and relative stability. Antisense compositions may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell. Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which are substantially complementary
10 to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software and/or the BLASTN 2.0.5 algorithm software (Altschul *et al.*, Nucleic Acids Res. 1997 Sep 1;25(17):3389-402).

The use of an antisense delivery method employing a short peptide
15 vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, Nucleic Acids Res. 1997 Jul 15;25(14):2730-6). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered
20 into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane.

According to another embodiment of the invention, the polynucleotide compositions described herein are used in the design and preparation of ribozyme
25 molecules for inhibiting expression of the tumor polypeptides and proteins of the present invention in tumor cells. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc Natl Acad Sci U S A. 1987 Dec;84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24;49(2):211-20). For
30 example, a large number of ribozymes accelerate phosphoester transfer reactions with a

high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, Cell. 1981 Dec;27(3 Pt 2):487-96; Michel and Westhof, J Mol Biol. 1990 Dec 5;216(3):585-610; Reinhold-Hurek and Shub, Nature. 1992 May 14;357(6374):173-6). This specificity has been attributed to the requirement
5 that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general,
10 enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to
15 cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over many
20 technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of
25 target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action
30 (Woolf *et al.*, Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7305-9). Thus, the

specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA
5 guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* Nucleic Acids Res. 1992 Sep 11;20(17):4559-65. Examples of hairpin motifs are described by Hampel *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry 1989 Jun 13;28(12):4929-33; Hampel *et al.*, Nucleic
10 Acids Res. 1990 Jan 25;18(2):299-304 and U. S. Patent 5,631,359. An example of the hepatitis δ virus motif is described by Perrotta and Been, Biochemistry. 1992 Dec 1;31(47):11843-52; an example of the RNaseP motif is described by Guerrier-Takada
et al., Cell. 1983 Dec;35(3 Pt 2):849-57; Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and Collins, Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8826-30; Collins and Olive,
15 Biochemistry. 1993 Mar 23;32(11):2795-9); and an example of the Group I intron is described in (U. S. Patent 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have
20 nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as
25 described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that
30 prevent their degradation by serum ribonucleases (see *e.g.*, Int. Pat. Appl. Publ. No. WO

92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells. Ribozymes

expressed from such promoters have been shown to function in mammalian cells. Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as
5 retroviral, semliki forest virus, sindbis virus vectors).

In another embodiment of the invention, peptide nucleic acids (PNAs) compositions are provided. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, *Antisense Nucleic Acid Drug Dev.* 1997 7(4) 431-37). PNA is able to be utilized in a number methods that
10 traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (*Trends Biotechnol* 1997 Jun;15(6):224-9). As such, in certain embodiments, one may prepare PNA sequences
15 that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

PNAs have 2-aminoethyl-glycine linkages replacing the normal
20 phosphodiester backbone of DNA (Nielsen *et al.*, *Science* 1991 Dec 6;254(5037):1497-500; Hanvey *et al.*, *Science*. 1992 Nov 27;258(5087):1481-5; Hyrup and Nielsen, *Bioorg Med Chem.* 1996 Jan;4(1):5-23). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a
25 stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc or Fmoc protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used.

PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or
30 Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*,

Bioorg Med Chem. 1995 Apr;3(4):437-45). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

As with peptide synthesis, the success of a particular PNA synthesis will
5 depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed
10 by the purification of PNAs by reverse-phase high-pressure liquid chromatography, providing yields and purity of product similar to those observed during the synthesis of peptides.

Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that
15 contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and
20 utilized modifications of PNAs (for example, Norton *et al.*, Bioorg Med Chem. 1995 Apr;3(4):437-45; Petersen *et al.*, J Pept Sci. 1995 May-Jun;1(3):175-83; Orum *et al.*, Biotechniques. 1995 Sep;19(3):472-80; Footer *et al.*, Biochemistry. 1996 Aug 20;35(33):10673-9; Griffith *et al.*, Nucleic Acids Res. 1995 Aug 11;23(15):3003-8; Pardridge *et al.*, Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5592-6; Boffa *et al.*,
25 Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1901-5; Gambacorti-Passerini *et al.*, Blood. 1996 Aug 15;88(4):1411-7; Armitage *et al.*, Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12320-5; Seeger *et al.*, Biotechniques. 1997 Sep;23(3):512-7). U.S. Patent No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to
30 therapeutics.

Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (Anal Chem. 1993 Dec 15;65(24):3545-9) and Jensen *et al.* (Biochemistry. 1997 Apr 22;36(16):5072-7). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made
5 by Jensen *et al.* using BIAcore™ technology.

Other applications of PNAs that have been described and will be apparent to the skilled artisan include use in DNA strand invasion, antisense inhibition, mutational analysis, enhancers of transcription, nucleic acid purification, isolation of
10 transcriptionally active genes, blocking of transcription factor binding, genome cleavage, biosensors, *in situ* hybridization, and the like.

Polynucleotide Identification, Characterization and Expression

Polynucleotide compositions of the present invention may be identified, prepared and/or manipulated using any of a variety of well established techniques (see
15 generally, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989, and other like references). For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a
20 representative assay provided herein). Such screens may be performed, for example, using the microarray technology of Affymetrix, Inc. (Santa Clara, CA) according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA
25 prepared from cells expressing the proteins described herein, such as tumor cells.

Many template dependent processes are available to amplify a target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by

reference in its entirety. Briefly, in PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present
5 in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse
10 transcription and PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

Any of a number of other template dependent processes, many of which are variations of the PCR™ amplification technique, are readily known and available in
15 the art. Illustratively, some such methods include the ligase chain reaction (referred to as LCR), described, for example, in Eur. Pat. Appl. Publ. No. 320,308 and U.S. Patent No. 4,883,750; Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880; Strand Displacement Amplification (SDA) and Repair Chain Reaction (RCR). Still other amplification methods are described in Great Britain Pat.
20 Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025. Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. Eur. Pat. Appl. Publ. No. 329,822 describes a nucleic acid amplification process involving cyclically synthesizing single-stranded
25 RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA). PCT Intl. Pat. Appl. Publ. No. WO 89/06700 describes a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. Other amplification methods such as "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara,
30 1989) are also well-known to those of skill in the art.

An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (e.g., a tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification.

- 5 Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

- For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ^{32}P) using well known techniques. A bacterial or
10 bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may
15 be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can
20 then assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

- Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (see Triglia et al., *Nucl. Acids Res.*
25 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a
30 known region. The amplified sequences are typically subjected to a second round of

amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or
5 RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic. 1*:111-19, 1991) and walking PCR (Parker et al.; *Nucl. Acids. Res. 19*:3055-60, 1991). Other methods employing amplification may also be employed
10 to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs
15 may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct
20 expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous
25 in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring
30 sequence.

Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

10 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. 20 (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.) or other comparable techniques available in the art. The composition of the synthetic peptides may be

confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

5 In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing
10 sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York.
15 N.Y.

A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid,
20 or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids); or animal cell systems.

25 The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription
30 and translation elements, including constitutive and inducible promoters, may be used.

For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPO1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses
5 are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

In bacterial systems, any of a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example,
10 when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with
15 sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are
20 soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

25 In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of
30 sequences encoding polypeptides may be driven by any of a number of promoters. For

example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) *Proc. Natl. Acad. Sci.* 91 :3224-3227).

In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which

successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or apt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of

skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

5 A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal
10 antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

15 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions
20 thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used
25 include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

 Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained
30 intracellularly depending on the sequence and/or the vector used. As will be understood

by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

Antibody Compositions, Fragments Thereof and Other Binding Agents

According to another aspect, the present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that exhibit immunological binding to a tumor polypeptide disclosed herein, or to a portion, variant
5 or derivative thereof. An antibody, or antigen-binding fragment thereof, is said to "specifically bind," "immunologically bind," and/or is "immunologically reactive" to a polypeptide of the invention if it reacts at a detectable level (within, for example, an ELISA assay) with the polypeptide, and does not react detectably with unrelated polypeptides under similar conditions.

10 Immunological binding, as used in this context, generally refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K_d) of the interaction, wherein a smaller K_d represents a greater
15 affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and on geometric parameters that equally influence the rate in both directions. Thus, both
20 the "on rate constant" (K_{on}) and the "off rate constant" (K_{off}) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of K_{off}/K_{on} enables cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant K_d . See, generally, Davies et al. (1990) Annual Rev. Biochem. 59:439-473.

25 An "antigen-binding site," or "binding portion" of an antibody refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable
30 regions" which are interposed between more conserved flanking stretches known as

"framework regions," or "FRs". Thus the term "FR" refers to amino acid sequences which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs."

Binding agents may be further capable of differentiating between patients with and without a cancer, such as prostate cancer, using the representative assays provided herein. For example, antibodies or other binding agents that bind to a tumor protein will preferably generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (*e.g.*, blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. Preferably, a statistically significant number of samples with and without the disease will be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation

of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

A number of therapeutically useful molecules are known in the art which comprise antigen-binding sites that are capable of exhibiting immunological binding properties of an antibody molecule. The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the "F(ab)" fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the "F(ab)₂" fragment which comprises both antigen-binding sites. An "Fv" fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecule. Fv fragments are, however, more commonly derived using recombinant techniques known in the art. The Fv fragment includes a non-covalent V_H::V_L heterodimer including an antigen-binding site which retains much of the antigen recognition and binding capabilities of the native antibody molecule. Inbar et al. (1972) Proc. Nat. Acad. Sci. USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; and Ehrlich et al. (1980) Biochem 19:4091-4096.

A single chain Fv ("sFv") polypeptide is a covalently linked V_H::V_L heterodimer which is expressed from a gene fusion including V_H- and V_L-encoding genes linked by a peptide-encoding linker. Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883. A number of methods have been described to discern chemical structures for converting the naturally aggregated--but chemically separated--light and heavy polypeptide chains from an antibody V region into an sFv molecule which will fold into a three dimensional structure substantially similar to the structure of an

antigen-binding site. See, *e.g.*, U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

Each of the above-described molecules includes a heavy chain and a light chain CDR set, respectively interposed between a heavy chain and a light chain FR set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. As used herein, the term "CDR set" refers to the three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as "CDR1," "CDR2," and "CDR3" respectively. An antigen-binding site, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. A polypeptide comprising a single CDR, (*e.g.*, a CDR1, CDR2 or CDR3) is referred to herein as a "molecular recognition unit." Crystallographic analysis of a number of antigen-antibody complexes has demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units are primarily responsible for the specificity of an antigen-binding site.

As used herein, the term "FR set" refers to the four flanking amino acid sequences which frame the CDRs of a CDR set of a heavy or light chain V region. Some FR residues may contact bound antigen; however, FRs are primarily responsible for folding the V region into the antigen-binding site, particularly the FR residues directly adjacent to the CDRs. Within FRs, certain amino residues and certain structural features are very highly conserved. In this regard, all V region sequences contain an internal disulfide loop of around 90 amino acid residues. When the V regions fold into a binding-site, the CDRs are displayed as projecting loop motifs which form an antigen-binding surface. It is generally recognized that there are conserved structural regions of FRs which influence the folded shape of the CDR loops into certain "canonical" structures--regardless of the precise CDR amino acid sequence. Further, certain FR residues are known to participate in non-covalent interdomain contacts which stabilize the interaction of the antibody heavy and light chains.

A number of "humanized" antibody molecules comprising an antigen-binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent V regions and their associated CDRs fused to human constant domains (Winter et al. (1991) Nature 349:293-299; Lobuglio et al. (1989) Proc. Nat. Acad. Sci. USA 86:4220-4224; Shaw et al. (1987) J Immunol. 138:4534-4538; and Brown et al. (1987) Cancer Res. 47:3577-3583), rodent CDRs grafted into a human supporting FR prior to fusion with an appropriate human antibody constant domain (Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536; and Jones et al. (1986) Nature 321:522-525), and rodent CDRs supported by recombinantly veneered rodent FRs (European Patent Publication No. 519,596, published Dec. 23, 1992). These "humanized" molecules are designed to minimize unwanted immunological response toward rodent antihuman antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.

As used herein, the terms "veneered FRs" and "recombinantly veneered FRs" refer to the selective replacement of FR residues from, *e.g.*, a rodent heavy or light chain V region, with human FR residues in order to provide a xenogeneic molecule comprising an antigen-binding site which retains substantially all of the native FR polypeptide folding structure. Veneering techniques are based on the understanding that the ligand binding characteristics of an antigen-binding site are determined primarily by the structure and relative disposition of the heavy and light chain CDR sets within the antigen-binding surface. Davies et al. (1990) Ann. Rev. Biochem. 59:439-473. Thus, antigen binding specificity can be preserved in a humanized antibody only wherein the CDR structures, their interaction with each other, and their interaction with the rest of the V region domains are carefully maintained. By using veneering techniques, exterior (*e.g.*, solvent-accessible) FR residues which are readily encountered by the immune system are selectively replaced with human residues to provide a hybrid molecule that comprises either a weakly immunogenic, or substantially non-immunogenic veneered surface.

The process of veneering makes use of the available sequence data for human antibody variable domains compiled by Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S. Dept. of Health and Human Services, U.S. Government Printing Office, 1987), updates to the Kabat database, and other accessible U.S. and foreign databases (both nucleic acid and protein). Solvent accessibilities of V region amino acids can be deduced from the known three-dimensional structure for human and murine antibody fragments. There are two general steps in veneering a murine antigen-binding site. Initially, the FRs of the variable domains of an antibody molecule of interest are compared with corresponding FR sequences of human variable domains obtained from the above-identified sources. The most homologous human V regions are then compared residue by residue to corresponding murine amino acids. The residues in the murine FR which differ from the human counterpart are replaced by the residues present in the human moiety using recombinant techniques well known in the art. Residue switching is only carried out with moieties which are at least partially exposed (solvent accessible), and care is exercised in the replacement of amino acid residues which may have a significant effect on the tertiary structure of V region domains, such as proline, glycine and charged amino acids.

In this manner, the resultant "veneered" murine antigen-binding sites are thus designed to retain the murine CDR residues, the residues substantially adjacent to the CDRs, the residues identified as buried or mostly buried (solvent inaccessible), the residues believed to participate in non-covalent (*e.g.*, electrostatic and hydrophobic) contacts between heavy and light chain domains, and the residues from conserved structural regions of the FRs which are believed to influence the "canonical" tertiary structures of the CDR loops. These design criteria are then used to prepare recombinant nucleotide sequences which combine the CDRs of both the heavy and light chain of a murine antigen-binding site into human-appearing FRs that can be used to transfect mammalian cells for the expression of recombinant human antibodies which exhibit the antigen specificity of the murine antibody molecule.

In another embodiment of the invention, monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in

this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{211}At , and ^{212}Bi . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred
5 toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a
10 substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an
15 antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which
20 otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups,
25 sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of
30 different cleavable linker groups have been described. The mechanisms for the

intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by
5 serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody.
10 Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent
15 bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for
20 radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For
25 example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

T Cell Compositions

The present invention, in another aspect, provides T cells specific for a tumor polypeptide disclosed herein, or for a variant or derivative thereof. Such cells

may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

T cells may be stimulated with a polypeptide, polynucleotide encoding a polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide of interest. Preferably, a tumor polypeptide or polynucleotide of the invention is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a polypeptide of the present invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., *Cancer Res.* 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a tumor polypeptide (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 days will typically result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (*see* Coligan et

al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a tumor polypeptide, polynucleotide or polypeptide-expressing APC may be CD4⁺ and/or CD8⁺. Tumor polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to a tumor polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a tumor polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of the tumor polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

Pharmaceutical Compositions

In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell and/or antibody compositions disclosed herein in pharmaceutically-acceptable carriers for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

It will be understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, such as, *e.g.*, other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as

described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

Therefore, in another aspect of the present invention, pharmaceutical compositions are provided comprising one or more of the polynucleotide, polypeptide, antibody, and/or T-cell compositions described herein in combination with a physiologically acceptable carrier. In certain preferred embodiments, the pharmaceutical compositions of the invention comprise immunogenic polynucleotide and/or polypeptide compositions of the invention for use in prophylactic and therapeutic vaccine applications. Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Generally, such compositions will comprise one or more polynucleotide and/or polypeptide compositions of the present invention in combination with one or more immunostimulants.

It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable salts of the polynucleotides and polypeptides of the invention. Such salts can be prepared, for example, from pharmaceutically acceptable non-toxic bases, including organic bases (*e.g.*, salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (*e.g.*, sodium, potassium, lithium, ammonium, calcium and magnesium salts).

In another embodiment, illustrative immunogenic compositions, *e.g.*, vaccine compositions, of the present invention comprise DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the polynucleotide may be administered within any of a variety of delivery systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable promoter and terminating signal). Alternatively, bacterial delivery systems may involve

the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (*e.g.*, U.S. Pat. No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A. D. (1990) *Human Gene Therapy* 1:5-14; Scarpa et al. (1991) *Virology* 180:849-852; Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109.

In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett et al. (1993) *J. Virol.* 67:5911-5921; Mittereder et al. (1994) *Human Gene Therapy* 5:717-729; Seth et al. (1994) *J. Virol.* 68:933-940; Barr et al. (1994) *Gene Therapy* 1:51-58; Berkner, K. L. (1988) *BioTechniques* 6:616-629; and Rich et al. (1993) *Human Gene Therapy* 4:461-476).

Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, *e.g.*, U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines 90* (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129;

Kotin, R. M. (1994) *Human Gene Therapy* 5:793-801; Shelling and Smith (1994) *Gene Therapy* 1:165-169; and Zhou et al. (1994) *J. Exp. Med.* 179:1867-1875.

Additional viral vectors useful for delivering the polynucleotides encoding polypeptides of the present invention by gene transfer include those derived
5 from the pox family of viruses, such as vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is
10 then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK.sup.(-) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

15 A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in
20 that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level,
25 transient, cytoplasmic production of large quantities of RNA and its translation products. See, e.g., Elroy-Stein and Moss, *Proc. Natl. Acad. Sci. USA* (1990) 87:6743-6747; Fuerst et al. *Proc. Natl. Acad. Sci. USA* (1986) 83:8122-8126.

Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox
30 viruses, expressing immunogens from mammalian pathogens, are known to confer

protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and therefore are not infective in mammalian cells. Methods for producing recombinant

5 Avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, *e.g.*, WO 91/12882; WO 89/03429; and WO 92/03545.

Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in

10 U.S. Patent Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Patent Nos. 5,505,947 and 5,643,576.

Moreover, molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al. *J. Biol. Chem.* (1993) 268:6866-6869 and Wagner et

15 al. *Proc. Natl. Acad. Sci. USA* (1992) 89:6099-6103, can also be used for gene delivery under the invention.

Additional illustrative information on these and other known viral-based delivery systems can be found, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner

20 et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al.,

25 *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993.

In certain embodiments, a polynucleotide may be integrated into the genome of a target cell. This integration may be in a specific location and orientation *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the

30 polynucleotide may be stably maintained in the cell as a separate, episomal segment of

DNA. Such polynucleotide segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. The manner in which the expression construct is delivered to a cell and where in the cell the polynucleotide remains is dependent on the type of expression
5 construct employed.

In another embodiment of the invention, a polynucleotide is administered/delivered as "naked" DNA, for example as described in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable
10 beads, which are efficiently transported into the cells.

In still another embodiment, a composition of the present invention can be delivered via a particle bombardment approach, many of which have been described. In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK)
15 and Powderject Vaccines Inc. (Madison, WI), some examples of which are described in U.S. Patent Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device,
20 propelling the particles into a target tissue of interest.

In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include those provided by Bioject, Inc. (Portland, OR), some examples of which are described in U.S. Patent Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639
25 and 5,993,412.

According to another embodiment, the pharmaceutical compositions described herein will comprise one or more immunostimulants in addition to the immunogenic polynucleotide, polypeptide, antibody, T-cell and/or APC compositions of this invention. An immunostimulant refers to essentially any substance that enhances
30 or potentiates an immune response (antibody and/or cell-mediated) to an exogenous

antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins.

5 Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated

10 sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Within certain embodiments of the invention, the adjuvant composition

15 is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (*e.g.*, IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as

20 provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman,

25 *Ann. Rev. Immunol.* 7:145-173, 1989.

Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL[®] adjuvants are available from Corixa Corporation (Seattle, WA; *see*, for example, US

30 Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing

oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by

5 Sato et al., *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example

10 combinations of at least two of the following group comprising QS21, QS7, Quil A, β -escin, or digitonin.

Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix,

15 particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or

20 suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol^R to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one preferred embodiment, the adjuvant system includes the


25 combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL[®] adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-

MPL[®] adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of
5 CpG and QS21 is disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series
10 of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn[®]; Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene
15 ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula



wherein, n is 1-50, A is a bond or $-\text{C}(\text{O})-$, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

20 One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably
25 from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck
30 index (12th edition: entry 7717). These adjuvant molecules are described in WO

99/52549. The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

5 According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or
10 maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

15 Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (*see* Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In
20 general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex*
25 *vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see* Zitvogel et al., *Nature Med.* 4:594-600, 1998).

 Dendritic cells and progenitors may be obtained from peripheral blood,
30 bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph

nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from
5 peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature"
10 cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature
15 phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide of the
20 invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a pharmaceutical composition comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be
25 administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or
30 progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or

RNA; or with antigen-expressing recombinant bacterium or viruses (*e.g.*, vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (*e.g.*, a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated
5 immunological partner, separately or in the presence of the polypeptide.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will typically vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration,
10 including for example, topical, oral, nasal, mucosal, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

Carriers for use within such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release.
15 In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such compositions is well within the level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers
20 include supramolecular biovectors, which comprise a non-liquid hydrophilic core (*e.g.*, a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (*see e.g.*, U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends
25 upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

In another illustrative embodiment, biodegradable microspheres (*e.g.*, polylactate polyglycolate) are employed as carriers for the compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S.
30 Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763;

5,814,344, 5,407,609 and 5,942,252. Modified hepatitis B core protein carrier systems, such as described in WO/99 40934, and references cited therein, will also be useful for many applications. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

The pharmaceutical compositions of the invention will often further comprise one or more buffers (*e.g.*, neutral buffered saline or phosphate buffered saline), carbohydrates (*e.g.*, glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (*e.g.*, aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate.

The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they

may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (see, for example, Mathiowitz *et al.*, Nature 5 1997 Mar 27;386(6623):410-4; Hwang *et al.*, Crit Rev Ther Drug Carrier Syst 1998;15(3):243-84; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451). Tablets, troches, pills, capsules and the like may also contain any of a variety of additional components, for example, a binder, such as gum tragacanth, acacia, 10 cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to 15 materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds 20 may be incorporated into sustained-release preparation and formulations.

Typically, these formulations will contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of 25 active compound(s) in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a 30 variety of dosages and treatment regimens may be desirable.

For oral administration, the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

10 In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363. In certain embodiments, solutions of the active compounds
15 as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

20 Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (for example, see U. S. Patent 5,466,468). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and
25 storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as
30 lecithin, by the maintenance of the required particle size in the case of dispersion and/or

by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- 5 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered
10 isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml
15 of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations will of course preferably meet sterility, pyrogenicity, and the general safety and purity
20 standards as required by FDA Office of Biologics standards.

In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for
25 example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be

administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption
5 delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. The phrase
10 "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the
15 lungs *via* nasal aerosol sprays has been described, *e.g.*, in U. S. Patent 5,756,353 and U. S. Patent 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, J Controlled Release 1998 Mar 2;52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871) are also well-known in the pharmaceutical arts. Likewise, illustrative transmucosal drug delivery in the form of
20 a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045.

In certain embodiments, liposomes, nanocapsules, microparticles, lipid particles, vesicles, and the like, are used for the introduction of the compositions of the present invention into suitable host cells/organisms. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid
25 particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like. Alternatively, compositions of the present invention can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

The formation and use of liposome and liposome-like preparations as potential drug carriers is generally known to those of skill in the art (see for example,
30 Lasic, Trends Biotechnol 1998 Jul;16(7):307-21; Takakura, Nippon Rinsho 1998

Mar;56(3):691-5; Chandran *et al.*, Indian J Exp Biol. 1997 Aug;35(8):801-9; Margalit, Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61; U.S. Patent 5,567,434; U.S. Patent 5,552,157; U.S. Patent 5,565,213; U.S. Patent 5,738,868 and U.S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

5 Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, J Biol Chem. 1990 Sep 25;265(27):16337-42; Muller *et al.*, DNA Cell Biol. 1990 Apr;9(3):221-9). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery
10 systems. Liposomes have been used effectively to introduce genes, various drugs, radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, the use of liposomes does not appear to be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

15 In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)).

 Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the
20 present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (see, for example, Quintanar-Guerrero *et al.*, Drug Dev Ind Pharm. 1998 Dec;24(12):1113-28). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μ m) may be designed using polymers able to be degraded *in vivo*. Such particles can be made as described, for
25 example, by Couvreur *et al.*, Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20; zur Muhlen *et al.*, Eur J Pharm Biopharm. 1998 Mar;45(2):149-55; Zambaux *et al.* J Controlled Release. 1998 Jan 2;50(1-3):31-40; and U. S. Patent 5,145,684.

Cancer Therapeutic Methods

In further aspects of the present invention, the pharmaceutical compositions described herein may be used for the treatment of cancer, particularly for the immunotherapy of prostate cancer. Within such methods, the pharmaceutical compositions described herein are administered to a patient, typically a warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. As discussed above, administration of the pharmaceutical compositions may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The

polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (*see, for example, Cheever et al., Immunological Reviews 157:177, 1997*).

Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g., intracutaneous,*

intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25 μ g to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

Cancer Detection and Diagnostic Compositions, Methods and Kits

In general, a cancer may be detected in a patient based on the presence of one or more prostate tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies)

obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as prostate cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the
5 biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a prostate tumor sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue

There are a variety of assay formats known to those of ordinary skill in
10 the art for using a binding agent to detect polypeptide markers in a sample. *See, e.g.,* Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c)
15 comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding
20 agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized
25 binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length prostate tumor proteins and polypeptide portions thereof to which the binding agent binds, as
30 described above.

The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μ g, and preferably about 100 ng to about 1 μ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (*see, e.g.*, Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized

on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a
5 different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically
10 blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact
15 time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve
20 equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM. The second
25 antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of
30 binding that occurs over a period of time. Unbound detection reagent is then removed

and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

10 To determine the presence or absence of a cancer, such as prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with
15 samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985,
20 p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a
25 signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such tumor protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (e.g., 5 - 25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of tumor polypeptide to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a tumor protein of the invention that is at least 10

nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the
5 diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence as disclosed herein. Techniques for both PCR based assays and hybridization assays are well known in the art (*see, for example, Mullis et al., Cold*
10 *Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules.
15 PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold
20 or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above
25 for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the

cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound
5 binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific
10 for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

15 The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a tumor protein.
20 Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

25 Alternatively, a kit may be designed to detect the level of mRNA encoding a tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be

present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a tumor protein.

The following Examples are offered by way of illustration and not by way of limitation.

5

EXAMPLES

EXAMPLE 1

ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC POLYPEPTIDES

10

This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library was constructed from prostate tumor poly A⁺ RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A⁺ RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, CA) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax *E. coli* DH10B cells (BRL Life Technologies) by electroporation.

Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis.

30

The prostate tumor library contained 1.64×10^7 independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained 3.3×10^6 independent colonies, with 69% of clones having inserts and the average insert size being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.

cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara *et al.* (*Blood*, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70 μ g) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 μ l of H₂O, heat-denatured and mixed with 100 μ l (100 μ g) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 μ l) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 μ l H₂O to form the driver DNA.

To form the tracer DNA, 10 μ g prostate tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 μ l H₂O. Tracer DNA was mixed with 15 μ l driver DNA and 20 μ l of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 μ l H₂O, mixed with 8 μ l driver DNA and 20 μ l of 2 x hybridization buffer, and subjected to a hybridization at 68

⁰C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK⁺ (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax *E. coli* DH10B cells by electroporation to generate a prostate tumor specific subtracted
5 cDNA library (referred to as "prostate subtraction 1").

To analyze the subtracted cDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems
10 Division Automated Sequencer Model 373A (Foster City, CA). Six cDNA clones, hereinafter referred to as F1-13, F1-12, F1-16, H1-1, H1-9 and H1-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3' and 5' cDNA sequences for F1-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3' cDNA sequences for F1-13, F1-16, H1-1, H1-9 and H1-4 being provided
15 in SEQ ID NO: 1 and 4-7, respectively.

The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, F1-13, F1-16, H1-1, and H1-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA),
20 human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. H1-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for F1-12 were found.

Subsequent studies led to the isolation of a full-length cDNA sequence
25 for F1-12 (also referred to as P504S). This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108. cDNA splice variants of P504S are provided in SEQ ID NO: 600-605.

To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described
30 above with the normal pancreas cDNA library and with the three most abundant genes

in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1 µg each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNA3.1 were added to the driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the "subtracted prostate tumor specific cDNA library with spike".

Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3' and 5' cDNA sequences for the clones referred to as J1-17, L1-12, N1-1862, J1-13, J1-19, J1-25, J1-24, K1-58, K1-63, L1-4 and L1-14 are provided in SEQ ID NOS: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-27 and 28-29, respectively. The determined 3' cDNA sequences for the clones referred to as J1-12, J1-16, J1-21, K1-48, K1-55, L1-2, L1-6, N1-1858, N1-1860, N1-1861, N1-1864 are provided in SEQ ID NOS: 30-40, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (J1-17, L1-12 and N1-1862; SEQ ID NOS: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (J1-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein, and the other (K1-48; SEQ ID NO:33) was determined to have some homology to *R. norvegicus* mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (J1-16, K1-55, L1-6 and N1-1864; SEQ ID NOS:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (J1-21 and N1-1860; SEQ ID NOS: 32 and 38, respectively) were found to show some homology to non-human sequences, and two (L1-2 and N1-1861; SEQ ID NOS: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides J1-13, J1-19, J1-24, J1-25, K1-58, K1-63, L1-4, L1-14 (SEQ ID NOS: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29, respectively).

Subsequent studies led to the isolation of full length cDNA sequences for J1-17, L1-12 and N1-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114. L1-12 is also referred to as P501S. A cDNA splice variant of P501S is provided in SEQ ID NO: 606.

- 5 In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (referred to as "prostate subtraction 2"). The determined cDNA sequences for these clones, hereinafter referred to as U1-3064, U1-3065, V1-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively.
- 10 Comparison of the determined sequences with those in the gene bank revealed no significant homologies to U1-3065.

- A second subtraction with spike (referred to as "prostate subtraction spike 2") was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, J1-17,
- 15 pulmonary surfactant-associated protein, mitochondrial DNA, cytochrome c oxidase subunit II, N1-1862, autonomously replicating sequence, L1-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as V1-3686, R1-2330, 1B-3976 and V1-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO: 73-76, respectively. Comparison of these sequences
- 20 with those in the gene bank revealed no significant homologies to V1-3686 and R1-2330.

- Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones,
- 25 referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4810, 1I-4811, 1J-4876, 1K-4884 and 1K-4896. The determined cDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 1I-4807, 1J-4876 and
- 30 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively). Further analysis of the

isolated clones led to the determination of extended cDNA sequences for 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4807, 1J-4876, 1K-4884 and 1K-4896, provided in SEQ ID NOS: 179-188 and 191-193, respectively, and to the determination of additional partial cDNA sequences for 1I-4810
5 and 1I-4811, provided in SEQ ID NOS: 189 and 190, respectively.

Additional studies with prostate subtraction spike 2 resulted in the isolation of three more clones. Their sequences were determined as described above and compared to the most recent GenBank. All three clones were found to have homology to known genes, which are Cysteine-rich protein, KIAA0242, and KIAA0280
10 (SEQ ID NO: 317, 319, and 320, respectively). Further analysis of these clones by Synteni microarray (Synteni, Palo Alto, CA) demonstrated that all three clones were over-expressed in most prostate tumors and prostate BPH, as well as in the majority of normal prostate tissues tested, but low expression in all other normal tissues.

An additional subtraction was performed by subtracting a normal
15 prostate cDNA library with normal pancreas cDNA (referred to as "prostate subtraction 3"). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively). Further analysis of the
20 isolated clones led to the determination of extended cDNA sequences for 1G-4761, 1G-4762, 1H-4766 and 1H-4772 provided in SEQ ID NOS: 194-196 and 199, respectively, and to the determination of additional partial cDNA sequences for 1H-4770 and 1H-4771, provided in SEQ ID NOS: 197 and 198, respectively.

Subtraction of a prostate tumor cDNA library, prepared from a pool of
25 polyA+ RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS:
30 103 and 104, respectively). Further analysis of the isolated clones led to the

determination of extended cDNA sequences for 1D-4309, 1D-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280, provided in SEQ ID NOS: 200-206, respectively.

cDNA clones isolated in prostate subtraction 1 and prostate subtraction
5 2, described above, were colony PCR amplified and their mRNA expression levels in prostate tumor, normal prostate and in various other normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted onto slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested,
10 reverse transcribed, and fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity. Two clones (referred to as P509S and P510S) were found to be over-expressed in prostate tumor and normal prostate and expressed at low levels in all other
15 normal tissues tested (liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon). The determined cDNA sequences for P509S and P510S are provided in SEQ ID NO: 223 and 224, respectively. Comparison of these sequences with those in the gene bank as described above, revealed some homology to previously
20 identified ESTs.

Additional studies led to the isolation of the full-length cDNA sequence for P509S. This sequence is provided in SEQ ID NO: 332, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 339. Two variant full-length cDNA sequences for P510S are provided in SEQ ID NO: 535 and 536, with the
25 corresponding predicted amino acid sequences being provided in SEQ ID NO: 537 and 538, respectively. Additional splice variants of P510S are provided in SEQ ID NO: 598 and 599.

EXAMPLE 2

DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE-SPECIFIC POLYPEPTIDES

Using gene specific primers, mRNA expression levels for the
5 representative prostate-specific polypeptides F1-16, H1-1, J1-17 (also referred to as P502S), L1-12 (also referred to as P501S), F1-12 (also referred to as P504S) and N1-1862 (also referred to as P503S) were examined in a variety of normal and tumor tissues using RT-PCR.

Briefly, total RNA was extracted from a variety of normal and tumor
10 tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 μ g of total RNA with SuperScript II reverse transcriptase (BRL Life Technologies) at 42 °C for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, β -actin was used as an internal control for each of the tissues examined. First, serial dilutions of the
15 first strand cDNAs were prepared and RT-PCR assays were performed using β -actin specific primers. A dilution was then chosen that enabled the linear range amplification of the β -actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the β -actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was
20 minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.

mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver,
25 lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. F1-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. H1-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon
30 and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin,

small intestine, bone marrow, and was not detected in the other tissues tested. J1-17 (P502S) and L1-12 (P501S) appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in prostate tumor and normal prostate but at low to undetectable levels in all the other tissues examined. N1-1862 (P503S) was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that F1-16, H1-1, J1-17 (P502S), N1-1862 (P503S) and L1-12 (P501S) are either prostate specific or are expressed at significantly elevated levels in prostate.

Further RT-PCR studies showed that F1-12 (P504S) is over-expressed in 60% of prostate tumors, detectable in normal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. U1-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not detectable in normal tissues.

RT-PCR characterization of R1-2330, U1-3064 and 1D-4279 showed that these three antigens are over-expressed in prostate and/or prostate tumors.

Northern analysis with four prostate tumors, two normal prostate samples, two BPH prostates, and normal colon, kidney, liver, lung, pancreas, skeletal muscle, brain, stomach, testes, small intestine and bone marrow, showed that L1-12 (P501S) is over-expressed in prostate tumors and normal prostate, while being undetectable in other normal tissues tested. J1-17 (P502S) was detected in two prostate tumors and not in the other tissues tested. N1-1862 (P503S) was found to be over-expressed in three prostate tumors and to be expressed in normal prostate, colon and kidney, but not in other tissues tested. F1-12 (P504S) was found to be highly expressed in two prostate tumors and to be undetectable in all other tissues tested.

The microarray technology described above was used to determine the expression levels of representative antigens described herein in prostate tumor, breast tumor and the following normal tissues: prostate, liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon. L1-12 (P501S) was found to be

over-expressed in normal prostate and prostate tumor, with some expression being detected in normal skeletal muscle. Both J1-12 and F1-12 (P504S) were found to be over-expressed in prostate tumor, with expression being lower or undetectable in all other tissues tested. N1-1862 (P503S) was found to be expressed at high levels in prostate tumor and normal prostate, and at low levels in normal large intestine and normal colon, with expression being undetectable in all other tissues tested. R1-2330 was found to be over-expressed in prostate tumor and normal prostate, and to be expressed at lower levels in all other tissues tested. 1D-4279 was found to be over-expressed in prostate tumor and normal prostate, expressed at lower levels in normal spinal cord, and to be undetectable in all other tissues tested.

Further microarray analysis to specifically address the extent to which P501S (SEQ ID NO: 110) was expressed in breast tumor revealed moderate over-expression not only in breast tumor, but also in metastatic breast tumor (2/31), with negligible to low expression in normal tissues. This data suggests that P501S may be over-expressed in various breast tumors as well as in prostate tumors.

The expression levels of 32 ESTs (expressed sequence tags) described by Vasmatazis *et al.* (*Proc. Natl. Acad. Sci. USA* 95:300-304, 1998) in a variety of tumor and normal tissues were examined by microarray technology as described above. Two of these clones (referred to as P1000C and P1001C) were found to be over-expressed in prostate tumor and normal prostate, and expressed at low to undetectable levels in all other tissues tested (normal aorta, thymus, resting and activated PBMC, epithelial cells, spinal cord, adrenal gland, fetal tissues, skin, salivary gland, large intestine, bone marrow, liver, lung, dendritic cells, stomach, lymph nodes, brain, heart, small intestine, skeletal muscle, colon and kidney). The determined cDNA sequences for P1000C and P1001C are provided in SEQ ID NO: 384 and 472, respectively. The sequence of P1001C was found to show some homology to the previously isolated Human mRNA for JM27 protein. Subsequent comparison of the sequence of SEQ ID NO: 384 with sequences in the public databases, led to the identification of a full-length cDNA sequence of P1000C (SEQ ID NO: 786), which encodes a 492 amino acid sequence. Analysis of the amino acid sequence using the PSORT II program led to the

identification of a putative transmembrane domain from amino acids 84-100. The cDNA sequence of the open reading frame of P1000C, including the stop codon, is provided in SEQ ID NO: 787, with the open reading frame without the stop codon being provided in SEQ ID NO: 788. The full-length amino acid sequence of P1000C is
5 provided in SEQ ID NO: 789. SEQ ID NO: 790 and 791 represent amino acids 1-100 and 100-492 of P1000C, respectively.

The expression of the polypeptide encoded by the full length cDNA sequence for F1-12 (also referred to as P504S; SEQ ID NO: 108) was investigated by immunohistochemical analysis. Rabbit-anti-P504S polyclonal antibodies were
10 generated against the full length P504S protein by standard techniques. Subsequent isolation and characterization of the polyclonal antibodies were also performed by techniques well known in the art. Immunohistochemical analysis showed that the P504S polypeptide was expressed in 100% of prostate carcinoma samples tested (n=5).

The rabbit-anti-P504S polyclonal antibody did not appear to label benign
15 prostate cells with the same cytoplasmic granular staining, but rather with light nuclear staining. Analysis of normal tissues revealed that the encoded polypeptide was found to be expressed in some, but not all normal human tissues. Positive cytoplasmic staining with rabbit-anti-P504S polyclonal antibody was found in normal human kidney, liver, brain, colon and lung-associated macrophages, whereas heart and bone marrow were
20 negative.

This data indicates that the P504S polypeptide is present in prostate cancer tissues, and that there are qualitative and quantitative differences in the staining between benign prostatic hyperplasia tissues and prostate cancer tissues, suggesting that this polypeptide may be detected selectively in prostate tumors and therefore be useful
25 in the diagnosis of prostate cancer.

EXAMPLE 3

ISOLATION AND CHARACTERIZATION OF PROSTATE-SPECIFIC
POLYPEPTIDES BY PCR-BASED SUBTRACTION

5 A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The
10 resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, WI) and transformed into XL-1 Blue MRF' *E. coli* (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.

Fifty-nine positive clones were sequenced. Comparison of the DNA
15 sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, P18, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79 and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO: 41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID
20 NO: 46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate.

Further studies employing the sequence of SEQ ID NO: 67 as a probe in standard full-length cloning methods, resulted in the isolation of three cDNA sequences
25 which appear to be splice variants of P80 (also known as P704P). These sequences are provided in SEQ ID NO: 620-622.

Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant homologies to known sequences. The determined cDNA
30 sequences for these clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145,

147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. Larger cDNA clones
5 containing the P20 sequence represent splice variants of a gene referred to as P703P. The determined DNA sequence for the variants referred to as DE1, DE13 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The determined cDNA sequence for an extended spliced form of P703 is
10 provided in SEQ ID NO: 225. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.

mRNA Expression levels for representative clones in tumor tissues (prostate (n=5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n=2), ovary (n=2), skeletal muscle, skin, stomach, small intestine
15 and brain), and activated and non-activated PBMC was determined by RT-PCR as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.

P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed
20 comparable expression. P20, a portion of the P703P gene, was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of P18 was found in normal prostate, prostate tumor and breast tumor
25 compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal
30 prostate and prostate tumor, compared to six of twelve other normal tissues tested.

Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to the majority of normal tissues. However, substantial expression of P29 was observed in normal colon and
5 normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.

Further studies resulted in the isolation of twelve additional clones, hereinafter referred to as 10-d8, 10-h10, 11-c8, 7-g6, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3, 8-
10 h11, 9-f12 and 9-f3. The determined DNA sequences for 10-d8, 10-h10, 11-c8, 8-d4, 8-d9, 8-h11, 9-f12 and 9-f3 are provided in SEQ ID NO: 207, 208, 209, 216, 217, 220, 221 and 222, respectively. The determined forward and reverse DNA sequences for 7-g6, 8-b5, 8-b6 and 8-g3 are provided in SEQ ID NO: 210 and 211; 212 and 213; 214 and 215; and 218 and 219, respectively. Comparison of these sequences with those in
15 the gene bank revealed no significant homologies to the sequence of 9-f3. The clones 10-d8, 11-c8 and 8-h11 were found to show some homology to previously isolated ESTs, while 10-h10, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3 and 9-f12 were found to show some homology to previously identified genes. Further characterization of 7-G6 and 8-G3 showed identity to the known genes PAP and PSA, respectively.

20 mRNA expression levels for these clones were determined using the micro-array technology described above. The clones 7-G6, 8-G3, 8-B5, 8-B6, 8-D4, 8-D9, 9-F3, 9-F12, 9-H3, 10-A2, 10-A4, 11-C9 and 11-F2 were found to be over-expressed in prostate tumor and normal prostate, with expression in other tissues tested being low or undetectable. Increased expression of 8-F11 was seen in prostate tumor
25 and normal prostate, bladder, skeletal muscle and colon. Increased expression of 10-H10 was seen in prostate tumor and normal prostate, bladder, lung, colon, brain and large intestine. Increased expression of 9-B1 was seen in prostate tumor, breast tumor, and normal prostate, salivary gland, large intestine and skin, with increased expression of 11-C8 being seen in prostate tumor, and normal prostate and large intestine.

An additional cDNA fragment derived from the PCR-based normal prostate subtraction, described above, was found to be prostate specific by both micro-array technology and RT-PCR. The determined cDNA sequence of this clone (referred to as 9-A11) is provided in SEQ ID NO: 226. Comparison of this sequence with those
5 in the public databases revealed 99% identity to the known gene HOXB13.

Further studies led to the isolation of the clones 8-C6 and 8-H7. The determined cDNA sequences for these clones are provided in SEQ ID NO: 227 and 228, respectively. These sequences were found to show some homology to previously isolated ESTs.

10 PCR and hybridization-based methodologies were employed to obtain longer cDNA sequences for clone P20 (also referred to as P703P), yielding three additional cDNA fragments that progressively extend the 5' end of the gene. These fragments, referred to as P703PDE5, P703P6.26, and P703PX-23 (SEQ ID NO: 326, 328 and 330, with the predicted corresponding amino acid sequences being provided in
15 SEQ ID NO: 327, 329 and 331, respectively) contain additional 5' sequence. P703PDE5 was recovered by screening of a cDNA library (#141-26) with a portion of P703P as a probe. P703P6.26 was recovered from a mixture of three prostate tumor cDNAs and P703PX_23 was recovered from cDNA library (#438-48). Together, the additional sequences include all of the putative mature serine protease along with part of
20 the putative signal sequence. The full-length cDNA sequence for P703P is provided in SEQ ID NO: 524, with the corresponding amino acid sequence being provided in SEQ ID NO: 525.

Using computer algorithms, the following regions of P703P were predicted to represent potential HLA A2-binding CTL epitopes: amino acids 164-172
25 of SEQ ID NO: 525 (SEQ ID NO: 723); amino acids 160-168 of SEQ ID NO: 525 (SEQ ID NO: 724); amino acids 239-247 of SEQ ID NO: 525 (SEQ ID NO: 725); amino acids 118-126 of SEQ ID NO: 525 (SEQ ID NO: 726); amino acids 112-120 of SEQ ID NO: 525 (SEQ ID NO: 727); amino acids 155-164 of SEQ ID NO: 525 (SEQ ID NO: 728); amino acids 117-126 of SEQ ID NO: 525 (SEQ ID NO: 729); amino acids
30 164-173 of SEQ ID NO: 525 (SEQ ID NO: 730); amino acids 154-163 of SEQ ID NO:

525 (SEQ ID NO: 731); amino acids 163-172 of SEQ ID NO: 525 (SEQ ID NO: 732); amino acids 58-66 of SEQ ID NO: 525 (SEQ ID NO: 733); and amino acids 59-67 of SEQ ID NO: 525 (SEQ ID NO: 734).

P703P was found to show some homology to previously identified
5 proteases, such as thrombin. The thrombin receptor has been shown to be preferentially expressed in highly metastatic breast carcinoma cells and breast carcinoma biopsy samples. Introduction of thrombin receptor antisense cDNA has been shown to inhibit the invasion of metastatic breast carcinoma cells in culture. Antibodies against thrombin receptor inhibit thrombin receptor activation and thrombin-induced platelet
10 activation. Furthermore, peptides that resemble the receptor's tethered ligand domain inhibit platelet aggregation by thrombin. P703P may play a role in prostate cancer through a protease-activated receptor on the cancer cell or on stromal cells. The potential trypsin-like protease activity of P703P may either activate a protease-activated receptor on the cancer cell membrane to promote tumorigenesis or activate a protease-
15 activated receptor on the adjacent cells (such as stromal cells) to secrete growth factors and/or proteases (such as matrix metalloproteinases) that could promote tumor angiogenesis, invasion and metastasis. P703P may thus promote tumor progression and/or metastasis through the activation of protease-activated receptor. Polypeptides and antibodies that block the P703P-receptor interaction may therefore be usefully
20 employed in the treatment of prostate cancer.

To determine whether P703P expression increases with increased severity of Gleason grade, an indicator of tumor stage, quantitative PCR analysis was performed on prostate tumor samples with a range of Gleason scores from 5 to > 8. The mean level of P703P expression increased with increasing Gleason score, indicating that
25 P703P expression may correlate with increased disease severity.

Further studies using a PCR-based subtraction library of a prostate tumor pool subtracted against a pool of normal tissues (referred to as JP: PCR subtraction) resulted in the isolation of thirteen additional clones, seven of which did not share any significant homology to known GenBank sequences. The determined cDNA sequences
30 for these seven clones (P711P, P712P, novel 23, P774P, P775P, P710P and P768P) are

provided in SEQ ID NO: 307-311, 313 and 315, respectively. The remaining six clones (SEQ ID NO: 316 and 321-325) were shown to share some homology to known genes. By microarray analysis, all thirteen clones showed three or more fold over-expression in prostate tissues, including prostate tumors, BPH and normal prostate as compared to
5 normal non-prostate tissues. Clones P711P, P712P, novel 23 and P768P showed over-expression in most prostate tumors and BPH tissues tested (n=29), and in the majority of normal prostate tissues (n=4), but background to low expression levels in all normal tissues. Clones P774P, P775P and P710P showed comparatively lower expression and expression in fewer prostate tumors and BPH samples, with negative to low expression
10 in normal prostate.

Further studies led to the isolation of an extended cDNA sequence for P712P (SEQ ID NO: 552). The amino acid sequences encoded by 16 predicted open reading frames present within the sequence of SEQ ID NO: 552 are provided in SEQ ID NO: 553-568.

15 The full-length cDNA for P711P was obtained by employing the partial sequence of SEQ ID NO: 307 to screen a prostate cDNA library. Specifically, a directionally cloned prostate cDNA library was prepared using standard techniques. One million colonies of this library were plated onto LB/Amp plates. Nylon membrane filters were used to lift these colonies, and the cDNAs which were picked up by these
20 filters were denatured and cross-linked to the filters by UV light. The P711P cDNA fragment of SEQ ID NO: 307 was radio-labeled and used to hybridize with these filters. Positive clones were selected, and cDNAs were prepared and sequenced using an automatic Perkin Elmer/Applied Biosystems sequencer. The determined full-length sequence of P711P is provided in SEQ ID NO: 382, with the corresponding predicted
25 amino acid sequence being provided in SEQ ID NO: 383.

Using PCR and hybridization-based methodologies, additional cDNA sequence information was derived for two clones described above, 11-C9 and 9-F3, herein after referred to as P707P and P714P, respectively (SEQ ID NO: 333 and 334). After comparison with the most recent GenBank, P707P was found to be a splice
30 variant of the known gene HoxB13. In contrast, no significant homologies to P714P

were found. Further studies employing the sequence of SEQ ID NO: 334 as a probe in standard full-length cloning methods, resulted in an extended cDNA sequence for P714P. This sequence is provided in SEQ ID NO: 619. This sequence was found to show some homology to the gene that encodes human ribosomal L23A protein.

5 Clones 8-B3, P89, P98, P130 and P201 (as disclosed in U.S. Patent Application No. 09/020,956, filed February 9, 1998) were found to be contained within one contiguous sequence, referred to as P705P (SEQ ID NO: 335, with the predicted amino acid sequence provided in SEQ ID NO: 336), which was determined to be a splice variant of the known gene NKX 3.1.

10 Further studies on P775P resulted in the isolation of four additional sequences (SEQ ID NO: 473-476) which are all splice variants of the P775P gene. The sequence of SEQ ID NO: 474 was found to contain two open reading frames (ORFs). The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 477 and 478. The cDNA sequence of SEQ ID NO: 475 was found to contain an
15 ORF which encodes the amino acid sequence of SEQ ID NO: 479. The cDNA sequence of SEQ ID NO: 473 was found to contain four ORFs. The predicted amino acid sequences encoded by these ORFs are provided in SEQ ID NO: 480-483. Additional splice variants of P775P are provided in SEQ ID NO: 593-597.

Subsequent studies led to the identification of a genomic region on
20 chromosome 22q11.2, known as the Cat Eye Syndrome region, that contains the five prostate genes P704P, P712P, P774P, P775P and B305D. The relative location of each of these five genes within the genomic region is shown in Fig. 10. This region may therefore be associated with malignant tumors, and other potential tumor genes may be contained within this region. These studies also led to the identification of a potential
25 open reading frame (ORF) for P775P (provided in SEQ ID NO: 533), which encodes the amino acid sequence of SEQ ID NO: 534.

Comparison of the clone of SEQ ID NO: 325 (referred to as P558S) with sequences in the GenBank and GeneSeq DNA databases showed that P558S is identical to the prostate-specific transglutaminase gene, which is known to have two forms. The
30 full-length sequences for the two forms are provided in SEQ ID NO: 630 and 631, with

the corresponding amino acid sequences being provided in SEQ ID NO: 632 and 633, respectively. The cDNA sequence of SEQ ID NO: 631 has a 15 pair base insert, resulting in a 5 amino acid insert in the corresponding amino acid sequence (SEQ ID NO: 633). This insert is not present in the sequence of SEQ ID NO: 630.

5 Further studies on P768P (SEQ ID NO: 315) led to the identification of the putative full-length open reading frame (ORF). The cDNA sequence of the ORF with stop codon is provided in SEQ ID NO: 764. The cDNA sequence of the ORF without stop codon is provided in SEQ ID NO: 765, with the corresponding amino acid sequence being provided in SEQ ID NO: 766. This sequence was found to show 86%
10 identity to a rat calcium transporter protein, indicating that P768P may represent a human calcium transporter protein. The locations of transmembrane domains within P768P were predicted using the PSORT II computer algorithm. Six transmembrane domains were predicted at amino acid positions 118-134, 172-188, 211-227, 230-246, 282-298 and 348-364. The amino acid sequences of SEQ ID NO: 767-772 represent
15 amino acids 1-134, 135-188, 189-227, 228-246, 247-298 and 299-511 of P768P, respectively.

EXAMPLE 4

SYNTHESIS OF POLYPEPTIDES

20 Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems 430A peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of
25 conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid
30 (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of

0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

5

EXAMPLE 5

FURTHER ISOLATION AND CHARACTERIZATION OF
PROSTATE-SPECIFIC POLYPEPTIDES BY PCR-BASED SUBTRACTION

10 A cDNA library generated from prostate primary tumor mRNA as described above was subtracted with cDNA from normal prostate. The subtraction was performed using a PCR-based protocol (Clontech), which was modified to generate larger fragments. Within this protocol, tester and driver double stranded cDNA were separately digested with five restriction enzymes that recognize six-nucleotide
15 restriction sites (MluI, MscI, PvuII, SalI and StuI). This digestion resulted in an average cDNA size of 600 bp, rather than the average size of 300 bp that results from digestion with RsaI according to the Clontech protocol. This modification did not affect the subtraction efficiency. Two tester populations were then created with different adapters, and the driver library remained without adapters.

20 The tester and driver libraries were then hybridized using excess driver cDNA. In the first hybridization step, driver was separately hybridized with each of the two tester cDNA populations. This resulted in populations of (a) unhybridized tester cDNAs, (b) tester cDNAs hybridized to other tester cDNAs, (c) tester cDNAs hybridized to driver cDNAs and (d) unhybridized driver cDNAs. The two separate
25 hybridization reactions were then combined, and rehybridized in the presence of additional denatured driver cDNA. Following this second hybridization, in addition to populations (a) through (d), a fifth population (e) was generated in which tester cDNA with one adapter hybridized to tester cDNA with the second adapter. Accordingly, the second hybridization step resulted in enrichment of differentially expressed sequences
30 which could be used as templates for PCR amplification with adaptor-specific primers.

The ends were then filled in, and PCR amplification was performed using adaptor-specific primers. Only population (e), which contained tester cDNA that did not hybridize to driver cDNA, was amplified exponentially. A second PCR amplification step was then performed, to reduce background and further enrich
5 differentially expressed sequences.

This PCR-based subtraction technique normalizes differentially expressed cDNAs so that rare transcripts that are overexpressed in prostate tumor tissue may be recoverable. Such transcripts would be difficult to recover by traditional subtraction methods.

10 In addition to genes known to be overexpressed in prostate tumor, seventy-seven further clones were identified. Sequences of these partial cDNAs are provided in SEQ ID NO: 29 to 305. Most of these clones had no significant homology to database sequences. Exceptions were JPTPN23 (SEQ ID NO: 231; similarity to pig valosin-containing protein), JPTPN30 (SEQ ID NO: 234; similarity to rat mRNA for
15 proteasome subunit), JPTPN45 (SEQ ID NO: 243; similarity to rat *norvegicus* cytosolic NADP-dependent isocitrate dehydrogenase), JPTPN46 (SEQ ID NO: 244; similarity to human subclone H8 4 d4 DNA sequence), JP1D6 (SEQ ID NO: 265; similarity to *G. gallus* dynein light chain-A), JP8D6 (SEQ ID NO: 288; similarity to human BAC clone RG016J04), JP8F5 (SEQ ID NO: 289; similarity to human subclone H8 3 b5 DNA
20 sequence), and JP8E9 (SEQ ID NO: 299; similarity to human Alu sequence).

Additional studies using the PCR-based subtraction library consisting of a prostate tumor pool subtracted against a normal prostate pool (referred to as PT-PN PCR subtraction) yielded three additional clones. Comparison of the cDNA sequences of these clones with the most recent release of GenBank revealed no significant
25 homologies to the two clones referred to as P715P and P767P (SEQ ID NO: 312 and 314). The remaining clone was found to show some homology to the known gene KIAA0056 (SEQ ID NO: 318). Using microarray analysis to measure mRNA expression levels in various tissues, all three clones were found to be over-expressed in prostate tumors and BPH tissues. Specifically, clone P715P was over-expressed in most
30 prostate tumors and BPH tissues by a factor of three or greater, with elevated expression

seen in the majority of normal prostate samples and in fetal tissue, but negative to low expression in all other normal tissues. Clone P767P was over-expressed in several prostate tumors and BPH tissues, with moderate expression levels in half of the normal prostate samples, and background to low expression in all other normal tissues tested.

5 Further analysis, by microarray as described above, of the PT-PN PCR subtraction library and of a DNA subtraction library containing cDNA from prostate tumor subtracted with a pool of normal tissue cDNAs, led to the isolation of 27 additional clones (SEQ ID NO: 340-365 and 381) which were determined to be over-expressed in prostate tumor. The clones of SEQ ID NO: 341, 342, 345, 347, 348, 349,
10 351, 355-359, 361, 362 and 364 were also found to be expressed in normal prostate. Expression of all 26 clones in a variety of normal tissues was found to be low or undetectable, with the exception of P544S (SEQ ID NO: 356) which was found to be expressed in small intestine. Of the 26 clones, 11 (SEQ ID NO: 340-349 and 362) were found to show some homology to previously identified sequences. No significant
15 homologies were found to the clones of SEQ ID NO: 350, 351, 353-361, and 363-365.

Comparison of the sequence of SEQ ID NO: 362 with sequences in the GenBank and GeneSeq DNA databases showed that this clone (referred to as P788P) is identical to GeneSeq Accession No. X27262, which encodes a protein found in the GeneSeq protein Accession No. Y00931. The full length cDNA sequence of P788P is
20 provided in SEQ ID NO: 634, with the corresponding predicted amino acid being provided in SEQ ID NO: 635. Subsequently, a full-length cDNA sequence for P788P that contains polymorphisms not found in the sequence of SEQ ID NO: 634, was cloned multiple times by PCR amplification from cDNA prepared from several RNA templates from three individuals. This determined cDNA sequence of this polymorphic variant of
25 P788P is provided in SEQ ID NO: 636, with the corresponding amino acid sequence being provided in SEQ ID NO: 637. The sequence of SEQ ID NO: 637 differs from that of SEQ ID NO: 635 by six amino acid residues. The P788P protein has 7 potential transmembrane domains at the C-terminal portion and is predicted to be a plasma membrane protein with an extracellular N-terminal region.

Further studies on the clone of SEQ ID NO: 352 (referred to as P790P) led to the isolation of the full-length cDNA sequence of SEQ ID NO: 526. The corresponding predicted amino acid is provided in SEQ ID NO: 527. Data from two quantitative PCR experiments indicated that P790P is over-expressed in 11/15 tested prostate tumor samples and is expressed at low levels in spinal cord, with no expression being seen in all other normal samples tested. Data from further PCR experiments and microarray experiments showed over-expression in normal prostate and prostate tumor with little or no expression in other tissues tested. P790P was subsequently found to show significant homology to a previously identified G-protein coupled prostate tissue receptor.

Additional studies on the clone of SEQ ID NO: 354 (referred to as P776P) led to the isolation of an extended cDNA sequence, provided in SEQ ID NO: 569. The determined cDNA sequences of three additional splice variants of P776P are provided in SEQ ID NO: 570-572. The amino acid sequences encoded by two predicted open reading frames (ORFs) contained within SEQ ID NO: 570, one predicted ORF contained within SEQ ID NO: 571, and 11 predicted ORFs contained within SEQ ID NO: 569, are provided in SEQ ID NO: 573-586, respectively. Further studies led to the isolation of the full-length sequence for the clone of SEQ ID NO: 570 (provided in SEQ ID NO: 737). Full-length cloning efforts on the clone of SEQ ID NO: 571 led to the isolation of two sequences (provided in SEQ ID NO: 738 and 739), representing a single clone, that are identical with the exception of a polymorphic insertion/deletion at position 1293. Specifically, the clone of SEQ ID NO: 739 (referred to as clone F1) has a C at position 1293. The clone of SEQ ID NO: 738 (referred to as clone F2) has a single base pair deletion at position 1293. The predicted amino acid sequences encoded by 5 open reading frames located within SEQ ID NO: 737 are provided in SEQ ID NO: 740-744, with the predicted amino acid sequences encoded by the clone of SEQ ID NO: 738 and 739 being provided in SEQ ID NO: 745-750.

Comparison of the cDNA sequences for the clones P767P (SEQ ID NO: 314) and P777P (SEQ ID NO: 350) with sequences in the GenBank human EST database showed that the two clones matched many EST sequences in common,

suggesting that P767P and P777P may represent the same gene. A DNA consensus sequence derived from a DNA sequence alignment of P767P, P777P and multiple EST clones is provided in SEQ ID NO: 587. The amino acid sequences encoded by three putative ORFs located within SEQ ID NO: 587 are provided in SEQ ID NO: 588-590.

5 The clone of SEQ ID NO: 342 (referred to as P789P) was found to show homology to a previously identified gene. The full length cDNA sequence for P789P and the corresponding amino acid sequence are provided in SEQ ID NO: 735 and 736, respectively.

10

EXAMPLE 6

PEPTIDE PRIMING OF MICE AND PROPAGATION OF CTL LINES

6.1. This Example illustrates the preparation of a CTL cell line specific for cells expressing the P502S gene.

15 Mice expressing the transgene for human HLA A2Kb (provided by Dr L. Sherman, The Scripps Research Institute, La Jolla, CA) were immunized with P2S#12 peptide (VLGWVAEL; SEQ ID-NO: 306), which is derived from the P502S gene (also referred to herein as J1-17, SEQ ID NO: 8), as described by Theobald et al., *Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995 with the following modifications. Mice were
20 immunized with 100 μ g of P2S#12 and 120 μ g of an I-A^b binding peptide derived from hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and using a nylon mesh single cell suspensions prepared. Cells were then resuspended at 6×10^6 cells/ml in complete media (RPMI-1640; Gibco BRL, Gaithersburg, MD) containing 10% FCS, 2mM Glutamine (Gibco BRL), sodium
25 pyruvate (Gibco BRL), non-essential amino acids (Gibco BRL), 2×10^{-5} M 2-mercaptoethanol, 50U/ml penicillin and streptomycin, and cultured in the presence of irradiated (3000 rads) P2S#12-pulsed (5mg/ml P2S#12 and 10mg/ml β 2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7 μ g/ml dextran sulfate and 25 μ g/ml LPS for 3 days). Six days later, cells (5×10^5 /ml) were
30 restimulated with 2.5×10^6 /ml peptide pulsed irradiated (20,000 rads) EL4A2Kb cells

(Sherman et al, *Science* 258:815-818, 1992) and 3×10^6 /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20U/ml IL-2. Cells continued to be restimulated on a weekly basis as described, in preparation for cloning the line.

P2S#12 line was cloned by limiting dilution analysis with peptide pulsed
5 EL4 A2Kb tumor cells (1×10^4 cells/ well) as stimulators and A2 transgenic spleen cells as feeders (5×10^5 cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, clones that were growing were isolated and maintained in culture. Several of these clones demonstrated significantly higher reactivity (lysis) against human fibroblasts (HLA A2Kb expressing) transduced with
10 P502S than against control fibroblasts. An example is presented in Figure 1.

This data indicates that P2S #12 represents a naturally processed epitope of the P502S protein that is expressed in the context of the human HLA A2Kb molecule.

15 6.2. This Example illustrates the preparation of murine CTL lines and CTL clones specific for cells expressing the P501S gene.

This series of experiments were performed similarly to that described above. Mice were immunized with the P1S#10 peptide (SEQ ID NO: 337), which is
20 derived from the P501S gene (also referred to herein as L1-12, SEQ ID NO: 110). The P1S#10 peptide was derived by analysis of the predicted polypeptide sequence for P501S for potential HLA-A2 binding sequences as defined by published HLA-A2 binding motifs (Parker, KC, et al, *J. Immunol.*, 152:163, 1994). P1S#10 peptide was synthesized as described in Example 4, and empirically tested for HLA-A2 binding
25 using a T cell based competition assay. Predicted A2 binding peptides were tested for their ability to compete HLA-A2 specific peptide presentation to an HLA-A2 restricted CTL clone (D150M58), which is specific for the HLA-A2 binding influenza matrix peptide fluM58. D150M58 CTL secretes TNF in response to self-presentation of peptide fluM58. In the competition assay, test peptides at 100-200 μ g/ml were added to
30 cultures of D150M58 CTL in order to bind HLA-A2 on the CTL. After thirty minutes,

CTL cultured with test peptides, or control peptides, were tested for their antigen dose response to the fluM58 peptide in a standard TNF bioassay. As shown in Figure 3, peptide P1S#10 competes HLA-A2 restricted presentation of fluM58, demonstrating that peptide P1S#10 binds HLA-A2.

- 5 Mice expressing the transgene for human HLA A2Kb were immunized as described by Theobald et al. (*Proc. Natl. Acad. Sci. USA* 92:11993-11997, 1995) with the following modifications. Mice were immunized with 62.5µg of P1S #10 and 120µg of an I-A^b binding peptide derived from Hepatitis B Virus protein emulsified in incomplete Freund's adjuvant. Three weeks later these mice were sacrificed and single
10 cell suspensions prepared using a nylon mesh. Cells were then resuspended at 6×10^6 cells/ml in complete media (as described above) and cultured in the presence of irradiated (3000 rads) P1S#10-pulsed (2µg/ml P1S#10 and 10mg/ml β2-microglobulin) LPS blasts (A2 transgenic spleens cells cultured in the presence of 7µg/ml dextran sulfate and 25µg/ml LPS for 3 days). Six days later cells (5×10^5 /ml) were restimulated
15 with 2.5×10^6 /ml peptide-pulsed irradiated (20,000 rads) EL4A2Kb cells, as described above, and 3×10^6 /ml A2 transgenic spleen feeder cells. Cells were cultured in the presence of 20 U/ml IL-2. Cells were restimulated on a weekly basis in preparation for cloning. After three rounds of *in vitro* stimulations, one line was generated that recognized P1S#10-pulsed Jurkat A2Kb targets and P501S-transduced Jurkat targets as
20 shown in Figure 4.

- A P1S#10-specific CTL line was cloned by limiting dilution analysis with peptide pulsed EL4 A2Kb tumor cells (1×10^4 cells/ well) as stimulators and A2 transgenic spleen cells as feeders (5×10^5 cells/ well) grown in the presence of 30U/ml IL-2. On day 14, cells were restimulated as before. On day 21, viable clones were
25 isolated and maintained in culture. As shown in Figure 5, five of these clones demonstrated specific cytolytic reactivity against P501S-transduced Jurkat A2Kb targets. This data indicates that P1S#10 represents a naturally processed epitope of the P501S protein that is expressed in the context of the human HLA-A2.1 molecule.

EXAMPLE 7

PRIMING OF CTL *IN VIVO* USING NAKED DNA IMMUNIZATION

WITH A PROSTATE ANTIGEN

The prostate-specific antigen L1-12, as described above, is also referred
5 to as P501S. HLA A2Kb Tg mice (provided by Dr L. Sherman, The Scripps Research
Institute, La Jolla, CA) were immunized with 100 µg P501S in the vector VR1012
either intramuscularly or intradermally. The mice were immunized three times, with a
two week interval between immunizations. Two weeks after the last immunization,
immune spleen cells were cultured with Jurkat A2Kb-P501S transduced stimulator
10 cells. CTL lines were stimulated weekly. After two weeks of *in vitro* stimulation, CTL
activity was assessed against P501S transduced targets. Two out of 8 mice developed
strong anti-P501S CTL responses. These results demonstrate that P501S contains at
least one naturally processed HLA-A2-restricted CTL epitope.

15

EXAMPLE 8

ABILITY OF HUMAN T CELLS TO RECOGNIZE PROSTATE-SPECIFIC POLYPEPTIDES

This Example illustrates the ability of T cells specific for a prostate
tumor polypeptide to recognize human tumor.

20 Human CD8⁺ T cells were primed *in vitro* to the P2S-12 peptide (SEQ
ID NO: 306) derived from P502S (also referred to as J1-17) using dendritic cells
according to the protocol of Van Tsai et al. (*Critical Reviews in Immunology* 18:65-75,
1998). The resulting CD8⁺ T cell microcultures were tested for their ability to
recognize the P2S-12 peptide presented by autologous fibroblasts or fibroblasts which
25 were transduced to express the P502S gene in a γ -interferon ELISPOT assay (see
Lalvani et al., *J. Exp. Med.* 186:859-865, 1997). Briefly, titrating numbers of T cells
were assayed in duplicate on 10⁴ fibroblasts in the presence of 3 µg/ml human β_2 -
microglobulin and 1 µg/ml P2S-12 peptide or control E75 peptide. In addition, T cells
were simultaneously assayed on autologous fibroblasts transduced with the P502S gene
30 or as a control, fibroblasts transduced with HER-2/*neu*. Prior to the assay, the

fibroblasts were treated with 10 ng/ml γ -interferon for 48 hours to upregulate class I MHC expression. One of the microcultures (#5) demonstrated strong recognition of both peptide pulsed fibroblasts as well as transduced fibroblasts in a γ -interferon ELISPOT assay. Figure 2A demonstrates that there was a strong increase in the number of γ -interferon spots with increasing numbers of T cells on fibroblasts pulsed with the P2S-12 peptide (solid bars) but not with the control E75 peptide (open bars). This shows the ability of these T cells to specifically recognize the P2S-12 peptide. As shown in Figure 2B, this microculture also demonstrated an increase in the number of γ -interferon spots with increasing numbers of T cells on fibroblasts transduced to express the P502S gene but not the HER-2/*neu* gene. These results provide additional confirmatory evidence that the P2S-12 peptide is a naturally processed epitope of the P502S protein. Furthermore, this also demonstrates that there exists in the human T cell repertoire, high affinity T cells which are capable of recognizing this epitope. These T cells should also be capable of recognizing human tumors which express the P502S gene.

EXAMPLE 9

ELICITATION OF PROSTATE ANTIGEN-SPECIFIC CTL RESPONSES

IN HUMAN BLOOD

20

This Example illustrates the ability of a prostate-specific antigen to elicit a CTL response in blood of normal humans.

Autologous dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal donors by growth for five days in RPMI medium containing 10% human serum, 50 ng/ml GMCSF and 30 ng/ml IL-4. Following culture, DC were infected overnight with recombinant P501S-expressing vaccinia virus at an M.O.I. of 5 and matured for 8 hours by the addition of 2 micrograms/ml CD40 ligand. Virus was inactivated by UV irradiation, CD8⁺ cells were isolated by positive selection using magnetic beads, and priming cultures were initiated in 24-well plates. Following five stimulation cycles using autologous fibroblasts

retrovirally transduced to express P501S and CD80, CD8+ lines were identified that specifically produced interferon-gamma when stimulated with autologous P501S-transduced fibroblasts. The P501S-specific activity of cell line 3A-1 could be maintained following additional stimulation cycles on autologous B-LCL transduced with P501S. Line 3A-1 was shown to specifically recognize autologous B-LCL transduced to express P501S, but not EGFP-transduced autologous B-LCL, as measured by cytotoxicity assays (^{51}Cr release) and interferon-gamma production (Interferon-gamma Elispot; *see above and Lalvani et al., J. Exp. Med. 186:859-865, 1997*). The results of these assays are presented in Figures 6A and 6B.

10

EXAMPLE 10

IDENTIFICATION OF A NATURALLY PROCESSED CTL EPITOPE CONTAINED WITHIN THE
PROSTATE-SPECIFIC ANTIGEN P703P

The 9-mer peptide p5 (SEQ ID NO: 338) was derived from the P703P antigen (also referred to as P20). The p5 peptide is immunogenic in human HLA-A2 donors and is a naturally processed epitope. Antigen specific human CD8+ T cells can be primed following repeated *in vitro* stimulations with monocytes pulsed with p5 peptide. These CTL specifically recognize p5-pulsed and P703P-transduced target cells in both ELISPOT (as described above) and chromium release assays. Additionally, immunization of HLA-A2Kb transgenic mice with p5 leads to the generation of CTL lines which recognize a variety of HLA-A2Kb or HLA-A2 transduced target cells expressing P703P.

Initial studies demonstrating that p5 is a naturally processed epitope were done using HLA-A2Kb transgenic mice. HLA-A2Kb transgenic mice were immunized subcutaneously in the footpad with 100 μg of p5 peptide together with 140 μg of hepatitis B virus core peptide (a Th peptide) in Freund's incomplete adjuvant. Three weeks post immunization, spleen cells from immunized mice were stimulated *in vitro* with peptide-pulsed LPS blasts. CTL activity was assessed by chromium release assay five days after primary *in vitro* stimulation. Retrovirally transduced cells expressing the

control antigen P703P and HLA-A2Kb were used as targets. CTL lines that specifically recognized both p5-pulsed targets as well as P703P-expressing targets were identified.

Human *in vitro* priming experiments demonstrated that the p5 peptide is immunogenic in humans. Dendritic cells (DC) were differentiated from monocyte
5 cultures derived from PBMC of normal human donors by culturing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, the DC were pulsed with 1 ug/ml p5 peptide and cultured with CD8+ T cell enriched PBMC. CTL lines were restimulated on a weekly basis with p5-pulsed monocytes. Five to six weeks after initiation of the CTL cultures,
10 CTL recognition of p5-pulsed target cells was demonstrated. CTL were additionally shown to recognize human cells transduced to express P703P, demonstrating that p5 is a naturally processed epitope.

Studies identifying a further peptide epitope (referred to as peptide 4) derived from the prostate tumor-specific antigen P703P that is capable of being
15 recognized by CD4 T cells on the surface of cells in the context of HLA class II molecules were carried out as follows. The amino acid sequence for peptide 4 is provided in SEQ ID NO: 638, with the corresponding cDNA sequence being provided in SEQ ID NO: 639.

Twenty 15-mer peptides overlapping by 10 amino acids and derived
20 from the carboxy-terminal fragment of P703P were generated using standard procedures. Dendritic cells (DC) were derived from PBMC of a normal female donor using GM-CSF and IL-4 by standard protocols. CD4 T cells were generated from the same donor as the DC using MACS beads and negative selection. DC were pulsed overnight with pools of the 15-mer peptides, with each peptide at a final concentration
25 of 0.25 microgram/ml. Pulsed DC were washed and plated at 1×10^4 cells/well of 96-well V-bottom plates and purified CD4 T cells were added at 1×10^5 /well. Cultures were supplemented with 60 ng/ml IL-6 and 10 ng/ml IL-12 and incubated at 37 °C. Cultures were restimulated as above on a weekly basis using DC generated and pulsed as above as antigen presenting cells, supplemented with 5 ng/ml IL-7 and 10 u/ml IL-2.
30 Following 4 *in vitro* stimulation cycles, 96 lines (each line corresponding to one well) were tested for specific proliferation and cytokine production in response to the

stimulating pools with an irrelevant pool of peptides derived from mammaglobin being used as a control.

One line (referred to as 1-F9) was identified from pool #1 that demonstrated specific proliferation (measured by ³H proliferation assays) and cytokine production (measured by interferon-gamma ELISA assays) in response to pool #1 of P703P peptides. This line was further tested for specific recognition of the peptide pool, specific recognition of individual peptides in the pool, and in HLA mismatch analyses to identify the relevant restricting allele. Line 1-F9 was found to specifically proliferate and produce interferon-gamma in response to peptide pool #1, and also to peptide 4 (SEQ ID NO: 638). Peptide 4 corresponds to amino acids 126-140 of SEQ ID NO: 327. Peptide titration experiments were conducted to assess the sensitivity of line 1-F9 for the specific peptide. The line was found to specifically respond to peptide 4 at concentrations as low as 0.25 ng/ml, indicating that the T cells are very sensitive and therefore likely to have high affinity for the epitope.

To determine the HLA restriction of the P703P response, a panel of antigen presenting cells (APC) was generated that was partially matched with the donor used to generate the T cells. The APC were pulsed with the peptide and used in proliferation and cytokine assays together with line 1-F9. APC matched with the donor at HLA-DRB0701 and HLA-DQB02 alleles were able to present the peptide to the T cells, indicating that the P703P-specific response is restricted to one of these alleles.

Antibody blocking assays were utilized to determine if the restricting allele was HLA-DR0701 or HLA-DQ02. The anti-HLA-DR blocking antibody L243 or an irrelevant isotype matched IgG2a were added to T cells and APC cultures pulsed with the peptide RMPTVLQCVNVS VVS (SEQ ID NO: 638) at 250 ng/ml. Standard interferon-gamma and proliferation assays were performed. Whereas the control antibody had no effect on the ability of the T cells to recognize peptide-pulsed APC, in both assays the anti-HLA-DR antibody completely blocked the ability of the T cells to specifically recognize peptide-pulsed APC.

To determine if the peptide epitope RMPTVLQCVNVS VVS (SEQ ID NO: 638) was naturally processed, the ability of line 1-F9 to recognize APC pulsed with recombinant P703P protein was examined. For these experiments a number of

recombinant P703P sources were utilized; *E. coli*-derived P703P, Pichia-derived P703P and baculovirus-derived P703P. Irrelevant protein controls used were *E. coli*-derived L3E (a lung-specific antigen) and baculovirus-derived mammaglobin. In interferon-gamma ELISA assays, line 1-F9 was able to efficiently recognize both *E. coli* forms of
5 P703P as well as Pichia-derived recombinant P703P, while baculovirus-derived P703P was recognized less efficiently. Subsequent Western blot analysis revealed that the *E. coli* and Pichia P703P protein preparations were intact while the baculovirus P703P preparation was approximately 75% degraded. Thus, peptide RMPTVLQCVNVSVVS (SEQ ID NO: 638) from P703P is a naturally processed peptide epitope derived from
10 P703P and presented to T cells in the context of HLA-DRB-0701

In further studies, twenty-four 15-mer peptides overlapping by 10 amino acids and derived from the N-terminal fragment of P703P (corresponding to amino acids 27-154 of SEQ ID NO: 525) were generated by standard procedures and their ability to be recognized by CD4 cells was determined essentially as described above.
15 DC were pulsed overnight with pools of the peptides with each peptide at a final concentration of 10 microgram/ml. A large number of individual CD4 T cell lines (65/480) demonstrated significant proliferation and cytokine release (IFN-gamma) in response to the P703P peptide pools but not to a control peptide pool. The CD4 T cell lines which demonstrated specific activity were restimulated on the appropriate pool of
20 P703P peptides and reassayed on the individual peptides of each pool as well as a peptide dose titration of the pool of peptides in a IFN-gamma release assay and in a proliferation assay.

Sixteen immunogenic peptides were recognized by the T cells from the entire set of peptide antigens tested. The amino acid sequences of these peptides are
25 provided in SEQ ID NO: 656-671, with the corresponding cDNA sequences being provided in SEQ ID NO: 640-655, respectively. In some cases the peptide reactivity of the T cell line could be mapped to a single peptide, however some could be mapped to more than one peptide in each pool. Those CD4 T cell lines that displayed a representative pattern of recognition from each peptide pool with a reasonable affinity
30 for peptide were chosen for further analysis (I-1A, -6A; II-4C, -5E; III-6E, IV-4B, -3F, -9B, -10F, V-5B, -4D, and -10F). These CD4 T cell lines were restimulated on the

appropriate individual peptide and reassayed on autologous DC pulsed with a truncated form of recombinant P703P protein made in *E. coli* (a.a. 96 - 254 of SEQ ID NO: 525), full-length P703P made in the baculovirus expression system, and a fusion between influenza virus NS1 and P703P made in *E. coli*. Of the T cell lines tested, line I-1A
5 recognized specifically the truncated form of P703P (*E. coli*) but no other recombinant form of P703P. This line also recognized the peptide used to elicit the T cells. Line 2-4C recognized the truncated form of P703P (*E. coli*) and the full length form of P703P made in baculovirus, as well as peptide. The remaining T cell lines tested were either peptide-specific only (II-5E, II-6F, IV-4B, IV-3F, IV-9B, IV-10F, V-5B and V-4D) or
10 were non-responsive to any antigen tested (V-10F). These results demonstrate that the peptide sequence RPLLANDLMLIKLDE (SEQ ID NO: 671; corresponding to a.a. 110-124 of SEQ ID NO: 525) recognized by the T cell line I-1A, and the peptide sequences SVSESDTIRSISIAS (SEQ ID NO: 668; corresponding to a.a. 125-139 of SEQ ID NO: 525) and ISIASQCPTAGNSCL (SEQ ID NO: 667; corresponding to a.a. 135-149 of
15 SEQ ID NO: 525) recognized by the T cell line II-4C may be naturally processed epitopes of the P703P protein.

EXAMPLE 11

EXPRESSION OF A BREAST TUMOR-DERIVED ANTIGEN

20

IN PROSTATE

Isolation of the antigen B305D from breast tumor by differential display is described in US Patent Application No. 08/700,014, filed August 20, 1996. Several different splice forms of this antigen were isolated. The determined cDNA sequences
25 for these splice forms are provided in SEQ ID NO: 366-375, with the predicted amino acid sequences corresponding to the sequences of SEQ ID NO: 292, 298 and 301-303 being provided in SEQ ID NO: 299-306, respectively. In further studies, a splice variant of the cDNA sequence of SEQ ID NO: 366 was isolated which was found to contain an additional guanine residue at position 884 (SEQ ID NO: 530), leading to a
30 frameshift in the open reading frame. The determined DNA sequence of this ORF is

provided in SEQ ID NO: 531. This frameshift generates a protein sequence (provided in SEQ ID NO: 532) of 293 amino acids that contains the C-terminal domain common to the other isoforms of B305D but that differs in the N-terminal region.

The expression levels of B305D in a variety of tumor and normal tissues were examined by real time PCR and by Northern analysis. The results indicated that B305D is highly expressed in breast tumor, prostate tumor, normal prostate and normal testes, with expression being low or undetectable in all other tissues examined (colon tumor, lung tumor, ovary tumor, and normal bone marrow, colon, kidney, liver, lung, ovary, skin, small intestine, stomach). Using real-time PCR on a panel of prostate tumors, expression of B305D in prostate tumors was shown to increase with increasing Gleason grade, demonstrating that expression of B305D increases as prostate cancer progresses.

EXAMPLE 12

GENERATION OF HUMAN CTL *IN VITRO* USING WHOLE GENE PRIMING AND STIMULATION TECHNIQUES WITH THE PROSTATE-SPECIFIC ANTIGEN P501S

Using *in vitro* whole-gene priming with P501S-vaccinia infected DC (see, for example, Yee et al, *The Journal of Immunology*, 157(9):4079-86, 1996), human CTL lines were derived that specifically recognize autologous fibroblasts transduced with P501S (also known as L1-12), as determined by interferon- γ ELISPOT analysis as described above. Using a panel of HLA-mismatched B-LCL lines transduced with P501S, these CTL lines were shown to be likely restricted to HLAB class I allele. Specifically, dendritic cells (DC) were differentiated from monocyte cultures derived from PBMC of normal human donors by growing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, DC were infected overnight with recombinant P501S vaccinia virus at a multiplicity of infection (M.O.I) of five, and matured overnight by the addition of 3 μ g/ml CD40 ligand. Virus was inactivated by UV irradiation. CD8+ T cells were isolated using a magnetic bead system, and priming cultures were initiated

using standard culture techniques. Cultures were restimulated every 7-10 days using autologous primary fibroblasts retrovirally transduced with P501S and CD80. Following four stimulation cycles, CD8+ T cell lines were identified that specifically produced interferon- γ when stimulated with P501S and CD80-transduced autologous
5 fibroblasts. A panel of HLA-mismatched B-LCL lines transduced with P501S were generated to define the restriction allele of the response. By measuring interferon- γ in an ELISPOT assay, the P501S specific response was shown to be likely restricted by HLA B alleles. These results demonstrate that a CD8+ CTL response to P501S can be elicited.

10 To identify the epitope(s) recognized, cDNA encoding P501S was fragmented by various restriction digests, and sub-cloned into the retroviral expression vector pBIB-KS. Retroviral supernatants were generated by transfection of the helper packaging line Phoenix-Ampho. Supernatants were then used to transduce Jurkat/A2Kb cells for CTL screening. CTL were screened in IFN-gamma ELISPOT
15 assays against these A2Kb targets transduced with the "library" of P501S fragments. Initial positive fragments P501S/H3 and P501S/F2 were sequenced and found to encode amino acids 106-553 and amino acids 136-547, respectively, of SEQ ID NO: 113. A truncation of H3 was made to encode amino acid residues 106-351 of SEQ ID NO: 113, which was unable to stimulate the CTL, thus localizing the epitope to amino acid
20 residues 351-547. Additional fragments encoding amino acids 1-472 (Fragment A) and amino acids 1-351 (Fragment B) were also constructed. Fragment A but not Fragment B stimulated the CTL thus localizing the epitope to amino acid residues 351-472. Overlapping 20-mer and 18-mer peptides representing this region were tested by pulsing Jurkat/A2Kb cells versus CTL in an IFN-gamma assay. Only peptides P501S-369(20)
25 and P501S-369(18) stimulated the CTL. Nine-mer and 10-mer peptides representing this region were synthesized and similarly tested. Peptide P501S-370 (SEQ ID NO: 539) was the minimal 9-mer giving a strong response. Peptide P501S-376 (SEQ ID NO: 540) also gave a weak response, suggesting that it might represent a cross-reactive epitope.

In subsequent studies, the ability of primary human B cells transduced with P501S to prime MHC class I-restricted, P501S-specific, autologous CD8 T cells was examined. Primary B cells were derived from PBMC of a homozygous HLA-A2 donor by culture in CD40 ligand and IL-4, transduced at high frequency with recombinant P501S in the vector pBIB, and selected with blastocidin-S. For *in vitro* priming, purified CD8⁺ T cells were cultured with autologous CD40 ligand + IL-4 derived, P501S-transduced B cells in a 96-well microculture format. These CTL microcultures were re-stimulated with P501S-transduced B cells and then assayed for specificity. Following this initial screen, microcultures with significant signal above background were cloned on autologous EBV-transformed B cells (BLCL), also transduced with P501S. Using IFN- γ ELISPOT for detection, several of these CD8 T cell clones were found to be specific for P501S, as demonstrated by reactivity to BLCL/P501S but not BLCL transduced with control antigen. It was further demonstrated that the anti-P501S CD8 T cell specificity is HLA-A2-restricted. First, antibody blocking experiments with anti-HLA-A,B,C monoclonal antibody (W6.32), anti-HLA-B,C monoclonal antibody (B1.23.2) and a control monoclonal antibody showed that only the anti-HLA-A,B,C antibody blocked recognition of P501S-expressing autologous BLCL. Secondly, the anti-P501S CTL also recognized an HLA-A2 matched, heterologous BLCL transduced with P501S, but not the corresponding EGFP transduced control BLCL.

A naturally processed, CD8, class I-restricted peptide epitope of P501S was identified as follows. Dendritic Cells (DC) were isolated by Percoll gradient followed by differential adherence, and cultured for 5 days in the presence of RPMI medium containing 1% human serum, 50ng/ml GM-CSF and 30ng/ml IL-4. Following culture, DC were infected for 24 hours with P501S-expressing adenovirus at an MOI of 10 and matured for an additional 24 hours by the addition of 2 μ g/ml CD40 ligand. CD8 cells were enriched for by the subtraction of CD4⁺, CD14⁺ and CD16⁺ populations from PBMC with magnetic beads. Priming cultures containing 10,000 P501S-expressing DC and 100,000 CD8⁺ T cells per well were set up in 96-well V-bottom plates with RPMI containing 10% human serum, 5ng/ml IL-12 and 10ng/ml IL-6. Cultures were stimulated every 7 days using autologous fibroblasts retrovirally

transduced to express P501S and CD80, and were treated with IFN-gamma for 48-72 hours to upregulate MHC Class I expression. 10u/ml IL-2 was added at the time of stimulation and on days 2 and 5 following stimulation. Following 4 stimulation cycles, one P501S-specific CD8+ T cell line (referred to as 2A2) was identified that produced
5 IFN-gamma in response to IFN-gamma-treated P501S/CD80 expressing autologous fibroblasts, but not in response to IFN-gamma-treated P703P/CD80 expressing autologous fibroblasts in a γ -IFN Elispot assay. Line 2A2 was cloned in 96-well plates with 0.5 cell/well or 2 cells/well in the presence of 75,000 PBMC/well, 10,000 B-LCL/well, 30ng/ml OKT3 and 50u/ml IL-2. Twelve clones were isolated that showed
10 strong P501S specificity in response to transduced fibroblasts.

Fluorescence activated cell sorting (FACS) analysis was performed on P501S-specific clones using CD3-, CD4- and CD8-specific antibodies conjugated to PercP, FITC and PE respectively. Consistent with the use of CD8 enriched T cells in the priming cultures, P5401S-specific clones were determined to be CD3+, CD8+ and
15 CD4-.

To identify the relevant P501S epitope recognized by P501S specific CTL, pools of 18-20 mer or 30-mer peptides that spanned the majority of the amino acid sequence of P501S were loaded onto autologous B-LCL and tested in γ -IFN Elispot assays for the ability to stimulate two P501S-specific CTL clones, referred to as 4E5
20 and 4E7. One pool, composed of five 18-20 mer peptides that spanned amino acids 411-486 of P501S (SEQ ID NO: 113), was found to be recognized by both P501S-specific clones. To identify the specific 18-20 mer peptide recognized by the clones, each of the 18-20 mer peptides that comprised the positive pool were tested individually in γ -IFN Elispot assays for the ability to stimulate the two P501S-specific CTL clones, 4E5 and
25 4E7. Both 4E5 and 4E7 specifically recognized one 20-mer peptide (SEQ ID NO: 710; cDNA sequence provided in SEQ ID NO: 711) that spanned amino acids 453-472 of P501S. Since the minimal epitope recognized by CD8+ T cells is almost always either a 9 or 10-mer peptide sequence, 10-mer peptides that spanned the entire sequence of SEQ ID NO: 710 were synthesized that differed by 1 amino acid. Each of these 10-mer
30 peptides was tested for the ability to stimulate two P501S-specific clones, (referred to as 1D5 and 1E12). One 10-mer peptide (SEQ ID NO: 712; cDNA sequence provided in

SEQ ID NO: 713) was identified that specifically stimulated the P501S-specific clones. This epitope spans amino acids 463-472 of P501S. This sequence defines a minimal 10-mer epitope from P501S that can be naturally processed and to which CTL responses can be identified in normal PBMC. Thus, this epitope is a candidate for use as a vaccine moiety, and as a therapeutic and/or diagnostic reagent for prostate cancer.

To identify the class I restriction element for the P501S-derived sequence of SEQ ID NO: 712, HLA blocking and mismatch analyses were performed. In γ -IFN Elispot assays, the specific response of clones 4A7 and 4E5 to P501S-transduced autologous fibroblasts was blocked by pre-incubation with 25ug/ml W6/32 (pan-Class I blocking antibody) and B1.23.2 (HLA-B/C blocking antibody). These results demonstrate that the SEQ ID NO: 712-specific response is restricted to an HLA-B or HLA-C allele.

For the HLA mismatch analysis, autologous B-LCL (HLA-A1,A2,B8,B51, Cw1, Cw7) and heterologous B-LCL (HLA-A2,A3,B18,B51,Cw5,Cw14) that share the HLAB51 allele were pulsed for one hour with 20ug/ml of peptide of SEQ ID NO: 712, washed, and tested in γ -IFN Elispot assays for the ability to stimulate clones 4A7 and 4E5. Antibody blocking assays with the B1.23.2 (HLA-B/C blocking antibody) were also performed. SEQ ID NO: 712-specific response was detected using both the autologous (D326) and heterologous (D107) B-LCL, and furthermore the responses were blocked by pre-incubation with 25ug/ml of B1.23.2 HLA-B/C blocking antibody. Together these results demonstrate that the P501S-specific response to the peptide of SEQ ID NO: 712 is restricted to the HLA-B51 class I allele. Molecular cloning and sequence analysis of the HLA-B51 allele from D3326 revealed that the HLA-B51 subtype of D326 is HLA-B51011.

Based on the 10-mer P501S-derived epitope of SEQ ID NO: 712, two 9-mers with the sequences of SEQ ID NO: 714 and 715 were synthesized and tested in Elispot assays for the ability to stimulate two P501S-specific CTL clones derived from line 2A2. The 10-mer peptide of SEQ ID NO: 712, as well as the 9-mer peptide of SEQ ID NO: 715, but not the 9-mer peptide of SEQ ID NO: 714, were capable of stimulating the P501S-specific CTL to produce IFN-gamma. These results demonstrate that the peptide of SEQ ID NO: 715 is a 9-mer P501S-derived epitope recognized by P501S-

specific CTL. The DNA sequence encoding the epitope of SEQ ID NO: 715 is provided in SEQ ID NO: 716.

To identify the class I restricting allele for the P501S-derived peptide of SEQ ID NO: 712 and 715 specific response, each of the HLA B and C alleles were
5 cloned from the donor used in the *in vitro* priming experiment. Sequence analysis indicated that the relevant alleles were HLA-B8, HLA-B51, HLA-Cw01 and HLA-Cw07. Each of these alleles were subcloned into an expression vector and co-transfected together with the P501S gene into VA-13 cells. Transfected VA-13 cells were then tested for the ability to specifically stimulate the P501S-specific CTL in
10 ELISPOT assays. VA-13 cells transfected with P501S and HLA-B51 were capable of stimulating the P501S-specific CTL to secrete gamma-IFN. VA-13 cells transfected with HLA-B51 alone or P501S + the other HLA-alleles were not capable of stimulating the P501S-specific CTL. These results demonstrate that the restricting allele for the P501S-specific response is the HLAB51 allele. Sequence analysis revealed that the
15 subtype of the relevant restricting allele is HLA-B51011.

To determine if the P501S-specific CTL could recognize prostate tumor cells that express P501S, the P501S-positive lines LnCAP and CRL2422 (both expressing "moderate" amounts of P501S mRNA and protein), and PC-3 (expressing low amounts of P501S mRNA and protein), plus the P501S-negative cell line DU-145
20 were retrovirally transduced with the HLA-B51011 allele that was cloned from the donor used to generate the P501S-specific CTL. HLA-B51011- or EGFP-transduced and selected tumor cells were treated with gamma-interferon and androgen (to upregulate stimulatory functions and P501S, respectively) and used in gamma-interferon Elispot assays with the P501S-specific CTL clones 4E5 and 4E7. Untreated
25 cells were used as a control.

Both 4E5 and 4E7 efficiently and specifically recognized LnCAP and CRL2422 cells that were transduced with the HLA-B51011 allele, but not the same cell lines transduced with EGFP. Additionally, both CTL clones specifically recognized PC-3 cells transduced with HLA-B51011, but not the P501S-negative tumor cell line
30 DU-145. Treatment with gamma-interferon or androgen did not enhance the ability of CTL to recognize tumor cells. These results demonstrate that P501S-specific CTL,

generated by *in vitro* whole gene priming, specifically and efficiently recognize prostate tumor cell lines that express P501S.

A naturally processed CD4 epitope of P501S was identified as follows.

CD4 cells specific for P501S were prepared as described above. A series
5 of 16 overlapping peptides were synthesized that spanned approximately 50% of the amino terminal portion of the P501S gene (amino acids 1- 325 of SEQ ID NO: 113). For priming, peptides were combined into pools of 4 peptides, pulsed at 4 μ g/ml onto dendritic cells (DC) for 24 hours, with TNF-alpha. DC were then washed and mixed with negatively selected CD4+ T cells in 96 well U-bottom plates. Cultures were re-
10 stimulated weekly on fresh DC loaded with peptide pools. Following a total of 4 stimulation cycles, cells were rested for an additional week and tested for specificity to APC pulsed with peptide pools using γ -IFN ELISA and proliferation assays. For these assays, adherent monocytes loaded with either the relevant peptide pool at 4ug/ml or an irrelevant peptide at μ g/ml were used as APC. T cell lines that demonstrated either
15 specific cytokine secretion or proliferation were then tested for recognition of individual peptides that were present in the pool. T cell lines could be identified from pools A and B that recognized individual peptides from these pools.

From pool A, lines AD9 and AE10 specifically recognized peptide 1 (SEQ ID NO: 719), and line AF5 recognized peptide 39 (SEQ ID NO: 718). From pool B, line BC6 could be identified that recognized peptide 58 (SEQ ID NO: 717). Each of these lines were stimulated on the specific peptide and tested for specific recognition of the peptide in a titration assay as well as cell lysates generated by infection of HEK 293 cells with adenovirus expressing either P501S or an irrelevant antigen. For these assays, APC-adherent monocytes were pulsed with either 10, 1, or 0.1 $\mu\text{g/ml}$ individual P501S peptides, and DC were pulsed overnight with a 1:5 dilution of adenovirally infected cell lysates. Lines AD9, AE10 and AF5 retained significant recognition of the relevant P501S-derived peptides even at 0.1 mg/ml . Furthermore, line AD9 demonstrated significant (8.1 fold stimulation index) specific activity for lysates from adenovirus-P501S infected cells. These results demonstrate that high affinity CD4 T cell lines can be generated toward P501S-derived epitopes, and that at least a subset of these T cells specific for the P501S derived sequence of SEQ ID NO: 719 are specific for an epitope that is naturally processed by human cells. The DNA sequences encoding the amino acid sequences of SEQ ID NO: 717-719 are provided in SEQ ID NO: 720-722, respectively.

To further characterize the P501S-specific activity of AD9, the line was cloned using anti-CD3. Three clones, referred to as 1A1, 1A9 and 1F5, were identified that were specific for the P501S-1 peptide (SEQ ID NO: 719). To determine the HLA restriction allele for the P501S-specific response, each of these clones was tested in class II antibody blocking and HLA mismatch assays using proliferation and gamma-interferon assays. In antibody blocking assays and measuring gamma-interferon production using ELISA assays, the ability of all three clones to recognize peptide pulsed APC was specifically blocked by co-incubation with either a pan-class II blocking antibody or a HLA-DR blocking antibody, but not with a HLA-DQ or an irrelevant antibody. Proliferation assays performed simultaneously with the same cells confirmed these results. These data indicate that the P501S-specific response of the clones is restricted by an HLA-DR allele. Further studies demonstrated that the restricting allele for the P501S-specific response is HLA-DRB1501.

EXAMPLE 13

IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS

BY MICROARRAY ANALYSIS

5 This Example describes the isolation of certain prostate-specific polypeptides from a prostate tumor cDNA library.

 A human prostate tumor cDNA expression library as described above was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to
10 non-prostate normal tissues (not including testis). 372 clones were identified, and 319 were successfully sequenced. Table I presents a summary of these clones, which are shown in SEQ ID NOs:385-400. Of these sequences SEQ ID NOs:386, 389, 390 and 392 correspond to novel genes, and SEQ ID NOs: 393 and 396 correspond to previously identified sequences. The others (SEQ ID NOs:385, 387, 388, 391, 394, 395 and 397-
15 400) correspond to known sequences, as shown in Table I.

Table I
Summary of Prostate Tumor Antigens

Known Genes	Previously Identified Genes	Novel Genes
T-cell gamma chain	P504S	23379 (SEQ ID NO:389)
Kallikrein	P1000C	23399 (SEQ ID NO:392)
Vector	P501S	23320 (SEQ ID NO:386)
CGI-82 protein mRNA (23319; SEQ ID NO:385)	P503S	23381 (SEQ ID NO:390)
PSA	P510S	
Ald. 6 Dehyd.	P784P	
L-iditol-2 dehydrogenase (23376; SEQ ID NO:388)	P502S	
Ets transcription factor PDEF (22672; SEQ ID NO:398)	P706P	
hTGR (22678; SEQ ID NO:399)	19142.2, bangur.seq (22621; SEQ ID NO:396)	
KIAA0295(22685; SEQ ID NO:400)	5566.1 Wang (23404; SEQ ID NO:393)	
Prostatic Acid Phosphatase(22655; SEQ ID NO:397)	P712P	
transglutaminase (22611; SEQ ID NO:395)	P778P	
HDLBP (23508; SEQ ID NO:394)		
CGI-69 Protein(23367; SEQ ID NO:387)		
KIAA0122(23383; SEQ ID NO:391)		
TEEG		

CGI-82 showed 4.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 43% of prostate tumors, 25% normal prostate, not detected in other normal tissues tested. L-idoitol-2 dehydrogenase showed 4.94 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 90% of prostate tumors, 100% of normal prostate, and not detected in other normal tissues tested. Ets transcription factor PDEF showed 5.55 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% prostate tumors, 25% normal prostate and not detected in other normal tissues tested. hTGR1 showed 9.11 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 63% of prostate tumors and is not detected in normal tissues tested including normal prostate. KIAA0295 showed 5.59 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 47% of prostate tumors, low to undetectable in normal tissues tested including normal prostate tissues. Prostatic acid phosphatase showed 9.14 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 67% of prostate tumors, 50% of normal prostate, and not detected in other normal tissues tested. Transglutaminase showed 14.84 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 30% of prostate tumors, 50% of normal prostate, and is not detected in other normal tissues tested. High density lipoprotein binding protein (HDLBP) showed 28.06 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% of normal prostate, and is undetectable in all other normal tissues tested. CGI-69 showed 3.56 fold over-expression in prostate tissues as compared to other normal tissues tested. It is a low abundant gene, detected in more than 90% of prostate tumors, and in 75% normal prostate tissues. The expression of this gene in normal tissues was very low. KIAA0122 showed 4.24 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 57% of prostate tumors, it was undetectable in all normal tissues tested including normal prostate tissues. 19142.2 bangur showed 23.25 fold over-expression in prostate tissues as compared to other

normal tissues tested. It was over-expressed in 97% of prostate tumors and 100% of normal prostate. It was undetectable in other normal tissues tested. .5566.1 Wang showed 3.31 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 97% of prostate tumors, 75% normal prostate and was also over-expressed in normal bone marrow, pancreas, and activated PBMC. Novel clone 23379 (also referred to as P553S) showed 4.86 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in 97% of prostate tumors and 75% normal prostate and is undetectable in all other normal tissues tested. Novel clone 23399 showed 4.09 fold over-expression in prostate tissues as compared to other normal tissues tested. It was over-expressed in 27% of prostate tumors and was undetectable in all normal tissues tested including normal prostate tissues. Novel clone 23320 showed 3.15 fold over-expression in prostate tissues as compared to other normal tissues tested. It was detectable in all prostate tumors and 50% of normal prostate tissues. It was also expressed in normal colon and trachea. Other normal tissues do not express this gene at high level.

Subsequent full-length cloning studies on P553S, using standard techniques, revealed that this clone is an incomplete spliced form of P501S. The determined cDNA sequences for four splice variants of P553S are provided in SEQ ID NO: 623-626. An amino acid sequence encoded by SEQ ID NO: 626 is provided in SEQ ID NO: 627. The cDNA sequence of SEQ ID NO: 623 was found to contain two open reading frames (ORFs). The amino acid sequences encoded by these two ORFs are provided in SEQ ID NO: 628 and 629.

EXAMPLE 14

IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY ELECTRONIC SUBTRACTION

This Example describes the use of an electronic subtraction technique to identify prostate-specific antigens.

Potential prostate-specific genes present in the GenBank human EST database were identified by electronic subtraction (similar to that described by Vasmatizis et al., *Proc. Natl. Acad. Sci. USA* 95:300-304, 1998). The sequences of EST clones (43,482) derived from various prostate libraries were obtained from the GenBank public human EST database. Each prostate EST sequence was used as a query sequence in a BLASTN (National Center for Biotechnology Information) search against the human EST database. All matches considered identical (length of matching sequence >100 base pairs, density of identical matches over this region > 70%) were grouped (aligned) together in a cluster. Clusters containing more than 200 ESTs were discarded since they probably represented repetitive elements or highly expressed genes such as those for ribosomal proteins. If two or more clusters shared common ESTs, those clusters were grouped together into a "supercluster," resulting in 4,345 prostate superclusters.

Records for the 479 human cDNA libraries represented in the GenBank release were downloaded to create a database of these cDNA library records. These 479 cDNA libraries were grouped into three groups: Plus (normal prostate and prostate tumor libraries, and breast cell line libraries, in which expression was desired), Minus (libraries from other normal adult tissues, in which expression was not desirable), and Other (libraries from fetal tissue, infant tissue, tissues found only in women, non-prostate tumors and cell lines other than prostate cell lines, in which expression was considered to be irrelevant). A summary of these library groups is presented in Table II.

Table II
Prostate cDNA Libraries and ESTs

Library	# of Libraries	# of ESTs
Plus	25	43,482
Normal	11	18,875
Tumor	11	21,769
Cell lines	3	2,838
Minus	166	
Other	287	

- 5 Each supercluster was analyzed in terms of the ESTs within the supercluster. The tissue source of each EST clone was noted and used to classify the superclusters into four groups: Type 1- EST clones found in the Plus group libraries only; no expression detected in Minus or Other group libraries; Type 2- EST clones derived from the Plus and Other group libraries only; no expression detected in the
- 10 Minus group; Type 3- EST clones derived from the Plus, Minus and Other group libraries, but the number of ESTs derived from the Plus group is higher than in either the Minus or Other groups; and Type 4- EST clones derived from Plus, Minus and Other group libraries, but the number derived from the Plus group is higher than the number derived from the Minus group. This analysis identified 4,345 breast clusters
- 15 (see Table III). From these clusters, 3,172 EST clones were ordered from Research Genetics, Inc., and were received as frozen glycerol stocks in 96-well plates.

Table III
Prostate Cluster Summary

Type	# of Superclusters	# of ESTs Ordered
1	688	677
2	2899	2484
3	85	11
4	673	0
Total	4345	3172

5 The EST clone inserts were PCR-amplified using amino-linked PCR primers for Synteni microarray analysis. When more than one PCR product was obtained for a particular clone, that PCR product was not used for expression analysis. In total, 2,528 clones from the electronic subtraction method were analyzed by microarray analysis to identify electronic subtraction breast clones that had high levels
10 of tumor vs. normal tissue mRNA. Such screens were performed using a Synteni (Palo Alto, CA) microarray, according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Within these analyses, the clones were arrayed on the chip, which was then probed with fluorescent probes
15 generated from normal and tumor prostate cDNA, as well as various other normal tissues. The slides were scanned and the fluorescence intensity was measured.

 Clones with an expression ratio greater than 3 (*i.e.*, the level in prostate tumor and normal prostate mRNA was at least three times the level in other normal tissue mRNA) were identified as prostate tumor-specific sequences (Table IV). The
20 sequences of these clones are provided in SEQ ID NO: 401-453, with certain novel sequences shown in SEQ ID NO: 407, 413, 416-419, 422, 426, 427 and 450.

Table IV

Prostate-tumor Specific Clones

SEQ ID NO.	Sequence Designation	Comments
401	22545	previously identified P1000C
402	22547	previously identified P704P
403	22548	known
404	22550	known
405	22551	PSA
406	22552	prostate secretory protein 94
407	22553	novel
408	22558	previously identified P509S
409	22562	glandular kallikrein
410	22565	previously identified P1000C
411	22567	PAP
412	22568	B1006C (breast tumor antigen)
413	22570	novel
414	22571	PSA
415	22572	previously identified P706P
416	22573	novel
417	22574	novel
418	22575	novel
419	22580	novel
420	22581	PAP
421	22582	prostatic secretory protein 94
422	22583	novel
423	22584	prostatic secretory protein 94
424	22585	prostatic secretory protein 94
425	22586	known
426	22587	novel
427	22588	novel
428	22589	PAP
429	22590	known
430	22591	PSA
431	22592	known
432	22593	Previously identified P777P
433	22594	T cell receptor gamma chain
434	22595	Previously identified P705P
435	22596	Previously identified P707P
436	22847	PAP
437	22848	known
438	22849	prostatic secretory protein 57

439	22851	PAP
440	22852	PAP
441	22853	PAP
442	22854	previously identified P509S
443	22855	previously identified P705P
444	22856	previously identified P774P
445	22857	PSA
446	23601	previously identified P777P
447	23602	PSA
448	23605	PSA
449	23606	PSA
450	23612	novel
451	23614	PSA
452	23618	previously identified P1000C
453	23622	previously identified P705P

Further studies on the clone of SEQ ID NO: 407 (also referred to as P1020C) led to the isolation of an extended cDNA sequence provided in SEQ ID NO: 591. This extended cDNA sequence was found to contain an open reading frame that
5 encodes the predicted amino acid sequence of SEQ ID NO: 592. The P1020C cDNA and amino acid sequences were found to show some similarity to the human endogenous retroviral HERV-K pol gene and protein.

EXAMPLE 15

10 FURTHER IDENTIFICATION OF PROSTATE-SPECIFIC ANTIGENS BY MICROARRAY ANALYSIS

This Example describes the isolation of additional prostate-specific polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library as described above
15 was screened using microarray analysis to identify clones that display at least a three fold over-expression in prostate tumor and/or normal prostate tissue, as compared to non-prostate normal tissues (not including testis). 142 clones were identified and sequenced. Certain of these clones are shown in SEQ ID NO: 454-467. Of these sequences, SEQ ID NO: 459-460 represent novel genes. The others (SEQ ID NO: 454-
20 458 and 461-467) correspond to known sequences. Comparison of the determined

cDNA sequence of SEQ ID NO: 461 with sequences in the Genbank database using the BLAST program revealed homology to the previously identified transmembrane protease serine 2 (TMPRSS2). The full-length cDNA sequence for this clone is provided in SEQ ID NO: 751, with the corresponding amino acid sequence being
5 provided in SEQ ID NO: 752. The cDNA sequence encoding the first 209 amino acids of TMPRSS2 is provided in SEQ ID NO: 753, with the first 209 amino acids being provided in SEQ ID NO: 754.

The sequence of SEQ ID NO: 462 (referred to as P835P) was found to correspond to the previously identified clone FLJ13518 (Accession AK023643; SEQ ID
10 NO: 774), which had no associated open reading frame (ORF). This clone was used to search the Geneseq DNA database and matched a clone previously identified as a G protein-coupled receptor protein (DNA Geneseq Accession A09351; amino acid Geneseq Accession Y92365), that is characterized by the presence of seven transmembrane domains. The sequences of fragments between these domains are
15 provided in SEQ ID NO: 778-785, with SEQ ID NO: 778, 780, 782 and 784 representing extracellular domains and SEQ ID NO: 779, 781, 783 and 785 representing intracellular domains. SEQ ID NO: 778-785 represent amino acids 1-28, 53-61, 83-103, 124-143, 165-201, 226-238, 263-272 and 297-381, respectively, of P835P. The full-length cDNA sequence for P835P is provided in SEQ ID NO: 773. The cDNA
20 sequence of the open reading frame for P835P, including stop codon, is provided in SEQ ID NO: 775, with the open reading frame without stop codon being provided in SEQ ID NO: 776 and the corresponding amino acid sequence being provided in SEQ ID NO: 777.

25

EXAMPLE 16

FURTHER CHARACTERIZATION OF PROSTATE-SPECIFIC ANTIGEN P710P

This Example describes the full length cloning of P710P.

The prostate cDNA library described above was screened with the P710P
30 fragment described above. One million colonies were plated on LB/Ampicillin plates.

Nylon membrane filters were used to lift these colonies, and the cDNAs picked up by these filters were then denatured and cross-linked to the filters by UV light. The P710P fragment was radiolabeled and used to hybridize with the filters. Positive cDNA clones were selected and their cDNAs recovered and sequenced by an automatic Perkin Elmer/Applied Biosystems Division Sequencer. Four sequences were obtained, and are presented in SEQ ID NO: 468-471. These sequences appear to represent different splice variants of the P710P gene. Subsequent comparison of the cDNA sequences of P710P with those in Genbank revealed homology to the DD3 gene (Genbank accession numbers AF103907 & AF103908). The cDNA sequence of DD3 is provided in SEQ ID NO: 618.

EXAMPLE 17

PROTEIN EXPRESSION OF PROSTATE-SPECIFIC ANTIGENS

This example describes the expression and purification of prostate-specific antigens in *E. coli*, baculovirus, mammalian and yeast cells.

a) Expression of P501S in *E. coli*

Expression of the full-length form of P501S was attempted by first cloning P501S without the leader sequence (amino acids 36-553 of SEQ ID NO: 113) downstream of the first 30 amino acids of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) in pET17b. Specifically, P501S DNA was used to perform PCR using the primers AW025 (SEQ ID NO: 485) and AW003 (SEQ ID NO: 486). AW025 is a sense cloning primer that contains a HindIII site. AW003 is an antisense cloning primer that contains an EcoRI site. DNA amplification was performed using 5 μ l 10X Pfu buffer, 1 μ l 20 mM dNTPs, 1 μ l each of the PCR primers at 10 μ M concentration, 40 μ l water, 1 μ l Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1 μ l DNA at 100 ng/ μ l. Denaturation at 95°C was performed for 30 sec, followed by 10 cycles of 95°C for 30 sec, 60°C for 1 min and by 72°C for 3 min. 20 cycles of 95°C for 30 sec, 65°C for 1 min and by 72°C for 3 min, and lastly by 1 cycle of 72°C for 10 min. The PCR product was

cloned to Ra12m/pET17b using HindIII and EcoRI. The sequence of the resulting fusion construct (referred to as Ra12-P501S-F) was confirmed by DNA sequencing.

The fusion construct was transformed into BL21(DE3)pLysE, pLysS and CodonPlus *E. coli* (Stratagene) and grown overnight in LB broth with kanamycin. The
5 resulting culture was induced with IPTG. Protein was transferred to PVDF membrane and blocked with 5% non-fat milk (in PBS-Tween buffer), washed three times and incubated with mouse anti-His tag antibody (Clontech) for 1 hour. The membrane was washed 3 times and probed with HRP-Protein A (Zymed) for 30 min. Finally, the membrane was washed 3 times and developed with ECL (Amersham). No expression
10 was detected by Western blot. Similarly, no expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage (Invitrogen).

An N-terminal fragment of P501S (amino acids 36-325 of SEQ ID NO: 113) was cloned down-stream of the first 30 amino acids of the *M. tuberculosis* antigen Ra12 in pET17b as follows. P501S DNA was used to perform PCR using the primers
15 AW025 (SEQ ID NO: 485) and AW027 (SEQ ID NO: 487). AW027 is an antisense cloning primer that contains an EcoRI site and a stop codon. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The fusion construct (referred to as
20 Ra12-P501S-N) was confirmed by DNA sequencing.

The Ra12-P501S-N fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, essentially as described above. Using Western blot analysis, protein bands were observed at the expected molecular weight of 36 kDa. Some high molecular weight bands were also observed, probably due to
25 aggregation of the recombinant protein. No expression was detected by Western blot when the Ra12-P501S-F fusion was used for expression in BL21CodonPlus by CE6 phage.

A fusion construct comprising a C-terminal portion of P501S (amino acids 257-553 of SEQ ID NO: 113) located down-stream of the first 30 amino acids of
30 the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 484) was prepared as follows. P501S

DNA was used to perform PCR using the primers AW026 (SEQ ID NO: 488) and AW003 (SEQ ID NO: 486). AW026 is a sense cloning primer that contains a HindIII site. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the HindIII and EcoRI sites. The
5 sequence for the fusion construct (referred to as Ra12-P501S-C) was confirmed.

The Ra12-P501S-C fusion construct was used for expression in BL21(DE3)pLysE, pLysS and CodonPlus, as described above. A small amount of protein was detected by Western blot, with some molecular weight aggregates also being observed. Expression was also detected by Western blot when the Ra12-P501S-C
10 fusion was used for expression in BL21CodonPlus induced by CE6 phage.

A fusion construct comprising a fragment of P501S (amino acids 36-298 of SEQ ID NO: 113) located down-stream of the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 705) was prepared as follows. P501S DNA was used to perform PCR using the primers AW042 (SEQ ID NO: 706) and AW053 (SEQ ID NO: 707). AW042 is a sense
15 cloning primer that contains a EcoRI site. AW053 is an antisense primer with stop and Xho I sites. DNA amplification was performed essentially as described above. The resulting PCR product was cloned to Ra12 in pET17b at the EcoRI and Xho I sites. The resulting fusion construct (referred to as Ra12-P501S-E2) was expressed in B834 (DE3) pLys S *E. coli* host cells in TB media for 2 h at room temperature. Expressed protein
20 was purified by washing the inclusion bodies and running on a Ni-NTA column. The purified protein stayed soluble in buffer containing 20 mM Tris-HCl (pH 8), 100 mM NaCl, 10 mM β -Me and 5% glycerol. The determined cDNA and amino acid sequences for the expressed fusion protein are provided in SEQ ID NO: 708 and 709, respectfully.

25 b) Expression of P501S in Baculovirus

The Bac-to-Bac baculovirus expression system (BRL Life Technologies, Inc.) was used to express P501S protein in insect cells. Full-length P501S (SEQ ID NO: 113) was amplified by PCR and cloned into the XbaI site of the donor plasmid pFastBacI. The recombinant bacmid and baculovirus were prepared according to the

manufacturer's instructions. The recombinant baculovirus was amplified in Sf9 cells and the high titer viral stocks were utilized to infect High Five cells (Invitrogen) to make the recombinant protein. The identity of the full-length protein was confirmed by N-terminal sequencing of the recombinant protein and by Western blot analysis (Figure 7). Specifically, 0.6 million High Five cells in 6-well plates were infected with either the unrelated control virus BV/ECD_PD (lane 2), with recombinant baculovirus for P501S at different amounts or MOIs (lanes 4-8), or were uninfected (lane 3). Cell lysates were run on SDS-PAGE under reducing conditions and analyzed by Western blot with the anti-P501S monoclonal antibody P501S-10E3-G4D3 (prepared as described below). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

The localization of recombinant P501S in the insect cells was investigated as follows. The insect cells overexpressing P501S were fractionated into fractions of nucleus, mitochondria, membrane and cytosol. Equal amounts of protein from each fraction were analyzed by Western blot with a monoclonal antibody against P501S. Due to the scheme of fractionation, both nucleus and mitochondria fractions contain some plasma membrane components. However, the membrane fraction is basically free from mitochondria and nucleus. P501S was found to be present in all fractions that contain the membrane component, suggesting that P501S may be associated with plasma membrane of the insect cells expressing the recombinant protein.

c) Expression of P501S in Mammalian Cells

Full-length P501S (553 amino acids; SEQ ID NO: 113) was cloned into various mammalian expression vectors, including pCEP4 (Invitrogen), pVR1012 (Vical, San Diego, CA) and a modified form of the retroviral vector pBMN, referred to as pBIB. Transfection of P501S/pCEP4 and P501S/pVR1012 into HEK293 fibroblasts was carried out using the Fugene transfection reagent (Boehringer Mannheim). Briefly, 2 ul of Fugene reagent was diluted into 100 ul of serum-free media and incubated at room temperature for 5-10 min. This mixture was added to 1 ug of P501S plasmid DNA, mixed briefly and incubated for 30 minutes at room temperature. The

Fugene/DNA mixture was added to cells and incubated for 24-48 hours. Expression of recombinant P501S in transfected HEK293 fibroblasts was detected by means of Western blot employing a monoclonal antibody to P501S.

Transfection of p501S/pCEP4 into CHO-K cells (American Type Culture Collection, Rockville, MD) was carried out using GenePorter transfection reagent (Gene Therapy Systems, San Diego, CA). Briefly, 15 μ l of GenePorter was diluted in 500 μ l of serum-free media and incubated at room temperature for 10 min. The GenePorter/media mixture was added to 2 μ g of plasmid DNA that was diluted in 500 μ l of serum-free media, mixed briefly and incubated for 30 min at room temperature. CHO-K cells were rinsed in PBS to remove serum proteins, and the GenePorter/DNA mix was added and incubated for 5 hours. The transfected cells were then fed an equal volume of 2x media and incubated for 24-48 hours.

FACS analysis of P501S transiently infected CHO-K cells, demonstrated surface expression of P501S. Expression was detected using rabbit polyclonal antisera raised against a P501S peptide, as described below. Flow cytometric analysis was performed using a FaCScan (Becton Dickinson), and the data were analyzed using the Cell Quest program.

d) Expression of P501S in *S. cerevisiae*

P501S was expressed in yeast, directed in membranes, using the yeast α prepro signal sequence. The natural signal sequence and first luminal domain of P501S was deleted in order to conserve the natural positioning of the expressed P501S protein.

Specifically, the α prepro signal sequence of *S. cerevisiae* linked to amino acids 55-553 of SEQ ID NO: 113 with a His tag tail was cloned into the plasmid pRIT15068 with the CUP1 promoter and transfected into *S. cerevisiae* strain Y1790. The Y1790 strain is Leu⁺ and His⁻. Expression of protein was induced by addition of either 500 μ M or 250 μ M of CuSO₄ at 30 °C in minimal medium supplemented with histidine. Cells were harvested 24 hours after induction. Extracts were prepared by growing cells to a concentration of OD600 5.0 in 50 mM citrate phosphate buffer (pH 4.0) plus 130 mM NaCl supplemented with protease inhibitors. Cells were disrupted

using glass beads and centrifuged for 20 min at 15,000 g. The recombinant protein was found to be 100% pellet associated.

Expression of the recombinant protein (molecular weight 63 kD) was demonstrated by Western blot analysis, using the anti-P501S monoclonal antibody 10E-D4-G3 described below. The amino acid sequence of the expressed protein is provided in SEQ ID NO: 792.

Fermentation processes for the production of the α prepro-P501S-His tag recombinant protein in *S. cerevisiae* (strain Y1790 – CUP1 inducible promoter) were evaluated as follows. One hundred μ l of a master seed containing 2.5×10^8 cells/ml of transformed *S. cerevisiae* Y1790 were spread on FSC004AA solid medium. The composition of the FSC004AA medium is as follows: glucose 10 g/l; $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ 0.0002 g/l; folic acid 0.000064 g/l; KH_2PO_4 1 g/l; $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 0.0004 g/l; Inositol 0.064 g/l; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.5 g/l; H_3BO_3 0.0005 g/l; Pyridoxine 0.008 g/l; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.00009 g/l; Niacin 0.000032 g/l; $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ 0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0.0004 g/l; $(\text{NH}_4)_2\text{SO}_4$ 5 g/l; agar 18 g/l; Histidine 0.1 g/l.

Two plates were incubated for 26 h at 30 °C. These solid pre-cultures were harvested in 5 ml of liquid medium FSC007AA and 0.5 ml (or 9.3×10^7 cells) of this suspension was used to inoculate 2 liquid pre-cultures.

The composition of the FSC007AA medium is as follows: Glucose 10 g/l; $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ 0.0002 g/l; folic acid 0.000064 g/l; KH_2PO_4 1 g/l; $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 0.0004 g/l; Inositol 0.064 g/l; $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.5 g/l; H_3BO_3 0.0005 g/l; Pyridoxine 0.008 g/l; $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 0.1 g/l; KI 0.0001 g/l; Thiamine 0.008 g/l; NaCl 0.1 g/l; $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.00009 g/l; Niacine 0.000032 g/l; $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ 0.0002 g/l; Riboflavin 0.000016 g/l; Panthotenate Ca 0.008 g/l; $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 0.00004 g/l; Biotin 0.000064 g/l; para-aminobenzoic acid 0.000016 g/l; $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 0.0004 g/l; $(\text{NH}_4)_2\text{SO}_4$ 5 g/l; Histidine 0.1 g/l.

These pre-cultures were run for 20 hours in 2L flasks containing 400 ml of medium FSC007AA in order to obtain an OD of 1.8. The other characteristics of these pre-cultures are as follows: pH 2.8; glucose 2.3 g/L; ethanol 3.4 g/L.

The best timing for liquid pre-cultures for strain Y1790 was determined in preliminary experiments. Liquid pre-cultures containing 400 ml of medium and inoculated with various volumes of Master Seed (0.25, 0.5, 1 or 2 ml) were monitored in order to identify the best inoculum size and timing. Glucose, ethanol, pH, OD and
5 cell number (determined by flow cytometry) were followed between 16 and 23 hours of culture. Glucose exhaustion and maximal biomass were obtained after 20 hour incubation with 0.5 inoculum. These conditions were adopted for transferring the pre-culture into fermentation.

In total, 800ml of pre-culture were used to inoculate a 20 L fermenter
10 containing 5L of medium FSC002AA. Three ml of irradiated antifoam were added before inoculation. The composition of the FSC002AA medium is as follows:
(NH₄)₂SO₄ 6.4 g/l; Na₂MoO₄·2H₂O 2.05 mg/l; folic acid 0.54 mg/l; KH₂PO₄ 8.25 g/l;
MnSO₄·H₂O 4.1 mg/l; inositol 540 mg/l; MgSO₄·7H₂O 4.69 g/l; H₃BO₃ 5.17 mg/l;
pyridoxine 68 mg/l; CaCl₂·2H₂O 0.92 g/l; KI 1.03 mg/l; thiamine 68 mg/l; NaCl 0.06g/l;
15 CoCl₂·6H₂O 0.92 mg/l; Niacine 0.27 mg/l; HCl 1 ml/l; FeCl₃·6H₂O 9.92 mg/l;
Riboflavin 0.13 mg/l; CuSO₄·5H₂O 0.41 mg/l; Glucose 0.14 g/l; Panthotenate Ca 68
mg/l; ZnSO₄·7H₂O 4.1 mg/l; Biotin 0.54 mg/l; para-aminobenzoic acid 0.13 mg/l;
Histidine 0.3 g/l

The carbon source (glucose) was supplemented by a continuous feeding
20 of FFB004AA medium. The composition of the FFB004AA medium is as follows:
glucose 350 g/l; Na₂MoO₄·2H₂O 5.15 mg/l; folic acid 1.36 mg/l; KH₂PO₄ 20.6 g/l;
MnSO₄·H₂O 10.3 mg/l; inositol 1350 mg/l; MgSO₄·7H₂O 11.7 g/l; H₃BO₃ 12.9 mg/l;
pyridoxine 170 mg/l; CaCl₂·2H₂O 2.35 g/l; KI 2.6 mg/l; thiamine 170 mg/l; NaCl 0.15 g/l;
CoCl₂·6H₂O 2.3 mg/l; niacine 0.67 mg/l; HCl 2.5 ml/l; FeCl₃·6H₂O 24.8 mg/l;
25 riboflavin; 0.33 mg/l; CuSO₄·5H₂O 1.03 mg/l; biotin 1.36 mg/l; panthotenate Ca 170
mg/l; ZnSO₄·7H₂O 10.3 mg/l; para-aminobenzoic acid: 0.33 mg/l; histidine 5.35 g/l.

The residual glucose concentration was maintained very low (≤ 50 mg/L)
in order to minimize ethanol production by fermentation. This was achieved by limiting
the development of the microorganism using a limited glucose feed rate. The Standard
30 biomass content (OD 80-90) was reached in fermentation after 44 hour growth phase.

CUP1 promoter was then induced by adding 500 μ M CuSO₄ in order to

produce P501S antigen. CuSO_4 addition was followed by ethanol accumulation (up to 6 g/L), and the glucose feeding rate was then reduced in order to consume the ethanol. The copper available for the microorganism was monitored by testing Cu ion concentration in the broth supernatant using a spectrophotometric copper assay (DETC
5 method). The fermentation was then supplemented by CuSO_4 throughout the induction phase in order to maintain its concentration between 150 and 250 μM in the supernatant. The biomass reached an OD of 100 at the end of induction. Cells were harvested after 8 hours of induction.

Cell homogenate was prepared and analysed by SDS-PAGE and Western
10 Blot using standard protocols. A major protein band with the expected molecular weight of 62KD was detected by Western blot using anti-P501S monoclonal antibodies. Western blot analysis also showed that the major 62KD band was progressively produced from 30 minutes of induction on, and reached a maximum after 3 hours. No more antigen seemed to be produced between 3 and 12 hours of induction.

15 The number of passages through a French Press necessary to extract all the antigen from the cells was evaluated. One, three and five passages were tested and total cell lysates, supernatants and pellets of cell lysates were analysed by Western blot. Three passages through a French Press were sufficient to completely extract the antigen. The antigen was present in the insoluble fraction.

20

e) Expression of P703P in Baculovirus

The cDNA for full-length P703P-DE5 (SEQ ID NO: 326), together with several flanking restriction sites, was obtained by digesting the plasmid pCDNA703 with restriction endonucleases Xba I and Hind III. The resulting restriction fragment
25 (approx. 800 base pairs) was ligated into the transfer plasmid pFastBacI which was digested with the same restriction enzymes. The sequence of the insert was confirmed by DNA sequencing. The recombinant transfer plasmid pFBP703 was used to make recombinant bacmid DNA and baculovirus using the Bac-To-Bac Baculovirus expression system (BRL Life Technologies). High Five cells were infected with the
30 recombinant virus BVP703, as described above, to obtain recombinant P703P protein.

e) Expression of P788P in *E. Coli*

A truncated, N-terminal portion, of P788P (residues 1-644 of SEQ ID NO: 777; referred to as P788P-N) fused with a C-terminal 6xHis Tag was expressed in *E. coli* as follows. P788P cDNA was amplified using the primers AW080 and AW081 (SEQ ID NO: 672 and 673). AW080 is a sense cloning primer with an NdeI site. AW081 is an antisense cloning primer with a XhoI site. The PCR-amplified P788P, as well as the vector pCRX1, were digested with NdeI and XhoI. Vector and insert were ligated and transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. P788P-N clone #6 was confirmed to be identical to the designed construct. The expression construct P788P-N #6/pCRX1 was transformed into *E. coli* BL21 CodonPlus-RIL competent cells. After induction, most of the cells grew well, achieving OD600 of greater than 2.0 after 3 hr. Coomassie stained SDS-PAGE showed an over-expressed band at about 75 kD. Western blot analysis using a 6xHisTag antibody confirmed the band was P788P-N. The determined cDNA sequence for P788P-N is provided in SEQ ID NO: 674, with the corresponding amino acid sequence being provided in SEQ ID NO: 675.

f) Expression of P510S in *E. Coli*

The P510S protein has 9 potential transmembrane domains and is predicted to be located at the plasma membrane. The C-terminal protein of this protein, as well as the predicted third extracellular domain of P510S were expressed in *E. coli* as follows.

The expression construct referred to as Ra12-P501S-C was designed to have a 6 HisTag at the N-terminal end, followed by the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and then the C-terminal portion of P510S (amino residues 1176-1261 of SEQ ID NO: 538). Full-length P510S was used to amplify the P510S-C fragment by PCR using the primers AW056 and AW057 (SEQ ID NO: 677 and 678, respectively). AW056 is a sense cloning primer with an EcoRI site. AW057 is an antisense primer with stop and XhoI sites. The amplified P501S fragment and Ra12/pCRX1 were digested with EcoRI and XhoI and then purified. The insert and

vector were ligated together and transformed into NovaBlue. Colonies were randomly screened for insert and sequences. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. A mini-induction screen was performed to optimize the expression conditions. After induction
5 the cells grew well, achieving OD 600 nm greater than 2.0 after 3 hours. Coomassie stain SDS-PAGE showed a highly over-expressed band at approx. 30 kD. Though this is higher than the expected molecular weight, western blot analysis was positive, showing this band to be the His tag-containing protein. The optimized culture conditions are as follows. Dilute overnight culture/daytime culture (LB + kanamycin +
10 chloramphenicol) into 2xYT (with kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2xYT. Allow to grow at 37 °C until OD600 = 0.6. Take an aliquot out as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3 sample, spin down cells and store at -80 °C. The determined cDNA and amino acid sequences for the Ra12-P510S-C construct are provided in SEQ ID NO: 679 and 682,
15 respectively.

The expression construct P510S-C was designed to have a 5' added start codon and a glycine (GGA) codon and then the P510S C terminal fragment followed by the in frame 6x histidine tag and stop codon from the pET28b vector. The cloning strategy is similar to that used for Ra12-P510S-C, except that the PCR primers employed were
20 those shown in SEQ ID NO: 685 and 686, respectively and the NcoI/XhoI cut in pET28b was used. The primer of SEQ ID NO: 685 created a 5' NcoI site and added a start codon. The antisense primer of SEQ ID NO: 686 creates a XhoI site on P510S C terminal fragment. Clones were confirmed by sequencing. For protein expression, the expression construct was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL
25 competent cells. An OD600 of greater than 2.0 was obtained 30 hours after induction. Coomassie stained SDS-PAGE showed an over-expressed band at about 11 kD. Western blot analysis confirmed that the band was P510S-C, as did N-terminal protein sequencing. The optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (+ kanamycin
30 and chloramphenicol) at a ratio of 25 mL culture to 1 liter 2x YT, and allow to grow at

37 °C until an OD 600 of about 0.5 is reached. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P510S-C construct are shown in SEQ ID NO: 680 and 683, respectively.

- 5 The predicted third extracellular domain of P510S (P510S-E3; residues 328-676 of SEQ ID NO: 538) was expressed in *E. coli* as follows. The P510S fragment was amplified by PCR using the primers shown in SEQ ID NO: 687 and 688. The primer of SEQ ID NO: 687 is a sense primer with an NdeI site for use in ligating into pPDM. The primer of SEQ ID NO: 688 is an antisense primer with an added XhoI site
- 10 for use in ligating into pPDM. The resulting fragment was cloned to pPDM at the NdeI and XhoI sites. Clones were confirmed by sequencing. For protein expression, the clone was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. After induction, an OD600 of greater than 2.0 was achieved after 3 hours. Coomassie stained SDS-PAGE showed an over-expressed band at about 39 kD, and N-terminal sequencing
- 15 confirmed the N-terminal to be that of P510S-E3. Optimized culture conditions are as follows: dilute overnight culture/daytime culture (LB + kanamycin + chloramphenicol) into 2x YT (kanamycin and chloramphenicol) at a ratio of 25 ml culture to 1 liter 2x YT. Allow to grow at 37 °C until OD 600 equals 0.6. Take out an aliquot as T0 sample. Add 1 mM IPTG and allow to grow at 30 °C for 3 hours. Take out a T3
- 20 sample, spin down the cells and store at -80 °C until purification. The determined cDNA and amino acid sequences for the P501S-E3 construct are provided in SEQ ID NO: 681 and 684, respectively.

g) Expression of P775S in *E. Coli*

- 25 The antigen P775P contains multiple open reading frames (ORF). The third ORF, encoding the protein of SEQ ID NO: 483, has the best motif score. An expression fusion construct containing the *M. tuberculosis* antigen Ra12 (SEQ ID NO: 676) and P775P-ORF3 with an N-terminal 6x HisTag was prepared as follows. P775P-ORF3 was amplified using the sense PCR primers of SEQ ID NO: 689 and the anti-sense PCR primer of SEQ ID NO: 690. The PCR amplified fragment of P775P and

Ra12/pCRX1 were digested with the restriction enzymes EcoRI and XhoI. Vector and insert were ligated and then transformed into NovaBlue cells. Colonies were randomly screened for insert and then sequenced. A clone having the desired sequence was transformed into *E. coli* BL21 (DE3) CodonPlus-RIL competent cells. Two hours after
5 induction, the cell density peaked at OD600 of approximately 1.8. Coomassie stained SDS-PAGE showed an over-expressed band at about 31 kD. Western blot using 6x HisTag antibody confirmed that the band was Ra12-P775P-ORF3. The determined cDNA and amino acid sequences for the fusion construct are provided in SEQ ID NO: 691 and 692, respectively.

10

H) EXPRESSION OF A P703P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P703P was prepared by PCR using the primers of SEQ ID NO: 693 and 694. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag
15 in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P703P are provided in SEQ ID NO: 695 and 696, respectively.

20

I) EXPRESSION OF A P705P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P705P was prepared by PCR using the primers of SEQ ID NO: 697 and 698. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag
25 in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P705P are provided in SEQ ID NO: 699 and 700, respectively.

30

J) EXPRESSION OF A P711P HIS TAG FUSION PROTEIN IN *E. COLI*

The cDNA for the coding region of P711P was prepared by PCR using the primers of SEQ ID NO: 701 and 702. The PCR product was digested with EcoRI restriction enzyme, gel purified and cloned into a modified pET28 vector with a His tag in frame, which had been digested with Eco72I and EcoRI restriction enzymes. The correct construct was confirmed by DNA sequence analysis and then transformed into *E. coli* BL21 (DE3) pLys S and BL21 (DE3) CodonPlus expression host cells. The determined amino acid and cDNA sequences for the expressed recombinant P711P are provided in SEQ ID NO: 703 and 704, respectively.

10

EXAMPLE 18

PREPARATION AND CHARACTERIZATION OF ANTIBODIES

AGAINST PROSTATE-SPECIFIC POLYPEPTIDES

15

a) Preparation and Characterization of Polyclonal Antibodies against P703P,

P504S and P509S

Polyclonal antibodies against P703P, P504S and P509S were prepared as follows.

20

Each prostate tumor antigen expressed in an *E. coli* recombinant expression system was grown overnight in LB broth with the appropriate antibiotics at 37°C in a shaking incubator. The next morning, 10 ml of the overnight culture was added to 500 ml to 2x YT plus appropriate antibiotics in a 2L-baffled Erlenmeyer flask. When the Optical Density (at 560 nm) of the culture reached 0.4-0.6, the cells were induced with IPTG (1 mM). Four hours after induction with IPTG, the cells were harvested by centrifugation. The cells were then washed with phosphate buffered saline and centrifuged again. The supernatant was discarded and the cells were either frozen for future use or immediately processed. Twenty ml of lysis buffer was added to the cell pellets and vortexed. To break open the *E. coli* cells, this mixture was then run

25

through the French Press at a pressure of 16,000 psi. The cells were then centrifuged again and the supernatant and pellet were checked by SDS-PAGE for the partitioning of the recombinant protein. For proteins that localized to the cell pellet, the pellet was resuspended in 10 mM Tris pH 8.0, 1% CHAPS and the inclusion body pellet was washed and centrifuged again. This procedure was repeated twice more. The washed inclusion body pellet was solubilized with either 8 M urea or 6 M guanidine HCl containing 10 mM Tris pH 8.0 plus 10 mM imidazole. The solubilized protein was added to 5 ml of nickel-chelate resin (Qiagen) and incubated for 45 min to 1 hour at room temperature with continuous agitation. After incubation, the resin and protein mixture were poured through a disposable column and the flow through was collected. The column was then washed with 10-20 column volumes of the solubilization buffer. The antigen was then eluted from the column using 8M urea, 10 mM Tris pH 8.0 and 300 mM imidazole and collected in 3 ml fractions. A SDS-PAGE gel was run to determine which fractions to pool for further purification.

As a final purification step, a strong anion exchange resin such as HiPrepQ (Biorad) was equilibrated with the appropriate buffer and the pooled fractions from above were loaded onto the column. Each antigen was eluted off the column with a increasing salt gradient. Fractions were collected as the column was run and another SDS-PAGE gel was run to determine which fractions from the column to pool. The pooled fractions were dialyzed against 10 mM Tris pH 8.0. The proteins were then vialled after filtration through a 0.22 micron filter and the antigens were frozen until needed for immunization.

Four hundred micrograms of each prostate antigen was combined with 100 micrograms of muramyl dipeptide (MDP). Every four weeks rabbits were boosted with 100 micrograms mixed with an equal volume of Incomplete Freund's Adjuvant (IFA). Seven days following each boost, the animal was bled. Sera was generated by incubating the blood at 4°C for 12-4 hours followed by centrifugation.

Ninety-six well plates were coated with antigen by incubating with 50 microliters (typically 1 microgram) of recombinant protein at 4 °C for 20 hours. 250 microliters of BSA blocking buffer was added to the wells and incubated at room

temperature for 2 hours. Plates were washed 6 times with PBS/0.01% Tween. Rabbit sera was diluted in PBS. Fifty microliters of diluted sera was added to each well and incubated at room temperature for 30 min. Plates were washed as described above before 50 microliters of goat anti-rabbit horse radish peroxidase (HRP) at a 1:10000 dilution was added and incubated at room temperature for 30 min. Plates were again washed as described above and 100 microliters of TMB microwell peroxidase substrate was added to each well. Following a 15 min incubation in the dark at room temperature, the colorimetric reaction was stopped with 100 microliters of 1N H₂SO₄ and read immediately at 450 nm. All polyclonal antibodies showed immunoreactivity to the appropriate antigen.

b) Preparation and Characterization of Antibodies against P501S

A murine monoclonal antibody directed against the carboxy-terminus of the prostate-specific antigen P501S was prepared as follows.

A truncated fragment of P501S (amino acids 355-526 of SEQ ID NO: 113) was generated and cloned into the pET28b vector (Novagen) and expressed in *E. coli* as a thioredoxin fusion protein with a histidine tag. The trx-P501S fusion protein was purified by nickel chromatography, digested with thrombin to remove the trx fragment and further purified by an acid precipitation procedure followed by reverse phase HPLC.

Mice were immunized with truncated P501S protein. Serum bleeds from mice that potentially contained anti-P501S polyclonal sera were tested for P501S-specific reactivity using ELISA assays with purified P501S and trx-P501S proteins. Serum bleeds that appeared to react specifically with P501S were then screened for P501S reactivity by Western analysis. Mice that contained a P501S-specific antibody component were sacrificed and spleen cells were used to generate anti-P501S antibody producing hybridomas using standard techniques. Hybridoma supernatants were tested for P501S-specific reactivity initially by ELISA, and subsequently by FACS analysis of reactivity with P501S transduced cells. Based on these results, a monoclonal hybridoma referred to as 10E3 was chosen for further subcloning. A number of subclones were

generated, tested for specific reactivity to P501S using ELISA and typed for IgG isotype. The results of this analysis are shown below in Table V. Of the 16 subclones tested, the monoclonal antibody 10E3-G4-D3 was selected for further study.

5

Table V

Isotype analysis of murine anti-P501S monoclonal antibodies

Hybridoma clone	Isotype	Estimated [Ig] in supernatant ($\mu\text{g/ml}$)
4D11	IgG1	14.6
1G1	IgG1	0.6
4F6	IgG1	72
4H5	IgG1	13.8
4H5-E12	IgG1	10.7
4H5-EH2	IgG1	9.2
4H5-H2-A10	IgG1	10
4H5-H2-A3	IgG1	12.8
4H5-H2-A10-G6	IgG1	13.6
4H5-H2-B11	IgG1	12.3
10E3	IgG2a	3.4
10E3-D4	IgG2a	3.8
10E3-D4-G3	IgG2a	9.5
10E3-D4-G6	IgG2a	10.4
10E3-E7	IgG2a	6.5
8H12	IgG2a	0.6

The specificity of 10E3-G4-D3 for P501S was examined by FACS analysis. Specifically, cells were fixed (2% formaldehyde, 10 minutes), permeabilized (0.1% saponin, 10 minutes) and stained with 10E3-G4-D3 at 0.5 – 1 $\mu\text{g/ml}$, followed by incubation with a secondary, FITC-conjugated goat anti-mouse Ig antibody (Pharmingen, San Diego, CA). Cells were then analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. For analysis of infected cells, B-LCL were infected with a vaccinia vector that expresses P501S. To demonstrate specificity in these assays, B-LCL transduced with a different antigen (P703P) and uninfected B-LCL vectors were utilized. 10E3-G4-D3 was shown to bind with P501S-transduced B-

LCL and also with P501S-infected B-LCL, but not with either uninfected cells or P703P-transduced cells.

To determine whether the epitope recognized by 10E3-G4-D3 was found on the surface or in an intracellular compartment of cells, B-LCL were transduced with
5 P501S or HLA-B8' as a control antigen and either fixed and permeabilized as described above or directly stained with 10E3-G4-D3 and analyzed as above. Specific recognition of P501S by 10E3-G4-D3 was found to require permeabilization, suggesting that the epitope recognized by this antibody is intracellular.

The reactivity of 10E3-G4-D3 with the three prostate tumor cell lines
10 Lncap, PC-3 and DU-145, which are known to express high, medium and very low levels of P501S, respectively, was examined by permeabilizing the cells and treating them as described above. Higher reactivity of 10E3-G4-D3 was seen with Lncap than with PC-3, which in turn showed higher reactivity than DU-145. These results are in agreement with the real time PCR and demonstrate that the antibody specifically
15 recognizes P501S in these tumor cell lines and that the epitope recognized in prostate tumor cell lines is also intracellular.

Specificity of 10E3-G4-D3 for P501S was also demonstrated by Western blot analysis. Lysates from the prostate tumor cell lines Lncap, DU-145 and PC-3, from P501S-transiently transfected HEK293 cells, and from non-transfected HEK293 cells
20 were generated. Western blot analysis of these lysates with 10E3-G4-D3 revealed a 46 kDa immunoreactive band in Lncap, PC-3 and P501S-transfected HEK cells, but not in DU-145 cells or non-transfected HEK293 cells. P501S mRNA expression is consistent with these results since semi-quantitative PCR analysis revealed that P501S mRNA is expressed in Lncap, to a lesser but detectable level in PC-3 and not at all in DU-145
25 cells. Bacterially expressed and purified recombinant P501S (referred to as P501SStr2) was recognized by 10E3-G4-D3 (24 kDa), as was full-length P501S that was transiently expressed in HEK293 cells using either the expression vector VR1012 or pCEP4. Although the predicted molecular weight of P501S is 60.5 kDa, both transfected and "native" P501S run at a slightly lower mobility due to its hydrophobic nature.

Immunohistochemical analysis was performed on prostate tumor and a panel of normal tissue sections (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder, ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). Tissue samples were fixed in formalin solution for 24 hours and embedded in paraffin before being sliced into 10 micron sections. Tissue sections were permeabilized and incubated with 10E3-G4-D3 antibody for 1 hr. HRP-labeled anti-mouse followed by incubation with DAB chromogen was used to visualize P501S immunoreactivity. P501S was found to be highly expressed in both normal prostate and prostate tumor tissue but was not detected in any of the other tissues tested.

To identify the epitope recognized by 10E3-G4-D3, an epitope mapping approach was pursued. A series of 13 overlapping 20-21 mers (5 amino acid overlap; SEQ ID NO: 489-501) was synthesized that spanned the fragment of P501S used to generate 10E3-G4-D3. Flat bottom 96 well microtiter plates were coated with either the peptides or the P501S fragment used to immunize mice, at 1 microgram/ml for 2 hours at 37 °C. Wells were then aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature, and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified antibody 10E3-G4-D3 was added at 2 fold dilutions (1000 ng – 16 ng) in PBST and incubated for 30 minutes at room temperature. This was followed by washing 6 times with PBST and subsequently incubating with HRP-conjugated donkey anti-mouse IgG (H+L)Affinipure F(ab') fragment (Jackson ImmunoResearch, West Grove, PA) at 1:20000 for 30 minutes. Plates were then washed and incubated for 15 minutes in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As shown in Fig. 8, reactivity was seen with the peptide of SEQ ID NO: 496 (corresponding to amino acids 439-459 of P501S) and with the P501S fragment but not with the remaining peptides, demonstrating that the epitope recognized by 10E3-G4-D3 is localized to amino acids 439-459 of SEQ ID NO: 113.

In order to further evaluate the tissue specificity of P501S, multi-array immunohistochemical analysis was performed on approximately 4700 different human tissues encompassing all the major normal organs as well as neoplasias derived from

these tissues. Sixty-five of these human tissue samples were of prostate origin. Tissue sections 0.6 mm in diameter were formalin-fixed and paraffin embedded. Samples were pretreated with HIER using 10 mM citrate buffer pH 6.0 and boiling for 10 min. Sections were stained with 10E3-G4-D3 and P501S immunoreactivity was visualized with HRP. All the 65 prostate tissues samples (5 normal, 55 untreated prostate tumors, 5 hormone refractory prostate tumors) were positive, showing distinct perinuclear staining. All other tissues examined were negative for P501S expression.

c) Preparation and Characterization of Antibodies against P503S

A fragment of P503S (amino acids 113-241 of SEQ ID NO: 114) was expressed and purified from bacteria essentially as described above for P501S and used to immunize both rabbits and mice. Mouse monoclonal antibodies were isolated using standard hybridoma technology as described above. Rabbit monoclonal antibodies were isolated using Selected Lymphocyte Antibody Method (SLAM) technology at Immgenics Pharmaceuticals (Vancouver, BC, Canada). Table VI, below, lists the monoclonal antibodies that were developed against P503S.

Table VI

Antibody	Species
20D4	Rabbit
JA1	Rabbit
1A4	Mouse
1C3	Mouse
1C9	Mouse
1D12	Mouse
2A11	Mouse
2H9	Mouse
4H7	Mouse
8A8	Mouse
8D10	Mouse
9C12	Mouse
6D12	Mouse

The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 20D4 and JA1 were determined and are provided in SEQ ID NO: 502 and 503, respectively.

5 In order to better define the epitope binding region of each of the antibodies, a series of overlapping peptides were generated that span amino acids 109-213 of SEQ ID NO: 114. These peptides were used to epitope map the anti-P503S monoclonal antibodies by ELISA as follows. The recombinant fragment of P503S that was employed as the immunogen was used as a positive control. Ninety-six well
10 microtiter plates were coated with either peptide or recombinant antigen at 20 ng/well overnight at 4 °C. Plates were aspirated and blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature then washed in PBS containing 0.1% Tween 20 (PBST). Purified rabbit monoclonal antibodies diluted in PBST were added to the wells and incubated for 30 min at room temperature. This was
15 followed by washing 6 times with PBST and incubation with Protein-A HRP conjugate at a 1:2000 dilution for a further 30 min. Plates were washed six times in PBST and incubated with tetramethylbenzidine (TMB) substrate for a further 15 min. The reaction was stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using at ELISA plate reader. ELISA with the mouse monoclonal antibodies was performed with
20 supernatants from tissue culture run neat in the assay.

All of the antibodies bound to the recombinant P503S fragment, with the exception of the negative control SP2 supernatant. 20D4, JA1 and 1D12 bound strictly to peptide #2101 (SEQ ID NO: 504), which corresponds to amino acids 151-169 of SEQ ID NO: 114. 1C3 bound to peptide #2102 (SEQ ID NO: 505), which corresponds
25 to amino acids 165-184 of SEQ ID NO: 114. 9C12 bound to peptide #2099 (SEQ ID NO: 522), which corresponds to amino acids 120-139 of SEQ ID NO: 114. The other antibodies bind to regions that were not examined in these studies.

Subsequent to epitope mapping, the antibodies were tested by FACS analysis on a cell line that stably expressed P503S to confirm that the antibodies bind to
30 cell surface epitopes. Cells stably transfected with a control plasmid were employed as

a negative control. Cells were stained live with no fixative. 0.5 ug of anti-P503S monoclonal antibody was added and cells were incubated on ice for 30 min before being washed twice and incubated with a FITC-labelled goat anti-rabbit or mouse secondary antibody for 20 min. After being washed twice, cells were analyzed with an Excalibur
5 fluorescent activated cell sorter. The monoclonal antibodies 1C3, 1D12, 9C12, 20D4 and JA1, but not 8D3, were found to bind to a cell surface epitope of P503S.

In order to determine which tissues express P503S, immunohistochemical analysis was performed, essentially as described above, on a panel of normal tissues (prostate, adrenal, breast, cervix, colon, duodenum, gall bladder,
10 ileum, kidney, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis). HRP-labeled anti-mouse or anti-rabbit antibody followed by incubation with TMB was used to visualize P503S immunoreactivity. P503S was found to be highly expressed in prostate tissue, with lower levels of expression being observed in cervix, colon, ileum and kidney, and no expression being observed in adrenal, breast, duodenum, gall
15 bladder, ovary, pancreas, parotid gland, skeletal muscle, spleen and testis.

Western blot analysis was used to characterize anti-P503S monoclonal antibody specificity. SDS-PAGE was performed on recombinant (rec) P503S expressed in and purified from bacteria and on lysates from HEK293 cells transfected with full length P503S. Protein was transferred to nitrocellulose and then Western blotted with
20 each of the anti-P503S monoclonal antibodies (20D4, JA1, 1D12, 6D12 and 9C12) at an antibody concentration of 1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to either a goat anti-mouse monoclonal antibody or to protein A-sepharose. The monoclonal antibody 20D4 detected the appropriate molecular weight 14 kDa recombinant P503S (amino acids 113-241) and the 23.5 kDa
25 species in the HEK293 cell lysates transfected with full length P503S. Other anti-P503S monoclonal antibodies displayed similar specificity by Western blot.

d) Preparation and Characterization of Antibodies against P703P

Rabbits were immunized with either a truncated (P703Ptr1; SEQ ID NO: 172) or full-length mature form (P703Pfl; SEQ ID NO: 523) of recombinant P703P

protein was expressed in and purified from bacteria as described above. Affinity purified polyclonal antibody was generated using immunogen P703Pfl or P703Ptrl attached to a solid support. Rabbit monoclonal antibodies were isolated using SLAM technology at Immgenics Pharmaceuticals. Table VII below lists both the polyclonal and monoclonal antibodies that were generated against P703P.

Table VII

Antibody	Immunogen	Species/type
Aff. Purif. P703P (truncated); #2594	P703Ptrl	Rabbit polyclonal
Aff. Purif. P703P (full length); #9245	P703Pfl	Rabbit polyclonal
2D4	P703Ptrl	Rabbit monoclonal
8H2	P703Ptrl	Rabbit monoclonal
7H8	P703Ptrl	Rabbit monoclonal

The DNA sequences encoding the complementarity determining regions (CDRs) for the rabbit monoclonal antibodies 8H2, 7H8 and 2D4 were determined and are provided in SEQ ID NO: 506-508, respectively.

Epitope mapping studies were performed as described above. Monoclonal antibodies 2D4 and 7H8 were found to specifically bind to the peptides of SEQ ID NO: 509 (corresponding to amino acids 145-159 of SEQ ID NO: 172) and SEQ ID NO: 510 (corresponding to amino acids 11-25 of SEQ ID NO: 172), respectively. The polyclonal antibody 2594 was found to bind to the peptides of SEQ ID NO: 511-514, with the polyclonal antibody 9427 binding to the peptides of SEQ ID NO: 515-517.

The specificity of the anti-P703P antibodies was determined by Western blot analysis as follows. SDS-PAGE was performed on (1) bacterially expressed recombinant antigen; (2) lysates of HEK293 cells and Ltk^{-/-} cells either untransfected or transfected with a plasmid expressing full length P703P; and (3) supernatant isolated from these cell cultures. Protein was transferred to nitrocellulose and then Western blotted using the anti-P703P polyclonal antibody #2594 at an antibody concentration of 1 ug/ml. Protein was detected using horse radish peroxidase (HRP) conjugated to an anti-rabbit antibody. A 35 kDa immunoreactive band could be observed with

recombinant P703P. Recombinant P703P runs at a slightly higher molecular weight since it is epitope tagged. In lysates and supernatants from cells transfected with full length P703P, a 30 kDa band corresponding to P703P was observed. To assure specificity, lysates from HEK293 cells stably transfected with a control plasmid were also tested and were negative for P703P expression. Other anti-P703P antibodies showed similar results.

Immunohistochemical studies were performed as described above, using anti-P703P monoclonal antibody. P703P was found to be expressed at high levels in normal prostate and prostate tumor tissue but was not detectable in all other tissues tested (breast tumor, lung tumor and normal kidney).

e) Preparation and Characterization of Antibodies against P504S

Full-length P504S (SEQ ID NO: 108) was expressed and purified from bacteria essentially as described above for P501S and employed to raise rabbit monoclonal antibodies using Selected Lymphocyte Antibody Method (SLAM) technology at Immgenics Pharmaceuticals (Vancouver, BC, Canada). The anti-P504S monoclonal antibody 13H4 was shown by Western blot to bind to both expressed recombinant P504S and to native P504S in tumor cells.

Immunohistochemical studies using 13H4 to assess P504S expression in various prostate tissues were performed as described above. A total of 104 cases, including 65 cases of radical prostatectomies with prostate cancer (PC), 26 cases of prostate biopsies and 13 cases of benign prostate hyperplasia (BPH), were stained with the anti-P504S monoclonal antibody 13H4. P504S showed strongly cytoplasmic granular staining in 64/65 (98.5%) of PCs in prostatectomies and 26/26 (100%) of PCs in prostatic biopsies. P504S was stained strongly and diffusely in carcinomas (4+ in 91.2% of cases of PC; 3+ in 5.5%; 2+ in 2.2% and 1+ in 1.1%) and high grade prostatic intraepithelial neoplasia (4+ in all cases). The expression of P504S did not vary with Gleason score. Only 17/91 (18.7%) of cases of NP/BPH around PC and 2/13 (15.4%) of BPH cases were focally (1+, no 2+ to 4+ in all cases) and weakly positive for P504S in large glands. Expression of P504S was not found in small atrophic glands, postatrophic hyperplasia, basal cell hyperplasia and transitional cell metaplasia in either biopsies or

prostatectomies. P504S was thus found to be over-expressed in all Gleason scores of prostate cancer (98.5 to 100% of sensitivity) and exhibited only focal positivities in large normal glands in 19/104 of cases (82.3% of specificity). These findings indicate that P504S may be usefully employed for the diagnosis of prostate cancer.

5

EXAMPLE 19

CHARACTERIZATION OF CELL SURFACE EXPRESSION AND
CHROMOSOME LOCALIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10 This example describes studies demonstrating that the prostate-specific antigen P501S is expressed on the surface of cells, together with studies to determine the probable chromosomal location of P501S.

The protein P501S (SEQ ID NO: 113) is predicted to have 11 transmembrane domains. Based on the discovery that the epitope recognized by the anti-
15 P501S monoclonal antibody 10E3-G4-D3 (described above in Example 17) is intracellular, it was predicted that following transmembrane determinants would allow the prediction of extracellular domains of P501S. Fig. 9 is a schematic representation of the P501S protein showing the predicted location of the transmembrane domains and the intracellular epitope described in Example 17. Underlined sequence represents the
20 predicted transmembrane domains, bold sequence represents the predicted extracellular domains, and italicized sequence represents the predicted intracellular domains. Sequence that is both bold and underlined represents sequence employed to generate polyclonal rabbit serum. The location of the transmembrane domains was predicted using HHMTOP as described by Tusnady and Simon (Principles Governing Amino
25 Acid Composition of Integral Membrane Proteins: Applications to Topology Prediction, *J. Mol. Biol.* 283:489-506, 1998).

Based on Fig. 9, the P501S domain flanked by the transmembrane domains corresponding to amino acids 274-295 and 323-342 is predicted to be extracellular. The peptide of SEQ ID NO: 518 corresponds to amino acids 306-320 of
30 P501S and lies in the predicted extracellular domain. The peptide of SEQ ID NO: 519,

which is identical to the peptide of SEQ ID NO: 518 with the exception of the substitution of the histidine with an asparagine, was synthesized as described above. A Cys-Gly was added to the C-terminus of the peptide to facilitate conjugation to the carrier protein. Cleavage of the peptide from the solid support was carried out using the
5 following cleavage mixture: trifluoroacetic acid:ethanediol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for two hours, the peptide was precipitated in cold ether. The peptide pellet was then dissolved in 10% v/v acetic acid and lyophilized prior to purification by C18 reverse phase hplc. A gradient of 5-60% acetonitrile (containing 0.05% TFA) in water (containing 0.05% TFA) was used to elute the peptide. The purity
10 of the peptide was verified by hplc and mass spectrometry, and was determined to be >95%. The purified peptide was used to generate rabbit polyclonal antisera as described above.

Surface expression of P501S was examined by FACS analysis. Cells were stained with the polyclonal anti-P501S peptide serum at 10 µg/ml, washed,
15 incubated with a secondary FITC-conjugated goat anti-rabbit Ig antibody (ICN), washed and analyzed for FITC fluorescence using an Excalibur fluorescence activated cell sorter. For FACS analysis of transduced cells, B-LCL were retrovirally transduced with P501S. To demonstrate specificity in these assays, B-LCL transduced with an irrelevant antigen (P703P) or nontransduced were stained in parallel. For FACS analysis of
20 prostate tumor cell lines, Lncap, PC-3 and DU-145 were utilized. Prostate tumor cell lines were dissociated from tissue culture plates using cell dissociation medium and stained as above. All samples were treated with propidium iodide (PI) prior to FACS analysis, and data was obtained from PI-excluding (*i.e.*, intact and non-permeabilized) cells. The rabbit polyclonal serum generated against the peptide of SEQ ID NO: 519
25 was shown to specifically recognize the surface of cells transduced to express P501S, demonstrating that the epitope recognized by the polyclonal serum is extracellular.

To determine biochemically if P501S is expressed on the cell surface, peripheral membranes from Lncap cells were isolated and subjected to Western blot analysis. Specifically, Lncap cells were lysed using a dounce homogenizer in 5 ml of
30 homogenization buffer (250 mM sucrose, 10 mM HEPES, 1mM EDTA, pH 8.0, 1

complete protease inhibitor tablet (Boehringer Mannheim)). Lysate samples were spun at 1000 g for 5 min at 4 °C. The supernatant was then spun at 8000g for 10 min at 4 °C. Supernatant from the 8000g spin was recovered and subjected to a 100,000g spin for 30 min at 4 °C to recover peripheral membrane. Samples were then separated by SDS-
5 PAGE and Western blotted with the mouse monoclonal antibody 10E3-G4-D3 (described above in Example 17) using conditions described above. Recombinant purified P501S, as well as HEK293 cells transfected with and over-expressing P501S were included as positive controls for P501S detection. LCL cell lysate was included as a negative control. P501S could be detected in Lncap total cell lysate, the 8000g
10 (internal membrane) fraction and also in the 100,000g (plasma membrane) fraction. These results indicate that P501S is expressed at, and localizes to, the peripheral membrane.

To demonstrate that the rabbit polyclonal antiserum generated to the peptide of SEQ ID NO: 519 specifically recognizes this peptide as well as the
15 corresponding native peptide of SEQ ID NO: 518, ELISA analyses were performed. For these analyses, flat-bottomed 96 well microtiter plates were coated with either the peptide of SEQ ID NO: 519, the longer peptide of SEQ ID NO: 520 that spans the entire predicted extracellular domain, the peptide of SEQ ID NO: 521 which represents the epitope recognized by the P501S-specific antibody 10E3-G4-D3, or a P501S fragment
20 (corresponding to amino acids 355-526 of SEQ ID NO: 113) that does not include the immunizing peptide sequence, at 1 µg/ml for 2 hours at 37 °C. Wells were aspirated, blocked with phosphate buffered saline containing 1% (w/v) BSA for 2 hours at room temperature and subsequently washed in PBS containing 0.1% Tween 20 (PBST). Purified anti-P501S polyclonal rabbit serum was added at 2 fold dilutions (1000 ng -
25 125 ng) in PBST and incubated for 30 min at room temperature. This was followed by washing 6 times with PBST and incubating with HRP-conjugated goat anti-rabbit IgG (H+L) Affinipure F(ab') fragment at 1:20000 for 30 min. Plates were then washed and incubated for 15 min in tetramethyl benzidine. Reactions were stopped by the addition of 1N sulfuric acid and plates were read at 450 nm using an ELISA plate reader. As
30 shown in Fig. 11, the anti-P501S polyclonal rabbit serum specifically recognized the

peptide of SEQ ID NO: 519 used in the immunization as well as the longer peptide of SEQ ID NO: 520, but did not recognize the irrelevant P501S-derived peptides and fragments.

In further studies, rabbits were immunized with peptides derived from the P501S sequence and predicted to be either extracellular or intracellular, as shown in Fig. 9. Polyclonal rabbit sera were isolated and polyclonal antibodies in the serum were purified, as described above. To determine specific reactivity with P501S, FACS analysis was employed, utilizing either B-LCL transduced with P501S or the irrelevant antigen P703P, or B-LCL infected with vaccinia virus-expressing P501S. For surface expression, dead and non-intact cells were excluded from the analysis as described above. For intracellular staining, cells were fixed and permeabilized as described above. Rabbit polyclonal serum generated against the peptide of SEQ ID NO: 548, which corresponds to amino acids 181-198 of P501S, was found to recognize a surface epitope of P501S. Rabbit polyclonal serum generated against the peptide SEQ ID NO: 551, which corresponds to amino acids 543-553 of P501S, was found to recognize an epitope that was either potentially extracellular or intracellular since in different experiments intact or permeabilized cells were recognized by the polyclonal sera. Based on similar deductive reasoning, the sequences of SEQ ID NO: 541-547, 549 and 550, which correspond to amino acids 109-122, 539-553, 509-520, 37-54, 342-359, 295-323, 217-274, 143-160 and 75-88, respectively, of P501S, can be considered to be potential surface epitopes of P501S recognized by antibodies.

In further studies, mouse monoclonal antibodies were raised against amino acids 296 to 322 of P501S, which are predicted to be in an extracellular domain. A/J mice were immunized with P501S/adenovirus, followed by subsequent boosts with an *E. coli* recombinant protein, referred to as P501N, that contains amino acids 296 to 322 of P501S, and with peptide 296-322 (SEQ ID NO: 755) coupled with KLH. The mice were subsequently used for splenic B cell fusions to generate anti-peptide hybridomas. The resulting 3 clones, referred to as 4F4 (IgG1,kappa), 4G5 (IgG2a,kappa) and 9B9 (IgG1,kappa), were grown for antibody production. The 4G5 mAb was purified by passing the supernatant over a Protein A-sepharose column,

followed by antibody elution using 0.2M glycine, pH 2.3. Purified antibody was neutralized by the addition of 1M Tris, pH 8, and buffer exchanged into PBS.

For ELISA analysis, 96 well plates were coated with P501S peptide 296-322 (referred to as P501-long), an irrelevant P775 peptide, P501S-N, P501TR2, P501S-long-KLH, P501S peptide 306-319 (referred to as P501-short)-KLH, or the irrelevant peptide 2073-KLH, all at a concentration of 2 ug/ml and allowed to incubate for 60 minutes at 37 °C. After coating, plates were washed 5X with PBS + 0.1% Tween and then blocked with PBS, 0.5% BSA, 0.4% Tween20 for 2 hours at room temperature. Following the addition of supernatants or purified mAb, the plates were incubated for 60 minutes at room temperature. Plates were washed as above and donkey anti-mouse IgHRP-linked secondary antibody was added and incubated for 30 minutes at room temperature, followed by a final washing as above. TMB peroxidase substrate was added and incubated 15 minutes at room temperature in the dark. The reaction was stopped by the addition of 1N H₂SO₄ and the OD was read at 450 nM. All three hybrid clones secreted mAb that recognized peptide 296-322 and the recombinant protein P501N.

For FACS analysis, HEK293 cells were transiently transfected with a P501S/VR1012 expression constructs using Fugene 6 reagent. After 2 days of culture, cells were harvested and washed, then incubated with purified 4G5 mAb for 30 minutes on ice. After several washes in PBS, 0.5% BSA, 0.01% azide, goat anti-mouse Ig-FITC was added to the cells and incubated for 30 minutes on ice. Cells were washed and resuspended in wash buffer including 1% propidium iodide and subjected to FACS analysis. The FACS analysis confirmed that amino acids 296-322 of P501S are in an extracellular domain and are cell surface expressed.

The chromosomal location of P501S was determined using the GeneBridge 4 Radiation Hybrid panel (Research Genetics). The PCR primers of SEQ ID NO: 528 and 529 were employed in PCR with DNA pools from the hybrid panel according to the manufacturer's directions. After 38 cycles of amplification, the reaction products were separated on a 1.2% agarose gel, and the results were analyzed through the Whitehead Institute/MIT Center for Genome Research web server

(<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>) to determine the probable chromosomal location. Using this approach, P501S was mapped to the long arm of chromosome 1 at WI-9641 between q32 and q42. This region of chromosome 1 has been linked to prostate cancer susceptibility in hereditary prostate cancer (Smith *et al.* *Science* 274:1371-1374, 1996 and Berthon *et al.* *Am. J. Hum. Genet.* 62:1416-1424, 1998). These results suggest that P501S may play a role in prostate cancer malignancy.

EXAMPLE 20

REGULATION OF EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGEN P501S

10

Steroid (androgen) hormone modulation is a common treatment modality in prostate cancer. The expression of a number of prostate tissue-specific antigens have previously been demonstrated to respond to androgen. The responsiveness of the prostate-specific antigen P501S to androgen treatment was examined in a tissue culture system as follows.

15

Cells from the prostate tumor cell line LNCaP were plated at 1.5×10^6 cells/T75 flask (for RNA isolation) or 3×10^5 cells/well of a 6-well plate (for FACS analysis) and grown overnight in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum (BRL Life Technologies, Gaithersburg, MD). Cell culture was continued for an additional 72 hours in RPMI 1640 media containing 10% charcoal-stripped fetal calf serum, with 1 nM of the synthetic androgen Methyltrienolone (R1881; New England Nuclear) added at various time points. Cells were then harvested for RNA isolation and FACS analysis at 0, 1, 2, 4, 8, 16, 24, 28 and 72-hours post androgen addition. FACS analysis was performed using the anti-P501S antibody 10E3-G4-D3 and permeabilized cells.

25

For Northern analysis, 5-10 micrograms of total RNA was run on a formaldehyde denaturing gel, transferred to Hybond-N nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ), cross-linked and stained with methylene blue. The filter was then prehybridized with Church's Buffer (250 mM Na_2HPO_4 , 70 mM H_3PO_4 , 1 mM EDTA, 1% SDS, 1% BSA in pH 7.2) at 65 °C for 1 hour. P501S DNA was

30

labeled with ^{32}P using High Prime random-primed DNA labeling kit (Boehringer Mannheim). Unincorporated label was removed using MicroSpin S300-HR columns (Amersham Pharmacia Biotech). The RNA filter was then hybridized with fresh Church's Buffer containing labeled cDNA overnight, washed with 1X SCP (0.1 M NaCl, 0.03 M $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 0.001 M Na_2EDTA), 1% sarkosyl (n-lauroylsarcosine) and exposed to X-ray film.

Using both FACS and Northern analysis, P501S message and protein levels were found to increase in response to androgen treatment.

10

EXAMPLE 20

PREPARATION OF FUSION PROTEINS OF PROSTATE-SPECIFIC ANTIGENS

The example describes the preparation of a fusion protein of the prostate-specific antigen P703P and a truncated form of the known prostate antigen PSA. The truncated form of PSA has a 21 amino acid deletion around the active serine site. The expression construct for the fusion protein also has a restriction site at 3' end, immediately prior to the termination codon, to aid in adding cDNA for additional antigens.

The full-length cDNA for PSA was obtained by RT-PCR from a pool of RNA from human prostate tumor tissues using the primers of SEQ ID NO: 607 and 608, and cloned in the vector pCR-Blunt II-TOPO. The resulting cDNA was employed as a template to make two different fragments of PSA by PCR with two sets of primers (SEQ ID NO: 609 and 610; and SEQ ID NO: 611 and 612). The PCR products having the expected size were used as templates to make truncated forms of PSA by PCR with the primers of SEQ ID NO: 611 and 613, which generated PSA (delta 208-218 in amino acids). The cDNA for the mature form of P703P with a 6X histidine tag at the 5' end, was prepared by PCR with P703P and the primers of SEQ ID NO: 614 and 615. The cDNA for the fusion of P703P with the truncated form of PSA (referred to as FOPP) was then obtained by PCR using the modified P703P cDNA and the truncated form of PSA cDNA as templates and the primers of SEQ ID NO: 614 and 615. The FOPP

cDNA was cloned into the NdeI site and XhoI site of the expression vector pCRX1, and confirmed by DNA sequencing. The determined cDNA sequence for the fusion construct FOPP is provided in SEQ ID NO: 616, with the amino acid sequence being provided in SEQ ID NO: 617.

5 The fusion FOPP was expressed as a single recombinant protein in *E. coli* as follows. The expression plasmid pCRX1FOPP was transformed into the *E. coli* strain BL21-CodonPlus RIL. The transformant was shown to express FOPP protein upon induction with 1 mM IPTG. The culture of the corresponding expression clone was inoculated into 25 ml LB broth containing 50 ug/ml kanamycin and 34 ug/ml
10 chloramphenicol, grown at 37 °C to OD600 of about 1, and stored at 4 °C overnight. The culture was diluted into 1 liter of TB LB containing 50 ug/ml kanamycin and 34 ug/ml chloramphenicol, and grown at 37 °C to OD600 of 0.4. IPTG was added to a final concentration of 1 mM, and the culture was incubated at 30 °C for 3 hours. The cells were pelleted by centrifugation at 5,000 RPM for 8 min. To purify the protein, the
15 cell pellet was suspended in 25 ml of 10 mM Tris-Cl pH 8.0, 2mM PMSF, complete protease inhibitor and 15 ug lysozyme. The cells were lysed at 4 °C for 30 minutes, sonicated several times and the lysate centrifuged for 30 minutes at 10,000 x g. The precipitate, which contained the inclusion body, was washed twice with 10 mM Tris-Cl pH 8.0 and 1% CHAPS. The inclusion body was dissolved in 40 ml of 10 mM Tris-Cl
20 pH 8.0, 100 mM sodium phosphate and 8 M urea. The solution was bound to 8 ml Ni-NTA (Qiagen) for one hour at room temperature. The mixture was poured into a 25 ml column and washed with 50 ml of 10 mM Tris-Cl pH 6.3, 100 mM sodium phosphate, 0.5% DOC and 8M urea. The bound protein was eluted with 350 mM imidazole, 10 mM Tris-Cl pH 8.0, 100 mM sodium phosphate and 8 M urea. The fractions containing
25 FOPP proteins were combined and dialyzed extensively against 10 mM Tris-Cl pH 4.6, aliquoted and stored at - 70 °C.

EXAMPLE 21

REAL-TIME PCR CHARACTERIZATION OF THE PROSTATE-SPECIFIC ANTIGEN P501S IN
PERIPHERAL BLOOD OF PROSTATE CANCER PATIENTS

5 Circulating epithelial cells were isolated from fresh blood of normal individuals and metastatic prostate cancer patients, mRNA isolated and cDNA prepared using real-time PCR procedures. Real-time PCR was performed with the TaqmanTM procedure using both gene specific primers and probes to determine the levels of gene expression.

10 Epithelial cells were enriched from blood samples using an immunomagnetic bead separation method (DynaL A.S., Oslo, Norway). Isolated cells were lysed and the magnetic beads removed. The lysate was then processed for poly A+ mRNA isolation using magnetic beads coated with Oligo(dT)25. After washing the beads in buffer, bead/poly A+ RNA samples were suspended in 10 mM Tris HCl pH 8.0

15 and subjected to reversed transcription. The resulting cDNA was subjected to real-time PCR using gene specific primers. Beta-actin content was also determined and used for normalization. Samples with P501S copies greater than the mean of the normal samples + 3 standard deviations were considered positive. Real time PCR on blood samples was performed using the TaqmanTM procedure but extending to 50 cycles using

20 forward and reverse primers and probes specific for P501S. Of the eight samples tested, 6 were positive for P501S and β -actin signal. The remaining 2 samples had no detectable β -actin or P501S. No P501S signal was observed in the four normal blood samples tested.

25

EXAMPLE 22

EXPRESSION OF THE PROSTATE-SPECIFIC ANTIGENS P703P AND P501S IN
SCID MOUSE-PASSAGED PROSTATE TUMORS

 When considering the effectiveness of antigens in the treatment of

30 prostate cancer, the continued presence of the antigens in tumors during androgen

ablation therapy is important. The presence of the prostate-specific antigens P703P and P501S in prostate tumor samples grown in SCID mice in the presence of testosterone was evaluated as follows.

Two prostate tumors that had metastasized to the bone were removed
5 from patients, implanted into SCID mice and grown in the presence of testosterone. Tumors were evaluated for mRNA expression of P703P, P501S and PSA using quantitative real time PCR with the SYBR green assay method. Expression of P703P and P501S in a prostate tumor was used as a positive control and the absence in normal intestine and normal heart as negative controls. In both cases, the specific mRNA was
10 present in late passage tumors. Since the bone metastases were grown in the presence of testosterone, this implies that the presence of these genes would not be lost during androgen ablation therapy.

EXAMPLE 23

15 ANTI-P503S MONOCLONAL ANTIBODY INHIBITS TUMOR GROWTH *IN VIVO*

The ability of the anti-P503S monoclonal antibody 20D4 to suppress tumor formation in mice was examined as follows.

Ten SCID mice were injected subcutaneously with HEK293 cells that expressed P503S. Five mice received 150 micrograms of 20D4 intravenously at day 0
20 (time of tumor cell injection), day 5 and day 9. Tumor size was measured for 50 days. Of the five animals that received no 20D4, three formed detectable tumors after about 2 weeks which continued to enlarge throughout the study. In contrast, none of the five mice that received 20D4 formed tumors. These results demonstrate that the anti-P503S Mab 20D4 displays potent anti-tumor activity *in vivo*.

25

EXAMPLE 24

CHARACTERIZATION OF A T CELL RECEPTOR CLONE FROM A P501S-SPECIFIC T CELL CLONE

30 T cells have a limited lifespan. However, cloning of T cell receptor (TCR) chains and subsequent transfer essentially enables infinite propagation of the T

cell specificity. Cloning of tumor-antigen TCR chains allows the transfer of the specificity into T cells isolated from patients that share the TCR MHC-restricting allele. Such T cells could then be expanded and used in adoptive transfer settings to introduce the tumor antigen specificity into patients carrying tumors that express the antigen. T
5 cell receptor alpha and beta chains from a CD8 T cell clone specific for the prostate-specific antigen P501S were isolated and sequenced as follows.

Total mRNA from 2×10^6 cells from CTL clone 4E5 (described above in Example 12) was isolated using Trizol reagent and cDNA was synthesized. To determine Va and Vb sequences in this clone, a panel of Va and Vb subtype-specific
10 primers was synthesized and used in RT-PCR reactions with cDNA generated from each of the clones. The RT-PCR reactions demonstrated that each of the clones expressed a common Vb sequence that corresponded to the Vb7 subfamily. Furthermore, using cDNA generated from the clone, the Va sequence expressed was determined to be Va6. To clone the full TCR alpha and beta chains from clone 4E5,
15 primers were designed that spanned the initiator and terminator-coding TCR nucleotides. The primers were as follows: TCR Valpha-6 5'(sense): GGATCC---GCCGCCACC---ATGTCACTTTCTAGCCTGCT (SEQ ID NO: 756) BamHI site Kozak TCR alpha sequence TCR alpha 3' (antisense): GTCGAC---TCAGCTGGACCACAGCCGCAG (SEQ ID NO: 757) SalI site TCR alpha constant
20 sequence TCR Vbeta-7. 5'(sense): GGATCC---GCCGCCACC---ATGGGCTGCAGGCTGCTCT (SEQ ID NO: 758) BamHI site Kozak TCR alpha sequence TCR beta 3' (antisense): GTCGAC---TCAGAAATCCTTTCTCTTGAC (SEQ ID NO: 759) SalI site TCR beta constant sequence. Standard 35 cycle RT-PCR reactions were established using cDNA synthesized from the CTL clone and the above
25 primers, employing the proofreading thermostable polymerase PWO (Roche, Nutley, NJ).

The resultant specific bands (approx. 850 bp for alpha and approx. 950 for beta) were ligated into the PCR blunt vector (Invitrogen) and transformed into *E. coli*. *E. coli* transformed with plasmids containing full-length alpha and beta chains
30 were identified, and large scale preparations of the corresponding plasmids were generated. Plasmids containing full-length TCR alpha and beta chains were submitted

for sequencing. The sequencing reactions demonstrated the cloning of full-length TCR alpha and beta chains with the determined cDNA sequences for the Vb and Va chains being shown in SEQ ID NO: 760 and 761, respectively. The corresponding amino acid sequences are shown in SEQ ID NO: 762 and 763, respectively. The Va sequence was
5 shown by nucleotide sequence alignment to be 99% identical (347/348) to Va6.2, and the Vb to be 99% identical to Vb7 (336/338).

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration,
10 various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is Claimed:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(b) complements of the sequences provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(d) sequences that hybridize to a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788 under moderately stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-

375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788;

(f) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788; and

(g) degenerate variants of a sequence provided in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 and 786-788.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(b) sequences having at least 70% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

(c) sequences having at least 90% identity to a sequence of SEQ ID NO: 112-114, 172, 176, 178, 327, 329, 331, 336, 339, 376-380, 383, 477-483, 496, 504, 505, 519, 520, 522, 525, 527, 532, 534, 537-551, 553-568, 573-586, 588-590, 592, 627-

629, 632, 633, 635, 637, 638, 656-671, 675, 683, 684, 710, 712, 714, 715, 717-719, 723-734, 736, 740-750, 752, 754, 755, 766-772, 777-785 and 789-791;

- (d) sequences encoded by a polynucleotide of claim 1;
- (e) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and
- (f) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. A host cell transformed or transfected with an expression vector according to claim 3.

5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. A method for detecting the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7. A fusion protein comprising at least one polypeptide according to claim 2.

8. The fusion protein of claim 7, wherein the fusion protein comprises a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NO: 682, 692, 695, 699, 703 and 709; and

(b) sequences encoded by SEQ ID NO: 679, 691, 696, 700, 704 and 708.

9. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO: 1-111, 115-171, 173-175, 177, 179-305, 307-315, 326, 328, 330, 332-335, 340-375, 381, 382 and 384-476, 524, 526, 530, 531, 533, 535, 536, 552, 569-572, 587, 591, 593-606, 618-626, 630, 631, 634, 636, 639-655, 674, 680, 681, 711, 713, 716, 720-722, 735, 737-739, 751, 753, 764, 765, 773-776 or 786-788 under moderately stringent conditions.

10. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

(a) polypeptides according to claim 2;
(b) polynucleotides according to claim 1; and
(c) antigen-presenting cells that express a polypeptide according to claim 1,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

11. An isolated T cell population, comprising T cells prepared according to the method of claim 10.

12. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 11; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

13. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 12.

14. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 12.

15. A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 9;
- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and
- (d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

16. A diagnostic kit comprising at least one oligonucleotide according to claim 9.

17. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

18. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate; and

(b) administering to the patient an effective amount of the proliferated T cells,

thereby inhibiting the development of a cancer in the patient.




Fig. 1




Fig. 2A




Fig. 25




Fig. 3




Fig. 4




Fig. 5




Fig. 6B





Fig. 6A


Expression of P501S by the Baculovirus Expression System



0.6 million high 5 cells in 8-well plate were infected with an unrelated control virus BV/ECD_PD (lane 2), without virus (lane 3), or with recombinant baculovirus for P501S at different MOIs (lane 4-8). Cell lysates were run on SDS-PAGE under the reducing conditions and analyzed by Western blot with a monoclonal antibody against P501S (P501S-10E3-G4D3). Lane 1 is the biotinylated protein molecular weight marker (BioLabs).

Fig. 7

Figure 8. Mapping of the epitope recognized by 10E3-G4-D3



Legend:
 [Patterned box] : P215 population
 [Solid black box] : Transformed naive dendritic

Full-length ISMIS

ISMIS fragment used for immunization




Fig. 8

Figure 1. Schematic of P501S with predicted transmembrane, cytoplasmic, and extracellular regions

MVQRLWVSRLLRRK AQLILLNLLTGLEVCLAACTT YVPPILLLEVGVREKFM TMVLGIGPVVLGLVCPILLGSAS
 DHWRGRYGRRRP EWALSLQILLSLFLPRAGWL AGLLCPDPRPLE LALLHGVGLIDFCCGQVCFTPL
 FALSLDLFRDPDHCRO AYSVYAFMSLGGCTQNTLPAL DWVDSALAPVLTGTQRE
 CLFGILLTLFLTCVVAATLLY AFEAAIGPTEPAEGLSAPSLSPICCPGRARIAFRNLGALLPRL
 HQLCYRSPRTLR LFVAELCSWMALNTFT FYTHP YGRGLLYOQVYPRAPPGTLEARRHYDEGVR
 MGSILGLFLQCAISLVESLYM DRLVQRECTRAVYLAS VAAFTVAAGATCLSHSVAVVTA SAA
 LTGLETSALQILPYTLASLY HREKQVFLPKYRGDTGGASSEDSTMTSFLPGPKGAPFPNGHVGAGGSGL
 LPPPPALCGASACDVSVRVVVGEPTEARVVVGRG ICLEALLDSAPLLSQVAPSLF MGSIVQLSQS
 VTAYMVSAAAGLGLVAYFAT QVVFDKSDIAKYSA

Underlined sequence: Predicted transmembrane domain; **Bold sequence**: Predicted extracellular domain;

italic sequence: Predicted intracellular domain. Sequence in bold/underlined: used to generate polyclonal rabbit serum

Localization of domains predicted using HMMTOP (G.R. Tusnady and I. Simon (1998) Principles

Governing Amino Acid Composition of Integral Membrane Proteins: Applications to topology Prediction. J. Mol Biol. 283, 489-506.

Genomic Map of (5) Corixa Candidate Genes




Fig. 10

FIGURE 4. Elisa assay of rabbit polyclonal antibody specificity




Fig. 11

SEQUENCE LISTING

<110> Corixa Corporation
 Smithkline Beechan Biologicals S.A.
 Xu, Jiangchun
 Dillon, Davin C.
 Mitcham, Jennifer L.
 Harlocker, Susan L.
 Jiang, Yuqui
 Reed, Steven G.
 Kalos, Michael D.
 Fanger, Gary R.
 Retter, Marc W.
 Stolk, John A.
 Day, Craig H.
 Skeiky, Yasir A.W.
 Wang, Aijun
 Meagher, Medeleine Joy
 Vanderbrugge, Didier
 Dewerchin, Marianne
 Dehottay, Ph.
 de Rop, Philippe

<120> COMPOSITIONS AND METHODS FOR THE THERAPY AND
 DIAGNOSIS OF PROSTATE CANCER

<130> 210121.42722PC

<140> PCT

<141> 2001-01-16

<160> 792

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 814

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(814)

<223> n = A,T,C or G

<400> 1

tttttttttt	tttttcacag	tataacagct	ctttatttct	gtgagttcta	ctaggaaatc	60
atcaaactctg	agggttgtct	ggaggacttc	aatacacctc	cccccatagt	gaatcagctt	120
ccaggggggtc	cagtcctctt	ccttacttca	tccccatccc	atgccaaagg	aagaccctcc	180
ctccttggtc	cacagccttc	tctaggcttc	ccagtgcctc	caggacagag	tgggttatgt	240
tttcagctcc	atccttgctg	tgagtgtctg	gtgcgttggtg	cctccagctt	ctgctcagtg	300
cttcatggac	agtgtccagc	acatgtcact	ctccactctc	tcagtgtgga	tccactagtt	360
ctagagcggc	cgccaccgcg	gtggagctcc	agcttttggt	cccttttagtg	agggttaatt	420
gcgcgcttgg	cgtaatcatg	gtcataactg	tttcctgtgt	gaaattgtta	tccgctcaca	480
attccacaca	acatacyagc	cggaagcata	aagtgtaaag	cctgggggtgc	ctaattgagtg	540
anctaactca	cattaattgc	gttgcgctca	ctgnccgctt	tccagtcngg	aaaactgtcg	600
tgccagctgc	attaatgaat	cggccaacgc	ncggggaaaa	gcggtttgcg	ttttgggggc	660

tcttccgctt	ctcgetcact	nantcctgcg	ctcggctcntt	cggctgcggg	gaacggatc	720
actcctcaaa	ggnggtatta	cggttatccn	naaatcnggg	gatacccnng	aaaaaanttt	780
aacaaaagg	cancaaagg	cngaaacgta	aaaa			814

<210> 2
 <211> 816
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(816)
 <223> n = A,T,C or G

<400> 2						
acagaaatgt	tggatggtgg	agcacctttc	tatacgactt	acaggacagc	agatggggaa	60
ttcatggctg	ttggagcaat	agaaccccag	ttctacgagc	tgctgatcaa	aggacttggg	120
ctaaagtctg	atgaacttcc	caatcagatg	agcatggatg	attggccaga	aatgaagaag	180
aagtttgacg	atgtatttgc	aaagaagacg	aaggcagagt	ggtgtcaa	ctttgacggc	240
acagatgcct	gtgtgactcc	ggttctgact	tttgaggagg	ttgttcatca	tgatcacaa	300
aaggaacggg	gctcgtttat	caccagttag	gagcaggacg	tgagcccccg	ccctgcacct	360
ctgctgttaa	acaccccagc	catcccttct	ttcaaaagg	atccactagt	tctagaagcg	420
gcggccaccg	cgggtggagct	ccagcttttg	ttccctttag	tgagggttaa	ttgcgcgctt	480
ggcgtaatca	tggatcatagc	tgtttctctg	gtgaaattgt	tatccgctca	caattccccc	540
aacatacgag	cgggaacata	aagtgttaag	cctgggtg	ctaagtantg	agctaactcn	600
cattaattgc	gttgcgctca	ctgcccgtt	tccagtcggg	aaaactgtcg	tgccactgcn	660
ttantgaatc	ngccaccccc	cgggaaaagg	cgggtgcntt	ttgggcctct	tccgctttcc	720
tcgctcattg	atcctngcnc	cgggtcttcg	gctgcggnga	acggttcaact	cctcaaaggc	780
ggtntnccgg	ttatcccca	acnggggata	cccnga			816

<210> 3
 <211> 773
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(773)
 <223> n = A,T,C or G

<400> 3						
cttttgaaag	aagggtggtg	tggggtgttt	aacagcagag	gtgcaggggc	ggggctcacg	60
tcctgtcctc	cactggtgat	aaacgagccc	cgttccttgt	tgtgatcatg	atgaacaacc	120
tcctcaaaag	tcagaaccgg	agtcacacag	gcatctgtgc	cgtcaaagat	ttgacaccac	180
tctgccttcg	tcttctttgc	aaatacatct	gcaaacttct	tcttcatttc	tgccaatca	240
tccatgctca	tctgattggg	aagttcatca	gactttagtc	canntccttt	gatcagcagc	300
tcgtagaact	ggggttctat	tgctccaaca	gccatgaatt	cccatctgc	tgtcctgtaa	360
gtcgtataga	aagggtctcc	accatccaac	atgttctgtc	ctcgaggggg	ggcccgttac	420
ccaattcgcc	ctatantgag	tcgtattacg	cgcgctcaact	ggccgctcgtt	ttacaacgct	480
gtgactggga	aaaccctggg	cgttaccaac	ttaatcgctt	tgacgacat	ccccctttcg	540
ccagctgggc	gtaatancga	aaaggcccgc	accgatcgcc	cttccaacag	ttgcgcacct	600
gaatgggnaa	atgggacccc	cctgttaccc	cgcattnaac	ccccgcnngg	tttngttggt	660
acccccacnt	nnaccgctta	cactttgcc	gcgccttanc	gcccgcctcc	tttncctttt	720
cttcccttcc	tttncnccn	ctttcccccg	gggtttcccc	cntcaaacc	cna	773

<210> 4
 <211> 828
 <212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(828)

<223> n = A,T,C or G

<400> 4

cctcctgagt	cctactgacc	tgtgctttct	ggtgtggagt	ccagggctgc	taggaaaagg	60
aatgggcaga	cacaggtgta	tgccaatgtt	tctgaaatgg	gtataatttc	gtcctctcct	120
tcggaacact	ggctgtctct	gaagacttct	cgtcagttt	cagtgaggac	acacacaaaag	180
acgtgggtga	ccatgtttgt	tgtgggggtgc	agagatggga	gggggtggggc	ccaccctgga	240
agagtggaca	gtgacacaag	gtggacactc	tctacagatc	actgaggata	agctggagcc	300
acaatgcatg	aggcacacac	acagcaagga	tgaacnctgt	aacatagccc	acgctgtcct	360
gngggcactg	ggaagcctan	atnaggccgt	gagcanaaag	aaggggagga	tccactagtt	420
ctanagcggc	cgccaccgcg	gtgganctcc	anccttttgt	ccttttagtg	agggttaatt	480
gcgcgcttgg	cntaatcatg	gtcatanctn	tttctgtgt	gaaattgtta	tccgctcaca	540
attccacaca	acatacganc	cggaaacata	aantgtaaac	ctggggtgcc	taatgantga	600
ctaactcaca	ttaattgcgt	tgcgctcact	gcccgtttc	caatcnggaa	acctgtcttg	660
ccncttgcat	tnatgaatcn	gccaaccccc	ggggaaaagc	gtttgcgttt	tgggcgctct	720
tccgcttcct	cncctcantta	ntccctncnc	tcggtcattc	cggctgcngc	aaaccggttc	780
accncctcca	aaggggggtat	tccggtttcc	ccnaatccgg	gghananc		828

<210> 5

<211> 834

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(834)

<223> n = A,T,C or G

<400> 5

tttttttttt	tttttactga	tagatggaat	ttattaagct	tttcacatgt	gatagcacat	60
agttttaatt	gcatccaaaag	tactaacaaa	aactctagca	atcaagaatg	gcagcatggt	120
atttttataac	aatcaacacc	tgtggctttt	aaaatttggt	tttcataaga	taatttatac	180
tgaagtaaat	ctagccatgc	ttttaaaaaa	tgcttttagt	cactccaagc	ttggcagtta	240
acatttggca	taaacaataa	taaaacaatc	acaatttaat	aaataacaaa	tacaacattg	300
taggccataa	tcatatacag	tataaggaaa	aggtggtagt	gttgagtaag	cagttattag	360
aatagaatac	cttggcctct	atgcaaatat	gtctagacac	tttgattcac	tcagccctga	420
cattcagttt	tcaaagtagg	agacaggttc	tacagtatca	ttttacagtt	tccaacacat	480
tgaaaacaag	tagaaaaatga	tgagttgatt	tttattaatg	cattacatcc	tcaagagtta	540
tcaccaacccc	ctcagttata	aaaaattttc	aagttatatt	agtcataata	cttgggtgtgc	600
ttattttaaa	ttagtgctaa	atggattaag	tgaagacaac	aatggtcccc	taatgtgatt	660
gatattggtc	atttttacca	gcttctaaat	ctnaactttc	aggcttttga	actggaacat	720
tgnatnacag	tgttccanag	ttncaacct	ctggaacatt	acagtgtgct	tgattcaaaa	780
tgttattttg	ttaaaaatta	aattttaacc	tggtggaaaa	ataatttgaa	atna	834

<210> 6

<211> 818

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(818)

<223> n = A,T,C or G

<400> 6

tttttttttt	tttttttttt	aagaccctca	tcaatagatg	gagacataca	gaaatagtca	60
aaccacatct	acaaaatgcc	agtatcaggc	ggcggcttcg	aagccaaagt	gatgtttgga	120
tgtaaagtga	aatattagtt	ggcggatgaa	gcagatagtg	aggaaagttg	agccaataat	180
gacgtgaagt	ccgtggaagc	ctgtggctac	aaaaaatgtt	gagccgtaga	tgccgtcgga	240
aatggtgaag	ggagactcga	agtactctga	ggcttgtagg	agggtaaaat	agagaccag	300
taaaattgta	ataagcagtg	cttgaattat	ttggtttcgg	ttgttttcta	ttagactatg	360
gtgagctcag	gtgattgata	ctcctgatgc	gagtaatacg	gatgtgttta	ggagtgggac	420
ttctagggga	tttagcgggg	tgatgcctgt	tgggggccag	tgccctccta	gttggggggg	480
aggggctagg	ctggagtggg	aaaaggctca	gaaaaatcct	gcgaagaaaa	aaacttctga	540
ggtaataaat	aggattatcc	cgtatcgaag	gccttttttg	acagggtggg	tgtggtggcc	600
ttggtatgtg	ctttctcgtg	ttacatcgcg	ccatcattgg	tatatgggta	gtgtgttggg	660
ttantanggc	ctantatgaa	gaacttttgg	antggaatta	aatcaatngc	ttggccggaa	720
gtcattanga	nggctnaaaa	ggccctgtta	ngggtctggg	ctnggtttta	cccnacccat	780
ggaatncncc	ccccggacna	ntgnatccct	attcttaa			818

<210> 7

<211> 817

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(817)

<223> n = A,T,C or G

<400> 7

tttttttttt	tttttttttt	tggctctaga	gggggtagag	ggggtgctat	agggtaaata	60
cgggccctat	ttcaaagatt	tttaggggaa	ttaattctag	gacgatgggt	atgaaactgt	120
ggtttgcctc	acagatttca	gagcattgac	cgtagtatac	ccccggtcgt	gtagcgggtga	180
aagtggtttg	gtttagacgt	ccgggaattg	catctgtttt	taagcctaata	gtggggacag	240
ctcatgagt	caagacgtct	tgtgatgtaa	ttattatacn	aatgggggct	tcaatcgga	300
gtactactcg	attgtcaacg	tcaaggagtc	gcaggtcgcc	tggttctagg	aataatgggg	360
gaagtatgta	ggaattgaag	attaatccgc	cgtagtcggg	gttctcctag	gttcaatacc	420
attggtggcc	aattgatttg	atggtaaggg	gagggatcgt	tgaactcgtc	tgttatgtaa	480
aggatncctt	ngggatggga	aggcnatnaa	ggactangga	tnaatggcgg	gcangatatt	540
tcaaacngtc	tctanttcct	gaaacgtctg	aaatgttaat	aanaattaan	tttngttatt	600
gaatnttnng	gaaaagggct	tacaggacta	gaaaccaaata	angaaaanta	atnntaangg	660
cnttatcntn	aaaggtnata	accnctccta	tnatcccacc	caatngnatt	ccccacncnn	720
acnattggat	nccccanttc	canaaaanggc	cnccccccgg	tgnannccnc	cttttgttcc	780
cttnantgan	ggttattcnc	ccctngcntt	atcance			817

<210> 8

<211> 799

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(799)

<223> n = A,T,C or G

<400> 8

catttcgggg	tttactttct	aaggaaagcc	gagcggaagc	tgctaacgtg	ggaatcgggt	60
cataaggaga	actttctgct	ggcacgcgct	agggacaagc	gggagagcga	ctccgagcgt	120
ctgaagcgca	cgtcccagaa	ggtggacttg	gcactgaaac	agctgggaca	catccgcgag	180
tacgaacagc	gcctgaaagt	gctggagcgg	gaggtccagc	agtgtagccg	cgtcctgggg	240

tggttgccg	angcctganc	cgtctgcct	tgttgcccc	angtgggccc	ccacccctg	300
acctgcctg	gtccaaacac	tgagccctgc	tggtgggactt	caagganaac	ccccacang	360
ggattttgct	cctanantaa	ggctcatctg	ggcctcgcc	ccccacctg	gttgccctg	420
tctttgangt	gagcccatg	tccatctggg	ccactgtcng	gaccacctt	ngggagtgt	480
ctccttacia	ccacannatg	cccggctcct	cccgaaacc	antccancc	tgngaaggat	540
caagnccctg	atccactnnt	nctanaaccg	gcncncnccg	cngtggaacc	cnccttntgt	600
tccttttct	tnagggttaa	tnnccgcttg	gccttnccan	ngtccctnnc	nttttccnnt	660
gttnaaattg	ttangcnccc	nccnntcccn	cnnennnnan	cccgaccnnc	annttnnann	720
ncctgggggt	nccnncngat	tgaccnnc	nccctntant	tgcttnggg	nncnntgccc	780
cttccctct	nggganncg					799

<210> 9

<211> 801

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(801)

<223> n = A,T,C or G

<400> 9

acgccttgat	cctcccaggc	tggtgactgt	tctgggagga	gccgggcatg	ctgtggtttg	60
taangatgac	actcccaaag	gtggtcctga	cagtggccca	gatggacatg	gggctcacct	120
caaggacaag	gccaccagg	gggggggccc	aagccacat	gatccttact	ctatgagcaa	180
aatccctgt	gggggcttct	ccttgaagtc	cgccancagg	gctcagtctt	tggaaccang	240
caggatcatg	ggttgtngnc	caactggggg	ccncaacgca	aaanggcna	gggcctcngn	300
cacccatccc	angacgcggc	tacactnctg	gacctccnc	tccaccactt	tcatgcgctg	360
ttcntaccgc	cgnatntgtc	ccanctgtt	cngtgcncac	tccancttct	nggaagtgcg	420
ctacatacgc	cggantcnc	notcccgtt	tgccctatc	cacgtncan	caacaaattt	480
cncctantg	caccnattcc	cacnttttnc	agntttccnc	nncgngcttc	cttntaaaag	540
ggttganc	ccgaaaatnc	cccaaagg	gggggcccng	tacccaaactn	ccccctnata	600
gctgaantcc	ccatnaccnn	gnctcnatgg	anccntccnt	tttaannacn	ttctnaactt	660
gggaanance	ctcgnccntn	ccccnttaa	tccnccctg	cnangnncnt	cccccnntcc	720
ncccnntng	gcntntnann	cnaaaaaggc	ccnnnancaa	tctcctnnnc	cctcanttgc	780
ccanccctgc	aatcgccn	c				801

<210> 10

<211> 789

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(789)

<223> n = A,T,C or G

<400> 10

cagtctatnt	ggccagtgtg	gcagctttcc	ctgtggtgc	cggtgccaca	tgctgtccc	60
acagtgtggc	cgtggtgaca	gcttcagccg	ccctcagccg	gttcaccttc	tcagccctgc	120
agatcctgcc	ctacacactg	gcctccctct	accacggga	gaagcagggtg	ttcctgccc	180
aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	cctgatgacc	agcttctgc	240
caggccctaa	gcctggagct	cccttcccta	atggacacgt	gggtgctgga	ggcagtggcc	300
tgctcccacc	tccaccgcg	ctctgcggg	cctctgcctg	tgatgtctcc	gtacgtgtgg	360
tggtgggtga	gccccccgan	gccagggtgg	ttccgggccc	gggcatctgc	ctggacctgc	420
ccatcctgga	tagtgcttcc	tgctgtccca	ngtgccccca	tccctgttta	tggtgtccat	480
tgccagctc	agccagctg	tactgccta	tatggtgtct	gccgcaggcc	tggtgtgtgt	540
ccatttact	ttgtacaca	ggtantattt	gacaagaacg	anttggccaa	atactcagcg	600

ttaaaaaatt	ccagcaacat	tgggggtgga	aggcctgcct	cactgggtcc	aactccccgc	660
tcctgttaac	cccatggggc	tgccggcttg	gccgccaat	tctgttgctg	ccaaantnat	720
gtggctctct	gctgccacct	gttgctggct	gaagtgcnta	cngcncanct	nggggggtng	780
gnggttccc						789

<210> 11
 <211> 772
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(772)
 <223> n = A,T,C or G

<400> 11						
cccaccctac	ccaaatatta	gacaccaaca	cagaaaagct	agcaatggat	tcccttctac	60
tttgttaaat	aaataagtta	aatattttaa	tgccgtgtgc	tctgtgatgg	caacagaagg	120
accaacaggc	cacatcctga	taaaaggtaa	gaggggggtg	gatcagcaaa	aagacagtgc	180
tgtgggctga	ggggacctgg	ttcttgtgtg	ttgcccctca	ggactcttcc	cctacaaata	240
actttcatat	gttcaaattc	catggaggag	tgtttcatcc	tagaaaactcc	catgcaagag	300
ctacattaaa	cgaagctgca	ggttaagggg	cttanagatg	ggaaaccagg	tgactgagtt	360
tattcagctc	ccaaaaaccc	ttctctaggt	gtgtctcaac	taggaggcta	gctgttaacc	420
ctgagcctgg	gtaatccacc	tgagagctcc	ccgcattcca	gtgcatggaa	cccttctggc	480
ctccctgtat	aagtccagac	tgaaaacccc	ttggaaggnc	tccagtccag	cagccctana	540
aactggggaa	aaaagaaaag	gacgccccan	ccccagctg	tgcanctacg	cacctcaaca	600
gcacagggtg	gcagcaaaaa	aaccacttta	ctttggcaca	aacaaaaact	ngggggggca	660
accccgccac	cccnangggg	gttaacagga	ancngggnaa	cntggaaccc	aattnaggca	720
ggcccnccac	ccnnaatntt	gctgggaaat	ttttcctccc	ctaaatnttt	tc	772

<210> 12
 <211> 751
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(751)
 <223> n = A,T,C or G

<400> 12						
gccccaatte	cagctgccac	accacccacg	gtgactgcat	tagttcggat	gtcatacaaa	60
agctgattga	agcaaccctc	tacttttttg	tcgtgagcct	tttgcttggg	gcaggtttca	120
ttggctgtgt	tggtgacgtt	gtcattgcaa	cagaatgggg	gaaaggcact	gttctctttg	180
aagtanggtg	agtctctaaa	atccgtatag	ttggtgaagc	cacagcactt	gagccctttc	240
atggtggtgt	tccacacttg	agtgaagtct	tcctgggaac	cataatcttt	cttgatggca	300
ggcactacca	gcaacgtcag	ggaagtgtc	agccattgtg	gtgtacacca	aggcgaccac	360
agcagctgcn	acctcagcaa	tgaagatgan	gaggangatg	aagaagaacg	tcnccgagggc	420
acacttgctc	tcagtcttan	caccatanca	gcccntgaaa	accaananca	aagaccacna	480
cnccggctgc	gatgaagaaa	tnaccccneg	ttgacaaact	tgcatggcac	tggganccac	540
agtggccena	aaaatcttca	aaaaggatgc	cccactnatt	gaccccccaa	atgccacttg	600
ccaacagggg	ctgccccacn	cncnnaacga	tgancnatt	gnacaagatc	tnenttggtct	660
tnatnaacnt	gaaccctgcn	tngtggctcc	gtttcaggnc	cnnggcctga	cttctnaann	720
aangaactcn	gaagncccca	cngganannc	g			751

<210> 13
 <211> 729
 <212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(729)

<223> n = A,T,C or G

<400> 13

gagccaggcg	tccctctgcc	tgcccactca	gtggcaacac	ccgggagctg	ttttgtcctt	60
tgtggancct	cagcagtncc	ctctttcaga	actcantgcc	aaganccctg	aacaggagcc	120
accatgcagt	gcttcagctt	cattaagacc	atgatgatcc	tcttcaattt	gctcatcttt	180
ctgtgtggtg	cagccctggt	ggcagtgggc	atctgggtgt	caatcgatgg	ggcatccttt	240
ctgaagatct	tggggccact	gtcgtccagt	gccatgcagt	ttgtcaacgt	gggctacttc	300
ctcatcgag	ccggcggtgt	ggtcttagct	ctagggttcc	tgggctgcta	tgggtgctaag	360
actgagagca	agtgtgccct	cgtgacgttc	ttcttcaccc	tcctcctcat	cttcattgct	420
gaggttgcaa	tgctgtggtc	gccttggtgt	acaccacaat	ggctgagcac	ttcctgacgt	480
tgctggtaat	gcctgccatc	aanaaaagat	tatgggttcc	caggaanact	tcactcaagt	540
gttggaacac	caccatgaaa	gggctcaagt	gctgtggctt	cnnccaacta	tacggatttt	600
gaagantcac	ctacttcaaa	gaaaanagtg	cctttccccc	atttctgttg	caattgacaa	660
acgtccccaa	cacagccaat	tgaaaacctg	cacccaaccc	aaanggtcc	ccaaccanaa	720
attnaagg						729

<210> 14

<211> 816

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(816)

<223> n = A,T,C or G

<400> 14

tgctcttct	caaagtgtgt	cttgttgcca	taacaaccac	cataggtaaa	gcggggcgag	60
tgctcgtga	aggggttgta	gtaccagcgc	gggatgtct	ccttgagag	tcctgtgtct	120
ggcaggtcca	cgcagtggcc	tttgtcactg	gggaaatgga	tgcgtggag	ctcgtcaaag	180
ccactcgtgt	atttttcaca	ggcagcctcg	tccgacgctg	cggggcagtt	gggggtgtct	240
tcacactcca	ggaaactgtc	natgcagcag	ccattgctgc	agcggaaactg	ggtgggctga	300
cangtgccag	agcacactgg	atggcgcctt	tccatgnnan	gggcccctgng	ggaaagtccc	360
tganccccc	anctgcctct	caaangcccc	accttgccac	ccccgacagg	ctagaatgga	420
atcttcttcc	cgaaaggtag	ttnttcttgt	tgcccaancc	anccccntaa	acaaactctt	480
gcanatctgc	tccngggggg	tctantacc	ancgtgggaa	aagaaccccca	ggcngcgaac	540
caancttggt	tggatncgaa	gcnataatct	nctnttctgc	ttggtggaca	gcaccantna	600
ctgtnnanct	ttagnccntg	gtcctcntgg	gttgnncttg	aacctaatcn	ccnntcaact	660
gggacaagg	aantngccnt	cctttnaatt	cccnanctn	ccccctgggt	tgggggtttt	720
cncnctcta	ccccagaaan	nccgtgttcc	cccccaacta	ggggccnaaa	ccnnttnttc	780
cacaacctn	ccccaccac	gggttcngnt	ggttng			816

<210> 15

<211> 783

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(783)

<223> n = A,T,C or G

<400> 15

ccaaggcctg	ggcaggcata	nacttgaagg	tacaacccca	ggaacccctg	gtgctgaagg	60
atgtggaaaa	cacagattgg	cgcctactgc	ggggtgacac	ggatgtcagg	gtagagagga	120
aagacccaaa	ccaggtggaa	ctgtggggac	tcaagggaang	cacctacctg	ttccagctga	180
cagtgtactag	ctcagaccac	ccagaggaca	cggccaacgt	cacagtcaact	gtgctgtcca	240
ccaagcagac	agaagactac	tgcctcgcac	ccaacaangt	gggtcgtgc	cggggtctct	300
tcccacgctg	gtactatgac	cccacggagc	agatctgcaa	gagtttcgtt	tatggagggt	360
gcttgggcaa	caagaacaac	taccttcggg	aagaagagt	cattctancc	tgtcnggggt	420
tgcaagggtg	gcctttgana	ngcanctctg	gggctcangc	gactttcccc	caggggccct	480
ccatggaaag	gcgcatoca	ntgttctctg	gcacctgtca	gcccaccag	ttccgttgca	540
ncaatggctg	ctgcatcnac	antttcctng	aattgtgaca	acaccccca	ntgccccaa	600
ccctcccaac	aaagcttccc	tgttnaaaaa	tacnccantt	ggcttttnac	aaacnccgg	660
cnctccntt	ttcccnntn	aacaaagggc	netngcnttt	gaactgccn	aaccnaggaa	720
tctnccnng	aaaaantncc	cccctgggt	cctnnaance	cctccncaa	anctncccc	780
ccc						783

<210> 16

<211> 801

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)... (801)

<223> n = A,T,C or G

<400> 16

gccccaatc	cagctgccac	accacccacg	gtgactgcat	tagttcggat	gtcatacaaa	60
agctgattga	agcaaccctc	tacttttttg	tcgtgagcct	tttgcttgg	gcagggtttca	120
ttggtgtgt	tggtgacgtt	gtcattgcaa	cagaatgggg	gaaaggcact	gttctctttg	180
aagttaggtg	agtcctcaaa	atccgtatag	ttggtgaagc	cacagcaact	gagccctttc	240
atggtggtgt	tccacacttg	agtgaagtct	tcctgggaac	cataatcttt	cttcatggca	300
ggcactacca	gcaacgtcag	gaagtgtctca	gccattgtgg	tgtacaccaa	ggcgaccaca	360
gcagctgcaa	cctcagcaat	gaagatgagg	aggaggatga	agaagaacgt	cncgagggca	420
cacttgtct	ccgtcttagc	accatagcag	cccangaaac	caagagcaaa	gaccacaacg	480
cnngctgcga	atgaaagaaa	ntaccacgt	tgacaaactg	catggccact	ggacgacagt	540
tggcccgaa	atcttcagaa	aagggatgcc	ccatcgattg	aacacccana	tgccactgc	600
cnacagggt	gcncncncn	gaaagaatga	gccattgaag	aaggatontc	ntggtcttaa	660
tgaactgaaa	cnctgcatgg	tggccctgt	tcagggtct	tggcagtga	ttctganaaa	720
aaggaaacng	ntnagcccc	ccaaangana	aaacaccccc	gggtgttgcc	ctgaattggc	780
ggccaaggan	ccctgccccn	g				801

<210> 17

<211> 740

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)... (740)

<223> n = A,T,C or G

<400> 17

gtgagagcca	ggcgtccctc	tgcctgccca	ctcagtggca	acacccggga	gctgttttgt	60
cctttgtgga	gcctcagcag	ttccctcttt	cagaactcac	tgccaagagc	cctgaacagg	120
agccaccatg	cagtgttca	gcttcattaa	gaccatgatg	atcctcttca	atttgcctcat	180
ctttctgtgt	ggtgcagccc	tggtggcagt	gggcatctgg	gtgtcaatcg	atggggcatc	240
ctttctgaag	atcttcgggc	cactgtcgtc	cagtgccatg	cagtttgtca	acgtgggcta	300

cttcctcctc	gcagccggcg	ttgtgggtctt	tgctcttggg	ttcctgggct	gctatgggtgc	360
taagacggag	agcaagtgtg	ccctcgtgac	gttcttcttc	atcctcctcc	tcctcttcat	420
tgctgaagtt	gcagctgctg	tggtcgccct	gggtgacacc	acaatggctg	aaccattcct	480
gacgttgctg	gtantgctg	ccatcaanaa	agattatggg	ttcccaggaa	aaattcactc	540
aantntggaa	caccnccatg	aaaagggctc	caatttctgn	tggtttcccc	aactataccg	600
gaattttgaa	agantcnccc	tacttccaaa	aaaaaanant	tgcttttncc	ccntttctgt	660
tgcaatgaaa	acntcccaan	acngccaatn	aaaacctgcc	cnnncaaaaa	ggntcncaaa	720
caaaaaaant	nnaagggttn					740

<210> 18
 <211> 802
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(802)
 <223> n = A,T,C or G

<400> 18	
ccgctgggtg	cgctgggtcca gngnagccac gaagcacgtc agcatacaca goctcaatca 60
caaggtcttc	cagctgccgc acattacgca gggcaagagc ctccagcaac actgcatatg 120
ggatacactt	tacttttagca gccagggtga caactgagag gtgtcgaagc ttattcttct 180
gagcctctgt	tagtggagga agattccggg cttcagctaa gtatgcagcg tatgtcccat 240
aagcaaacac	tgtgagcagc cggaaggtag aggcaaagtc actctcagcc agctctctaa 300
cattgggcat	gtccagcagt tctccaaaca cgtagacacc agnggcctcc agcacctgat 360
ggatgagtg	ggccagcgct gcccccttgg ccgacttggc taggagcaga aattgctcct 420
ggttctgccc	tgtcaccttc acttccgcac tcactactgc actgagtgtg ggggacttgg 480
gctcaggatg	tccagagacg tggttccgcc cctcnctta atgacaccgn ccanncaacc 540
gtcggtcccc	cagantgng ttogtcgtnc ctgggtcagg gtctgctggc cncactctgc 600
aancctctgc	nggcccatgg aattcacccc accggaactn gtangatcca ctnttctat 660
aaccggncgc	caccgcnnnt ggaactccac tcttnttncc ttacttgag gggttaaggtc 720
acccttnncc	ttaccttggt ccaaaccntn cntgtgtcgt anantngtnaa tcnggncnca 780
tnccancnc	atangaagcc ng 802

<210> 19
 <211> 731
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(731)
 <223> n = A,T,C or G

<400> 19	
cnaagcttcc	aggtnacggg ccgcnaance tgaccnagg tancanaang cagncngcgg 60
gagcccaccg	tcacngngng gngtctttat nggagggggc ggagccacat cnetggacnt 120
cntgacccca	actcccnccc ncnantgca gtgatgagtg cagaactgaa ggtnacgttg 180
caggaaacaa	gancaaannc tgctccnntc caagtccgcn nagggggcgg ggctggccac 240
gencatcct	cnagtgtgn aaagcccnng cctgtctact tgtttggaga acngcnnga 300
catgcccagn	gttanataac nggcnagag tnantttgcc tctcccttcc ggctgcgcan 360
cngntntgct	tagnggacat aacctgacta cttaactgaa cccnngaate tncnccccct 420
ccactaagct	cagaacaaaa aacttcgaca ccactcantt gtcacctgnc tgctcaagta 480
aagtgtaccc	catncccaat gntgtctnga ngctctgncc tgcnttangt tcggtcctgg 540
gaagacctat	caattnaagc tatgtttctg actgcctctt gctccctgna acaancnacc 600
cnnnntcca	agggggggnc ggcccccaat ccccccaacc ntnaattnan ttanccccn 660
ccccnnggcc	cggcctttta cnancntcn nnacngggna aaaccnnngc ttnccccaac 720

nnaatccncc t

731

<210> 20
 <211> 754
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(754)
 <223> n = A,T,C or G

<400> 20
 tttttttttt tttttttttt taaaaacccc ctccattnaa tgnaaacttc cgaaattgtc 60
 caacccccctc ntccaaatnn ccntttccgg gnggggggttc caaacccaan ttanntttgg 120
 annttaaatt aaatnttntt tggnggnnna anccnaatgt nangaaagt naaccanta 180
 tnacttnaa tncctggaaa cngtngntt ccaaaaatnt ttaaccctta antccctccg 240
 aaatngttta nggaaaaccc aanttctont aaggttggtt gaaggntnaa tnaaaanccc 300
 nnccaattgt ttttngccac gcctgaatta attggnnttc gntgttttcc nttaaaanaa 360
 gggnancccc ggttantnaa tcccccnnc cccaattata ccganttttt ttngaattgg 420
 gancccnccg gaattaacgg ggnnntccc tnttgggggg cnggnncccc ccccntcggg 480
 ggttngggnc agnccnaat tgtttaaggg tccgaaaaat ccctccnaga aaaaaanctc 540
 ccagntgag nntnggggtt ncccccccc canggcccc ctcgnanagt tgggggtttg 600
 ggggcctggg attttntttc cctnttncc tcccccccc cngggganag aggttngngt 660
 tttgntcnnc ggccccnccn aaganccttn ccganttnan ttaaatecnt gcctnggcga 720
 agtcnttgn agggntaaan ggccccctnn cggt 754

<210> 21
 <211> 755
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(755)
 <223> n = A,T,C or G

<400> 21
 atcancccat gacccnaac nngggaccnc tcanccggnc nnnnacccnc cggecnatca 60
 nngtnagnnc actncnnttn natcaacccc cncnactac gccnncnanc cnacgcnta 120
 nncanatncc actganngcg cgangtngan ngagaaanct nataccanag ncaccanacn 180
 ccagctgtcc nanaangcct nnnatacngg nnnatccaat ntgnancctc cnaagtattn 240
 nncnncanat gattttcctn anccgattac cctntcccc tanccctcc cccccaacna 300
 cgaaggcnct ggncnnaagg nngcgnccnc ccgctagntc ccnncaagt cncnenccta 360
 aactcanccn nattaacncc ttcttgagta tcaactcccc aatctcacc tactcaactc 420
 aaaaanatch gatacaaaat aatncaagcc tgnattatnac actntgactg ggtctctatt 480
 ttagnggtcc ntnaancntc ctaatacttc cagtctncc tcnccaattt cnaanggt 540
 ctttngaca gcatnttttg gttcccnntt gggttcttan ngaattgcc ttctngaac 600
 gggctctct tttccttcgg ttanccctgg ttcnccggc cagttattat ttccntttt 660
 aaattcntnc cntttanttt tggcnttca aacccccggc cttgaaaacg gccccctggt 720
 aaaaggttgt tttganaaaa tttttgtttt gtcc 755

<210> 22
 <211> 849
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(849)
 <223> n = A,T,C or G

<400> 22
 tttttttttt tttttangtg tngtcgtgca ggtagaggct tactacaant gtgaanacgt 60
 acgctnngan taangcgacc cgantttctag ganncnccct aaaatcanac tgtgaagatn 120
 atcctgnana cggaanggtc accggnggat nntgctaggg tgnccnctcc cannncttn 180
 cataacteng nggccctgcc caccaccttc ggccggcccng ngnccgggcc cgggtcattn 240
 gnnttaacn cactnngcna nccgtttccn nccccnng acccngggca tccggggtn 300
 tctgtcttc cctgnagncn anaaantggg ccnccgnccc ctttaccct nnacaagcca 360
 cngecnteta nccnngccc cccctccant nngggggact gccnanngt cgttntctng 420
 nnacccnngn gggtncctcg gttgtcgant cnaccgnang ccanggatc cnaagggaag 480
 tgcgtnttg gccctaccc ttcgtncgg nncacccttc ccgacnanga nccgtccccg 540
 cncnccngn cctncctcg caacacccgc nctntcngt nccgnnnccc cccacccgc 600
 nccctncnc nccnngnanc ctcnccncc gtctcannca ccaccccgcc ccgccaaggcc 660
 ntcnccacn ggngacnng nagnccntc gncccgcgn gcgnccctt cgcncngaa 720
 ctntctcng ccantnccgc tcaancnna cnaaacgcc ctgcgcggcc cgnagcgncc 780
 ncctcncga gtcctccgn cttccnacc angnttccn cgaggacacn nnaccccgcc 840
 nncangcgg 849

<210> 23
 <211> 872
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(872)
 <223> n = A,T,C or G

<400> 23
 gcgcaaacta tacttcgctc gnactcgtgc gcctcgtcnc tcttttctc cgcaaccatg 60
 tctgacnanc ccgattnggc ngatatcnan aagntcganc agtccaaact gantaacaca 120
 cacacnncan aganaaatcc nctgccttcc anagtanacn attgaacnng agaaccangc 180
 nggcgaatcg taatnaggcg tgcgcgcgca atntgtcncc gtttatntn ccagctcnc 240
 ctncnacc tactcttcn nagctgtcnn accctngtn cgnaccccc naggtcggga 300
 tccggttttn nntgaccng cnnccctcc cccctccat nacganccn ccgcaccacc 360
 nanngcncgc nccccgnct cttgcgcnc ctgtcctntn cccctgtngc ctggcncngn 420
 accgcattga cctcgcgcnn ctncnngaaa nccnancgt ccgggttggn annancgctg 480
 tgggngngcg tctgcncgc gttccttcn ncnncttcca ccatcttct tacngggct 540
 ccnccgcntc tcnncacnc cctgggacgc tntcctntgc ccccttnac tccccctt 600
 cgnctgncc cgncccccacc ntcatttnca nacgntcttc acaannncc ggntnnctcc 660
 cnancngn gtcnccnag ggaaggngg ggnnccntg nttgacgttg ngngangtc 720
 cgaanantcc tcnctnccan cctacccct cgggcgnct ctngttnc aacttanca 780
 ntctcccccg ngngcncntc tcagcctcnc cnccccnc ctctgcantg tntctgctc 840
 tnaccnntac gantnttcgn cncctctt cc 872

<210> 24
 <211> 815
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(815)
 <223> n = A,T,C or G

<400> 24

gcatgcaagc	ttgagtattc	tatagngtca	cctaaatanc	ttggcntaat	catgggtcnta	60
nctgncttcc	tgtgtcaaat	gtatacnaan	tanatatgaa	tctnatntga	caaganngta	120
tctnncatta	gtaacaantg	tnntgtccat	cctgtcngan	canattccca	tnnattncgn	180
cgcattcnen	gcncantatn	taatngggaa	ntcnntnnn	ncaccnncat	ctatcntncc	240
gcnccttgac	tggnagagat	ggatnanttc	tnntntgacc	nacatgttca	tcttggattn	300
aananccccc	cgcngnccac	cggttngnng	cnagccnntc	ccaagacctc	ctgtggaggt	360
aacctgcgtc	aganncatca	aacntgggaa	acccgcnncc	angtnnaagt	ngnnncanan	420
gatcccgctc	aggnttnacc	atcccttcnc	agcgccccct	ttngtgcctt	anagnngnagc	480
gtgtccnanc	cnetcaacat	ganacgcgcc	agnccanccg	caattnggca	caatgtcgnc	540
gaacccccta	gggggantna	tncaaanccc	caggattgtc	cncncangaa	atcccncanc	600
ccnccctac	ccncttttg	gacngtgacc	aantcccgga	gtncacgtcc	ggccngnctc	660
ccccaccggt	nnccntgggg	gggtgaanct	cngnntcanc	cngncgaggn	ntcgnaagga	720
accggnctn	ggncgaanng	ancnntcnga	agngccnct	cgtataacc	cccctcncca	780
nccnacngnt	agntcccccc	cngggtncgg	aangg			815

<210> 25

<211> 775

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(775)

<223> n = A,T,C or G

<400> 25

ccgagatgtc	tcgctccgtg	gccttagctg	tgctcgcgt	actctctctt	tctggcctgg	60
aggctatcca	gcgtactcca	aagattcagg	tttactcacg	tcattccagca	gagaatggaa	120
agtcaaattt	cctgaattgc	tatgtgtctg	ggtttcatcc	atccgacatt	gaanttgtact	180
tactgaagaa	tggnagagaa	attgaaaaag	tgagacattc	agacttgtct	ttcagcaagg	240
actggtcttt	ctatctcntg	tactacactg	aattcacccc	cactgaaaaa	gatgagtatg	300
cctgcccgtg	gaaccatgtg	actttgtcac	agcccaagat	agttaagtgg	gatcgagaca	360
tgtaaagcag	cnnatggaa	gtttgaagat	gcgcatttg	gattggatga	attccaaatt	420
ctgcttgctt	gcnttttaat	antgatatgc	ntatacaccc	taccctttat	gncccccatt	480
tgtagggggt	acatnantgt	tcnctntnga	catgatcttc	ctttataant	ccnccnttcg	540
aattgcccgt	cncnngttn	ngaattgttc	cnaaaccacg	gttggctccc	ccaggtcncc	600
tcttaaggaa	gggcctgggc	cnccttncaa	ggttggggga	accnaaaatt	tcncttntgc	660
ccnccncca	cnntcttgng	nnncantttt	ggaacccttc	cnattcccct	tggcctcnna	720
nccttnncta	aaaaaacttn	aaancgtngc	naaanntttn	acttcccccc	ttacc	775

<210> 26

<211> 820

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(820)

<223> n = A,T,C or G

<400> 26

anattantac	agtgtaatct	tttcccagag	gtgtgtanag	ggaacggggc	ctagaggcat	60
cccaagata	ncttatanca	acagtgettt	gaccaagagc	tgctgggcac	atttcctgca	120
gaaaagggtg	cggcccccat	cactcctcct	ctcccacagc	catcccagag	gggtgagtag	180
ccatcangcc	ttcgggtggga	gggagtcang	gaaacaacan	accacagagc	anacagacca	240
ntgatgacca	tgggcgggag	cgagcctctt	ccctgnaccg	gggtggcana	nganagccta	300
nctgaggggt	cacactataa	acgttaacga	ccnagatnan	cacctgcttc	aagtgcaccc	360

ttcctacctg	acnaccagng	accnnnaact	gcngcctggg	gacagcncctg	ggancagcta	420
acnnagcaact	cacctgcccc	cccatggccg	tncgcntccc	tggtcctgnc	aagggaagct	480
ccctgttgga	attncgggga	naccaaggga	nccccctcct	ccanctgtga	aggaaaaann	540
gatggaattt	tncccttccg	gcnntcccc	tcttccttta	cacgccccct	nntactcntc	600
tccctctntt	ntcctgncnc	acttttnacc	ccnnnatttc	ccttnattga	tcggannctn	660
ganattccac	tnnccgctnc	cntcnatcng	naanacnaaa	nactntctna	cccnggggat	720
gggnncctcg	ntcatcctct	ctttttcnc	accnccnntt	ctttgcctct	ccttngatca	780
tccaacntc	gntggccntn	ccccccnnt	tcctttnccc			820

<210> 27
 <211> 818
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(818)
 <223> n = A,T,C or G

<400> 27						
tctgggtgat	ggcctcttcc	tcctcagggg	cctctgactg	ctctgggcca	aagaatctct	60
tgtttcttct	ccgagcccca	ggcagcgggt	attcagccct	gcccacccctg	attctgatga	120
ctgcggatgc	tgtgacggac	ccaaggggca	aatagggtcc	cagggtccag	ggaggggcgc	180
ctgctgagca	cttcgcgcc	tcacctgcc	cagccctgc	catgagctct	gggctgggtc	240
tcgcctcca	gggttctgct	cttcangca	ngccancaa	tggcgctggg	ccacactggc	300
ttcttctctg	ccntccctg	gctctgantc	tctgtcttcc	tgctcctgtc	angcnccttg	360
gatctcagtt	tcctcncctc	anngaactct	gtttctgann	tcttcantta	actntgantt	420
tatnaccnan	tggnctgtnc	tgtnnactt	taatgggccc	gaccggctaa	tcctccctc	480
ntcccttcc	anttcnnna	accngcttnc	cntctctcc	ccntancccg	ccngggaanc	540
ctcctttgcc	gcnnnaccg	gcnnnaccg	ccntnnctn	ggggggcnng	gtnnctncnc	600
ctgntnnccc	cncctcncnt	tnccctgtcc	cnnnncgc	nngcannttc	ncngtcccn	660
tnnctcttcn	ngntcgnaa	ngntcncntn	tnnnnngncn	ngntnntncn	tcctctcnc	720
cnnntgnang	tnnttnnnnc	ncngnncccc	nnnnccnnnn	nggnntnnn	tctncncngc	780
ccnncccc	ngnatgaag	cctccntct	ccggccnc			818

<210> 28
 <211> 731
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(731)
 <223> n = A,T,C or G

<400> 28						
aggaagggcg	gagggatatt	gtangggatt	gagggatagg	agnataangg	gggaggtgtg	60
tcccaacatg	anggtgnngt	tctcttttga	angagggttg	ngtttttann	ccnggtgggt	120
gattnaaccc	cattgtatgg	agnnaaagg	tttnagggat	tttccggctc	ttatcagtat	180
ntanattcct	gtnaatcgga	aaatnatntt	tcnnccggaa	aatnttgctc	ccatccgnaa	240
attnctcccg	ggtagtgc	nttnggggg	cnccangtt	tcaccaggtg	ctanaatcgt	300
actaaagntt	naagtggan	tncaaatgaa	aacctnnac	agagnatccn	tacccgactg	360
tnnnntncc	tcgcccctng	actctgcng	agcccaatac	ccnnngnng	gtcncnccng	420
nnngcgnnc	tgaaannnnc	tcngggctnn	gancatcang	gggtttcgca	tcaaaagcnn	480
cgtttcncat	naaggcactt	tnccctcatc	caaccnctng	ccctcnncca	tttngccgtc	540
nggttcncct	acgctnnntg	cncctnnntn	ganattttnc	ccgctnnggg	naancctcct	600
gnaatgggta	gggncttntc	ttttnacnnc	gnggtntact	aatcnnctnc	acgctnctt	660
tctcnacccc	ccccctttt	caatcccanc	ggcnaatggg	gtctccccnn	cgangggggg	720

nnnccccannc c

731

<210> 29
 <211> 822
 <212> DNA
 <213> Homo sapien

 <220>
 <221> misc_feature
 <222> (1)...(822)
 <223> n = A,T,C or G

<400> 29
 actagtccag tgtggtggaa ttccattgtg ttggggncnc ttctatgant antnttagat 60
 cgctcanacc tcacancctc ccnacnangc ctataangaa nannaataga nctgtncnnt 120
 atntntacnc tcatanncct cnnnaccacac tccctcttaa cccntactgt gcctatngcn 180
 tnntantct ntgcgcctn cnanccaccn gtgggccnac cncnngnatt ctcatctcc 240
 tcnccatntn gcctananta ngtnccatcc ctatacctac nccaatgcta nnnctaancn 300
 tccatnantt annntaacta ccactgacnt ngactttcnc atnanctcct aatttgaatc 360
 tactctgact cccacngcct annnattagc ancntcccc nacnatntct caaccaaate 420
 ntcaacaacc tatctantctg ttcnccaacc nttncctccg atccccnnac aacccccctc 480
 ccaaataccc nccacctgac ncctaaccn caccatcccg gcaagccnan ggcatttan 540
 ccactggaat cacnatngga naaaaaaac ccnaactctc tancncnnat ctccctaana 600
 aatnctcctn naatttactn ncantnccat caancccaen tgaaacnnaa cccctgtttt 660
 tanatccctt ctttcgaaaa ccnacccttt annncccaac ctttngggcc ccccnctnc 720
 ccnaatgaag gncncccaat cnangaaacg nccntgaaaa ancaggcna anannntccg 780
 canatcctat cccttanttn ggggncctt nccngggcc cc 822

<210> 30
 <211> 787
 <212> DNA
 <213> Homo sapien

 <220>
 <221> misc_feature
 <222> (1)...(787)
 <223> n = A,T,C or G

<400> 30
 cggccgcctg ctctggcaCa tgcctcctga atggcatcaa aagtgatgga ctgcccattg 60
 ctagagaaga ccttctctcc tactgtcatt atggagccct gcagactgag ggctcccctt 120
 gtctgcagga tttgatgtct gaagtcgttg agtgtggctt ggagctcctc atctacatna 180
 gctggaagcc ctggagggcc tctctcgcca gcctccccct tctctccaag ctctccangg 240
 acaccagggg ctccaggcag cccattatc ccagnangac atggtgtttc tccacgcgga 300
 cccatggggc ctgnaaggcc aggggtctcct ttgacaccat ctctcccgct ctgctgggca 360
 ggccgtggga tccactantt ctanaacggn cgccaccncg gtgggagctc cagcttttgt 420
 tcccnttaat gaaggttaat tgcncgcttg gcgtaatcat nggtcanaac tntttcctgt 480
 gtgaaattgt ttntccctc ncnattcnc ncnacatacn aaccgggaan cataaagtgt 540
 taaagcctgg gggtnccctn nngaanaac tnaactcaat taattgcgtt ggctcatggc 600
 ccgctttccn ttcnngaaaa ctgtctctcc ctgcnttntt gaatcggcc ccccccnggg 660
 aaaagcggtt tgcnttttng ggggntcctt ccncttccc cctcnctaan ccctnccct 720
 cggtcgttnc nggtnccggg gaangggnat nnnctcccnc naagggggng agnnngntat 780
 ccccaaa 822

<210> 31
 <211> 799
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(799)
 <223> n = A,T,C or G

<400> 31
 tttttttttt tttttttggc gatgctactg ttttaattgca ggaggtgggg gtgtgtgtac 60
 catgtaccag ggctattaga agcaagaagg aaggaggag ggagagcgc cctgctgagc 120
 aacaaaggac tcctgcagcc ttctctgtct gtctcttggc gcaggcacat ggggaggcct 180
 cccgcagggt gggggccacc agtccagggt tgggagcact acanggggtg ggagtgggtg 240
 gtggctggtg cnaatggcct gncacanatc cctacgattc ttgacacctg gatttcacca 300
 ggggaccttc tgttctccca nggnaacttc nttnatctcn aaagaacaca actgtttctt 360
 cngcanttct ggctgttcat ggaaagcaca ggtgtccnat ttnggctggg acttggtaca 420
 tatggttcgc gccacacctc ccntcnaaa aagtaattca ccccccccn ccntctnttg 480
 cctgggccct taantaccca caccggaact canttanta ttcatcttng gntgggcttg 540
 nttnatcnccn cctgaangcg ccaagttgaa aggccacgcc gtncccnctc cccatagnan 600
 nttttnnent canctaagtc cccccnggc aacnatccaa tcccccccn tgggggcccc 660
 agcccanggc ccccgctcgc ggnnnccngn cncgnantcc ccagntctc ccantcngnc 720
 ccnnngcncc cccgcacgca gaacanaagg ntngagccnc cgcannnnnn nggttnncnac 780
 ctgcccccc cccnccgng 799

<210> 32
 <211> 789
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(789)
 <223> n = A,T,C or G

<400> 32
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
 ttttnccnag ggcaggttta ttgacaacct cncgggacac aancaggctg gggacaggac 120
 ggcaacaggc tccggcggcg gcggcggcg ccctacctgc ggtaccaaata ntgcagcctc 180
 cgctcccgct tgatnttcct ctgcagctgc aggatgccnt aaaacagggc ctccggccntn 240
 ggtgggcacc ctgggatttn aatttccacg ggcacaatgc ggtcgcanc cctcaccacc 300
 nattaggaat agtggnttta ccnccnccg ttggcncact cccntggaa accactntc 360
 gcggtcccg catctggtct taaaccttgc aaacnctggg gccctctttt tggttantnt 420
 nccngccaca atcatnactc agactggcnc gggctggccc caaaaaancn ccccaaaacc 480
 ggnccatgtc ttncgggggt tgetgcnatn tncatcacct cccgggcnc ncaggncaac 540
 ccaaaagtgc ttngggcccn caaaaaanct cccgggggnc ccagtttcaa caaagtcac 600
 ccccttggcc cccaaatcct cccccgntt nctgggttg ggaaccacg cctctnnctt 660
 tggnnngcaa gntggntccc ccttcgggccc cccgggtggc ccnctctaa ngaaaacncc 720
 ntccntnnca ccatcccccc nngnnacgnc tancaangna tccctttttt tanaaacggg 780
 cccccncg 799

<210> 33
 <211> 793
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(793)
 <223> n = A,T,C or G

<400> 33

gacagaacat	gttggatggt	ggagcacctt	tctatacgac	ttacaggaca	gcagatgggg	60
aattcatggc	tggttgagca	atanaacccc	agttctacga	gctgctgac	aaaggacttg	120
gactaaagtc	tgatgaactt	cccaatcaga	tgagcatgga	tgattggcca	gaaatgaana	180
agaagtttgc	agatgtatth	gcaaagaaga	cgaaggcaga	gtggtgtcaa	atctttgacg	240
gcacagatgc	ctgtgtgact	ccggttctga	cttttgagga	ggttgttcat	catgatcaca	300
acaangaacg	gggctcgttt	atcaccantg	aggagcagga	cgtgagcccc	cgccctgcac	360
ctctgctgtt	aaacacccca	gccatccctt	ctttcaaaaag	ggatccacta	cttctagagc	420
ggncgccacc	gcggtggagc	tccagctttt	gttcccttta	gtgagggtta	attgcgcgct	480
tggcgtaatc	atggtcatan	ctgtttcctg	tgtgaaattg	ttatccgctc	acaattccac	540
acaacatacg	anccggaagc	atnaaatttt	aaagcctggn	ggtngcctaa	tgantgaact	600
nactcacatt	aattggcttt	gcgctcactg	cccgttttcc	agtcgggaaa	acctgtcctt	660
gccagctgcc	nttaatgaat	cnggccaccc	cccggggaaa	aggcngtttg	cttnttgggg	720
cgcncctccc	gctttctcgc	ttcctgaant	ccttccccc	ggtctttcgg	cttgcggcna	780
acggtatcna	cct					793

<210> 34

<211> 756

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(756)

<223> n = A,T,C or G

<400> 34

gccgcgaccg	gcatgtacga	gcaactcaag	ggcgagtgga	accgtaaaag	ccccaatctt	60
ancaagtgcg	gggaanagct	gggtcgactc	aagctagttc	ttctggagct	caacttcttg	120
ccaaccacag	ggaccaagct	gaccaaacag	cagctaattc	tgccccgtga	catactggag	180
atcggggccc	aattggagcat	cctacgcaan	gacatcccct	ccttcgagcg	ctacatggcc	240
cagctcaaat	gctactactt	tgattacaan	gagcagctcc	ccgagtcagc	ctatatgcac	300
cagctcttgg	gcctcaacct	cctcttcctg	ctgtcccaga	accgggtggc	tgantnccac	360
acgganttgg	ancggctgcc	tgcccaanga	catacanacc	aatgtctaca	tcnaccacca	420
gtgtcctgga	gcaatactga	tggaangcag	ctaccncaaa	gtnttctctg	ccnagggtta	480
catccccgcg	cgagagctac	accttcttca	ttgacatcct	gctcgacact	atcagggatg	540
aaaatcgng	ggttgtctca	gaaaggctnc	aanaanatcc	ttttcncctga	aggccccggg	600
atnncctagt	nctagaatcg	gcccgccatc	gcggtgganc	ctccaacctt	tcgttncctt	660
ttactgaggg	ttnattgccc	cccttgccgt	tatcatggtc	acnccngttn	cctgtgttga	720
aattnttaac	ccccacaaat	tccacgcna	cattng			756

<210> 35

<211> 834

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(834)

<223> n = A,T,C or G

<400> 35

gggatctct	anactnacct	gnatgcatgg	ttgtcgggtg	ggtcgctgtc	gatgaanatg	60
aacagatct	tgcccttgaa	gctctcggt	gctgtnttta	agttgctcag	tctgccgtca	120
tagtcagaca	cncctctggg	caaaaaacan	caggatntga	gtcttgattt	cacctccaat	180
aatcttcngg	gctgtctgct	cggtgaactc	gatgacnang	ggcagctggg	tgtgtntgat	240
aaantccanc	angttctcct	tggtgacctc	cccttcaaag	ttgttccggc	cttcatcaaa	300
cttctnnaan	angannancc	canccttgtc	gagctggnat	ttgganaaca	cgctactgtt	360

```

ggaaactgat cccaaatggt atgtcatcca tgcctctgc tgctgcaaa aaacttgctt 420
ggcncaaata cgactcccn tccttgaaag aagccnatca cccccctc cctggactcc 480
nncaangact ctncgctnc ccontccnng cagggttggg ggcanncgg gccctgccc 540
ttcttcagcc agttcacnat ntctcatcagc ccctctgcca gctgttntat tccttggggg 600
ggaanccgctc tctcccttcc tgaannaact ttgaccgtng gaatagccgc gcntcnccnt 660
acntnctggg ccgggttcaa antccctccn ttgncnntcn cctcgggcca ttctggattt 720
nccnaacttt ttcttcccc cncccnccg ngtttgntt ttctatnggg ccccaactct 780
gctnttgccc antccctgg gggcntntan cncccctnt ggtcccntng ggcc 834

```

```

<210> 36
<211> 814
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(814)
<223> n = A,T,C or G

```

```

<400> 36
cggncgcttt cngccgccc cccgtttcca tgacnaaggc tcccttcang ttaaatacnn 60
cctagnaatac attaatgggt tgctctacta atacatcata cnaaccagta agcctgccc 120
naacgccaac tcaggccatt cctaccaaag gaagaaaggc tggctctctc accccctgta 180
ggaaaggcct gccttgtaag acaccacaat ncggctgaat ctnaagtctt gtgttttact 240
aatggaaaaa aaaaataaac aanaggtttt gttctcatgg ctgcccaccg cagcctggca 300
ctaaaacanc ccagcgctca cttctgcttg ganaaatatt ctttgcctt ttggacatca 360
ggcttgatgg tatcactgcc acntttccac ccagctgggc ncccttcccc catntttgtc 420
antganctgg aaggcctgaa ncttagtctc caaaagtctc ngcccacaag accggccacc 480
aggggagctc nttnncagtg gatctgcaa anantaccn tatcatcnnt gaataaaaag 540
gccctgaac ganatgctc cancancctt taagaccat aatcctngaa ccattggtgc 600
cttcgggtct gatccnaaag gaatgttcct ggggtccant cctcctttg ttncctacgt 660
tgtnttgac cntgctngn atnaccaan tganatccc ngaagcacc tncctctggc 720
atttganttt cntaaattct ctgccctacn nctgaaagca cnattccctn ggcncnaan 780
ggngaactca agaaggtctn ngaaaaacca cncn 814

```

```

<210> 37
<211> 760
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(760)
<223> n = A,T,C or G

```

```

<400> 37
gcatgctgct cttcctcaaa gttgttcttg ttgccataac aaccaccata ggtaaagcgg 60
gcgagtggt cgctgaagg gttgtagtac cagcgcgga tgctctcct gcagagtcc 120
gtgtctggca ggtccacgca atgcccttg tcactgggga aatggatgcg ctggagctcg 180
tcnaancac tcgtgtattt ttcacangca gcctcctcg aagcntccg gcagttgggg 240
gtgtcgtcac actccactaa actgtcgatn cancagccca ttgctgcagc ggaactgggt 300
gggctgacag gtgccagaac aactggatn ggcctttcca tggaaaggcc tgggggaaat 360
cncctnancc caaactgcct ctcaaaggcc accttgaca ccccgacagg ctagaaatgc 420
actctcttc ccaaaggtag ttgttcttg tgcccaagca ncctccanca aaccaaaanc 480
ttgcaaaatc tgctccgtgg gggcatnnn taccanggtt ggggaaanaa acccggcngn 540
ganccnccct gtttgaatgc naaggaata atcctcctgt cttgcttggg tggaanagca 600
caattgaact gttacnttg ggcgngttc cncnnggtg gtctgaaact aatcaccgtc 660
actggaaaaa ggtangtgcc ttccttgaat tcccaantt cccctngntt tgggtnttt 720

```

ctcctctncc ctaaaaatcg tnttcccccc ccntanggcg

760

<210> 38
 <211> 724
 <212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(724)
 <223> n = A,T,C or G

<400> 38
 tttttttttt tttttttttt tttttttttt ttttttaaaaa cccctcccat tgaatgaaaa 60
 ctccnaaat tgtccaaccc cctcnnccaa atnnccattt cggggggggg gttccaaacc 120
 caaattaatt ttgganttta aattaaatnt tnattnnggg aanaanccaa atgtnaagaa 180
 aatttaaccc attatnaact taaatncctn gaaaccntg gnttccaaaa atttttaacc 240
 cttaaattccc tccgaaattg ntaanggaaa accaaattcn cctaaggctn tttgaagggt 300
 ngatttaaac ccccttnant tnttttnacc cnngnctnaa ntatttnngt tccggtgttt 360
 tcctnttaan cntnggtaac tcccgnataa gaannnccct aanccaatta aaccgaattt 420
 tttttgaatt ggaaattccn ngggaattna cgggggtttt tccnttttg gggccatncc 480
 ccncttttcg ggggttggn ntaggttgaa tttttnnang nccccaaaaa ncccccaana 540
 aaaaaactcc caagnnttaa ttngaattnc ccccttccca ggccttttg gaaaggnngg 600
 tttntggggg ccngggantt cnttccccn ttncncccc cccccnggt aaanggttat 660
 ngnttttgtt ttttgggccc cttnanggac cttccgatn gaaattaaat ccccggnncg 720
 gccg 724

<210> 39
 <211> 751
 <212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(751)
 <223> n = A,T,C or G

<400> 39
 tttttttttt tttttctttg ctcacattta atttttattt tgattttttt taatgctgca 60
 caacacaata tttatttcat ttgtttcttt tatttcattt tatttgtttg ctgctgctgt 120
 tttatttatt tttactgaaa gtgagaggga acttttgttg ccttttttcc tttttctgta 180
 ggccgcctta agctttctaa atttgaaca tctaagcaag ctgaanggaa aaggggggtt 240
 cgcaaatca ctcgggggaa nggaaagggt gctttgttaa tcatgcccta tgggtgggtga 300
 ttaactgctt gtacaattac ntttcacttt taattaattg tgctnaangc tttaattana 360
 cttgggggtt cctccccan accaaccnccn ctgacaaaaa gtgccngccc tcaaatnatg 420
 tccggcnnt cnttgaaaca cacngcngaa ngttctcatt ntccccncnc caggtnaaaa 480
 tgaagggtta ccatntttaa cnccacctcc acntggcnnn gcctgaatcc tcnaaaancn 540
 cctcaancn aattnctnng ccccggtcnc gcntnngtcc cnccggggt ccgggaantn 600
 cccccnga anncnntnnc naacnaaatt ccgaaaatat tccnntcnc tcaattcccc 660
 cnnagactnt cctcnncnan cncaattttc ttttnttcac gaacncgnnc cnnaaatgn 720
 nnnncnctc cncnngtccn naatcnccan c 751

<210> 40
 <211> 753
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(753)
 <223> n = A,T,C or G

<400> 40
 gtggtatttt ctgtaagatc aggtgttcct ccctcgtagg tttagaggaa acaccctcat 60
 agatgaaaac ccccccgaga cagcagcact gcaactgcca agcagccggg gtaggagggg 120
 cgccctatgc acagctgggc ccttgagaca gcagggttc gatgtcaggc tcgatgtcaa 180
 tgggtctggaa gcggcggtcg tacctgcgta ggggcacacc gtcagggcc accaggaact 240
 tctcaaagtt ccaggcaacn tcgttgcgac acaccggaga ccaggtgatn agcttggggg 300
 cggtcataa cgcgggtggc tcgtcgtcgg gagctggcag ggctcccgc aggaaggcna 360
 ataaaagggt cgcggcgca cgtttcanct cgcacttctc naanaccatg angttgggct 420
 cnaaccacc accannccgg acttccttga nggaattccc aaatctcttc gntcttgggc 480
 ttctnctgat gccctanctg gttgcccn gn atgccaanca nccccancc cgggggtcct 540
 aaancccn cctcctcntt tcctctgggt tnttntcccc ggacntggt tcctctcaag 600
 ggancataa tctcnaccan tactcaccnt ncccccent gnnaccanc cttctanngn 660
 tcccccccg ncctctggcc cntcaaan gttncacna cctgggtctg ccttcccccc 720
 tncctatct gnaccncn tttgtctcan tnt 753

<210> 41
 <211> 341
 <212> DNA
 <213> Homo sapien

<400> 41
 actatatcca tcacaacaga catgcttcat cccatagact tcttgacata gcttcaaagt 60
 agtgaacca tccttgattt atatacatat atgttctcag tttttggga gcctttccac 120
 ttcttttaaac cttgttcatt atgaacactg aaaataggaa tttgtgaaga gttaaaaagt 180
 tatagcttgt ttacgtagta agtttttgaa gtctacattc aatccagaca cttagttgag 240
 tgttaaactg tgatttttaa aaaatatcat ttgagaatat tctttcagag gtattttcat 300
 ttttactttt tgattaattg tgttttatat attagggtag t 341

<210> 42
 <211> 101
 <212> DNA
 <213> Homo sapien

<400> 42
 acttactgaa ttttagttctg tgctcttcct tatttagtgt tgtatcataa atactttgat 60
 gtttcaaaca ttctaaataa ataatttca gtggcttcat a 101

<210> 43
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 43
 acatctttgt tacagtctaa gatgtgttct taaatcacca ttccttcctg gtcctcacc 60
 tccagggtgg tctcacactg taattagagc tattgaggag tctttacagc aaattaagat 120
 tcagatgcct tgctaagtct agagttctag agttatgttt cagaaagtct aagaaaccca 180
 cctcttgaga ggtcagtaaa gaggacttaa tatttcatat ctacaaaatg accacaggat 240
 tggatacaga acgagagtta tcctggataa ctcagagctg agtacctgcc cgggggcgc 300
 tcgaa 305

<210> 44
 <211> 852
 <212> DNA
 <213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(852)
<223> n = A,T,C or G

<400> 44
acataaatat cagagaaaag tagtctttga aatatttacg tccaggagtt ctttgtttct 60
gattatttgg tgtgtgtttt ggtttgtgtc caaagtattg gcagcttcag ttttcatttt 120
ctctccatcc tcgggcattc ttcccaaatt tatataccag tcttcgtcca tccacacgct 180
ccagaatttc tctttttag tagtatctca tagctcggct gagcttttca taggtcatgc 240
tgctgttgtt cttcttttta ccccatagct gagccactgc ctctgatttc aagaacctga 300
agacgccctc agatcgggtc tcccatttta ttaatcctgg gttcttgtct gggttcaaga 360
ggatgtcgcg gatgaattcc cataagttag tccctctcgg gtttgtgttt ttggtgtggc 420
acttggcagg ggggtcttgc tcctttttca tatcagggtga ctctgcaaca ggaaggtgac 480
tggtgttgt catggagatc tgagcccggc agaaagtttt gctgtccaac aaatctactg 540
tgctaccata gtttgtgtca tataaatagt tctngtcttt ccagggtgtc atgatggaag 600
gctcagtttg ttcagtcttg acaatgacat tgtgtgtgga ctggaacagg tcaactactgc 660
actggccgtt ccacttcaga tgcgtcaagt tgcgttagag gagntgcccc gccgtccctg 720
ccgcccgggt gaactcctgc aaactcatgc tgcaaagggt ctgcgcgttg atgtcgaact 780
cntggaaagg gatacaattg gcatccagct ggttgggtgc caggaggtga tggagccact 840
cccacacctg gt 852

<210> 45
<211> 234
<212> DNA
<213> Homo sapien

<400> 45
acaacagacc cttgctcgtc aacgacctca tgcctcatcaa gttggacgaa tccgtgtccg 60
agtctgacac catccggagc atcagcattg cttcgcagtg ccctaccgcg gggaactctt 120
gcctcgtttc tggctggggt ctgctggcga acggcagaat gcctaccgtg ctgcagtgcg 180
tgaacgtgtc ggtgggtgtc gaggaggtct gcagtaagct ctatgaccgg ctgt 234

<210> 46
<211> 590
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(590)
<223> n = A,T,C or G

<400> 46
actttttatt taaatgttta taaggcagat ctatgagaat gatagaaaac atggtgtgta 60
atttgatagc aatatttttg agattacaga gtttttagtaa ttaccaatta cacagttaaa 120
aagaagataa tatattccaa gcanatacaa aatatctaat gaaagatcaa ggcaggaaaa 180
tgantataac taattgacaa tggaaaatca attttaattg gaattgcaca ttatccttta 240
aaagctttca aaanaanaaa ttattgcagt ctanttaatt caaacagtgt taaatgggtat 300
caggataaan aactgaaggg canaaagaat taattttcac ttcatgtaac ncaccanant 360
ttacaatggc ttaaatgcan ggaaaaagca gtggaagtag ggaagtantc aaggtctttc 420
tggtctctaa tctgccttac tctttgggtg tggctttgat cctctggaga cagctgccag 480
ggctcctggt atatccacaa tcccagcagc aagatgaagg gatgaaaaag gacacatgct 540
gccttccttt gaggagactt catctcactg gccaacactc agtcacatgt 590

<210> 47
<211> 774

<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(774)
<223> n = A,T,C or G

<400> 47
acaagggggc ataatgaagg agtggggana gatttttaag aaggaaaaaa aacgaggccc 60
tgaacagaat tttcctgnac aacggggcctt caaaataatt ttcttgggga ggttcaagac 120
gcttcaactgc ttgaaactta aatggatgtg ggacanaatt ttctgtaatg accctgaggg 180
cattacagac gggactctgg gaggaaggat aaacagaaag gggacaaagg ctaatcccaa 240
aacatcaaag aaaggaagggt ggcgtcatac ctcccagcct acacagttct ccagggtctt 300
cctcatccct ggaggacgac agtggaggaa caactgacca tgtcccagg ctctgtgtg 360
ctggctcctg gtcttcagcc cccagctctg gaagcccacc ctctgctgat cctgcgtggc 420
ccacactcct tgaacacaca tcccaggtt atattcctgg acatggctga acctcctatt 480
cctacttccg agatgccttg ctccctgcag cctgtcaaaa tcccactcac cctccaaacc 540
acggcatggg aagcctttct gacttgcttg attactccag catcttgga caatccctga 600
ttcccactc cttagaggca agatagggtg gtttaagagta gggctggacc acttggagcc 660
aggctgctgg cttcaaattt tggctcattt acgagctatg ggaccttggg caagtnatct 720
tcacttctat gggcntcatt ttgttctacc tgcaaaatgg gggataataa tagt 774

<210> 48
<211> 124
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(124)
<223> n = A,T,C or G

<400> 48
canaaattga aattttataa aaaggcattt ttctottata tccataaaat gatataattt 60
ttgcaantat anaaatgtgt cataaattat aatgttcctt aattacagct caacgcaact 120
tggt 124

<210> 49
<211> 147
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(147)
<223> n = A,T,C or G

<400> 49
gccgatgcta ctattttatt gcaggaggtg ggggtgtttt tattattctc tcaacagctt 60
tgtggctaca ggtgggtgtct gactgcatna aaaanttttt tacgggtgat tgcaaaaatt 120
ttagggcacc catatcccaa gcantgt 147

<210> 50
<211> 107
<212> DNA
<213> Homo sapien

<400> 50
acatttaaatt aataaaaagga ctgttggggt tctgctaaaa cacatggctt gatatatattgc 60
atggtttgag gttaggagga gttaggcata tgttttggga gaggggt 107

<210> 51
<211> 204
<212> DNA
<213> Homo sapien

<400> 51
gtcctaggaa gtctagggga cacacgactc tgggggtcacg gggccgacac acttgcacgg 60
cggaaggaa aggcagagaa gtgacaccgt cagggggaaa tgacagaaag gaaaatcaag 120
gccttgcaag gtcagaaagg ggactcaggg cttccaccac agccctgcc cacttggcca 180
ctccctttt gggaccagca atgt 204

<210> 52
<211> 491
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(491)
<223> n = A,T,C or G

<400> 52
acaaagataa catTTatctt ataacaaaaa tttgatagtt ttaaaggTTa gtattgtgta 60
gggtattttt caaaagacta aagagataac tcaggtaaaa agttagaaat gtataaaaca 120
ccatcagaca ggTTTTttaa aaacaacata ttacaaaatt agacaatcat ccttaaaaaa 180
aaaacttctt gtatcaattt cttttgttca aaatgactga cttaantatt tttaaatatt 240
tcanaaacac ttcttcaaaa attttcaana tggtagcttt canatgtnc ctcagtccca 300
atgttgctca gataaataaa tctogtgaga acttaccacc caccacaagc tttctggggc 360
atgcaacagt gtcttttctt tnttttttct tttttttttt ttacaggcac agaaactcat 420
caattttatt tggataacaa aggttctcca aattatattg aaaaataaat ccaagttaat 480
atcactcttg t 491

<210> 53
<211> 484
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(484)
<223> n = A,T,C or G

<400> 53
acataattta gcagggctaa ttaccataag atgctattta ttaanaggtn tatgatctga 60
gtattaacag ttgctgaagt ttggtatttt tatgcagcat tttctttttg ctttgataac 120
actacagaac ccttaaggac actgaaaatt agtaagtaaa gttcagaaac attagctgct 180
caatcaaatt tctacataac actatagtaa ttaaaacgtt aaaaaaaagt gttgaaatct 240
gcactagtat anaccgctcc tgtcaggata anactgcttt ggaacagaaa gggaaaaanc 300
agctttgant ttctttgtgc tgatangagg aaaggctgaa ttaccttggt gcctctccct 360
aatgattggc aggtcnggta aatnccaaa catattccaa ctcaacactt cttttcnog 420
tancctgant ctgtgtattc caggancagg cggatggaaat gggccagccc ncggatgttc 480
cant 484

<210> 54

<211> 151
 <212> DNA
 <213> Homo sapien

<400> 54
 actaaacctc gtgcttgga actccatata gaaaacgggtg ccacccctga acacggctgg 60
 ccactgggta tactgctgac aaccgcaaca acaaaaacac aaatccttgg cactggctag 120
 tctatgtcct ctcaagtgcc tttttgtttg t 151

<210> 55
 <211> 91
 <212> DNA
 <213> Homo sapien

<400> 55
 acctggcttg tctccgggtg gttcccggcg cccccacagg tccccagAAC ggacatttc 60
 gccctccagt ggatactcga gccaaagtgg t 91

<210> 56
 <211> 133
 <212> DNA
 <213> Homo sapien

<400> 56
 ggcgatgtg cggttggtat atacaaatat gtcattttat gtaagggact tgagtatact 60
 tggatttttg gtatctgtgg gttgggggga cgggccagga accaataccc catggatacc 120
 aagggacaac tgt 133

<210> 57
 <211> 147
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(147)
 <223> n = A,T,C or G

<400> 57
 actctggaga acctgagccg ctgctccgcc tctgggatga ggtgatgcan gcngtggcgc 60
 gactgggagc tgagcccttc cttttgcgcc tgcctcagag gattgttgcc gacntgcana 120
 tctcantggg ctggatncat gcagggt 147

<210> 58
 <211> 198
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(198)
 <223> n = A,T,C or G

<400> 58
 acagggatat aggtttnaag ttattgtnat tgtaaaatac attgaatttt ctgtatactc 60
 tgattacata catttatcct ttaaaaaaga tgtaaatcctt aatttttatg ccactctatta 120
 atttaccat gagttacctt gtaaatgaga agtcatgata gcactgaatt ttaactagtt 180
 ttgacttcta agtttgggt 198

<210> 59
 <211> 330
 <212> DNA
 <213> Homo sapien

<400> 59
 acaacaaatg ggttgtagg aagtcttata agcaaaactg gtgatggcta ctgaaaagat 60
 ccattgaaaa ttatcattaa tgattttaaa tgacaagtta tcaaaaactc actcaatttt 120
 cacctgtgct agcttgctaa aatgggagtt aactctagag caaatatagt atcttctgaa 180
 tacagtcaat aaatgacaaa gccaggcct acaggtggtt tccagacttt ccagaccag 240
 cagaaggaat ctattttata acatggatct ccgtctgtgc tcaaaatacc taatgatatt 300
 tttcgtcttt attggacttc tttgaagagt 330

<210> 60
 <211> 175
 <212> DNA
 <213> Homo sapien

<400> 60
 accgtgggtg ccttctacat tcctgacggc tccttcacca acatctggtt ctacttcggc 60
 gtcgtgggct ccttctcttt catctcctc cagctgggtg tgctcatcga ctttgcgac 120
 tcctggaacc agcgggtggct gggcaaggcc gaggagtgcg attcccgtgc ctggt 175

<210> 61
 <211> 154
 <212> DNA
 <213> Homo sapien

<400> 61
 accccacttt tcctcctgtg agcagttctg acttctcact gctacatgat gaggggtgagt 60
 ggttggtgct cttcaacagt atcctcccct ttccggatct gctgagccgg acagcagtg 120
 tggaactgcac agccccgggg ctccacattg ctgt 154

<210> 62
 <211> 30
 <212> DNA
 <213> Homo sapien

<400> 62
 cgctcgagcc ctatagtgag tcgtattaga 30

<210> 63
 <211> 89
 <212> DNA
 <213> Homo sapien

<400> 63
 acaagtcatt tcagcacctt ttgtcttca aaactgacca tcttttatat ttaatgcttc 60
 ctgtatgaat aaaaatggtt atgtcaagt 89

<210> 64
 <211> 97
 <212> DNA
 <213> Homo sapien

<400> 64
 accggagtaa ctgagtcggg acgctgaatc tgaatccacc aataaataaa ggttctgcag 60

aatcagtgc tccaggattg gtccttggat ctggggg

97

<210> 65
 <211> 377
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(377)
 <223> n = A,T,C or G

<400> 65
 acaacaanaa ntcccttctt taggccactg atggaaacct ggaacccctt tttgatggca 60
 gcatggcgct ctaggccttg acacagcggc tgggggtttg gctntcccaa accgcacacc 120
 ccaaccctgg tctaccaca nttctggcta tgggctgtct ctgccactga acatcagggg 180
 tcggtcataa natgaaatcc caanggggac agaggtcagt agaggaaagt caatgagaaa 240
 ggtgctgttt gctcagccag aaaacagctg cctggcattc gccgctgaac tatgaacccg 300
 tgggggtgaa ctaccccan gaggaatcat gcctgggcga tgcaanggtg ccaacaggag 360
 gggcgggagg agcatgt 377

<210> 66
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 66
 acgcctttcc ctccagaattc agggaagaga ctgtcgctg ccttctccg ttgttgctg 60
 agaaccctg tgcccttcc caccatatcc accctcgctc catctttgaa ctcaaacacg 120
 aggaactaac tgcaccctg tctctcccc agtcccagt tcaccctca tccctcacct 180
 tctccactc taaggatata caacactgcc cagcacagg gccctgaatt tatgtggtt 240
 ttatatattt ttaataaga tgcactttat gtcattttt aataaagtct gaagaattac 300
 tgttt 305

<210> 67
 <211> 385
 <212> DNA
 <213> Homo sapien

<400> 67
 actacacaca ctccacttgc ccttgtaga cactttgtcc cagcacttta ggaatgctga 60
 ggtcggaacca gccacatctc atgtgcaaga ttgccagca gacatcagg ctgagagttc 120
 cccttttaaa aaaggggact tgcttaaaaa agaagtctag ccacgattgt gtagagcagc 180
 tgtgctgtgc tggagattca cttttgagag agttctctc tgagacctga tctttagagg 240
 ctgggcagtc ttgcacatga gatggggctg gtctgatctc agcactcctt agtctgcttg 300
 cctctcccag ggcccagcc tggccacacc tgcttacagg gcactctcag atgccatac 360
 catagtttct gtgctagtgg accgt 385

<210> 68
 <211> 73
 <212> DNA
 <213> Homo sapien

<400> 68
 acttaaccag atatattttt accccagatg gggatattct ttgtaaaaaa tgaaaataaa 60
 gtttttttaa tgg 73

<210> 69

<211> 536
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(536)
<223> n = A,T,C or G

<400> 69
actagtccag tgtggtggaa ttccattgtg ttgggggctc tcaccctcct ctctgcagc 60
tccagctttg tgctctgcct ctgaggagac catggcccag catctgagta ccctgctgct 120
cctgctggcc accctagctg tggccctggc ctggagcccc aaggaggagg ataggataat 180
cccggtggc atctataacg cagacctcaa tgatgagtgg gtacagcgtg cccttcactt 240
cgccatcagc gagtataaca aggccaccaa agatgactac tacagacgtc cgctgcgggt 300
actaagagcc aggcaacaga ccgttggggg ggtgaattac ttcttcgacg tagagggtgg 360
ccgaaccata tgtaccaagt cccagcccaa cttggacacc tgtgccttcc atgaacagcc 420
agaactgcag aagaacagt tgtgctcttt cgagatctac gaagttccct ggggagaaca 480
gaangtcctt gggtgaaatc caggtgtcaa gaaatcctan ggatctgttg ccaggc 536

<210> 70
<211> 477
<212> DNA
<213> Homo sapien

<400> 70
atgacccta acaggggccc tctcagccct cctaattgacc tcgggcctag ccatgtgatt 60
tcaacttcac tccataacgc tctcataact aggcctacta accaacacac taaccatata 120
ccaatgatgg cgcgatgtaa cagagaaaag cacataccaa ggccaccaca caccacctgt 180
ccaaaaaggc cttcgatacg ggataatcct atttattacc tcagaagttt ttttcttcgc 240
agggattttt ctgagccttt taccactcca gcctagcccc tccccccaa ctaggagggc 300
actggccccc aacaggcatc accccgctaa atcccctaga agtcccactc ctaaaccat 360
ccgtattact cgcatacaga gtatcaatca cctgagctca ccatagtcta atagaaaaca 420
accgaaacca aattattcaa agcactgctt attacaattt tactgggtct ctatttt 477

<210> 71
<211> 533
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(533)
<223> n = A,T,C or G

<400> 71
agagctatag gtacagtgtg atctcagctt tgcaaacaca ttttctacat agatagtact 60
aggtattaat agatatgtaa agaaagaaat cacaccatta ataatggtaa gattggttta 120
tgtgatttta gtggtatttt tggcaccctt atatatgttt tccaaacttt cagcagtgat 180
attatttcca taacttaaaa agtgagtttg aaaaagaaa tctccagcaa gcatctcatt 240
taaataaagg tttgtcatct ttaaaaatac agcaatatgt gactttttaa aaaagctgtc 300
aaatagggtg gaccctacta ataattatta gaaatacatt taaaaacatc gagtacctca 360
agtcagtttg ccttgaaaaa tatcaaatat aactcttaga gaaatgtaca taaaagaatg 420
cttcgtaatt ttggagtang aggttccctc ctcaattttg tatttttaaa aagtacatgg 480
taaaaaaaaa aattcacaac agtatataag gctgtaaaaat gaagaattct gcc 533

<210> 72
<211> 511

<212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(511)
 <223> n = A,T,C or G

<400> 72
 tattacggaa aaacacacca cataattcaa ctancaaaga anactgcttc agggcgtgta 60
 aaatgaaagg ctccaggca gttatctgat taaagaacac taaaagagg acaaggctaa 120
 aagccgcagg atgtctacac tatancaggc gctatttggg ttggctggag gagctgtgga 180
 aaacatggan agattggtgc tgganatcgc cgtggctatt cctcattgtt attacanagt 240
 gaggttctct gtgtgcccac tggtttgaaa accgttctnc aataatgata gaatagtaca 300
 cacatgagaa ctgaaatggc ccaaaccag aaagaaagg caactagatc ctcagaanac 360
 gcttctaggg acaataaccg atgaagaaaa gatggcctcc ttgtgcccc gtctgttatg 420
 atttctctcc attgcagcna naaaccggtt cttctaagca aacncagggtg atgatggcna 480
 aaatacacc cctcttgaag naccnggagg a 511

<210> 73
 <211> 499
 <212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(499)
 <223> n = A,T,C or G

<400> 73
 cagtgccagc actggtgcc gtaccagtac caataacagt gccagtgcc gtgccagcac 60
 cagtgggtgc ttcagtgtg gtgccagcct gaccgccact ctcacatttg ggtcttctgc 120
 tggccttggg ggagctggg ccagcaccag tggcagctct ggtgcctgtg gtttctccta 180
 caagtgagat tttagatatt gttaatcctg ccagtcttct tcttcaagcc aggggtgcac 240
 ctcagaaacc tactcaacac agcactctag gcagccacta tcaatcaatt gaagttgaca 300
 ctctgcatta aatctatttg ccatttctga aaaaaaaaaa aaaaaaagg cgcccgctcg 360
 antctagagg gccggtttaa acccgctgat cagcctcgac tgtgccttct anttgccagc 420
 catctgttgt ttgcccctcc cccgntgcct tccttgacct tggaaagtgc cactccact 480
 gtcctttcct aantaaaat 499

<210> 74
 <211> 537
 <212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (1)...(537)
 <223> n = A,T,C or G

<400> 74
 tttcatagga gaacacactg aggagatact tgaagaattt ggattcagcc gcgaagagat 60
 ttatcagctt aactcagata aaatcattga aagtaataag gtaaaagcta gtctctaact 120
 tocaggccca cggctcaagt gaatttgaat actgcattta cagtgtagag taacacataa 180
 cattgtatgc atggaaacat ggaggaacag tattacagtg tcctaccact ctaatcaaga 240
 aaagaattac agactctgat tctacagtga tgattgaatt ctaaaaatgg taatcattag 300
 ggcttttgat ttataanact ttgggtactt atactaaatt atggtagtta tactgccttc 360
 cagtttgctt gatataattg ttgatattaa gattcctgac ttatatattg aatgggttct 420

actgaaaaan gaatgatata ttcttgaaga catcgatata cattttattta cactottgat 480
tctacaatgt agaaaatgaa ggaaatgccc caaattgtat ggtgataaaa gtccccgt 537

<210> 75
<211> 467
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(467)
<223> n = A,T,C or G

<400> 75
caaanacaat tgttcaaaag atgcaaatag tacactactg ctgcagctca caaacacctc 60
tgcatattac acgtacctcc tcctgtctct caagtagtgt ggtctatattt gccatcatca 120
cctgctgtct gcttagaaga acggctttct gctgcaangg agagaaatca taacagacgg 180
tggcacaagg aggccatctt ttctctcatcg gttattgtcc ctagaagcgt ctcttgagga 240
tctagtggg ctttctttct gggtttgggc catttcantt ctcatgtgtg tactattcta 300
tcattattgt ataacggttt tcaaaccngt gggcacncag agaacctcac tctgtaataa 360
caatgaggaa tagccacggg gatctccagc accaaatctc tccatgttnt tccagagctc 420
ctccagccaa cccaaatagc cgctgctatn gtgtagaaca tccctgn 467

<210> 76
<211> 400
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(400)
<223> n = A,T,C or G

<400> 76
aagctgacag cattcggggc gagatgtctc gctccgtggc cttagctgtg ctgcgctac 60
tctctctttc tggcctggag gctatccagc gtactccaaa gattcaggtt tactcacgtc 120
atccagcaga gaatggaaag tcaaatttcc tgaattgcta tgtgtctggg ttcatccat 180
ccgacattga agttgactta ctgaagaatg gagagagaat tgaaaaagtg gagcattcag 240
acttgtcttt cagcaaggac tggctttct atctcttgta ctacactgaa ttcaccccca 300
ctgaaaaaga tgagtatgcc tggcgtgtga accatgtgac ttgtgcacag cccaagatng 360
ttnagtggga tcganacatg taagcagcan catgggaggt 400

<210> 77
<211> 248
<212> DNA
<213> Homo sapien

<400> 77
ctggagtgcc ttggtgtttc aagcccctgc aggaagcaga atgcaccttc tgaggcacct 60
ccagctgccc cggcggggga tgcgaggctc ggagaccctc tgcccggctg tgattgctgc 120
caggcactgt tcatctcagc ttttctgtcc ctttgcctcc ggcaagcgtc tctgtgaaa 180
gttcatactt ggagcctgat gtcttaacga ataaaggctc catgctccac ccgaaaaaaa 240
aaaaaaaa 248

<210> 78
<211> 201
<212> DNA
<213> Homo sapien

<400> 78
 actagtccag tgtggtggaa ttccattgtg ttgggcccaa cacaatggct acctttaaca 60
 tcacccagac cccgccctgc ccgtgcccc aacgacagta tgatgcttac 120
 tctgctactc ggaaactatt tttatgtaat taatgtatgc tttcttgttt ataaatgcct 180
 gatttaaaaa aaaaaaaaaa a 201

<210> 79
 <211> 552
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(552)
 <223> n = A,T,C or G

<400> 79
 tccttttgtt aggtttttga gacaacccta gacctaaact gtgtcacaga cttctgaatg 60
 tttaggcagt gctagtaatt tcctcgtaat gattctgtta ttactttcct attctttatt 120
 cctctttctt ctgaagatta atgaagttga aaattgaggt ggataaatac aaaaaggtag 180
 tgtgatagta taagtatcta agtgcagatg aaagtgtgtt atatatatcc attcaaaatt 240
 atgcaagta gtaattactc aggtttaaact aaattacttt aatatgctgt tgaacctact 300
 ctgttccttg gctagaaaaa attataaaca ggactttgtt agtttgggaa gccaaattga 360
 taatattcta tgttctaaaa gttgggctat acataaanta tnaagaaata tggaaattta 420
 ttcccaggaa tatgggggttc atttatgaat antacccggg anagaagttt tgantnaaac 480
 cngttttgtt taatacgtta atatgtcctn aatnaacaag gcntgactta tttccaaaaa 540
 aaaaaaaaaa aa 552

<210> 80
 <211> 476
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(476)
 <223> n = A,T,C or G

<400> 80
 acagggattt gagatgctaa ggccccagag atcgtttgat ccaaccctct tattttcaga 60
 ggggaaaatg gggcctagaa gttacagagc atctagctgg tgcgctggca cccctggcct 120
 cacacagact cccgagtagc tgggactaca ggcacacagt cactgaagca ggcctgtttt 180
 gcaattcacg ttgccacctc caacttaaac attcttcata tgtgatgtcc ttagtcacta 240
 aggttaaact ttcccacca gaaaaggcaa cttagataaa atcttagagt actttcatac 300
 tcttctaagt cctcttcag cctcactttg agtcctcctt gggggttgat aggaantntc 360
 tcttggtttt ctcaataaaa tctctatcca tctcatgttt aatttggtac gcntaaaaat 420
 gctgaaaaaa ttaaaatgtt ctggtttcnc tttaaaaaaa aaaaaaaaaa aaaaaa 476

<210> 81
 <211> 232
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(232)
 <223> n = A,T,C or G

<400> 81
 tttttttttg tatgccntcn ctgtggngtt attgttgctg ccaccctgga ggagcccagt 60
 ttcttctgta tctttctttt ctgggggata ttcttggtc tgccctcca ttcccagcct 120
 ctcatcccca tcttgcaatt ttgctagggt tggaggcgt ttcttggtag cccctcagag 180
 actcagtcag cgggaataag tcctaggggt ggggggtgtg gcaagccggc ct 232

<210> 82
 <211> 383
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(383)
 <223> n = A,T,C or G

<400> 82
 aggcgggagc agaagctaaa gccaaagccc aagaagagtg gcagtgccag cactggtgcc 60
 agtaccagta ccaataacat gccagtgccg gtgccagcac cagtgggtggc ttcagtgctg 120
 gtgccagcct gaccgccact ctacattttg ggctcttcgc tggccttggg ggagctggtg 180
 ccagcaccag tggcagctct ggtgcctgtg gtttctccta caagtgagat tttagatatt 240
 gttaatcctg ccagtctttc tcttcaagcc aggggtgcac ctcaaaaacc tactcaacac 300
 agcactctng gcagccacta tcaatcaatt gaagttgaca ctctgcatta aatctatttg 360
 ccatttcaaa aaaaaaaaaa aaa 383

<210> 83
 <211> 494
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(494)
 <223> n = A,T,C or G

<400> 83
 accgaattgg gaccgctggc ttataagcga tcatgtcctc cagtattacc tcaacgagca 60
 gggagatcga gtctatacgc tgaagaaatt tgaccgatg ggacaacaga cctgctcagc 120
 ccacctctgt cggttctccc cagatgacaa atactctcga caccgaatca ccatcaagaa 180
 acgcttcaag gtgctcatga cccagcaacc gcgccctgtc ctctgagggt ccttaaactg 240
 atgtcttttc tgccacctgt taccctcgg agactccgta accaaactct tcggactgtg 300
 agccctgatg cctttttgcc agccatactc tttggcntcc agtctctcgt ggcgattgat 360
 tatgcttgtg tgaggcaatc atggtggcat caccatnaa gggaacacat ttganttttt 420
 tttncatat tttaaattac naccagaata nttcagaata aatgaattga aaaactctta 480
 aaaaaaaaaa aaaa 494

<210> 84
 <211> 380
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(380)
 <223> n = A,T,C or G

<400> 84

```

gctggtagcc tatggcgtgg ccaaggangg gctcctgagg cacgggacag tgacttccca    60
agtatcctgc gccgcgtctt ctaccgtccc tacctgcaga tcttcgggca gattccccag    120
gaggacatgg acgtggccct catggagcac agcaactgct cgtcggagcc cggcttctgg    180
gcacaccctc ctggggccca ggccggcacc tgcgtctccc agtatgccaa ctggctggtg    240
gtgctgctcc tcgtcatctt cctgctcgtg gccaacatcc tgctggtcac ttgctcattg    300
ccatgttcag ttacacattc ggcaaagtac agggcaacag cnatctctac tgggaaggcc    360
agcgttnccg cctcatccgg

```

```

<210> 85
<211> 481
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(481)
<223> n = A,T,C or G

```

```

<400> 85
gagttagctc ctccacaacc ttgatgaggt cgtctgcagt ggccctctcg ttcataccgc    60
tcccatcgtc atactgtagg ttggccacca cctcctgcat ctggggcg ctaatatcca    120
ggaaactctc aatcaagtca ccgtcnatna aacctgtggc tggttctgtc ttccgctcgg    180
tgtgaaagga tctccagaag gagtgctcga tcttccccac acttttgatg actttattga    240
gtcgattctg catgtccagc aggaggttgt accagctctc tgacagtgag gtcaccagcc    300
ctatcatgcc nttgaacgtg ccgaagaaca ccgagccttg tgtggggggt gnagtctcac    360
ccagattctg cattaccaga nagccgtggc aaaaganatt gacaactcgc ccaggngaa    420
aaagaacacc tcctggaagt gctngccgct cctcgtccnt tggtggnngc gcntnccttt    480
t

```

```

<210> 86
<211> 472
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(472)
<223> n = A,T,C or G

```

```

<400> 86
aacatcttcc tgtataatgc tgtgtaatat cgatccgatn ttgtctgctg agaattcatt    60
acttgaaaaa gcaacttnaa gcctggacac tggattataa attcacaata tgcaaacatt    120
taaacagtgt gtcaatctgc tcccttactt tgtcatcacc agtctgggaa taagggtatg    180
ccctattcac acctgttaaa agggcgctaa gcatttttga ttcaacatct ttttttttga    240
cacaagtccg aaaaaagcaa aggtaaacag ttnttaattt gttagccaat tcactttctt    300
catgggacag agccatttga tttaaaaagc aaattgcata atattgagct ttgggagctg    360
atatntgagc ggaagantag cctttctact tcaccagaca caactccttt catattggga    420
tgtnnacnaa agttatgtct cttacagatg ggatgctttt gtggcaattc tg

```

```

<210> 87
<211> 413
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(413)
<223> n = A,T,C or G

```

```

<400> 87
agaaaccagt atctctnaaa acaacctctc ataccttggt gacctaatgt tgtgtgcgtg      60
tgtgtgtgcg cgcataattat atagacaggc acatcttttt tacttttgta aaagcttatg      120
cctcttttgt atctatatct gtgaaagttt taatgatctg ccataatgtc ttggggacct      180
ttgtcttctg tgtaaattggt actagagaaa acacctatnt tatgagtcaa tctagttngt      240
tttattcgac atgaaggaaa tttccagatn acaacactna caaactctcc cttgactagg      300
ggggacaaaag aaaagcanaa ctgaacatna gaaacaattn cctggtgaga aattncataa      360
acagaaattg ggtngtatat tgaaanang catcattnaa acgttttttt ttt                413

```

```

<210> 88
<211> 448
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(448)
<223> n = A,T,C or G

```

```

<400> 88
cgcagcgggt cctctctatc tagctccagc ctctcgctg cccactccc cgcgtcccgc      60
gtcctagccn accatggccg ggccctgctg cgcctgctg ccctcctggc      120
cgtggccctg gccgtgagcc ccgcggcccg ctccagctcc ggcaagccgc cgcgcctggt      180
gggaggccca tggaccccgcc gtggaagaag aaggtgtgct gcgtgcaact gactttgccg      240
tcggcnanta caacaaaccc gcaacnactt ttaccnagcn cgcgtgcag gttgtgccgc      300
cccaancaaa ttgttactng ggtaantaa ttcttggaag ttgaacctg gccaaacnng      360
tttaccagaa ccnagccaat tngaacaatt ncccctccat aacagcccct tttaaaaagg      420
gaancantcc tgntcttttc caaat      448

```

```

<210> 89
<211> 463
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(463)
<223> n = A,T,C or G

```

```

<400> 89
gaatthttgt cactggccac tgtgatggaa ccattgggcc aggatgcttt gagtttatca      60
gtagtgtatc tgccaaagtt ggtgttgtaa catgagtatg taaaatgtca aaaaattagc      120
agaggtctag gtctgcatat cagcagacag tttgtccgtg tattttgtag ccttgaagtt      180
ctcagtgaca agttnnttct gatgcgaagt tctnattcca gtgttttagt cctttgcac      240
tttnatgtn agacttgccct ctntnaaatt gcttttgtnt tctgcaggta ctatctgtgg      300
tttaacaaaa tagaannact tctctgcttn gaanatttga atatcttaca tctnaaaatn      360
aattctctcc ccataanna acccangccc ttggganaat ttgaaaaang gntccttcnn      420
aattcnana anttcagntn tcatacaaca naacngganc ccc                463

```

```

<210> 90
<211> 400
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(400)

```

<223> n = A,T,C or G

<400> 90

agggattgaa	ggtctnttnt	actgtcggac	tggtcancca	ccaactctac	aagttgctgt	60
cttccactca	ctgtctgtaa	gcntnttaac	ccagactgta	tcttcataaa	tagaacaaat	120
tcttcaccag	tcacatcttc	taggaccttt	ttggattcag	ttagtataag	ctcttccact	180
tcctttgtta	agacttcac	tggtaaagtc	ttaagttttg	tagaaaggaa	tttaattgct	240
cgttctctaa	caatgtcctc	tccttgaagt	atttggctga	acaaccacc	tnaagtcct	300
ttgtgcatcc	attttaaata	tacttaatag	ggcattggtn	cactagggtta	aattctgcaa	360
gagtcacatg	tctgcaaaag	ttgcgttagt	atatctgcca			400

<210> 91

<211> 480

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(480)

<223> n = A,T,C or G

<400> 91

gagctcggat	ccaataatct	ttgtctgagg	gcagcacaca	tatncagtgc	catgnaact	60
ggtctacccc	acatgggagc	agcatgccgt	agntatataa	ggtcattccc	tgagtcagac	120
atgcctcttt	gactaccgtg	tgccagtgtc	gggtgattctc	acacacctcc	nnccgctctt	180
tgtggaaaaa	ctggcacttg	ncgtggaacta	gcaagacatc	acttacaat	tcacccacga	240
gacacttgaa	aggtgtaaca	aagcgactct	tgcatgtgtt	tttgtccctc	cggcaccagt	300
tgtcaatact	aacccgctgg	tttgcctcca	tcacatttgt	gatctgtagc	tctggatata	360
tctcctgaca	gtactgaaga	acttcttctt	ttgtttcaaa	agcaactctt	ggtgcctgtt	420
ngatcagggt	ccatttccc	agtcggaatg	ttcacatggc	atatnttact	tcccacaaaa	480

<210> 92

<211> 477

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(477)

<223> n = A,T,C or G

<400> 92

atacagccca	natcccacca	cgaagatgag	cttgttgact	gagaacctga	tgcggtcact	60
ggtcccgtg	tagccccagc	gactctccac	ctgctggaag	cgggtgatgc	tgactcctt	120
cccacgcagg	cagcagcggg	gccggtcaat	gaactccact	cgtggcttgg	ggttgacggt	180
taantgcagg	aagaggctga	ccacctcgcg	gtccaccagg	atgcccgact	gtgcgggacc	240
tgacgcgaaa	ctcctcgatg	gtcatgagcg	ggaagcgaat	gangcccagg	gccttgccca	300
gaaccttccg	cctgttctct	ggcgtcacct	gcagctgctg	ccgctnacac	tcggcctcgg	360
accagcggac	aaacggcggt	gaacagccgc	acctcacgga	tgcccantgt	gtcgcgctcc	420
aggaacggcn	ccagcgtgtc	caggtcaatg	tcggtgaanc	ctccgcgggt	aatggcg	477

<210> 93

<211> 377

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(377)

<223> n = A,T,C or G

<400> 93

gaacggctgg	accttgctc	gcattgtgt	gctggcagga	ataccttggc	aagcagctcc	60
agtcggagca	gcccagacc	gctgccgccc	gaagctaagc	ctgcctctgg	ccttcccctc	120
cgcctcaatg	cagaaccant	agtgggagca	ctgtgtttag	agttaagagt	gaacactgtn	180
tgattttact	tggaatttc	ctctgttata	tagcttttcc	caatgctaata	ttccaaacaa	240
caacaacaaa	ataacatgtt	tgccgtttna	gttgtataaa	agtangtgat	tctgtatnta	300
aagaaaatat	tactgttaca	tatactgctt	gcaantttctg	tattttattgg	tnctctggaa	360
ataaatatat	tattaaa					377

<210> 94

<211> 495

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(495)

<223> n = A,T,C or G

<400> 94

ccctttgagg	ggttagggc	cagttcccag	tggaagaaac	aggccaggag	aantgcgtgc	60
cgagctgang	cagatttccc	acagtgaccc	cagagccctg	ggctatagtc	tctgaccctt	120
ccaaggaaag	accaccttct	ggggacatgg	gctggagggc	aggacctaga	ggcaccaagg	180
gaaggcccca	ttccggggct	gttcccagag	gaggaaggga	aggggctctg	tgtgcccccc	240
acgaggaana	ggccctgant	cctgggatca	nacacccctt	cacgtgtatc	cccacacaaa	300
tgcaagctca	ccaaggtccc	ctctcagtc	cttcctaca	ccctgaacgg	ncactggccc	360
acacccaccc	agancancca	cccgccatgg	ggaatgttct	caaggaatcg	cngggcaacg	420
tggactctng	tcccnnaagg	gggcagaatc	tccaatagan	gganngaacc	cttgctnana	480
aaaaaaaaa	aaaaa					495

<210> 95

<211> 472

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(472)

<223> n = A,T,C or G

<400> 95

ggttacttgg	tttcattgcc	accaottagt	ggatgtcatt	tagaaccatt	ttgtctgctc	60
cctctggaag	ccttgccgag	agcggacttt	gtaattgttg	gagaataact	gctgaatttt	120
tagctgtttt	gagttgattc	gcaccactgc	accacaactc	aatatgaaaa	ctatttnact	180
tattttattat	cttgtgaaaa	gtatacaatg	aaaattttgt	tcatactgta	tttatcaagt	240
atgatgaaaa	gcaatagata	tatatctttt	tattatgttn	aattatgatt	gccattatta	300
atcggaacaa	tgtggagtgt	atgttctttt	cacagtaata	tatgcctttt	gtaacttcac	360
ttgggttattt	tattgtaaat	gaattacaaa	attcttaatt	taagaaaatg	gtangttata	420
tttanttcan	taatttcttt	ccttgtttac	gttaattttg	aaaagaatgc	at	472

<210> 96

<211> 476

<212> DNA

<213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(476)
 <223> n = A,T,C or G

<400> 96
 ctgaagcatt tcttcaaact tntctacttt tgtcattgat acctgtagta agttgacaat 60
 gtgggtgaaat ttcaaaatta tatgtaactt ctactagtgt tactttctcc occaagtctt 120
 ttttaactca tgattttttac acacacaatc cagaacttat tatatagcct ctaagtcttt 180
 attcttcaca gtagatgatg aaagagtcct ccagtgtctt gngcanaatg ttctagntat 240
 agctggatac atacngtggg agttctataa actcatacct cagtgggact naaccaaaat 300
 tgtgttagtc tcaattccta ccacactgag ggagcctccc aaatcactat attcttatct 360
 gcagggtact ctccagaaaa acngacaggg caggccttgca tgaaaaagtn acatctgcgt 420
 taaaaagtct atcttctcta nangtctgtt aaggaacaat ttaatcttct agcttt 476

<210> 97
 <211> 479
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(479)
 <223> n = A,T,C or G

<400> 97
 actctttcta atgctgatat gatcttgagt ataagaatgc atatgtcact agaattggata 60
 aaataatgct gcaaaacttaa tgttcttatg caaaatggaa cgctaataga acacagctta 120
 caatcgcaaa tcaaaactca caagtgtctc tctgtttag atttagtgtg ataagactta 180
 gattgtgtct cttcggatat gattgtttct canatcttgg gcaatnttcc ttagtcaaat 240
 caggctacta gaattctgtt attggatatn tgagagcatg aaatttttaa naatacactt 300
 gtgattatna aattaatcac aaatttcact tatacctgct atcagcagct agaaaaacat 360
 ntnnttttta natcaaagta ttttgtgttt ggaantgttn aaatgaaatc tgaatgtggg 420
 ttcnatctta ttttttcccn gacnactant tntttttta gggncatttc tganccatc 479

<210> 98
 <211> 461
 <212> DNA
 <213> Homo sapien

<400> 98
 agtgacttgt cctccaacaa aacccttga tcaagtttgt ggactgaca atcagaccta 60
 tgctagtcc tgtcatctat tcgctactaa atgcagactg gaggggacca aaaaggggca 120
 tcaactccag ctggattatt ttggagcctg caaatctatt cctacttgta cggactttga 180
 agtgattcag tttcctctac ggatgagaga ctggctcaag aatatcctca tgcagcttta 240
 tgaagccact ctgaacacgc tggttatcta gatgagaaca gagaaataaa gtcagaaaat 300
 ttacctggag aaaagaggct ttggctggg accatcccat tgaaccttct cttaaggact 360
 ttaagaaaaa ctaccacatg ttgtgtatcc tgggtcgggc cgtttatgaa ctgaccaccc 420
 tttggaataa tcttgacgct cctgaacttg ctctctgag a 461

<210> 99
 <211> 171
 <212> DNA
 <213> Homo sapien

<400> 99
 gtggcgcgc gcaggtgttt cctcgtaccg cagggccccc tcccttcccc aggcgtccct 60
 cggcgctct gcgggcccga ggaggagcgg ctggcggggtg gggggagtgt gaccaccct 120

cggtgagaaa agccttctct agcgatctga gaggcgtgcc ttgggggtac c 171

<210> 100
 <211> 269
 <212> DNA
 <213> Homo sapien

<400> 100
 cggccgcaag tgcaactcca gctggggcgg tgccgacgaa gattctgcca gcagttggtc 60
 cgactgcgac gacggcggcg gcgacagtcg caggtgcagc gcgggcgcct ggggtcttgc 120
 aagcctgagc tgacgcgcga gaggtcgtgt cactgccac gacctgacg ccgtcgggga 180
 cagccggaac agagcccggt gaagcgggag gcctcgggga gcccctcggg aagggcggcc 240
 cgagagatac gcaggtgcag gtggccgcc 269

<210> 101
 <211> 405
 <212> DNA
 <213> Homo sapien

<400> 101
 tttttttttt ttttggaaac tactgcgagc acagcaggtc agcaacaagt ttattttgca 60
 gctagcaagg taacagggta gggcatgggt acatgttcag gtcaacttcc tttgtcgtgg 120
 ttgattgggt tgtctttatg gggcgggggt ggggtagggg aaacgaagca aataacatgg 180
 agtgggtgca ccctccctgt agaacctgggt tacaaagctt ggggcagttc acctgggtctg 240
 tgaccgtcat tttcttgaca tcaatgttat tagaagtcag gatattcttt agagagtcca 300
 ctgttctgga gggagattag ggtttcttgc caaatccaac aaaatccact gaaaaagttg 360
 gatgatcagt acgaataacc aggcattatc tcatatcggt ggcca 405

<210> 102
 <211> 470
 <212> DNA
 <213> Homo sapien

<400> 102
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
 ggcacttaat ccattttttat ttcaaaatgt ctacaaattt aatcccatta tacgggtattt 120
 tcaaaatcta aattattcaa attagccaaa tccttaccaa ataataccca aaaatcaaaa 180
 atatacttct ttcagcaaac ttgttacata aattaaaaaa atatatacgg ctgggtgtttt 240
 caaagtacaa ttatcttaac actgcaaaaca ttttaaggaa ctaaaataaa aaaaaacact 300
 ccgcaaaagg taaggggaac aacaaattct tttaacaac cattataaaa atcatatctc 360
 aaatcttagg ggaatatata ctacacacgg gatcttaact ttactcact ttgtttattt 420
 ttttaaacca ttgtttgggc ccaacacaat ggaatcccc ctggactagt 470

<210> 103
 <211> 581
 <212> DNA
 <213> Homo sapien

<400> 103
 tttttttttt ttttttttga cccccctctt ataaaaaaca agttaccatt ttattttact 60
 tacacatatt tattttataa ttgggtattag atattcaaaa ggcagctttt aaaatcaaac 120
 taaatggaaa ctgccttaga tacataattc ttaggaatta gcttaaaatc tgcctaaagt 180
 gaaaatcttc tctagctctt ttgactgtaa atttttgact ctgtgaaac atccaaattc 240
 atttttcttg tctttaaaaa tatctaactt ttccattttt tccctattcc aagtcaattt 300
 gcttctctag cctcatttcc tagctcttat ctactattag taagtggctt ttttcctaaa 360
 agggaaaaca ggaagagaaa tggcacacaa aacaaacatt ttatattcat atttctacct 420
 acgttaataa aatagcattt tgtgaagcca gctcaaaaga aggcttagat ccttttatgt 480
 ccatttttagt cactaaacga tatcaaagtg ccagaatgca aaaggtttgt gaacatttat 540

tcaaaagcta atataagata tttcacatac tcactctttct g

581

<210> 104
<211> 578
<212> DNA
<213> Homo sapien

<400> 104
 tttttttttt tttttttttt tttttctott cttttttttt gaaatgagga tgcagttttt 60
 cactctctag ataggcatg aagaaaactc atctttccag ctttaaaata acaatcaaat 120
 ctcttatgct atatacatatt ttaagttaaa ctaatgagtc actggcttat cttctcctga 180
 aggaaatctg ttcattcttc tcattcatat agttatatca agtactacct tgcataattga 240
 gaggtttttc ttctctatatt acacatatat ttccatgtga atttgatca aacctttatt 300
 ttcattgcaa ctagaaaata atgtttcttt tgcataagag aagagaacaa tatagcatta 360
 caaaaactgct caaattgttt gttaagtatt ccattataat tagttggcag gagctaatac 420
 aaatcacatt tacgacagca ataataaaac tgaagtacca gttaaatatc caaaataatt 480
 aaaggaacat ttttagcctg ggtataatta gctaattcac tttacaagca tttattagaa 540
 tgaattcaca tgttattatt cctagcccaa cacaatgg 578

<210> 105
<211> 538
<212> DNA
<213> Homo sapien

<400> 105
 tttttttttt tttttcagta ataatacagaa caataatttat ttttatattt aaaattcata 60
 gaaaagtgc ttacatttaa taaaagtgtt tttctcaaag tgatcagagg aattagatat 120
 gtcttgaaac ccaatattaa tttgaggaaa atacacccaa atacattaag taaattattt 180
 aagatcatag agcttgtaag tgaaaagata aaatttgacc tcagaaactc tgagcattaa 240
 aaatccacta tttagcaata aattactatg gacttcttgc ttaatttttg tgatgaatat 300
 ggggtgtcac tggtaaacca acacattctg aaggatacat tacttagtga tagattctta 360
 tgtactttgc taatacgtgg atatgagttg acaagtttct ctttcttcaa tcttttaagg 420
 ggcgagaaat gaggaagaaa agaaaaggat tacgcatact gttctttcta tggaaggatt 480
 agatatgttt cctttgccaa tattaaaaaa ataataatgt ttactactag tgaaaccc 538

<210> 106
<211> 473
<212> DNA
<213> Homo sapien

<400> 106
 tttttttttt ttttttagtc aagtttctat ttttattata attaaagtct tggtcatttc 60
 atttattagc tctgcaactt acatatttaa attaaagaaa cgttttagac aactgtacaa 120
 tttataaatg taagggtgcc ttattgagta atataattcct ccaagagtgg atgtgtccct 180
 tctccacca actaatgaac agcaacatta gttaattttt attagtagat atacactgct 240
 gcaaacgcta attctcttct ccatcccat gtgatatgtg gtatatgtgt gagttggtag 300
 aatgcatcac aatctacaat caacagcaag atgaagctag gctgggcttt cggtgaaaat 360
 agactgtgtc tgtctgaatc aaatgatctg acctatcctc ggtggcaaga actcttcgaa 420
 ccgcttcctc aaaggcgctg ccacatttgt ggctctttgc acttgtttca aaa 473

<210> 107
<211> 1621
<212> DNA
<213> Homo sapien

<400> 107
 cgccatggca ctgcagggca tctcgggtcat ggagctgtcc ggctgggcc cgggcccgtt 60
 ctgtgctatg gtccgtggctg acttcggggc gcgtgtggta cgcgtggacc ggcccggctc 120

```

ccgctacgac gtgagccgct tgggccgggg caagcgctcg ctagtgctgg acctgaagca 180
gccgcgggga gccgcgctgc tgcggcgctct gtgcaagcgg tcggatgtgc tgctggagcc 240
cttccgcccgc ggtgtcatgg agaaactcca gctgggcccga gagattctgc agcgggaaaa 300
tccaaggctt atttatgcca ggctgagtgg atttggccag tcaggaagct tctgccggtt 360
agctggccac gatatacaact atttggcttt gtcagggtgt ctctcaaaaa ttggcagaag 420
tggtgagaat ccgtatgccc cgctgaatct cctggctgac tttgctggtg gtggccttat 480
gtgtgcactg ggcattataa tggctctttt tgaccgcaca cgcactgaca agggtcaggt 540
cattgatgca aatatgggtg aaggacagc atatttaagt tcttttctgt ggaaaactca 600
gaaatcgagt ctgtgggaag cacctcgagg acagaacatg ttggatggtg gagcaccttt 660
ctatacgact tacaggacag cagatgggga attcatggct gttggagcaa tagaacccca 720
gtttctacgag ctgctgatca aaggacttgg actaaagtct gatgaacttc ccaatcagat 780
gagcatggat gattggccag aaatgaagaa gaagtttgca gatgtatttg caaagaagac 840
gaaggcagag tgggtgcaaa tctttgacgg cacagatgcc tgtgtgactc cggttctgac 900
ttttgaggag gttgttcac atgatcaca caaggaacgg ggctcgttta tcaccagtga 960
ggagcaggac gtgagccccc gccctgcacc tctgctgtta aacaccccag ccaccccttc 1020
tttcaaaagg gatcctttca taggagaaca cactgaggag atacttgaag aatttggatt 1080
cagccgcgaa gagatttatc agcttaactc agataaaatc attgaaagta ataaggtaaa 1140
agctagtctc taacttcag gccacggct caagtgaatt tgaatactgc atttacagt 1200
tagagtaaca cataacattg tatgcatgga aacatggagg aacagtatta cagtgtccta 1260
ccactcta at caagaaaaga attacagact ctgattctac agtgatgatt gaattctaaa 1320
aatggttatc attagggctt ttgatttata aaactttggg tacttatact aaattatggt 1380
agttattctg ccttcagtt tgcttgatat atttgttgat attaagattc ttgacttata 1440
ttttgaatgg gttctagtga aaaaggaatg atatattctt gaagacatcg atatacattt 1500
atttacactc ttgattctac aatgtagaaa atgaggaaat gccacaaatt gtatggtgat 1560
aaaagtcacg tgaacaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
a

```

<210> 108
 <211> 382
 <212> PRT
 <213> Homo sapien

<400> 108

```

Met Ala Leu Gln Gly Ile Ser Val Met Glu Leu Ser Gly Leu Ala Pro
1      5      10      15
Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val
20      25      30
Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg
35      40      45
Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gln Pro Arg Gly Ala Ala
50      55      60
Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe
65      70      75      80
Arg Arg Gly Val Met Glu Lys Leu Gln Leu Gly Pro Glu Ile Leu Gln
85      90      95
Arg Glu Asn Pro Arg Leu Ile Tyr Ala Arg Leu Ser Gly Phe Gly Gln
100     105     110
Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp Ile Asn Tyr Leu Ala
115     120     125
Leu Ser Gly Val Leu Ser Lys Ile Gly Arg Ser Gly Glu Asn Pro Tyr
130     135     140
Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Gly Leu Met Cys
145     150     155     160
Ala Leu Gly Ile Ile Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys
165     170     175
Gly Gln Val Ile Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser
180     185     190
Ser Phe Leu Trp Lys Thr Gln Lys Ser Ser Leu Trp Glu Ala Pro Arg

```

```
<210> 109
<211> 1524
<212> DNA
<213> Homo sapien
```

<400> 109						
ggcacgagggc	tgcgccaggg	cctgagcggga	ggcgggggcca	gcctcgccag	cgggggcccc	60
gggcctggcc	atgcctcact	gagccagcgc	ctgcgcctct	acctcgccga	cagctggaac	120
cagtgcgacc	tagtggtctct	caoctgcttc	ctcctgggcg	tgggctgccg	gctgaccccg	180
ggtttgtacc	acctgggccg	cactgtcctc	tgcctcgact	tcatggtttt	cacggtgcgg	240
ctgcttcaca	tcttcacggg	caacaaacag	ctggggccca	agatcgtcat	cgtgagcaag	300
atgatgaagg	acgtgttctt	cttcctcttc	ttcctcggcg	tgtggctggt	agcctatggc	360
gtggccacgg	aggggctcct	gaggccacgg	gacagtgaat	tcccaagtat	cctgcgccgc	420
gtcttctacc	gtccctacct	gcagatcttc	gggcagattc	cccaggagga	catggacgtg	480
gccctcatgg	agcagagcaa	ctgctcgtcg	gagcccggtc	tctgggcaca	cctctcgggg	540
gcccaggcgg	gcacctgcgt	ctcccagtat	gccaactggc	tgggtggtgt	gctcctcgtc	600
atcttctctg	tcggtggcaa	catcctgctg	gtcaacttgc	tatttgccat	gttcagttac	660
acattcggca	aagtacaggg	caacagcgat	ctctactgga	aggcgcagcg	ttaccgcctc	720
atccgggaat	tccactctcg	gcccgcgctg	gccccgccct	ttatcgtcat	ctcccacttg	780
cgctcctctg	tagggaatt	gtgcaggcga	ccccggagcc	cccagccgtc	ctccccggcc	840
ctcgagcatt	tccgggttta	cttttctaag	gaagccgagc	ggaagctgct	aacgtgggaa	900
tcggtgcata	aggagaactt	tctgtcgga	cgcgttaggg	acaagcggga	gagcgactcc	960
gagcgtctga	agcgcacgtc	ccagaaggtg	gacttggcac	tgaacacagt	gggacacatc	1020
cgcgagtacg	aacagcgctt	gaaagtctg	gagcggagg	tccagcagct	tagccgcgtc	1080
ctggggtggg	tggccgaggg	cctgagccgc	tctgccttgc	tgcccccagg	tgggcgcgca	1140
ccccctgacc	tgcctgggtc	caaagactga	gccctgctgg	cggacttcaa	ggagaagccc	1200
ccacagggga	ttttgtcct	agagtaaggc	tcatctgggc	ctcgcccccc	gcacctggtg	1260
gccttgtcct	tgaggtgagc	cccatgtcca	tctgggccac	tgtcaggacc	acctttggga	1320
gtgtcatcct	tacaaaccac	agcatgcccg	gctcctccca	gaaccagttc	cagcctggga	1380
ggatcaaggc	ctggatcccg	ggccggtatc	catctggagg	ctgcagggtc	cttggggtaa	1440
cagggaccac	agacccctca	ccactcacag	attcctcaca	ctggggaaat	aaagccattt	1500
caqaggaaaa	aaaaaaaaaa	aaaa				1524

 $\langle 210 \rangle$ 110

<211> 3410

<212> DNA

<213> Homo sapien

<400> 110

gggaaccagc	ctgcacgcgc	tggctccggg	tgacagccgc	gpgcctcggc	caggatctga	60
gtgatgagac	gtgtccccac	tgaggtgccc	cacagcagca	ggtgttgagc	atgggctgag	120
aagctggacc	ggcaccaaag	ggctggcaga	aatgggcgcc	tggctgattc	ctaggcagtt	180
ggcggcagca	aggaggagag	gcccagcgtt	ctggagcaga	gcccagacga	agcagttctg	240
gagtgcctga	acggccccct	gagccctacc	cgctggccc	actatggtcc	agaggctgtg	300
ggtgagccgc	ctgctcgggc	accggaaaagc	ccagctcttg	ctggtcaacc	tgctaaccctt	360
tggcctggag	gtgtgttttg	ccgcaggcat	cacctatgtg	ccgcctctgc	tgctggaagt	420
gggggtagag	gagaagttca	tgaccatggt	gctgggcatt	ggtccagtgc	tgggcctggt	480
ctgtgtcccg	ctcctaggct	cagccagtga	ccactggcgt	ggacgctatg	gcccgcgccg	540
gcccctcatc	tgggcactgt	ccttgggcat	cctgctgagc	ctctttctca	tcccaagggc	600
cggtcggcta	gcagggctgc	tgtgcccggg	tcccaggccc	ctggagctgg	cactgctcat	660
cctgggcgtg	gggtcgtgg	acttctgtgg	ccaggtgtgc	ttcactccac	tggaggccct	720
gctctctgac	ctcttccggg	accggacca	ctgtcgcag	gcctactctg	tctatgcctt	780
catgatcagt	cctgggggct	gcctgggcta	cctcctgcct	gccattgact	gggacaccag	840
tgccctggcc	ccctacctgg	gcacccagga	ggagtgcctc	tttggcctgc	tcaccctcat	900
cttctcacc	tgcgtagcag	ccacactgct	ggtggctgag	gaggcagcgc	tgggccccac	960
cgagccagca	gaagggctgt	cggccccctc	cttgtcgcgc	cactgctgtc	catgccgggc	1020
cgcttggct	ttccggaaac	tgggcgccct	gcttccccgg	ctgcaccagc	tgtgctgccg	1080
catgccccgc	accctgcgcc	ggctcttcgt	ggctgagctg	tgcagctgga	tggcactcat	1140
gaccttcacg	ctgttttaca	cggatttcgt	gggcagggg	ctgtaccagg	gcgtgccag	1200
agctgagccg	ggcaccgagg	cccgagaca	ctatgatgaa	ggcgttcgga	tgggcagcct	1260
ggggtgttc	ctgcagtgcg	ccatctccct	ggtcttctct	ctggtcatgg	accggctggt	1320
gcagcgattc	ggcactcgag	cagtctatct	ggccagtgtg	gcagctttcc	ctgtggctgc	1380
cgggtgccaca	tgcctgtccc	acagtgtggc	cgtggtgaca	gcttcagccg	ccctcacccg	1440
gttcaccttc	tcagccctgc	agatccctgc	ctacacactg	gcctccctct	accacccgga	1500
gaagcagggtg	ttcctgcccc	aataccgagg	ggacactgga	ggtgctagca	gtgaggacag	1560
cctgatgacc	agcttctcgc	caggccctaa	gcctggagct	ccctcccta	atggacacgt	1620
gggtgctgga	ggcagtggcc	tgcctccacc	tccaccgcgc	ctctgcgggg	cctctgcctg	1680
tgatgtctcc	gtacgtgtgg	tgggtgggtga	gcccaccgag	gccagggtgg	ttccgggccg	1740
gggcatctgc	ctggacctcg	ccatcctgga	tagtgccctc	ctgctgtccc	aggtggcccc	1800
atccctgttt	atgggtcca	ttgtccagct	cagccagtct	gtcactgcct	atatggtgtc	1860
tgcgcgaggc	ctgggtctgg	tgcattta	ctttgtaca	caggtagtat	ttgacaagag	1920
cgacttggcc	aaatactcag	cgtagaaaac	ttccagcaca	ttgggtgga	gggcctgcct	1980
cactgggtcc	cagctccccg	ctcctgttag	ccccatgggg	ctgccgggct	ggccgccagt	2040
ttctgttgc	gccaagttaa	tgtggctctc	tgtgtccacc	ctgtgctgct	gaggtgcgta	2100
gctgcacagc	tgggggctgg	ggcgtccctc	tctctctoc	ccagtctcta	gggctgcctg	2160
actggaggcc	ttccaagggg	gtttcagtct	ggacttatac	agggaggcca	gaagggtccc	2220
atgcactgga	atgcggggac	tctgcagggtg	gattaccacg	gctcagggtt	aacagctagc	2280
ctcctagtgtg	agacacacct	agagaagggt	ttttgggagc	tgaataaact	cagtcacctg	2340
gtttcccatc	tctaagcccc	ttaacctgca	gcttcgttta	atgtagctct	tgcatgggag	2400
tttctaggat	gaaacactcc	tccatgggat	ttgaacatat	gacttatctg	taggggaaga	2460
gtcctgagg	gcaacacaca	agaaccaggt	cccctcagcc	cacagcactg	tctttttgct	2520
gatccacccc	cctcttacct	tttatcagga	tgtggcctgt	tggctcttct	gttgccatca	2580
cagagacaca	ggcattttaa	tatttaactt	atttatttaa	caaagtagaa	gggaatccat	2640
tgctagcttt	tctgtgttgg	tgtctaatat	ttgggtaggg	tgggggatcc	ccaacaatca	2700
ggtcccctga	gatagctggt	cattgggctg	atcattgcca	gaatcttctt	ctcctggggg	2760
ctggccccc	aaaatgccta	accagggacc	ttggaatttc	tactcatccc	aaatgataat	2820
tccaaatgct	gttacccaag	gttaggggtg	tgaagggaag	tagagggtgg	ggcttcagggt	2880
ctcaacggct	tccctaacca	cccctcttct	cttggccacg	cctgggtccc	cccacttcca	2940
ctccctcta	ctctctctag	gactgggctg	atgaaggcag	tgcccaaat	ttccctacc	3000
cccaactttc	ccctaccccc	aactttcccc	accagctcca	caaccctgtt	tggagctact	3060
gcaggaccag	aagcacaaag	tgcggtttcc	caagcctttg	tccatctcag	ccccagagt	3120
atatctgtgc	ttggggaatc	tcacacagaa	actcaggagc	acccctgcc	tgagctaagg	3180

gaggtcttat	ctctcagggg	gggtttaagt	gccgtttgca	ataatgtcgt	cttattttatt	3240
tagcggggtg	aatattttat	actgtaagt	agcaatcaga	gtataatgtt	tatggtgaca	3300
aaattaaagg	ctttcttata	tgtttaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3360
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		3410

<210> 111
 <211> 1289
 <212> DNA
 <213> Homo sapien

<400> 111

agccaggcgt	ccctctgcct	gcccactcag	tggcaacacc	cgggagctgt	tttgccttt	60
gtggagcctc	agcagttccc	tctttcagaa	ctcactgcc	agagccctga	acaggagcca	120
ccatgcagtg	cttcagcttc	attaagacca	tgatgatcct	cttcaatttg	ctcatctttc	180
tgtgtggtgc	agccctgttg	gcagtgggca	tctgggtgtc	aatcgatggg	gcaccccttc	240
tgaagatctt	cgggccactg	tcgtccaagt	ccatgcagtt	tgtcaacgtg	ggctacttcc	300
tcacgcagc	cggcgttggt	gtccttgctc	ttggtttcct	gggctgctat	ggtgctaaga	360
ctgagagcaa	gtgtgccctc	gtgacgttct	tcttcaccc	cctcctcatc	ttcattgctg	420
aggttgagc	tgctgtggtc	gccttggtgt	acaccacaat	ggctgagcac	ttcctgacgt	480
tgctggtagt	gcctgccatc	aagaaagatt	atggttccca	ggaagacttc	actcaagtgt	540
ggaacaccac	catgaaagg	ctcaagtgt	gtggcctcac	caactatacg	gattttgagg	600
actcaccccta	cttcaagag	aacagtgcct	ttccccatt	ctggtgcaat	gacaacgtca	660
ccaacacagc	caatgaaac	tgacccaagc	aaaaggctca	cgaccaaaaa	gtagagggtt	720
gcttcaatca	gcttttgtat	gacatccgaa	ctaatacagt	caccgtgggt	ggtgtggcag	780
ctggaattgg	gggcctcgag	ctggctgcca	tgattgtgtc	catgtatctg	tactgcaatc	840
tacaataagt	ccactctgc	ctctgccact	actgtgcca	catgggaact	gtgaagaggc	900
accctggcaa	gcagcagtga	ttgggggagg	ggacaggatc	taacaatgtc	acttgggcca	960
gaatggacct	gccctttctg	ctccagactt	ggggctagat	agggaccact	ccttttagcg	1020
atgcctgact	ttccttccat	tggtgggtgg	atgggtgggg	ggcattccag	agcctctaag	1080
gtagcagctt	ctgttgcca	ttccccag	ctattaaacc	cttgatatgc	cccagggcc	1140
tagtggtgat	cccagtgtc	tactggggga	tgagagaaag	gcattttata	gcctgggcat	1200
aagtgaatc	agcagagcct	ctgggtggat	gtgtagaagg	cacttcaaaa	tgcataaacc	1260
tgttacaatg	ttaaaaaaa	aaaaaaaaa				1289

<210> 112
 <211> 315
 <212> PRT
 <213> Homo sapien

<400> 112

Met	Val	Phe	Thr	Val	Arg	Leu	Leu	His	Ile	Phe	Thr	Val	Asn	Lys	Gln
1				5					10					15	
Leu	Gly	Pro	Lys	Ile	Val	Ile	Val	Ser	Lys	Met	Met	Lys	Asp	Val	Phe
			20					25					30		
Phe	Phe	Leu	Phe	Phe	Leu	Gly	Val	Trp	Leu	Val	Ala	Tyr	Gly	Val	Ala
			35				40					45			
Thr	Glu	Gly	Leu	Leu	Arg	Pro	Arg	Asp	Ser	Asp	Phe	Pro	Ser	Ile	Leu
			50				55				60				
Arg	Arg	Val	Phe	Tyr	Arg	Pro	Tyr	Leu	Gln	Ile	Phe	Gly	Gln	Ile	Pro
							70			75				80	
Gln	Glu	Asp	Met	Asp	Val	Ala	Leu	Met	Glu	His	Ser	Asn	Cys	Ser	Ser
				85					90					95	
Glu	Pro	Gly	Phe	Trp	Ala	His	Pro	Pro	Gly	Ala	Gln	Ala	Gly	Thr	Cys
				100				105					110		
Val	Ser	Gln	Tyr	Ala	Asn	Trp	Leu	Val	Val	Leu	Leu	Leu	Val	Ile	Phe
				115			120					125			
Leu	Leu	Val	Ala	Asn	Ile	Leu	Leu	Val	Asn	Leu	Leu	Ile	Ala	Met	Phe
				130			135					140			

Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys
 145 150 155 160
 Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu
 165 170 175
 Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln
 180 185 190
 Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu
 195 200 205
 His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr
 210 215 220
 Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp
 225 230 235 240
 Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val
 245 250 255
 Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg
 260 265 270
 Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly
 275 280 285
 Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly
 290 295 300
 Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp
 305 310 315

<210> 113
 <211> 553
 <212> PRT
 <213> Homo sapien

<400> 113
 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
 1 5 10 15
 Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu
 20 25 30
 Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val
 35 40 45
 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly
 50 55 60
 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly
 65 70 75 80
 Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile
 85 90 95
 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu
 100 105 110
 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly
 115 120 125
 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu
 130 135 140
 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala
 145 150 155 160
 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr
 165 170 175
 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu
 180 185 190
 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu
 195 200 205
 Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly
 210 215 220
 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His

[illegible]

```
<210> 114
<211> 241
<212> PRT
<213> Homo sapien
```

<400> 114															
Met	Gln	Cys	Phe	Ser	Phe	Ile	Lys	Thr	Met	Met	Ile	Leu	Phe	Asn	Leu
1				5					10					15	
Leu	Ile	Phe	Leu	Cys	Gly	Ala	Ala	Leu	Leu	Ala	Val	Gly	Ile	Trp	Val
			20					25					30		
Ser	Ile	Asp	Gly	Ala	Ser	Phe	Leu	Lys	Ile	Phe	Gly	Pro	Leu	Ser	Ser
		35					40					45			
Ser	Ala	Met	Gln	Phe	Val	Asn	Val	Gly	Tyr	Phe	Leu	Ile	Ala	Ala	Gly
	50					55					60				
Val	Val	Val	Phe	Ala	Leu	Gly	Phe	Leu	Gly	Cys	Tyr	Gly	Ala	Lys	Thr
65					70					75					80

Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile
 85 90 95
 Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr
 100 105 110
 Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
 115 120 125
 Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
 130 135 140
 Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
 145 150 155 160
 Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
 165 170 175
 Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
 180 185 190
 His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
 195 200 205
 Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
 210 215 220
 Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu
 225 230 235 240
 Gln

<210> 115
 <211> 366
 <212> DNA
 <213> Homo sapien

<400> 115
 gctctttctc tccctctctc tgaatttaac tctttcaact tgcaatttgc aaggattaca 60
 catttcactg tgatgtatat tgtgttgcaa aaaaaaaaaa gtgtctttgt ttaaaattac 120
 ttggtttgtg aatccatctt gctttttcgc catttgaact agtcattaac ccattctctga 180
 actggttagaa aaacatctga agagctagtc tatcagcatc tgacagggtga attggatggt 240
 tctcagaacc atttcaccca gacagcctgt ttctatcctg ttttaataaat tagtttgggt 300
 tctctacatg cataacaaac cctgctccaa tctgtcacat aaaagtctgt gacttgaagt 360
 ttagtc 366

<210> 116
 <211> 282
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(282)
 <223> n = A,T,C or G
 <400> 116
 acaaagatga accatttcct atattatagc aaaattaaaa tctacccgta ttctaattatt 60
 gagaaatgag atnaaacaca atnttataaa gtctacttag agaagatcaa gtgacctcaa 120
 agactttact attttcatat ttttaagacac atgatttatc ctattttagt aacctggttc 180
 atacgttaaa caaaggataa tgtgaacagc agagaggatt tgttggcaga aaatctatgt 240
 tcaatctnga actatctana tcacagacat ttctattcct tt 282

<210> 117
 <211> 305
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(305)
 <223> n = A,T,C or G

<400> 117
 acacatgtcg cttcactgcc ttcttagatg cttctgggtca acatanagga acagggacca 60
 tattttatcct ccctcctgaa acaattgcaa aataanacaa aatatatgaa acaattgcaa 120
 aataaggcaa aatatatgaa acaacagggtc tcgagatatt ggaaatcagt caatgaagga 180
 tactgatccc tgatcactgt cctaattgcag gatgtgggaa acagatgagg tcacctctgt 240
 gactgccccca gcttactgcc tgtagagagt ttctangctg cagttcagac agggagaaat 300
 tgggt 305

<210> 118
 <211> 71
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(71)
 <223> n = A,T,C or G

<400> 118
 accaagtggt ntgaatctct gacgtgggga tctctgattc ccgcacaatc tgagtggaaa 60
 aantcctggg t 71

<210> 119
 <211> 212
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(212)
 <223> n = A,T,C or G

<400> 119
 actccggttg gtgtcagcag cacgtggcat tgaacatngc aatgtggagc ccaaaccaca 60
 gaaaatgggg tgaaattggc caactttcta tnaacttatg ttggcaantt tgccaccaac 120
 agtaagctgg cccttctaataaaaagaaaat tgaaaggttt ctcactaanc ggaattaant 180
 aatggantca aganactccc aggcctcagc gt 212

<210> 120
 <211> 90
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(90)
 <223> n = A,T,C or G

<400> 120
 actcgttgca natcaggggc cccccagagt caccgttgca ggagtccttc tggctttgcc 60
 ctccgccggc gcagaacatg ctggggtggt 90

<210> 121
 <211> 218
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(218)
 <223> n = A,T,C or G

<400> 121
 tgtancgtga anacgacaga nagggttgct aaaaatggag aanccttgaa gtcattttga 60
 gaataagatt tgctaaaaga tttggggcta aaacatgggt attgggagac atttctgaag 120
 atatncangt aaattangga atgaattcat ggttcttttg ggaattcctt tacgatngcc 180
 agcatanact tcatgtgggg atancagcta cccttgta 218

<210> 122
 <211> 171
 <212> DNA
 <213> Homo sapien

<400> 122
 taggggtgta tgcaactgta aggacaaaaa ttgagactca actggcttaa ccaataaagg 60
 catttgtag ctcatggaac aggaagtcgg atggtggggc atcttcagtg ctgcatgagt 120
 caccaccccg gcggggtcat ctgtgccaca ggtccctgtt gacagtgcgg t 171

<210> 123
 <211> 76
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(76)
 <223> n = A,T,C or G

<400> 123
 tgtagcgtga agacnacaga atggtgtgtg ctgtgctatc caggaacaca ttattatca 60
 ttatcaanta ttgtgt 76

<210> 124
 <211> 131
 <212> DNA
 <213> Homo sapien

<400> 124
 acctttcccc aaggccaatg tcctgtgtgc taactggccg gctgcaggac agctgcaatt 60
 caatgtgctg ggtcatatgg aggggaggag actctaaaat agccaatttt attctcttg 120
 ttaagatttg t 131

<210> 125
 <211> 432
 <212> DNA
 <213> Homo sapien

<400> 125
 actttatcta ctggctatga aatagatggg ggaatttgc gttaccaact ataccactgg 60
 cttgaaaaag aggtgatagc tcttcagagg acttgtgact tttgctcaga tgctgaagaa 120

```

ctacagtctg catttggcag aaatgaagat gaatttggat taaatgagga tgctgaagat 180
ttgcctcacc aaacaaaagt gaaacaactg agagaaaatt ttcaggaaaa aagacagtgg 240
ctcttgaagt atcagtcact tttgagaatg tttcttagtt actgcatact tcatggatcc 300
catggtgggg gtcttgcata tgtaagaatg gaattgattt tgcttttgca agaattctcag 360
caggaaacat cagaaccact attttctagc cctctgtcag agcaaaccctc agtgcctctc 420
ctctttgctt gt 432

```

```

<210> 126
<211> 112
<212> DNA
<213> Homo sapien

```

```

<400> 126
acacaacttg aatagtaaaa tagaaactga gctgaaattt ctaattcact ttctaaccat 60
agtaagaatg atatttcccc ccagggatca ccaaataatt ataaaaattt gt 112

```

```

<210> 127
<211> 54
<212> DNA
<213> Homo sapien

```

```

<400> 127
accacgaaac cacaacaag atggaagcat caatccactt gccaagcaca gcag 54

```

```

<210> 128
<211> 323
<212> DNA
<213> Homo sapien

```

```

<400> 128
acctcattag taattgtttt gttgtttcat ttttttctaa tgtctcccct ctaccagctc 60
acctgagata acagaatgaa aatggaagga cagccagatt tctcctttgc tctctgctca 120
ttctctctga agtctagggt acccattttg gggacccatt ataggcaata aacacagttc 180
ccaaagcatt tggacagttt cttgttgtgt tttagaatgg ttttcctttt tcttagcctt 240
ttcctgcaaa aggctcactc agtccccttg ttgctcagtg gactgggctc cccagggcct 300
aggctgcctt cttttccatg tcc 323

```

```

<210> 129
<211> 192
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(192)
<223> n = A,T,C or G

```

```

<400> 129
acatacatgt gtgtatatat ttaaatatca cttttgtatc actctgactt tttagcatatc 60
tgaaaacaca ctaacataat ttntgtgaac catgatcaga tacaaccaa atcattcatc 120
tagcacattc atctgtgata naaagatagg tgagtttcat ttccttcacg ttggccaatg 180
gataaacaaa gt 192

```

```

<210> 130
<211> 362
<212> DNA
<213> Homo sapien

```

<220>
 <221> misc_feature
 <222> (1)...(362)
 <223> n = A,T,C or G

<400> 130
 ccctttttta tggaatgagt agactgtatg tttgaanatt tanccacaac ctctttgaca 60
 tataatgacg caacaaaaag gtgctgttta gtcctatggg tcagtttatg cccctgacaa 120
 gtttccattg tgttttgccg atcttctggc taatcgtggg atcctccatg ttattagtaa 180
 ttctgtattc catttttgta acgcctggta gatgtaacct gctangaggc taactttata 240
 cttattttaa agctcttatt ttgtggtcat taaaatggca atttatgtgc agcactttat 300
 tgcagcagga agcacgtgtg ggttggttgt aaagctcttt gctaattcta aaaagtaatg 360
 gg 362

<210> 131
 <211> 332
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(332)
 <223> n = A,T,C or G

<400> 131
 ctttttgaag gatcgtgtcc actcctgtgg acatcttgtt ttaatggagt ttcccatgca 60
 gtangactgg tatggttgca gctgtccaga taaaaacatt tgaagagctc caaaatgaga 120
 gttctcccag gttcgccctg ctgctccaag tctcagcagc agcctctttt aggaggcatc 180
 ttctgaacta gattaaggca gcttgtaaatt ctgatgtgat ttgggtttatt atccaactaa 240
 cttccatctg ttatcactgg agaaagccca gactcccan gacnggtacg gattgtgggc 300
 atanaaggat tgggtgaagc tggcgttgtg gt 332

<210> 132
 <211> 322
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(322)
 <223> n = A,T,C or G

<400> 132
 acttttgcca ttttgtatat ataaacaatc ttgggacatt ctcctgaaaa ctaggtgtcc 60
 agtggctaag agaactcgat ttcaagcaat tctgaaagga aaaccagcat gacacagaat 120
 ctcaaattcc caaacagggg ctctgtggga aaaatgaggg aggaccttg tatctcgggt 180
 tttagcaagt taaaatgaan atgacaggaa aggcttattt atcaacaaag agaagagttg 240
 ggatgcttct aaaaaaaact ttggtagaga aaataggaat gctnaatcct agggaagcct 300
 gtaacaatct acaattggtc ca 322

<210> 133
 <211> 278
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(278)

<223> n = A,T,C or G

<400> 133

acaagccttc	acaagtttaa	ctaaattggg	attaatcttt	ctgtanttat	ctgcataatt	60
cttggttttc	tttccatctg	gctcctgggt	tgacaatttg	tggaacaac	tctattgcta	120
ctatttaaaa	aaaatcacaa	atctttccct	ttaagctatg	ttnaattcaa	actattcctg	180
ctattcctgt	tttgtcaaag	aaatttatatt	tttcaaaaata	tgtnatattg	tttgatgggt	240
cccacgaaac	actaataaaa	accacagaga	ccagcctg			278

<210> 134

<211> 121

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(121)

<223> n = A,T,C or G

<400> 134

gtttanaaaa	cttggttagc	tccatagagg	aaagaatggt	aaactttgta	ttttaaaaca	60
tgattctctg	agggttaaact	tggttttcaa	atgttatatt	tacttgatt	ttgcttttg	120
t						121

<210> 135

<211> 350

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(350)

<223> n = A,T,C or G

<400> 135

acttanaacc	atgcctagca	catcagaatc	cctcaaagaa	catcagtata	atcctataacc	60
atancaagtg	gtgactggtt	aagcgtgcga	caaaggtcag	ctggcacatt	acttgtgtgc	120
aaacttgata	cttttgttct	aagtaggaac	tagtatacac	tnctaggan	tggtactcca	180
gggtgcccc	caactcctgc	agcgcctcct	ctgtgccagn	ccctgnaagg	aaactttcgt	240
ccacctcaat	caagccctgg	gccatgctac	ctgcaattgg	ctgaacaaac	gtttgctgag	300
ttccaagga	tgcaaagcct	ggtgctcaac	tcctggggcg	tcaactcagt		350

<210> 136

<211> 399

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(399)

<223> n = A,T,C or G

<400> 136

tgtaccgtga	agacgacaga	agttgcatgg	cagggacagg	gcagggccga	ggccagggtt	60
gctgtgattg	tatccgaata	ntcctcgtga	gaaaagataa	tgagatgacg	tgagcagcct	120
gcagacttgt	gtctgccttc	aanaagccag	acaggaaggc	cctgcctgcc	ttggctctga	180
cctggcggcc	agccagccag	ccacaggtgg	gcttcttcct	tttgtggtga	caacnccaag	240
aaaactgcag	aggcccaggg	tcaggtgtna	gtgggtangt	gaccataaaa	caccagggtg	300

tcccaggaac ccgggcaaag gccatcccca cctacagcca gcatgcccac tggcgtgatg 360
 ggtgcagang gatgaagcag ccagntgttc tgctgtggt 399

<210> 137
 <211> 165
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(165)
 <223> n = A,T,C or G

<400> 137
 actggtgtgg tngggggtga tgctggtggt anaagttgan gtgacttcan gatggtgtgt 60
 ggaggaaagtg tgtgaacgta gggatgtaga ngttttggcc gtgctaaatg agcttcggga 120
 ttggtgtgtc ccactggtgg tcactgtcat tgggtggggtt cctgt 165

<210> 138
 <211> 338
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(338)
 <223> n = A,T,C or G

<400> 138
 actcactgga atgccacatt cacaacagaa tcagaggtct gtgaaaacat taatggctcc 60
 ttaactttct cagtaagaat cagggaacttg aaatggaaac gttaacagcc acatgcccac 120
 tgctgggcag tctcccatgc cttccacagt gaaagggctt gagaaaaatc acatccaatg 180
 tcatgtgttt ccagccacac caaaagggtgc ttgggggtgga gggctggggg catananggt 240
 cangcctcag gaagcctcaa gttccattca gctttgccac tgtacattcc ccatntttaa 300
 aaaaactgat gccttttttt tttttttttg taaaattc 338

<210> 139
 <211> 382
 <212> DNA
 <213> Homo sapien

<400> 139
 gggaatcttg gtttttggca tctggtttgc ctatagccga ggccactttg acagaacaaa 60
 gaaagggact tcgagtaaga aggtgattta cagccagcct agtgcccga gtgaaggaga 120
 attcaaacag acctcgatcat tcctggtgtg agcctggctg gctcaccgcc tatcatctgc 180
 atttgcctta ctcaggtgct accggactct ggcccctgat gtctgtagt tccacaggatg 240
 ccttatttgt cttctacacc ccacagggcc ccctacttct tcggatgtgt ttttaataat 300
 gtcagctatg tgcccacatcc tccttcacgc cctccctccc tttcctacca ctgctgagt 360
 gcctggaact tgtttaaagt gt 382

<210> 140
 <211> 200
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(200)

<223> n = A,T,C or G

<400> 140

accaaancctt ctttctgttg tgtingattt tactataggg gttingcttn ttctaaanat	60
acttttcatt taacancctt tgtaagtgt caggctgcac ttgctccat anaattattg	120
ttttcacatt tcaacttgta tgtgtttgtc tcttanagca ttggtgaaat cacatatttt	180
atattcagca taaaggagaa	200

<210> 141

<211> 335

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(335)

<223> n = A,T,C or G

<400> 141

actttatttt caaaacactc atatgttgca aaaaacacat agaaaaataa agtttggtgg	60
gggtgctgac taaacttcaa gtcacagact tttatgtgac agattggagc agggtttgtt	120
atgcatgtag agaaccctaa ctaatttatt aaacaggata gaaacaggct gtctgggtga	180
aatggttctg agaaccatcc aattcacctg tcagatgctg atanactagc tcttcagatg	240
tttttctacc agttcagaga tnggttaatg actanttcca atggggaaaa agcaagatgg	300
attcacaac caagtaattt taaacaaaga cactt	335

<210> 142

<211> 459

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(459)

<223> n = A,T,C or G

<400> 142

accagggttaa tattgccaca tatatccttt ccaattgcgg gctaaacaga cgtgtattta	60
gggttggtta aagacaaccc agcttaatat caagagaaat tgtgaccttt catggagtat	120
ctgatggaga aaacactgag ttttgacaaa tcttatttta ttcatagatgc agtctgatca	180
cacatggtcc aacaacactc aaataataaa tcaaataatna tcagatgtta aagattgggtc	240
ttcaaacatc atagccaatg atgccccgct tgcctataat ctctccgaca taaaaccaca	300
tcaacacctc agtggccacc aaaccattca gcacagcttc cttaactgtg agctgtttga	360
agctaccagt ctgagcacta ttgactatnt ttttcangct ctgaatagct ctagggatct	420
cagcanggggt gggaggaacc agtcaacct tggcgtant	459

<210> 143

<211> 140

<212> DNA

<213> Homo sapien

<400> 143

acatttcctt ccaccaagtc aggactcctg gcttctgtgg gagttcttat cacctgaggg	60
aatccaaac agtctctcct agaaaggaat agtgtcacca accccaccca tctccctgag	120
accatccgac ttccctgtgt	140

<210> 144

<211> 164

<212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(164)
 <223> n = A,T,C or G

<400> 144
 acttcagtaa caacatacaa taacaacatt aagtgtatat tgccatcttt gtcattttct 60
 atctatacca ctctcccttc tgaaaacaan aatcactanc caatcactta tacaaatttg 120
 aggcaattaa tccatatttg ttttcaataa ggaaaaaaag atgt 164

<210> 145
 <211> 303
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(303)
 <223> n = A,T,C or G

<400> 145
 acgtagacca tccaactttg tatttgtaat ggcaaacatc cagnagcaat tcctaaacaa 60
 actggagggt atttataccc aattatccca ttcattaaca tgccctcctc ctccaggctat 120
 gcaggacagc tatcataagt cggcccaggc atccagatac taccatttgt ataaacttca 180
 gtaggggagt ccatccaagt gacaggtcta atcaaaggag gaaatggaac ataagcccag 240
 tagtaaaatn ttgcttagct gaaacagcca caaaagactt accgccgtgg tgattaccat 300
 caa 303

<210> 146
 <211> 327
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(327)
 <223> n = A,T,C or G

<400> 146
 actgcagctc aattagaagt ggtctctgac tttcatcanc ttctccctgg gctccatgac 60
 actggcctgg agtgactcat tgctctggtt ggttgagaga gctcctttgc caacaggcct 120
 ccaagtcagg gctgggattt gtttcctttc cacattctag caacaatatg ctggccactt 180
 cctgaacagg gaggggtgga ggagccagca tggaacaagc tgccactttc taaagtagcc 240
 agacttgccc ctgggcctgt cacacctact gatgacctc tgtgcctgca ggatggaatg 300
 taggggtgag ctgtgtgact ctatggt 327

<210> 147
 <211> 173
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(173)
 <223> n = A,T,C or G

<400> 147
acattgtttt tttagataa agcattgana gagctctcct taacgtgaca caatggaagg 60
actggaacac ataccacat ctttgttctg agggataatt ttctgataaa gtcttgctgt 120
atattcaagc acatatgtta tatattattc agttccatgt ttatagccta gtt 173

<210> 148
<211> 477
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(477)
<223> n = A,T,C or G

<400> 148
acaaccactt tatctcatcg aatttttaac ccaaactcac tcaactgtgcc ttctatcct 60
atgggatata ttatttgatg ctccatttca tcacacatat atgaataata cactcatact 120
gccctactac ctgctgcaat aatcacattc ccttcctgtc ctgaccctga agccattggg 180
gtggtcctag tggccatcag tccangcctg caccttgagc ccttgagctc cattgctcac 240
nccanccac ctacccgacc ccacctctt acacagctac ctccctgtc tctaacccca 300
tagattatnt ccaaattcag tcaattaagt tactattaac actctaccg acatgtccag 360
caccactggg aagccttctc cagccaacac acacacacac acacncacac acacacatat 420
ccaggcacag gctacctcat cttcacaatc acccctttaa ttaccatgct atggtgg 477

<210> 149
<211> 207
<212> DNA
<213> Homo sapien

<400> 149
acagttgtat tataatatca agaaataaac ttgcaatgag agcatttaag agggaagaac 60
taacgtatit tagagagcca aggaaggttt ctgtggggag tgggatgtaa ggtggggcct 120
gatgataaat aagagtcagc caggtaagtg ggtggtgtgg tatgggcaca gtgaagaaca 180
tttcaggcag agggaacagc agtgaaa 207

<210> 150
<211> 111
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(111)
<223> n = A,T,C or G

<400> 150
accttgatit cattgctgct ctgatggaaa cccaactatc taatttagct aaaacatggg 60
cacttaaatg tggtcagtgt ttggacttgt taactantgg catctttggg t 111

<210> 151
<211> 196
<212> DNA
<213> Homo sapien

<400> 151
agcgcggcag gtcatttga acattccaga tacctatcat tactcgatgc tgttgataac 60

```

agcaagatgg ctttgaactc aggggtcacca ccagctattg gaccttacta tgaaaaccat    120
ggataccaac cggaaaaccc ctatcccgca cagcccactg tggccccac tgtctacgag    180
gtgcatccgg ctcagt                                                    196

```

```

<210> 152
<211> 132
<212> DNA
<213> Homo sapien

```

```

<400> 152
acagcacttt cacatgtaag aaggagagaaa ttcctaaatg taggagaaag ataacagAAC    60
cttccccttt tcatctagtG gtggaaacct gatgctttat gttgacagga atagaaccag    120
gaggagttt gt                                                    132

```

```

<210> 153
<211> 285
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(285)
<223> n = A,T,C or G

```

```

<400> 153
acaanaccca nganaggcca ctggccgtgg tgtcatggcc tccaaacatg aaagtgtcag    60
cttctgctct tatgtcctca tctgacaact ctttaccatt tttatcctcg ctcagcagga    120
gcacatcaat aaagtccaaa gtcttgact tggccttggc ttggaggaag tcatcaacac    180
cctggtagt gagggtgCG cgccgtcct ggatgacggc atctgtgaag tcgtgcacca    240
gtctgcaggc cctgtggaag cgccgtccac acggagtnag gaatt                285

```

```

<210> 154
<211> 333
<212> DNA
<213> Homo sapien

```

```

<400> 154
accacagtcc tgttgggcca gggcttcatg accctttctg tgaaaagcca tattatcacc    60
accccaaatt ttctcttaaa tatctttaac tgaaggggtc agcctcttga ctgcaaagac    120
cctaagccgg ttacacagct aactccact ggccctgatt tgtgaaattg ctgctgcctg    180
attggcacag gagtCGaagg tgttcagctc ccctcctccg tggaaCGaga ctctgatttg    240
agtttcacaa attctCGggc cacctCGtca ttgctcctct gaaataaaat ccggagaatg    300
gtcaggcctg tctcatccat atggatcttc cgg                                333

```

```

<210> 155
<211> 308
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(308)
<223> n = A,T,C or G

```

```

<400> 155
actggaaata ataaaaccca catcacagtG ttgtgtcaaa gatcatcagg gcatggatgg    60
gaaagtGctt tgggaactgt aaagtGccta acacatgatc gatgattttt gttataatat    120
ttgaatcacg gtgcatacaa actctcctgc ctgctcctcc tgggccccag cccagcccc    180

```

atcacagctc actgctctgt tcatccaggc ccagcatgta gtggctgatt cttcttggct	240
gcttttagcc tccanaagtt tctctgaagc caaccaaacc tctangtgta aggcattgctg	300
gccctggg	308

<210> 156
 <211> 295
 <212> DNA
 <213> Homo sapien

<400> 156	
accttgctcg gtgcttgga catattagga actcaaaata tgagatgata acagtgccta	60
ttattgatta ctgagagaa tgtagacat ttagttgaag attttctaca caggaaactga	120
gaataggaga ttatgtttgg cctcatatt ctctcctatc ctcttgcct cattctatgt	180
ctaataatatt ctcaatcaaa taaggtttagc ataatacagga aatcgaccaa ataccaatat	240
aaaaccagat gtctatcctt aagattttca aatagaaaac aaattaacag actat	295

<210> 157
 <211> 126
 <212> DNA
 <213> Homo sapien

<400> 157	
acaagttaa atagtgtgt cactgtgcat gtgtgaaat gtgaaatcca ccacatttct	60
gaagagcaaa acaaattctg tcatgtaatc tctatcttgg gtctgggta tatctgtccc	120
cttagt	126

<210> 158
 <211> 442
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(442)
 <223> n = A,T,C or G

<400> 158	
accactggg cttggaaca cccatcctta atacgatgat tttctgtcg tgtgaaaatg	60
aanccagcag gctgcccta gtcagtcctt ccttccagag aaaaagagat ttgagaaagt	120
gcctgggtaa ttcaccatta atttcctccc ccaaactctc tgagtcttcc cttaatat	180
ctggtgggtc tgacaaaagc aggtcatggg ttgttgagca tttgggatcc cagtgaagta	240
natgtttgta gccttgcata cttagccctt cccacgcaca aacggagtgg cagagtggg	300
ccaaccctgt tttccagtc cacgtagaca gattcacagt gcggaattct ggaagctgga	360
nacagacggg ctctttgcag agccgggact ctgagangga catgagggcc tctgcctctg	420
tgttcattct ctgatgtcct gt	442

<210> 159
 <211> 498
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(498)
 <223> n = A,T,C or G

<400> 159	
acttccaggt aacgttgttg tttccgttga gcctgaactg atgggtgacg ttgtaggttc	60

```

tccaacaaga actgaggttg cagagcgggt aggggaagagt gctgttccag ttgcacctgg      120
gctgctgtgg actgttggtt attcctcact acggccaag gttgtggaac tggcanaaag      180
gtgtgtgtgt gganttgagc tcgggcggct gtggtagggt gtgggctctt caacaggggc      240
tgctgtggtg ccgggangtg aangtggtgt gtcacttgag cttggccagc tctggaaagt      300
antanattct tcctgaaggc cagcgttgtt ggagctggca ngggtcantg ttgtgtgtaa      360
cgaaccagtg ctgctgtggg tgggtgtana tcctccaca agcctgaagt tatggtgtcn      420
tcaggtaana atgtggtttc agtgtccctg ggcngctgtg gaaggttgta nattgtcacc      480
aagggaataa gctgtggt                                     498

```

<210> 160

<211> 380

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(380)

<223> n = A,T,C or G

<400> 160

```

acctgcattc agcttccctg ccaaactcac aaggagacat caacctctag acagggaaac      60
agcttcagga tacttccagg agacagagcc accagcagca aaacaaatat tcccatgcct      120
ggagcatggc atagaggaag ctganaaatg tggggtctga ggaagccatt tgagtctggc      180
cactagacat ctcatcagcc acttgtgtga agagatgccc catgacccca gatgcctctc      240
ccacccttac ctccatctca cacacttgag ctttccactc tgtataattc taacatcctg      300
gagaaaaatg gcagtttgac cgaacctgtt cacaacggta gaggtctgatt tctaacgaaa      360
cttgtagaat gaagcctgga                                     380

```

<210> 161

<211> 114

<212> DNA

<213> Homo sapien

<400> 161

```

actccacatc ccctctgagc aggcgggtgt cgttcaaggt gtatttggcc ttgcctgtca      60
cactgtccac tggcccctta tccacttggt gcttaatccc tcgaaagagc atgt          114

```

<210> 162

<211> 177

<212> DNA

<213> Homo sapien

<400> 162

```

actttctgaa tcgaatcaaa tgatacttag tgtagtttta atatcctcat atatatcaaa      60
gttttactac tctgataatt ttgtaaacca ggtaaccaga acatccagtc atacagcttt      120
tggtgatata taacttggca ataaccagc ctggtgatac ataaaactac tcactgt          177

```

<210> 163

<211> 137

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(137)

<223> n = A,T,C or G

<400> 163

57

```

catttataca gacaggcgtg aagacattca cgacaaaaac gcgaaattct atcccgtgac    60
canagaaggc agctacggct actcctacat cctggcgtgg gtggccttcg cctgcacctt    120
catcagcggc atgatgt                                     137

```

<210> 164

<211> 469

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(469)

<223> n = A,T,C or G

<400> 164

```

cttatcacia tgaatgttct cctgggcagc gttgtgatct ttgccacctt cgtgacttta    60
tgcaatgcat catgctatct catacctaata gagggagtgc caggagattc aaccaggaaa    120
tgcatggatc tcaaaggaaa caaacaccca ataaactcgg agtggcagac tgacaactgt    180
gagacatgca cttgctacga aacagaaatt tcatgttgca cccttgtttc tacacctgtg    240
ggttatgaca aagacaactg ccaaagaatc ttcaagaagg aggactgcaa gtatatcgtg    300
gtggagaaga aggacccaaa aaagacctgt tctgtcagtg aatggataat ctaatgtgct    360
tctagtaggc acagggtctc caggccaggc ctcattctcc tctggcctct aatagtcaat    420
gattgtgtag ccattgcctat cagtaaaaag atntttgagc aaacacttt             469

```

<210> 165

<211> 195

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(195)

<223> n = A,T,C or G

<400> 165

```

acagtttttt atanatatcg acattgccgg cacttgtgtt cagtttcata aagctgggtg    60
atccgctgtc atccactatt ccttggttag agtaaaaatt attcttatag cccatgtccc    120
tgcaggccgc ccgccgtag ttctcgttcc agtcgtcttg gcacacaggg tgccaggact    180
tcctctgaga tgagt                                     195

```

<210> 166

<211> 383

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(383)

<223> n = A,T,C or G

<400> 166

```

acatcttagt agtgtggcac atcagggggc catcagggtc acagtcactc atagcctcgc    60
cgaggctcga gtccacacca ccggtgtagg tgtgtcfaat cttgggcttg gcgcccacct    120
ttggagaagg gatatgctgc acacacatgt ccacaaagcc tgtgaactcg ccaaagaatt    180
tttgagacc agcctgagca aggggaggat gttcagcttc agctcctcct tcgtcagggtg    240
gatgccaaac tcgtctangg tccgtgggaa gctgggtgtc acntcaccta caacctgggc    300
gangatctta taaagaggct ccnagataaa ctccacgaaa cttctctggg agctgctagt    360
nggggccttt ttggtgaact ttc                                     383

```

<210> 167
 <211> 247
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(247)
 <223> n = A,T,C or G

<400> 167
 acagagccag accttggcca taaatgaanc agagattaag actaaacccc aagtcganat 60
 tggagcagaa actggagcaa gaagtgggcc tggggctgaa gtagagacca aggccactgc 120
 tatanccata cacagagcca actctcaggc caaggcnatg gttggggcag anccagagac 180
 tcaatctgan tccaaagtgg tggctggaac actggtcatg acanaggcag tgactctgac 240
 tgangtc 247

<210> 168
 <211> 273
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(273)
 <223> n = A,T,C or G

<400> 168
 acttctaagt tttctagaag tggaaggatt gtantcatcc tgaaaatggg tttacttcaa 60
 aatccctcan ccttgttctt cacnactgtc tatactgana gtgtcatgtt tccacaaagg 120
 gctgacacct gagcctgnat tttactcat ccctgagaag ccctttccag taggggtggc 180
 aattcccaac ttccttgcca caagcttccc aggctttctc ccctggaaaa ctccagcttg 240
 agtcccagat acactcatgg gctgccctgg gca 273

<210> 169
 <211> 431
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(431)
 <223> n = A,T,C or G

<400> 169
 acagccttgg cttcccaaaa ctccacagtc tcagtgcaga aagatcatct tccagcagtc 60
 agctcagacc agggtaaaag gatgtgacat caacagtttc tggtttcaga acagggttcta 120
 ctactgtcaa atgaccccc atacttcctc aaaggctgtg gtaagttttg cacagggtgag 180
 ggcagcagaa aggggtant tactgatgga caccatcttc tctgtatact ccacactgac 240
 cttgccatgg gcaaaggccc ctaccacaaa aacaatagga tcaactgctgg gcaccagctc 300
 acgcacatca ctgacaaccg ggatggaaaa agaantgcc aactttcatac atccaactgg 360
 aaagtgatct gatactggat tcttaattac cttcaaaagc ttctgggggc catcagctgc 420
 tcgaacactg a 431

<210> 170
 <211> 266
 <212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(266)

<223> n = A,T,C or G

<400> 170

acctgtgggc	tgggctgtta	tgctgtgcc	ggctgtgaa	agggagttca	gaggtggagc	60
tcaaggagct	ctgcaggcat	tttgccaanc	ctctccanag	canagggagc	aacctacact	120
ccccgctaga	aagacaccag	attggagtcc	tgggaggggg	agttgggggtg	ggcatttgat	180
gtatacttgt	cacctgaatg	aangagccag	agaggaanga	gacgaanatg	anattggcct	240
tcaaagctag	gggtctggca	ggtgga				266

<210> 171

<211> 1248

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1248)

<223> n = A,T,C or G

<400> 171

ggcagccaaa	tcataaacgg	cgaggactgc	agcccgcaact	cgcagccctg	gcaggcgcca	60
ctggtcatgg	aaaacgaatt	gttctgctcg	ggcgtcctgg	tgcatccgca	gtgggtgctg	120
tcagccgcac	actgtttcca	gaagtgagtg	cagagctcct	acaccatcgg	gctgggcctg	180
cacagtcttg	aggccgacca	agagccaggg	agccagatgg	tggaggccag	cctctccgta	240
cggcaocccag	agtacaacag	acccttgctc	gctaacgacc	tcattgctcat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcggggaact	cttgccctcg	ttctggctgg	ggtctgctgg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcgggtggtg	tctgaggagg	tctgcagtaa	gctctatgac	480
ccgctgtacc	accccagcat	gttctgcgcc	ggcgaggaggc	aagaccagaa	ggactcctgc	540
aacggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgaggggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agttggcgtg	ccagggtgtct	acaccaacct	ctgcaaattc	660
actgagtgga	tagagaaaac	cgtccaggcc	agttaactct	ggggactggg	aacctatgaa	720
attgaccccc	aaatacatcc	tgcggaagga	attcaggaat	atctgttccc	agccccctct	780
ccctcaggcc	caggagtcca	ggcccccagc	ccctcctccc	tcaaaccaag	ggtacagatc	840
cccagcccct	cctccctcag	acccaggagt	ccagaccccc	cagcccctcc	tccctcagac	900
ccaggagtcc	agcccctcct	ccctcagacc	caggagtcca	gacccccccag	cccctcctcc	960
ctcagaccca	gggtgccagg	cccccaaccc	ctcctcctcc	agactcagag	gtccaagccc	1020
ccaaccntc	attccccaga	cccagaggtc	cagggtcccag	cccctcntcc	ctcagaccca	1080
gcggtccaat	gccacctaga	ctntccctgt	acacagtgcc	cccttggtggc	acgttgacct	1140
aaccttacca	gttggttttt	catttttngt	ccctttcccc	tagatccaga	aataaagttt	1200
aagagaagng	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1248

<210> 172

<211> 159

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(159)

<223> Xaa = Any Amino Acid

<400> 172


```

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
 1           5           10           15
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
      20           25           30
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
      35           40           45
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 50           55           60
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
65           70           75           80
Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe
      85           90           95
Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser
      100           105           110
Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe
      115           120           125
Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn
      130           135           140
Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
145           150           155

```

<210> 173

<211> 1265

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1265)

<223> n = A,T,C or G

<400> 173

```

ggcagcccgcc actgcagccc ctggcaggcg gcactggtca tggaaaacga attgttctgc      60
tggggcgctcc tgggtgcatcc gcagtgggtg ctgtcagccg cacactgttt ccagaactcc      120
tacaccatcg ggctgggcct gcacagtctt gaggccgacc aagagccagg gagccagatg      180
gtggaggcca gcctctccgt acggcaccca gagtacaaca gacccttgct cgctaacgac      240
ctcatgtctca tcaagtggga cgaatccgtg tccgagtctg acaccatccg gagcatcagc      300
attgcttcgc agtgccctac cgcggggaac tcttgccctg tttctggctg gggctctgctg      360
gcgaacggtg agctcacggg tgtgtgtctg ccctcttcaa ggaggtcctc tgcccagtcg      420
cgggggctga cccagagctc tgcgtcccag gcagaatgcc taccgtgctg cagtgcgtga      480
acgtgtcggg ggtgtctgag gaggtctgca gtaagctcta tgaccgctg taccaccca      540
gcatgttctg cgccggcgga gggcaagacc agaaggactc ctgcaacggt gactctgggg      600
ggcccctgat ctgcaacggg tacttgagg gccttggtg tttcggaata gcccgtgtg      660
gccaaagtgg cgtgccagg gtctacacca acctctgcaa attcactgag tggatagaga      720
aaaccgtcca ggccagttaa ctctggggac tgggaacca tgaaattgac ccccaatac      780
atcctgcgga aggaattcag gaatatctgt tcccagcccc tcctccctca ggcccaggag      840
tccaggcccc cagcccctcc tccctcaaac caagggtaca gatccccagc ccctcctccc      900
tcagaccagc gagtccagac ccccagccc ctccctcctc agaccagga gtccagcccc      960
tcctccntca gaccaggag tccagacccc ccagcccctc ctccctcaga cccaggggtt     1020
gaggccccc acccctcctc cttcagagtc agaggtccaa gcccccaacc cctcgttccc     1080
cagaccaga ggttnaggtc ccagcccctc ttccntcaga ccagnggtc caatgccacc     1140
tagattttcc ctgnacacag tgcccccttg tggngangtt acccaacctt accagttggt     1200
ttttcatttt tngtcccttt cccctagatc cagaaataaa gtttaagaga ngngcaaaaa     1260
aaaaa                                           1265

```

<210> 174

<211> 1459

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1459)

<223> n = A,T,C or G

<400> 174

ggtcagccgc	acactgtttc	cagaagtgcg	tgacagagctc	ctacaccatc	gggctggggc	60
tgacacagtct	tgaggccgac	caagagccag	ggagccagat	ggaggaggcc	agcctctccg	120
tacggcacc	agagtacaac	agacccttgc	tcgctaacga	cctcatgctc	atcaagtgtg	180
acgaatccgt	gtccgagtct	gacaccatcc	ggagcatcag	cattgtctcg	cagtgccta	240
ccgcggggaa	ctcttgccct	gtttctggct	gggtctgct	ggcgaacggt	gagctcacgg	300
gtgtgtgtct	gccctcttca	aggaggtcct	ctgccagtc	gcgggggctg	acccagagct	360
ctgcgtccca	ggcagaatgc	ctaccgtgct	gcagtgcgtg	aacgtgtcgg	tggtgtctga	420
ngaggtctgc	antaagctct	atgaccgct	gtaccacccc	ancatgttct	gcgccggcgg	480
agggcaagac	cagaaggact	cctgcaacgt	gagagagggg	aaaggggagg	gcaggcgact	540
cagggaaggg	tggaagaagg	ggagacagag	acacacaggg	ccgcatggcg	agatgcagag	600
atggagagac	acacagggag	acagtgacaa	ctagagagag	aaactgagag	aaacagagaa	660
ataaacacag	gaataaagag	aagcaaagga	agagagaaac	agaaacagac	atggggaggc	720
agaaacacac	acacatagaa	atgcagttga	ccttccaaca	gcatggggcc	tgagggcggt	780
gacctccacc	caatagaaaa	tcctcttata	acttttgact	ccccaaaaac	ctgactagaa	840
atagcctact	gttgacgggg	agccttacca	ataacataaa	tagtcgattt	atgcatacgt	900
tttatgcatt	catgatatac	ctttgttga	attttttgat	atttctaagc	tacacagttc	960
gtctgtgaat	ttttttaaat	tggtgcaact	ctcctaaaat	ttttctgatg	tgtttattga	1020
aaaaatccaa	gtataagtgg	acttgtgcat	tcaaaccagg	gttgttcaag	ggtcaactgt	1080
gtaccagag	ggaaacagtg	acacagattc	atagaggtga	aacacgaaga	gaaacaggaa	1140
aatcaagac	ctacaaaga	ggctgggcag	ggagggtcat	gcctgtaatc	ccagcacttt	1200
gggaggcgag	tccagcagat	cacttgaggt	aaggagttca	agaccagcct	ggccaaaatg	1260
gtgaaatcct	gtctgtacta	aaaatacaaa	agttagctgg	atatggtggc	aggcgctgt	1320
aatcccagct	acttgggagg	ctgaggcagg	agaattgctt	gaatatggga	ggcagagggt	1380
gaagtgcgtt	gagatcacac	cactatactc	cagctggggc	aacagagtaa	gactctgtct	1440
caaaaaaaaa	aaaaaaaaa					1459

<210> 175

<211> 1167

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1167)

<223> n = A,T,C or G

<400> 175

gcgcagccct	ggcaggcggc	actgggtcatg	gaaaacgaat	tggtctgctc	gggctgctctg	60
gtgcatccgc	agtgggtgct	gtcagccgca	cactgtttcc	agaactccta	caccatcggg	120
ctgggcctgc	acagtcttga	ggccgaccaa	gagccaggga	gccagatggg	ggaggccagc	180
ctctccgtac	ggcaccaga	gtacaacaga	ctcttgcctg	ctaaccagct	catgtctatc	240
aagtgtgacg	aatccgtgtc	cgagtctgac	accatccgga	gcatcagcat	tgcttcgcag	300
tgccctaccg	cggggaactc	ttgcctcgtn	tctggctggg	gtctgctggc	gaacggcaga	360
atgcctaccg	tgctgcactg	cgtgaacgtg	tcggtgggtg	ctgaggangt	ctgcagtaag	420
ctctatgacc	cgctgtacca	cccagcatg	ttctgcgcgg	gcggagggca	agaccagaag	480
gactcctgca	acggtgactc	tggggggccc	ctgatctgca	acgggtactt	gcagggcctt	540
gtgtctttcg	gaaaagcccc	gtgtggccaa	cttggcgtgc	cagggtgtcta	caccaacctc	600
tgcaaatcca	ctgagtggat	agagaaaacc	gtccagncca	gttaactctg	gggactggga	660
acccatgaaa	ttgaccccca	aatacatcct	gcggaangaa	ttcaggaata	tctgttccca	720
gccccctctc	cctcaggccc	aggagtcag	gccccagcc	cctcctccct	caaaccaagg	780

```

gtacagatcc ccagcccctc ctccctcaga cccaggagtc cagaccccc agcccctcnt      840
ccntcagacc caggagtcca gccctcctc cntcagacgc aggagtccag acccccagc      900
ccntcntccg tcagaccag ggggtgcaggc cccaacccc tcntcntca gagtcagagg      960
tccaagcccc caaccctcg ttcccagac ccagaggtnc aggtcccagc cctcctccc      1020
tcagaccag cggccaatg ccacctagan tntccctgta cacagtgcc cttgtggca      1080
ngttgacca acctaccag ttggttttc atttttgtc ctttcccct agatccagaa      1140
ataaagtnta agagaagcgc aaaaaaa      1167

```

<210> 176
 <211> 205
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (1) ... (205)
 <223> Xaa = Any Amino Acid

<400> 176

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
  1              5              10              15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
      20              25              30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
      35              40              45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu
      50              55              60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
      65              70              75              80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
      85              90              95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met
      100             105             110
Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val
      115             120             125
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala
      130             135             140
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly
      145             150             155             160
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys
      165             170             175
Ala Pro Cys Gly Gln Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys
      180             185             190
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Xaa Ser
      195             200             205

```

<210> 177
 <211> 1119
 <212> DNA
 <213> Homo sapien

<400> 177

```

gcgcactcgc agccctggca ggcggcactg gtcattgaaa acgaattggt ctgctcgggc      60
gtcctgggtgc atccgcagtg ggtgctgtca gccgcacact gtttccagaa ctctacacc      120
atcgggctgg gcctgcacag tcttgaggcc gaccaagagc caggagacca gatgggtggag      180
gccagcctct ccgtacggca cccagagtac aacagaccct tgctcgctaa cgacctcatg      240
ctcatcaagt tggacgaatc cgtgtccgag tctgacacca tccggagcat cagcattgct      300
tcgcagtgcc ctaccggggg gaactcttgc ctcgtttctg gctgggggtct gctggcgaac      360

```

```

gatgctgtga ttgccatcca gtcccagact gtgggaggct gggagtgtga gaagctttcc 420
caaccctggc agggttgtac catttcggca acttccagtg caaggacgtc ctgctgcatc 480
ctcactgggt gctcactact gctcactgca tcacccggaa cactgtgata aactagccag 540
caccatagtt ctccgaagtc agactatcat gattactgtg ttgactgtgc tgtctattgt 600
actaaccatg ccgatgttta ggtgaaatta gcgtcacttg gcctcaacca tcttggtatc 660
cagttatcct cactgaattg agatttcctg cttcagtgtc agccattccc acataatttc 720
tgacctacag aggtgaggga tcatatagct cttcaaggat gctggtactc ccctcacaaa 780
ttcattttctc ctgttgtagt gaaagggtgcg cctctggag cctcccaggg tgggtgtgca 840
ggtcacaatg atgaatgtat gatcgtgttc ccattaccca aagcctttaa atccctcatg 900
ctcagtacac cagggcaggt ctagcatttc ttcatttagt gtatgctgtc cattcatgca 960
accacctcag gactcctgga ttctctgctt agttgagctc ctgcatgctg cctccttggg 1020
gaggtgaggg agagggccca tggttcaatg ggatctgtgc agttgtaaca cattaggtgc 1080
ttaataaaca gaagctgtga tgttaaaaaa aaaaaaaaa 1119

```

<210> 178
 <211> 164
 <212> PRT
 <213> Homo sapien

<220>
 <221> VARIANT
 <222> (1)...(164)
 <223> Xaa = Any Amino Acid

<400> 178

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
 1          5          10          15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
          20          25          30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
          35          40          45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
          50          55          60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65          70          75          80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
          85          90          95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val
          100         105         110
Ile Ala Ile Gln Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu
          115         120         125
Ser Gln Pro Trp Gln Gly Cys Thr Ile Ser Ala Thr Ser Ser Ala Arg
          130         135         140
Thr Ser Cys Cys Ile Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser
145          150          155          160
Pro Gly Thr Leu

```

<210> 179
 <211> 250
 <212> DNA
 <213> Homo sapien

<400> 179

```

ctggagtgcc ttggtgtttc aagcccctgc aggaagcaga atgcaccttc tgaggcacct 60
ccagctgccc ccggccgggg gatgcgaggc tgggagcacc cttgcccggc tgtgattgct 120
gccaggcact gttcatctca gcttttctgt ccttttctc cgggcaagcg cttctgtgta 180
aagttcatat ctggagcctg atgtcttaac gaataaaggc cccatgctcc acccgaaaaa 240

```

```

aaaaaaaaa                                     250

<210> 180
<211> 202
<212> DNA
<213> Homo sapien

<400> 180
actagtccag tgtggtggaa ttccattgtg ttggggccaa cacaatgggt acctttaaca      60
tcaccagac cccgcccctg cccgtgcccc acgctgctgc taacgacagt atgatgctta      120
ctctgctact cggaaactat ttttatgtaa ttaatgtatg ctttcttggt tataaatgcc      180
tgatttaaaa aaaaaaaaaa aa                                     202

<210> 181
<211> 558
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(558)
<223> n = A,T,C or G

<400> 181
tccytttgkt naggtttkkk agacamccck agacctwaan ctgtgtcaca gacttcyngg      60
aatgtttagg cagtgtcagt aatttcytcg taatgattct gttattactt tcctnattct      120
ttattcctct ttcttctgaa gattaatgaa gttgaaaatt gaggtggata aatacaaaaa      180
ggtagtgtga tagtataagt atctaagtgc agatgaaagt gtgttatata tatccattca      240
aaattatgca agttagtaat tactcagggg taactaaatt actttaatat gctgttgaac      300
ctactctggt ccttggtctag aaaaaattat aaacaggact ttgttagttt gggaagccaa      360
attgataata ttctatgttc taaaagttgg gctatacata aattattaag aaatatggaw      420
ttttattccc aggaatatgg kgttcatttt atgaatatta cscrggatag awgtwtgagt      480
aaaaycagtt ttgtwaata ygtwaatatg tcmtaaataa acaakgcttt gacttatttc      540
caaaaaaaaa aaaaaaaaaa                                     558

<210> 182
<211> 479
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(479)
<223> n = A,T,C or G

<400> 182
acagggwttk grggatgcta agsccccrga rwtggttga tccaaccctg gcttwttttc      60
agaggggaaa atgggggccta gaagttacag mscatytagy tgggtgcgmg gcacccctgg      120
cstcacacag astcccgagt agctgggact acaggcacac agtcactgaa gcaggccctg      180
ttwgcaattc acgttgccac ctccaactta aacattcttc atatgtgatg tccttagtca      240
ctaagggttaa actttcccac ccagaaaagg caacttagat aaaatcttag agtactttca      300
tactmttcta agtcctcttc cagcctcact kkgagtcctm cytggggggt gataggaant      360
ntctcttggc tttctcaata aartctctat ycatctcatg ttttaatttg tacgcataa      420
awtgstgara aaattaaaaa gttctgggty macttttaaa aaaaaaaaaa aaaaaaaaaa      479

<210> 183
<211> 384
<212> DNA

```

<213> Homo sapien

<400> 183

aggcgaggagc	agaagctaaa	gccaaagccc	aagaagagt	gcagtgccag	cactggtgcc	60
agtaccagta	ccaataacag	tgccagtgcc	agtgccagca	ccagtgggtg	cttcagtgt	120
ggtgccagcc	tgaccgccac	tctcacattt	gggtctctcg	ctggccttgg	tgagctggt	180
gccagcacca	gtggcagctc	tggtgcctgt	ggtttctcct	acaagtgaga	tttagatat	240
tgtaaatcct	gccagtcttt	ctcttcaagc	cagggtgcat	cctcagaaac	ctactcaaca	300
cagcactcta	ggcagccact	atcaatcaat	tgaagttgac	actctgcatt	aratctattt	360
gccatttcaa	aaaaaaaaaa	aaaa				384

<210> 184

<211> 496

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(496)

<223> n = A,T,C or G

<400> 184

accgaattgg	gaccgctggc	ttataagoga	tcatgtyynt	ccrgtatcac	ctcaacgagc	60
aggagatcg	agtctatacg	ctgaagaaat	ttgaccgat	gggacaacag	acctgctcag	120
cccatacctgc	tcggttctcc	ccagatgaca	aatactctsg	acaccgaatc	accatcaaga	180
aacgcttcaa	ggtgctcatg	acccagcaac	cgcgccctgt	cctctgaggg	tcccttaaac	240
tgatgtcttt	tctgccacct	gttaccctc	ggagactcgg	taaccaaact	cttcggactg	300
tgagccctga	tgcttttttg	ccagccatac	tctttggcat	ccagtctctc	gtggcgattg	360
attatgcttg	tgtagggcaa	tcatggtggc	atcacccata	aagggaacac	atttgacttt	420
tttttctcat	attttaaat	actacmagaw	tattwmagaw	waaatgawtt	gaaaaactst	480
taaaaaaaaa	aaaaaa					496

<210> 185

<211> 384

<212> DNA

<213> Homo sapien

<400> 185

gctggtagcc	tatggcgkkg	cccacggagg	ggctcctgag	gccacggrac	agtgacttcc	60
caagtatcyt	gcgcsgcgtc	ttctaccgtc	cctacctgca	gatcttcggg	cagattcccc	120
aggaggacat	ggacgtggcc	ctcatggagc	acagcaactg	ytcgctggag	ccgggttct	180
gggcacaccc	tcctggggcc	caggcgggca	cctgcgtctc	ccagtatgcc	aactggctgg	240
tggtgctgct	cctcgatc	ttcctgctcg	tgccaacat	cctgctggtc	aacttgctca	300
ttgccatgtt	cagttacaca	ttcggcaaa	tacagggcaa	cagcgatctc	tactgggaag	360
gcgcagcgtt	accgctcat	ccgg				384

<210> 186

<211> 577

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(577)

<223> n = A,T,C or G

<400> 186

gagttagctc	ctccacaacc	ttgatgaggt	cgtctgcagt	ggcctctcgc	ttcataccgc	60
------------	------------	------------	------------	------------	------------	----

tnccatcgtc	atactgtagg	tttgccacca	cytcctggca	tcttggggcg	gcntaatatt	120
ccaggaaact	ctcaatcaag	tcaccgtcga	tgaaacctgt	gggctgggtc	tgtcttccgc	180
tcgggtgtgaa	aggatctccc	agaaggagt	ctcgatcttc	cccacacttt	tgatgacttt	240
attgagtcga	ttctgcatgt	ccagcaggag	gttgtaccag	ctctctgaca	gtgaggcac	300
cagccctatc	atgccgttga	mcgtgccgaa	garcaccgag	ccttgtgtgg	gggkkgaa	360
ctcaccacaga	ttctgcatta	ccagagagcc	gtggcaaaag	acattgacaa	actcgcccag	420
gtggaaaaag	amcamctcct	ggargtgctn	gccgctcctc	gtcmgttgg	ggcagcgctw	480
tccttttgac	acacaaacaa	gttaaaggca	ttttcagccc	ccagaaantt	gtcatcatcc	540
aagatntcgc	acagcactna	tccagttggg	attaaat			577

<210> 187

<211> 534

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(534)

<223> n = A,T,C or G

<400> 187

aacatcttcc	tgtataatgc	tgtgtaatat	cgatccgatn	ttgtctgstg	agaatycatw	60
actkggaaaa	gmaacattaa	agcctggaca	ctggtattaa	aattcacaat	atgcaacact	120
ttaaaccagt	tgatcaatctg	ctcccyynac	tttgtcatca	ccagtctggg	aakaagggtg	180
tgccctattc	acacctgtta	aaagggcgct	aagcatTTTT	gattcaacat	cttttttttt	240
gacacaagtc	cgaaaaaagc	aaaagttaac	agttatyaat	ttgttagcca	attcactttc	300
ttcatgggac	agagccatyt	gattttaaaaa	gcaaattgca	taataattgag	cttygggagc	360
tgatatttga	gcggaagagt	agcctttcta	cttcaccaga	cacaactccc	tttcatattg	420
ggatgttnac	naaagtwatg	tctctwacag	atgggatgct	tttgtggcaa	ttctgttctg	480
aggatctccc	agtttatitta	ccacttgcac	aagaaggcgt	tttcttctc	aggc	534

<210> 188

<211> 761

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(761)

<223> n = A,T,C or G

<400> 188

agaaaccagt	atctctnaaa	acaacctctc	ataccttggt	gacctaat	ttgtgtgcgtg	60
tggtgtgtgcg	cgcatattat	atagacaggc	acatcttttt	tactttttgta	aaagcttatg	120
cctcttttgg	atctatatct	gtgaaagttt	taatgatctg	ccataatgtc	ttggggacct	180
ttgtcttctg	tgtaaatggg	actagagaaa	acacctatnt	tatgagtcaa	tctagttngt	240
tttattogac	atgaaggaaa	tttccagatn	acaacactna	caaactctcc	ctkgackarg	300
ggggacaaaag	aaaagcaaaa	ctgamcataa	raaacaatwa	cctgggtgaga	arttgcataa	360
acagaaatwr	ggtagtatat	tgaarnacag	catcattaaa	rmgttwtktt	wttctccctt	420
gcaaaaaaca	tgtaacngact	tcccgttgag	taatgccaag	ttgttttttt	tatnataaaa	480
cttgcccttc	attacatggt	tnaaagtggg	gtggtggggc	aaaatattga	aatgatggaa	540
ctgactgata	aagctgtaca	aataagcagt	gtgcctaaca	agcaacacag	taatgttgac	600
atgcttaatt	cacaaatgct	aatttcatta	taaatgtttg	ctaaaataca	ctttgaacta	660
ttttctgtgn	ttccagagc	tgagatntta	gattttatgt	agtatnaagt	gaaaaantac	720
gaaaataata	acattgaaga	aaaananaaa	aaanaaaaaa	a		761

<210> 189

<211> 482

<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(482)
<223> n = A,T,C or G

<400> 189
 tttttttttt ttgcccgatn ctactatattt attgcaggan gtgggggtgt atgcaccgca 60
 caccggggct atnagaagca agaaggaagg agggagggca cagccccttg ctgagcaaca 120
 aagccgcctg ctgccttctc tgtctgtctc ctgggtgcagg cacatgggga gaccttcccc 180
 aaggcagggg ccaccagtcc aggggtggga atacaggggg tgggangtgt gcataagaag 240
 tgataggcac aggccacccg gtacagaccc ctccgctcct gacaggtnga tticgaccag 300
 gtcatgtgtc cctgcccagg cacagcgtn atctggaaaa gacagaatgc tticcttttc 360
 aaatttggct ngtcatngaa ngggcanttt tccaanttng gctnngtctt ggtaacncttg 420
 gttcggccca gtcncnctc caaaaantat tcaccnct ccnaattgct tgcngncccc 480
 cc 482

<210> 190
<211> 471
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(471)
<223> n = A,T,C or G

<400> 190
 tttttttttt ttttaaaaca gtttttcaca acaaaattta ttagaagaat agtgggtttg 60
 aaaactctcg catccagtga gaactacat acaccacatt acagctngga atgtntctca 120
 aatgtctggt caaatgatac aatggaacca ttcaatctta cacatgcacg aaagaacaag 180
 cgcttttgac atacaatgca caaaaaaaaa aggggggggg gaccacatgg attaaaattt 240
 taagtactca tcacatacat taagacacag ttctagtcca gtcnaaaatc agaactgcnt 300
 tgaaaaattt catgtatgca atccaacca agaacttnat tgggtgatcat gantnctcta 360
 ctacatcnac cttgatcatt gccaggaacn aaaagttnaa ancacnctg acaaaaanaa 420
 tctgtaattn anttcaacct ccgtacngaa aaatnttnt tatacactcc c 471

<210> 191
<211> 402
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(402)
<223> n = A,T,C or G

<400> 191
 gagggattga aggtctgttc tastgtcggm ctgttcagcc accaactcta acaagttgct 60
 gtcttccact cactgtctgt aagcttttta acccagacwg tatottcata aatagaacaa 120
 attcttcacc agtcacatct tctaggacct ttttggattc agttagtata agctcttcca 180
 cttcctttgt taagacttca tctggtaaag tcttaagttt tgtagaaagg aattyaattg 240
 ctcgttctct aacaatgtcc tctccttgaa gtatttggct gaacaaccca cctaaagtcc 300
 ctttgtgcat ccatttttaa tatacttaat agggcattgk tncactaggt taaattctgc 360
 aagagtcatc tgtctgcaaa agttgcgtta gtatatctgc ca 402

<210> 192
 <211> 601
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(601)
 <223> n = A,T,C or G

<400> 192
 gagctcggat ccaataatct ttgtctgagg gcagcacaca tatncagtgc catggnaact 60
 ggtctacccc acatgggagc agcatgccgt agntatataa ggtcattccc tgagtcagac 120
 atgcytyttt gaytaccgtg tgccaagtgc tgggtgattct yaacacacyt ccatcccgyt 180
 cttttgtgga aaaactggca cttktctgga actagcarga catcacttac aaattcaccc 240
 acgagacact tgaaagggtg aacaaagcga ytottgcatt gctttttgtc cctccggcac 300
 cagttgtcaa tactaaccog ctggtttgcc tccatcacat ttgtgatctg tagctctgga 360
 tacatctcct gacagtactg aagaacttct tcttttgttt caaaagcarg tcttggtgcc 420
 tgttggatca ggttcccatt toccagtcyg aatgttcaca tggcatattt wacttcccac 480
 aaaacattgc gatttgaggc tcagcaacag caaatcctgt tccggcattg gctgcaagag 540
 cctcgatgta gccggccagc gccaaaggcag gcgccgtgag ccccaccagc agcagaagca 600
 g 601

<210> 193
 <211> 608
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(608)
 <223> n = A,T,C or G

<400> 193
 atacagccca natcccacca cgaagatgcg cttgttgact gagaacctga tgcggtcact 60
 ggtcccgtg tagccccagc gactctccac ctgctggaag cggttgatgc tgcactcytt 120
 cccaacgcag gcagmagcgg gcccggtcaa tgaactccay tcgtggcttg gggtkgacgg 180
 tkaagtgcag gaagaggctg accacctcgc ggtccaccag gatgcccgac tgtgcgggac 240
 ctgcagcgaa actcctcgat ggatcatgagc gggaagcgaa tgaggcccag gcccttgccc 300
 agaaccttcc gcctgttctc tggcgtcacc tgcagctgct gccgctgaca ctccggcctcg 360
 gaccagcggg caaacggcrt tgaacagccg cacctcacgg atgcccagtg tgtcgcgctc 420
 caggammgsc accagcgtgt ccagggtcaat gtcggtgaag ccctccgcgg gtrattggcgt 480
 ctgcagtgtt tttgtcgatg ttctccaggc acaggctggc cagctgcggg tcatogaaga 540
 gtcgcgcctg cgtgagcagc atgaaggcgt tgtcggctcg cagttcttct tcaggaactc 600
 cacgcaat 608

<210> 194
 <211> 392
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(392)
 <223> n = A,T,C or G

<400> 194
 gaacggctgg accttgccctc gcattgtgct tgcgtggcagg gaataccttg gcaagcagyt 60

ccagtccgag	cagccccaga	ccgctgccgc	ccgaagctaa	gcctgcctct	ggccttcccc	120
tccgcctcaa	tgacagaacca	gtagtgggag	cactgtgttt	agagttaaga	gtgaacactg	180
tttgatttta	cttggaatt	tcctctgtta	tatagctttt	cccaatgcta	atttccaaac	240
aacaacaaca	aaataacatg	tttgctgtt	aagttgtata	aaagtaggtg	attctgtatt	300
taaagaaaat	attactgtta	catatactgc	ttgcaatttc	tgtattttatt	gktinctstgg	360
aaataaatat	agttattaaa	ggtgtgcant	cc			392

<210> 195
 <211> 502
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(502)
 <223> n = A,T,C or G

ccsttkgagg	ggtkaggkyc	cagttyccga	gtggaagaaa	caggccagga	gaagtgcgtg	60
ccgagctgag	gcagatgttc	ccacagtgc	ccccagagcc	stgggstata	gtytctgacc	120
cctcncaagg	aaagaccacs	ttctggggac	atgggctgga	gggcaggacc	tagaggcacc	180
aagggaaggc	cccattccgg	ggstgttccc	cgaggaggaa	gggaaggggc	tctgtgtgcc	240
ccccasgagg	aagaggccct	gagtcctggg	atcacacacc	ccttcacgtg	tatccccaca	300
caaatgcaag	ctcaccaagg	tcccctctca	gtccccttcc	stacaccctg	amcggccact	360
gscscacacc	caccagagc	acgccaccg	ccatggggar	tgtgctcaag	gartcgcnng	420
gcarcgtgga	catctngtcc	cagaaggggg	cagaatctcc	aatagangga	ctgarcmstt	480
gctnanaaaa	aaaaanaaaa	aa				502

<210> 196
 <211> 665
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(665)
 <223> n = A,T,C or G

ggttacttg	tttcattgcc	accacttagt	ggatgtcatt	tagaaccatt	ttgtctgctc	60
cctctggaag	ccttgcgcag	agcggacttt	gtaattgttg	gagaataact	gctgaatttt	120
wagctgtttk	gagttgatts	gcaccactgc	accacaact	tcaatatgaa	aacyawttga	180
actwatattat	tatcttgtga	aaagtataac	aatgaaaatt	ttgttcatac	tgtattkatc	240
aagtatgatg	aaaagcaawa	gatatatatt	cttttattat	gttaaattat	gattgccatt	300
attaatcggc	aaaatgtgga	gtgtatgttc	ttttcacagt	aatatatgcc	ttttgtaact	360
tcacttggtt	attttattgt	aatgarita	caaaattctt	aatttaagar	aatgggtatgt	420
watatttatt	tcattaattt	ctttcctkgt	ttacgtwaat	tttgaaaaga	wtgcatgatt	480
tcttgacaga	aatcgatctt	gatgctgtgg	aagtagtttg	accacatcc	ctatgagttt	540
ttcttagaat	gtataaagg	tgtagcccat	cnaacttcaa	agaaaaaat	gaccacatac	600
tttgcaatca	ggctgaaatg	tggcatgctn	ttctaattcc	aactttataa	actagcaaan	660
aagtg						665

<210> 197
 <211> 492
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(492)
 <223> n = A,T,C or G

<400> 197

ttttnttttt	ttttttttgc	aggaaggatt	ccattttattg	tggatgcatt	ttcacaaat	60
atgtttattg	gagcgatcca	ttatcagtga	aaagtatcaa	gtgtttataa	natttttagg	120
aaggcagatt	cacagaacat	gctngtcngc	ttgcagtttt	acctcgtana	gatnacagag	180
aattatagtc	naaccagtaa	acnaggaatt	tacttttcaa	aagattaaat	ccaaactgaa	240
caaaattcta	ccctgaaact	tactocatcc	aaatattgga	ataanagtca	gcagtgatac	300
attctcttct	gaactttaga	ttttctagaa	aaatatgtaa	tagtgatcag	gaagagctct	360
tgttcaaaag	tacaacnaag	caatgttccc	ttaccatagg	ccttaattca	aactttgatc	420
catttcactc	ccatcacggg	agtcaatgct	acctgggaca	cttgtatttt	gttcatnctg	480
ancntggctt	aa					492

<210> 198
 <211> 478
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(478)
 <223> n = A,T,C or G

<400> 198

tttnttttgn	atttcantct	gtannaanta	ttttcattat	gtttattana	aaaatatnaa	60
tgtnctccacn	acaaatcatn	ttacnfnagt	aagaggccan	ctacattgta	caacatacac	120
tgagtatat	ttgaaaagga	caagtttaaa	gtanacncat	attgccganc	atancacatt	180
tatacatggc	ttgattgata	tttagcacag	canaaaactga	gtgagttacc	agaaanaaat	240
natatattgc	aatcngattt	aagatacaaa	acagatccta	tggtacatan	catcntgtag	300
gagttgtggc	tttatgttta	ctgaaaagta	atgcagttcc	tgtacaaaga	gatggccgta	360
agcattctag	tacctctact	ccatggttaa	gaatcgtaca	cttatgttta	catatgtnc	420
gggtaagaat	tgtgttaagt	naanttatgg	agaggtccan	gagaaaaatt	tgatncaa	478

<210> 199
 <211> 482
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(482)
 <223> n = A,T,C or G

<400> 199

agtgaattgt	cctccaacaa	aaccocctga	tcaagtttgt	ggcactgaca	atcagacct	60
tgctagttcc	tgtcatctat	tcgtactaa	atgcagactg	gagggggacca	aaaaggggca	120
tcaactccag	ctggattatt	ttggagcctg	caaattctatt	cctacttgta	cggactttga	180
agtgattcag	tttctctac	ggatgagaga	ctggctcaag	aatatcctca	tgcagcttta	240
tgaagccnac	tctgaacacg	ctggttatct	nagatgagaa	ncagagaaat	aaagtcnaga	300
aaatttacct	ggangaaaag	aggctttngg	ctgggggacca	tcccattgaa	ccttctctta	360
anggacttta	agaanaaact	accacatgtn	tgtngtatcc	tggtgccngg	ccgtttantg	420
aacntngacn	ncacccttnt	ggaatanant	cttgacngcn	tcctgaactt	gctcctctgc	480
ga						482

<210> 200
 <211> 270

```
<220>
<221> misc_feature
<222> (1)...(270)
<223> n = A,T,C or G
```

<400>	200						
cggccgcaag	tgcaactcca	gctggggccg	tgcggacgaa	gattctgcc	gcagttggct		60
cgactgcgac	gacggcggcg	gcgacagtcg	caggtgcagc	gcgggcgctt	ggggtcttgc		120
aaggctgagc	tgacgcgcga	gaggtcgtgt	cacgtccac	gacctgacg	ccgtcgggga		180
cagccggaac	agagcccggt	gaangcggga	ggcctcgggg	agccctcgg	gaagggcgcc		240
ccgaagata	ccqaggtgca	ggtggccgcc					270

```
<210> 201
<211> 419
<212> DNA
<213> Homo sapien
```

```
<220>
<221> misc_feature
<222> (1)...(419)
<223> n = A,T,C or G
```

<400>	201						
tttttttttt	ttttggaatc	tactgcgagc	acagcagggtc	agcaacaagt	ttatttttgca		60
gctagcaagg	taacagggta	gggcatggtt	acatgttcag	gtcaacttcc	tttgtcgtgg		120
ttgattgggt	tgtctttatg	ggggcggggt	ggggtagggg	aaancgaagc	anaantaaca		180
tggagtgggt	gcacctccc	tgtagaacct	ggttacnaaa	gcttggggca	gttcacctgg		240
tctgtgaccg	tcattttctt	gatatcaatg	ttattagaag	tcaggatatc	tttagagag		300
tccactgtnt	ctggaggggag	attagggttt	cttggcaana	tccaancaaa	atccacntga		360
aaaaqtttga	tgtatncanq	acnqaatacc	qanggcatan	ttctcatant	cggttggcca		419

```
<210> 202
<211> 509
<212> DNA
<213> Homo sapien
```

```
<220>
<221> misc_feature
<222> (1)...(509)
<223> n = A,T,C or G
```

<400> 202							
tttntttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	60
tggcacttaa	tccattttta	tttcaaaatg	tctacaaant	ttnaatncnc	cattatacng		120
gtanattttnc	aaaatctaaa	nnttatctca	atntnagcca	aantccttac	ncaaatnnaa		180
tacnncnaaa	aatcaaaaaat	atacntntct	ttcagcaaac	ttngttacat	aaattaaaaa		240
aatatatacg	gctggtgttt	tcaaagtaca	attatcttaa	cactgcaaac	atnttttnnaa		300
ggaactaaaa	taaaaaaaaa	cactnccgca	aagggttaaag	ggaacaacaa	attcntttta		360
caacancnnc	nattataaaa	atcatatctc	aaatcttagg	ggaatatata	cttcacacng		420
ggatcttaac	ttttactnca	ctttgtttat	ttttttanaa	ccattgtntt	gggccaacaa		480
caatgqnaat	nccnccnnc	tggaactagt					509

<210>	203
<211>	583
<212>	DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(583)

<223> n = A,T,C or G

<400> 203

tttttttttt	ttttttttga	ccccctctt	ataaaaaaca	agttaccatt	ttattttact	60
tacacatatt	tattttataa	ttggtattag	atattcaaaa	ggcagctttt	aaaatcaaac	120
taaatggaaa	ctgccttaga	tacataattc	ttaggaatta	gcttaaaaac	tgcttaaagt	180
gaaaatcttc	tctagctctt	ttgactgtaa	atttttgact	cttgtaaaac	atccaaattc	240
atttttcttg	tctttaaaat	tatctaattc	ttccattttt	tccctattcc	aagtcaattt	300
gcttctctag	cctcatttcc	tagctcttat	ctactattag	taagtggctt	ttttcctaaa	360
agggaaaaaca	ggaagagana	atggcacaca	aaacaaacat	tttatattca	tattttctacc	420
tacgttaata	aaatagcatt	ttgtgaagcc	agctcaaaaag	aaggcttaga	tccttttatg	480
tcatttttag	tcactaaacg	atatacnaag	tgccagaatg	caaaagggtt	gtgaacattt	540
attcaaaaagc	taatataaga	tatttcacat	actcatcttt	ctg		583

<210> 204

<211> 589

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(589)

<223> n = A,T,C or G

<400> 204

tttttttttt	tttttttttt	ttttttttct	ttcttttttt	ttganaatga	ggatcgagtt	60
tttcaactct	tagatagggc	atgaagaaaa	ctcatctttc	cagcttttaa	ataacaatca	120
aatctcttat	gctatatcat	attttaagtt	aaactaatga	gtcactggct	tatcttctcc	180
tgaaggaaat	ctgttcattc	ttctcattca	tatagttata	tcaagtacta	ccttgcatat	240
tgagaggttt	ttcttctcta	tttacacata	tatttccatg	tgaatttgta	tcaaaccttt	300
attttcatgc	aaactagaaa	ataatgtntt	cttttgcata	agagaagaga	acaatatnag	360
cattacaaaa	ctgctcaaat	tgtttggtta	gnttatccat	tataattagt	tnngcaggag	420
ctaatacaaa	tcacattttac	ngacnagcaa	taataaaaact	gaagtaccag	ttaaatatcc	480
aaaataatta	agggaacatt	tttagcctgg	gtataattag	ctaattcact	ttacaagcat	540
ttattnagaa	tgaattcaca	tgttattatt	ccntagccca	acacaatgg		589

<210> 205

<211> 545

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(545)

<223> n = A,T,C or G

<400> 205

tttttttttt	ttttttcagt	aataatcaga	acaatattta	tttttatatt	taaaattcat	60
agaaaagtgc	cttacattta	ataaaagtgt	gtttctcaaa	gtgatcagag	gaattagata	120
tngtcttgaa	caccaatatt	aatttgagga	aaatacacca	aaatacatta	agtaaattat	180
ttaagatcat	agagcttgta	agtgaaaaaga	taaaatttga	cctcagaaac	tctgagcatt	240
aaaaatccac	tattagcaaa	taaattacta	tggaacttct	gctttaattt	tgtgatgaat	300
atgggggtgc	actggtaaac	caacacattc	tgaaggatac	attacttagt	gatagattct	360

tatgtacttt	gctanatnac	gtggatatga	gttgacaagt	ttctctttct	tcaatctttt	420
aaggggonga	ngaaatgagg	aagaaaagaa	aaggattacg	catactgttc	tttctatngg	480
aaggattaga	tatgtttcct	ttgccaatat	taaaaaata	ataatgttta	ctactagtga	540
aaccc						545

<210> 206
 <211> 487
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(487)
 <223> n = A,T,C or G

<400> 206						
tttttttttt	tttttagtc	aagtttctna	tttttattat	aattaaagtc	ttggtcattt	60
catttattag	ctctgcaact	tacatattta	aattaaagaa	acgttnttag	acaactgtna	120
caatttataa	atgtaagggtg	ccattattga	gtanatatat	tcctccaaga	gtggatgtgt	180
cccttctccc	accaactaat	gaancagcaa	cattagttta	attttattag	tagatnatac	240
actgctgcaa	acgctaattc	tcttctccat	ccccatgtng	atattgtgta	tatgtgtgag	300
ttggttagaa	tgcatacanca	atctnacaat	caacagcaag	atgaagctag	gcntgggctt	360
tcgggtgaaa	tagactgtgt	ctgtctgaat	caaatgatct	gacctatcct	cggtggcaag	420
aactcttcga	accgcttcct	caaaaggcngc	tgccacattt	gtggcntctn	ttgcacttgt	480
ttcaaaa						487

<210> 207
 <211> 332
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(332)
 <223> n = A,T,C or G

<400> 207						
tgaattggct	aaaagactgc	atttttanaa	ctagcaactc	ttatttcttt	cctttaaaaa	60
tacatagcat	taaatcccaa	atcctattta	aagacctgac	agcttgagaa	ggtcactact	120
gcatttatag	gaccttctgg	tggttctgct	gttacntttg	aantctgaca	atccttgana	180
atctttgcat	gcagaggagg	taaaagggtat	tggattttca	cagaggaana	acacagcgca	240
gaaatgaagg	ggccaggctt	actgagcttg	tcactggag	ggctcatggg	tgggacatgg	300
aaaagaaggc	agcctaggcc	ctggggagcc	ca			332

<210> 208
 <211> 524
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(524)
 <223> n = A,T,C or G

<400> 208						
agggcggtgt	gcggaggcgc	ttactgtttt	gtctcagtaa	caataaatac	aaaaagactg	60
gttgtgttcc	ggccccatcc	aaccacgaag	ttgatttctc	ttgtgtgcag	agtgactgat	120
tttaaaggac	atggagcttg	tcacaatgtc	acaatgtcac	agtggtgaagg	gcacactcac	180

tcccgcgtga	ttcacattta	gcaaccaaca	atagctcatg	agtcataact	tgtaaatact	240
tttggcagaa	tacttnttga	aacttgcaga	tgataactaa	gatccaagat	atttcccaaa	300
gtaaatagaa	gtgggtcata	atattaatta	cctgttcaca	tcagcttcca	tttacaagtc	360
atgagcccag	acactgacat	caaactaagc	ccacttagac	tcctcaccac	cagtctgtcc	420
tgtcatcaga	caggaggctg	tcaccttgac	caaattctca	ccagtcaatc	atctatccaa	480
aaaccattac	ctgatccact	tccggtaatg	caccaccttg	gtga		524

<210> 209

<211> 159

<212> DNA

<213> Homo sapien

<400> 209

gggtgaggaa	atccagagtt	gccatggaga	aaattccagt	gtcagcattc	ttgctccttg	60
tgccctctc	ctacactctg	gccagagata	ccacagtcaa	acctggagcc	aaaaaggaca	120
caaaggactc	tcgacccaaa	ctgcccaga	ccctctcca			159

<210> 210

<211> 256

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(256)

<223> n = A,T,C or G

<400> 210

actccctggc	agacaaaggc	agaggagaga	gctctgttag	ttctgtgttg	ttgaactgcc	60
actgaatttc	tttccacttg	gactattaca	tgccanttga	gggactaatg	gaaaaacgta	120
tggggagatt	ttanccaatt	tangtntgta	aatggggaga	ctggggcagg	cgggagagat	180
ttgcaggggtg	naaatgggan	ggctggtttg	ttanatgaac	agggacatag	gaggtaggca	240
ccaggatgct	aatca					256

<210> 211

<211> 264

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(264)

<223> n = A,T,C or G

<400> 211

acattgtttt	tttgagataa	agcattgaga	gagctctcct	taacgtgaca	caatggaagg	60
actggaacac	ataccacacat	ctttgttctg	agggataatt	ttctgataaa	gtcttgctgt	120
atattcaagc	acat'atg'tta	tatattattc	agttccatgt	ttatagccta	gttaaggaga	180
ggggagatac	attcngaaag	aggactgaaa	gaaatactca	agtnggaaaa	cagaaaaaga	240
aaaaaggag	caaatgagaa	gcct				264

<210> 212

<211> 328

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(328)

<223> n = A,T,C or G

<400> 212

acccaaaaat	ccaatgctga	atatttggct	tcattattcc	canattcttt	gattgtcaaa	60
ggatttaatg	ttgtctcagc	ttgggcactt	cagttaggac	ctaaggatgc	cagccggcag	120
gtttatatat	gcagcaacaa	tattcaagcg	cgacaacagg	ttattgaact	tgcccggcag	180
ttnaatttca	ttcccattga	cttgggatcc	ttatcatcag	ccagagagat	tgaaaattta	240
cccctacnac	tctttactct	ctgganaggg	ccagtgggtg	tagctataag	cttggccaca	300
tttttttttc	ctttattcct	ttgtcaga				328

<210> 213

<211> 250

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(250)

<223> n = A,T,C or G

<400> 213

acttatgagc	agagcgacat	atccnagtgt	agactgaata	aaactgaatt	ctctccagtt	60
taaagcattg	ctcactgaag	ggatagaagt	gactgccagg	agggaaagta	agccaaggct	120
cattatgccca	aagganatat	acattttcaat	tctocaaact	tcttcctcat	tccaagagtt	180
ttcaatattt	gcotgaacct	gctgataanc	catgttaana	aacaaatata	tctctnacct	240
tctcatcggt						250

<210> 214

<211> 444

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(444)

<223> n = A,T,C or G

<400> 214

accagaatc	caatgctgaa	tatttggctt	cattattccc	agattctttg	attgtcaaag	60
gattttaatgt	tgtctcagct	tgggcacttc	agttaggacc	taaggatgcc	agccggcagg	120
tttatatatg	cagcaacaat	attcaagcgc	gacaacagg	tattgaactt	gcccggcagg	180
tgaatttcat	tcccattgac	ttgggatcct	tatcatcagc	canagagatt	gaaaatttac	240
ccctacgact	ctttactctc	tggagagggc	cagtgggtgt	agctataagc	ttggccacat	300
ttttttttcc	tttattcctt	tgctcagagat	gcgattcatc	catatgctan	aaaccaacag	360
agtgactttt	acaaaattcc	tataganatt	gtgaataaaa	cottacctat	agttgccatt	420
actttgctct	ccctaataata	cctc				444

<210> 215

<211> 366

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(366)

<223> n = A,T,C or G

<400> 215
 acttatgagc agagcgacat atccaagtgt anactgaata aaactgaatt ctctccagtt 60
 taaagcattg ctcaactgaag ggatagaagt gactgccagg agggaaagta agccaaggct 120
 cattatgcc aagganatat acatttcaat tctccaaact tcttcctcat tccaagagtt 180
 ttcaatattt gcatgaacct gctgataagc catgttgaga aacaaatata tctctgacct 240
 tctcatcggt aagcagaggc tgtaggcaac atggaccata gcgaanaaaa aacttagtaa 300
 tccaagctgt tttctacact gtaaccaggt ttccaacaa ggtggaaatc tctataactt 360
 ggtgcc 366

<210> 216

<211> 260

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(260)

<223> n = A,T,C or G

<400> 216
 ctgtataaac agaactccac tgcangaggg agggccgggc caggagaatc tccgcttgtc 60
 caagacaggg gcctaaggag ggtctccaca ctgctnntaa gggctnttnc atttttttat 120
 taataaaaag tnnaaaagc ctcttctcaa cttttttccc ttnggctgga aaatttataa 180
 atcaaaaatt tctnaagtt ntcaagctat catatatact ntatcctgaa aaagcaacat 240
 aattcttctt tccctccttt 260

<210> 217

<211> 262

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(262)

<223> n = A,T,C or G

<400> 217
 acctacgtgg gtaagtttan aaatgttata atttcaggaa naggaacgca tataattgta 60
 tcttgctat aattttctat tttaataagg aaatagcaaa ttgggggtgg gggaatgtag 120
 ggcattctac agtttgagca aaatgcaatt aaatgtggaa ggacagcact gaaaaatttt 180
 atgaataatc tgatgatta tatgtctcta gagtagattt ataattagcc acttacccta 240
 atatccttca tgcttgtaaa gt 262

<210> 218

<211> 205

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(205)

<223> n = A,T,C or G

<400> 218
 accaaggtgg tgcattaccg gaantggatc aangacacca tctgtggccaa cccctgagca 60
 cccctatcaa ctcccttttg tagtaaaactt ggaaccttgg aaatgaccag gccaaagactc 120
 aggcctcccc agttctactg acctttgtcc ttangtntna ngtcagggt tgctaggaaa 180
 anaaatcagc agacacaggt gtaaa 205

<210> 219
 <211> 114
 <212> DNA
 <213> Homo sapien

<400> 219
 tactgttttg tctcagtaac aataaataca aaaagactgg ttgtgttccg gccccatcca 60
 accacgaagt tgattttctct tgtgtgcaga gtgactgatt ttaaaggaca tgga 114

<210> 220
 <211> 93
 <212> DNA
 <213> Homo sapien

<400> 220
 actagccagc acaaaaggca gggtagcctg aattgctttc tgctctttac atttctttta 60
 aaataagcat ttagtgctca gtccctactg agt 93

<210> 221
 <211> 167
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(167)
 <223> n = A,T,C or G

<400> 221
 actangtgca ggtgcgcaca aatatttgtc gatattccct tcatcttgga ttccatgagg 60
 tcttttgccc agcctgtggc tctactgtag taagtttctg ctgatgagga gccagnatgc 120
 cccccactac cttccctgac gtcgccana aatcacccaa cctctgt 167

<210> 222
 <211> 351
 <212> DNA
 <213> Homo sapien

<400> 222
 agggcgtggt gcgaggggcg gtactgacct cattagtagg aggatgcatt ctggcacccc 60
 gttcttcacc tgtcccccaa tccttaaaag gccatactgc ataaagtcaa caacagataa 120
 atgtttgctg aattaaagga tggatgaaaa aaattaataa tgaatttttg cataatccaa 180
 ttttctcttt tatatttcta gaagaagttt ctttgagcct attagatccc gggaatcttt 240
 taggtgagca tgattagaga gcttgtaggt tgcttttaca tatatctggc atatttgagt 300
 ctcgatatcaa aacaatagat tggtaaaggt ggtattattg tattgataag t 351

<210> 223
 <211> 383
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(383)
 <223> n = A,T,C or G

<400> 223

aaaacaaaca	aacaaaaaaa	acaattcttc	attcagaaaa	attatcttag	ggactgatat	60
tggttaattat	ggtcaattta	atwrrtrttkt	ggggcatttc	cttacattgt	cttgacaaga	120
ttaaaatgtc	tgtgccaaaa	ttttgtattt	tatttgaga	cttcttatca	aaagtaatgc	180
tgccaaagga	agtctaagga	attagtagtg	ttcccmcac	ttgtttggag	tgtgctattc	240
taaaagattt	tgatttcctg	gaatgacaat	tatatattta	ctttgggtgg	ggaaanagtt	300
ataggaccac	agtcttcact	tctgatactt	gtaaattaat	cttttattgc	acttgttttg	360
accattaagc	tatatgttta	aaa				383

<210> 224

<211> 320

<212> DNA

<213> Homo sapien

<400> 224

cccctgaagg	cttcttgta	gaaaatagta	cagttacaac	caataggaa	aacaaaaaga	60
aaaagtgtgt	gacattgtag	tagggagtgt	gtacccctta	ctcccatca	aaaaaaaaat	120
ggatacatgg	ttaaaggata	raagggaat	atttatcat	atgttctaaa	agagaaggaa	180
gagaaaaatac	tactttctcr	aaatggaagc	ccttaaagggt	gctttgatac	tgaaggacac	240
aaatgtggcc	gtccatcctc	ctttaragtt	gcatgacttg	gacacggtaa	ctgttgacgt	300
tttaractcm	gcattgtgac					320

<210> 225

<211> 1214

<212> DNA

<213> Homo sapien

<400> 225

gaggactgca	gcccgcactc	gcagccctgg	caggcggcac	tggtcatgga	aaacgaattg	60
ttctgctcgg	gcgtcctggt	gcatccgcag	tgggtgctgt	cagccgcaca	ctgtttccag	120
aactcctaca	ccatcgggct	gggcctgcac	agtcttgagg	ccgaccaaga	gccagggagc	180
cagatgggtg	aggccagcct	ctccgtacgg	caccagagt	acaacagacc	cttgctcgt	240
aacgcacctca	tgctcatcaa	gttgacgaa	tccgtgtccg	agtctgacac	catccggagc	300
atcagcattg	cttcgcagtg	ccctaccgcg	gggaactctt	gcctcgtttc	tggctggggt	360
ctgctggcga	acggcagaat	gcctaccgtg	ctgcagtgcg	tgaacgtgtc	ggtggtgtct	420
gaggaggtct	gcagtaagct	ctatgaccgg	ctgtaccacc	ccagcatgtt	ctgcgccggc	480
ggagggaag	accagaagga	ctcctgcaac	ggtgactctg	gggggcccct	gatctgcaac	540
gggtacttgc	agggccttgt	gtctttcgga	aaagcccctg	gtggccaagt	tggcgtgcca	600
ggtgtctaca	ccaacctctg	caaattcact	gagtggatag	agaaaaccgt	ccaggccagt	660
taactctggg	gactgggaac	ccatgaaatt	gaccccaaaa	tacatcctgc	ggaaggaatt	720
caggaatatc	tgttcccagc	ccctcctccc	tcaggcccag	gagtcagggc	ccccagcccc	780
tcctccctca	aaccaagggt	acagatcccc	agcccctcct	ccctcagacc	caggagtcca	840
gaccccccag	cccctcctcc	ctcagaccca	ggagtccagc	ccctcctccc	tcagacccag	900
gagtcagac	ccccagccc	ctcctccctc	agaccagggg	gtccaggccc	ccaacccctc	960
ctccctcaga	ctcagaggtc	caagccccc	acccctcctt	ccccagacc	agaggtccag	1020
gtcccagccc	ctcctccctc	agaccagcgg	gtccaatgcc	acctagactc	tcctgtgaca	1080
cagtgcctcc	ttgtggcag	ttgacccaac	cttaccagtt	ggtttttcat	ttttgtccc	1140
tttccctag	atccagaaat	aaagtctaag	agaagcgcaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaa					1214

<210> 226

<211> 119

<212> DNA

<213> Homo sapien

<400> 226

accagtatg	tgcagggaga	cggaacccca	tgtgacagcc	cactccacca	gggttcccaa	60
agaacctggc	ccagtcataa	tcattcatcc	tgacagtggc	aataatcacg	ataaccagt	119

<210> 227
 <211> 818
 <212> DNA
 <213> Homo sapien

<400> 227
 acaattcata gggacgacca atgaggacag ggaatgaacc cggctctccc ccagccctga 60
 tttttgctac atatggggtc ctttttcatt ctttgcaaaa acactgggtt ttctgagaac 120
 acggacgggt cttagcaca tttgtgaaat ctgtgtaraa cggggctttg caggggagat 180
 aattttcttc ctctggagga aaggtggtga ttgacaggca gggagacagt gacaaggcta 240
 gagaaagcca cgctcggcct tctctgaacc aggatggaac ggcagacccc tgaaaacgaa 300
 gcttgctccc ttccaatcag ccacttctga gaacccccat ctaacttcct actggaaaag 360
 agggcctcct caggagcagt ccaagagttt tcaaagataa cgtgacaact accatctaga 420
 ggaaagggtg caccctcagc agagaagcgc agagcttaac tctggtcgtt tccagagaca 480
 acctgctggc tgtcttggga tgcgcccagc ctttgagagg ccactacccc atgaacttct 540
 gccatccact ggacatgaag ctgaggacac tgggcttcaa cactgagttg tcatgagagg 600
 gacaggctct gccctcaagc cggctgaggg cagcaaccac tctcctcccc tttctcacgc 660
 aaagccattc ccacaaatcc agaccatacc atgaagcaac gagacccaa cagtttggtc 720
 caagaggata tgaggactgt ctacgcctgg ctttggtgtg acaccatgca cacacacaag 780
 gtccacttct aggttttcag cctagatggg agtcgtgt 818

<210> 228
 <211> 744
 <212> DNA
 <213> Homo sapien

<400> 228
 actggagaca ctggtgaact tgatcaagac ccagaccacc ccaggtctcc ttcgtgggat 60
 gtcatacagt ttgacatacc tttggaacga gcctcctcct tggaagatgg aagaccgtgt 120
 tcgtggcoga cctggcctct cctggcctgt ttcttaagat gcggagtcac atttcaatgg 180
 taggaaaagt ggcttcgtaa aatagaagag cagtcaactgt ggaactacca aatggcgaga 240
 tgctcgggtg acattggggg gctttgggat aaaagattta tgagccaact attctctggc 300
 accagattct aggcagttt gttccactga agcttttccc acagcagtc acctctgcag 360
 gctggcagct gaatggcctt cgggtggctc tgtggcaaga tcacactgag atcgatgggt 420
 gagaaggcta ggatgcttgt ctagtgttct tagctgtcac gttggctcct tccaggttgg 480
 ccagacgggt ttggccactc ctttctaaaa cacaggcgcc ctctgggtga cagtgacccg 540
 ccgtgggtat ccttggccca ttccagcagt ccagtttatg catttcaagt ttggggtttg 600
 ttcttttctg taatgttctt ctgtgttctc agctgtcttc atttctctgg ctaagcagca 660
 ttgggagatg tggaccagag atccactcct taagaaccag tggcgaaaga cactttcttt 720
 cttcactctg aagtagctgg tgg 744

<210> 229
 <211> 300
 <212> DNA
 <213> Homo sapien

<400> 229
 cgagtctggg ttttgtctat aaagtttgat cctcctttt ctcatccaaa tcatgtgaac 60
 cattacacat cgaaataaaa gaaagggtgg agacttgccc aacgccaggc tgacatgtgc 120
 tgcagggttg ttgtttttta attattattg ttgaaaacgt caccacagat cctgttaat 180
 ttgtatgtga cagccaactc tgagaaggtc ctatttttcc acctgcagag gatccagtct 240
 cactaggctc ctcttgccc tcacactgga gtctccgcca gtgtgggtgc ccactgacat 300

<210> 230
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 230

cagcagaaca	aatacaaata	tgaagagtg	aaagatctca	taaaatctat	gctgaggaat	60
gagcgacagt	tcaaggagga	gaagcttgca	gagcagctca	agcaagctga	ggagctcagg	120
caatataaag	tcttggttca	cactcaggaa	cgagagctga	cccagttaag	ggagaagttg	180
cggaagggg	gagatgcctc	cctctcattg	aatgagcatc	tccaggccct	cctcactccg	240
gatgaaccgg	acaagtccca	ggggcaggac	ctccaagaaa	cagacctcgg	ccgcgaccac	300
g						301

<210> 231

<211> 301

<212> DNA

<213> Homo sapien

<400> 231

gcaagcacgc	tggaatct	ctgtcaggtc	agctccagag	aagccattag	tcatttttagc	60
caggaactcc	aagtccacat	ccttggaac	tggggacttg	cgcaggttag	ccttgaggat	120
ggcaacacgg	gactttctcat	caggaagtgg	gatgtagatg	agctgatcaa	gacggccagg	180
tctgaggatg	gcaggatcaa	tgatgtcagg	ccggttggtg	ccgccaatga	tgaacacatt	240
ttttttgtg	gacatgccat	ccatttctgt	caggatctgg	ttgatgactc	ggtcagcagc	300
c						301

<210> 232

<211> 301

<212> DNA

<213> Homo sapien

<400> 232

agtaggtatt	tcgtgagaag	ttcaacacca	aaactggaac	atagttctcc	ttcaagtgtt	60
ggcgacagcg	gggcttctg	attctggaat	ataactttgt	gtaaattaac	agccacctat	120
agaagagtcc	atctgctgtg	aaggagagac	agagaactct	gggttccgtc	gtcctgtcca	180
cgtgctgtac	caagtgtctg	tgccagcctg	ttacctgttc	tactgaaaa	tctggctaatt	240
gctctgtgt	atcacttctg	attctgacaa	tcaatcaatc	aatggcctag	agcactgact	300
g						301

<210> 233

<211> 301

<212> DNA

<213> Homo sapien

<400> 233

atgactgact	tcccagtaag	gctctctaag	gggtaagtag	gaggatccac	aggatttgag	60
atgctaaggc	cccagagatc	gtttgatcca	accctcttat	tttcagaggg	gaaaatgggg	120
cctagaagtt	acagagcatc	tagctggtgc	gctggcacc	ctggcctcac	acagactccc	180
gagtagctgg	gactacaggc	acacagtcac	tgaagcaggc	cctgttagca	attctatgcg	240
tacaaattaa	catgagatga	gtagagactt	tattgagaaa	gcaagagaaa	atcctatcaa	300
c						301

<210> 234

<211> 301

<212> DNA

<213> Homo sapien

<400> 234

aggtcctaca	catcgagact	catccatgat	tgatatgaat	ttaaaaatta	caagcaaaga	60
cattttatcc	atcatgatgc	tttcttttgt	ttcttctttt	cgttttcttc	tttttctttt	120
tcaatttcag	caacatactt	ctcaattttc	tcaggattta	aaatcttgag	ggattgatct	180
cgctcatga	cagcaagttc	aatgtttttg	ccacctgact	gaaccacttc	caggagtgcc	240
ttgatcacca	gcttaatggg	cagatcatct	gcttcaatgg	cttcgtcagt	atagttcttc	300

t		301
<210>	235	
<211>	283	
<212>	DNA	
<213>	Homo sapien	
<400>	235	
tggggctgtg	catcaggcgg gtttgagaaa tattcaattc tcagcagaag ccagaatttg	60
aattccctca	tcttttaggg aatcatttac caggtttggg gaggattcag acagctcagg	120
tgctttcact	aatgtctctg aacttctgtc cctctttgtt catggatagt ccaataaata	180
atgttatctt	tgaactgatg ctcataggag agaataaag aactctgagt gatatcaaca	240
ttagggattc	aaagaaatat tagatttaag ctcacactgg tca	283
<210>	236	
<211>	301	
<212>	DNA	
<213>	Homo sapien	
<400>	236	
aggtcctcca	ccaactgcct gaagcacggt taaaattggg aagaagtata gtgcagcata	60
aatactttta	aatcgatcag atttccctaa cccacatgca atcttcttca ccagaagagg	120
tcggagcagc	atcattaata ccaagcagaa tgcgtaatag ataaatacaa tggatatatag	180
tgggtagacg	gcttcatgag tacagtgtac tgtggtatcg taatctggac ttgggttgta	240
aagcatcgtg	taccagtcag aaagcatcaa tactcgacat gaacgaatat aaagaacacc	300
a		301
<210>	237	
<211>	301	
<212>	DNA	
<213>	Homo sapien	
<400>	237	
cagtggtagt	ggtgggtggac gtggcggttg tctggttgcc ttttttggtg cccgtcacaa	60
actcaatttt	tgttcgctcc tttttggcct tttccaattt gtccatctca attttctggg	120
ccttggctaa	tgctcatag taggagtcct cagaccagcc atggggatca aacatatcct	180
ttgggtagtt	ggtgccaaagc tgcgcaatgg cacagaatgg atcagcttct cgtaaatcta	240
gggttcgaa	attctttctt cctttggata atgtagttca tatccattcc ctccctttatc	300
t		301
<210>	238	
<211>	301	
<212>	DNA	
<213>	Homo sapien	
<400>	238	
gggcaggttt	tttttttttt ttttttgatg gtgcagaccc ttgctttatt tgtctgactt	60
gttcacagtt	cagccccctg ctcagaaaac caacgggcca gctaaggaga ggaggaggca	120
ccttgagact	tccggagtcg aggtctctca gggttcccca gccatcaat cattttctgc	180
acccccctgc	tgggaagcag ctccctgggg ggtgggaatg ggtgactaga agggatttca	240
gtgtgggacc	cagggctctgt tottcacagt agggagtggg agggatgact aattttctta	300
t		301
<210>	239	
<211>	239	
<212>	DNA	
<213>	Homo sapien	

<400> 239

ataagcagct aggggaattct ttatttagta atgtcctaac ataaaagttc acataactgc	60
ttctgtcaaa ccatgatact gagctttgtg acaaccaga aataactaag agaaggcaaa	120
cataatacct tagagatcaa gaaacattta cacagttcaa ctgtttaaaa atagctcaac	180
attcagccag tgagtagagt gtgaatgcc aacatacacag tatacaggtc cttcaggga	239

<210> 240

<211> 300

<212> DNA

<213> Homo sapien

<400> 240

ggtcctaattg aagcagcagc ttccacattt taacgcaggt ttacgggtgat actgtccttt	60
gggatctgcc ctccagtga accttttaag gaagaagtgg gcccaagcta agttccacat	120
gctgggtgag ccagatgact tctgttccct ggtcactttc ttcaatgggg cgaatggggg	180
ctgccaggtt tttaaaatca tgcttcatct tgaagcacac ggtcacttca cctcctcac	240
gctgtgggtg tactttgatg aaaataccca ctttgttggc ctttctgaag ctataatgtc	300

<210> 241

<211> 301

<212> DNA

<213> Homo sapien

<400> 241

gaggtctggt gctgaggtct ctgggctagg aagaggagtt ctgtggagct ggaagccaga	60
cctctttgga ggaaactcca gcagctatgt tgggtgtctct gagggaatgc aacaaggctg	120
ctcctccatg tattggaaaa ctgcaaaactg gactcaactg gaaggaagtg ctgctgccag	180
tgtgaagaac cagcctgagg tgacagaaac ggaagcaaac aggaacagcc agtcttttct	240
tctcctcct gtcatacgtt ctctctcaag catcctttgt tgtcaggggc ctaaaaggga	300
g	301

<210> 242

<211> 301

<212> DNA

<213> Homo sapien

<400> 242

ccgaggtcct gggatgcaac caatcactct gtttcacgtg acttttatca ccatacaatt	60
tgtggcattt cctcattttc tacattgtag aatcaagagt gtaaataaat gtatatcgat	120
gtcttcaaga atatatcatt cctttttcac tagaaccat tcaaaatata agtcaagaat	180
cttaatatca acaaatatat caagcaaact ggaaggcaga ataactacca taatttagta	240
taagtaccca aagttttata aatcaaaagc cctaatagata accattttta gaattcaatc	300
a	301

<210> 243

<211> 301

<212> DNA

<213> Homo sapien

<400> 243

aggtaagtcc cagtttgaag ctcaaaagat ctggtatgag cataggctca tcgacgacat	60
ggtggcccaa gctatgaaat cagaggagg cttcatctgg gcctgtaaaa actatgatgg	120
tgacgtgcag tcggactctg tggcccaagg gtatggctct ctcgcatga tgaccagcgt	180
gctggtttgt ccagatggca agacagtaga agcagaggct gccacggga ctgtaacccg	240
tcactaccgc atgttccaga aaggacagga gacgtccacc aatcccattg cttccatttt	300
t	301

<210> 244

<211> 300
 <212> DNA
 <213> Homo sapien

<400> 244
 gctggtttgc aagaatgaaa tgaatgattc tacagctagg acttaacctt gaaatggaaa 60
 gtcattgcaat cccatttgca ggatctgtct gtgcacatgc ctctgtagag agcagcattc 120
 ccaggacact tggaaacagt tgacactgta aggtgcttgc tccccaaagac acatcctaaa 180
 aggtgttgta atggtgaaaa cgtcttcctt ctttattgcc ctttcttatt tatgtgaaca 240
 actgtttgtc ttttgtgtat cttttttaa ctgtaaagtt caattgtgaa aatgaatata 300

<210> 245
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 245
 gtctgagtat ttaaaatggt attgaaatta tccccaaacca atgttagaaa agaaagaggt 60
 tatatactta gataaaaaat gaggtgaatt actatccatt gaaatcatgc tcttagaatt 120
 aaggccagga gatattgtca ttaatgtara cttcaggaca ctagagtata gcagccctat 180
 gttttcaaag agcagagatg caattaaata ttgttttagca tcaaaaaggc cactcaatac 240
 agctaataaa atgaaagacc taatttctaa agcaattctt tataattttac aaagttttaa 300
 g 301

<210> 246
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 246
 ggtctgtcct acaatgcctg cttcttgaaa gaagtcggca ctttctagaa tagctaaata 60
 acctgggctt attttaaaga actatttgta gtcagattg gttttcctat ggctaaaata 120
 agtgcttctt gtgaaaatta aataaaacag ttaattcaaa gccttgatat atgttaccac 180
 taacaatcat actaaatata ttttgaagta caaagtttga catgctctaa agtgacaacc 240
 caaatgtgtc ttacaaaaca cgttcctaac aaggtatgct ttacactacc aatgcagaaa 300
 c 301

<210> 247
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 247
 aggtcctttg gcagggtcga tggatcagag ctcaaactgg agggaaaggc atttcgggta 60
 gcctaagagg gcgactggcg gcagcacaac caaggaaggc aaggttggtt cccccacgt 120
 gtgtcctgtg ttcagggtgcg acacacaatc ctcatgggaa caggatcacc catgcgctgc 180
 ccttgatgat caaggttggg gcttaagtgg attaagggag gcaagttctg ggttccttgc 240
 cttttcaaac catgaagtca ggctctgtat ccctcctttt cctaactgat attctaacta 300
 a 301

<210> 248
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 248
 aggtccttgg agatgccatt tcagccgaag gactcttctw ttcggaagta caccctcact 60
 attaggaaga ttottagggg taatttttct gaggaaggag aactagccaa ctttaagaatt 120

acaggaagaa agtgggttgg aagacagcca aagaaataaa agcagattaa attgtatcag 180
 gtacattcca gcctgttggc aactccataa aaacatttca gattttaatc ccgaatttag 240
 ctaatgagac tggatttttg ttttttatgt tgtgtgtcgc agagctaaaa actcagttcc 300
 c 301

<210> 249
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 249
 gtccagagga agcacctggg gctgaactag gcttgccctg ctgtgaactt gcacttggag 60
 ccctgacgct gctgttctcc ccgaaaaacc cgaccgacct ccgcgatctc cgtcccgccc 120
 ccagggagac acagcagtga ctacagagctg gtgcacact gtgcctccct cctcaccgcc 180
 catcgtaatg aattattttg aaaattaatt ccaecatcct ttcagattct ggatggaaag 240
 actgaatctt tgactcagaa ttgtttgctg aaaagaatga tgtgactttc ttagtcattt 300
 a 301

<210> 250
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 250
 ggtctgtgac aaggacttgc aggctgtggg aggcaagtga cccttaacac tacacttctc 60
 cttatcttta ttggcttgat aaacataatt atttctaaca ctacgttatt tccagttgcc 120
 cataagcaca tcagtacttt tctctggctg gaatagtaaa ctaaagtatg gtacatctac 180
 ctaaaagact actatgtgga ataatacata ctaatgaagt attacatgat ttaaagacta 240
 caataaaacc aaacatgctt ataacattaa gaaaaacaat aaagatacat gattgaaacc 300
 a 301

<210> 251
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 251
 gccgaggtcc tacatttggc ccagtttccc cctgcatoct ctccagggcc cctgcctcat 60
 agacaacctc atagagcata ggagaactgg ttgccctggg ggagggggga ctgtctggat 120
 ggcaggggtc ctcaaaaatg cactgtcac tgccaggaaa tgcttctgag cagtacacct 180
 cattgggac aatgaaaagc ttcaagaaat cttcaggctc actctcttga aggccggaa 240
 cctctggagg ggggcagtgg aatcccagct ccaggacgga tcctgtcgaa aagatatcct 300
 c 301

<210> 252
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 252
 gcaaccaatc actctgtttc acgtgacttt tatcaccata caatttgtgg catttctca 60
 ttttctacat tgtagaatca agagtgtaaa taaatgtata tcgatgtctt caagaatata 120
 tcattccttt ttcactagga acccattcaa aatataagtc aagaatctta atatcaacaa 180
 atatatcaag caaactggaa ggcagaataa ctaccataat ttagtataag taccctaaagt 240
 ttataaatc aaaagcccta atgataacca tttttagaat tcaatcatca ctgtagaatc 300
 a 301

<210> 253

<211> 301
 <212> DNA
 <213> Homo sapien

<400> 253
 ttccctaaga agatgttatt ttgttgggtt ttgttccccc tccatctcga ttctcgtacc 60
 caactaaaaa aaaaaataa agaaaaaatg tgctgcgttc tgaaaaataa ctcccttagct 120
 tggctctgatt gttttcagac cttaaaaatat aaacttggtt cacaagcttt aatccatgtg 180
 gatttttttt cttagagAAC cacaaaacat aaaaggagca agtcggactg aatacctgtt 240
 tccatagtgc ccacagggtA ttctcACat tttctccata ggaaaatgct ttttcccaag 300
 g 301

<210> 254
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 254
 cgctgcgcct ttcccttggg ggaggggcaa ggccagaggg ggtccaagtg cagcacgagg 60
 aacttgacca attcccttga agcgggtggg ttaaaccctg taaatgggaa caaaatcccc 120
 ccaaattctt tcatcttacc ctggtggact cctgactgta gaattttttg gttgaaacaa 180
 gaaaaaataa aagctttgga cttttcaagg ttgcttaaca ggtactgaaa gactggcctc 240
 acttaaaactg agccaggaaa agctgcagat ttattaatgg gtgtgttagt gtgcagtgcc 300
 t 301

<210> 255
 <211> 302
 <212> DNA
 <213> Homo sapien

<400> 255
 agcttttttt tttttttttt tttttttttt ttcattaaaa aatagtgtct tttattataa 60
 attactgaaa tgtttctttt ctgaatataa atataaatat gtgcaaagtt tgacttggat 120
 tgggattttg ttgagttctt caagcatctc ctaataccct caagggcctg agtagggggg 180
 aggaaaaagg actggagggtg gaatctttat aaaaaacaag agtgattgag gcagattgta 240
 aacattatta aaaaacaaga aacaaacaaa aaaatagaga aaaaaaccac cccaacacac 300
 aa 302

<210> 256
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 256
 gttccagaaa acattgaagg tggttcccca aagtctaact agggataccc cctotagcct 60
 aggacctcc tccccacacc tcaatccacc aaaccatcca taatgcaccc agataggccc 120
 acccccacaa gctgggacac cttgagcaca cagttaatgac caggacagac tcatctctat 180
 aggcaaatag ctgctggcaa actggcatta cctggtttgt ggggatggg gggcaagtgt 240
 gtggcctctc ggcttggtta gcaagaacat tcagggtagg cctaagttaa tcgtgttagt 300
 t 301

<210> 257
 <211> 301

<212> DNA

<213> Homo sapien

<400> 257

```

gttggtggagg aactctggct tgctcattaa gtctactga ttttcactat cccctgaatt      60
tccccactta tttttgtctt tcaactatcg aggccttaga agaggtctac ctgcctccag      120
tcttacctag tccagtctac cccctggagt tagaatggcc atcctgaagt gaaaagtaat      180
gtcacattac tcccttcagt gatttcttgt agaagtgcc atccctgaat gccaccaaga      240
tcttaatctt cacatcttta atcttatctc ttgtactcct ctttacaccg gagaaggctc      300
c                                                                                   301

```

<210> 258

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 258

```

cagcagtagt agatgccgta tgccagcacg occagcactc ccaggatcag caccagcacc      60
aggggccccag ccaccaggcg cagaagcaag ataaacagta ggctcaagac cagagccacc      120
cccagggcaa caagaatcca ataccaggac tgggcaaaat cttcaaagat cttaacactg      180
atgtctcggg cattgaggct gtcaataana cgctgatccc ctgctgtatg gtggtgtcat      240
tggtgatccc tgggagcgcc ggtggagtaa cgttggtcca tggaaagcag cgcccacaac      300
t                                                                                   301

```

<210> 259

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 259

```

tcatatatgc aaacaatgc agactangcc tcaggcagag actaaaggac atctcttggg      60
gtgtcctgaa gtgatttgga cccctgaggg cagacaccta agtaggaatc ccagtgggaa      120
gcaaagccat aaggaagccc aggattcctt gtgatcagga agtgggccag gaaggctctg      180
tccagctcac atctcatctg catgcagcac ggaccggatg cgcccactgg gtcttggett      240
ccctcccatc ttctcaagca gtgtccttgt tgagccattt gcatccttgg ctccagggtg      300
c                                                                                   301

```

<210> 260

<211> 301

<212> DNA

<213> Homo sapien

<400> 260

```

tttttttct ccctaaggaa aaagaaggaa caagtctcat aaaaccaa at aagcaatggt      60
aagggtgtctt aacttgaaaa agattaggag tcaactggttt acaagttata attgaatgaa      120
agaactgtaa cagccacagt tggccatttc atgccaatgg cagcaaacia caggattaac      180
tagggcaaaa taaataagtg tgtggaagcc ctgataagtg cttataaac agactgattc      240
actgagacat cagtacctgc ccggggcgcc gctcgagccg aattctgcag atatccatca      300

```

c 301

<210> 261
<211> 301
<212> DNA
<213> Homo sapien

<400> 261
aaatattcga gcaaattcctg taactaatgt gtctccataa aaggctttga actcagtgaa 60
tctgcttcca tccacgattc tagcaatgac ctctcggaca tcaaagctcc tcttaagggtt 120
agcaccact attccataca attcatcagc aggaaataaa ggctcttcag aaggttcaat 180
ggtgacatcc aatttcttct gataatttag attcctcaca accttcctag ttaagtgaag 240
ggcatgatga tcatccaaag ccagtggtc acttactcca gactttctgc aatgaagatc 300
a 301

<210> 262
<211> 301
<212> DNA
<213> Homo sapien

<400> 262
gaggagagcc tgttacagca tttgtaagca cagaatactc caggagtatt tgtaattgtc 60
tgtgagcttc ttgccgcaag tctctcagaa atttaaaaag atgcaaatcc ctgagtcacc 120
cctagacttc ctaaaccaga tcctctgggg ctggaacctg gcactctgca tttgtaatga 180
gggtttctg gtgcacacct aattttgtgc atctttgcc taaatcctgg attagtgcc 240
catcattacc cccacattat aatgggatag attcagagca gatactctcc agcaaagaat 300
c 301

<210> 263
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 263
tttagcttgt ggtaaatgac tcacaaaact gattttaaaa tcaagttaat gtgaattttg 60
aaaattacta cttaatccta attcacaata acaatggcat taaggtttga cttgagttgg 120
ttcttagtat tatttatggg aaataggctc ttaccacttg caaataactg gccacatcat 180
taatgactga cttcccagta aggcctctcta aggggtaagt angaggatcc acaggatttg 240
agatgctaag gcccagaga tcgtttgatc caaccctctt atttccagag gggaaaatgg 300
g 301

<210> 264
<211> 301
<212> DNA
<213> Homo sapien

<400> 264
aaagacgtta aaccactcta ctaccacttg tggaactctc aaagggtaaa tgacaaascc 60
aatgaatgac tctaaaaaca atatttacat ttaatggttt gtagacaata aaaaaacaag 120
gtggatagat ctagaattgt aacattttta gaaaaccata scatttgaca gatgagaaag 180
ctcaattata gatgcaaagt tataactaaa ctactatagt agtaaagaaa tacatttcac 240
acccttcata taaattcact atcttggtt gaggcactcc ataaaatgta tcacgtgcac 300
a 301

<210> 265
<211> 301
<212> DNA
<213> Homo sapien

<400> 265
tgcccaagtt atgtgtaagt gtatccgcac ccagaggtaa aactacactg tcatctttgt 60
cttcttgtga cgcagtattt cttctctggg gagaagccgg gaagtcttct cctggctcta 120
catattcttg gaagtctcta atcaactttt gttccatttg ttccatttct tcaggaggga 180
ttttcagttt gtcaacatgt tctctaacia cacttgccca tttctgtaaa gaatccaaag 240
cagtccaagg ctttgacatg tcaacaacca gcataactag agtatccttc agagatacgg 300
c 301

<210> 266
<211> 301
<212> DNA
<213> Homo sapien

<400> 266
taccgtctgc ctttctctcc atccaggcca tctgcgaatc tacatgggtc ctctatttcg 60
acaccagatc actctttcct ctaccacag gcttgctatg agcaagagac acaacctcct 120
ctcttctgtg ttccagcttc ttttctgtt cttccacccc cttaagttct attcctgggg 180
atagagacac caatacccat aacctctctc ctaagcctcc ttataaccca ggggtgcacag 240
cacagactcc tgacaactgg taaggccaat gaactgggag ctcacagctg gctgtgcctg 300
a 301

<210> 267
<211> 301
<212> DNA
<213> Homo sapien

<400> 267
aaagagcaca ggccagctca gcctgccctg gccatctaga ctcagcctgg ctccatgggg 60
gttctcagtg ctgagtccat ccaggaaaag ctcacctaga ctttctgagg ctgaatcttc 120
atcctcacag gcagcttctg agagcctgat attcctagcc ttgatggtct ggagtaaagc 180
ctcattctga ttctctcct tcttttctt caagttggct ttctcacat ccctctgttc 240
aattcgcttc agcttgtctg ctttagccct catttccaga agcttcttct ctttggcatc 300
t 301

<210> 268
<211> 301
<212> DNA
<213> Homo sapien

<400> 268
aatgtctcac tcaactactt ccagcctac cgtggcctaa ttctgggagt tttcttctta 60
gatcttggga gagctgggtc ttctaaggag aaggaggaag gacagatgta actttggatc 120
tcgaagagga agtctaattg aagtaattag tcaacgggtc ttgtttagac tcttgggaata 180
tgctgggtgg ctgagtggc ctttttggag aaagcaagta ttattcttaa ggagtaacca 240
cttcccattg ttctactttc taccatcatc aattgtatat tatgtattct ttggagaact 300
a 301

<210> 269
<211> 301
<212> DNA
<213> Homo sapien

<400> 269
 taacaatata cactagctat ctttttaact gtccatcatt agcaccaatg aagattcaat 60
 aaaattacct ttattcacac atctcaaaac aattctgcaa attcttagtg aagtttaact 120
 atagtcacag accttaaata ttcacattgt tttctatgtc tactgaaaat aagttcacta 180
 cttttctgga tattctttac aaaatcttat taaaattcct ggtattatca cccccaatta 240
 tacagtagca caaccacctt atgtagtttt tacatgatag ctctgtagaa gtttcacatc 300
 t 301

<210> 270
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 270
 cattgaagag cttttgcgaa acatcagaac acaagtgcct ataaaattaa ttaagcctta 60
 cacaagaata catattcctt ttatttctaa ggagttaaac atagatgtag ctgatgtgga 120
 gagcttgctg gtgcagtgc tttggataa cactattcat ggccgaattg atcaagtcaa 180
 ccaactcctt gaactggatc atcagaagaa ggggtggtgca cgatatactg cactagataa 240
 tggaccaacc aactaaattc tctcaccagg ctgtatcagt aaactggctt aacagaaaaa 300
 a 301

<210> 271
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 271
 aaaagggttct cataagatta acaatttaaa taaatatttg atagaacatt ctttctcatt 60
 tttatagctc atcttttagg ttgatattca gttcatgcct cccttgctgt tcttgatcca 120
 gaattgcaat cacttcatca gctgtattc gctccaattc tctataaagt ggggtccaagg 180
 tgaaccacag agccacagca cacctctttc ccttggtgac tgccttcacc ccatganggt 240
 tctctctcc agatganaac tgatcatgag ccacatttt gggttttata gaagcagtc 300
 c 301

<210> 272
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 272
 taaattgcta agccacagat aacaccaatc aaatggaaca aatcactgtc ttcaaagtgc 60
 ttatcagaaa accaaatgag cctggaatct tcataatacc taaacatgcc gtatttagga 120
 tccaataatt ccctcatgat gagcaagaaa aattctttgc gcaccctcc tgcattccaca 180
 gcatcttctc caacaaatat aaccttgagt ggcttcttgt aatctatgtt ctttgttttc 240
 ctaaggactt ccattgcac tctacaata ttttctctac gcaccactag aattaagcag 300
 g 301

<210> 273
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>

<221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 273
 acatgtgtgt atgtgtatct ttgggaaaaa aanaagacat cttgtttayt atttttttgg 60
 agagangctg ggacatggat aatcacwtaa tttgctayta tyactttaat ctgactygaa 120
 gaaccgtcta aaaataaaat ttaccatgtc dtatatcct tatagtatgc ttatttcacc 180
 tttytttctgt ccagagagag tatcagtgac ananatttma gggatgaamac atgmattggg 240
 gggacttnty tttaacngagm accctgcccg sgcgccctcg makcngantt ccgcsananc 300
 t 301

<210> 274
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 274
 cttatatact ctttctcaga ggcaaaagag gagatgggta atgtagacaa ttctttgagg 60
 aacagttaa atgattattaga gagaangaat ggaccaagga gacagaaatt aacttgtaaa 120
 tgattctctt tggaatctga atgagatcaa gaggccagct ttagcttggtg gaaaagtcca 180
 tctaggtatg gttgcattct cgtcttcttt tctgcagtag ataatgaggt aaccgaaggc 240
 aattgtgctt cttttgataa gaagctttct tggatcatatc aggaattcc aganaaagtc 300
 c 301

<210> 275
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 275
 tcggtgtcag cagcacgtgg cattgaacat tgcaatgtgg agcccaaacc acagaaaatg 60
 ggggtgaaat ggccaacttt ctattaactt atgttggaat ttttgccacc aacagtaagc 120
 tggcccttct aataaaagaa aattgaaagg tttctcacta aacggaatta agtagtggag 180
 tcaagagact cccaggcctc agcgtacctg cccgggaggc cgctcgaagc cgaattctgc 240
 agatatccat cacactggcg gncgctcgan catgcatcta gaaggnccaa ttcgccctat 300
 a 301

<210> 276
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 276
 tgtacacata ctcaataaat aaatgactgc attgtggtat tattactata ctgattatat 60
 ttatcatgtg acttctaatt agaaaatgta tccaaaagca aaacagcaga tatacaaaat 120
 taaagagaca gaagatagac attaacagat aaggcaactt atacattgag aatccaaatc 180
 caatacatth aaacatttgg gaaatgaggg ggacaaatgg aagccagatc aaatttgtgt 240

aaaactattc agtatgtttc ctttgettca tgtctgagaa ggctctcctt caatggggat 300
g 301

<210> 277
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 277
tttgttgatg tcagtatttt attacttgcg ttatgagtgc tcacctggga aattctaaag 60
atacagagga cttggaggaa gcagagcaac tgaatttaat ttaaaagaag gaaaacattg 120
gaatcatggc actcctgata ctttcccaa tcaacactct caatgcccc ccctcgtcct 180
caccatagtg gggagactaa agtggccacg gatttgcctt angtgtgcag tgcgttctga 240
gttcnctgtc gattacatct gaccagtctc ctttttccga agtcctccg ttcaatcttg 300
c 301

<210> 278
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 278
taccactaca ctccagcctg ggcaacagag caagacctgt ctcaaagcat aaaatggaat 60
aacatatcaa atgaaacagg gaaaatgaag ctgacaattt atggaagcca gggcttgtca 120
cagtctctac tgttattatg cattacctgg gaatttatat aagcccttaa taataatgcc 180
aatgaacatc tcatgtgtgc tcacaatgtt ctggcactat tataagtgtc tcacagggtt 240
tatgtgttct tcgtaacttt atggantagg tactcgccg cgaacacgct aagccgaatt 300
c 301

<210> 279
<211> 301
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1)...(301)
<223> n = A,T,C or G

<400> 279
aaagcaggaa tgacaaagct tgcttttctg gtatgttota ggtgtattgt gacttttact 60
gttatattaa ttgccaatat aagtaaatat agattatata tgtatagtgt ttcacaaagc 120
ttagaccttt accttcagc caccacacag tgcttgatat ttcagagtca gtcattgggt 180
atacatgtgt agttccaaag cacataagct agaanaanaa atatttctag ggagcactac 240
catctgtttt cacatgaaat gccacacaca tagaactcca acatcaattt cattgcacag 300
a 301

<210> 280

<211> 301
 <212> DNA
 <213> Homo sapien

<400> 280
 ggtactggag ttttctccc ctgtgaaaac gtaactactg ttgggagtga attgaggatg 60
 tagaaagggtg gtggaaccaa attgtggtca atggaaatag gagaatatgg ttctcactct 120
 tgagaaaaaa acctaagatt agcccaggta gttgcctgta acttcagttt ttctgcctgg 180
 gtttgatata gtttaggggtt ggggttagat taagatctaa attacatcag gacaaagaga 240
 cagactatta actccacagt taattaagga ggtatgttcc atgtttattt gttaaagcag 300
 t 301

<210> 281
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 281
 aggtacaaga aggggaatgg gaaagagctg ctgctgtggc attgttcaac ttggatatctc 60
 gccgagcaat ccaaatacctg aatgaagggg catcttctga aaaaggagat ctgaatctca 120
 atgtggtagc aatggcttta tcgggttata cggatgagaa gaactccctt tggagagaaa 180
 tgtgtagcac actgcgatta cagctaaata acccgatttt gtgtgtcatg tttgcatttc 240
 tgacaagtga aacaggatct tacgatggag ttttgtatga aaacaaagtt gcagtacctc 300
 g 301

<210> 282
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 282
 caggtactac agaattaaaa tactgacaag caagtagttt cttggcgtgc acgaattgca 60
 tccagaaccc aaaaatttaag aaattcaaaa agacattttg tgggcacctg ctagcacaga 120
 agcgcagaag caaagcccag gcagaaccat gctaacctta cagctcagcc tgcacagaag 180
 cgcagaagca aagcccaggc agaaccatgc taaccttaca gctcagcctg cacagaagcg 240
 cagaagcaaa gccccaggcag aacatgctaa ccttacagct cagcctgcac agaagcacag 300
 a 301

<210> 283
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 283
 atctgtatac ggcagacaaa ctttatarag tgtagagagg tgagcgaaag gatgcaaaag 60
 cactttgagg gctttataat aatatgctgc ttgaaaaaaa aaatgtgtag ttgatactca 120
 gtgcatctcc agacatagta aggggttgct ctgaccaatc aggtgatcat tttttctatc 180
 acttcccagg ttttatgcaa aaattttgtt aaattctata atgggtgatat gcattcttta 240
 ggaaacatat acatttttaa aaatctattt tatgtaagaa ctgacagacg aatttgcttt 300
 g 301

<210> 284
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 284
 caggtacaaa acgctattaa gtggccttaga atttgaacat ttgtggtctt tatttacttt 60

```

gcttcgtgtg tgggcaaagc aacatcttcc ctaaatatat attaccaaga aaagcaagaa    120
gcagattagg tttttgacaa aacaaacagg ccaaaagggg gctgacctgg agcagagcat    180
ggtgagaggg aaggcatgag agggcaagtt tgttgtggac agatctgtgc ctactttatt    240
actggagtaa aagaaaacaa agttcattga tgtcgaagga tatatacagt gttagaaatt    300
a                                                                    301

```

<210> 285

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 285

```

acatcaccat gatcggtacc cccacccatt atacgttgta tgtttacata aatactcttc    60
aatgatcatt agtgttttta aaaaaatact gaaaactcct tctgcatccc aatctctaac    120
caggaaagca aatgctatct acagacctgc aagccctccc tcaaacnaaa ctatttctgg    180
attaaatatg tctgacttct tttgaggtca cagcactagg caaatgctat ttacgatctg    240
caaaagctgt ttgaagagtc aaagccccc a tgtgaacacg atttctggac cctgtaacag    300
t                                                                    301

```

<210> 286

<211> 301

<212> DNA

<213> Homo sapien

<400> 286

```

taccactgca ttccagcctg ggtgacagag tgagactcgg tctccaaaaa aaactttgct    60
tgtatattat ttttgccctta cagtggatca ttctagtagg aaaggacagt aagatttttt    120
atcaaaatgt gtcatgccag taagagatgt tatattcttt tctcatttct tccccaccca    180
aaaataagct accatatagc ttataagtct caaatttttg ccttttacta aaatgtgatt    240
gtttctgttc attgtgtatg cttcatcacc tatattaggg aaattccatt ttttcccttg    300
t                                                                    301

```

<210> 287

<211> 301

<212> DNA

<213> Homo sapien

<400> 287

```

tacagatctg ggaactaaat attaaaaatg agtgtggctg gatatatgga gaatgttggg    60
cccagaagga acgtagagat cagatattac aacagctttg ttttgagggg tagaaatatg    120
aaatgatttg gttatgaacg cacagttagg gcagcagggc cagaatcctg accctctgcc    180
ccgtgggtat ctctcccca gcttggctgc ctcatgttat cacagtatc cattttgttt    240
gttgcattgc ttgtgaagcc atcaagattt tctcgtctgt tttcctctca ttgtaaatgc    300
t                                                                    301

```

<210> 288

<211> 301

<212> DNA

<213> Homo sapien

<400> 288

```

gtacacctaa ctgcaaggac agctgaggaa tgtaatgggc agccgctttt aaagaagtag    60
agtcaatagg aagacaaatt ccagttccag ctcaagtctgg gtatctgcaa agctgcaaaa    120

```

```

gatcttttaaa gacaatttca agagaatatt tccttaaagt tggcaatttg gagatcatac 180
aaaagcatct gcttttgtga ttttaatttag ctcatctggc cactggaaga atccaaacag 240
tctgccttaa ttttgatga atgcatgatg gaaattcaat aatttagaaa gttaaaaaaa 300
a 301

```

<210> 289

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 289

```

ggtacactgt ttocatgtta tgtttctaca cattgctacc tcagtgtcc tggaaactta 60
gcttttgatg tctccaagta gtocacctc atttaactct ttgaaactgt atcatcttg 120
ccaagtaaga gtggtggcct atttcagctg ctttgacaaa atgactggct cctgacttaa 180
cgttctataa atgaatgtgc tgaagcaaag tgcccatggt ggcggcgaan aagagaaaga 240
tgtgttttgt tttggactct ctgtggtccc ttccaatgct gtgggtttcc aaccagnnga 300
a 301

```

<210> 290

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 290

```

acactgagct cttcttgata aatatacaga atgcttggca tatacaagat tctatactac 60
tgactgatct gttcatttct ctcacagctc ttaccccaa aagcttttcc accctaagtg 120
ttctgacctc cttttctaata cacagtaggg atagaggcag anccacctac aatgaacatg 180
gagttctatc aagaggcaga aacagcacag aatcccagtt ttaccattcg cttagcagtgc 240
tgccttgaac aaaaacattt ctccatgtct cattttcttc atgcctcaag taacagtgc 300
a 301

```

<210> 291

<211> 301

<212> DNA

<213> Homo sapien

<400> 291

```

caggtacca tttcttctat cctagaaaca tttcatttta tgttggtgaa acataacaac 60
tatatcagct agattttttt tctatgcttt acctgctatg gaaaatttga cacattctgc 120
ttactcttt tgtttatagg tgaatcacia aatgtatttt tatgtattct gtagtccaat 180
agccatggct gtttacttca ttttaatttat ttagcataaa gacattatga aaaggcctaa 240
acatgagctt cacttcccca ctaactaatt agcatctgtt atttcttaac cgtaatgcct 300
a 301

```

<210> 292

<211> 301

<212> DNA

<213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 292
 accttttagt agtaatgtct aataataaat aagaaatcaa ttttataagg tccatatagc 60
 tgtattaaat aatttttaag tttaaaagat aaaataccat cattttaaat gttggtattc 120
 aaaaccaaag natataaccg aaaggaaaaa cagatgagac ataaaaatgat ttgcnagatg 180
 ggaaatatag tasttyatga atgttnatta aattccagtt ataatagtgg ctacacactc 240
 tcactacaca cacagacccc acagtcctat atgccacaaa cacatttcca taacttgaaa 300
 a 301

<210> 293
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 293
 ggtaccaagt gctggtgcca gcctgttacc tgttctcact gaaaagtctg gctaagtctc 60
 ttgtgtagtc acttctgatt ctgacaatca atcaatcaat ggcctagagc actgactggt 120
 aacacaaacg tcaactagcaa agtagcaaca gctttaagtc taaatacaaa gctgttctgt 180
 gtgagaattt tttaaaaggc tacttgtata ataacccttg tcatttttaa tgtacctggg 240
 ccgcgaccac gctaagccga attctgcaga tatccatcac actggcggcc gctcgagcat 300
 g 301

<210> 294
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 294
 tgacccataa caatatacac tagctatctt ttttaactgtc catcattagc accaatgaag 60
 attcaataaa attaccttta ttcacacatc tcaaaaacaat tctgcaaatt cttagtgaag 120
 ttttaactata gtcacaganc ttaaataatc acattgtttt ctatgtctac tgaaaaataag 180
 ttcactactt ttctgggata ttctttacaa aatcttatta aaattcctgg tattatcacc 240
 cccaattata cagtagcaca accaccttat gtagttttta catgatatgct ctgtagaggt 300
 t 301

<210> 295
 <211> 305
 <212> DNA
 <213> Homo sapien

<400> 295
 gtactctttc tctccctcc tctgaattta attctttcaa cttgcaattt gcaaggatta 60
 cacatttcac tgtgatgtat attgtgttgc aaaaaaaaaa gtgtctttgt ttaaaattac 120
 ttggtttgtg aatccatctt gctttttccc cattggaact agtcattaac ccatctctga 180
 actggtagaa aaacrtctga agagctagtc tatcagcatc tgacagggtga attggatggg 240
 tctcagaacc atttcaccca gacagcctgt ttctatcctg ttttaataaat tagtttgggt 300
 tctct 305

<210> 296
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 296
 aggtactatg ggaagctgct aaaataatat ttgatagtaa aagtatgtaa tgtgctatct 60
 cacctagtag taaactaaaa ataaactgaa actttatgga atctgaagtt attttccttg 120
 attaaataga attaataaac caatatgagg aaacatgaaa ccatgcaatc tactatcaac 180
 tttgaaaaag tgattgaacg aaccacttag ctttcagatg atgaacactg ataagtcatt 240
 tgtcattact ataaatttta aaatctgtta ataagatggc ctatagggag gaaaaagggg 300
 c 301

<210> 297
 <211> 300
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(300)
 <223> n = A,T,C or G

<400> 297
 actgagtttt aactggacgc caagcaggca aggctggaag gttttgctct ctttgtgcta 60
 aaggttttga aaaccttgaa ggagaatcat ttgacaaga agtacttaag agtctagaga 120
 acaaagangt gaaccagctg aaagctctcg ggggaanctt acatgtgttg ttaggcctgt 180
 tccatcattg ggagtgcact ggccatccct caaaatttgt ctgggctggc ctgagtggtc 240
 accgcacctc ggccgcgacc acgctaagcc gaattctgca gatatccatc aactggcgcg 300

<210> 298
 <211> 301
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(301)
 <223> n = A,T,C or G

<400> 298
 tatggggttt gtcacccaaa agctgatgct gagaaaggcc tccctggggc cctcccgcg 60
 ggcactctgag agacctggtg ttccagtgtt tctggaaatg ggtcccagtg ccgccggctg 120
 tgaagctctc agatcaatca cgggaagggc ctggcggttg tggccacctg gaaccaccct 180
 gtctgtctc tttacatttc actaycaggt tttctctggg cattacnatt tgttccccta 240
 caacagtgac ctgtgcattc tgctgtggcc tgctgtgtct gcaggtggct ctcagcgagg 300
 t 301

<210> 299
 <211> 301
 <212> DNA
 <213> Homo sapien

<400> 299
 gttttgagac ggagtttcac tcttgttgcc cagactggac tgcaatggca gggctctctgc 60
 tcactgcacc ctctgcctcc caggttcgag caattctcct gcctcagcct ccaggtagc 120
 tgggattgca ggctcacgcc accataccca gctaattttt ttgtattttt agtagagacg 180
 gagtttcgcc atgttgacca gctgggtctca aactcctgac ctcaagcgac ctgcctgcct 240

cggcctccca aagtgtgga attataggca tgagtcaaca cgcccagcct aaagatattt 300
t 301

<210> 300
<211> 301
<212> DNA
<213> Homo sapien

<400> 300
attcagtttt atttgtctgcc ccagtatctg taaccaggag tgccacaaaa tcttgccaga 60
tatgtcccac acccactggg aaaggctccc acctggctac ttcctctatc agctgggtca 120
gctgcattcc acaagggttct cagcctaata agtttcaacta cctgccagtc tcaaaactta 180
gtaaagcaag accatgacat tccccacgg aaatcagagt ttgcccacc gtcttggtac 240
tataaagcct gcctctaaca gtccttgctt cttcacacca atcccagagc catcccccat 300
g 301

<210> 301
<211> 301
<212> DNA
<213> Homo sapien

<400> 301
ttaaattttt gagaggataa aaaggacaaa taatctagaa atgtgtcttc ttcagtctgc 60
agaggacccc aggtctccaa gcaaccacat ggtcaagggc atgaataatt aaaagttggt 120
gggaactcac aaagaccctc agagctgaga caccacacac agtgggagct cacaagacc 180
ctcagagctg agacaccac aacagtggga gtcacaaaag accctcagag ctgagacacc 240
cacaacagca cctcgttcag ctgccacatg tgtgaataag gatgcaatgt ccagaagtgt 300
t 301

<210> 302
<211> 301
<212> DNA
<213> Homo sapien

<400> 302
aggtacacat ttagcttgtg gtaaagtact cacaaaactg attttaaaat caagttaatg 60
tgaattttga aaattactac ttaatcctaa ttcacaataa caatggcatt aaggtttgac 120
ttgagttggt tcttagtatt atttatggta aataggctct taccacttgc aaataactgg 180
ccacatcatt aatgactgac ttcccagtaa ggctctctaa ggggtaagta ggaggatcca 240
caggatttga gatgctaagg ccccagagat cgtttgatcc aaccctctta ttttcagagg 300
g 301

<210> 303
<211> 301
<212> DNA
<213> Homo sapien

<400> 303
aggtaccaac tgtggaaata ggtagaggat ctttttttct ttccatatca actaagttgt 60
atattgtttt ttgacagttt aacacatctt cttctgtcag agattctttc acaatagcac 120
tggtaatgg aactaccgct tgcattgtaa aaatggtggg ttgtgaaatg atcataggcc 180
agtaacgggt atgtttttct aactgatctt ttgctcgttc caaagggacc tcaagacttc 240
catcgatttt atatctgggg tctagaaaag gagttaatct gttttccctc ataaattcac 300
c 301

<210> 304
<211> 301
<212> DNA

<213> Homo sapien

<400> 304

acatggatgt	tatTTTgcag	actgtcaacc	tgaatttgta	tttgcttgac	attgccta	60
tattagtttc	agtttcagct	taccacttt	ttgtctgcaa	catgcaraas	agacagtgcc	120
cttttttagtg	tatcatatca	ggaatcatct	cacattgggt	tgtgccatta	ctgggtgcagt	180
gactttcagc	cacttgggta	aggtggagtt	ggccatatgt	ctccactgca	aaattactga	240
ttttcctttt	gtaattaata	agtgtgtgtg	tgaagattct	ttgagatgag	gtatataatct	300
c						301

<210> 305

<211> 301

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(301)

<223> n = A,T,C or G

<400> 305

gangtacagc	gtgggtcaagg	taacaagaag	aaaaaaatgt	gagtggcatc	ctgggatgag	60
cagggggaca	gacctggaca	gacacgttgt	catttctgtc	tgtgggtagg	aaaatgggag	120
taaaggagga	gaaacagata	caaaatctcc	aactcagtat	taaggtatc	tcatgcctag	180
aatattggta	gaaacaagaa	tacattcata	tggcaaataa	ctaaccatgg	tggacaacaaa	240
ttctgggatt	taagttggat	accaangaaa	ttgtattaaa	agagctgttc	atggaataag	300
a						301

<210> 306

<211> 8

<212> PRT

<213> Homo sapien

<400> 306

Val	Leu	Gly	Trp	Val	Ala	Glu	Leu
1				5			

<210> 307

<211> 637

<212> DNA

<213> Homo sapien

<400> 307

acaggggratg	aagggaaagg	gagaggatga	ggaagcccc	ctggggattt	ggtttgggtcc	60
ttgtgatcag	gtgggtctatg	gggcttatcc	ctacaaagaa	gaatccagaa	atagggggcac	120
attgaggaat	gatacttgag	cccaaagagc	attcaatcat	tgttttattt	gccttmtttt	180
cacaccattg	gtgagggagg	gattaccacc	ctgggggttat	gaagatgggt	gaacacccca	240
cacatagcac	cggagatatg	agatcaacag	tttcttagcc	atagagattc	acagcccaga	300
gcaggaggac	gcttgacac	catgcaggat	gacatggggg	atgcgctcgg	gattgggtgtg	360
aagaagcaag	gactgttaga	ggcaggcttt	atagtaacaa	gacgggtggg	caaactctga	420
tttccgtggg	ggaatgtcat	ggtcttgctt	tactaagttt	tgagactggc	aggtagtgaa	480
actcattagg	ctgagaacct	tgtggaatgc	acttgaccca	sctgatagag	gaagtagcca	540
ggtgggagcc	tttcccagtg	ggtgtgggac	atatctggca	agattttgtg	gcactcctgg	600
ttacagatac	tggggcagca	aataaaactg	aatcttg			637

<210> 308

<211> 647

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(647)

<223> n = A,T,C or G

<400> 308

acgattttca ttatcatgta aatcggtca ctcaaggggc caaccacagc tgggagccac	60
tgctcagggg aaggttcata tgggactttc tactgcccac gggtctatac aggatataaa	120
ggngcctcac agtatagatc tggtagcaaa gaagaagaaa caaacactga tctctttctg	180
ccaccctct gaccctttgg aactcctctg accctttaga acaagcctac ctaatatctg	240
ctagagaaaa gaccaacaac ggcctcaaag gatctcttac catgaaggtc tcagctaatt	300
cttggctaag atgtgggttc cacattaggt tctgaatatg gggggaagg tcaatttgct	360
cattttgtgt gtggataaag tcaggatgcc caggggccag agcagggggc tgcttgcttt	420
gggaacaatg gctgagcata taaccatagg ttatggggaa caaaacaaca tcaaagtcac	480
tgtatcaatt gccatgaaga cttgagggac ctgaatctac cgattcatct taaggcagca	540
ggaccagttt gagtggcaac aatgcagcag cagaatcaat ggaaacaaca gaatgattgc	600
aatgtccttt ttttctcct gcttctgact tgataaaagg ggaccgt	647

<210> 309

<211> 460

<212> DNA

<213> Homo sapien

<400> 309

actttatagt ttaggctgga cattggaaaa aaaaaaagc cagaacaaca tgtgatagat	60
aatatgattg gctgcacact tccagactga tgaatgatga acgtgatgga ctattgtatg	120
gagcacatct tcagcaagag ggggaaatac tcatcatitt tggccagcag ttgtttgatc	180
accaaacatc atgccagaat actcagcaaa cttcttagc tcttgagaag tcaaagtccg	240
ggggaattta ttcttgga ttttaattgg actccttatg tgagagcagc ggctaccag	300
ctggggtggt ggagcgaacc cgtcactagt ggacatgcag tggcagagct cctggttaacc	360
acctagagga atacacaggc acatgtgtga tgccaagcgt gacacctgta gcactcaaat	420
ttgtcttggt tttgtctttc ggtgtgtaag attcttaagt	460

<210> 310

<211> 539

<212> DNA

<213> Homo sapien

<400> 310

acgggactta tcaataaag ataggaaaag aagaaaactc aaatattata ggcagaaatg	60
ctaaagggtt taaaatatgt caggattgga agaaggcatg gataaagaac aaagttcagt	120
taggaaagag aaacacagaa ggaagagaca caataaaagt cattatgtat tctgtgagaa	180
gtcagacagt aagatttggt ggaatgggt tggttgttg tatggtatgt attttagcaa	240
taatctttat ggcagagaaa gctaaaatcc tttagcttgc gtgaatgatc acttgctgaa	300
ttcctcaagg taggcatgat gaaggagggt ttagaggaga cacagacaca atgaactgac	360
ctagatagaa agccttagta tactcagcta ggaatagtga ttctgagggc aactgtgac	420
atgattatgt cattacatgt atggtagtga tgggtagat aggaaggaag aacttatggc	480
atattttcac cccacaaaa gtcagttaaa tattgggaca ctaaccatcc aggtcaaga	539

<210> 311

<211> 526

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

100

<222> (1)...(526)

<223> n = A,T,C or G

<400> 311

caaatttgag ccaatgacat agaattttac aaatcaagaa gcttattctg gggccatttc	60
ttttgacgtt ttctctaaac tactaaagag gcattaatga tccataaatt atattatcta	120
catttacagc attttaaagt tggtcagcat gaaatattag ctacagggga agctaaataa	180
attaaacatg gaataaagat ttgtccttaa atataatcta caagaagact ttgatatttg	240
tttttcacaa gtgaagcatt cttataaagt gtcataacct ttttggggaa actatgggaa	300
aaaatgggga aactctgaag ggttttaagt atcttacctg aagctacaga ctccataacc	360
tctctttaca gggagctcct gcagccccta cagaaatgag tggctgagat tcttgattgc	420
acagcaagag cttctcatct aaacccttcc cctttttagt atctgtgtat caagtataaa	480
agttctataa actgtagtnt acttatttta atccccaaag cacagt	526

<210> 312

<211> 500

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(500)

<223> n = A,T,C or G

<400> 312

cctctctctc cccaccccct gactctagag aactgggttt tctcccagta ctccagcaat	60
tcattttctga aagcagttga gccactttat tccaaagtac actgcagatg ttcaaactct	120
ccattttctct ttcccctcca cctgccagtt ttgtcgactc tcaacttgct atgagtgtaa	180
gcattaagga cattatgctt cttcgattct gaagacaggc cctgctcatg gatgactctg	240
gcttcttagg aaaaatatttt tcttccaaaa tcagtaggaa atctaaactt atcccctctt	300
tgcatgtgc tagcagcttc agacatttgg ttaagaacct atgggaaaaa aaaaaatcct	360
tgtaaatgtg gtttcctttg taaaccanga ttcttatttg nctggtatag aatatcagct	420
ctgaacgtgt ggtaaagatt tttgtgttg aatataggag aaatcagttt gctgaaaagt	480
tagtcttaat tatctattgg	500

<210> 313

<211> 718

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(718)

<223> n = A,T,C or G

<400> 313

ggagatttgt gtggtttgca gccgagggag accaggaaga tctgcatggt gggaaggacc	60
tgatgataca gaggtgagaa ataagaaagg ctgctgactt taccatctga ggccacacat	120
ctgctgaaat ggagataatt aacatcacta gaaacagcaa gatgacaata taatgtctaa	180
gtagtgcacat gtttttgcac atttccagcc cttttaaata tccacacaca caggaagcac	240
aaaaggaagc acagagatcc ctgggagaaa tgcccggccg ccatcttggg tcatcgatga	300
gcctcgccct gtgcctgntc ccgcttgtga gggaaggaca ttagaaaatg aattgatgtg	360
ttccttaaag gatggcagga aaacagatcc tgttgtggat atttatttga acgggattac	420
agatttgaaa tgaagtcaca aagtgcagat taccaatgag aggaaaacag acgagaaaat	480
cttgatgggt cacaagacat gcaacaaaca aaatggaata ctgtgatgac acgagcagcc	540
aactggggag gagataccac ggggcagagg tcaggattct ggccctgctg cctaactgtg	600
cgttatacca atcatttcta tttctaccct caaacaagct gtngaataac tgacttacgg	660
ttcttntggc ccacattttc atnatccacc ccntcntttt aannttantc caaantgt	718

<210> 314
 <211> 358
 <212> DNA
 <213> Homo sapien

<400> 314
 gtttattttac attacagaaa aaacatcaag acaatgtata ctattttcaaa tatatccata 60
 cataatcaaaa tatagctgta gtacatgttt tcattgggtg agattaccac aaatgcaagg 120
 caacatgtgt agatctcttg tcttattctt ttgtctataa tactgtattg tgtagtccaa 180
 gctctcggtg gtccagccac tgtgaaacat gctcccttta gattaacctc gtggacgctc 240
 ttgttggtatt gctgaactgt agtgccctgt attttgcttc tgtctgtgaa ttctgttgct 300
 tctggggcat ttccttgtga tgcagaggac caccacacag atgacagcaa tctgaatt 358

<210> 315
 <211> 341
 <212> DNA
 <213> Homo sapien

<400> 315
 taccacctcc ccgctggcac tgatgagccg catcaccatg gtcaccagca ccatgaaggc 60
 ataggtgatg atgaggacat ggaatgggccc cccaaggatg gtctgtccaa agaagcgagt 120
 gacccccatt ctgaagatgt ctggaacctc taccagcagg atgatgatag ccccaatgac 180
 agtcaccagc tccccgacca gccggatata gtccctaggg gtcatgtagg cttcctgaag 240
 tagcttctgc tgtaagaggg tgttgtcccg ggggctcgtg cggttattgg tcctgggctt 300
 gagggggcgg tagatgcagc acatggtgaa gcagatgatg t 341

<210> 316
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 316
 agactgggca agactcttac gccccacact gcaatttggt cttgttgccg tatccattta 60
 tgtgggcctt tctcgagttt ctgattataa acaccactgg agcgaatgtg tgactggact 120
 cattcaggga gctctgggtg caatattagt t 151

<210> 317
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 317
 agaactagtg gatcctaatt aaataacctga aacatatatt ggcattttatc aatggctcaa 60
 atcttcattt atctctggcc ttaacctggg ctccctgaggc tgcggccagc agatcccagg 120
 ccagggtctt gttcttgcca cacctgcttg a 151

<210> 318
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 318
 actggtggga ggcgctgttt agttggctgt tttcagaggg gtctttcgga gggacctcct 60
 gctgcaggct ggagtgtctt tattcctggc gggagaccgc acattccact gctgaggctg 120
 tgggggcggt ttatcaggca gtgataaaca t 151

<210> 319

<211> 151
 <212> DNA
 <213> Homo sapien

<400> 319
 aactagtgga tccagagcta taggtacagt gtgatctcag ctttgcaaac acattttcta 60
 catagatagt actaggtatt aatagatatg taaagaaaga aatcacacca ttaataatgg 120
 taagattggg tttatgtgat tttagtgggt a 151

<210> 320
 <211> 150
 <212> DNA
 <213> Homo sapien

<400> 320
 aactagtgga tccactagtc cagtgtgggt gaattccatt gtgttgggt tctagatcgc 60
 gagcggctgc cttttttttt tttttttttg ggggggaatt tttttttttt aatagttatt 120
 gagtgttcta cagcttacag taaataccat 150

<210> 321
 <211> 151
 <212> DNA
 <213> Homo sapien

<400> 321
 agcaactttg tttttcatcc aggtattttt aggcttagga tttcctctca cactgcagtt 60
 tagggtggca ttgtaaccag ctatggcata ggtgttaacc aaaggctgag taaacatggg 120
 tgcctctgag aaatcaaagt cttcatacac t 151

<210> 322
 <211> 151
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(151)
 <223> n = A,T,C or G

<400> 322
 atccagcatc ttctcctggt tcttgccctc ctttttcttc ttcttasatt ctgcttgagg 60
 tttgggcttg gtcagtttgc cacagggctt ggagatgggt acagtcttct ggcattcggc 120
 attgtgcagg gctcgttca nacttcagtt t 151

<210> 323
 <211> 151
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(151)
 <223> n = A,T,C or G

<400> 323
 tgaggacttg tktttctttt ctttattttt aatcctctta ckttgtaaatt atattgccta 60
 nagactcant tactaccag tttgtggtt twtgggagaa atgtaactgg acagtttagct 120
 gttcaatyaa aaagacactt ancccatgtg g 151

<210> 324
 <211> 461
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(461)
 <223> n = A,T,C or G

<400> 324
 acctgtgtgg aatttcagct ttctcatgc aaaaggattt tgtatccccg gcctacttga 60
 agaagtggc agctaaagga atccagggtg ttggttgac tgtaataacc tttgatgaaa 120
 agagttacta cgaatcccat cttggttcca gctatatcac tgacagcatg gtagaagact 180
 gcgaacctca cttctagact ttacgggtgg gacgaaacgg gttcagaaac tgccaggggc 240
 ctcatcacagg gatatacaaaa taccctttgt gctaccagg ccctggggaa tcagggtgact 300
 cacacaaatg caatagttgg tcaactgcatt tttacctgaa ccaaagctaa acccggtgtt 360
 gccaccatgc accatggcat gccagagttc aacactgttg ctcttgaaaa ttgggtctga 420
 aaaaacgcac aagagcccct gccctgccct agctgangca c 461

<210> 325
 <211> 400
 <212> DNA
 <213> Homo sapien

<400> 325
 acactgtttc catgttatgt ttctacacat tgctacctca gtgtcctgg aaacttagct 60
 tttgatgtct ccaagtagtc caccttcatt taactctttg aaactgtatc atctttgcc 120
 agtaagagtg gtggcctatt tcagctgctt tgacaaaatg actggctcct gacttaacgt 180
 tctataaatg aatgtgctga agcaaagtgc ccatgggtggc ggcgaagaag agaaagatgt 240
 gttttgtttt ggactctctg tggctccttc caatgctgtg ggtttccaac cagggggaagg 300
 gtcctctttg cattgccaaag tgccataacc atgagcacta cgctaccatg gttctgcctc 360
 ctggccaagc aggctggttt gcaagaatga aatgaatgat 400

<210> 326
 <211> 1215
 <212> DNA
 <213> Homo sapien

<400> 326
 ggaggactgc agcccgcaact cgcagccctg gcaggcggca ctggatcatgg aaaacgaatt 60
 gttctgctcg ggcgtcctgg tgcacccgca gtgggtgctg tcagccgcac actgtttcca 120
 gaactctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccaggag 180
 ccagatggtg gaggccagcc tctcgtacg gcacccagag tacaacagac cttgtctcg 240
 taacgacctc atgctcatca agttggacga atccgtgtcc gactctgaca ccatccggag 300
 catcagcatt gcttcgcagt gccctaccgc ggggaactct tgccctgctt ctggctgggg 360
 tctgctggcg aacggcagaa tgcctaccgt gctgcagtgc gtgaacgtgt cgggtggtgc 420
 tgaggaggtc tgcagtaagc tctatgacct gctgtaccac ccagcatgt tctgcgccgg 480
 cggagggcaa gaccagaagg actcctgcaa cgggtgactct ggggggcccc tgatctgcaa 540
 cgggtacttg cagggccttg tgtctttcgg aaaagccccg tgtggccaag ttggcgtgcc 600
 aggtgtctac accaactctc gcaaattcac tgagtggata gagaaaaccg tccaggccag 660
 ttaactctgg ggactgggaa cccatgaaat tgacccccaa atacatcctg cggaaggaat 720
 tcagggaatat ctgttcccag cccctcctcc ctacaggcca ggagtccagg cccccagccc 780
 ctctccctc aaaccaaggg tacagatccc cagccctcct tccctcagac ccaggagtcc 840
 agacccccca gccctcctc cctcagacct aggagtccag cccctcctc ctacagacca 900
 ggagtccaga ccccccagcc cctcctcctc cagacccagg ggtccaggcc cccaaccct 960
 cctccctcag actcagaggt ccaagcccc aaccctcct tccccagacc cagaggtcca 1020

```

gggccagcc cctcctccct cagaccacgc ggtccaatgc cacctagact ctccctgtac 1080
acagtgcgcc cttgtggcac gttgacccaa ccttaccagt tggtttttca tttttgtcc 1140
ctttccccta gatccagaaa taaagtctaa gagaagcgca aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaaa 1215

```

```

<210> 327
<211> 220
<212> PRT
<213> Homo sapien

```

```

<400> 327
Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu Val Met
 1          5          10          15
Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
          20          25          30
Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly
          35          40          45
Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu
          50          55          60
Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu Ala
          65          70          75          80
Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp
          85          90          95
Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn
          100          105          110
Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met Pro
          115          120          125
Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val Cys
          130          135          140
Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala Gly
          145          150          155          160
Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro
          165          170          175
Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys Ala
          180          185          190
Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys
          195          200          205
Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
          210          215          220

```

```

<210> 328
<211> 234
<212> DNA
<213> Homo sapien

```

```

<400> 328
cgctcgtctc tggtagctgc agccaaatca taaacggcga ggactgcagc ccgcactcgc 60
agccctggca ggcggcactg gtcattgaaa acgaattgtt ctgctcgggc gtcctggtgc 120
atccgcagtg ggtgctgtca gccacacact gttccagaa ctccctacacc atcgggctgg 180
gcctgcacag tcttgaggcc gaccaagagc caggagacca gatggtggag gcca 234

```

```

<210> 329
<211> 77
<212> PRT
<213> Homo sapien

```

```

<400> 329
Leu Val Ser Gly Ser Cys Ser Gln Ile Ile Asn Gly Glu Asp Cys Ser

```

105

1	5	10	15
Pro His Ser Gln	Pro Trp Gln Ala	Ala Leu Val Met Glu	Asn Glu Leu
	20	25	30
Phe Cys Ser Gly	Val Leu Val His	Pro Gln Trp Val	Leu Ser Ala Thr
	35	40	45
His Cys Phe Gln	Asn Ser Tyr Thr	Ile Gly Leu Gly	Leu His Ser Leu
	50	55	60
Glu Ala Asp Gln	Glu Pro Gly Ser	Gln Met Val Glu	Ala
65	70	75	

<210> 330
 <211> 70
 <212> DNA
 <213> Homo sapien

<400> 330
 cccaacacaa tggcccgatc ccattccctga ctccgcccctc aggatcgctc gtctctggta 60
 gctgcagcca 70

<210> 331
 <211> 22
 <212> PRT
 <213> Homo sapien

<400> 331
 Gln His Asn Gly Pro Ile Pro Ser Leu Thr Pro Pro Ser Gly Ser Leu
 1 5 10 15
 Val Ser Gly Ser Cys Ser
 20

<210> 332
 <211> 2507
 <212> DNA
 <213> Homo sapien

<400> 332
 tgggtgccgct gcagccggca gagatgggtg agctcatgtt cccgctgttg ctccctccttc 60
 tgcccttcct tctgtatatg gctgcgcccc aaatcaggaa aatgctgtcc agtgggggtgt 120
 gtacatcaac tgttcagctt cctgggaaag tagttgtggt cacaggagct aatacaggta 180
 tcgggaagga gacagccaaa gagctggctc agagaggagc tcgagtatat ttagcttgcc 240
 gggatgtgga aaagggggaa ttgggtggcca aagagatcca gaccacgaca gggaaccagc 300
 aggtgttggg gcggaaaactg gacctgtctg atactaagtc tattcgagct ttgctaagg 360
 gcttccttagc tgaggaaaaag cacctccacg ttttgatcaa caatgcagga gtgatgatgt 420
 gtcogtactc gaagacagca gatggctttg agatgcacat aggagtcaac cacttgggtc 480
 acttcctcct aacctatctg ctgctagaga aactaaagga atcagcccca tcaaggatag 540
 taaatgtgtc ttccctcgca catcacctgg gaaggatcca cttccataac ctgcagggcg 600
 agaaattcta caatgcaggc ctggcctact gtcacagcaa gctagccaac atcctcttca 660
 cccaggaact ggcccggaga ctaaaaggct ctggcggttac gacgtattct gtacaccctg 720
 gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg tgggtggcttt 780
 tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac tgtgccttaa 840
 cagaaggtct tgagattcta agtgggaatc atttcagtga ctgtcatgtg gcatgggtct 900
 ctgcccgaagc tggtaatgag actatagcaa ggcggctgtg ggacgtcagt tgtgacctgc 960
 tgggcctccc aatagactaa caggcagtgc cagttggacc caagagaaga ctgcagcaga 1020
 ctacacagta cttcttgtca aaatgattct ccttcaaggt tttcaaaacc tttagcacia 1080
 agagagcaaa acctccagc cttgcctgct tgggtgtccag ttaaaactca gtgtactgcc 1140
 agattcgtct aaatgtctgt catgtccaga tttactttgc ttctgttact gccagagtta 1200
 ctagagatat cataatagga taagaagacc ctcatatgac ctgcacagct cattttcctt 1260
 ctgaaagaaa ctactaccta ggagaatcta agctatagca gggatgattt atgcaaattt 1320

gaactagctt	ctttgttcac	aattcagttc	ctcccaacca	accagtcttc	acttcaagag	1380
ggccacactg	caacctcagc	ttaacatgaa	taacaaaagac	tggctcagga	gcagggcttg	1440
cccaggcatg	gtggatcacc	ggaggtcagt	agttcaagac	cagcctggcc	aacatggtga	1500
aacccacct	ctactaaaa	ttgtgtatat	ctttgtgtgt	cttcctgttt	atgtgtgcca	1560
agggagtatt	ttcacaaagt	tcaaaacagc	cacaataatc	agagatggag	caaaccagtg	1620
ccatccagtc	tttatgcaaa	tgaaatgctg	caaaggaag	cagattctgt	atatgttgg	1680
aactaccac	caagagcaca	tgggtagcag	ggaagaagta	aaaaaagaga	aggagaatac	1740
tggaagataa	tgcacaaaat	gaagggacta	gttaaggatt	aactagccct	ttaaggatta	1800
actagttaag	gattaatagc	aaaagayatt	aaatatgcta	acatagctat	ggaggaattg	1860
agggcaagca	cccaggactg	atgaggtctt	aacaaaaacc	agtgtggcaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaatccta	aaaacaaaca	aacaaaaaaa	acaattcttc	attcagaaaa	1980
attatcttag	ggactgatat	tggttaattat	ggtcaattta	ataatatttt	ggggcatttc	2040
cttacattgt	cttgacaaga	ttaaaatgtc	tgtgccaaaa	ttttgtattt	tatttgagga	2100
cttcctatca	aaagtaatgc	tgccaaagga	agtctaagga	attagtagtg	ttcccatcac	2160
ttgtttggag	tgtgctattc	taaaagattt	tgatttcctg	gaatgacaat	tatatatttaa	2220
ctttggtggg	ggaaagagtt	ataggaccac	agtcttcact	tctgatactt	gtaaattaat	2280
cttttattgc	acttggtttg	accattaagc	tatatgttta	gaaatgggtca	ttttacggaa	2340
aaattagaaa	aattctgata	atagtgcaga	ataaatgaat	taatgtttta	cttaatttat	2400
attgaactgt	caatgacaaa	taaaaattct	ttttgattat	ttttgtttt	catttaccag	2460
aataaaaacg	taagaattaa	aagtttgatt	acaaaaaaa	aaaaaaa		2507

<210> 333

<211> 3030

<212> DNA

<213> Homo sapien

<400> 333

gcaggcgact	tgcgagctgg	gagcgattta	aaacgctttg	gattcccccg	gcctgggtgg	60
ggagagcgag	ctgggtgccc	cctagattcc	ccgccccgc	acctcatgag	ccgaccctcg	120
gctccatgga	gcccggcaat	tatgccacct	tgatggagc	caaggatata	gaaggcttgc	180
tgggagcggg	agggggcg	aatctggtcg	ccactcccc	tctgaccagc	caccagcgg	240
cgctacgct	gagcctgct	gtcaactatg	ccccttgga	tctgccaggc	tcggcggagc	300
cgccaaagca	atgccacca	tgccctgggg	tgccccagg	gacgtcccca	gctccgtgc	360
cttatggtta	ctttggaggc	gggtactact	cctgccgagt	gtcccgagc	tcgctgaaac	420
cctgtgccc	ggcagccacc	ctggccgct	accgccgga	gactccacg	gccggggaag	480
agtacccag	ycgcccact	gagtttgct	tctatccgg	atatccggga	acctaccagc	540
ctatggccag	ttacctggac	gtgtctgtgg	tgcagactct	gggtgctcct	ggagaaccgc	600
gacatgactc	cctgttgct	gtggacagtt	accagtcttg	ggctctcgct	ggtggctgga	660
acagccagat	gtgttgccag	ggagaacaga	accaccagg	tcccttttg	aaggcagcat	720
ttgcagactc	cagcgggcag	caccctcctg	acgcctgcgc	ctttcgtcgc	ggccgcaaga	780
aacgcattcc	gtacagcaag	gggcagttgc	gggagctgga	gcgggagtat	gcggctaaca	840
agttcatcac	caaggacaag	aggcgcaaga	tctcgcgagc	caccagcctc	tcggagcgcc	900
agattaccat	ctggtttcag	aaccgcccgg	tcaaagagaa	gaaggttctc	gccaaggtga	960
agaacagcgc	tacccttaa	gagatctcct	tgctgggtg	ggaggagcga	aagtgggggt	1020
gtcctgggga	gaccaggaac	ctgccaagcc	caggctggg	ccaaggactc	tgctgagagg	1080
cccctagaga	caacaccctt	cccaggccac	tggtgctgg	actgttcctc	aggagcggcc	1140
tgggtaccca	gtatgtgcag	ggagacggaa	cccattgtga	cagcccactc	caccagggtt	1200
cccaagaac	ctggcccagt	cataatcatt	cctcctgaca	gtggcaataa	tcacgataac	1260
cagtactagc	tgccatgac	gttagcctca	tattttctat	ctagagctct	gtagagcact	1320
ttagaaaccg	ctttcatgaa	ttgagctaata	tatgaataaa	tttgaaggc	gatccctttg	1380
caggggaagct	ttctctcaga	cccccttcca	ttacacctct	caccctggta	acagcaggaa	1440
gactgaggag	aggggaacgg	gcagattcgt	tgtgtggctg	tgatgtccgt	ttagcatttt	1500
tctcagctga	cagctgggta	ggtggacaat	tgtagaggct	gtctcttctc	ccctccttgt	1560
ccacccata	gggtgtacct	actggtcttg	gaagcaccga	tccttaatac	gatgattttt	1620
ctgtcgtgtg	aaaatgaagc	cagcaggctg	ccctagtca	gtccttctct	ccagagaaaa	1680
agagatttga	gaaagtgcct	gggtaattca	ccattaattt	cctcccccaa	actctctgag	1740
tcttccctta	atatttctgg	tggttctgac	caaagcagg	catggtttgt	tgagcatttt	1800
ggatcccagt	gaagtagatg	tttgtagcct	tgcatactta	gccccttcca	ggcacaacg	1860

gagtggcaga	gtggtgccaa	ccctgttttc	ccagtccacg	tagacagatt	cacagtgcgg	1920
aattctggaa	gctggagaca	gacgggctct	ttgcagagcc	gggactctga	gagggacatg	1980
agggcctctg	cctctgtgtt	cattctctga	tgtcctgtac	ctgggctcag	tgcccggtgg	2040
gactcatctc	ctggccgcgc	agcaaagcca	gcgggttcgt	gctggctcctt	cctgcacctt	2100
aggctggggg	tggggggcct	gccggcgcat	tctccacgat	tgagcgcaca	ggcctgaagt	2160
ctggacaacc	cgagaaccg	aagctccgag	cagcgggtcg	gtggcgagta	gtggggtcgg	2220
tggcgagcag	ttggtggtgg	gccgcggccg	ccactacctc	gaggacattt	ccctcccga	2280
gccagctctc	ctagaaaccc	cgcgcgggcc	gccgcagcca	agtgtttatg	gcccgcggtc	2340
gggtgggatc	ctagccctgt	ctcctctcct	gggaaggagt	gagggtgga	cgtgacttag	2400
acacctacaa	atctattttac	caaagaggag	cccgggactg	agggaaaagg	ccaaagagt	2460
tgagtgcatt	cggactgggg	gttcagggga	agaggacgag	gaggaggaag	atgaggtcga	2520
tttctgtatt	taaaaaatcg	tccaagcccc	gtggtccagc	ttaaggctct	cggttacatg	2580
cgccgctcag	agcaggtcac	tttctgcctt	ccacgtcctc	cttcaaggaa	gccccatgtg	2640
ggtagctttc	aatatcgag	tttcttactc	ctctgcctct	ataagctcaa	acccaccaac	2700
gatcgggcaa	gtaaaccccc	tccctcgccg	acttcggaac	tggcgagagt	tcagcgagca	2760
tgggcctgtg	gggagggggc	aagatagatg	agggggagcg	gcatggtgcg	gggtgacccc	2820
ttggagagag	gaaaaaggcc	acaagagggg	ctgccaccgc	cactaacgga	gatggccctg	2880
gtagagacct	ttgggggtct	ggaacctctg	gactcccat	gctctaactc	ccacactctg	2940
ctatcagaaa	cttaaaactt	aggattttct	ctgtttttca	ctcgcaataa	aytcagagca	3000
aacaaaaaaa	aaaaaaaaaa	aaaactcgag				3030

<210> 334
 <211> 2417
 <212> DNA
 <213> Homo sapien

<400> 334						
ggcgccgct	ctagagctag	tgggatcccc	cgggctgcac	gaattcggca	cgagtgaagt	60
ggagttttac	ctgtattgtt	ttaatttcaa	caagcctgag	gactagccac	aatgtaccc	120
agtttacaaa	tgaggaaaca	ggtgcaaaaa	ggttggtacc	tgtcaaagg	cgtatgtggc	180
agagccaaga	tttgagccca	gttatgtctg	atgaacttag	cctatgctct	ttaaacttct	240
gaatgctgac	cattgaggat	atctaaactt	agatcaattg	cattttccct	ccaagactat	300
ttactttatc	atacaataat	accaccttta	ccaatctatt	gttttgatac	gagactcaaa	360
tatgccagat	atatgtaaaa	gcaacctaca	agctctctaa	tcatgctcac	ctaaaagatt	420
cccgggatct	aataggctca	aagaaacttc	ttctagaaat	ataaaagaga	aaattggatt	480
atgcaaaaat	tcattattaa	tttttttcat	ccatccttta	attcagcaaa	catttatctg	540
ttgttgactt	tatgcagtat	ggccttttaa	ggattggggg	acagggtgaag	aacgggggtgc	600
cagaatgcat	cctcctacta	atgaggtcag	tacacatttg	cattttaaaa	tgccctgtcc	660
agctgggcat	ggtggatcat	gcctgtaatc	tcaacatttg	aaggccaagg	caggaggatt	720
gcttcagccc	aggagttcaa	gaccagcctg	ggcaacatag	aaagaccca	tctctcaatc	780
aatcaatcaa	tgccctgtct	ttgaaaataa	aactccttaa	gaaaggttta	atgggcaggg	840
tgtggtagct	catgcctata	atacagcact	ttgggaggct	gaggcaggag	gatcacttta	900
gccagaagt	tcaagaccag	cctgggcaac	aagtgcaccc	tcactctcaat	tttttaataa	960
aatgaataca	tacataagga	aagataaaaa	gaaaagttta	atgaaagaat	acagtataaa	1020
acaaatctct	tggacctaaa	agtatttttg	ttcaagccaa	atattgtgaa	tcacctctct	1080
gtgttgagga	tacagaatat	ctaagcccag	gaaactgagc	agaaagttca	tgtactaact	1140
aatcaaccog	aggcaaggca	aaaatgagac	taactaatca	atccgaggca	aggggcaaat	1200
tagacggaac	ctgactctgg	tctattaagc	gacaactttc	cctctgttgt	atttttcttt	1260
tattcaatgt	aaaaggataa	aaactctcta	aaactaaaaa	caatgtttgt	caggagttac	1320
aaaccatgac	caactaatta	tggggaatca	taaaatatga	ctgtatgaga	tottgatggg	1380
ttacaagtgt	taccactgtt	taatcacttt	aaacattaat	gaacttaaaa	atgaatttca	1440
ggagatttga	atgtttcttt	cctgttgat	tagttggctc	aggctgccat	aacaaaatac	1500
cacagactgg	gaggcttaag	taacagaaat	tcattttctca	cagttctggg	ggctggaagt	1560
ccacgatcaa	ggtgcaggaa	aggcaggctt	cattctgagg	cccctctctt	ggctcacatg	1620
tggccaccct	cccactgcgt	gctcacatga	cctctttgtg	ctcctggaaa	gaggggtgtg	1680
gggacagagg	gaaagagaag	gagagggaa	tctctgggtg	ctcgtctttc	aaggacccta	1740
acctgggcca	ctttggccca	ggcactgtgg	ggtggggggg	tgtggctgct	ctgctctgag	1800
tggccaagat	aaagcaacag	aaaaatgtcc	aaagctgtgc	agcaaagaca	agccaccgaa	1860

cagggatctg	ctcatcagtg	tggggacctc	caagtcggcc	accctggagg	caagccccc	1920
cagagcccat	gcaaggtggc	agcagcagaa	gaagggaatt	gtccctgtcc	ttggcacatt	1980
cctcacccgac	ctggtgatgc	tggacactgc	gatgaatggg	aatgtggatg	agaatatgat	2040
ggactcccag	aaaaggagac	ccagctgtc	aggtggctgc	aaatcattac	agccttcac	2100
ctggggagga	actggggggc	tggttctggg	tcagagagca	gcccagtgag	ggtgagagct	2160
acagcctgtc	ctgccagctg	gatccccagt	ccgggtcaac	cagtaatcaa	ggctgagcag	2220
atcaggcttc	ccggagctgg	tcttgggaag	ccagccctgg	ggtgagttgg	ctcctgtgt	2280
ggtactgaga	caatattgtc	ataaattcaa	tgcgcccttg	tatccctttt	tcttttttat	2340
ctgtctacat	ctataatcac	tatgcatact	agtctttgtt	agtgtttcta	ttcmacttaa	2400
tagagatatg	ttatact					2417

<210> 335

<211> 2984

<212> DNA

<213> Homo sapien

<400> 335

atccctcctt	ccccactctc	ctttccagaa	ggcacttggg	gtcttatctg	ttggactctg	60
aaaacacttc	aggcgccctt	ccaaggcttc	cccaaacccc	taagcagccg	cagaagcgct	120
cccagctgc	cttctccac	actcaggtga	tcgagttgga	gaggaagttc	agccatcaga	180
agtacctgtc	ggccccgaa	cgggcccacc	tggccaagaa	cctcaagctc	acggagaccc	240
aagtgaagat	atggttccag	aacagacgct	ataagactaa	gcgaaagcag	ctctcctcgg	300
agctgggaga	cttgagagaag	cactcctctt	tgccggccct	gaaagaggag	gccttctccc	360
gggcctccct	ggtctccgtg	tataacagct	atccttacta	cccatacctg	tactgcgtgg	420
gcagctggag	cccagctttt	tggtaatgcc	agctcaggtg	acaaccatta	tgatcaaaaa	480
ctgccttccc	caggtgtgtc	ctatgaaaag	cacaaggggc	caaggtcagg	gagcaagagg	540
tgtgcacacc	aaagctattg	gagatttgog	tggaaatctc	asattcttca	ctggtgagac	600
aatgaaacaa	cagagacagt	gaaagtttta	atacctaagt	cattccccca	gtgcatactg	660
taggtcattt	tttttgcttc	tggctacctg	tttgaagggg	agagagggaa	aatcaagtgg	720
tattttccag	cactttgtat	gattttggat	gagctgtaca	cccaaggatt	ctgttctgca	780
actccatcct	cctgtgtcac	tgaatatcaa	ctctgaaaga	gcaaacctaa	caggagaaaag	840
gcaaacagg	atgaggatgt	caccaactga	attaaactta	agtccagaag	cctcctgttg	900
gccttggaa	atggccaagg	ctctctctgt	ccctgtaaaa	gagaggggca	aatagagagt	960
ctccaagaga	acgccctcat	gctcagcaca	tattttgcac	ggagggggag	atgggtggga	1020
ggagatgaaa	atatcagctt	ttcttattcc	tttttattcc	ttttaaaatg	gtatgccaac	1080
ttaagtattt	acaggtggc	ccaaatagaa	caagatgcac	tcgctgtgat	tttaagacaa	1140
gctgtataaa	cagaactcca	ctgcaagagg	gggggcccgg	ccaggagaat	ctcgcgttgt	1200
ccaagacagg	ggcctaagga	gggtctccac	actgctgcta	gggctgttg	cattttttta	1260
ttagtagaaa	gtggaaaggc	ctcttctcaa	cttttttccc	ttgggctgga	gaatttagaa	1320
tcagaagtgt	cctggagttt	tcaggctatc	atatatactg	tatcctgaaa	ggcaacataa	1380
ttcttccttc	cctcctttta	aaattttgtg	ttcctttttg	cagcaattac	tcactaaagg	1440
gcttcatttt	agtccagatt	tttagtctgg	ctgcacctaa	cttatgcctc	gcttatttag	1500
cccagatctt	ggtctttttt	tttttttttt	tttttccgtc	tccccaaagc	tttatctgtc	1560
ttgacttttt	aaaaaagttt	gggggcagat	tctgaattgg	ctaaaagaca	tgcattttta	1620
aaactagcaa	ctcttatttc	tttcctttta	aaatacatag	cattaaatcc	caaatcctat	1680
ttaaagacct	gacagcttga	gaaggtcact	actgcattta	taggaccttc	tgggtggttct	1740
gctgttacgt	ttgaagtctg	acaatccttg	agaatctttg	catgcagagg	aggtaagagg	1800
tattggattt	tcacagagga	agaacacagc	gcagaatgaa	gggccaggct	tactgagctg	1860
tccagtgagg	ggctcatggg	tgggacatgg	tgggaaaggc	agcctaggcc	ctggggagcc	1920
cagtccactg	agcaagcaag	ggactgagtg	agccttttgc	aggaaaaggc	taagaaaaag	1980
gaaaaccatt	ctaaaacaca	acaagaaact	gtccaaatgc	tttggaact	gtgtttattg	2040
cctataatgg	gtccccaaaa	tgggtaacct	agacttcaga	gagaatgagc	agagagcaaa	2100
ggagaaatct	ggctgtcctt	ccattttcat	tctgttatct	caggtgagct	ggtagagggg	2160
agacattaga	aaaaaatgaa	acaacaaaac	aattactaat	gaggtacgct	gaggcctggg	2220
agtctcttga	ctccactact	taattccgtt	tagtgagaaa	cctttcaatt	ttcttttatt	2280
agaagggcca	gcttactgtt	ggtggcaaaa	ttgccacat	aagttaatag	aaagttggcc	2340
aatttcaccc	cattttctgt	ggtttgggct	ccacattgca	atgttcaatg	ccacgtgctg	2400
ctgacaccga	ccggagtact	agccagcaca	aaaggcaggg	tagcctgaat	tgctttctgc	2460

```

tctttacatt tcttttaaaa taagcattta gtgctcagtc cctactgagt actctttctc 2520
tcccctctc tgaatttaat tctttcaact tgcaatttgc aaggattaca catttcactg 2580
tgatgtatat tgtgttgcaa aaaaaaaaaa aagtgtcttt gtttaaaatt acttggtttg 2640
tgaatccatc ttgctttttc cccatttgaa ctagtcatta acccatctct gaactggtag 2700
aaaaacatct gaagagctag tctatcagca tctgacaggt gaattggatg gttctcagaa 2760
ccatttcacc cagacagcct gtttctatcc tgtttaataa attagtttgg gttctctaca 2820
tgcataacaa accctgctcc aatctgtcac ataaaagtct gtgacttgaa gtttagtcag 2880
caccgccacc aaactttatt tttctatgtg ttttttgcaa catatgagtg ttttgaaaat 2940
aaagtaccca tgtctttatt agaaaaaaaa aaaaaaaaaa aaaa 2984

```

<210> 336
 <211> 147
 <212> PRT
 <213> Homo sapien

<400> 336

Pro	Ser	Phe	Pro	Thr	Leu	Leu	Ser	Arg	Arg	His	Leu	Gly	Ser	Tyr	Leu
1				5					10					15	
Leu	Asp	Ser	Glu	Asn	Thr	Ser	Gly	Ala	Leu	Pro	Arg	Leu	Pro	Gln	Thr
	20						25					30			
Pro	Lys	Gln	Pro	Gln	Lys	Arg	Ser	Arg	Ala	Ala	Phe	Ser	His	Thr	Gln
	35					40					45				
Val	Ile	Glu	Leu	Glu	Arg	Lys	Phe	Ser	His	Gln	Lys	Tyr	Leu	Ser	Ala
	50					55				60					
Pro	Glu	Arg	Ala	His	Leu	Ala	Lys	Asn	Leu	Lys	Leu	Thr	Glu	Thr	Gln
65				70					75					80	
Val	Lys	Ile	Trp	Phe	Gln	Asn	Arg	Arg	Tyr	Lys	Thr	Lys	Arg	Lys	Gln
			85					90					95		
Leu	Ser	Ser	Glu	Leu	Gly	Asp	Leu	Glu	Lys	His	Ser	Ser	Leu	Pro	Ala
			100				105						110		
Leu	Lys	Glu	Glu	Ala	Phe	Ser	Arg	Ala	Ser	Leu	Val	Ser	Val	Tyr	Asn
	115					120					125				
Ser	Tyr	Pro	Tyr	Tyr	Pro	Tyr	Leu	Tyr	Cys	Val	Gly	Ser	Trp	Ser	Pro
	130					135					140				
Ala	Phe	Trp													
145															

<210> 337
 <211> 9
 <212> PRT
 <213> Homo sapien

<400> 337

Ala	Leu	Thr	Gly	Phe	Thr	Phe	Ser	Ala
1				5				

<210> 338
 <211> 9
 <212> PRT
 <213> Homo sapien

<400> 338

Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile
1				5				

<210> 339
 <211> 318

<212> PRT

<213> Homo sapien

<400> 339

Met Val Glu Leu Met Phe Pro Leu Leu Leu Leu Leu Leu Pro Phe Leu
 1 5 10 15
 Leu Tyr Met Ala Ala Pro Gln Ile Arg Lys Met Leu Ser Ser Gly Val
 20 25 30
 Cys Thr Ser Thr Val Gln Leu Pro Gly Lys Val Val Val Val Thr Gly
 35 40 45
 Ala Asn Thr Gly Ile Gly Lys Glu Thr Ala Lys Glu Leu Ala Gln Arg
 50 55 60
 Gly Ala Arg Val Tyr Leu Ala Cys Arg Asp Val Glu Lys Gly Glu Leu
 65 70 75 80
 Val Ala Lys Glu Ile Gln Thr Thr Thr Gly Asn Gln Gln Val Leu Val
 85 90 95
 Arg Lys Leu Asp Leu Ser Asp Thr Lys Ser Ile Arg Ala Phe Ala Lys
 100 105 110
 Gly Phe Leu Ala Glu Glu Lys His Leu His Val Leu Ile Asn Asn Ala
 115 120 125
 Gly Val Met Met Cys Pro Tyr Ser Lys Thr Ala Asp Gly Phe Glu Met
 130 135 140
 His Ile Gly Val Asn His Leu Gly His Phe Leu Leu Thr His Leu Leu
 145 150 155 160
 Leu Glu Lys Leu Lys Glu Ser Ala Pro Ser Arg Ile Val Asn Val Ser
 165 170 175
 Ser Leu Ala His His Leu Gly Arg Ile His Phe His Asn Leu Gln Gly
 180 185 190
 Glu Lys Phe Tyr Asn Ala Gly Leu Ala Tyr Cys His Ser Lys Leu Ala
 195 200 205
 Asn Ile Leu Phe Thr Gln Glu Leu Ala Arg Arg Leu Lys Gly Ser Gly
 210 215 220
 Val Thr Thr Tyr Ser Val His Pro Gly Thr Val Gln Ser Glu Leu Val
 225 230 235 240
 Arg His Ser Ser Phe Met Arg Trp Met Trp Trp Leu Phe Ser Phe Phe
 245 250 255
 Ile Lys Thr Pro Gln Gln Gly Ala Gln Thr Ser Leu His Cys Ala Leu
 260 265 270
 Thr Glu Gly Leu Glu Ile Leu Ser Gly Asn His Phe Ser Asp Cys His
 275 280 285
 Val Ala Trp Val Ser Ala Gln Ala Arg Asn Glu Thr Ile Ala Arg Arg
 290 295 300
 Leu Trp Asp Val Ser Cys Asp Leu Leu Gly Leu Pro Ile Asp
 305 310 315

<210> 340

<211> 483

<212> DNA

<213> Homo sapien

<400> 340

gccgaggtct gccttcacac ggaggacacg agactgcttc ctcaagggt cctgcctgcc 60
 tggacactgg tgggaggcgc tggttagttg gctgttttca gaggggtctt tcggagggac 120
 ctctgtctgc aggctggagt gtctttattc ctggcgggag accgcacatt ccaactgtga 180
 ggttggtggg gcggtttatc aggcagtgat aaacataaga tgtcatttcc ttgactccgg 240
 ccttcaattt tctctttggc tgacgacgga gtccgtggtg tccgatgta actgaccct 300
 gctccaaacg tgacatcact gatgctcttc tcgggggtgc tgatggcccg cttggtcacg 360
 tgctcaatct cgccattcga ctcttgctcc aaactgtatg aagacacctg actgcacgtt 420

ttttctgggc ttccagaatt taaagtgaaa ggcagcactc ctaagctccg actccgatgc 480
ctg 483

<210> 341
<211> 344
<212> DNA
<213> Homo sapien

<400> 341
ctgctgctga gtcacagatt tcattataaa tagcctccct aaggaaaata cactgaatgc 60
tatttttact aaccattcta tttttataga aatagctgag agtttctaaa ccaactctct 120
gctgccttac aagtattaaa tatttttactt ctttccataa agagtagctc aaaatatgca 180
attaatttaa taattttctga tgatggtttt atctgcagta atatgtatat catctattag 240
aatttactta atgaaaaact gaagagaaca aaatttgtaa ccactagcac ttaagtactc 300
ctgattctta acattgtctt taatgaccac aagacaacca acag 344

<210> 342
<211> 592
<212> DNA
<213> Homo sapien

<400> 342
acagcaaaaa agaaactgag aagcccaaty tgctttcttg ttaacatcca cttatccaac 60
caatgtggaa acttcttata cttggttcca ttatgaagtt ggacaattgc tgctatcaca 120
cctggcaggt aaaccaatgc caagagagt atggaaacca ttggcaagac tttgttgatg 180
accaggattg gaattttata aaaatattgt tgatgggaag ttgctaaagg gtgaattact 240
tccctcagaa gagtgtaaag aaaagtcaga gatgctataa tagcagctat ttaattggc 300
aagtgccact gtggaaagag ttcctgtgtg tgctgaagtt ctgaagggca gtcaaattca 360
tcagcatggg ctggttggtg caaatgcaaa agcacaggctc tttttagcat gctggtctct 420
cccgtgtcct tatgcaata atcgtcttct tctaaatttc tcttaggctt cattttccaa 480
agttcttctt gggttgatgt gtcttttctg ctttccatta attctataaa atagtatggc 540
ttcagccacc cactcttcgc cttagcttga ccgtgagctc cggtgccgc tg 592

<210> 343
<211> 382
<212> DNA
<213> Homo sapien

<400> 343
ttcttgacct cctcctcctt caagctcaaa caccacctcc cttattcagg accggcactt 60
cttaatgttt gtggctttct ctccagcctc tcttaggagg ggtaatggtg gagttggcat 120
cttgtaactc tcctttctcc tttcttcccc tttctctgcc cgcctttccc atcctgctgt 180
agacttcttg attgtcagtc tgtgtcacat ccagtgattg ttttggtttc tgttcccttt 240
ctgactgcc aaggggctca gaacccagc aatcccttcc tttcactacc ttcttttttg 300
gggtagttg gaagggactg aaattgtggg ggggaaggtag gaggcacatc aataaagagg 360
aaaccaccaa gctgaaaaaa aa 382

<210> 344
<211> 536
<212> DNA
<213> Homo sapien

<400> 344
ctgggcctga agctgtagg taaatcagag gcaggcttct gagtgatgag agtcctgaga 60
caataggcca cataaacttg gctggatgga acctcacaat aagggtgtca cctcttgttt 120
gtttaggggg atgccaagga taaggccagc tcagttatat gaagagaagc agaacaaaca 180
agtctttcag agaaatggat gcaatcagag tgggatcccg gtcacatcaa ggtcacactc 240
caccttcatg tgctgaatg gttgccaggt cagaaaaatc cacccttac gaggcggtct 300

tcgaccctat atcccccgcc cgcgtccctt tctccataaa attcttctta gtagctatta	360
ccttcttatt atttgatcta gaaattgcc tccttttacc cctaccatga gccctacaaa	420
caactaacct gccactaata gttatgtcat ccctcttatt aatcatcatc ctagccctaa	480
gtctggccta tgagtgacta caaaaaggat tagactgagc cgaataacaa aaaaaa	536

<210> 345
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 345	
accttttgag gtctctctca ccacctccac agccaccgtc accgtgggat gtgctggatg	60
tgaatgaagc ccccatcttt gtgcctctcg aaaagagagt ggaagtgtcc gaggactttg	120
gcgtgggcca ggaaatcaca tcctacactg cccaggagcc agacacattt atggaacaga	180
aaataacata tcggatttgg agagacactg ccaactggct ggagattaat ccggacactg	240
gtgccatttc c	251

<210> 346
 <211> 282
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(282)
 <223> n = A,T,C or G

<400> 346	
cgctgtctctg aactgtgat catgacaggg gttcaaacag aaagtgcctg ggccctcctt	60
ctaagtcttg ttacaaaaaa aaggaaaaag aaaagatctt ctgagttaca aattctggga	120
agggagacta tacctggctc ttgccctaag tgagaggtct tccctcccgc accaaaaaat	180
agaaaggctt tctatttcac tggcccaggt agggggaagg agagtaactt tgagtctgtg	240
ggtctcattt cccaagggtgc ctccaatgct catnaaaacc aa	282

<210> 347
 <211> 201
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(201)
 <223> n = A,T,C or G

<400> 347	
acacacataa tattataaaa tgccatctaa ttggaaggag ctttctatca ttgcaagtca	60
taaatataac ttttaaaana ntactancag cttttacctt ngctcctaaa tgcttgtaaa	120
tctgagactg actggaccba cccagaccba gggcaaagat acatgttacc atatcatctt	180
tataaagaat ttttttttgt c	201

<210> 348
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 348	
ctgttaatca caacatttgt gcatcacttg tgccaagtga gaaaatgttc taaaatcaca	60
agagagaaca gtgccagaat gaaactgacc ctaagtccca ggtgcccctg ggcaggcaga	120

aggagacact	cccagcatgg	aggaggggtt	atcttttcat	cctaggtcag	gtctacaatg	180
ggggaagggt	ttattataga	actcccaaca	gccacactca	ctcctgccac	ccacccgatg	240
gccctgcctc	c					251

<210> 349
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 349						
taaaaatcaa	gccatttaat	tgtatctttg	aaggtaaaca	atatatggga	gctggatcac	60
aacccctgag	gatgccagag	ctatgggtcc	agaacatggg	gtggatttat	caacagagtt	120
cagaagggtc	tgaactctac	gtgttaccag	agaacataat	gcaattcatg	cattccactt	180
agcaattttg	taaaatacca	gaaacagacc	ccaagagtc	ttcaagatga	ggaaaattca	240
actcctggtt	t					251

<210> 350
 <211> 908
 <212> DNA
 <213> Homo sapien

<400> 350						
ctggacactt	tgcgagggct	tttgctggct	gctgctgctg	cccgatcatgc	tactcatcgt	60
agcccgcccg	gtgaagctcg	ctgctttccc	tacctcctta	agtgactgcc	aaacgcccac	120
cggctggaat	tgctctgggt	atgatgacag	agaaaatgat	ctcttcctct	gtgacaccaa	180
cacctgtaaa	tttgatgggg	aatgtttaag	aattggagac	actgtgactt	gcgtctgtca	240
gttcaagtgc	aacaatgact	atgtgcctgt	gtgtgggtcc	aatggggaga	gctaccagaa	300
tgagtgttac	ctgcgacagg	ctgcatgcaa	acagcagagt	gagatacttg	tggtgtcaga	360
aggatcatgt	gccacagtc	atgaaggctc	tgagaaaact	agtcaaaagg	agacatccac	420
ctgtgatatt	tgccagtttg	gtgcagaatg	tgacgaagat	gccgaggatg	tctgggtgtg	480
gtgtaaatatt	gactgtttct	aaaccaactt	caatcccctc	tgcgcttctg	atgggaaatc	540
ttatgataat	gcatgccaaa	tcaaagaagc	atcgtgtcag	aaacaggaga	aaattgaagt	600
catgtctttg	ggtcgatgtc	aagataacac	aactacaact	actaagtctg	aagatgggca	660
ttatgcaaga	acagattatg	cagagaatgc	taacaaatta	gaagaaaagt	ccagagaaca	720
ccacatacct	tgtccggaac	attacaatgg	cttctgcatg	catgggaagt	gtgagcattc	780
tatcaatatg	caggagccat	cttgaggtg	tgatgctggt	tatactggac	aacactgtga	840
aaaaaaggac	tacagtgttc	tatacgttgt	tcccggtcct	gtacgatttc	agtatgtctt	900
aatcgag						908

<210> 351
 <211> 472
 <212> DNA
 <213> Homo sapien

<400> 351						
ccagttattt	gcaagtggta	agagcctatt	taccataaat	aatactaaga	accaactcaa	60
gtcaaacctt	aatgccattg	ttattgtgaa	ttaggattaa	gtagtaattt	tcaaaattca	120
cattaacttg	atttttaa	cagwtttgyg	agtcatttac	cacaagctaa	atgtgtacac	180
tatgataaaa	acaaccattg	tattcctgtt	tttctaaaca	gtcctaattt	ctaacactgt	240
atatatcctt	cgacatcaat	gaactttgtt	ttcttttact	ccagtaataa	agtaggcaca	300
gatctgtcca	caacaaaactt	gccctctcat	gccttgctc	tcaccatgct	ctgctccagg	360
tcagccccct	tttgccctgt	ttgttttgtc	aaaaacctaa	tctgcttctt	gcttttcttg	420
gtaatatata	tttaggggaag	atgttgcttt	gccacacac	gaagcaaagt	aa	472

<210> 352
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 352
 ctcaaagcta atctctcggg aatcaaacca gaaaagggca aggatcttag gcatgggtga 60
 tgtggataag gccagggtcaa tggctgcaag catgcagaga aagagggtaca tcggagcggtg 120
 caggctgcgt tccgtcctta cgatgaagac cacgatgcag tttccaaaca ttgccactac 180
 atacatggaa aggaggggga agccaaccca gaaatgggct ttctctaatac ctgggataacc 240
 aataagcaca a 251

<210> 353
 <211> 436
 <212> DNA
 <213> Homo sapien

<400> 353
 tttttttttt tttttttttt ttttttacaa caatgcagtc atttatttat tgagtatgtg 60
 cacattatgg tattattact atactgatta tttttatcat gtgacttcta attaraaaat 120
 gtatccaaaa gcaaaacagc agatatacaa aattaaagag acagaagata gacattaaca 180
 gataaggcaa cttatacatt gacaatccaa atccaatata tttaaacatt tgggaaatga 240
 gggggacaaa tggaagccar atcaaatttg tgtaaaacta ttcagtatgt ttcccttgct 300
 tcatgtctga raaggctctc ccttcaatgg ggatgacaaa ctccaaatgc cacacaaatg 360
 ttaacagaat actagattca cactggaacg ggggtaaaga agaaattatt ttctataaaa 420
 gggctcctaa tgtagt 436

<210> 354
 <211> 854
 <212> DNA
 <213> Homo sapien

<400> 354
 ccttttctag ttcaccagtt ttctgcaagg atgctggtta gggagtgtct gcaggaggag 60
 caagtctgaa accaaatcta ggaaacatag gaaacgagcc aggcacaggg ctggtggggc 120
 atcagggacc accctttggg ttgatatttt gcttaatctg catcttttga gtaagatcat 180
 ctggcagtag aagctgttct ccaggtagat ttctctagct catgtacaaa aacatcctga 240
 aggactttgt cagggtgcctt gctaaaagcc agatgcgttc ggcacttcct tggctgaggg 300
 ttaattgcac acctacaggc actgggctca tgctttcaag tattttgtcc tcaactttagg 360
 gtgagtgaag gatccccatt ataggagcac ttgggagaga tcatataaaa gctgactctt 420
 gagtacatgc agtaatgggg tagatgtgtg tgggtgtgtc tcatctctgc aagggtgctt 480
 gttaggaggat gtttccagga ggaacaagtc tgaaccaaata catgaaataa atggtagggtg 540
 tgaactggaa aactaattca aaagagagat cgtgatatca gtgtggttga tacaccttgg 600
 caatatggaa ggctctaatt tgcccatatt tgaaataata attcagcttt ttgtaataca 660
 aaataacaaa ggattgagaa tcatgtgtgc taatgtataa aagaccagc aaacataaat 720
 atatcaactg cataaatgta aaatgcatgt gacccaagaa ggccccaag tggcagacaa 780
 cattgtaccc attttccctt ccaaaatgtg agcggcgggc ctgctgcttt caaggctgtc 840
 acacgggatg tcag 854

<210> 355
 <211> 676
 <212> DNA
 <213> Homo sapien

<400> 355
 gaaattaagt atgagctaaa ttccctgtta aaacctctag ggggtgacaga tctcttcaac 60
 cagggtcaaa ctgatctttc tggaatgtca ccaaccaagg gcctatatatt atcaaaaagcc 120
 atccacaagt catacctgga tgtcagcgaa gagggcacgg aggcagcagc agccactggg 180
 gacagcagtg ctgtaaaaag cctaccaatg agagctcagt tcaaggcgaa ccacccttc 240
 ctgttcttta taaggcacac tcataccaac acgatcctat tctgtggcaa gcttgctct 300
 ccctaatacag atgggggttg gtaaggctca gagttgcaga tgagggtcag agacaatcct 360
 gtgactttcc cacggccaaa aagctgttca cacctcacgc acctctgtgc ctcagtttgc 420

tcacatctgcaa	aataggtcta	ggattttcttc	caaccatttc	atgagttgtg	aagctaaggc	480
tttggttaatc	atggaaaaag	gtagacttat	gcagaaagcc	tttctggctt	tcttatctgt	540
ggtgtctcat	ttgagtgtg	tccagtgcac	tgatcaagtc	aatgagtaaa	attttaaggg	600
attagatttt	cttgacttgt	atgtatctgt	gagatcttga	ataagtgacc	tgacatctct	660
gcttaaagaa	aaccag					676

<210> 356
 <211> 574
 <212> DNA
 <213> Homo sapien

<400> 356						
tttttttttt	tttttcagga	aaacattctc	ttactttatt	tgcatctcag	caaaggttct	60
catgtggcac	ctgactggca	tcaaaccaaa	gttcgtaggc	caacaaagat	gggccactca	120
caagcttccc	attttagat	ctcagtgcc	atgagtatct	gacacctgtt	cctctcttca	180
gtctcttagg	gaggtttaa	tctgtctcag	gtgtgctaag	agtgccagcc	caaggkgtc	240
aaaagtccac	aaaactgcag	tctttgctgg	gatagtaagc	caagcagtgc	ctggacagca	300
gagttctttt	cttgggcaac	agataaccag	acaggactct	aatcgtgctc	ttattcaaca	360
ttcttctgtc	tctgcctaga	ctggaataaa	aagccaatct	ctctcgtggc	acagggaagg	420
agatacaagc	tcgtttacat	gtgatagatc	taacaaaggc	atctaccgaa	gtctggtctg	480
gatagacggc	acaggggagct	cttaggtcag	cgctgctggt	tggaggacat	tcctgagtc	540
agctttgcag	cctttgtgca	acagtacttt	ccca			574

<210> 357
 <211> 393
 <212> DNA
 <213> Homo sapien

<400> 357						
tttttttttt	tttttttttt	tttttttttt	tacagaatat	aratgcttta	tcactgkact	60
taatattgkg	kcttggtcac	tatacttaaa	aatgcaccac	tcataaatat	ttaattcagc	120
aagccacaac	caaracttga	ttttatcaac	aaaaaccct	aatataaac	ggsaaaaaag	180
atagatataa	ttattccagt	ttttttaaaa	cttaaaarat	attccattgc	cgaattaara	240
araarataag	tggttatatg	aaagaagggc	attcaagcac	actaaaraaa	cctgaggkaa	300
gcataatctg	tacaaaatta	aactgtcctt	tttggcattt	taacaaattt	gcaacgktct	360
tttttttctt	tttctgtttt	tttttttttt	tac			393

<210> 358
 <211> 630
 <212> DNA
 <213> Homo sapien

<400> 358						
acagggtaaa	caggaggatc	cttgctctca	oggagcttac	attctagcag	gaggacaata	60
ttaatgttta	taggaaaatg	atgagtttat	gacaaaggaa	gtagatagtg	ttttacaaga	120
gcatagagta	gggaagctaa	tccagcacag	ggaggtcaca	gagacatccc	taaggaaagt	180
gagtttaaac	tgagagaagc	aagtgcctaa	actgaaggat	gtgttgaaga	agaagggaga	240
gtagaacaat	ttgggcagag	ggaaccttat	agaccctaag	gtgggaagg	tcaaagaact	300
gaaagagagc	tagaacagct	ggagccgttc	tccggtgtaa	agaggagtca	aagagataag	360
attaagatg	tgaagattaa	gatcttggtg	gcattcaggg	attggcactt	ctacaagaaa	420
tcactgaagg	gagtaatgtg	acattacttt	tcacttcagg	atggccattc	taactccagg	480
gggtagactg	gactaggtaa	gactggaggc	aggtagacct	cttctaaggc	ctgcgatagt	540
gaaagacaaa	aataagtggg	gaaattcagg	ggatagtga	aatcagtagg	acttaatgag	600
caagccagag	gttcctccac	aacaaccagt				630

<210> 359
 <211> 620
 <212> DNA

<213> Homo sapien

<400> 359

acagcattcc	aaaatataca	tctagagact	aarrgtaaat	gctctatagt	gaagaagtaa	60
taattaaaa	atgctactaa	tatagaaaat	ttataatcag	aaaaataaat	attcagggag	120
ctcaccagaa	gaataaagt	ctctgccagt	tattaaagga	ttactgctgg	tgaattaaat	180
atggcattcc	ccaagggaaa	tagagagatt	cttctggatt	atgttcaata	tttatttcac	240
aggattaact	gttttaggaa	cagatataaa	gcttcgccac	ggaagagatg	gacaaagcac	300
aaagacaaca	tgatacctta	ggaagcaaca	ctaccctttc	aggcataaaa	tttggagaaa	360
tgcaacatta	tgcttcatga	ataatatgta	gaaagaaggt	ctgatgaaa	tgacatcctt	420
aatgtaagat	aactttataa	gaattctggg	tcaataaaaa	ttctttgaag	aaaacatcca	480
aatgtcattg	acttatcaaa	tactatcttg	gcataatacc	tatgaaggca	aaactaaaac	540
aacaaaaagc	tcacaccaa	caaaaccatc	aacttatttt	gtattctata	acatacgaga	600
ctgtaaagat	gtgacagtgt					620

<210> 360

<211> 431

<212> DNA

<213> Homo sapien

<400> 360

aaaaaaaaa	agccagaaca	acatgtgata	gataatatga	ttggctgcac	acttccagac	60
tgatgaatga	tgaacgtgat	ggactattgt	atggagcaca	tcttcagcaa	gagggggaaa	120
tactcatcat	ttttggccag	cagttgtttg	atcaccaaac	atcatgccag	aatactcagc	180
aaaccttctt	agctcttgag	aagtcaaagt	ccgggggaat	ttattcctgg	caattttaat	240
tggaactcct	atgtgagagc	agcggctacc	cagctggggg	ggtggagcga	acccgtcact	300
agtggacatg	cagtggcaga	gctcctggta	accacctaga	ggaatacaca	ggcacatgtg	360
tgatgccaa	cgtagacac	gtagcactca	aatttgtctt	gtttttgtct	ttcgggtgtg	420
agattcttag	t					431

<210> 361

<211> 351

<212> DNA

<213> Homo sapien

<400> 361

acactgattt	ccgatcaaaa	gaatcatcat	ctttaccttg	acttttcagg	gaattactga	60
actttcttct	cagaagatag	ggcacagcca	ttgccttggc	ctcacttgaa	gggtctgcat	120
ttgggtcctc	tggtctcttg	ccaagtttcc	cagccactcg	aggagaaaat	atcgggaggt	180
ttgacttctc	ccggggcttt	cccaggggct	tcaccgtgag	ccctgcggcc	ctcaggggctg	240
caatcctgga	ttcaatgtct	gaaacctcgc	tctctgcctg	ctggacttct	gaggccgtca	300
ctgccactct	gtcctccagc	tctgacagct	cctcatctgt	ggtcctgttg	t	351

<210> 362

<211> 463

<212> DNA

<213> Homo sapien

<400> 362

acttcatcag	gccataatgg	gtgcctcccg	tgagaatcca	agcacctttg	gactgcgcga	60
tgatagatgag	ccggctgaag	atcttgcgca	tgccgggctt	cagggcgaag	ttcttggcgc	120
ccccggtcac	agaaatgacc	aggttgggtg	ttttcagggtg	ccagtgtctg	gtcagcagct	180
cgtaaaggat	ttccgcgtcc	gtgtcgcagg	acagacgtat	atacttccct	ttcttcccca	240
gtgtctcaaa	ctgaatatcc	ccaaaggcgt	cggtaggaaa	ttccttgggtg	tgtttcttgt	300
agttccattt	ctcacttttg	ttgatctggg	tgcttcccat	gtgctggctc	tgggcatagc	360
cacacttgca	cacattctcc	ctgataagca	cgatggtgtg	gacaggaagg	aaggatttca	420
ttgagcctgc	ttatggaaac	tggattgtt	agcttaata	gac		463

<210> 363
 <211> 653
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1)...(653)
 <223> n = A,T,C or G

<400> 363
 acccccagagt ncctgntctgg catactgnga acgaccaacg acacacccaa gctcggcctc 60
 ctcttgngga ttctgggtga catcttcattg aatggcaacc gtgccagwga ggctgtcctc 120
 tgggaggcac tacgcaagat gggactgctg cctgggggtga gacatcctct ccttgagat 180
 ctaacgaaac ttctcaccta tgagttgtaa agcagaaata cctgnactac agacgagtgc 240
 ccaacagcaa cccccggaa gtatgagttc ctctrgggcc tccgttccta ccatgagasc 300
 tagcaagatg naagtgttga gantcattgc agaggttcag aaaagagacc cntcgtgact 360
 ggtctgcaca gttcatggag gctgcagatg aggccttga tgctctggat gctgctgcag 420
 ctgaggccga agcccgggct gaagcaagaa ccgcgatggg aattggagat gaggctgtgt 480
 ntgggccctg gagctgggat gacattgagt ttgagctgct gacctgggat gaggaaggag 540
 attttgaga tccntggtcc agaattccat ttaccttctg ggccagatac caccagaatg 600
 cccgctccag attcctcag acctttgccg gtcccattat tggctcstggt ggt 653

<210> 364
 <211> 401
 <212> DNA
 <213> Homo sapien

<400> 364
 actagaggaa agacgttaaa ccactctact accacttgtg gaactctcaa agggtaaatg 60
 acaaagccaa tgaatgactc taaaaacaat atttacattt aatggtttgt agacaataaa 120
 aaaacaaggt ggatagatct agaattgtaa cattttaaga aaaccatagc atttgacaga 180
 tgagaaagct caattataga tgcaaagtta taactaaact actatagtag taaagaaata 240
 catttcacac cttcatata aattcactat cttggcttga ggcactccat aaaatgtatc 300
 acgtgcatag taaatcttta tatttgctat ggcgttgac tagaggactt ggactgcaac 360
 aagtggatgc gcggaaaatg aaatcttctt caatagccca g 401

<210> 365
 <211> 356
 <212> DNA
 <213> Homo sapien

<400> 365
 ccagtgtcat atttgggctt aaaatttcaa gaagggcact tcaaattggct ttgcatttgc 60
 atgtttcagt gctagagcgt aggaatagac cctggcgtcc actgtgagat gttcttcagc 120
 taccagagca tcaagtctct gcagcaggtc attcttgggt aaagaaatga cttccacaaa 180
 ctctccatcc cctggctttg gcttcggcct tgcgttttcg gcatcatctc cgttaatggt 240
 gactgtcacg atgtgtatag tacagtttga caagcctggg tccatacaga ccgctggaga 300
 acattcggca atgtcccctt tgtagccagt ttcttcttcg agctcccga gagcag 356

<210> 366
 <211> 1851
 <212> DNA
 <213> Homo sapien

<400> 366
 tcatcaccat tgccagcagc ggcaccgtta gtcaggtttt ctgggaatcc cacatgagta 60
 cttccgtgtt cttcattctt cttcaatagc cataaatctt ctagctctgg ctggctgttt 120

tcacttcctt	taagcctttg	tgactcttcc	tctgatgtca	gctttaagtc	ttgttctgga	180
ttgctgtttt	cagaagagat	ttttaacatc	tgtttttctt	tgtagtcaga	aagtaactgg	240
caaattacat	gatgatgact	agaaacagca	tactctctgg	ccgtctttcc	agatcttgag	300
aagatacatc	aacattttgc	tcaagtagag	ggctgactat	acttgctgat	ccacaacata	360
cagcaagtat	gagagcagtt	cttccatata	tatccagcgc	atttaaattc	gcttttttct	420
tgattaaaaa	tttcaccact	tgctgttttt	gctcatgtat	accaagtagc	agtgggtgga	480
ggccatgctt	gttttttgat	tcgatatcag	caccgtataa	gagcagtgc	ttggccatta	540
atttatcttc	attgtagaca	gcatagtgtg	gagtggattt	tccatactca	tctggaatat	600
ttggatcagt	gccatgttcc	agcaacatta	acgcacattc	atcttcctgg	cattgtacgg	660
cctttgtcag	agctgtcctc	tttttggtgt	caaggacatt	aagttgacat	cgtctgtcca	720
gcacgagttt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	gcagtcctct	780
tttgcttgct	cctcttggtc	acatccgtgt	ccctgagcat	gacgatgaga	tcctttctgg	840
ggactttacc	ccaccaggca	gctctgtgga	gcttgctccag	atcttctcca	tggacgtggg	900
acctgggcat	catgaaggcg	ctgtcatcgt	agtctcccca	agcgaccacg	ttgctcttgc	960
cgctcccctg	cagcagggga	agcagtggca	gcaccacttg	cacctcttgc	tcccaagcgt	1020
cttcacagag	gagtcgttgt	ggtctccaga	agtgccacag	ttgctcttgc	cgctccccct	1080
gtccatccag	ggaggaagaa	atgcaggaaa	tgaaagatgc	atgcacgatg	gtatactcct	1140
cagccatcaa	acttctggac	agcaggtcac	ttccagcaag	gtggagaaag	ctgtccaccc	1200
acagaggatg	agatccagaa	accacaatat	ccattcacia	acaaacactt	ttcagccaga	1260
cacaggtact	gaaatcatgt	catctgcggc	aacatgggtg	aacctacca	atcacacatc	1320
aagagatgaa	gacactgcag	tatatctgca	caacgtaata	ctcttcatcc	ataacaaaat	1380
aataataatt	tcctctggag	ccatatggat	gaactatgaa	ggaagaactc	cccgaagaag	1440
ccagtgcgag	agaagccaca	ctgaagctct	gtcctcagcc	atcagcgcca	cggacaggar	1500
tggtgttctt	ccccagtgat	gcagcctcaa	gttatcccga	agctgccgca	gcacacgggtg	1560
gctcctgaga	aacaccccag	ctcttcgggt	ctaacacagg	caagtcaata	aatgtgataa	1620
tcacataaac	agaattaaaa	gcaaagtcac	ataagcatct	caacagacac	agaaaaggca	1680
tttgacaaaa	tccagcatcc	ttgtatttat	tggtgcagtt	ctcagaggaa	atgcttctaa	1740
cttttcccca	tttagtatta	tggtggctgt	gggcttgtca	taggtgggtt	ttattacttt	1800
aaggtagtgc	ccttctatgc	ctgttttgct	gagggtttta	attctcgtgc	c	1851

<210> 367
 <211> 668
 <212> DNA
 <213> Homo sapien

<400> 367						
cttgagcttc	caaataygga	agactggccc	ttacacasgt	caatgtttaa	atgaatgc	60
ttcagtat	tgaagataaa	attrgtagat	ctataccttg	ttttttgatt	cgatatcagc	120
accrtataag	agcagtgtct	tggccattaa	tttatctttc	attttagaca	gcrtagtgya	180
gagtggtatt	tccatactca	tctggaatat	ttggatcagt	gccatgttcc	agcaacatta	240
acgcacattc	atcttcctgg	cattgtacgg	cctgtcagta	ttagacccaa	aaacaaatta	300
catatcttag	gaattcaaaa	taacattcca	cagctttcac	caactagtta	tattttaaagg	360
agaaaactca	tttttatgcc	atgtattgaa	atcaaaccca	cctcatgctg	atatagttgg	420
ctactgcata	cctttatcag	agctgtcctc	tttttggtgt	caaggacatt	aagttgacat	480
cgtctgtcca	gcaggagttt	tactacttct	gaattcccat	tggcagaggc	cagatgtaga	540
gcagtcctat	gagagtgaga	agacttttta	ggaaattgta	gtgcactagc	tacagccata	600
gcaatgattc	atgtaactgc	aaacactgaa	tagcctgcta	ttactctgcc	ttcaaaaaaa	660
aaaaaaa						668

<210> 368
 <211> 1512
 <212> DNA
 <213> Homo sapien

<400> 368						
gggtgcacca	ggggsgcgt	gggttttctt	cggttggtg	tgggttttcc	ctgggtgggg	60
tgggtgggc	trgaatcccc	tgctgggtt	ggcaggtttt	ggctgggatt	gacttttytc	120
ttcaaacaga	ttggaaaccc	ggagttacct	gctagttggt	gaaactgggt	ggtagacgcg	180

atctgttggc	tactactggc	ttctcctggc	tgttaaaagc	agatggtggt	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagt	600
gccttcatgg	agcccaggta	ccacgtccgt	ggagaagatc	tggacaagct	ccacagagct	660
gcctggtggg	gtaaagtccc	cagaaaggat	ctcatcgtca	tgctcaggga	cactgacgtg	720
aacaagaagg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcggt	aatgttgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	aggtatagat	ctactaattt	tatcttcaaa	atactgaaat	gcattcattt	1080
taacattgac	gtgtgtaagg	gccagtcttc	cgtatttggg	agctcaagca	taacttgaat	1140
gaaaaatatt	tgaaatgacc	taattatctm	agactttatt	ttaaatattg	ttattttcaa	1200
agaagcatta	gagggtagac	tttttttttt	ttaaatgcac	ttctggtaaa	tacttttggt	1260
gaaaacactg	aatttgtaaa	aggttaatact	tactattttt	caatttttcc	ctcctaggat	1320
ttttttcccc	taatgaatgt	aagatggcaa	aatttgcctt	gaaataggtt	ttacatgaaa	1380
actccaagaa	aagttaaaca	tgtttcagtg	aatagagatc	ctgctccttt	ggcaagttcc	1440
taaaaaacag	taatagatac	gaggtgatgc	gcctgtcagt	ggcaagggtt	aagatatttc	1500
tgatctcgtg	cc					1512

<210> 369

<211> 1853

<212> DNA

<213> Homo sapien

<400> 369

gggtcgccca	gggggsgcgt	gggctttcct	cgggtgggtg	tgggttttcc	ctgggtgggg	60
tgggtcgggc	trgaatcccc	tgctgggggt	ggcaggtttt	ggctgggatt	gacttttytc	120
ttcaaacaga	ttggaaaccc	ggagttacct	gctagttggt	gaaactgggt	ggtagacgcg	180
atctgttggc	tactactggc	ttctcctggc	tgttaaaagc	agatggtggt	tgaggttgat	240
tccatgccgg	ctgcttcttc	tgtgaagaag	ccatttggtc	tcaggagcaa	gatgggcaag	300
tggtgctgcc	gttgcttccc	ctgctgcagg	gagagcggca	agagcaacgt	gggcacttct	360
ggagaccacg	acgactctgc	tatgaagaca	ctcaggagca	agatgggcaa	gtggtgccgc	420
cactgcttcc	cctgctgcag	ggggagtggc	aagagcaacg	tgggcgcttc	tggagaccac	480
gacgaytctg	ctatgaagac	actcaggaac	aagatgggca	agtgggtgctg	ccactgcttc	540
ccctgctgca	gggggagcrg	caagagcaag	gtgggcgctt	ggggagacta	cgatgacagy	600
gccttcatgg	akcccaggta	ccacgtccrt	ggagaagatc	tggacaagct	ccacagagct	660
gcctggtggg	gtaaagtccc	cagaaaggat	ctcatcgtca	tgctcaggga	cackgaygtg	720
aacaagargg	acaagcaaaa	gaggactgct	ctacatctgg	cctctgccaa	tgggaattca	780
gaagtagtaa	aactcstgct	ggacagacga	tgtcaactta	atgtccttga	caacaaaaag	840
aggacagctc	tgayaaaggc	cgtacaatgc	caggaagatg	aatgtgcggt	aatgttgctg	900
gaacatggca	ctgatccaaa	tattccagat	gagtatggaa	ataccactct	rcactaygct	960
rtctayaatg	aagataaatt	aatggccaaa	gcactgctct	tatayggtgc	tgatatcgaa	1020
tcaaaaaaca	agcatggcct	cacaccactg	ytacttggtr	tacatgagca	aaaacagcaa	1080
gtsgtgaaat	ttttaatyaa	gaaaaaagcg	aattttaaag	gcrctggata	gatatggaag	1140
rgctgctctc	atacttgctg	tatggttggt	atcagcaagt	atagtcagcc	ytctacttga	1200
gcaaaatrtt	gatgtatctt	ctcaagatct	ggaaagacgg	ccagagagta	tgctgtttct	1260
agtcattcatc	atgtaatttg	ccagttactt	tctgactaca	aagaaaaaca	gatgttaaaa	1320
atctcttctg	aaaacagcaa	tccagaacaa	gacttaaagc	tgacatcaga	ggaagagtca	1380
caaaggctta	aaggaagtga	aaacagccag	ccagaggcat	ggaaactttt	aaattttaa	1440
ttttggttta	atgttttttt	tttttgcctt	aataatatta	gatagtccca	aatgaaatwa	1500
cctatgagac	tagggcttga	gaatcaatag	attctttttt	taagaatctt	ttggctagga	1560
gcggtgtctc	acgcctgtaa	ttccagcacc	ttgagaggct	gaggtgggca	gatcacgaga	1620
tcaggagatc	gagaccatcc	tggctaacac	ggtgaaaccc	catctctact	aaaaatacaa	1680

120

aaacttagct	gggtgtggtg	gcgggtgcct	gtagtcccag	ctactcagga	rgctgaggca	1740
ggagaatggc	atgaacccgg	gaggtggagg	ttgcagttag	ccgagatccg	ccactacact	1800
ccagcctggg	tgacagagca	agactctgtc	tcaaaaaaaaa	aaaaaaaaaaa	aaa	1853

<210> 370

<211> 2184

<212> DNA

<213> Homo sapien

<400> 370

ggcacgagaa	ttaaaaccct	cagcaaaaaca	ggcatagaag	ggacatacct	taaagtaata	60
aaaaccacct	atgacaagcc	cacagccaac	ataatactaa	atggggaaaa	gttagaagca	120
tttcctctga	gaactgcaac	aataaataca	aggatgctgg	attttgtcaa	atgccttttc	180
tgtgtctggt	gagatgctta	tgtgactttg	cttttaattc	tgtttatgtg	attatcacat	240
ttattgactt	gcctgtgtta	gaccggaaga	gctgggggtg	ttctcaggag	ccaccgtgtg	300
ctgcggcagc	ttcgggataa	cttgaggctg	catcactggg	gaagaaacac	aytccctgtc	360
gtggcgctga	tggttgagga	cagagcttca	gtgtggcttc	tctgcgactg	gcttcttcgg	420
ggagtctctc	cttcatagtt	catccatagc	gctccagagg	aaaattatat	tattttgtta	480
tggatgaaga	gtattacgtt	gtgcagatat	actgcagtgt	cttcatctct	tgatgtgtga	540
ttgggtaggt	tccaccatgt	tgccgcagat	gacatgattt	cagtacctgt	gtctggctga	600
aaagtgtttg	tttgtgaatg	gatattgtgg	tttctggatc	tcactctctg	tgggtggaca	660
gctttctcca	ccttgctgga	agtgcctgac	tgtccagaag	tttgatggct	gaggagtata	720
ccatcgtgca	tgcactcttc	atttctctga	tttcttcttc	cctggatgga	caggggggagc	780
ggcaagagca	acgtgggcac	ttctggagac	cacaacgact	cctctgtgaa	gacgcttggg	840
agcaagaggt	gcaagtgggt	ctgccactgc	ttcccctgct	gcaggggagc	ggcaagagca	900
acgtggctgc	ttggggagac	tacgatgaca	gcgccttcat	ggatcccagg	taccacgtcc	960
atggagaaga	tctggacaag	ctccacagag	ctgcctgggt	gggtaaagtc	cccagaaagg	1020
atctcatcgt	catgctcagg	gacacggatg	tgaacaagag	ggacaagcaa	aagaggactg	1080
ctctacatct	ggcctctgcc	aatgggaatt	cagaagtagt	aaaactcgtg	ctggacagac	1140
gatgtcaact	taatgtcctt	gacaacaaaa	agaggacagc	tctgacaaaag	gccgtacaat	1200
gccaggaaga	tgaatgtgcg	ttaatgttgc	tgaacatgg	cactgatcca	aatattccag	1260
atgagtatgg	aaataccact	ctacactatg	ctgtctacaa	tgaagataaa	ttaatggcca	1320
aagcactgct	cttatacggg	gctgatatcg	aatcaaaaaa	caagcatggc	ctcacaccac	1380
tgtactttgg	tatacatgag	caaaaacagc	aagtggtgaa	atttttaatc	aagaaaaaag	1440
cgaattttaa	tgcgctggat	agatatggaa	gaactgctct	catacttgct	gtatgtttgt	1500
gatcagcaag	tatagtcagc	cctctacttg	agcaaaatgt	tgatgtatct	tctcaagatc	1560
tggaaagacg	gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	1620
ttctgactac	aaagaaaaac	agatgtttaa	aatctcttct	gaaaacagca	atccagaaca	1680
agacttaaa	ctgacatcag	aggaagagtc	acaaaggctt	aaaggaagtg	aaaacagcca	1740
gccagaggca	tggaaacttt	taaattttaa	cttttggttt	aatgtttttt	ttttttgcct	1800
taataatatt	agatagtccc	aaatgaaatw	acctatgaga	ctaggctttg	agaatcaata	1860
gattcttttt	ttaagaatct	tttggctagg	agcgggtgtc	cacgcctgta	attccagcac	1920
cttgagaggc	tgaggtgggc	agatcacgag	atcaggagat	cgagaccatc	ctggctaaca	1980
cgggtgaaacc	ccatctctac	taaaaataca	aaaacttagc	tgggtgtggt	ggcgggtgcc	2040
tgtagtccca	gctactcagg	argctgaggc	aggagaatgg	catgaaccgc	ggaggtggag	2100
gttgcagtga	gccgagatcc	gccactacac	tccagcctgg	gtgacagagc	aagactctgt	2160
ctcaaaaaaa	aaaaaaaaaa	aaaa				2184

<210> 371

<211> 1855

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(1855)

<223> n = A,T,C or G

<400> 371

tgacgcgcac	ggccagtgct	tgtgccacgt	acactgacgc	cccctgagat	gtgcacgccg	60
cacgcgcacg	ttgcacgcgc	ggcagcggct	tggctggctt	gtaacggctt	gcacgcgcac	120
gcccgcgcgc	cataaccgtc	agactggcct	gtaacggctt	gcagggcgac	gcccgcgcgc	180
cgtaacggct	tggctgccct	gtaacggctt	gcacgtgcat	gctgcacgcg	cgtaacggc	240
ttggctggca	tgtagccgct	tggcttggct	ttgcattt	tgctkggctk	ggcggtgkty	300
tcttggattg	acgcttcctc	cttggatkga	cgtttcctcc	ttggatkga	gtttctyty	360
tcgcttctct	ttgctggact	tgacctttty	tctgctgggt	ttggcattcc	tttgggggtg	420
gctgggtgtt	ttctccgggg	gggkkgccc	ttctgggggt	gggctgggk	cgcgcgcgcg	480
gggctgggg	tttcccggg	tgggtgtggg	ttttcctggg	gtgggggtgg	ctgtgctggg	540
atccccctgc	tgggggttgg	agggattgac	tttttcttct	aaacagattg	gaaacccgga	600
gtaacntgct	agttggtgaa	actggttggg	agacgcgcat	tgctggtact	actgtttctc	660
ctggctgtta	aaagcagatg	gtggctgagg	ttgattcaat	gcccgtgct	tcttctgtga	720
agaagccatt	tggctcag	agcaagatgg	gcaagtggg	cgccactgct	tcccctgctg	780
cagggggagc	ggcaagagca	acgtgggcac	ttctggagac	cacaacgact	cctctgtgaa	840
gacgcttggg	agcaagaggt	gcaagtggg	ctgcccactg	cttcccctgc	tgagggggag	900
cggcaagagc	aacgtggkcg	cttggggaga	ctacgatgac	agcgccttca	tggaacccag	960
gtaccacgtc	crtggagaag	atctggacaa	gctccacaga	gctgcctggt	ggggtaaagt	1020
ccccagaaag	gatctcatcg	tcctgctcag	ggacactgay	gtgaacaaga	rggacaagca	1080
aaagaggact	gctctacatc	tggcctctgc	caatgggaat	tcagaagtag	taaaactcgt	1140
gctggacaga	cgatgtcaac	ttaatgtcct	tgacaacaaa	aagaggacag	ctctgacaaa	1200
ggcgtacaa	tggcaggaag	atgaatgtgc	gttaatgttg	ctggaacatg	gcactgatcc	1260
aaatattcca	gatgagtatg	gaaataccac	tctacactat	gctgtctaca	atgaagataa	1320
attaatggcc	aaagcactgc	tcttatacgg	tgctgatatc	gaatcaaaaa	acaaggtata	1380
gatctactaa	ttttatcttc	aaaatactga	aatgcattca	ttttaacatt	gacgtgtgta	1440
agggccagtc	ttccgtattt	ggaagctcaa	gcataacttg	aatgaaaata	ttttgaaatg	1500
acctaattat	ctaagacttt	attttaata	ttgttatttt	caaagaagca	ttagagggtg	1560
cagttttttt	tttttaaatg	cacttctggt	aaatactttt	gttgaaaaca	ctgaatttgt	1620
aaaagtaaat	acttactatt	tttcaatttt	tccctcctag	gatttttttc	ccctaataga	1680
tgtaagatgg	caaaatttgc	cctgaaatag	gttttacatg	aaaactccaa	gaaaagttaa	1740
acatgtttca	gtgaatagag	atcctgctcc	tttggaaggt	tcctaaaaaa	cagtaataga	1800
tacgaggtga	tgccgctgtc	agtggcaagg	tttaagatat	ttctgatctc	gtgcc	1855

<210> 372

<211> 1059

<212> DNA

<213> Homo sapien

<400> 372

gcaacgtggg	cacttctgga	gaccacaacg	actcctctgt	gaagacgctt	gggagcaaga	60
ggtgcaagt	gtgctgccca	ctgcttcccc	tgctgcaggg	gagcggcaag	agcaacgtgg	120
gcgcttgrgg	agactmcgat	gacagygcct	tcctggagcc	caggtaccac	gtccgtggag	180
aagatctgga	caagctccac	agagctgcc	tgggtgggta	aagtcccag	aaaggatctc	240
atcgctcatg	tcagggacac	tgaygtgaac	aagarggaca	agcaaaaagag	gactgctcta	300
catctggcct	ctgccaatgg	gaattcagaa	gtagtataac	tcstgctgga	cagacgatgt	360
caacttaatg	tccttgacaa	caaaaagagg	acagctctga	yaaaggccgt	acaatgccag	420
gaagatgaat	gtgcgttaat	gttgctggaa	catggcactg	atccaaatat	tccagatgag	480
tatggaaata	ccactctrca	ctaygctrtc	tayaatgaag	ataaattaat	ggccaaagca	540
ctgctcttat	aygggtctga	tatcgaatca	aaaaacaagg	tatagatcta	ctaattttat	600
cttcaaaata	ctgaaatgca	ttcattttta	cattgacgtg	tgtaagggcc	agtcctccgt	660
atttgaagc	tcaagcataa	cttgaatgaa	aatattttga	aatgacctaa	ttatctaaaga	720
ctttatttta	aatattgtta	ttttcaaaga	agcattagag	ggtacagttt	ttttttttta	780
aatgcaactc	tggtaaatac	ttttgtgaa	aacactgaat	ttgtaaaagg	taatacttac	840
tatttttcaa	ttttccctc	ctaggatttt	tttcccctaa	tgaatgtaag	atggcaaaat	900
ttgcctgaa	ataggtttta	catgaaaact	ccaagaaaag	ttaaactatg	ttcagtgaat	960
agagatcctg	ctcctttggc	aagttcctaa	aaaacagtaa	tagatacagag	gtgatgcgcc	1020
tgctcagtgg	aaggtttaag	atatttctga	tctcgtgcc			1059

<210> 373
 <211> 1155
 <212> DNA
 <213> Homo sapien

<400> 373
 atggtggttg aggttgattc catgccggct gcctcttctg tgaagaagcc atttggctctc 60
 aggagcaaga tgggcaagtg gtgctgccgt tgcttccct gctgcaggga gagcggcaag 120
 agcaacgtgg gcacttctgg agaccacgac gactctgcta tgaagacact caggagcaag 180
 atgggcaagt ggtgccgcca ctgcttcccc tgctgcaggg ggagtggcaa gagcaacgtg 240
 ggcgcttctg gagaccacga cgactctgct atgaagacac tcaggaacaa gatgggcaag 300
 tgggtgctgcc actgcttccc ctgctgcagg gggagcggca agagcaaggt gggcgcttgg 360
 ggagactacg atgacagtgc cttcatggag ccaggtacc acgtccgtgg agaagatctg 420
 gacaagctcc acagagctgc ctggtggggt aaagtcccca gaaaggatct catcgtcatg 480
 ctcagggaca ctgacgtgaa caagaaggac aagcaaaaga ggactgctct acatctggcc 540
 tctgccaatg ggaattcaga agtagtaaaa ctctgctgg acagacgatg tcaacttaat 600
 gtccttgaca acaaaaagag gacagctctg ataaaggccg tacaatgcca ggaagatgaa 660
 tgtgcgttaa tgttgctgga acatggcact gatccaaata ttccagatga gtatggaaat 720
 accactctgc actacgctat ctataatgaa gataaattaa tggccaaagc actgctctta 780
 tatggtgctg atatcgaatc aaaaaacaag catggcctca caccactgtt acttgggtga 840
 catgagcaaa aacagcaagt cgtgaaattt ttaatcaaga aaaaagcgaa tttaaatgca 900
 ctggatagat atggaaggac tgctctcata cttgctgtat gttgtggatc agcaagtata 960
 gtcagccttc tacttgagca aaatattgat gtatcttctc aagatctatc tggacagacg 1020
 gccagagagt atgctgttct tagtcatcat catgtaattt gccagttact ttctgactac 1080
 aaagaaaaac agatgctaaa aatctcttct gaaaacagca atccagaaaa tgtctcaaga 1140
 accagaaata aataa 1155

<210> 374
 <211> 2000
 <212> DNA
 <213> Homo sapien

<400> 374
 atggtggttg aggttgattc catgccggct gcctcttctg tgaagaagcc atttggctctc 60
 aggagcaaga tgggcaagtg gtgctgccgt tgcttccct gctgcaggga gagcggcaag 120
 agcaacgtgg gcacttctgg agaccacgac gactctgcta tgaagacact caggagcaag 180
 atgggcaagt ggtgccgcca ctgcttcccc tgctgcaggg ggagtggcaa gagcaacgtg 240
 ggcgcttctg gagaccacga cgactctgct atgaagacac tcaggaacaa gatgggcaag 300
 tgggtgctgcc actgcttccc ctgctgcagg gggagcggca agagcaaggt gggcgcttgg 360
 ggagactacg atgacagtgc cttcatggag ccaggtacc acgtccgtgg agaagatctg 420
 gacaagctcc acagagctgc ctggtggggt aaagtcccca gaaaggatct catcgtcatg 480
 ctcagggaca ctgacgtgaa caagaaggac aagcaaaaga ggactgctct acatctggcc 540
 tctgccaatg ggaattcaga agtagtaaaa ctctgctgg acagacgatg tcaacttaat 600
 gtccttgaca acaaaaagag gacagctctg ataaaggccg tacaatgcca ggaagatgaa 660
 tgtgcgttaa tgttgctgga acatggcact gatccaaata ttccagatga gtatggaaat 720
 accactctgc actacgctat ctataatgaa gataaattaa tggccaaagc actgctctta 780
 tatggtgctg atatcgaatc aaaaaacaag catggcctca caccactgtt acttgggtga 840
 catgagcaaa aacagcaagt cgtgaaattt ttaatcaaga aaaaagcgaa tttaaatgca 900
 ctggatagat atggaaggac tgctctcata cttgctgtat gttgtggatc agcaagtata 960
 gtcagccttc tacttgagca aaatattgat gtatcttctc aagatctatc tggacagacg 1020
 gccagagagt atgctgttct tagtcatcat catgtaattt gccagttact ttctgactac 1080
 aaagaaaaac agatgctaaa aatctcttct gaaaacagca atccagaaaa agacttaag 1140
 ctgacatcag aggaagatc acaaaaggctc aaaggcagtg aaaaatgcca gccagagaaa 1200
 atgtctcaag aaccagaaat aaataaggat ggtgatagag aggttgaaga agaaatgaag 1260
 aagcatgaaa gtaataatgt gggattacta gaaaacctga ctaatggtgt cactgctggc 1320
 aatggtgata atggattaat tcctcaaagg aagagcagaa cacctgaaaa tcagcaattt 1380
 cctgacaacg aaagtgaaga gtatcacaga atttgcaaat tagtttctga ctacaaagaa 1440
 aaacagatgc caaataactc ttctgaaaac agcaaccagc aacaagactt aaagctgaca 1500

tcagaggaag	agtcacaaaag	gcttgagggc	agtgaaaatg	gccagccaga	gctagaaaat	1560
tttatggcta	tcgaagaaat	gaagaagcac	ggaagtactc	atgtcggatt	cccagaaaac	1620
ctgactaatg	gtgccactgc	tggcaatggt	gatgatggat	taattcctcc	aaggaagagc	1680
agaacacctg	aaagccagca	atttcctgac	actgagaatg	aagagtatca	cagtgcagaa	1740
caaaatgata	ctcagaagca	attttgtgaa	gaacagaaca	ctggaatatt	acacgatgag	1800
attctgattc	atgaagaaaa	gcagatagaa	gtggttgaaa	aaatgaattc	tgagctttct	1860
cttagttgta	agaaagaaaa	agacatcttg	catgaaaata	gtacgttgcg	ggaagaaatt	1920
gccatgctaa	gactggagct	agacacaatg	aaacatcaga	gccagctaaa	aaaaaaaaaa	1980
aaaaaaaaaa	aaaaaaaaaa					2000

<210> 375

<211> 2040

<212> DNA

<213> Homo sapien

<400> 375

atggttggtg	aggttgattc	catgccggct	gcctcttctg	tgaagaagcc	atttggtctc	60
aggagcaaga	tgggcaagtg	gtgctgccgt	tgcttcccct	gctgcaggga	gagcgccaag	120
agcaacgtgg	gcacttctgg	agaccacgac	gactctgcta	tgaagacact	caggagcaag	180
atgggcaagt	ggtgcccga	ctgcttccc	tgctgcaggg	ggagtggcaa	gagcaacgtg	240
ggcgcttctg	gagaccacga	cgactctgct	atgaagacac	tcaggaaaca	gatgggcaag	300
tgggtgctgcc	actgcttccc	ctgctgcagg	gggagcggca	agagcaaggt	ggcgcttgg	360
ggagactacg	atgacagtgc	cttcatggag	cccagggtacc	acgtccgtgg	agaagatctg	420
gacaagctcc	acagagctgc	ctggtggggt	aaagtcccca	gaaaggatct	catcgtcatg	480
ctcagggaca	ctgacgtgaa	caagaaggac	aagcaaaaga	ggactgctct	acatctggcc	540
tctgccaatg	ggaattcaga	agtagtaaaa	ctcctgctgg	acagacgatg	tcaacttaat	600
gtccttgaca	acaaaaagag	gacagctctg	ataaaggccg	tacaatgcca	ggaagatgaa	660
tgtgcgttaa	tgttgctgga	acatggcact	gatccaaata	ttccagatga	gtatggaaat	720
accactctgc	actacgctat	ctataatgaa	gataaattaa	tggccaaagc	actgctotta	780
tatggtgctg	atatcgaatc	aaaaaacaag	catggcctca	caccactggt	acttggtgta	840
catgagcaaa	aacagcaagt	cgtgaaatgt	ttaatcaaga	aaaaagcgaa	tttaaatgca	900
ctggatagat	atggaaggac	tgctctcata	cttgctgtat	gttgtggatc	agcaagtata	960
gtcagccttc	tacttgagca	aaatattgat	gtatcttctc	aagatctatc	tggacagacg	1020
gccagagagt	atgctgtttc	tagtcatcat	catgtaattt	gccagttact	ttctgactac	1080
aaagaaaaac	agtgctaaa	aatctcttct	gaaaacagca	atccagaaca	agacttaaag	1140
ctgacatcag	aggaagagtc	acaaagggtc	aaaggcagtg	aaaatagcca	gccagagaaa	1200
atgtctcaag	aaccagaaat	aaataaggat	ggtgatagag	aggttgaaga	agaaatgaag	1260
aagcatgaaa	gtaataatgt	gggattacta	gaaaacctga	ctaattggtg	cactgctggc	1320
aatggtgata	atggattaat	tcctcaaagg	aagagcagaa	cacctgaaa	tcagcaattt	1380
cctgacaacg	aaagtgaaga	gtatcacaga	atttgcgaat	tagtttctga	ctacaagaaa	1440
aaacagatgc	caaaatactc	ttctgaaaac	agcaaccag	aacaagactt	aaagctgaca	1500
tcagaggaag	agtcacaaaag	gcttgagggc	agtgaaaatg	gccagccaga	gaaaagatct	1560
caagaaccag	aaataaataa	ggatggtgat	agagagctag	aaaattttat	ggctatcgaa	1620
gaaatgaaga	agcacggaag	tactcatgtc	ggattcccag	aaaacctgac	taatggtgcc	1680
actgctggca	atggtgatga	tggattaatt	cctccaaggga	agagcagaac	acctgaaagc	1740
cagcaatttc	ctgacactga	gaatgaagag	tatcacagtg	acgaacaaaa	tgatactcag	1800
aagcaatttt	gtgaagaaca	gaacactgga	atattacacg	atgagattct	gattcatgaa	1860
gaaaagcaga	tagaagtgg	tgaaaaaatg	aattctgagc	tttctcttag	ttgtaagaaa	1920
gaaaagaca	tcttgcatga	aaatagtacg	ttgcgggaag	aaattgccat	gctaagactg	1980
gagctagaca	caatgaaaca	tcagagccag	ctaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2040

<210> 376

<211> 329

<212> PRT

<213> Homo sapien

<400> 376

Met Asp Ile Val Val Ser Gly Ser His Pro Leu Trp Val Asp Ser Phe


```

1           5           10           15
Leu His Leu Ala Gly Ser Asp Leu Leu Ser Arg Ser Leu Met Ala Glu
      20           25           30
Glu Tyr Thr Ile Val His Ala Ser Phe Ile Ser Cys Ile Ser Ser Ser
      35           40           45
Leu Asp Gly Gln Gly Glu Arg Gln Glu Gln Arg Gly His Phe Trp Arg
      50           55           60
Pro Gln Arg Leu Leu Cys Glu Asp Ala Trp Glu Gln Glu Val Gln Val
      65           70           75           80
Val Leu Pro Leu Leu Pro Leu Leu Gln Gly Ser Gly Lys Ser Asn Val
      85           90           95
Val Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe Met Asp Pro Arg Tyr
      100          105          110
His Val His Gly Glu Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp
      115          120          125
Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp
      130          135          140
Val Asn Lys Arg Asp Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser
      145          150          155          160
Ala Asn Gly Asn Ser Glu Val Val Lys Leu Val Leu Asp Arg Arg Cys
      165          170          175
Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala
      180          185          190
Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly
      195          200          205
Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr
      210          215          220
Ala Val Tyr Asn Glu Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr
      225          230          235          240
Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu
      245          250          255
Leu Gly Ile His Glu Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys
      260          265          270
Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu
      275          280          285
Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile Val Ser Pro Leu Leu
      290          295          300
Glu Gln Asn Val Asp Val Ser Ser Gln Asp Leu Glu Arg Arg Pro Glu
      305          310          315          320
Ser Met Leu Phe Leu Val Ile Ile Met
      325

```

<210> 377

<211> 148

<212> PRT

<213> Homo sapien

<220>

<221> VARIANT

<222> (1)...(148)

<223> Xaa = Any Amino Acid

<400> 377

```

Met Thr Xaa Pro Ser Trp Ser Pro Gly Thr Thr Ser Val Glu Lys Ile
1           5           10           15
Trp Thr Ser Ser Thr Glu Leu Pro Trp Trp Gly Lys Val Pro Arg Lys
      20           25           30
Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Xaa Asp Lys

```

35 40 45
 Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu
 50 55 60
 Val Val Lys Leu Xaa Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp
 65 70 75 80
 Asn Lys Lys Arg Thr Ala Leu Xaa Lys Ala Val Gln Cys Gln Glu Asp
 85 90 95
 Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro
 100 105 110
 Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Xaa Tyr Asn Glu Asp
 115 120 125
 Lys Leu Met Ala Lys Ala Leu Leu Tyr Gly Ala Asp Ile Glu Ser
 130 135 140
 Lys Asn Lys Val
 145

<210> 378
 <211> 1719
 <212> PRT
 <213> Homo sapien

<400> 378
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
 1 5 10 15
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
 20 25 30
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
 35 40 45
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
 50 55 60
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
 65 70 75 80
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
 85 90 95
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
 100 105 110
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe
 115 120 125
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His
 130 135 140
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met
 145 150 155 160
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala
 165 170 175
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu
 180 185 190
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr
 195 200 205
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met
 210 215 220
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn
 225 230 235 240
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys
 245 250 255
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly
 260 265 270
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val
 275 280 285

Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr
 290 295 300
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile
 305 310 315 320
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu
 325 330 335
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His His Val
 340 345 350
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile
 355 360 365
 Ser Ser Glu Asn Ser Asn Pro Glu Asn Val Ser Arg Thr Arg Asn Lys
 370 375 380
 Pro Arg Thr His Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser
 385 390 395 400
 Ser Val Lys Lys Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys
 405 410 415
 Cys Arg Cys Phe Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly
 420 425 430
 Thr Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys
 435 440 445
 Met Gly Lys Trp Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly
 450 455 460
 Lys Ser Asn Val Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys
 465 470 475 480
 Thr Leu Arg Asn Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys
 485 490 495
 Cys Arg Gly Ser Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp
 500 505 510
 Asp Ser Ala Phe Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu
 515 520 525
 Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp
 530 535 540
 Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln
 545 550 555 560
 Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val
 565 570 575
 Val Lys Leu Leu Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn
 580 585 590
 Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu
 595 600 605
 Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp
 610 615 620
 Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys
 625 630 635 640
 Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys
 645 650 655
 Asn Lys His Gly Leu Thr Pro Leu Leu Gly Val His Glu Gln Lys
 660 665 670
 Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala
 675 680 685
 Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly
 690 695 700
 Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser
 705 710 715 720
 Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser
 725 730 735
 His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln
 740 745 750

Met	Leu	Lys	Ile	Ser	Ser	Glu	Asn	Ser	Asn	Pro	Glu	Gln	Asp	Leu	Lys
		755					760					765			
Leu	Thr	Ser	Glu	Glu	Glu	Ser	Gln	Arg	Phe	Lys	Gly	Ser	Glu	Asn	Ser
		770					775				780				
Gln	Pro	Glu	Lys	Met	Ser	Gln	Glu	Pro	Glu	Ile	Asn	Lys	Asp	Gly	Asp
785						790				795					800
Arg	Glu	Val	Glu	Glu	Glu	Met	Lys	Lys	His	Glu	Ser	Asn	Asn	Val	Gly
						805			810						815
Leu	Leu	Glu	Asn	Leu	Thr	Asn	Gly	Val	Thr	Ala	Gly	Asn	Gly	Asp	Asn
			820					825					830		
Gly	Leu	Ile	Pro	Gln	Arg	Lys	Ser	Arg	Thr	Pro	Glu	Asn	Gln	Gln	Phe
		835					840					845			
Pro	Asp	Asn	Glu	Ser	Glu	Glu	Tyr	His	Arg	Ile	Cys	Glu	Leu	Val	Ser
		850				855					860				
Asp	Tyr	Lys	Glu	Lys	Gln	Met	Pro	Lys	Tyr	Ser	Ser	Glu	Asn	Ser	Asn
865						870				875					880
Pro	Glu	Gln	Asp	Leu	Lys	Leu	Thr	Ser	Glu	Glu	Glu	Ser	Gln	Arg	Leu
				885					890					895	
Glu	Gly	Ser	Glu	Asn	Gly	Gln	Pro	Glu	Leu	Glu	Asn	Phe	Met	Ala	Ile
			900					905					910		
Glu	Glu	Met	Lys	Lys	His	Gly	Ser	Thr	His	Val	Gly	Phe	Pro	Glu	Asn
		915					920					925			
Leu	Thr	Asn	Gly	Ala	Thr	Ala	Gly	Asn	Gly	Asp	Asp	Gly	Leu	Ile	Pro
		930				935					940				
Pro	Arg	Lys	Ser	Arg	Thr	Pro	Glu	Ser	Gln	Gln	Phe	Pro	Asp	Thr	Glu
945					950					955					960
Asn	Glu	Glu	Tyr	His	Ser	Asp	Glu	Gln	Asn	Asp	Thr	Gln	Lys	Gln	Phe
				965					970					975	
Cys	Glu	Glu	Gln	Asn	Thr	Gly	Ile	Leu	His	Asp	Glu	Ile	Leu	Ile	His
			980					985					990		
Glu	Glu	Lys	Gln	Ile	Glu	Val	Val	Glu	Lys	Met	Asn	Ser	Glu	Leu	Ser
		995					1000					1005			
Leu	Ser	Cys	Lys	Lys	Glu	Lys	Asp	Ile	Leu	His	Glu	Asn	Ser	Thr	Leu
		1010				1015						1020			
Arg	Glu	Glu	Ile	Ala	Met	Leu	Arg	Leu	Glu	Leu	Asp	Thr	Met	Lys	His
1025					1030					1035					1040
Gln	Ser	Gln	Leu	Pro	Arg	Thr	His	Met	Val	Val	Glu	Val	Asp	Ser	Met
				1045					1050					1055	
Pro	Ala	Ala	Ser	Ser	Val	Lys	Lys	Pro	Phe	Gly	Leu	Arg	Ser	Lys	Met
			1060					1065					1070		
Gly	Lys	Trp	Cys	Cys	Arg	Cys	Phe	Pro	Cys	Cys	Arg	Glu	Ser	Gly	Lys
		1075					1080					1085			
Ser	Asn	Val	Gly	Thr	Ser	Gly	Asp	His	Asp	Asp	Ser	Ala	Met	Lys	Thr
		1090				1095						1100			
Leu	Arg	Ser</													

Lys Asp Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly
 1220 1225 1230
 Asn Ser Glu Val Val Lys Leu Leu Leu Asp Arg Arg Cys Gln Leu Asn
 1235 1240 1245
 Val Leu Asp Asn Lys Lys Arg Thr Ala Leu Ile Lys Ala Val Gln Cys
 1250 1255 1260
 Gln Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro
 1265 1270 1275 1280
 Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Ile Tyr
 1285 1290 1295
 Asn Glu Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp
 1300 1305 1310
 Ile Glu Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Val
 1315 1320 1325
 His Glu Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala
 1330 1335 1340
 Asn Leu Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala
 1345 1350 1355 1360
 Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln Asn
 1365 1370 1375
 Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu Tyr
 1380 1385 1390
 Ala Val Ser Ser His His His Val Ile Cys Gln Leu Leu Ser Asp Tyr
 1395 1400 1405
 Lys Glu Lys Gln Met Leu Lys Ile Ser Ser Glu Asn Ser Asn Pro Glu
 1410 1415 1420
 Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Phe Lys Gly
 1425 1430 1435 1440
 Ser Glu Asn Ser Gln Pro Glu Lys Met Ser Gln Glu Pro Glu Ile Asn
 1445 1450 1455
 Lys Asp Gly Asp Arg Glu Val Glu Glu Glu Met Lys Lys His Glu Ser
 1460 1465 1470
 Asn Asn Val Gly Leu Leu Glu Asn Leu Thr Asn Gly Val Thr Ala Gly
 1475 1480 1485
 Asn Gly Asp Asn Gly Leu Ile Pro Gln Arg Lys Ser Arg Thr Pro Glu
 1490 1495 1500
 Asn Gln Gln Phe Pro Asp Asn Glu Ser Glu Glu Tyr His Arg Ile Cys
 1505 1510 1515 1520
 Glu Leu Val Ser Asp Tyr Lys Glu Lys Gln Met Pro Lys Tyr Ser Ser
 1525 1530 1535
 Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu Glu Glu
 1540 1545 1550
 Ser Gln Arg Leu Glu Gly Ser Glu Asn Gly Gln Pro Glu Lys Arg Ser
 1555 1560 1565
 Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Leu Glu Asn Phe
 1570 1575 1580
 Met Ala Ile Glu Glu Met Lys Lys His Gly Ser Thr His Val Gly Phe
 1585 1590 1595 1600
 Pro Glu Asn Leu Thr Asn Gly Ala Thr Ala Gly Asn Gly Asp Asp Gly
 1605 1610 1615
 Leu Ile Pro Pro Arg Lys Ser Arg Thr Pro Glu Ser Gln Gln Phe Pro
 1620 1625 1630
 Asp Thr Glu Asn Glu Glu Tyr His Ser Asp Glu Gln Asn Asp Thr Gln
 1635 1640 1645
 Lys Gln Phe Cys Glu Glu Gln Asn Thr Gly Ile Leu His Asp Glu Ile
 1650 1655 1660
 Leu Ile His Glu Glu Lys Gln Ile Glu Val Val Glu Lys Met Asn Ser
 1665 1670 1675 1680

Glu Leu Ser Leu Ser Cys Lys Lys Glu Lys Asp Ile Leu His Glu Asn
 1685 1690 1695
 Ser Thr Leu Arg Glu Glu Ile Ala Met Leu Arg Leu Glu Leu Asp Thr
 1700 1705 1710
 Met Lys His Gln Ser Gln Leu
 1715

<210> 379
 <211> 656
 <212> PRT
 <213> Homo sapien

<400> 379
 Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
 1 5 10 15
 Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
 20 25 30
 Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
 35 40 45
 His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
 50 55 60
 Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
 65 70 75 80
 Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
 85 90 95
 Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
 100 105 110
 Gly Lys Ser Lys Val Gly Ala Trp Gly Asp Tyr Asp Asp Ser Ala Phe
 115 120 125
 Met Glu Pro Arg Tyr His Val Arg Gly Glu Asp Leu Asp Lys Leu His
 130 135 140
 Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu Ile Val Met
 145 150 155 160
 Leu Arg Asp Thr Asp Val Asn Lys Lys Asp Lys Gln Lys Arg Thr Ala
 165 170 175
 Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu Val Val Lys Leu Leu
 180 185 190
 Leu Asp Arg Arg Cys Gln Leu Asn Val Leu Asp Asn Lys Lys Arg Thr
 195 200 205
 Ala Leu Ile Lys Ala Val Gln Cys Gln Glu Asp Glu Cys Ala Leu Met
 210 215 220
 Leu Leu Glu His Gly Thr Asp Pro Asn Ile Pro Asp Glu Tyr Gly Asn
 225 230 235 240
 Thr Thr Leu His Tyr Ala Ile Tyr Asn Glu Asp Lys Leu Met Ala Lys
 245 250 255
 Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu Ser Lys Asn Lys His Gly
 260 265 270
 Leu Thr Pro Leu Leu Leu Gly Val His Glu Gln Lys Gln Gln Val Val
 275 280 285
 Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu Asn Ala Leu Asp Arg Tyr
 290 295 300
 Gly Arg Thr Ala Leu Ile Leu Ala Val Cys Cys Gly Ser Ala Ser Ile
 305 310 315 320
 Val Ser Leu Leu Leu Glu Gln Asn Ile Asp Val Ser Ser Gln Asp Leu
 325 330 335
 Ser Gly Gln Thr Ala Arg Glu Tyr Ala Val Ser Ser His His Val
 340 345 350
 Ile Cys Gln Leu Leu Ser Asp Tyr Lys Glu Lys Gln Met Leu Lys Ile

```

          355          360          365
Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp Leu Lys Leu Thr Ser Glu
  370          375          380
Glu Glu Ser Gln Arg Phe Lys Gly Ser Glu Asn Ser Gln Pro Glu Lys
  385          390          395          400
Met Ser Gln Glu Pro Glu Ile Asn Lys Asp Gly Asp Arg Glu Val Glu
          405          410          415
Glu Glu Met Lys Lys His Glu Ser Asn Asn Val Gly Leu Leu Glu Asn
          420          425          430
Leu Thr Asn Gly Val Thr Ala Gly Asn Gly Asp Asn Gly Leu Ile Pro
          435          440          445
Gln Arg Lys Ser Arg Thr Pro Glu Asn Gln Gln Phe Pro Asp Asn Glu
          450          455          460
Ser Glu Glu Tyr His Arg Ile Cys Glu Leu Val Ser Asp Tyr Lys Glu
  465          470          475          480
Lys Gln Met Pro Lys Tyr Ser Ser Glu Asn Ser Asn Pro Glu Gln Asp
          485          490          495
Leu Lys Leu Thr Ser Glu Glu Glu Ser Gln Arg Leu Glu Gly Ser Glu
          500          505          510
Asn Gly Gln Pro Glu Leu Glu Asn Phe Met Ala Ile Glu Glu Met Lys
          515          520          525
Lys His Gly Ser Thr His Val Gly Phe Pro Glu Asn Leu Thr Asn Gly
          530          535          540
Ala Thr Ala Gly Asn Gly Asp Asp Gly Leu Ile Pro Pro Arg Lys Ser
  545          550          555          560
Arg Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu Asn Glu Glu Tyr
          565          570          575
His Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe Cys Glu Glu Gln
          580          585          590
Asn Thr Gly Ile Leu His Asp Glu Ile Leu Ile His Glu Glu Lys Gln
          595          600          605
Ile Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser Leu Ser Cys Lys
          610          615          620
Lys Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu Arg Glu Glu Ile
  625          630          635          640
Ala Met Leu Arg Leu Glu Leu Asp Thr Met Lys His Gln Ser Gln Leu
          645          650          655

```

<210> 380
 <211> 671
 <212> PRT
 <213> Homo sapien

```

          <400> 380
Met Val Val Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys Lys
  1          5          10          15
Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys Arg Cys Phe
          20          25          30
Pro Cys Cys Arg Glu Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp
          35          40          45
His Asp Asp Ser Ala Met Lys Thr Leu Arg Ser Lys Met Gly Lys Trp
          50          55          60
Cys Arg His Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val
  65          70          75          80
Gly Ala Ser Gly Asp His Asp Asp Ser Ala Met Lys Thr Leu Arg Asn
          85          90          95
Lys Met Gly Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser
          100          105          110

```

Gly	Lys	Ser	Lys	Val	Gly	Ala	Trp	Gly	Asp	Tyr	Asp	Asp	Ser	Ala	Phe
	115						120					125			
Met	Glu	Pro	Arg	Tyr	His	Val	Arg	Gly	Glu	Asp	Leu	Asp	Lys	Leu	His
	130						135					140			
Arg	Ala	Ala	Trp	Trp	Gly	Lys	Val	Pro	Arg	Lys	Asp	Leu	Ile	Val	Met
	145					150				155					160
Leu	Arg	Asp	Thr	Asp	Val	Asn	Lys	Lys	Asp	Lys	Gln	Lys	Arg	Thr	Ala
			165						170					175	
Leu	His	Leu	Ala	Ser	Ala	Asn	Gly	Asn	Ser	Glu	Val	Val	Lys	Leu	Leu
			180					185					190		
Leu	Asp	Arg	Arg	Cys	Gln	Leu	Asn	Val	Leu	Asp	Asn	Lys	Lys	Arg	Thr
	195						200					205			
Ala	Leu	Ile	Lys	Ala	Val	Gln	Cys	Gln	Glu	Asp	Glu	Cys	Ala	Leu	Met
	210					215					220				
Leu	Leu	Glu	His	Gly	Thr	Asp	Pro	Asn	Ile	Pro	Asp	Glu	Tyr	Gly	Asn
	225					230					235				240
Thr	Thr	Leu	His	Tyr	Ala	Ile	Tyr	Asn	Glu	Asp	Lys	Leu	Met	Ala	Lys
			245						250					255	
Ala	Leu	Leu	Leu	Tyr	Gly	Ala	Asp	Ile	Glu	Ser	Lys	Asn	Lys	His	Gly
			260					265					270		
Leu	Thr	Pro	Leu	Leu	Leu	Gly	Val	His	Glu	Gln	Lys	Gln	Gln	Val	Val
		275					280					285			
Lys	Phe	Leu	Ile	Lys	Lys	Lys	Ala	Asn	Leu	Asn	Ala	Leu	Asp	Arg	Tyr
	290					295					300				
Gly	Arg	Thr	Ala	Leu	Ile	Leu	Ala	Val	Cys	Cys	Gly	Ser	Ala	Ser	Ile
	305					310					315				320
Val	Ser	Leu	Leu	Leu	Glu	Gln	Asn	Ile	Asp	Val	Ser	Ser	Gln	Asp	Leu
				325					330					335	
Ser	Gly	Gln	Thr	Ala	Arg	Glu	Tyr	Ala	Val	Ser	Ser	His	His	His	Val
			340					345					350		
Ile	Cys	Gln	Leu	Leu	Ser	Asp	Tyr	Lys	Glu	Lys	Gln	Met	Leu	Lys	Ile
		355					360					365			
Ser	Ser	Glu	Asn	Ser	Asn	Pro	Glu	Gln	Asp	Leu	Lys	Leu	Thr	Ser	Glu
	370					375					380				
Glu	Glu	Ser	Gln	Arg	Phe	Lys	Gly	Ser	Glu	Asn	Ser	Gln	Pro	Glu	Lys
	385					390				395					400
Met	Ser	Gln	Glu	Pro	Glu	Ile	Asn	Lys	Asp	Gly	Asp	Arg	Glu	Val	Glu
				405					410					415	
Glu	Glu	Met	Lys	Lys	His	Glu	Ser	Asn	Asn	Val	Gly	Leu	Leu	Glu	Asn
			420					425					430		
Leu	Thr	Asn	Gly	Val	Thr	Ala	Gly	Asn	Gly	Asp	Asn	Gly	Leu	Ile	Pro
		435					440					445			
Gln	Arg	Lys	Ser	Arg	Thr	Pro	Glu	Asn	Gln	Gln	Phe	Pro	Asp	Asn	Glu
		450				455					460				
Ser	Glu	Glu	Tyr	His	Arg	Ile	Cys	Glu	Leu	Val	Ser	Asp	Tyr	Lys	Glu
	465				470					475					480
Lys	Gln	Met	Pro	Lys	Tyr	Ser	Ser	Glu	Asn	Ser	Asn	Pro	Glu	Gln	Asp
				485					490					495	
Leu	Lys	Leu	Thr	Ser	Glu	Glu	Glu	Ser	Gln	Arg	Leu	Glu	Gly	Ser	Glu
			500					505					510		
Asn	Gly	Gln	Pro	Glu	Lys	Arg	Ser	Gln	Glu	Pro	Glu	Ile	Asn	Lys	Asp
		515						520				525			
Gly	Asp	Arg	Glu	Leu	Glu	Asn	Phe	Met	Ala	Ile	Glu	Glu	Met	Lys	Lys
	530					535					540				
His	Gly	Ser	Thr	His	Val	Gly	Phe	Pro	Glu	Asn	Leu	Thr	Asn	Gly	Ala
	545				550					555					560
Thr	Ala	Gly	Asn	Gly	Asp	Asp	Gly	Leu	Ile	Pro	Pro	Arg	Lys	Ser	Arg
			565						570					575	

Thr Pro Glu Ser Gln Gln Phe Pro Asp Thr Glu Asn Glu Glu Tyr His
 580 585 590
 Ser Asp Glu Gln Asn Asp Thr Gln Lys Gln Phe Cys Glu Glu Gln Asn
 595 600 605
 Thr Gly Ile Leu His Asp Glu Ile Leu Ile His Glu Glu Lys Gln Ile
 610 615 620
 Glu Val Val Glu Lys Met Asn Ser Glu Leu Ser Leu Ser Cys Lys Lys
 625 630 635 640
 Glu Lys Asp Ile Leu His Glu Asn Ser Thr Leu Arg Glu Glu Ile Ala
 645 650 655
 Met Leu Arg Leu Glu Leu Asp Thr Met Lys His Gln Ser Gln Leu
 660 665 670

<210> 381
 <211> 251
 <212> DNA
 <213> Homo sapien

<400> 381
 ggagaagcgt ctgctggggc aggaaggggt ttccctgccc tctcacctgt ccctcaccaa 60
 ggtaacatgc ttcccctaag ggtatcccaa cccagggggc tcaccatgac ctctgagggg 120
 ccaatatccc aggagaagca ttggggaggt gggggcaggt gaaggaccca ggactcacac 180
 atcctggggc tccaaggcag aggagagggg cctcaagaag gtcaggagga aaatccgtaa 240
 caagcagtcg g 251

<210> 382
 <211> 3279
 <212> DNA
 <213> Homo sapiens

<400> 382
 cttcctgcag ccccatgct ggtgaggggc acgggcagga acagtggacc caacatggaa 60
 atgctggagg gtgtcaggaa gtgatcgggc tctggggcag ggaggagggg tggggagtgt 120
 cactgggagg ggacatcctg cagaaggtag gagtgcagaa acacccgctg caggggaggg 180
 gagagccctg cggcacctgg gggagcagag ggagcagcac ctgccaggc ctgggaggag 240
 gggcctggag ggcgtgagga ggagcgaggg ggctgcatgg ctggagttag ggatcagggg 300
 cagggcgcgga gatggcctca cacagggaag agagggcccc tcctgcaggg cctcacctgg 360
 gccacaggag gacactgctt ttctctgag gagtgcaggag ctgtggatgg tgctggacag 420
 aagaaggaca gggcctggct cagggtgtcca gaggtgtcgc ctggcttccc tttgggatca 480
 gactgcaggg agggagggcg gcagggttgt ggggggagtg acgatgagga tgacctgggg 540
 gtggctccag gccttgcccc tgctggggc ctcacccagc ctccctcaca gtctcctggc 600
 cctcagtcct tcccctccac tccatcctcc atctggcctc agtgggtcat tctgatcact 660
 gaactgacca taccagccc tgcccacggc cctccatggc tcccgaatgc cctggagagg 720
 ggacatctag tcagagagta gtcctgaaga ggtggcctct gcgatgtgcc tgtgggggca 780
 gcatectgca gatggctccg gccctcatcc tgctgacctg tctgcaggga ctgtcctcct 840
 ggaccttgcc ccttgtgcag gagctggacc ctgaagtccc ctcccatag gccaagactg 900
 gagccttggt cctctgttg gactccctgc ccatattctt gtgggagtgg gttctggaga 960
 catttctgtc tgttctctgag agctgggaat tgctctcagt catctgcctg cgcgggttctg 1020
 agagatggag ttgcctaggc agttattggg gccaatcttt ctactgtgt ctctcctcct 1080
 ttacccttag ggtgattctg ggggtccact tgtctgtaat ggtgtgcttc aaggtatcac 1140
 atcatggggc cctgagccat gtgccctgcc tgaaaagcct gctgtgtaca ccaaggtggg 1200
 gcattaccgg aagtgatca aggacaccat cgcagccaac ccctgagtgc ccctgtccca 1260
 cccctacctc tagtaaatct aagtcacact cacgttctgg catcacttgg cctttctgga 1320
 tgctggacac ctgaagcttg gaactcacct ggccgaagct cgagcctcct gagtccctact 1380
 gacctgtgct ttctgggtgtg gagtccaggg ctgctaggaa aaggaatggg cagacacagg 1440
 tgtatgcaa tgtttctgaa atgggtataa tttcgtctc tccttcggaa cactggctgt 1500
 ctctgaagac ttctcgctca gtttcagtga ggacacacac aaagacgtgg gtgacctgt 1560
 tgtttgtggg gtgcagagat gggaggggtg gggccacccc tggaagagtg gacagtgcac 1620

```

caaggtggac actctctaca gatcactgag gataagctgg agccacaatg catgaggcac 1680
acacacagca aggttgacgc tgtaaacata gcccaacgctg tcctgggggc actgggaagc 1740
ctagataagg ccgtgagcag aaagaagggg aggatcctcc tatgttggtg aaggaggagc 1800
tagggggaga aactgaaagc tgattaatta caggagggtt gtccagggtc cccaaaccac 1860
cgtcagattt gatgatttcc tagcaggact tacagaaata aagagctatc atgctgtggt 1920
ttattatggt ttgttacatt gataggatac atactgaaat cagcaaaca aacagatgta 1980
tagattagag tgtggagaaa acagaggaaa acttgcagtt acgaagactg gcaacttggc 2040
tttactaagt tttcagactg gcaggaagtc aaacctatta ggctgaggac cttgtggagt 2100
gtagctgac cagctgatag aggaactagc caggtggggg cctttccctt tggatggggg 2160
gcatatccga cagttattct ctccaagtgg agacttacgg acagcatata attctccctg 2220
caaggatgta tgataatatg tacaaagtaa ttccaactga ggaagctcac ctgatcctta 2280
gtgtccaggg tttttactgg ggggtctgtg gacgagtatg gagtacttga ataattgacc 2340
tgaagtctc agacctgagg ttccctagag ttcaaacaga tacagcatgg tccagagtcc 2400
cagatgtaca aaacaggga ttcatcaca atcccatctt tagcatgaag ggtctggcat 2460
ggcccaaggc cccaagtata tcaaggcact tgggcagAAC atgccaagga atcaaagtgc 2520
atctcccagg agttattcaa gggtagagcc tttacttggg atgtacaggc tttgagcagt 2580
gcagggctgc tgagtcaacc ttttattgta caggggatga gggaaaggga gaggatgagg 2640
aagccccctt ggggatttgg tttggtcttg tgatcaggtg gtctatgggg ctatccctac 2700
aaagaagaat ccagaaatag gggcacattg aggaatgata ctgagcccaa agagcattca 2760
atcattgttt tatttgctt cttttcacac cattggtgag ggagggatta ccaccctggg 2820
gttatgaaga tgggtgaaca cccacacat agcaccggag atatgagatc aacagtttct 2880
tagccataga gattcacagc ccagagcagg aggacgctgc acaccatgca ggatgacatg 2940
ggggatgcgc tcgggatttg tgtgaagaag caaggactgt tagaggcagg ctttatagta 3000
acaagacggt ggggcaaact ctgatttccg tgggggaatg tcatggtctt gctttactaa 3060
gttttgagac tggcaggtag tgaaactcat taggctgaga accttgtgga atgcagctga 3120
cccagctgat agaggaagta gccaggtggg agcctttccc agtgggtgtg ggacatatct 3180
ggcaagattt tgtggcactc ctggttacag atactggggc agcaaataaa actgaatctt 3240
gttttcagac cttaaaaaaa aaaaaaaaaa aaaagtttt 3279

```

<210> 383

<211> 154

<212> PRT

<213> Homo sapiens

<400> 383

```

Met Ala Gly Val Arg Asp Gln Gly Gln Gly Ala Arg Trp Pro His Thr
          5                      10                      15

```

```

Gly Lys Arg Gly Pro Leu Leu Gln Gly Leu Thr Trp Ala Thr Gly Gly
          20                      25                      30

```

```

His Cys Phe Ser Ser Glu Glu Ser Gly Ala Val Asp Gly Ala Gly Gln
          35                      40                      45

```

```

Lys Lys Asp Arg Ala Trp Leu Arg Cys Pro Glu Ala Val Ala Gly Phe
          50                      55                      60

```

```

Pro Leu Gly Ser Asp Cys Arg Glu Gly Gly Arg Gln Gly Cys Gly Gly
          65                      70                      75                      80

```

```

Ser Asp Asp Glu Asp Asp Leu Gly Val Ala Pro Gly Leu Ala Pro Ala
          85                      90                      95

```

```

Trp Ala Leu Thr Gln Pro Pro Ser Gln Ser Pro Gly Pro Gln Ser Leu
          100                      105                      110

```

```

Pro Ser Thr Pro Ser Ser Ile Trp Pro Gln Trp Val Ile Leu Ile Thr
          115                      120                      125

```

Glu Leu Thr Ile Pro Ser Pro Ala His Gly Pro Pro Trp Leu Pro Asn
 130 135 140

Ala Leu Glu Arg Gly His Leu Val Arg Glu
 145 150

<210> 384
 <211> 557
 <212> DNA
 <213> Homo sapiens

<400> 384
 ggatcctcta gagcgccgc ctactactac taaattcgcg gccgcgtcga cgaagaagag 60
 aaagatgtgt tttgttttg actctctgtg gtcccttcca atgctgtggg tttccaacca 120
 gyygaagggt cccttttgca ttgccaagt ccataaccat gagcactact ctaccatggg 180
 tctgcctcct ggccaagcag gctggtttgc aagaatgaaa tgaatgattc tacagctagg 240
 acttaacctt gaaatggaaa gtcttgcaat cccatttgca ggatccgtct gtgcacatgc 300
 ctctgtagag agcagcattc ccagggacct tggaaacagt tggcactgta aggtgcttgc 360
 tccccagac acatcctaaa aggtgttgta atggtgaaa cgtcttcctt ctttattgcc 420
 ccttcttatt tatgtgaaca actgtttgtc tttttttgta tcttttttaa actgtaaagt 480
 tcaattgtga aaatgaatat catgcaaata aattatgcga ttttttttcc aaagtaaaaa 540
 aaaaaaaaa aaaaaaa 557

<210> 385
 <211> 337
 <212> DNA
 <213> Homo sapiens

<400> 385
 ttcccagggtg atgtgcgagg gaagacacat ttactatcct tgatggggct gattccttta 60
 gtttctctag cagcagatgg gttaggagga agtgaccaa gtggttgact cctatgtgca 120
 tctcaaagcc atctgtgtc ttcgagtagc gacacatcat cactcctgca ttgttgatca 180
 aaacgtggag gtgcttttcc tcagctaaga agcccttagc aaaagctcga atagacttag 240
 tatcagacag gtccagtttc cgcaccaaca cctgctggtt ccctgtcgtg gtctggatct 300
 ctttgccac caattcccc tttccacat cccggca 337

<210> 386
 <211> 300
 <212> DNA
 <213> Homo sapiens

<400> 386
 gggcccgtc cggcccagg ccccgctcg cgagtcctcc tcccgggtg cctgcccga 60
 gccgctcgg ccagaggggt gggcgcggg ctgcctctac cggctggcg ctgtaactca 120
 gcgaccttg ccgaaggct ctagcaagga cccaccgacc ccagccgcg cggcggcggc 180
 gcggactttg ccggtgtgt gggcgggagc ggactgcgtg tccgcgacg ggcagcgaag 240
 atgttagcct tcgctgccag gaccgtggac cgatcccagg gctgtggtgt aacctcagcc 300

<210> 387
 <211> 537
 <212> DNA
 <213> Homo sapiens

<400> 387
 gggccgagtc gggcaccaag ggactctttg caggcttcct tctcggatc atcaaggctg 60
 cccctcctg tgccatcatg atcagcacct atgagttcgg caaaagcttc ttccagaggc 120

```

tgaaccagga ccggtctctg ggaggctgaa aggggcaagg aggcaaggac cccgtctctc 180
ccacggatgg ggagagggca ggaggagacc cagccaagtg ccttttcctc agcactgagg 240
gagggggcctt gtttcccttc cctcccggcg acaagctcca gggcagggct gtccctctgg 300
gcggcccagc acttcctcag acacaacttc ttctgtctgc tccagtcgtg gggatcatca 360
cttaccacc ccccaagttc aagaccaaatt cttccagctg ccccttcgt gtttccctgt 420
gtttgtctga gctgggcatg tctccaggaa ccaagaagcc ctcagcctgg tgtagtctcc 480
ctgacccttg ttaattcctt aagtctaaag atgatgaact tcaaaaaaaa aaaaaaa 537

```

<210> 388

<211> 520

<212> DNA

<213> Homo sapiens

<400> 388

```

aggataattt ttaaaccaat caaatgaaaa aaacaaacaa acaaaaaagg aaatgtcatg 60
tgagggttaaa ccagtttgca ttcccctaatt gtggaaaaag taagaggact actcagcact 120
gtttgaagat tgctcttctt acagcttctg agaatttgtt tatttcactt gccaaagtga 180
ggacccccctc cccaacatgc ccagcccac ccctaagcat ggtcccttgt caccaggcaa 240
ccaggaaact gctacttgtg gacctacca gagaccagga gggtttggtt agctcacagg 300
acttccccca cccagaaga ttagcatccc atactagact cataactcaac tcaactaggc 360
tcataactcaa ttgatggta ttagacaatt ccatttcttt ctggttatta taaacagaaa 420
atctttcctc ttctcattac cagtaaaggc tcttggtatc tttctgttgg aatgatttct 480
atgaacttgt cttattttta tgggtgggtt ttttctggt 520

```

<210> 389

<211> 365

<212> DNA

<213> Homo sapiens

<400> 389

```

cggtgcccc gtttgacaga aggaaaggcg gagcttattc aaagtctaga gggagtggag 60
gagtttaaggc tggatttcag atctgcctgg ttccagccgc agtgtgccct ctgctcccc 120
aacgactttc caaataatct caccagcgcc ttccagctca ggcgtcctag aagcgtcttg 180
aagcctatgg ccagctgtct ttgtgttccc tctcaccgc ctgtcctcac agctgagact 240
cccaggaaac cttcagacta ccttcctctg ccttcagcaa ggggcgttgc ccacattctc 300
tgagggtcag tggaagaacc tagactccca ttgctagagg tagaaagggg aagggtgctg 360
gggag 365

```

<210> 390

<211> 221

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(221)

<223> n = A,T,C or G

<400> 390

```

tgctctccca tcttgcccc gacttctctg tcaggaaagt ggggatggac cccatctgca 60
tacacggnnt ctcatgggtg tggaacatct ctgcttgagg ttccaggaag gcctctggct 120
gctctangag tctgannga ntogttgccc cantntgaca naaggaaagg cggagcttat 180
tcaaagtcta gagggagtgg aggagttaag gctggatttc a 221

```

<210> 391

<211> 325

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(325)
 <223> n = A,T,C or G

<400> 391
 tggagcaggt cccgaggcct ccctagagcc tggggccgac tctgtgncga tgcangcttt 60
 ctctcgcgcc cagcctggag ctgctcctgg catctaccaa caatcagncg aggcgagcag 120
 tagccagggc actgctgcca acagccagtc cnnataccat catgtnaccc ggtgngctct 180
 naanttingat ntccanagcc ctacccatcn tagttctgct ctcccacgg ntaccagccc 240
 cactgcccag gaatcctaca gccagtaccc tgtcccagcg tctctaccta ccagtacgat 300
 gagacctccg gctactacta tgacc 325

<210> 392
 <211> 277
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(277)
 <223> n = A,T,C or G

<400> 392
 atattgttta actccttccct ttatatcttt taacattttc atggngaaaag gttcacatct 60
 agtctcactt nggcnagnn ctctacttg agtctcttcc ccggcctggn ccagtnghaa 120
 antaccanga accgncatgn cttanaaen nctgggttn tgggttnntc aatgactgca 180
 tgcagtgcac caccctgtcc actacgtgat gctgtaggat taaagtctca cagtgggcgg 240
 ctgaggatac agcgccgcgt cctgtgttgc tggggaa 277

<210> 393
 <211> 566
 <212> DNA
 <213> Homo sapiens

<400> 393
 actagtccag tgtgggtggaa ttcggggccg cgtcgacgga caggtcagct gtctggctca 60
 gtgatctaca ttctgaagtt gtctgaaaat gtcttcatga ttaaattcag cctaaacggt 120
 ttgccgggaa cactgcagag acaatgctgt gaggtttcaa ccttagccca tctgcgggca 180
 gagaaggctc agtttgtcca tcagcattat catgatata ggactgggta cttgggtaag 240
 gaggggtcta ggagatctgt cctttttaga gacaccttac ttataatgaa gtatttggga 300
 ggggtggttt caaaagtaga aatgtcctgt attccgatga tcatcctgta aacattttat 360
 catttattaa tcatccctgc ctgtgtctat tattatattc atatctctac gctggaaact 420
 ttctgcctca atgtttactg tgcccttgtt ttgtctagtt tgtgtgtgtg aaaaaaaaaa 480
 cattctctgc ctgagtttta atttttgtcc aaagttattt taatctatac aattaaaagc 540
 ttttgcctat caaaaaaaaa aaaaaa 566

<210> 394
 <211> 384
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(384)
 <223> n = A,T,C or G

<400> 394
gaacatacat gtccccggcac ctgagctgca gtctgacatc atcgccatca cgggcctcgc 60
tgcaaattng gaccggggcca aggctggact gctggagcgt gtgaaggagc tacaggccna 120
gcaggaggac cgggctttta ggagttttta gctgagtgtc actgtagacc ccaaatacca 180
tcccaagatt atcgggagaa agggggcagt aattacccaa atccggttgg agcatgacgt 240
gaacatccag tttcctgata aggacgatgg gaaccagccc caggaccaa ttaccatcac 300
agggtacgaa aagaacacag aagctgccag ggatgctata ctgagaattg tgggtgaact 360
tgagcagatg gtttctgagg acgt 384

<210> 395
<211> 399
<212> DNA
<213> Homo sapiens

<400> 395
ggcaaaactg tgtgacctca ataagacctc gcagatccaa ggtcaagtat cagaagtgc 60
tctgaccttg gactccaaga cctacatcaa cagcctggct atattagatg atgagccagt 120
tatcagaggt ttcattcattg cggaaattgt ggagtctaag gaaatcatgg cctctgaagt 180
attcacgtct ttccagtacc ctgagttctc tatagagttg cctaacacag gcagaattgg 240
ccagctactt gtctgcaatt gtatcttcaa gaataccctg gccatccctt tgactgacgt 300
caagttctct ttggaaagcc tgggcatctc ctactacag acctctgacc atgggacggt 360
gcagcctggt gagaccatcc aatcccaaat aaaatgcac 399

<210> 396
<211> 403
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(403)
<223> n = A,T,C or G

<400> 396
tggagtntc agtgcaaaca agccataaag cttcagtagc aaattactgt ctcacagaaa 60
gacattttca acttctgctc cagctgctga taaaacaaat catgtgttta gcttgactcc 120
agacaaggac aacctgttcc ttcataactc tctagagaaa aaaaggagtt gttagtagat 180
actaaaaaaaa gtggatgaat aatctggata tttttcctaa aaagattcct tgaaacacat 240
taggaaaaatg gagggcctta tgatcagaat gctagaatta gtccattgtg ctgaagcagg 300
gtttagggga gggagtgagg gataaaagaa ggaaaaaaag aagagtgaga aaacctattt 360
atcaaagcag gtgctatcac tcaatgtag gcctgtctct ttt 403

<210> 397
<211> 100
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(100)
<223> n = A,T,C or G

<400> 397
actagtncag tgtggtggaa ttcgoggccg cgctgacctc naanccatct ctatagcaaa 60
tccatccccg ctctgtgttg gtnacagaat gactgacaaa 100

<210> 398
<211> 278

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(278)

<223> n = A,T,C or G

<400> 398

```
gcggccgcgt cgacagcagt tccgccagcg ctcgccctg ggtggggatg tgctgcacgc 60
ccacctggac atctggaagt cagcggcctg gatgaaagag cggacttcac ctggggcgat 120
tactactgt gcctcgacca gtgaggagag ctggaccgac agcgagggtg actcatcatg 180
ctccgggcag cccatccacc tgtggcagtt cctcaaggag ttgctactca agccccacag 240
ctatggccgc ttcattangt ggctcaacaa ggagaagg 278
```

<210> 399

<211> 298

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(298)

<223> n = A,T,C or G

<400> 399

```
acggagggtg aggaagcgnc cctgggatcg anaggatggg tcctgncatt gaccncctcn 60
ggggtgccng catggagcgc atgggcgcgg gcctgggcca cggcatggat cgcgtgggct 120
ccgagatcga gcgcattggc ctggcatgg accgcatggg ctccgtggag cgcattgggct 180
ccggcattga gcgcattggc ccgctgggce tcgaccacat ggctccanc attganccga 240
tgggccagac catggagcgc attggctctg gcgtggagcn catgggtgcc ggcattggg 298
```

<210> 400

<211> 548

<212> DNA

<213> Homo sapiens

<400> 400

```
acatcaacta cttcctcatt ttaagggtatg gcagttccct tcatcccctt ttcctgcctt 60
gtacatgtac atgtatgaaa ttctcttctc ttaccgaact ctctccacac atcacaagg 120
caaagaacca cacgcttaga agggtaagag ggcaccctat gaaatgaaat ggtgatttct 180
tgagtctctt tttccacgt ttaaggggccc atggcaggac ttagagttgc gagttaagac 240
tgcagagggc tagagaatta ttccatacag gctttgaggc caccatgtc acttatccc 300
tataccctct caccatcccc ttgtctactc tgatgcccc aagatgcaac tgggcagcta 360
gttggcccca taattctggg cctttgttgt ttgttttaat tacttgggca tcccaggaag 420
ctttccagt atctctacc atggggcccc ctctgggat caagcccctc ccaggccctg 480
tccccagccc ctctgcccc agcccacccg cttgccttgg tgctcagccc tcccattggg 540
agcaggtt 548
```

<210> 401

<211> 355

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(355)

<223> n = A,T,C or G

```

<400> 401
actgtttcca tgttatgttt ctacacattg ctacctcagt gtccttgga acttagcttt 60
tgatgtctcc aagtagtcca ccttcattta actccttgaa actgtatcat ctttgccaag 120
taagagtggg ggcctatttc agctgctttg acaaaatgac tggctcctga cttaacgttc 180
tataaatgaa tgtgctgaag caaagtgcc atggtggcgg cgaagaagan aaagatgtgt 240
tttgttttg actctctgtg gtcccttcca atgctgnngg tttccaacca ggggaagggt 300
cccttttgca ttgccaagtg ccataacat gagcactact ctaccatggn tctgc 355

```

```

<210> 402
<211> 407
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(407)
<223> n = A,T,C or G

```

```

<400> 402
atggggcaag ctggataaag aaccaagacc cactggagta tgctgtcttc aagaaaccca 60
tctcacatgc ggtggcatcac ataggctcaa aataaaggaa tggagaaaaa tatttcaagc 120
aaatggaaaa cagaaaaaag caggtgttgc actcctactt tctgacaaaa cagactatgc 180
gaataaagat aaaaaagaga aggacattac aaaggtggtc ctgacctttg ataatctca 240
ttgttgata ccaacctggg ctgttttaat tgcccaaacc aaaaggataa tttgctgagg 300
ttgtggagct tctcccctgc agagagtcctc tgatctccca aaatttggtt gagatgtaag 360
gntgatattg ctgacaactc cttttctgaa gttttactca tttccaa 407

```

```

<210> 403
<211> 303
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (1)...(303)
<223> n = A,T,C or G

```

```

<400> 403
cagtatttat agccnaactg aaaagctagt agcaggcaag tctcaaatcc aggcaccaa 60
tcctaagcaa gagccatggc atggtgaaaa tgcaaaagga gagtctggcc aatctacaaa 120
tagagaacaa gacctactca gtcataaaca aaaaggcaga caccaacatg gatctcatgg 180
gggattggat attgtaatta tagagcagga agatgacagt gatcgctatt tggcacaaca 240
tcttaacaac gaccgaaacc cattatttac ataaacctcc attcggtaac catgttgaaa 300
gga 303

```

```

<210> 404
<211> 225
<212> DNA
<213> Homo sapiens

```

```

<400> 404
aagtgttaact tttaaaaatt tagtggattt tgaaaattct tagaggaaag taaaggaaaa 60
attgttaatg cactcattta cctttacatg gtgaaagtgc tctcttgatc ctacaaacag 120
acattttcca ctctgttttc catagtgtt aagtgtatca gatgtgttgg gcatgtgaat 180
ctccaagtgc ctgtgtaata aataaagtat ctttatttca ttcat 225

```

```

<210> 405

```


<211> 334
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(334)
<223> n = A,T,C or G

<400> 405
gagctgttat actgtgagtt ctactaggaa atcatcaa atctgaggggtg tctggaggac 60
ttcaatacac ctcccccat agtgaatcag cttccagggg gtccagtccc tctccttact 120
tcatccccat cccatgccaa aggaagaccc tccctccttg gctcacagcc ttctctaggc 180
ttccagtgct ctccaggaca gaggggggtta tgttttcagc tccatccttg ctgtgagtg 240
ctggtgcggg tgtgcctcca gcttctgctc agtgcttcat ggacagtgtc cagcccatgt 300
cactctccac tctctcannn tggatccac ccct 334

<210> 406
<211> 216
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(216)
<223> n = A,T,C or G

<400> 406
tttcatacct aatgaggag ttganatnac atnnaaccag gaaatgcatg gatctcaang 60
gaaacaaaca cccaataaac tcggagtggc agactgacaa ctgtgagaca tgcacttgct 120
acnaaacaca aatttntatgt tgcacccttg tttctacacc tgtgggttat gacaaagaca 180
actgccaaag aatnttcaag aaggaggact gccant 216

<210> 407
<211> 413
<212> DNA
<213> Homo sapiens

<400> 407
gttgacttgc tagtatcatc tgcattcatt gaagcacaag aacttcatgc cttgactcat 60
gtaaatgcaa taggattaaa aaataaattt gatatcacat ggaaacagac aaaaaatatt 120
gtacaacatt gcaccagtg tcagattcta cacctggcca ctccaggaagc aagagttaat 180
cccagaggtc tatgtcctaa tgtgttatgg caaatggatg tcatgcacgt accttcattt 240
ggaaaattgt catttgtcca tgtgacagtt gatacttatt cacatttcat atgggcaacc 300
tgccagacag gagaaagtct tcccatgtta aaagacattt attatcttgt tttcctgtca 360
tgggagttcc agaaaaagtt aaaacagaca atggggccagg ttctgtagta aag 413

<210> 408
<211> 183
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(183)
<223> n = A,T,C or G

<400> 408

ggagctngcc ctcaattcct ccatntctat gttancatat ttaatgtctt ttgnnattaa 60
tnccttaacta gttaatcctt aaagggctan ntaatcctta actagtcctt ccatgtgag 120
cattatcctt ccagtatctn ccttctnttt tatttactcc ttcctggcta cccatgtact 180
ntt 183

<210> 409
<211> 250
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(250)
<223> n = A,T,C or G

<400> 409
cccacgcatg ataagctctt tatttctgta agtctctgta ggaaatcatc aaatctgacg 60
gtgggtttggg ggacctgaac aaacctcctg taattaatca gctttcagtt tctcccccta 120
gtccctcctt caacaacata ggaggatcct ccccttcttt ctgctcacgg ccttatctag 180
gcttcccagt gccccaggga cagcgtgggc tatgtttaca gcgntcctt gctggggggg 240
ggcctatgc 250

<210> 410
<211> 306
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(306)
<223> n = A,T,C or G

<400> 410
ggctggtttg caagaatgaa atgaatgatt ctacagctag gacttaacct tgaaatggaa 60
agtcttgcaa tcccatttgc aggatccgtc tgtgcacatg cctctgtaga gagcagcatt 120
cccagggaacc ttggaacag ttggcactgt aagggtgctt ctccccaaga cacatcctaa 180
aagggtgttg aatggtgaaa accgcttctt tctttattgc cccttcttat ttatgtgaac 240
nactggttgg ctttttttgn atctttttta aactggaaag ttcaattgng aaaatgaata 300
tcntgc 306

<210> 411
<211> 261
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(261)
<223> n = A,T,C or G

<400> 411
agagatattn cttaggtnaa agttcataga gttcccatga actatatgac tggccacaca 60
ggatcttttg tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaattgc tgaaatggaa cagatttcaa aaaaaaaccc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa ggngaggcaa a 261

<210> 412

<211> 241
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(241)
<223> n = A,T,C or G

<400> 412
gttcaatggt acctgacatt tctacaacac cccactcacc gatgtattcg ttgcccagtg 60
ggaacatacc agcctgaatt tggaaaaaat aattgtgttt cttgcccagg aaatactacg 120
actgactttg atggctccac aaacataacc cagtgtaaaa acagaagatg tggaggggag 180
ctgggagatt tctactgggta cattgaattc ccaaactacc cangcaatta cccagccaac 240
a 241

<210> 413
<211> 231
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(231)
<223> n = A,T,C or G

<400> 413
aactcttaca atccaagtga ctcatctgtg tgcttgaatc ctttccactg tctcatctcc 60
ctcatccaag tttctagtag cttctctttg ttgtgaagga taatcaaact gaacaacaaa 120
aagtttactc tcctcatttg gaacctaaaa actctcttct tcctgggtct gaggggtcca 180
agaatccttg aatcanttct cagatcattg gggacaccan atcaggaacc t 231

<210> 414
<211> 234
<212> DNA
<213> Homo sapiens

<400> 414
actgtccatg aagcactgag cagaagctgg aggcacaacg caccagacac tcacagcaag 60
gatggagctg aaaacataac ccactctgtc ctggaggcac tgggaagcct agagaaggct 120
gtgagccaag gagggagggt cttccttttg catgggatgg ggatgaagta aggagaggga 180
ctggaccccc tggaagctga ttcactatgg ggggaggtgt attgaagtcc tcca 234

<210> 415
<211> 217
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(217)
<223> n = A,T,C or G

<400> 415
gcataggatt aagactgagt atcttttcta cattctttta acttttctaag gggcacttct 60
caaaacacag accaggtagc aaatctccac tgctctaagg ntctcaccac cacttttctca 120
cacctagcaa tagtagaatt cagtcctact tctgaggcca gaagaatggt tcagaaaaat 180
antggattat aaaaaataac aattaagaaa aataatc 217

<210> 416
<211> 213
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(213)
<223> n = A,T,C or G

<400> 416
atgcatatnt aaagganact gcctcgcttt tagaagacat ctggncctgct ctctgcatga 60
ggcacagcag taaagctctt tgattcccag aatcaagaac tctccccttc agactattac 120
cgaatgcaag gtggttaatt gaaggccact aattgatgct caaatagaag gatattgact 180
atattggaac agatggagtc tctactacaa aag 213

<210> 417
<211> 303
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(303)
<223> n = A,T,C or G

<400> 417
nagtcttcag gcccatcagg gaagttcaca ctggagagaa gtcatacata tgtactgtat 60
gtgggaaagg ctttactctg agttcaaata ttcaagccca tcagagagtc cacactggag 120
agaagccata caaatgcaat gagtggtgga agagcttcag gagggattcc cattatcaag 180
ttcatctagt ggtccacaca ggagagaaac cctataaatg tgagatatgt gggaagggct 240
tcantcaaag ttcgtatctt caaatccatc ngaaggncca cagtatanan aaacctttta 300
agt 303

<210> 418
<211> 328
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(328)
<223> n = A,T,C or G

<400> 418
tttttggcgg tgggtggggca gggacgggac angagtctca ctctgttgcc caggctggag 60
tgcacaggca tgatctcggc tcactacaac ccctgcctcc catgtccaag cgattcttgt 120
gcctcagcct tccctgtagc tagaattaca ggcacatgcc accacaccca gctagttttt 180
gtatttttag tagagacagg gtttcaccat gttggccagg ctggtctcaa actcctnacc 240
tcagnggtca ggctgggtctc aaactcctga cctcaagtga tctgcccacc tcagcctccc 300
aaagtgctan gattacaggc cgtgagcc 328

<210> 419
<211> 389
<212> DNA
<213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(389)
 <223> n = A,T,C or G

<400> 419
 cctcctcaag acggcctgtg gtccgcctcc cggcaaccaa gaagcctgca gtgccatattg 60
 acccctgagc catggactgg agcctgaaag gcagcgtaca ccctgctcct gatcttgctg 120
 cttgtttcct ctctgtggct ccattcatag cacagttggt gactgaggc ttgtgcaggc 180
 cgagcaaggc caagctggct caaagagcaa ccagtcaact ctgccacggt gtgccaggca 240
 ccggttctcc agccaccaac ctactcgtc cccgcaaatt gcacatcagt tcttctaccc 300
 taaaggtagg accaaagggc atctgctttt ctgaagtctc ctgctctatc agccatcacg 360
 tggcagccac tcnggctgtg tcgacgcgg 389

<210> 420
 <211> 408
 <212> DNA
 <213> Homo sapiens

<400> 420
 gttcctccta actcctgcca gaaacagctc tcctcaacat gagagctgca cccctcctcc 60
 tggccagggc agcaagcctt agccttggct tcttgtttct gctttttttc tggctagacc 120
 gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
 gtccattga cacctttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
 gccaaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaaga 300
 gatatagaaa attcttgaat gagtccctata aacatgaaca ggtttatatt cgaagcacag 360
 acgttgaccg gactttgatg aagtgtctatg acaaacctgg caagcccg 408

<210> 421
 <211> 352
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(352)
 <223> n = A,T,C or G

<400> 421
 gctcaaaaat ctttttactg atnggcatgg ctacacaatc attgactatt acggaggcca 60
 gaggagaatg aggcctggcc tgggagccct gtgcctacta naagcacatt agattatcca 120
 ttactgaca gaacaggctc tttttgggtc cttcttctcc accacnatat acttgagtc 180
 ctccctcttg aagattcttt ggcagttgtc tttgtcataa cccacagggt tagaaaacaag 240
 ggtgcaacat gaaatttctg tttcgtagca agtgcatgtc tcacaagttg gcangtctgc 300
 cactccgagt ttattgggtg tttgtttcct ttgagatcca tgcatttcct gg 352

<210> 422
 <211> 337
 <212> DNA
 <213> Homo sapiens

<400> 422
 atgccacat gctggcaatg cagcgggcgg tcgaaggcct gcatatccag cccaagctgg 60
 cgatgatcga cggcaaccgt tgcccgaagt tgccgatgcc agccgaagcg gtgggtcaagg 120
 gcgatagcaa ggtgccggcg atcggcggcg cgtcaatcct ggccaaggtc agccgtgatc 180
 gtgaaatggc agctgtcgaa ttgatctacc cgggttatgg catcggcggg cataagggct 240
 atccgacacc ggtgcacctg gaagccttgc agcggctggg gccgacgccg attcaccgac 300
 gcttcttccg ccggtacggc tggcctatga aaattat 337

<210> 423
 <211> 310
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(310)
 <223> n = A,T,C or G

<400> 423
 gctcaaaaat ctttttactg atatggcatg gctacacaat cattgactat tagaggccag 60
 aggagaatga ggcctggcct gggagccctg tgcctactan aagcncatta gattatccat 120
 tcaactgacag aacaggtctt ttttgggtcc ttcttctcca ccacgatata cttgcagtcc 180
 tccttcttga agattctttg gcagtgtgtc ttgtcataac ccacaggtgt anaaacaagg 240
 gtgcaacatg aaatttctgt ttcgtagcaa gtgcatgtct cacagttgtc aagtctgccc 300
 tccgagttta 310

<210> 424
 <211> 370
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(370)
 <223> n = A,T,C or G

<400> 424
 gctcaaaaat ctttttactg ataggcatgg ctacacaatc attgactatt agaggccaga 60
 ggagaatgag gcctggcctg ggagccctgt gcctactaga agcacattag attatccatt 120
 cactgacaga acaggtcttt tttgggtcct tcttctccac cacgatatac ttgcagtcct 180
 ccttcttgaa gattcttttg cagttgtctt tgtcataacc cacaggtgta gaaacatcct 240
 gggtgaatct cctggaaactc cctcattagg tatgaaatag catgatgcat tgcataaagt 300
 cacgaaggtg gcaaagatca caacgctgcc cagganaaca ttcattgtga taagcaggac 360
 tccgtcgacg 370

<210> 425
 <211> 216
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(216)
 <223> n = A,T,C or G

<400> 425
 aattgctatn ntttattttg ccactcaaaa taattaccaa aaaaaaaaaa tnttaaatga 60
 taacaacnca acatcaaggn aananaaca ggaatggntg actntgcata aatnggccga 120
 anattatcca ttatnttaag gggtgacttc aggntacagc acacagacaa acatgcccag 180
 gaggnntnca ggaccgctcg atgtntntng aggagg 216

<210> 426
 <211> 596
 <212> DNA
 <213> Homo sapiens

<400> 426

```

cttccagtga ggataaccct gttgccccgg gccgagggtc tccattaggc tctgattgat 60
tggcagtcag tgatggaagg gtgttctgat cattccgact gcccgaaggg tcgctggcca 120
gctctctgtt ttgctgagtt ggcagtagga cctaatttgt taattaagag tagatggtga 180
gctgtccttg tattttgatt aacctaatgg ccttcccagc acgactcgga ttcagctgga 240
gacatcacgg caacttttaa tgaaatgatt tgaagggccca ttaagaggca cttcccgtta 300
ttaggcagtt catctgcact gataacttct tggcagctga gctggtcgga gctgtggccc 360
aaacgcacac ttggcttttg gttttgagat acaactctta atcttttagt catgcttgag 420
ggtggatggc cttttcagct ttaacccaat ttgactgcc ttggaagtgt agccaggaga 480
atacactcat atactcgtgg gcttagaggc cacagcagat gtcattgggt tactgcctga 540
gtcccgtggt tcccatcca ggaccttcca tcggcgagta cctgggagcc cgtgct 596

```

<210> 427

<211> 107

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(107)

<223> n = A,T,C or G

<400> 427

```

gaagaattca agttaggttt attcaaaggg cttacngaga atcctanacc caggnccag 60
cccgggagca gccttanaga gctcctgttt gactgcccgg ctcagn 107

```

<210> 428

<211> 38

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(38)

<223> n = A,T,C or G

<400> 428

```

gaacttcna anaangactt tattcactat tttacatt 38

```

<210> 429

<211> 544

<212> DNA

<213> Homo sapiens

<400> 429

```

ctttgctgga cggaataaaa gtggacgcaa gcatgacctc ctgatgaggg cgctgcattt 60
attgaagagc ggctgcagcc ctgcggttca gattaaaatc cgagaattgt atagacgccg 120
atatccacga actcttgaag gactttctga tttatccaca atcaaatcat cggttttcag 180
tttggatggt ggctcatcac ctgtagaacc tgacttgccc gtggctggaa tccactcgtt 240
gccttccact tcagttacac ctactcacc atcctctcct gttggttctg tgctgcttca 300
agatactaag cccacatttg agatgcagca gccatctccc ccaattcctc ctgtccatcc 360
tgatgtgcag ttaaaaaatc tgccctttta tgatgtcctt gatgttctca tcaagcccac 420
gagtttagtt caaagcagta ttcagcgatt tcaagagaag ttttttattt ttgctttgac 480
acctcaacaa gttagagaga tatgcataac cagggatttt ttgccagggt gtaggagaga 540
ttat 544

```

<210> 430

<211> 507
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(507)
<223> n = A,T,C or G

<400> 430
cttatcncaa tggggctccc aaacttggct gtgcagtgga aactccgggg gaattttgaa 60
gaacactgac acccatcttc caccocgaca ctctgattta attgggctgc agtgagaaca 120
gagcatcaat ttaaaaagct gcccagaatg ttntcctggg cagcgttgtg atctttgccn 180
ccttcgtgac tttatgcaat gcatcatgct atttcatacc taatgaggga gttccaggag 240
attcaaccag gatgtttcta cncctgtggg ttatgacaaa gacaactgcc aaagaatntt 300
caagaaggag gactgcaagt atatcgtggg ggagaagaag gacccaaaaa agacctgttc 360
tgtcagttaa tggataatct aatgtgcttc tagtaggcac agggctccca ggccaggcct 420
cattctcttc tggcctctaa tagtcaatga ttgtgtagcc atgcctatca gtaaaaagat 480
ttttgagcaa aaaaaaaaaa aaaaaaa 507

<210> 431
<211> 392
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(392)
<223> n = A,T,C or G

<400> 431
gaaaattcag aatggataaa aacaaatgaa gtacaaaata tttcagattt acatagcgat 60
aaacaagaaa gcacttatca ggaggactta caaatggaag tacactctan aaccatcatc 120
tatcatggct aaatgtgaga ttagcacagc tgtattattt gtacattgca aacacctaga 180
aagagatggg aaacaaaatc ccaggagttt tgtgtgtgga gtcctgggtt ttccaacaga 240
catcattcca gcattctgag attagggnga ttggggatca ttctggagtt ggaatgttca 300
acaaaagtga tgttggttag taaaatgtac aacttctgga tctatgcaga cattgaaggt 360
gcaatgagtc tggcttttac tctgctgttt ct 392

<210> 432
<211> 387
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(387)
<223> n = A,T,C or G

<400> 432
ggtatccnta cataatcaaa tatagctgta gtacatgttt tcattggngt agattaccac 60
aaatgcaagg caacatgtgt agatctcttg tcttattctt ttgtctataa tactgtattg 120
ngtagtccaa gctctcggn a gtccagccac tngaaacat gctcccttta gattaacctc 180
gtggacnctn ttgttgnatt gtctgaactg tagngccctg tatitttgctt ctgtctgnga 240
attctgttgc ttctgtggga ttctcttgng atgcagagga ccaccacaca gatgacagca 300
atctgaattg ntccaatcac agctgcgatt aagacatact gaaatcgtac aggaccggga 360
acaacgtata gaacactgga gtccttt 387

<210> 433
 <211> 281
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(281)
 <223> n = A,T,C or G

<400> 433
 ttcaactagc anagaanact gcttcagggn gtgtaaaatg aaaggcttcc acgcagttat 60
 ctgattaag aacactaaga gagggacaag gctagaagcc gcaggatgtc tacactatag 120
 caggcnctat ttgggttggc tggaggagct gtggaaaaca tggagagatt ggcgctggag 180
 atcgccgtgg ctattcctcn ttgntattac accagnaggg ntctctgtnt gccactgggt 240
 tnnaaaaccg ntatacaata atgatagaat aggacacaca t 281

<210> 434
 <211> 484
 <212> DNA
 <213> Homo sapiens

<400> 434
 ttttaaaata agcattttagt gctcagtcoc tactgagtag tctttctctc ccctcctctg 60
 aatttaattc tttcaacttg caatttgcaa ggattacaca tttcactgtg atgtatattg 120
 tgttgcaaaa aaaaaaaagt gtctttgttt aaaattactt ggtttgtaga tccatcttgc 180
 tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa acatctgaag 240
 agctagtcta tcagcatctg acaggtgaat tggatgggtc tcagaacccat ttcacccaga 300
 cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca taacaaaccc 360
 tgctccaatc tgtcacataa aagtctgtga cttgaagttt agtcagcacc cccaccaaac 420
 tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataaag taccatgtc 480
 tttta 484

<210> 435
 <211> 424
 <212> DNA
 <213> Homo sapiens

<400> 435
 gcgcccgtca gagcaggtca ctttctgcct tccacgtcct ccttcaagga agccccatgt 60
 gggtagcttt caatatcgca ggttcttact cctctgcctc tataagctca aaccaccaa 120
 cgatcgggca agtaaaccoc ctccctcgcc gacttcggaa ctggcgagag ttcagcgag 180
 atgggcctgt ggggaggggg caagatagat gagggggagc ggcattggtc ggggtgacc 240
 cttggagaga ggaaaaaggc cacaagaggg gctgccaccg ccactaacgg agatggccct 300
 ggtagagacc tttgggggtc tggaaacctc ggactcccca tgctctaact cccacactct 360
 gctatcagaa acttaaaactt gaggattttc tctgtttttc actcgcaata aattcagagc 420
 aaac 424

<210> 436
 <211> 667
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(667)
 <223> n = A,T,C or G

<400> 436

```
accttgggaa nactctcaca atataaaggg tcgtagactt tactccaaat tccaaaaagg 60
tcctggccat gtaatcctga aagttttccc aaggtagcta taaaatcctt ataaggggtgc 120
agcctcttct ggaattcctc tgatttcaaa gtctcactct caagttcttg aaaacgaggg 180
cagttcctga aaggcaggta tagcaactga tcttcagaaa gaggaactgt gtgcaccggg 240
atgggctgcc agagtaggat aggattccag atgtgacac cttctggggg aaacagggct 300
gccaggtttg tcatagcact catcaaagtc cggtaacgt ctgtgcttcg aatataaacc 360
tgttcatgtt tataggactc attcaagaat tttctatata tctttcttat atactctcca 420
agttcataat gctgctccat gccagctgg gtgagttggc caaatccttg tggccatgag 480
gattccttta tggggtcagt gggaaagggt tcaatgggac ttcggtctcc atgccgaaac 540
accaaagtca caaacttcaa ctcttggct agtacacttc ggtctagcca gaaaaaagc 600
agaaacaaga agccaaggct aaggcttgc gccctgccag gaggaggggt gcagctctca 660
tgttgag                                     667
```

<210> 437

<211> 693

<212> DNA

<213> Homo sapiens

<400> 437

```
ctacgtctca accctcatth ttaggtaagg aatcttaagt ccaaagatat taagtgactc 60
acacagccag gtaaggaaag ctggattggc acactaggac tctaccatac cgggttttgt 120
taaagctcag gttaggaggc tgataagctt ggaaggaaact tcagacagct ttttcagatc 180
ataaaaagata attcttagcc catgtttctc tccagagcag acctgaaatg acagcacagc 240
aggtactcct ctattttcac ccctcttgc tctactctct gccagtcaga cctgtgggag 300
gccatgggag aaagcagctc tctggatgtt tgtacagatc atggactatt ctctgtggac 360
catttctcca ggttacccta ggtgtcacta ttgggggggac agccagcatc tttagctttc 420
atttgagttt ctgtctgtct tcagtagagg aaacttttgc tcttcacact tcacatctga 480
acacctaaact gctgttgctc ctgaggtggt gaaagacaga tatagagctt acagtattta 540
tcctatttct aggcactgag ggctgtggg taccttgtgg tgccaaaaca gatcctgttt 600
taaggacatg ttgcttcaga gatgtctgta actatctggg ggctctgttg gctctttacc 660
ctgcatcatg tgctctcttg gctgaaaatg acc                                     693
```

<210> 438

<211> 360

<212> DNA

<213> Homo sapiens

<400> 438

```
ctgcttatca caatgaatgt tctcctgggc agcgttgtga tctttgccac cttcgtgact 60
ttatgcaatg catcatgcta tttcatacct aatgagggag ttccaggaga ttcaaccagg 120
atgtttctac acctgtgggt tatgacaaag acaactgcc aagaatcttc aagaaggagg 180
actgcaagta tatctggtgg agaagaagga cccaaaaaag acctgttctg tcagtgaatg 240
gataatctaa tgtgcttcta gtaggcacag ggctcccagg ccaggcctca ttctcctctg 300
gcctctaata gtcaataatt gtgtagccat gcctatcagt aaaaagattt ttgagcaaac 360
```

<210> 439

<211> 431

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(431)

<223> n = A,T,C or G

<400> 439

```
gttcctnnta actcctgcc aaaaacagctc tctcaacat gagagctgca cccctcctcc 60
```

```

tggccagggc agcaagcctt agccttggct tcttggttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
gtcccattga cacctttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcggccgcg 420
aatttagtag t                                     431

```

<210> 440

<211> 523

<212> DNA

<213> Homo sapiens

<400> 440

```

agagataaag cttaggtcaa agttcataga gttcccatga actatatgac tggccacaca 60
ggatcctttt tatttaagga ttctgagatt ttgcttgagc aggattagat aaggctgttc 120
tttaaatgtc tgaaatggaa cagatttcaa aaaaaaaccc cacaatctag ggtgggaaca 180
aggaaggaaa gatgtgaata ggctgatggg caaaaaacca atttaccat cagttccagc 240
cttctctcaa ggagaggcaa agaaaggaga tacagtggag acatctggaa agttttctcc 300
actggaaaac tgctactatc tgtttttata tttctgttaa aatatatgag gctacagaac 360
taaaaattaa aacctctttg tgtcccttgg tcctggaaca tttatgttcc ttttaagaa 420
acaaaaatca aactttacag aaagatttga tgtatgtaat acatatagca gctcttgaag 480
tatatatatc atagcaaata agtcatctga tgagaacaag cta                               523

```

<210> 441

<211> 430

<212> DNA

<213> Homo sapiens

<400> 441

```

gttcctccta actcctgcca gaaacagctc tcctcaacat gagagctgca cccctcctcc 60
tggccagggc agcaagcctt agccttggct tcttggttct gctttttttc tggctagacc 120
gaagtgtact agccaaggag ttgaagtttg tgactttggt gtttcggcat ggagaccgaa 180
gtcccattga cacctttccc actgacccca taaaggaatc ctcatggcca caaggatttg 240
gccaactcac ccagctgggc atggagcagc attatgaact tggagagtat ataagaaaga 300
gatatagaaa attcttgaat gagtccata aacatgaaca ggtttatatt cgaagcacag 360
acgttgaccg gactttgatg agtgctatga caaacctggc agcccgtcga cgcggccgcg 420
aatttagtag                                     430

```

<210> 442

<211> 362

<212> DNA

<213> Homo sapiens

<400> 442

```

ctaaggaatt agtagtggtc ccatcacttg tttggagtgt gctattctaa aagattttga 60
tttctggaa tgacaattat attttaactt tgggtgggga aagagttata ggaccacagt 120
cttacttct gatacttgta aattaatctt ttattgcact tgttttgacc attaagctat 180
atgttttagaa atggtcattt tacggaaaaa ttagaaaaat tctgataata gtgcagaata 240
aatgaattaa tgttttactt aatttatatt gaactgtcaa tgacaaataa aaattctttt 300
tgattatatt ttgttttcat ttaccagaat aaaaactaag aattaaaagt ttgattacag 360
tc                                     362

```

<210> 443

<211> 624

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(624)

<223> n = A,T,C or G

<400> 443

```
tttttttttt gcaacacaat atacatcaca gtgaaatgtg taatccttgc aaattgcaag 60
ttgaaagaat taaattcaga ggaggggaga gaaagagtag tcagtaggga ctgagcacta 120
aatgcttatt ttaaaagaaa tgtaaagagc agaaagcaat tcaggctacc ctgccttttg 180
tgctggctag tactccggtc ggtgtcagca gcacgtggca ttgaacattg caatgtggag 240
cccaaaccac agaaaatggg gtgaaattgg ccaactttct attaacttgg cttcctgttt 300
tataaaatat tgtgaataat atcacctact tcaaagggca gttatgaggc ttaaatgaac 360
taacgcctac aaaacactta aacatagata acatagggtgc aagtactatg tatctggtac 420
atggtaaaca tccttattat taaagtcaac gctaaaatga atgtgtgtgc atatgctaata 480
agtacagaga gagggcactt aaaccaacta agggcctgga gggaagggtt cctggaaaga 540
ngatgcttgt gctgggtcca aatcttggtc tactatgacc ttggccaaat tatttaaact 600
ttgtccctat ctgctaaaca gatc 624
```

<210> 444

<211> 425

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(425)

<223> n = A,T,C or G

<400> 444

```
gcacatcatt nntcttgcatt tctttgagaa taagaagatc agtaaatagt tcagaagtgg 60
gaagctttgt ccaggcctgt gtgtgaaccc aatgttttgc ttagaaatag aacaagtaag 120
ttcattgcta tagcataaca caaaatttgc ataagtgggtg gtcagcaaat ccttgaatgc 180
tgcttaaatgt gagagggttg taaaatcctt tgtgcaacac tctaactccc tgaatgtttt 240
gctgtgctgg gacctgtgca tgccagacaa ggccaagctg gctgaaagag caaccagcca 300
cctctgcaat ctgccacctc ctgctggcag gatttgtttt tgcacacctg gaagagccaa 360
ggaggcacca gggcataagt gagtagactt atggtcgacg cggccgcgaa tttagtagta 420
gtaga 425
```

<210> 445

<211> 414

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(414)

<223> n = A,T,C or G

<400> 445

```
catgtttatg nttttggatt actttgggca cctagtgttt ctaaaatcgtc tatcattctt 60
ttctgttttt caaaagcaga gatggccaga gtctcaacaa actgtatctt caagtctttg 120
tgaaattctt tgcatgtggc agattatttg atgtagtctt ctttaactag catataaatc 180
tggtgtgttt cagataaatg aacagcaaaa tgtgggtggaa ttaccatttg gaacattgtg 240
aatgaaaaat tgtgtctcta gattatgtaa caaataacta ttccctaacc attgatcttt 300
ggatttttat aatcctactc acaaatgact aggccttctc tcttgatatt tgaagcagtg 360
tggtgtgctg attgataaaa aaaaaaaaag tcgacgcggc cgcgaattta gtag 414
```

<210> 446

<211> 631
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(631)
<223> n = A,T,C or G

<400> 446
acaaattaga anaaagtgcc agagaacacc acataccttg tccggaacat tacaatggct 60
tctgcatgca tgggaagtgt gagcattcta tcaatatgca ggagccatct tgcagggtgtg 120
atgtcgggta tactggacaa cactgtgaaa aaaaggacta cagtgttcta tacgttggtc 180
ccggtcctgt acgatttcag tatgtcttaa tcgcagctgt gattggaaca attcagattg 240
ctgtcatctg tgtgggtgtc ctctgcatca caagggccaa actttaggta atagcattgg 300
actgagattt gtaaaccttc caaccttcca ggaaatgccc cagaagcaac agaattcaca 360
gacagaagca aaatacaggg cactacagtt cagacaatac aacaagagcg tccacgagggt 420
taatctaaag ggagcatgtt tcacagtggc tggactaccg agagcttgga ctacacaata 480
cagtattata gacaaaagaa taagacaaga gatctacaca tgttgccctg catttgtgggt 540
aatctacacc aatgaaaaca tgtactacag ctatatattga ttatgtatgg atatatattga 600
aatagtatac attgtcttga tgttttttct g 631

<210> 447
<211> 585
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(585)
<223> n = A,T,C or G

<400> 447
ccttgggaaa antntcacia tataaagggt cgtagacttt actccaaatt ccaaaaagggt 60
cctggccatg taatcctgaa agttttcca aggtagctat aaaatcctta taagggtgca 120
gcctcttctg gaattcctct gatttcaaag tctcactctc aagttcttga aaacgagggc 180
agttcctgaa aggcaagtat agcaactgat cttcagaaa aggaaactgtg tgcaccggga 240
tgggctgcca gattaggata ggattccaga tgctgacacc ttctggggga aacaggggctg 300
ccaggtttgt catagactc atcaaagtcc ggtcaacgtc tgtgcttcga atataaacct 360
gttcatgttt ataggactca ttcaagaatt ttctatatct ctttcttata tactctccaa 420
gttcataatg ctgctccatg cccagctggg tgagttggcc aaatccttgt ggccatgagg 480
attcctttat ggggtcagtg ggaaagggtg caatgggact tcggtctcca tgccgaaaca 540
ccaaagtcac aaacttcaac tccttggcta gtacacttcg gtcta 585

<210> 448
<211> 93
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(93)
<223> n = A,T,C or G

<400> 448
tgctcgtggg tcattctgan nnccgaactg accntgccag ccctgccgan gggccnccat 60
ggctccctag tgccctggag agganggggc tag 93

<210> 449
 <211> 706
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(706)
 <223> n = A,T,C or G

<400> 449
 ccaagttcat gctntgtgct ggacgctgga cagggggcaa aagcnnttgc tcgtgggtca 60
 ttctgancac cgaactgacc atgccagccc tggcgatggt cctccatggc tccctagtgc 120
 cctggagagg aggtgtctag tcagagagta gtccctggaag gtggcctctg ngaggagcca 180
 cggggacagc atcctgcaga tggctcggcg cgtcccatc gccattcagg ctgcgcaact 240
 gttgggaagg gcgatcgggt cgggcctctt cgctattacg ccagctggcg aaagggggat 300
 gtgctgcaag gcgattaagt tgggtaacgc caggggtttc ccagtcncga cgttgtaaaa 360
 cgacggccag tgaattgaat ttaggtgacn ctatagaaga gctatgacgt cgcattgcacg 420
 cgtacgtaag ctgtgatcct ctagagcggc cgcctactac tactaaattc gcggccgcgt 480
 cgacgtggga tccnactga gagagtggag agtgacatgt gctggacnct gtccatgaag 540
 cactgagcag aagctggagg cacaacgcnc cagacactca cagctactca ggaggctgag 600
 aacaggttga acctgggagg tggaggttgc aatgagctga gatcaggccn ctgcncacca 660
 gcatggatga cagagtgaat ctccatctta aaaaaaaaaa aaaaaa 706

<210> 450
 <211> 493
 <212> DNA
 <213> Homo sapiens

<400> 450
 gagacggagt gtcactctgt tgcccaggct ggagtgcagc aagacactgt ctaagaaaaa 60
 acagttttta aaggtaaaac aacataaaaa gaaatatacct atagtggaaa taagagagtc 120
 aaatgaggct gagaacttta caaagggatc ttacagacat gtcgccaata tcactgcatg 180
 agcctaagta taagaacaac ctttggggag aaaccatcat ttgacagtga ggtacaattc 240
 caagtcaagg agtgaaatgg gtggaattaa actcaaatta atcctgccag ctgaaacgca 300
 agagacactg tcagagagtt aaaaagttag ttctatccat gaggtgattc cacagtcttc 360
 tcaagtcaac acatctgtga actcacagac caagttctta aaccactgtt caaactctgc 420
 tacacatcag aatcacctgg agagctttac aaactcccat tgccgagggt cgacgcggcc 480
 gcgaatttag tag 493

<210> 451
 <211> 501
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(501)
 <223> n = A,T,C or G

<400> 451
 gggcgcgctc cattcgccat tcaggctgcg caactgttgg gaagggcgat cgggtgcgggc 60
 ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct gcaaggcgat taagttgggt 120
 aacgccaggg ttttcccagt cncgacgttg taaaacgacg gccagtgaat tgaatttagg 180
 tgacnctata gaagagctat gacgtcgcat gcacgcgtac gtaagcttgg atcctctaga 240
 gcggccgctt actactacta aattcgcggc cgcgtcgacg tgggatccnc actgagagag 300
 tggagagtga catgtgctgg acnctgtcca tgaagcactg agcagaagct ggaggcacia 360
 cgcncacagc actcacagct actcaggagg ctgagaacag gttgaacctg ggaggtggag 420

gttgcaatga gctgagatca ggcncctgcn ccccagcatg gatgacagag tgaaactcca 480
tcttaaaaaa aaaaaaaaaa a 501

<210> 452
<211> 51
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(51)
<223> n = A,T,C or G

<400> 452
agacggtttc accntttacaa cnccttttag gatgggnntt ggggagcaag c 51

<210> 453
<211> 317
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(317)
<223> n = A,T,C or G

<400> 453
tacatcttgc tttttcccca ttggaactag tcattaaccc atctctgaac tggtagaaaa 60
acatctgaag agctagtcta tcagcatctg gcaagtgaat tggatgggtc tcagaacct 120
ttcaccana cagcctgttt ctatcctgtt taataaatta gtttgggttc tctacatgca 180
taacaaaccc tgctccaatc tgtcacataa aagtctgtga cttgaagttt antcagcacc 240
cccaccaaac tttatttttc tatgtgtttt ttgcaacata tgagtgtttt gaaaataagg 300
taccatgtc tttatta 317

<210> 454
<211> 231
<212> DNA
<213> Homo sapiens

<400> 454
ttcaggtac aatcaactct cagagtgtag tttccttcta tagatgagtc agcattaata 60
taagccacgc cagctcttg aaggagtctt gaattctcct ctgctcactc agtagaacca 120
agaagaccaa attctcttgc atcccagctt gcaaacaaaa ttgttcttct aggtctccac 180
ccttcctttt tcagtgttcc aaagctcctc acaatttcat gaacaacagc t 231

<210> 455
<211> 231
<212> DNA
<213> Homo sapiens

<400> 455
taccaaagag ggcataataa tcagtctcac agtaggggtc accatcctcc aagtgaaaaa 60
cattgttccg aatgggcttt ccacaggcta cacacacaaa acaggaaaca tgccaagttt 120
gtttcaacgc attgatgact tctccaagga tcttcctttg gcatcgacca cattcagggg 180
caaagaattt ctcatagcac agctcacaat acagggtctc tttctcctct a 231

<210> 456
<211> 231

<212> DNA

<213> Homo sapiens

<400> 456

```

ttggcaggta cccttacaaa gaagacacca taccttatgc gttattaggt ggaataatca 60
ttccattcag tattatcggt attattcttg gagaaaccct gtctgtttac tgtaaccttt 120
tgcactcaaa ttcctttatc aggaataact acatagccac tatttacaaa gccattggaa 180
cctttttatt tggtagcagct gctagtcagt cctgactga cattgccaaag t      231

```

<210> 457

<211> 231

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(231)

<223> n = A,T,C or G

<400> 457

```

cgaggtagcc aggggtctga aaatctctnn ttantagtc gatagcaaaa ttgttcatca 60
gcattcctta atatgatctt gctataatta gatttttctc cattagagtt catacagttt 120
tatttgattt tatttagcaat ctctttcaga agacccttga gatcattaag ctttgtatcc 180
agttgtctaa atcgaatgct catttctctt gaggtgtcgc tggcttttgt g      231

```

<210> 458

<211> 231

<212> DNA

<213> Homo sapiens

<400> 458

```

agggtctggt ccccccaatt ccactccctt ctactctctc taggactggg ctgggccaaag 60
agaagagggg tggttaggga agccgttgag acctgaagcc ccaccctcta ctttcttca 120
acaccctaac cttgggtaac agcatttgga attatcattt gggatgagta gaatttccaa 180
ggtcctgggt taggcatttt ggggggccag accccaggag aagaagattc t      231

```

<210> 459

<211> 231

<212> DNA

<213> Homo sapiens

<400> 459

```

ggtaccgagg ctgctgaca cagagaaacc ccaacgcgag gaaaggaatg gccagccaca 60
ccttcgcgaa acctgtggtg gcccaccagt cctaacggga caggacagag agacagagca 120
gccctgcaat gttttccctc caccacagcc atcctgtccc tcattggctc tgtgctttcc 180
actatacaca gtcaccgtcc caatgagaaa caagaaggag caccctccac a      231

```

<210> 460

<211> 231

<212> DNA

<213> Homo sapiens

<400> 460

```

gcaggataaa catgctgcaa caacagatgt gactaggaac ggccggtgac atggggaggg 60
cctatcacc ctttctggg ggctgcttct tcacagtgat catgaagcct agcagcaaat 120
cccacctccc cacacgcaca cggccagcct ggagcccaca gaagggtcct cctgcagcca 180
gtggagcttg gtccagctc cagtccaccc ctaccaggct taaggataga a      231

```


<210> 461
<211> 231
<212> DNA
<213> Homo sapiens

<400> 461
cgaggtttga gaagctctaa tgtgcagggg agccgagaag caggcggcct agggagggtc 60
gcgtgtgctc cagaagagtg tgtgcatgcc agaggggaaa caggcgcctg tgtgtcctgg 120
gtggggttca gtgaggagtg ggaaattggt tcagcagaac caagccgttg ggtgaataag 180
agggggattc catggcactg atagagccct atagtttcag agctgggaat t 231

<210> 462
<211> 231
<212> DNA
<213> Homo sapiens

<400> 462
aggtaccctc attgtagcca tgggaaaatt gatgttcagt ggggatcagt gaattaaatg 60
gggtcatgca agtataaaaa ttaaaaaaaa aagacttcac gcccaatctc atatgatgtg 120
gaagaactgt tagagagacc aacagggtag tgggttagag atttccagag tcttacattt 180
tctagaggag gtatttaatt tcttctcact catccagtgt tgtatttagg a 231

<210> 463
<211> 231
<212> DNA
<213> Homo sapiens

<400> 463
tactccagcc tgggtgacaga gcgagaccct atcaccgccc cccaccccac caaaaaaaaa 60
actgagtaga caggtgtcct cttggcatgg taagtcttaa gtccctctcc agatctgtga 120
catttgacag gtgtcttttc ctctggacct cggtgtcccc atctgagtga gaaaaggcag 180
tggggagggtg gatcttccag tcgaagcggg atagaagccc gtgtgaaaag c 231

<210> 464
<211> 231
<212> DNA
<213> Homo sapiens

<400> 464
gtactctaag attttatcta agttgccttt tctgggtggg aaagtttaac cttagtgact 60
aaggacatca catatgaaga atgtttaagt tggagggtggc aacgtgaatt gcaaacaggg 120
cctgtctcag tgaactgtgtg cctgtagtcc cagctactcg ggagtctgtg tgaggccagg 180
ggtgccagcg caccagctag atgctctgta acttctaggc cccattttcc c 231

<210> 465
<211> 231
<212> DNA
<213> Homo sapiens

<400> 465
catgttggtg tagctgtggt aatgctggct gcatctcaga cagggttaac ttcagctcct 60
gtggcaaat agcaacaaat tctgacatca tatttatggt ttctgtatct ttgttgatga 120
aggatggcac aatttttgc tgtgttcata atatactcag attagttcag ctccatcaga 180
taaactggag acatgcagga cattagggta gtgttgtagc tctggtaatg a 231

<210> 466
<211> 231
<212> DNA

<213> Homo sapiens

<400> 466

```

caggtagctc tttccattgg atactgtgct agcaagcatg ctctccgggg tttttttaat 60
ggccttcgaa cagaacttgc cacataccca ggtataatag tttctaacat ttgccaggga 120
cctgtgcaat caaatattgt ggagaattcc ctactgtgag aagtcacaaa gactataggc 180
aataatggag accagtccca caagatgaca accagtcggt gtgtgcggct g          231

```

<210> 467

<211> 311

<212> DNA

<213> Homo sapiens

<400> 467

```

gtacaccctg gcacagtcca atctgaactg gttcggcact catctttcat gagatggatg 60
tggtggcttt tctccttttt catcaagact cctcagcagg gagcccagac cagcctgcac 120
tgtgccttaa cagaaggtct tgagattcta agtgggaatc atttcagtga ctgtcatgtg 180
gcatgggtct ctgcccaagc tcgtaatgag actatagcaa ggcggctgtg ggacgtcagt 240
tgtgacctgc tgggcctccc aatagactaa caggcagtgc cagttggacc caagagaaga 300
ctgcagcaga c          311

```

<210> 468

<211> 3112

<212> DNA

<213> Homo sapiens

<400> 468

```

cattgtgttg ggagaaaaac agaggggaga tttgtgtggc tgcagccgag ggagaccagg 60
aagatctgca tgggtgggaag gacctgatga tacagagttt gataggagac aattaaaggc 120
tggaaggcac tggatgcctg atgatgaagt ggactttcaa actggggcac tactgaaacg 180
atgggatggc cagagacaca ggagatgagt tggagcaagc tcaataacaa agtggttcaa 240
cgaggacttg gaattgcatg gagctggagc tgaagtttag cccaattggt tactagttag 300
gtgaatgtgg atgattggat gatcatttct catctctgag cctcaggttc cccatccata 360
aaatgggata cagagtatga tctataaagt gggatatagt atgatctact tcaactgggt 420
atttgaagga tgaattgaga taatttattt caggtgccta gaacaatgcc cagattagta 480
catttggtgg aactgagaaa tggcataaca ccaaatttaa tatatgtcag atgttactat 540
gattatcatt caatctcata gttttgtcat ggcccaattt atcctcactt gtgcctcaac 600
aaattgaact gttaacaaag gaatctctgg tcctgggtaa tggctgagca ccaactgagca 660
tttccattcc agttggcttc ttgggtttgc tagctgcata actagtcata ttaataaata 720
gaagttttta catttctcca gtgatttttt tatctcacct ttgaagatac tatgttatgt 780
gattaaataa agaacttgag aagaacaggt ttcattaaac ataaaatcaa tgtagacgca 840
aattttctgg atgggcaata cttatgttca caggaaatgc tttaaaatat gcagaagata 900
attaaatggc aatggacaaa gtgaaaaact tagacttttt tttttttttt ggaagtatct 960
ggatgttctt tagtacttta aaggagaact gaaaaatagc agtgagttcc acataatcca 1020
acctgtgaga ttaaggctct ttgtggggaa ggacaaagat ctgtaaattt acagtttctt 1080
tccaaagcca acgtcgaatt ttgaaacata tcaaagctct tcttcaagac aaataatcta 1140
tagtacatct ttcttatggg atgcacttat gaaaaatggt ggctgtcaac atctagtcac 1200
tttagctctc aaaaatgggtc attttaagag aaagtttttag aatctcatat ttattcctgt 1260
ggaaggacag cattgtggct tggactttat aaggtcttta ttcaactaaa taggtgagaa 1320
ataagaaagg ctgctgactt taccatctga ggcacacat ctgctgaaat ggagataatt 1380
aacatcacta gaaacagcaa gatgacaata taatgtctaa gtagtgacat gtttttgcac 1440
atttcagacc cctttaaata tccacacaca caggaagcac aaaaggaagc acagagatcc 1500
ctggggagaaa tgcccgcccg ccatcttggg tcatcgatga gcctcgccct gtgcctggtc 1560
ccgcttgtga ggggaaggaca ttagaaaaatg aattgatgtg ttccttaaag gatgggcagg 1620
aaaacagatc ctgttgtgga tatttatttg aacgggatta cagatttgaa atgaagtcac 1680
aaagtgcaca ttaccaatga gaggaaaaa tcttgatggc ttcacaagac 1740
atgcaacaaa caaaatggaa tactgtgatg acatgaggca gccaaagctg ggaggagata 1800
accacggggc agaggggtcag gattctggcc ctgctgccta aactgtgcgt tcataaccaa 1860

```

```

atcatttcat atttctaacc ctcaaaacaa agctgttgta atatctgata tctacggttc 1920
cttctggggc caacattctc catatatcca gccacactca tttttaatat ttagttccca 1980
gatctgtact gtgacctttc tacactgtag aataacatta ctcatittgt tcaaagaccc 2040
ttcgtgttgc tgcctaatat gtagctgact gtttttccta aggagtgttc tggcccaggg 2100
gatctgtgaa caggctggga agcatctcaa gatctttcca gggttatact tactagcaca 2160
cagcatgata attacggagt gaattatcta atcaacatca tcctcagtg tttgcccatt 2220
actgaaattc atttccact tttgtgcccc ttctcaagac ctcaaatgt cattccatta 2280
atatcacagg attaactttt tttttaacc tggagaatt caatgttaca tgcagctatg 2340
ggaatttaac tacatatatt gttttccagt gcaaagatga ctaagtcctt tatccctccc 2400
ctttgtttga ttttttttcc agtataaagt taaaatgctt agccttgta tggaggctga 2460
tacagccaca gcctctcccc atccctccag ccttatctgt catcaccatc aaccctctcc 2520
atgcacctaa acaaaatcta acttgtaatt ccttgaacat gtcaggcata cattattcct 2580
tctgcctgag aagctcttcc ttgtctctta aatctagaat gatgtaaagt ttggaataag 2640
ttgactatct tacttcatgc aaagaaggga cacatatgag attcatcatc acatgagaca 2700
gcaaatacta aaagtgtaat ttgattataa gagtttagat aaatatatga aatgcaagag 2760
ccacagaggg aatgtttatg gggcacgttt gtaagcctgg gatgtgaagc aaaggcaggg 2820
aacctcatag tatcttatat aatatacttc atttctctat ctctatcaca atatccaaca 2880
agcttttcac agaattcatg cagtgc aaat ccccaaagg t aacctttatc catttcatgg 2940
tgagtgcgct ttagaatttt ggcaaatcat actggctact tatctcaact ttgagatgtg 3000
tttgccttg tagttaattg aaagaaatag ggcaactctg tgagccactt taggggtcac 3060
tcctggcaat aaagaattta caaagagcaa aaaaaaaaaa aaaaaaaaaa aa 3112

```

<210> 469

<211> 2229

<212> DNA

<213> Homo sapiens

<400> 469

```

agctctttgt aaattcttta ttgccaggag tgaaccttaa agtggctcac aagagtgtcc 60
tattcttttc aattaactac aaggacaaac acatctcaaa gttgagataa gtgaccagta 120
tgatttgcca aaattctaaa gcgcactcac catgaaatgg ataaaggtta cctttgggga 180
tttgactgac atgaattctg tgaaggctt gttgatatt gtgatagaga tagagaaatg 240
aagtatatta tataagatac tatgagggtc cctgcctttg cttcacatcc caggcttaca 300
aacgtgcccc ataaacattc cctctgtggc tcttgcatth catatattha tctaaactct 360
tataatcaaa tacactttta gtatttgctg tctcatgtga tgatgaatct catatgtgtc 420
ccttctttgc atgaagtaag atagtcaact tattcaaaac ttacatcat tctagattta 480
agagacaagg aagagcttct caggcagaag gaataatgta tgctgacat gttcaaggaa 540
ttacaagtta gattttgttt aggtgcatgg gaggggttga tgggtgatgac agataaggct 600
ggagggtatg ggagaggctg tggctgtata gcgcctcagt acaaggctaa gcattttaac 660
tttatactgg aaaaaaaatc aaacaaaggg gagggataaa ggacttagtc atctttgcac 720
tggaatacaa aatatgtaat taaattccca tagctgcatg taacattgaa ttcttccagg 780
ttaaaaaaaa agttaatcct gtgatattaa tggaaatgaca ttttgaggtc ttgagaatgg 840
gcacaaaagt gggaaatgaa ttctcagtatg ggcaaagaca ctgaggatga tgttgattag 900
ataattcact ccgtaatatg catgctgtgt gctagtaagt ataaccctgg aaagatcttg 960
agatgcttcc cagcctgttc acagatcccc tgggcccagaa cactccttag gaaaaacagt 1020
cagctacata ttaggcagca acacgaagg tctttgaaca aaatgagtaa tgttattcta 1080
cagtgtagaa aggtcacagt acagatctgg gaactaaata ttaaaaatga gtgtggctgg 1140
atatatggag aatgttgggc ccagaaggaa ccgtagagat cagatattac aacagctttg 1200
ttttgagggt tagaaatatg aaatgatttg gttatgaacg cacagtttag gcagcagggc 1260
cagaatcctg accctctgcc ccgtggttat ctctcccca gcttggtgctc ctcatgtcat 1320
cacagtattc cattttgttt gttgcatgtc ttgtgaagcc atcaagattt tctcgtctgt 1380
tttctcttca ttggtaatgc tcaactttgt acttcatttc aaatctgtaa tcccgttcaa 1440
ataaatatcc acaacaggat ctgttttctt gccatcctt taaggaacac atcaattcat 1500
tttctaattg ccttccctca caagcgggac caggcacagg gcgaggctca tcatgacccc 1560
aagatggcgg ccgggcattt ctcccaggga tctctgtgct tctttttgtg cttcctgtgt 1620
gtgtggatat ttaagggggc tggaaatgtg caaaaacatg tcaactacta gacattatat 1680
tgtcatcttg ctgtttctag tgatgttaat tatctccatt tcagcagatg tgtggcctca 1740
gatggtaaag tcagcagcct ttcttatttc tcacctgtaa atacatacga ccatttgagg 1800

```

```

agacaaatgg caaggtgtca gcataccctg aacttgagtt gagagctaca cacaatatta 1860
ttggtttccg agcatcacia acaccctctc tgtttcttca ctgggcacag aattttaata 1920
cttatttcag tgggctgttg gcaggaacaa atgaagcaat ctacataaag tcactagtgc 1980
agtgcctgac acacaccatt ctcttgaggt cccctctaga gatccacag gtcatatgac 2040
ttcttgggga cagtggtc acacctgtaa tcccagcact ttgggaggct gaggcagggt 2100
ggtcacctga ggtcaggagt tcaagaccag cctggccaat atggtgaaac ccatctcta 2160
ctaaaaatac aaaaattagc tgggcgtgct ggtgcatgcc tgtaatccca gcccacac 2220
aatggaatt                                     2229

```

<210> 470

<211> 2426

<212> DNA

<213> Homo sapiens

<400> 470

```

gtaaattctt tattgccagg agtgaacct aaagtggctc acaagagtgc cctatttctt 60
tcaattaact acaaggacaa acacatctca aagttgagat aagtgaccag tatgatttgc 120
caaaattcta aagcgcactc accatgaaat ggataaagg tacccttggg gatttgcact 180
gcatgaattc tgtgaaaagc ttgttgata ttgtgataga gatagagaaa tgaagtatat 240
tatataagat actatgaggt tccctgcctt tgcttcacat cccaggctta caaacgtgcc 300
ccataaacat tccctctgtg gctcttgcac ttcatatatt tatctaaact cttataatca 360
aattacactt ttagtatttg ctgtctcatg tgatgatgaa tctcatatgt gtcccttctt 420
tgcatgaagt aagatagtca acttattcaa aactttacat cattctagat ttaagagaca 480
aggaagagct tctcaggcag aaggaataat gtatgcctga catgttcaag gaattacaag 540
ttagattttg tttagggtgca tgggaggggt tgatgggtgat gacagataag gctggaggga 600
tggggagagg ctgtggctgt atacagcctc agtacaaggc taagcatitt aactttatac 660
tggaaaaaaa atcaaacaaa ggggagggat aaaggactta gtcatctttg cactggaaaa 720
caaaatatgt aattaaattc ccatagctgc atgtaacatt gaattcttcc aggttaaaaa 780
aaaaagttaa tctcttgata ttaatggaat gacattttga ggtcttgaga atgggcacaa 840
aagtgggaaa tgaatttcag tatgggcaaa gacactgagg atgatgttga ttagataatt 900
cactccgtaa tgatcatgct gtgtgctagt aagtataacc ctggaaagat cttgagatgc 960
ttcccagcct gttcacagat cccctgggcc agaacactcc ttaggaaaaa cagtcagcta 1020
catattaggc agcaacacga agggctcttg aacaaaatga gtaatgttat tctacagtgt 1080
agaaaggtag agaacagat ctgggaacta aatattaaaa atgagtgttg ctggatata 1140
ggagaatgtt gggccagaa ggaaccgtag agatcagata ttacaacagc ttgtttttga 1200
gggttagaaa tatgaaatga tttggttatg aacgcacagt ttaggcagca gggccagaat 1260
cctgaccctc tgccccgtgg ttatctctc cccagcttgg ctgcctcatg tcatcacagt 1320
attccatttt gtttgttgca tgtcttgtga agccatcaag attttctcgt ctgttttctt 1380
ctcatttgta atgtcactt tgtgacttca ttccaatct gtaatcccgt tcaaataaat 1440
atccacaaca ggatctgttt tccctgccc atcttaagga acacatcaat tcattttcta 1500
atgtccttcc ctcaacagcg ggaccaggca cagggcgagg ctcatcgatg acccaagatg 1560
gcgccggggc atttctccca gggatctctg tgcctccttt tgtgcttcc gtgtgtgtgg 1620
atatttaaag gggctggaat tgtgcaaaaa catgtcacta cttagacatt atattgtcat 1680
cttgctgttt ctagtgtatg taattatctc catttcagca gatgtgtggc ctcagatggg 1740
aaagtcagca gcctttctta tttctcact ggaaatacat acgaccattt gaggagacaa 1800
atggcaagggt gtcagcatac cctgaacttg agttgagagc tacacacaat attattgggt 1860
tccgagcatc acaaacaccc tctctgtttt ttcactgggc acagaatttt aatacttatt 1920
tcagtggcgt gttggcagga acaaatgaag caatctacat aaagtcacta gtgcagtgcc 1980
tgacacacac cattctcttg aggtcccctc tagagatccc acaggtcata tgacttcttg 2040
gggagcagtg gctcacacct gtaatccag cactttggga ggctgaggca ggtgggtcac 2100
ctgaggtcag gagttcaaga ccagcctggc caatatggtg aaaccccatc tctactaaaa 2160
atacaaaaat tagctgggcg tgctgggtgca tgctgtaat cccagctact tgggaggctg 2220
aggcaggaga attgctggaa catgggaggc ggaggttgca gtgagctgta attgtgccat 2280
tgcaactcga cctgggcgac agagtggaac tctgtttcca aaaaacaaac aaacaaaaaa 2340
ggcatagtca gatacaacgt ggggtgggat tgtaaataga agcaggatat aaagggcatg 2400
gggtgacggt tttgccaac acaatg                                     2426

```

<210> 471

<211> 812
<212> DNA
<213> Homo sapiens

<400> 471
gaacaaaatg agtaatgtta ttctacagt tagaaaggtc acagtacaga tctgggaact 60
aaatattaaa aatgagtgtg gctggatata tggagaatgt tgggccaga aggaaccgta 120
gagatcagat attacaacag ctttgttttg agggtttagaa atatgaaatg atttggttat 180
gaacgcacag tttaggcagc agggccagaa tctgaccct ctgccccgtg gttatctcct 240
ccccagcttg gctgcctcat gtcacacag tattccattt tgtttgttg atgtcttgtg 300
aagccatcaa gattttctcg tctgttttcc tctcattggt aatgctcact ttgtgacttc 360
atttcaaadc tgtaatccc ttcaaataaa tatccacaac aggatctgtt ttctgcca 420
tcctttaagg aacacatcaa ttcattttct aatgtcctc cctcacaagc gggaccaggc 480
acaggcgag gctcatcgat gaccaagat ggcggccggg catttctccc agggatctct 540
gtgcttcctt ttgtgcttcc tgtgtgtgtg gatatttaa ggggctggaa atgtgcaaaa 600
acatgtcact acttagacat tatattgtca tcttgctgtt tctagtgtg ttaattatct 660
ccatttcagc agatgtgtgg cctcagatgg taaagtacg agcctttctt atttctcacc 720
tctgtatcat caggctcttc ccaccatgca gatcttcctg gtctccctcg gctgcagcca 780
cacaatctc ccctctgttt ttctgatgcc ag 812

<210> 472
<211> 515
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(515)
<223> n = A,T,C or G

<400> 472
acggagactt attttctgat attgtctgca tatgtatgtt ttttaagagtc tggaaatagt 60
cttatgactt tcctatcatg cttattaata aataatacag cccagagaag atgaaaatgg 120
gttcagaat tatttgctct tgcagcccg tgaatctcag caagaggaa caccaactga 180
caatcaggat attgaacctg gacaagagag agaaggaa cctccgatcg aagaacgtaa 240
agtagaagg gattgccagg aatggatct ggaaaagact cggagtggagc gtggagatgg 300
ctctgatgta aaagagaaga ctccacctaa tcctaagcat gctaagacta aagaagcagg 360
agatgggcag ccataagtta aaaagaagac aagctgaagc tacacacatg gctgatgtca 420
cattgaaaat gtgactgaaa atttgaaaat tctctcaata aagtttgagt tttctctgaa 480
gaaaaaaaaa naaaaaaaaa aaanaaaan aaaaa 515

<210> 473
<211> 5829
<212> DNA
<213> Homo sapiens

<400> 473
cgcattgccgg ggaagcccaa gctggctcga agagccacca gccacctgtg caagggtggg 60
cctggaccag ttggaccagc caccaagctc acctactcaa ggaagcaggg atggccagg 120
tgcaacagcc tgagtggctg ccacctgata gctgatggag cagaggcctg aggaaaatca 180
gatggcacat ttatgtcttt aatggatctt aagttaattt ttctataaag cacatggcac 240
cagtcocatg ctgagagctc gtatggcact gcggaccaca gcaggccgag ttcccaggat 300
tgccatccag gggggccttc tgtagccctg gccagacctt gcagagggtg ctgggtgctc 360
tttgagcgag ctgcgcctcc ctggcatgca caggccccag gtactgacac gctgctctga 420
gtgagcttgt cctgccttgg ctgccacct actgctgatg gagcagcggc cttaggaaaa 480
gcaaatggcg ctgtagccca actttaggg aagaagaagat gtaccatgtc cgqccgctag 540
ttggtgactg gtgcacctgc tcctggcgta cccttgacga ggtgggtggg tgctctttgg 600
ccagcttggc ctgcctggc atgcacaagc ctcagtgcga caactgtcct acaaatggag 660

acacagagag	gaaacaagca	gcgggctcag	gagcaggggtg	tgtgctgcct	ttggggctcc	720
agtccatgcc	tcgggtcgta	tggtagctga	ggcttcttgg	ttgccaagag	gcggaccaca	780
ggccttcttg	aggaggactt	tacgttcaag	tgcaaaaagc	agccaaaatt	accatccatg	840
agactaagcc	ttctgtggcc	ctggcgagac	ttaaaatttg	tgccaaggca	ggacaagctc	900
actcggagca	gcgtgtcagt	agctggggcc	tatgcatgcc	gggcagggcc	gggctggctg	960
aaggagcaac	cagccacctc	tgcaagggtg	cgctagtgc	aggcggagca	tccaccacct	1020
cacccgctcg	aggaagtggg	gatggccagg	ttcccacagc	ctgagtgtct	gccaccttat	1080
tgctgatgga	gcagaggcct	taagaaaagc	agatggcact	gtggccctac	ctttagggtg	1140
gaagaagtga	tgtacatgtc	cgagcgctaa	ttgggtgactg	gtacaccggc	tctgtctaca	1200
cctttgcaga	ggtggctggt	tgtcttttga	gccagcttgt	ccttgcccgg	catgcacaag	1260
tttcagtga	acaactttgc	cacaaatgga	gccatataga	ggaaacaaga	agcaggttca	1320
ggagaagggt	gtaccctgcc	tttggggctc	cagtccatgc	ctcaggtgtc	acatggcact	1380
gcgggcttct	tggttgccag	gagggcgacc	acaggccatc	ttggggagga	ctttgtgttc	1440
aagtgcagaa	agcagccagg	attgccatcc	agggggacct	tctatagccc	tggccaaacc	1500
ttgcaggggt	gtctggttgc	tctttgagcc	ggcttggcct	ccctggcatg	cacgggcccc	1560
aggtgctggc	acgtgctccc	gagtgtgctt	gtcctgcctt	ggctgccacc	tctgcggggg	1620
tgcgtctgga	gggggtggac	cggccaccaa	ccttaccagg	tcaaggaaagt	ggatggccat	1680
gttcccacag	cctgagtggc	tgccacctga	tggtgatgg	agcaaaggcc	ttaggaaaag	1740
cagatggccc	ttggccctac	ctttttgtta	gaagaactga	tgttccatgt	cctgcagcga	1800
gtgaggttgg	tggctgtgcc	cccagctcct	ggcgcgccct	cgagaggtg	actggttgc	1860
ctttggggccc	tcttggcctt	gccagcatg	cacaagcctc	agtgtacta	ctgtgtctaca	1920
aatggagcca	tataggggaa	acgagcagcc	atctcaggag	caaggtgtat	gctgcctttg	1980
ggggctccag	tccttgccctc	aagggcttta	tgctactgtg	ggcttcttgg	ttgtcaagag	2040
gcagaccata	ggccgtcttg	agagggactt	tatgttcaag	tgcaaaaagc	agccaggatt	2100
gccaccctcg	ggactctgcc	ttctgtggcc	ctggccaaac	ttagaatttg	gccgtagaca	2160
ggacaggctc	acttggagta	gcgtgtccgt	agctggggtc	tgtgcatgcc	gggcaaggcc	2220
gggctggctc	ggggagcaac	cagccacctc	tgcggggggtg	cgcttgagc	aggtggagca	2280
gccaccagct	caccactcc	aggaagccgg	ggtagccagg	ttcccaaggc	ctgagtgggt	2340
gccacctaat	ggctgaagaa	acagaggcct	tgggaaaacc	agatggcact	gtggccctac	2400
ctttatggta	gaagagctga	tttagcctga	ctggcagcgt	gtgggggttg	tggctggtct	2460
gcctgctgct	ggcgcatccg	tgcaaggatg	gctggttgcc	ctttgagcca	gcttgccctt	2520
gcccgcatg	cgcaagcctc	agtgaacaa	ctgtgctgca	aatggggcca	tatagaggaa	2580
aggagcagct	ggctctggag	catggtgtgc	actccctttg	ggccttcagt	ccatgtctca	2640
tgggtcggtat	gacactcggg	gcttgttgg	tgccaagagg	cagaccacag	gtcatcttga	2700
ggaggacttt	atgttccagt	ccagaaaagca	gccagtggta	ccaccaggg	gacttgtgct	2760
tctgtgcccc	ggccagacgt	agaatttgac	aaagtcagga	cggtctcagt	cagagcggcg	2820
tgctgggtccc	cggggcctgt	gcatgccggg	cagggccggg	ctggcttggg	gagcaagcag	2880
ccacctctgt	taaggggtgtg	cctggagcag	gtggagcagc	caccaacctc	acgcaactga	2940
agaagcaggg	atggccagg	tccaacatcc	tgagtggctg	ccacctgatg	gctgatggag	3000
cagaggcctg	aggaagca	gatggcactg	ctttgtagt	ctgttctttg	tctctcttga	3060
tctttttcag	ttaatgtctg	ttttatcaga	gactaggatt	gcaaaccctg	ctcttttttg	3120
ctttccattt	gcttggtaaa	tattcctcca	tccctttatt	ttaagcctat	gtgtgtcttt	3180
gcacatgaga	tgggtctcct	gaatacagga	caacaatggg	tctttactct	ttatccaact	3240
tgccagtctg	tgtcttttaa	ctggggcatt	tagccattt	acatttaagt	ttagtattgt	3300
tacatgtgaa	atttatcctg	tcatgatgtt	gctagctttt	tatttttccc	attagtttgc	3360
agtttcttta	tagtgtcaat	ggtctttaca	attcgatatg	tttttgtagt	ggctggtaact	3420
ggtttttcct	ttctacgttt	agtgtctcct	tcaggagctc	ttgtaacaca	agaatgtgga	3480
tttatttctt	gtaaggtaaa	tatgtggatt	tatttcttgg	gactgtattc	tatggccttt	3540
accccaagaa	tcattacttt	ttaaaatgca	attcaaatta	gcataaaaca	tttacagcct	3600
atggaaaggc	ttgtggcatt	agaatcctta	tttataggat	tatttttgtgt	ttttttgaga	3660
tatggtcttt	gtcatcgagg	cagaagtgcc	gtggtttgat	cataattcac	cacagccctg	3720
aactcttgag	tccaagccat	ccttttgcc	taatctccca	accagttgga	tctgcaggca	3780
taaggcatca	tgcgtggcta	attttttca	gtttttttt	ttttttgtc	gagattatgg	3840
tgctactgtg	ttgctctggc	tgatctcaaa	tgtttgacct	caagggatct	ttctgccacg	3900
gcctcctaaa	gtgctaggat	tatatgcatg	atacaccatg	cctattgtag	agtattacat	3960
tattttcaaa	gtcttattgt	aagagccatt	tattgccttt	ggcctaata	actcaatata	4020
atatctctga	aacttttttt	tgacaaat	tggggcgtga	tgatgagaga	aggggggttg	4080
aaactttcta	ataagagtta	acttagagcc	atttaagaaa	ggaaaaaaca	caaattatca	4140

```

gaaaaacaac agtaagatca agtgcaaaaag ttctgtggca aagatgatga gagtaaagaa 4200
tatatgtttg tgactcatgg tggcttttac tttgttcttg aatttctgag tacgggttaa 4260
catttaaaga atctacatta tagataacat tttattgcaa gtaaatgtat ttcaaaattt 4320
gttattgggtt ttgtatgaga ttattctcag cctacttcat tatcaagcta tattatttta 4380
ttaatgtagt tcgatgatct tacagcaaaag ctgaaagctg tatcttcaa atagtctat 4440
ttgactaaaa agttattcaa caggagttaa tatctataaa aaaaatacaa caggaatata 4500
aaaaacttga ggataaaaag atgttggaaa aagtaaatatt aaatcttaaa aaacatatgg 4560
aaactacaca atggtgaaga cacattgggtg aagtaaaaaa atataaattg gatctagaag 4620
aaaggccaat gcaggcaata gaaaaattag tagaaatccc tttaaagggtt agtttgtaaa 4680
atcaggtaaag tttatttata atttgctttc atttatttca ctgcaaatta tattttggat 4740
atgtatatat atttgcttcc ctctgcctgt cttacagcaa tttgccttgc agagttctag 4800
gaaaaagggtg gcatgtgttt ttactttcaa aatattttaa tttccatcat tataacaaaa 4860
tcaatttttc agagtaatga ttctcactgt ggagtcattt gattattaag acccggttggc 4920
ataagattac atctcttgac tataaaaatc ctggaagaaa acctaggaaa tattcgtctg 4980
gacattgcac ttggcaatga atttatgggt aaccttgat ccacttccag tcactatcca 5040
tgagttttta ttccagata catgaaatca tatgagttga aactttcttt tgattgagca 5100
gtttggaac cgtctttttg tagaatctgc aagtggatat ttggaacctt ttgaggccta 5160
tgctgaaaaa agaaatatct tcactacatg atgaccacca gcagcagctg gggaaaccag 5220
cacctgtgg aattccatac ggtgcataga atacatcctc ccttcagtcg gcttgggtca 5280
acttaggtca tgggccacct ggctgatagc agtttcacca gaaatgcttc aagatgaaag 5340
tggatgacgg ggcacacctc caccactgcc ctgtaagacc atgggacaca caggccacca 5400
gttcttttca tgtggtcatc ccctgttaga tgggagaaaa tacacctgcc tcatttttgt 5460
accttctgtg tgaacattcc acggcagact gtcgctaaat gtggatgaag aattgaatga 5520
atgaatgaat atgagagaaa atgaataaat ggttcagatc ctgggctgga aggctgtgta 5580
tgaggatggt gggtagagga gggctgtgtt ttcttgctt taagtcacta attgtcactt 5640
tggggcagga gcacaggtt tgaatgcaga ccgactggac tttaatctg gctttactag 5700
ttgtgattgt gtgacctgtg gaaagttact taaacctct gtgcctgttt ctttatctgt 5760
aaaatggaga taataagatg tcaaaggact gtggtagaag ttaaatgctt taaaaaaaaa 5820
aaaaaaaaa

```

<210> 474

<211> 1594

<212> DNA

<213> Homo sapiens

<400> 474

```

atttatggat cattaatgcc tcttttagtag tttagagaaa acgtcaaaaag aaatggcccc 60
agaataagct tcttgatttg taaaattcta tgtcattggc tcaaatttgt atagtatctc 120
aaaatataaa tatatagaca tctcagataa tatatttgaa atagcaaatt cctgttagaa 180
aataatagta cttactaga tgagaataac aggtcgccat tatttgaatt gtctcctatt 240
cgtttttcat ttgttgtgtt actcatgttt tacttatgag ggatatatat aacttccact 300
gttttcagaa ttattgtatg cagtcagtat gagaatgcaa tttaaagttc cttgatgctt 360
tttcacactt ctattactag aaataagaat acagtaatat tggcaaagaa aattgaccag 420
ttcaataaaa ttttttagta aatctgattg aaaaataaca ttgcttatgg ctttcttaca 480
tcaatattgt tatgtcctag acaccttatc tgaattacg gcttcaaaat tctaattatg 540
tgcaaatgtg taaaatatca atactttatg ttcaagctgg ggcctcttca ggcgtcctgg 600
gctgagagag aaagatgcta gctccgcaag ccggagaggg aacaccgcca cattgttaca 660
cggacacacc gccacgtgga cacatgacca gactcacatg tacagacaca cggagacatt 720
accacatgga gacaccgtca cacagtcaca cggacacact ggcatagtca catggacgga 780
cacacagaca tatggagaaa tcacatggac acaccaccac actatcacag ggacacagac 840
acacggagac atcaccacat ggacacactg tcacactacc acagggacac gagacatcac 900
actgtcacat ggacacacca tcacacacat gaacacaccg acacactgcc atatggacac 960
tggcacacac actgccacac tgtcacatgg acacacctc acaccatcac accaccacac 1020
acactgcctg tggacacaag gacacacaga cactgtcaca cagatacaca aaacactgtc 1080
acacggagac atcaccatgc agatacacca ccactctggt gccgtctgaa ttacctgtct 1140
ggggggacag cagtggcata ctcatgccta agtgactggc tttcacccca gtagtgattg 1200
ccctccatca acactgccc ccccgagttg gggctacccc agcccatctt taaaaacag 1260
ggcaaggatg actaatggag tgggtggagg agttggaaga aatcccagcg tcagtcaccg 1320

```

```

ggatagaatt cccaaggaac cctctttttg gaggatgggt tccatttctg gaggcgatct 1380
gccgacaggg tgaatgcctt cttgcttgct ttctggggaa tcagagagag tccgttttgt 1440
ggtgggaaga gtgtggctgt gtactttgaa ctctgtaaa ttctctgact catgtccaca 1500
aaaccaacag ttttgtgaat gtgtctggag gcaaggaag ggccactcag gatctatgtt 1560
gaagggaaga ggcttggggc tggagtattc gctt 1594

```

<210> 475

<211> 2414

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (33)

<223> n=A,T,C or G

<400> 475

```

cccaacacaa tggctttata agaatgcttc acntgtgaaa aacaaatata aaagtcttct 60
tgtagattat ttttaaggac aaatctttat tccatgttta atttatttag ctttccctgt 120
agctaataat tcatgctgaa cacattttaa atgctgtaaa tgtagataat gtaatttatg 180
tatcattaat gcctctttag tagtttagag aaaacgtcaa aagaaatggc cccagaataa 240
gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt tgtatagtat ctcaaaatat 300
aaatatatag acatctcaga taatatattt gaaatagcaa attcctgtta gaaaaataa 360
gtacttaact agatgagaat aacaggctgc cattatttga attgtctoct attcgttttt 420
catttgttgt gttactcatg ttttacttat ggggggatat atataacttc cgctgttttc 480
agaagtattg tatgcagtca gtatgagaat gcaatttaag tttccttgat gctttttcac 540
acttctatta ctagaaataa gaatacacga atattggcaa agaaaattga ccagtccaat 600
aaaatttttt agtaaatctg attgaaaata aacattgctt atggctttct tacatcaata 660
ttgttatgtc ctagacacct tatctgaaat tacggcttca aaattctaata tatgtgcaaa 720
tgtgtaaaat atcaatactt tatgttcaag ctggggcctc ttcaggcgctc ctgggctgag 780
agagaaagat gctagctcgg caagccgggg agggaaacacc gccacattgt tacatggaca 840
caccgccacg tggacacatg accagactca catgtacaga cacacggaga cattaccaca 900
tggagacacc gtcacacagt cacacgagca cactggcata gtcacatgga cggacacaca 960
gacatatgga gaaatcacac tgacacacca ccacactatc acagggacac agacacacgg 1020
agacatcacc acatggacac actgtcacac taccacaggg acacgagaca tcacactgtc 1080
acatggacac accatcacac acatgaacac accgacacac tgccatatgg acaactgccac 1140
acacactgcc acaactgtcac atggacacac ctccatacca tcacaccacc acacacactg 1200
ccatgtggac acaaggacac acagacactg tcacacagat acacaaaaca ctgtcacacg 1260
gagacatcac catgcagata caccaccaca tggacatagc accagacact ctgccacaca 1320
gatacaccac cacacagaaa tgcggacaca ctgccacaca gacaccacca catcgttgcc 1380
acactttcat gtgtcagctg gcggtgtggg ccccacgact ctgggctcta atcgagaaat 1440
tacttgagaca tatagtgaag gcaaaatttt tttttatttt ctgggtaacc aagcgcgact 1500
ctgtctcaaa aaaagaaaaa aaaagcaata tactgtgtaa tcgttgacag cataattcac 1560
tattatgtag atcggagagc agaggattct gaatgcatga acatatcatt aacatttcaa 1620
tacattactc ataattactg atgaactaaa gagaaaccaa gaaattatgg tgatagttat 1680
attgacctgg agaaatgtag acacaaaaga accgtaagat gagaaatgtg ttaacacagt 1740
ctataagggc atgcaagaat aaaaataggg gagaaaacag gagagttttt caagagcttt 1800
ctggtcttct aagtcaactt gtatcggtta atttttaaaa ggtttattta catgcaataa 1860
actgcacata cttcaattgt acatttttgt aattcttggc attttagct ctataaaacc 1920
agcaacatat taaaatagca aacatatcca ttacctttac caccaaagtt ttcttgtgtt 1980
ttttctactc actttttcct gcctatcccc ccatctcttc cacaggtaac cactgatcca 2040
cttccagtca ctatccatga gtttttattt ccaaatatcat gaaatcatat gaatttctgg 2100
tttttctgt tggagcccaa ggagcaaggg cagaatgagg aacatgatgt ttcttwccga 2160
cagttactca tgacgtctcc atccaggact gaggggggca tccttctcca tctaggactg 2220
ggggcatcct tctccatcca gtattggggg tactccttct ccatccagta ttgggggtca 2280
tcctctccca tccaggacct gaggggtgtc cttttctgcg cttccttgga tggcagctct 2340
tcccttcatg tttatagtra cttaccatta aatcaactgt cggttttttc ctaaaaataa 2400
aaaaaaaaaa aaaa 2414

```


<210> 476
<211> 3434
<212> DNA
<213> Homo sapiens

<400> 476

```
ctgtgctgca aatggggcca tatagaggaa aggagcagct ggctctggag catggtgtgc 60
actccctttg ggccttcagt ccatgtctca tgggtcgtat gacactgcgg gcttgttgg 120
tgccaagagg cagaccacag gtcactctga ggaggacttt atgttccagt ccagaaagca 180
gccagtggta ccaccagg gacttgtgct tctgtggccc aggccagacg tagaatttga 240
caaagtcagg acggtctcag tcagagcagc atgtcggctc ccggggcctg tgcattgccg 300
gcagggccag gctggcttaa ggagcaagca gccacctctg ttaggggtgt gcctggagca 360
ggtggagcag ccaccaacct cactgactga aagaagcagg gatggccagg ttccaacatc 420
ctgagtggct gccacctgat ggctgatgga gcagaggcct gaggaaaagc agatggcact 480
gctttgtagt gcttctcttt gtctctcttg atctttttca gttaatgtct gttttatcag 540
agactaggat tgcaaacctt gctctttttt gctttccatt tgcttggtaa atattcctcc 600
atccctttat ttttaagccta tgtgtgtctt tgcacatgag atgggtctcc tgaatacagg 660
acaacaatgg gtctttactc tttatccaac ttgccagtct gtgtctttta actggggcat 720
ttagccattt tacatttaag ttttagtatt gttacatgtg aaatttatcc tgcattgatg 780
ttgctagctt tttatttttc ccattagttt gcagtttctt tatagtgtca atggtcttta 840
caattcgata tgtttttgta gtggctggta ctggtttttc ctttctacgt ttagtgtctc 900
cttcaggagc tcttgtaaca caagaatgtg gatttatttc ttgtaaggta aatatgtgga 960
tttattctgg gactgtatcc tatggccttt accccaagaa tcattacttt ttaaaatgca 1020
attcaaatta gcataaaaca tttacagcct atggaaaggc ttgtggcatt agaattcctta 1080
tttataggat tttttgtgtt ttttttgaga tatggtcttt gtcactgagg cagaagtgcc 1140
gtggtttgat cataattcac cactgacctg aactcttgag tccaagccat ccttttgcc 1200
taattcctcca accagtggga tctacaagca taaggcatca tgcgtggcta attttttcac 1260
gttttttttt tttttgtcga gattatggta tcaactgtgt gctctggctg atctcaaatg 1320
tttgacctca aggatctttt ctgccacagc ctctaaagt gctaggatta tatgatgat 1380
acaccaatgcc tattgtagag tattacatta ttttcaaagt cttattgtaa gagccattta 1440
ttgcctttgg cctaaataac tcaatataat atctctgaaa cttttttttg acaaattttg 1500
gggctgtgat atgagagaag ggggtttgaa actttctaata aagagttaac ttagagccat 1560
ttaagaaagg aaaaaacaca aattatcaga aaaacaacag taagatcaag tgcaaaagt 1620
ctgtggcaaa gatgatgaga gtaaaagaata tatgtttgtg actcatgggt gcttttactt 1680
tgttcttgaa tttctgagta cgggttaaca ttttaagaat ctacattata gataacattt 1740
tattgcaagt aaagtattt caaaatttgt tattggtttt gtatgagatt attctcagcc 1800
tactcatta tcaagctata ttattttatt aatgtagttc gatgatctta cagcaaaagt 1860
gaaagctgta tcttcaaaat atgtctattt gactaaaaag ttattcaaca ggagttatta 1920
tctataaaaa aatacaacag gaatataaaa aacttgagga taaaaagatg ttggaaaaag 1980
taatattaaa tcttaaaaaa catatggaaa ctacacaatg gtgaagacac attggtgaag 2040
tacaataata taaattggat ctagaagaaa gggcaatgca ggcaatagaa aaattagtag 2100
aaatcccttt aaaggtagt ttgtaaaatc aggttaagttt atttataatt tgctttcatt 2160
tatttctactg caaattatat tttggatatg tatatatatt gtgcttcttc tgctgtctt 2220
acagcaattt gccttgca ga gttctaggaa aaagggtggc tgtgttttta ctttcaaat 2280
atttaaatat ccactattat aacaaaatca atttttcaga gtaattgatc tcaactgtga 2340
gtcatttgat tattaagacc cgttggcata agattacatc ctctgactat aaaaatcctg 2400
gaagaaaacc taggaatat tctctggac attgcacttg gcaatgaatt tatgggcgt 2460
ttggaatcct gcagatataa taatgataat taaacaaaac actcagagaa actgccaacc 2520
ctaggatgaa gtatattgtt actgtgcttt gggattaaaa taagtaacta cagtttatag 2580
aacttttata ctgatacaca gactaaaaa agggaaaggg tttagatgag aagctctgct 2640
atgcaatcaa gaatctcagc cactcatttc ttagggggtc gcaggagctc cctgtaaaag 2700
gaggttatgg agtctgtagc ttcaggtaag atacttaaaa cccttcagag tttctccatt 2760
ttttcccata gtttcccaa aaaggttatg acactttata agaattgctc acttgtgaaa 2820
aacaatatc aaagtcttct ttagattat ttttaaggac aaatctttat tccatgttta 2880
atttatttag ctttccctgt agctaattt tcatgtgaa cacattttta atgctgtaaa 2940
ttagatataat gtaatttatg tatcattaat gcccttttag tagtttagag aaaacgtcaa 3000
aagaaatggc ccagaaataa gcttcttgat ttgtaaaatt ctatgtcatt ggctcaaatt 3060
```

tgtatagtat ctcaaaatat aaatatatag acatctcaga taatatatatt gaaatagcaa 3120
 attcctgtta gaaaataata gtacttaact agatgagaat aacagggtcgc cattatttga 3180
 attgtctcct attcgttttt catttgttgt gttactcatg ttttacttat ggggggatat 3240
 atataacttc cgctgttttc agaagtattg tatgcagtca gtatgagaat gcaatttaag 3300
 tttccttgat gctttttcac acttctatta ctagaaataa gaatacagta atattggcaa 3360
 agaaaattga ccagttcaat aaaatttttt agtaaacttg attgaaaata aaaaaaaaaa 3420
 aaaaaaaaaa aaaa 3434

<210> 477

<211> 140

<212> PRT

<213> Homo sapiens

<400> 477

Met Asp Gly His Thr Asp Ile Trp Arg Asn His Met Asp Thr Pro Pro
 5 10 15
 His Tyr His Arg Asp Thr Asp Thr Arg Arg His His His Met Asp Thr
 20 25 30
 Leu Ser His Tyr His Arg Asp Thr Arg His His Thr Val Thr Trp Thr
 35 40 45
 His His His Thr His Glu His Thr Asp Thr Leu Pro Tyr Gly His Trp
 50 55 60
 His Thr His Cys His Thr Val Thr Trp Thr His Leu His Thr Ile Thr
 65 70 75 80
 Pro Pro His Thr Leu Pro Val Asp Thr Arg Thr His Arg His Cys His
 85 90 95
 Thr Asp Thr Gln Asn Thr Val Thr Arg Arg His His His Ala Asp Thr
 100 105 110
 Pro Pro Leu Trp Cys Arg Leu Asn Tyr Pro Ala Gly Gly Thr Ala Val
 115 120 125
 Ala Tyr Ser Cys Leu Ser Asp Trp Leu Ser Pro Gln
 130 135 140

<210> 478

<211> 143

<212> PRT

<213> Homo sapiens

<400> 478

Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln
 5 10 15
 Ser His Gly His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr
 20 25 30
 Gly Glu Ile Thr Trp Thr His His His Thr Ile Thr Gly Thr Gln Thr
 35 40 45
 His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr

50 55 60
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr
 65 70 75 80
 Pro Thr His Cys His Met Asp Thr Gly Thr His Thr Ala Thr Leu Ser
 85 90 95
 His Gly His Thr Ser Thr Pro Ser His His His Thr His Cys Leu Trp
 100 105 110
 Thr Gln Gly His Thr Asp Thr Val Thr Gln Ile His Lys Thr Leu Ser
 115 120 125
 His Gly Asp Ile Thr Met Gln Ile His His His Ser Gly Ala Val
 130 135 140

<210> 479

<211> 222

<212> PRT

<213> Homo sapiens

<400> 479

Met Tyr Arg His Thr Glu Thr Leu Pro His Gly Asp Thr Val Thr Gln
 5 10 15
 Ser His Glu His Thr Gly Ile Val Thr Trp Thr Asp Thr Gln Thr Tyr
 20 25 30
 Gly Glu Ile Thr Leu Thr His His His Thr Ile Thr Gly Thr Gln Thr
 35 40 45
 His Gly Asp Ile Thr Thr Trp Thr His Cys His Thr Thr Thr Gly Thr
 50 55 60
 Arg Asp Ile Thr Leu Ser His Gly His Thr Ile Thr His Met Asn Thr
 65 70 75 80
 Pro Thr His Cys His Met Asp Thr Ala Thr His Thr Ala Thr Leu Ser
 85 90 95
 His Gly His Thr Ser Ile Pro Ser His His His Thr His Cys His Val
 100 105 110
 Asp Thr Arg Thr His Arg His Cys His Thr Asp Thr Gln Asn Thr Val
 115 120 125
 Thr Arg Arg His His His Ala Asp Thr Pro Pro His Gly His Ser Thr
 130 135 140
 Arg His Ser Ala Thr Gln Ile His His His Thr Glu Met Arg Thr His
 145 150 155 160
 Cys His Thr Asp Thr Thr Thr Ser Leu Pro His Phe His Val Ser Ala
 165 170 175
 Gly Gly Val Gly Pro Thr Thr Leu Gly Ser Asn Arg Glu Ile Thr Trp

```
<210> 480
<211> 144
<212> PRT
<213> Homo sapiens
```

<400> 480

Met Glu Pro Tyr Arg Gly Asn Glu Gln Pro Ser Gln Glu Gln Gly Val
5 10 15 :

Cys Cys Leu Trp Gly Leu Gln Ser Leu Pro Gln Gly Ser Tyr Val Thr
20 25 30

Val Gly Phe Leu Val Val Lys Arg Gln Thr Ile Gly Arg Leu Glu Arg
35 40 45

Asp Phe Met Phe Lys Cys Arg Lys Gln Pro Gly Leu Pro Pro Ser Gly
50 55 60

Leu Cys Leu Leu Trp Pro Trp Pro Asn Leu Glu Phe Gly Arg Arg Gln
65 70 75 80

Asp Arg Leu Thr Trp Ser Ser Val Ser Val Ala Gly Val Cys Ala Cys
85 90 95

Arg Ala Arg Pro Gly Trp Leu Gly Glu Gln Pro Ala Thr Ser Ala Gly
100 105 110

Val Arg Leu Glu Gln Val Glu Gln Pro Pro Ala His Pro Leu Gln Glu
115 120 125

Ala Gly Val Ala Arg Phe Pro Arg Pro Glu Trp Val Pro Pro Asn Gly
130 135 140

```
<210> 481
<211> 167
<212> PRT
<213> Homo sapiens
```

```

<400> 481
Met His Gly Pro Gln Val Leu Ala Arg Cys Ser Glu Cys Ala Cys Pro
          5              10              15
Ala Leu Ala Ala Thr Ser Ala Gly Val Arg Leu Glu Gly Val Asp Arg
          20              25              30

```

Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys Ser His Ser
 35 40 45
 Leu Ser Gly Cys His Leu Met Ala Asp Gly Ala Lys Ala Leu Gly Lys
 50 55 60
 Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr Asp Val Pro
 65 70 75 80
 Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser Ser Trp Arg
 85 90 95
 Ala Leu Ala Glu Val Thr Gly Cys Ser Leu Gly Pro Leu Gly Leu Ala
 100 105 110
 Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys Trp Ser His
 115 120 125
 Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr Ala Ala Phe
 130 135 140
 Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu Trp Ala Ser
 145 150 155 160
 Trp Leu Ser Arg Gly Arg Pro
 165

<210> 482

<211> 143

<212> PRT

<213> Homo sapiens

<400> 482

Met Glu Pro Tyr Arg Gly Asn Lys Lys Gln Val Gln Glu Lys Gly Val
 5 10 15
 Pro Cys Leu Trp Gly Ser Ser Pro Cys Leu Arg Cys His Met Ala Leu
 20 25 30
 Arg Ala Ser Trp Leu Pro Gly Gly Gly Pro Gln Ala Ile Leu Gly Arg
 35 40 45
 Thr Leu Cys Ser Ser Ala Glu Ser Ser Gln Asp Cys His Pro Gly Gly
 50 55 60
 Pro Ser Ile Ala Leu Ala Lys Pro Cys Arg Gly Val Trp Leu Leu Phe
 65 70 75 80
 Glu Pro Ala Trp Pro Pro Trp His Ala Arg Ala Pro Gly Ala Gly Thr
 85 90 95
 Leu Leu Arg Val Cys Leu Ser Cys Leu Gly Cys His Leu Cys Gly Gly
 100 105 110
 Ala Ser Gly Gly Gly Gly Pro Ala Thr Asn Leu Thr Gln Ser Arg Lys
 115 120 125

169

Trp Met Ala Met Phe Pro Gln Pro Glu Trp Leu Pro Pro Asp Gly
 130 135 140

<210> 483
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 483
 Met Glu Thr Gln Arg Gly Asn Lys Gln Arg Ala Gln Glu Gln Gly Val
 5 10 15
 Cys Cys Leu Trp Gly Ser Ser Pro Cys Leu Gly Ser Tyr Gly Thr Ala
 20 25 30
 Gly Phe Leu Val Ala Lys Arg Arg Thr Thr Gly Leu Leu Glu Glu Asp
 35 40 45
 Phe Thr Phe Lys Cys Arg Lys Gln Pro Lys Leu Pro Ser Met Arg Leu
 50 55 60
 Ser Leu Leu Trp Pro Trp Arg Asp Leu Lys Phe Val Pro Arg Gln Asp
 65 70 75 80
 Lys Leu Thr Arg Ser Ser Val Ser Val Ala Gly Ala Tyr Ala Cys Arg
 85 90 95
 Ala Gly Pro Gly Trp Leu Lys Glu Gln Pro Ala Thr Ser Ala Arg Val
 100 105 110
 Arg Leu Val Gln Ala Glu His Pro Pro Pro His Pro Leu Glu Glu Val
 115 120 125
 Gly Met Ala Arg Phe Pro Gln Pro Glu Cys Leu Pro Pro Tyr Cys
 130 135 140

<210> 484
 <211> 30
 <212> PRT
 <213> Homo Sapien

<400> 484
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
 1 5 10 15
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile
 20 25 30

<210> 485
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 485
 gggaagctta tcacctatgt gccgcctctg c

<210> 486
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 486
 gcgaattctc acgctgagta tttggcc 27

<210> 487
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 487
 cccgaattct tagctgccca tccgaacgcc ttcac 36

<210> 488
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 488
 gggaagcttc ttccccggct gcaccagctg tgc 33

<210> 489
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 489
 Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 1 5 10 15
 Ser Val Ala

<210> 490
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 490
 Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys

```

1
Leu Ser His Ser
20
5
10
15
<210> 491
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Made in a lab
<400> 491
Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu
1 5 10 15
Thr Gly Phe Thr
20
<210> 492
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Made in a lab
<400> 492
Ala Leu Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr
1 5 10 15
Leu Ala Ser Leu
20
<210> 493
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Made in a lab
<400> 493
Tyr Thr Leu Ala Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro
1 5 10 15
Lys Tyr Arg Gly
20
<210> 494
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Made in a lab
<400> 494
Leu Pro Lys Tyr Arg Gly Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser
1 5 10 15
Leu Met Ile Ser

```


<220>
<223> Made in a lab

<220>
<223> Made in a lab

<220>
<223> Made in a lab

<220>
<223> Made in a lab

```

      <400> 498
Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val
 1          5          10          15
Val Pro Gly Arg
      20

```

<210> 499
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 499
 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp
 1 5 10 15
 Ser Ala Phe Leu
 20

<210> 500
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 500
 Leu Asp Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met
 1 5 10 15
 Gly Ser Ile Val
 20

<210> 501
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 501
 Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met
 1 5 10 15
 Val Ser Ala Ala
 20

<210> 502
 <211> 414
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (1)...(414)
 <223> n=A,T,C or G

<400> 502
 caccatggag acaggcctgc gctggctttt cctggtcgct gtgctcaaag gtgtccaatg 60
 tcagtcggtg gaggagtccg ggggtcgcct ggtcacgcct gggacacctt tgacantcac 120
 ctgtagagtt tttggaatng acctcagtag caatgcaatg agctgggtcc gccaggctcc 180
 agggaagggg ctggaatgga tcggagccat tgataattgt ccacantacg cgacctgggc 240

```

gaaaggccga ttatnatntt caaaaacctn gaccacggtg gatttgaaaa tgaccagtcc 300
gacaaccgag gacacggcca cctatntttg tggcagaatg aatactggta atagtgggtg 360
gaagaatatt tggggcccag gcaccctggt caccgtntcc tcagggaac ctaa 414

```

```

<210> 503
<211> 379
<212> DNA
<213> Homo Sapien

```

```

<220>
<221> misc_feature
<222> (1)...(379)
<223> n=A,T,C or G

```

```

<400> 503
atnccgatggt gcttggtcaa aggtgtccag tgtcagtcgg tggaggagtc cggggggtcgc 60
ctggtcacgc ctgggacacc cctgacactc acctgcaccg tntctggatt ngacatcagt 120
agctatggag tgagctgggt ccgccaggct ccagggaagg ggctgggnata catcggtatca 180
ttagtagtag tggtagatntt tacgagagct gggcgaaagg ccgattcacc atttccaaaa 240
cctngaccac ggtggatttg aaaatcacca gtttgacaac cgaggacacg gccacattt 300
tntgtgccag agggggggtt aattataaag acatttgggg cccaggacac ctggtcaccg 360
tntccttagg gcaacctaa 379

```

```

<210> 504
<211> 19
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Made in a lab

```

```

<400> 504
Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp Ser Pro Tyr Phe Lys Glu
  1             5             10             15
Asn Ser Ala

```

```

<210> 505
<211> 20
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Made in a lab

```

```

<400> 505
Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn Asp Asn Val Thr
  1             5             10             15
Asn Thr Ala Asn
                20

```

```

<210> 506
<211> 407
<212> DNA
<213> Homo Sapien

```

```

<400> 506

```

```

atggagacag gcctgcgctg gcttctcctg gtcgctgcgc tcaaaggtgt ccagtgtcag      60
tcgctggagg agtccggggg tcgctgggtc acgcctggga caccctgac actcacctgc      120
accgtctctg gattctccct cagtagcaat gcaatgatct gggcccgcca ggctccaggg      180
aaggggctgg aatacatcgg atacattagt tatggtggta gcgcatacta cgcgagctgg      240
gtgaaaggcc gattcaccat ctccaaaacc tcgaccacgg tggatctgag aatgaccagt      300
ctgacaaccg aggacacggc cacctatttc tgtgccagaa atagtgattt tagtggtagt      360
ttgtggggcc caggcacctt ggtcaccgtc tcctcagggc aacctaa                      407

```

<210> 507
 <211> 422
 <212> DNA
 <213> Homo Sapien

```

<400> 507
atggagacag gcctgcgctg gcttctcctg gtcgctgtgc tcaaaggtgt ccagtgtcag      60
tcggtggagg agtccggggg tcgctgggtc acgcctggga caccctgac actcacctgt      120
acagtctctg gattctccct cagcaactac gacctgaact gggcccgcca ggctccaggg      180
aaggggctgg aatggatcgg gatcattaat tatgttggta ggacggacta cgcgaactgg      240
gcaaaaggcc ggttcaccat ctccaaaacc tcgaccacgg tggatctcaa gatcgccagt      300
ccgacaaccg aggacacggc cacctatttc tgtgccagag ggtggaagtg cgatgagtct      360
ggcccgctgt tgcgcatctg gggcccaggc accctgggtc ccgtctcctt agggcaacct      420
aa                                                                422

```

<210> 508
 <211> 411
 <212> DNA
 <213> Homo Sapien

<220>
 <221> misc_feature
 <222> (1)...(411)
 <223> n=A,T,C or G

```

<400> 508
atggagacag gcctgcgctg cttctcctgg tcgctgtgct caaaggtgtc cagtgtcagt      60
cgttggagga gtccgggggt cgcctgggtc cgcctgggac accctgaca ctcacctgca      120
cagtctctgg aatcgacctc agtagctact gcatgagctg ggtccgcccag gctccagggg      180
aggggctgga atggatcggg atcattggta ctctgggtga cacatactac gcgaggtggg      240
cgaaaggccg attcaccatc tccaaaacct cgaccacggg gcatntgaaa atcnccagtc      300
cgacaaccga ggacacggcc acctatttct gtgccagaga tcttcgggat ggtagtagta      360
ctggttatta taaaatctgg ggcccaggca ccctgggtcac cgtctccttg g                      411

```

<210> 509
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

```

<400> 509
Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
 1              5              10             15

```

<210> 510
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Made in a lab

<400> 510

Pro	Glu	Tyr	Asn	Arg	Pro	Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu	Ile
1				5					10					15

<210> 511

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 511

Tyr	His	Pro	Ser	Met	Phe	Cys	Ala	Gly	Gly	Gly	Gln	Asp	Gln	Lys
1				5					10					15

<210> 512

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 512

Asp	Ser	Gly	Gly	Pro	Leu	Ile	Cys	Asn	Gly	Tyr	Leu	Gln	Gly	Leu
1				5					10					15

<210> 513

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 513

Ala	Pro	Cys	Gly	Gln	Val	Gly	Val	Pro	Asx	Val	Tyr	Thr	Asn	Leu
1				5					10					15

<210> 514

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 514

Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu	Lys	Thr	Val	Gln	Ala	Ser
1				5					10					15

<210> 515

177

<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 515
Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg
1 5 10 15

<210> 516
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 516
Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln
1 5 10 15

<210> 517
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 517
Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met
1 5 10 15

<210> 518
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 518
Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly
1 5 10 15

<210> 519
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 519
Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg Asn Tyr Asp Glu Gly Cys
1 5 10 15

Gly

<210> 520
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 520
Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr
1 5 10 15
Glu Ala Arg Arg His Tyr Asp Glu Gly
20 25

<210> 521
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 521
Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly Ser Gly Leu Leu
1 5 10 15
Pro Pro Pro Pro Ala
20

<210> 522
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 522
Leu Leu Val Val Pro Ala Ile Lys Lys Asp Tyr Gly Ser Gln Glu Asp
1 5 10 15
Phe Thr Gln Val
20

<210> 523
<211> 254
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<220>
<221> VARIANT
<222> (1)...(254)
<223> Xaa = any amino acid

<400> 523

```

Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
  1          5          10          15
Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
          20          25          30
Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
          35          40          45
Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
          50          55          60
Trp Val Leu Ser Ala Thr His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
          65          70          75          80
Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
          85          90          95
Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
          100          105          110
Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
          115          120          125
Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
          130          135          140
Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
          145          150          155          160
Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
          165          170          175
Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
          180          185          190
Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser Gly
          195          200          205
Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
          210          215          220
Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
          225          230          235          240
Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
          245          250

```

<210> 524

<211> 765

<212> DNA

<213> Homo sapien

<400> 524

```

atggccacag caggaaatcc ctggggctgg ttctctgggt accatcatcct tgggtgtcgca      60
ggatcgctcg tctctggtag ctgcagccaa atcataaacg gcgaggactg cagcccgcac      120
tcgcagccct ggcaggcggc actggtcatg gaaaacgaat tgttctgctc gggcgctcctg      180
gtgcatccgc agtgggtgct gtcagccgca cactgtttcc agaactccta caccatcggg      240
ctggggcctgc acagtcttga ggccgaccaa gagccaggga gccagatggt ggaggccagc      300
ctctccgtac ggcacccaga gtacaacaga cccttgctcg ctaacgacct catgctcatc      360
aagttggacg aatccgtgtc cgagttctgac accatccgga gcatcagcat tgcttcgcag      420
tgccctaccg cggggaactc ttgcctcgtt tctggctggg gtctgctggc gaacggcaga      480
atgacctaccg tgctgcagtg cgtgaacgtg tcggtggtgt ctgaggaggt ctgcagtaag      540
ctctatgacc cgctgtacca cccagcatg ttctgcgccg gcggagggca agaccagaag      600
gactcctgca acggtgactc tggggggccc ctgatctgca acgggtactt gcagggcctt      660
gtgtcttttcg gaaaagcccc gtgtggccaa gttggcgtgc caggtgtcta caccaacctc      720
tgcaaattca ctgagtggat agagaaaacc gtccaggcca gttaa      765

```

<210> 525

<211> 254

<212> PRT

<213> Homo sapien

<400> 525

```

Met Ala Thr Ala Gly Asn Pro Trp Gly Trp Phe Leu Gly Tyr Leu Ile
 1           5           10           15
Leu Gly Val Ala Gly Ser Leu Val Ser Gly Ser Cys Ser Gln Ile Ile
      20           25           30
Asn Gly Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu
      35           40           45
Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln
 50           55           60
Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly
65           70           75           80
Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
      85           90           95
Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu
      100          105          110
Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu
      115          120          125
Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala
      130          135          140
Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg
145          150          155          160
Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu
      165          170          175
Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys
      180          185          190
Ala Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly
      195          200          205
Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly
      210          215          220
Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu
225          230          235          240
Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
      245          250

```

<210> 526

<211> 963

<212> DNA

<213> Homo sapiens

<400> 526

```

atgagttcct gcaacttcac acatgccacc tttgtgctta ttggtatccc aggattagag 60
aaagcccatt tctgggttgg cttccccctc ctttccatgt atgtagtggc aatgtttggg 120
aactgcatcg tggctttcat cgtaaggacg gaacgcagcc tgcacgctcc gatgtacctc 180
tttctctgca tgcttgacgc cattgacctg gccttatcca catccaccat gcctaagatc 240
cttgcccttt tctgggttga ttcccagagag attagctttg aggcctgtct taccagatg 300
ttctttattc atgccctctc agccattgaa tccaccatcc tgctggccat ggcctttgac 360
cgttatgtgg ccatctgcca cccactgcgc catgctgcag tgctcaacaa tacagtaaca 420
gccagattg gcactgtggc tgtggtccgc ggatccctct tttttttccc actgcctctg 480
ctgatcaagc ggctggcctt ctgccactcc aatgtcctct cgcaactccta ttgtgtccac 540
caggatgtaa tgaagtggc ctatgcagac actttgccc aatgtgtata tggctttact 600
gccattctgc tggcatggg cgtggacgta atgttcatct ccttgtccta ttttctgata 660
atacgaacgg ttctgcaact gccttccaag tcagagcggg ccaaggcctt tggaaacctg 720
gtgtcacaca ttggtgtggt actgccttc tatgtgccac ttattggcct ctcagttgta 780
caccgctttg gaaacagcct tcatccatt gtgcgtgttg tcatgggtga catctacctg 840
ctgtgcctc ctgtcatcaa tccatcatc tatggtgcc aaaccaaaca gatcagaaca 900
cgggtgctgg ctatgttcaa gatcagctgt gacaaggact tgcaggctgt gggaggcaag 960
tga

```

<400> 527

Leu Ser Val Val His Arg Phe Gly Asn Ser Leu His Pro Ile Val Arg
260 265 270

Val Val Met Gly Asp Ile Tyr Leu Leu Leu Pro Pro Val Ile Asn Pro
275 280 285

Ile Ile Tyr Gly Ala Lys Thr Lys Gln Ile Arg Thr Arg Val Leu Ala
290 295 300

Met Phe Lys Ile Ser Cys Asp Lys Asp Leu Gln Ala Val Gly Gly Lys
305 310 315 320

<210> 528
<211> 20
<212> DNA
<213> Homo Sapien

<400> 528
actatgggtcc agaggctgtg 20

<210> 529
<211> 20
<212> DNA
<213> Homo Sapien

<400> 529
atcacctatg tgccgcctct 20

<210> 530
<211> 1852
<212> DNA
<213> Homo sapiens

<400> 530
ggcacgagaa ttaaaaccct cagcaaaaca ggcatagaag ggacatacct taaagtaata 60
aaaaccacct atgacaagcc cacagccaac ataatactaa atggggaaaa gttagaagca 120
tttctctgga gaactgcaac aataaatata aggatgctgg attttgtcaa atgccttttc 180
tgtgtctggt gagatgctta tgtgactttg cttttaattc tgtttatgtg attatcacat 240
ttattgactt gcctgtgtta gaccggaaga gctgggggtg ttctcaggag ccaccgtgtg 300
ctgcggcagc ttcgggataa cttgaggctg catcactggg gaagaaacac aytccctgtcc 360
gtggcgctga tggctgagga cagagcttca gtgtggcttc tctgcgactg gcttcttcgg 420
ggagtcttcc cttcatagtt catccatatg gctccagagg aaaattatat tattttgtta 480
tggatgaaga gtattacgtt gtgcagatat actgcagtgt cttcatctct tgatgtgtga 540
ttgggtaggt tccaccatgt tgccgcagat gacatgattt cagtacctgt gtctggctga 600
aaagtgtttg tttgtgaatg gatattgtgg tttctggatc tcatcctctg tgggtggaca 660
gctttctcca ccttgctgga agtgacctgc tgtccagaag tttgatggct gaggagtata 720
ccatcgtgca tgcattcttc atttctctga tttcttcctc cctggatgga cagggggagc 780
ggcaagagca acgtgggcac ttctggagac cacaacgact cctctgtgaa gacgcttggg 840
agcaagaggt gcaagtgtg ctgccactgc ttccctgct gcagggggag cggcaagagc 900
aacgtggtcg cttggggaga ctacgatgac agcgccttca tggatccag gtaccacgtc 960
catggagaag atctggacaa gctccacaga gctgcctggt ggggtaaagt ccccgaaaag 1020
gatctcatcg tcatgctcag ggacacggat gtgaacaaga gggacaagca aaagaggact 1080
gctctacatc tggcctctgc caatgggaat tcagaagtag taaaactcgt gctggacaga 1140
cgatgtcaac ttaatgtcct tgacaacaaa aagaggacag ctctgacaaa ggccgtacaa 1200
tgccaggaag atgaatgtgc gttaatgttg ctggaacatg gactgatcc aaatattcca 1260
gatgagtatg gaaataccac tctacactat gctgtctaca atgaagataa attaattggc 1320
aaagcactgc tcttatacgg tgctgatatc gaatcaaaaa acaagcatgg cctcacacca 1380
ctgctacttg gtatacatga gcaaaaacag caagtgttga aatttttaat caagaaaaaa 1440
gcgaatttaa atgcgctgga tagatatgga agaactgctc tcatacttgc tgtatgttgt 1500
ggatcagcaa gtagctcag ccctctactt gagcaaaatg ttgatgtatc ttctcaagat 1560
ctggaaagac ggccagagag tatgtctgtt ctagtcatca tcatgtaatt tgccagttac 1620

```
<210> 531
<211> 879
<212> DNA
<213> Homo sapiens
```

```
<210> 532
<211> 292
<212> PRT
<213> Homo sapiens
```

```

<400> 532
Met His Leu Ser Phe Pro Ala Phe Leu Pro Pro Trp Met Asp Arg Gly
      5                      10                      15

Ser Gly Lys Ser Asn Val Gly Thr Ser Gly Asp His Asn Asp Ser Ser
      20                      25                      30

Val Lys Thr Leu Gly Ser Lys Arg Cys Lys Trp Cys Cys His Cys Phe
      35                      40                      45

Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val Val Ala Trp Gly Asp
      50                      55                      60

Tyr Asp Asp Ser Ala Phe Met Asp Pro Arg Tyr His Val His Gly Glu
      65                      70                      75                      80

Asp Leu Asp Lys Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg
      85                      90                      95

Lys Asp Leu Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Arg Asp
      100                      105                      110

Lys Gln Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser
      115                      120                      125

Glu Val Val Lys Leu Val Leu Asp Arg Arg Cys Gln Leu Asn Val Leu

```

184

130 135 140
 Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala Val Gln Cys Gln Glu
 145 150 155 160
 Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro Asn Ile
 165 170 175
 Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Val Tyr Asn Glu
 180 185 190
 Asp Lys Leu Met Ala Lys Ala Leu Leu Leu Tyr Gly Ala Asp Ile Glu
 195 200 205
 Ser Lys Asn Lys His Gly Leu Thr Pro Leu Leu Leu Gly Ile His Glu
 210 215 220
 Gln Lys Gln Gln Val Val Lys Phe Leu Ile Lys Lys Lys Ala Asn Leu
 225 230 235 240
 Asn Ala Leu Asp Arg Tyr Gly Arg Thr Ala Leu Ile Leu Ala Val Cys
 245 250 255
 Cys Gly Ser Ala Ser Ile Val Ser Pro Leu Leu Glu Gln Asn Val Asp
 260 265 270
 Val Ser Ser Gln Asp Leu Glu Arg Arg Pro Glu Ser Met Leu Phe Leu
 275 280 285
 Val Ile Ile Met
 290

 <210> 533
 <211> 801
 <212> DNA
 <213> Homo sapiens

 <400> 533
 atgtacaagc ttccagtgcac caactgtgct acaaatggag ccacagagag gaaacaagca 60
 gcaggctcag gagcagggtg tgcgctgcct tcggtctctc aatccatgcc tcagggtctcc 120
 tatgccactg cagcattctt ggttgccaag aggccaaacca caggccatct tgagaaggag 180
 tttatgttcc actgcagaaa gcagccagga tcaccatcca ggggacttgg tcttctgtgg 240
 ccctggccag acatagaatt tgtgccaagg caggacaagc tactcagag cagcgtgtta 300
 gtacctcaaa tctgtgcgtg ccagacaagg ccaaactggc tcaatgagca accagccacc 360
 tctgcagggg tgcgtctgga ggaggtggac cagccaccaa ccttaccag tcaagggaagt 420
 ggatggccat gttcccacag cctgagtggc tgccacctga tggctgatat agcaaaggcc 480
 ttaggaaaag cagatggccc ttggccctac ctttttggtg gaagaactga tgttccatgt 540
 cctgcagcga gtgaggttgg tggctgtgcc cccagctcct ggcacaccct cgcagagggtg 600
 actggttgct ctttgagccc tcttagcctt gccagcatg cacaagcctc agtgcacta 660
 ctgtgctaca aatggagcca tataggggaa acgagcagcc atctcaggag caaggtgtat 720
 gctgcctttg ggggtccag tccttgccctc aagggtctta tgtcactgtg ggcttcttgg 780
 ttgccaagag gcagaccata g 801

 <210> 534
 <211> 266
 <212> PRT
 <213> Homo sapiens

185

<400> 534

Met Tyr Lys Leu Gln Cys Asn Asn Cys Ala Thr Asn Gly Ala Thr Glu
 5 10 15
 Arg Lys Gln Ala Ala Gly Ser Gly Ala Gly Tyr Ala Leu Pro Ser Ala
 20 25 30
 Leu Gln Ser Met Pro Gln Gly Ser Tyr Ala Thr Ala Arg Phe Leu Val
 35 40 45
 Ala Lys Arg Pro Thr Thr Gly His Leu Glu Lys Glu Phe Met Phe His
 50 55 60
 Cys Arg Lys Gln Pro Gly Ser Pro Ser Arg Gly Leu Gly Leu Leu Trp
 65 70 75 80
 Pro Trp Pro Asp Ile Glu Phe Val Pro Arg Gln Asp Lys Leu Thr Gln
 85 90 95
 Ser Ser Val Leu Val Pro Gln Ile Cys Ala Cys Gln Thr Arg Pro Asn
 100 105 110
 Trp Leu Asn Glu Gln Pro Ala Thr Ser Ala Gly Val Arg Leu Glu Glu
 115 120 125
 Val Asp Gln Pro Pro Thr Leu Pro Ser Gln Gly Ser Gly Trp Pro Cys
 130 135 140
 Ser His Ser Leu Ser Gly Cys His Leu Met Ala Asp Ile Ala Lys Ala
 145 150 155 160
 Leu Gly Lys Ala Asp Gly Pro Trp Pro Tyr Leu Phe Val Arg Arg Thr
 165 170 175
 Asp Val Pro Cys Pro Ala Ala Ser Glu Val Gly Gly Cys Ala Pro Ser
 180 185 190
 Ser Trp His Thr Leu Ala Glu Val Thr Gly Cys Ser Leu Ser Pro Leu
 195 200 205
 Ser Leu Ala Gln His Ala Gln Ala Ser Val Leu Leu Leu Cys Tyr Lys
 210 215 220
 Trp Ser His Ile Gly Glu Thr Ser Ser His Leu Arg Ser Lys Val Tyr
 225 230 235 240
 Ala Ala Phe Gly Gly Ser Ser Pro Cys Leu Lys Gly Leu Met Ser Leu
 245 250 255
 Trp Ala Ser Trp Leu Pro Arg Gly Arg Pro
 260 265

<210> 535

<211> 6082

<212> DNA

<213> Homo sapiens

<400> 535

```

cctccactat tacagcttat aggaaattac aatccacttt acaggcctca aaggttcatt 60
ctggccgagc ggacaggcgt ggccggccgga gccccagcat ccctgcttga ggtccaggag 120
cggagcccgcc ggccactgcc gcctgatcag cgcgaccccg gcccgcgccc gccccgccc 180
gcaagatgct gcccggtgtac caggagggtga agcccaaccc gctgcaggac gcgaacctct 240
gctcacgcgt gttcttcttg tggctcaatc ccttgtttaa aattggccat aaacggagat 300
tagaggaaga tgatatgtat tcagtgtctc cagaagaccg ctcacagcac cttggagagg 360
agttgcaagg gttctgggat aaagaagttt taagagctga gaatgacgca cagaagcctt 420
ctttaacaag agcaatcata aagtgttact ggaaatctta tttagttttg ggaattttta 480
cgtaattga ggaaagtgcc aaagtaatcc agcccatatt tttgggaaaa attatttaatt 540
attttgaaaa ttatgatccc atggattctg tggctttgaa cacagcgtac gcctatgcca 600
cgggtgctgac tttttgcacg ctcatthttg ctatactgca tcacttata ttttatcacg 660
ttcagtgtgc tgggatgagg ttacgagtag ccatgtgcca tatgatttat cggaaggcac 720
ttcgtcttag taacatggcc atggggaaga caaccacagg ccagatagtc aatctgctgt 780
ccaatgatgt gaacaagttt gatcagggtga cagtgttctt acacttctctg tgggcaggac 840
cactgcaggc gatcgagtg actgccctac tctggatgga gataggaata tcgtgccttg 900
ctgggatggc agttctctac attctcctcg ccttgcaaa ctgttttggg aagttgttct 960
catcactgag gagtaaaact gcaactttca cggatgccag gatcaggacc atgaatgaag 1020
ttataactgg tataaggata ataaaaatgt acgcctggga aaagtcattt tcaaacttta 1080
ttaccaatth gagaaagaag gagatttcca agattctgag aagttcctgc ctcaggggga 1140
tgaatttggc ttcgtttttc agtgcaagca aaatcatcgt gtttgtgacc ttcaccacct 1200
acgtgctcct cggcagtggt atcacagcca gccgcgtgtt cgtggcagtg acgctgtatg 1260
gggctgtgcg gctgacgggt accctcttct tccctcagc cattgagagg gtgtcagagg 1320
caatcgtcag catccgaaga atccagacct ttttgcact tgatgagata tcacagcgca 1380
accgtcagct ccgcgcagat ggtaaaaaga tggatgcagt gcaggatttt actgcttttt 1440
gggataaggc atcagagacc ccaactctac aaggcctttc ctttactgtc agacctggcg 1500
aattgttagc tgtggtcggc cccgtgggag cagggaagtc atcactgtta agtgccgtgc 1560
tcggggaatt ggcccaagc cacgggctgg tcagcgtgca tggagaatt gcctatgtgt 1620
ctcagcagcc ctgggtgttc tcgggaaactc tgaggagtaa tattttattt gggaagaaat 1680
acgaaaagga acgatatgaa aaagtcataa aggcttgtgc tctgaaaaag gatttacagc 1740
tggtggagga tggatgatcg actgtgatag gagatcgggg aaccacgctg agtggaggcg 1800
agaaagcacg ggttaaacctt gcaagacgag tggatcaaga tgctgacatc tatctcctgg 1860
acgatcctct cagtgcagta gatgcggaag ttagcagaca cttgttcgaa ctgtgtattt 1920
gtcaaatttt gcatgagaag atcacaattt tagtgactca tcagttgcag tacctcaaag 1980
ctgcaagtca gattctgata ttgaaagatg gtaaaatggt gcagaagggg acttacactg 2040
agttcctaaa atctgggtata gattttggct cctttttaa gaaggataat gaggaaagt 2100
aacaacctcc agttccagga actccacac taaggaatcg taccttctca gagtcttcgg 2160
tttggtctca acaatcttct agacctctct tgaaagatgg tgctctggag agccaagata 2220
cagagaatgt ccagtttaca ctatcagagg agaaccgttc tgaaggaaaa gttggtttc 2280
aggcctataa gaattacttc agagctgggt ctcactggat tgtcttcatt ttccttattc 2340
tcctaaacac tgcagctcag gttgcctatg tgcttcaaga ttgggtggct tcatactggg 2400
caaacaaaca aagtatgcta aatgtcactg taaatggagg aggaaatgta accgagaagc 2460
tagatcttaa ctggtactta ggaatttatt caggtttaac tgtagctacc gttctttttg 2520
gcatagcaag atctotattg gtattctacg tcttgtttaa ctcttcacaa actttgcaca 2580
acaaaatgth tgagtcaatt ctgaaagtc cggtattatt ctttgataga aatccaatag 2640
gaagaatttt aaatcgthtc tcaaagaca ttggacactt ggatgatttg ctgccgtga 2700
cgthtttaga tttcatccag acattgtctc aagtggttgg tgtggtctct gtggctgtgg 2760
ccgtgattcc ttggatcgca atacccttgg tcccccttgg aatcattttc atttttcttc 2820
ggcgatattt tttggaaacg tcaagagatg tgaagcgctt ggaatctaca actcggagtc 2880
cagtgttttc ccacttgtca tcttctctcc aggggctctg gaccatccgg gcatacaaa 2940
cagaagagag gtgtcaggaa ctgtttgatg cacaccagga tttacattca gaggttgggt 3000
tcttgttttt gacaacgtcc cgctggttcc ccgtccgtct ggatgccatc tgtgccatgt 3060
ttgtcatcat cgttgctttt gggctccctga tcttgcaaaa aactctggat gccgggcagg 3120
ttggtttggc actgctctat gccctcacgc tcatgggatg gtttcagtgg tgtgttcgac 3180
aaagtgtctga agttgagaat atgatgatct cagtagaaaq qgtcattgaa tacacagacc 3240
ttgaaaaaga agcaccttgg gaatatcaga aacgcccacc accagcctgg ccccatgaag 3300
gagtataat ctttgacaat gtgaacttca tgtacagtcc aggtgggcct ctggtactga 3360

```

```

agcatctgac agcactcatt aaatcacaag aaaaggttgg cattgtggga agaaccggag 3420
ctggaaaaag ttccctcatc tcagcccttt ttagattgtc agaaccggaa ggtaaaaattt 3480
ggattgataa gatcttgaca actgaaattg gacttcacga ttttaaggaa aaaatgtcaa 3540
tcatacctca ggaacctgtt ttgttctactg gaacaatgag gaaaaacctg gatcccttta 3600
atgagcacac ggatgaggaa ctgtggaaatg ccttacaaga ggtacaactt aaagaaacca 3660
ttgaagatct tcctggtaaa atggatactg aattagcaga atcaggatcc aatttttagtg 3720
ttggacaaaag acaactggtg tgccttgcca gggcaattct caggaaaaat cagatattga 3780
ttattgatga agcgacggca aatgtggatc caagaactga tgagttaata caaaaaaat 3840
ccgggagaaa tttgccact gcacctgtct aaccttgca cacagattga acaccattat 3900
tgacagcgac aagataatgg ttttagattc aggaagactg aaagaatatg atgagccgta 3960
tgttttgctg caaaataaag agagcctatt ttacaagatg gtgcaacaac tgggcaaggc 4020
agaagccgct gccctcactg aaacagcaaa acaggtatac ttcaaagaa attatccaca 4080
tattggtcac actgaccaca tggttacaaa cacttccaat ggacagccct cgaccttaac 4140
tattttcgag acagcactgt gaatccaacc aaaatgtcaa gtccgttccg aaggcatttg 4200
ccactgattt ttggactatg taaaccacat tgtacttttt tttacttttg caacaaatat 4260
ttatacatat aagatgctag ttcatctgaa tattctccc aacttatcca aggatctcca 4320
gctctaacia aatggtttat ttttatttaa atgtcaatag ttgtttttta aaatccaaat 4380
cagaggtgca ggccaccagt taaatgccgt ctatcagggt ttgtgcctta agagactaca 4440
gagtcaaaagc tcatttttaa aggagtagga cagagttgtc acaggttttt gttgttggtt 4500
ttattgcccc caaaattaca tgtaatttc catttatatc agggattcta tttacttgaa 4560
gactgtgaag ttgccatttt gtctcattgt tttctttgac ataactagga tccattattt 4620
cccctgaagg cttcttgtaa gaaaatagta cagttacaac caataggaac aacaaaaaga 4680
aaaagtttgt gacattgtag tagggagtgt gtaccctta tccccatca aaaaaaaa 4740
tggtacatg gttaaaggat agaagggcaa tttttatca tatgttctaa aagagaagga 4800
agagaaaata ctactttctc aaaatggaag cccttaaagg tgctttgata ctgaaggaca 4860
caaatgtgac cgtccatcct ccttagagt tgcagtactt ggacacggta actgttgacg 4920
ttttagactc agcattgtga cacttcccaa gaaggccaaa cctctaaccg acattcctga 4980
aatacgtggc attattcttt tttggatttc tcatttatgg aaggctaacc ctctgttgac 5040
tgtaagcctt ttggtttggg ctgtattgaa atcctttcta aattgcatga ataggctctg 5100
ctaagctgat gagacaaact gaaaattatt gcaagcattg actataatta tgcagtacgt 5160
tctcaggatg catccagggg ttcattttca tgagcctgtc cagggttagtt tactcctgac 5220
cactaatagc attgtcattt gggctttctg ttgaatgaat caacaaacca caatacttcc 5280
tgggaccttt tgtactttat ttgaactatg agtctttaat ttttctgat gatgggtggc 5340
gtaatatggt gagtctagtt tactaaagggt tttactatta tgggttgaa gaggagtctc 5400
tgacctctca gaataagggt tcacctccct gaaattgcat atatgtatat agacatgcac 5460
acgtgtgcat ttgtttgtat acatatattt gtccttcgta tagcaagttt tttgctcatc 5520
agcagagagc aacagatggt ttattgagtg aagccttaaa aagcacacac cacacacagc 5580
taactgccaa aatacattga ccgtagtagc tgttcaactc ctagtactta gaaatacacg 5640
tatggttaat gttcagtcca acaaaaccaca cacagtaaat gtttattaat agtcatggtt 5700
cgtatttttag gtgactgaaa ttgcaacagt gatcataatg aggtttgtta aaatgatagc 5760
tatattcaaa atgtctatat gtttatttgg acttttgagg ttaaagacag tcatataaac 5820
gtcctgtttc tgttttaatg ttatcataga attttttaat gaaactaaat tcaattgaaa 5880
taaagatag ttttcatctc caaaaaaaa aaaaaaagg gcggccgctc gagtctagag 5940
ggcccgttta aaccogctga tcagcctcga ctgtgccttc tagttgccag ccactctgtt 6000
tttgcccttc cccogtgcct tccttgacct tggaagggtc cactccact gtcctttcct 6060
aataaaatga ggaaattgca tc 6082

```

<210> 536

<211> 6140

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(6140)

<223> n=A,T,C or G

<400> 536

cagtggcgca	gtctcagctc	actgcagcct	ccacctcctg	tgttcaagca	gtcctcctgc	60
ctcagccacc	agactagcag	gtctcccccg	cctctttctt	ggaaggacac	ttgccattgg	120
athtaggacc	cacttgata	atccaggatg	atgtcttcac	tccaacatcc	tcagtttaaat	180
tccatgtgca	aatacccttt	tcccaaataa	cattcaattc	tttaccagga	aaggtggctc	240
aatcccttgt	ttaaaattgg	ccataaacgg	agattagagg	aagatgatat	gtattcagtg	300
ctgccagaag	accgctcaca	gcaccttgga	gaggagtgtg	aagggttctg	ggataaagaa	360
gttttaagag	ctgagaatga	cgcacagaag	ccttctttaa	caagagcaat	cataaagtgt	420
tactggaaat	cttatttagt	tttgggaatt	tttacgttaa	ttgaggaaag	tgccaaagta	480
atccagccca	tatttttggg	aaaaattatt	aattattttg	aaaattatga	tcccatggat	540
tctgtggctt	tgaacacagc	gtacgcctat	gccacgggtg	tgactttttg	cacgctcatt	600
ttggctatac	tgcatcactt	atatttttat	cacgttcagt	gtgctgggat	gaggttacga	660
gtagccatgt	gccatatgat	ttatcggaag	gcacttcgtc	ttagtaacat	ggccatgggg	720
aagacaacca	caggccagat	agtcaatctg	ctgtccaatg	atgtgaacaa	gtttgatcag	780
gtgacagtgt	tcttacactt	cctgtgggca	ggaccactgc	aggcgatcgc	agtgaactgcc	840
ctactctgga	tggagatagg	aatatcgtgc	cttgcctggg	tgccagttct	aatcattctc	900
ctgcctttgc	aaagtctgtt	tgggaagttg	ttctcatcac	tgaggagtta	aactgcaact	960
ttcacggatg	ccaggatcag	gacctgaat	gaagttataa	ctggtataag	gataataaaa	1020
atgtacgcct	gggaaaagtc	attttcaaat	cttattacca	atttgagaaa	gaaggagatt	1080
tccaagattc	tgagaagttc	ctgcctcagg	gggatgaatt	tggtctcgtt	tttcagtgc	1140
agcaaaatca	tcgtgtttgt	gaccttcacc	acctacgtgc	tctcggcgag	tgtgatcaca	1200
gccagccgcg	tgttcgtggc	agtgcgctg	tatggggctg	tgccggtgac	ggttaccctc	1260
ttcttccctt	cagccattga	gaggggtgca	gaggcaatcg	tcagcatccg	aagaatccag	1320
acctttttgc	tacttgatga	gatatacag	cgcaaccgtc	agctgccgtc	agatggtaaa	1380
aagatggtgc	atgtgcagga	ttttactgct	ttttgggata	aggcatcaga	gaccccaact	1440
ctacaaggcc	tttcttttac	tgtcagacct	ggcgaattgt	tagctgtggt	cggccccctg	1500
ggagcaggg	agtcatactt	gttaagtgc	gtgctcgggg	aattggcccc	aagtcacggg	1560
ctggtcagcg	tgcattggaag	aattgcctat	gtgtctcagc	agccctgggt	gttctcggga	1620
actctgagga	gtaataattt	atttgggaag	aaatacga	aggaacgata	tgaaaaagtc	1680
ataaaggctt	gtgctctgaa	aaaggattta	cagctgttgg	aggatggtga	tctgactgtg	1740
ataggagatc	ggggaaccac	gctgagtgga	gggcagaaag	cacgggtaaa	ccttgcaaga	1800
gcagtgtatc	aagatgctga	catctatctc	ctggacgatc	ctctcagtcg	agtagatgcg	1860
gaagttagca	gacacttggt	cgaactgtgt	atttgtcaaa	ttttgcatga	gaagatcaca	1920
attttagtga	ctcatcagtt	gcagtacctc	aaagctgcaa	gtcagattct	gatattgaaa	1980
gatggttaaaa	tgtgtcagaa	ggggacttac	actgagttcc	taaaatctgg	tatagatttt	2040
ggctcccttt	taaataagga	taattgaggaa	agtgaacaac	ctccagttcc	aggaactccc	2100
acactaagga	atcgtaacct	ctcagagtct	tcgggtttgt	ctcaacaatc	ttctagacct	2160
tccttgaaag	atggtgtctt	ggagagccaa	gatacagaga	atgtcccagt	tacactatca	2220
gaggagaacc	gttctgaagg	aaaagttggt	tttcaggcct	ataagaatta	cttcagagct	2280
ggtgtcact	ggattgtctt	cattttcctt	attctcctaa	acactgcagc	tcaggttgcc	2340
tatgtgtctc	aagattggtg	gctttcatac	tgggcaaaaca	aacaaagtat	gctaaatgtc	2400
actgtaaatg	gaggagga	tgtaaccgag	aagctagatc	ttactggta	cttaggaatt	2460
tattcagggtt	taactgtagc	taccgttctt	tttggcatag	caagatctct	attggtattc	2520
tacgtccttg	ttactcttct	acaaactttg	cacaacaaaa	tgtttgagtc	aattctgaaa	2580
gctccggtat	tattctttga	tagaaatcca	ataggaagaa	ttttaaatcg	tttctccaaa	2640
gacattggac	acttgatga	tttgctgccg	ctgacgtttt	tagatttcat	ccagacattg	2700
ctacaagtgg	ttggtgtggt	ctctgtggct	gtggccgtga	ttccttggtg	cgcaataccc	2760
ttggttcccc	ttggaatcat	tttcattttt	cttcggcgat	attttttggg	aacgtcaaga	2820
gatgtgaagc	gcctggaatc	tacaactcgg	agtccagtgt	tttcccactt	gtcatcttct	2880
ctccaggggc	tctggaccat	ccgggcatac	aaagcagaag	agaggtgtca	ggaactgttt	2940
gatgcacacc	aggatttaca	ttcagaggct	tggttcttgt	ttttgacaac	gtcccgctgg	3000
ttcgccgtcc	gtctggatgc	catctgtgcc	atgtttgtca	tcacgtgtgc	ctttgggtcc	3060
ctgattctgg	caaaaactct	ggatgccggg	caggttggtt	tgccactgtc	ctatgccctc	3120
acgtcatggt	ggatgtttca	gtggtgtgtt	cgacaaagtg	ctgaagttga	gaatatgatg	3180
atctcagtag	aaagggtcat	tgaatacaca	gaccttgaaa	aagaagcacc	ttgggaatat	3240
cagaaacgcc	caccaccagc	ctggcccat	gaaggagtga	taatctttga	caatgtgaac	3300
ttcatgtaca	gtccaggtgg	gcctctggta	ctgaagcatc	tgacagcact	cattaaatca	3360
caagaaaagg	ttggcattgt	gggaagaacc	ggagctggaa	aaagttccct	catctcagcc	3420
cttttttagat	tgtcagaacc	cgaaggtaaa	atttggattg	ataagatctt	gacaactgaa	3480

```

attggacttc acgattttaag gaagaaaatg tcaatcatac ctcaggaacc tgttttgttc 3540
actggaacaa tgaggaaaaa cctggatccc tttaatgagc acacggatga ggaactgtgg 3600
aatgccttac aagaggtaca acttaaagaa accattgaag atcttcctgg taaaatggat 3660
actgaattag cagaatcagg atccaatttt agtgttggac aaagacaact ggtgtgcctt 3720
gccagggcaa ttctcaggaa aaatcagata ttgattattg atgaagcgac ggcaaatgtg 3780
gatccaagaa ctgatgagtt aatacaaaaa aaaatccggg agaaatttgc ccactgcacc 3840
gtgctaacca ttgcacacag attgaacacc attattgaca gcgacaagat aatggtttta 3900
gattcaggaa tttttaaaga atatgatgag ccgtatgttt tgctgcacaa taaagagagc 3960
ctatttttaca agatgggtgca acaactgggc aaggcagaag ccgctgccct cactgaaaca 4020
gcaaaacaga gatgggggttt caccatgttg gccaggctgg tctcaaactc ctgacctcaa 4080
gtgatccacc tgccttggcc tcccaaactg ctgagattac aggtgtgagc caccacgccc 4140
agcctgagta tacttcaaaa gaaattatcc acatattggt cactactgacc acatggttac 4200
aaacacttcc aatggacagc cctcgacctt aactattttc gagacagcac tgtgaatcca 4260
acccaaatgt caagtccgtt ccgaaggcat ttggccactag tttttggact atgtaaacca 4320
cattgtactt ttttttactt tggcaacaaa tatttataca tacaagatgc tagttcattt 4380
gaatattttct cccaacttat ccaaggatct ccagctctaa caaaatggtt tattttttatt 4440
taaattgtcaa tagtkgkttt ttaaaatcca aatcagaggt gcaggccacc agttaaatgc 4500
cgtctatcag gttttgtgcc ttaagagact acagnagtca gaagctcatt tttaaaggag 4560
taggacagag ttgtcacagg tttttgttgg tgtttktatt gcccccaaaa ttacatgtta 4620
atttccattt atatcagggg attctattta cttgaagact gtgaagttgc cattttgtct 4680
cattgttttc tttgacatam ctaggatcca ttatttcccc tgaaggcttc ttgkagaaaa 4740
tagtacagtt acaaccaata ggaactamca aaaagaaaaa gtttgtgaca ttgtagtagg 4800
gagtgtgtac cccttactcc ccatcaaaaa aaaaaatgga tacatggtta aaggatagaa 4860
gggcaatatt ttatcatatg ttctaaaaga gaaggaagag aaaatactac tttctcaaaa 4920
tggaagccct taaaggtgct ttgatactga aggacacaaa tgtgaccgtc catcctcctt 4980
tagagttgca tgacttggac acggtaactg ttgcagtttt agactcagca ttgtgacact 5040
tcccaagaag gccaaacctc taaccgacat tcttgaaata cgtggcatta ttcttttttg 5100
gattttctcat ttaggaaggc taaccctctg ttgamtgam kccttttggg ttgggctgta 5160
ttgaaatcct ttctaaattg catgaatagg ctctgctaac cgtgatgaga caaactgaaa 5220
attattgcaa gcattgacta taattatgca gtacgttctc aggatgcac cagggttca 5280
ttttcatgag cctgtccagg ttagtttact cctgaccact aatagcattg tcatttgggc 5340
tttctgttga atgaatcaac aaaccacaat acttctctgg acccttttga ctttatttga 5400
actatgagtc ttttaattttt cctgatgatg gtggctgtaa tatgttgagt tcagtttact 5460
aaagggtttta ctattatggt ttgaaggagg tctcatgacc tctcagaaaa ggtgcacctc 5520
cctgaaattg catatatgta tatagacatg cacacgtgtg catttggttg tatacatata 5580
tttgccttc gtatagcaag ttttttgctc atcagcagag agcaacagat gttttattga 5640
gtgaagcctt aaaaagcaca caccacacac agctaactgc caaaatacat tgaccgtagt 5700
agctgttcaa ctccatgtac ttagaaatac acgtatggtt aatgttcagt ccaacaaacc 5760
acacacagta aatgtttatt aatagtcatt gttcgtattt taggtgactg aaattgcaac 5820
agtgatcata atgaggtttg ttaaaatgat agctatattc aaaatgtcta tatgtttatt 5880
tggaacttttg aggttaaaga cagtcatata aacgtcctgt ttctgtttta atgttatcat 5940
agaatttttt aatgaaacta aattcaattg aaataaatga tagttttcat ctccaaaaaa 6000
aaaaaaaag ggccggccgc tcgagtcctag agggcccggt ttaaaccgc tgatcagcct 6060
cgactgtgcc ttctagttag cagccatctg ttgtttggcc ctccccgtg ctttcttga 6120
ccctggaagg ggccactccc

```

<210> 537

<211> 1228

<212> PRT

<213> Homo sapiens

<400> 537

Met Leu Pro Val Tyr Gln Glu Val Lys Pro Asn Pro Leu Gln Asp Ala
5 10 15

Asn Leu Cys Ser Arg Val Phe Phe Trp Trp Leu Asn Pro Leu Phe Lys
20 25 30

Ile Gly His Lys Arg Arg Leu Glu Glu Asp Asp Met Tyr Ser Val Leu
 35 40 45
 Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu Leu Gln Gly Phe Trp
 50 55 60
 Asp Lys Glu Val Leu Arg Ala Glu Asn Asp Ala Gln Lys Pro Ser Leu
 65 70 75 80
 Thr Arg Ala Ile Ile Lys Cys Tyr Trp Lys Ser Tyr Leu Val Leu Gly
 85 90 95
 Ile Phe Thr Leu Ile Glu Glu Ser Ala Lys Val Ile Gln Pro Ile Phe
 100 105 110
 Leu Gly Lys Ile Ile Asn Tyr Phe Glu Asn Tyr Asp Pro Met Asp Ser
 115 120 125
 Val Ala Leu Asn Thr Ala Tyr Ala Tyr Ala Thr Val Leu Thr Phe Cys
 130 135 140
 Thr Leu Ile Leu Ala Ile Leu His His Leu Tyr Phe Tyr His Val Gln
 145 150 155 160
 Cys Ala Gly Met Arg Leu Arg Val Ala Met Cys His Met Ile Tyr Arg
 165 170 175
 Lys Ala Leu Arg Leu Ser Asn Met Ala Met Gly Lys Thr Thr Thr Gly
 180 185 190
 Gln Ile Val Asn Leu Leu Ser Asn Asp Val Asn Lys Phe Asp Gln Val
 195 200 205
 Thr Val Phe Leu His Phe Leu Trp Ala Gly Pro Leu Gln Ala Ile Ala
 210 215 220
 Val Thr Ala Leu Leu Trp Met Glu Ile Gly Ile Ser Cys Leu Ala Gly
 225 230 235 240
 Met Ala Val Leu Ile Ile Leu Leu Pro Leu Gln Ser Cys Phe Gly Lys
 245 250 255
 Leu Phe Ser Ser Leu Arg Ser Lys Thr Ala Thr Phe Thr Asp Ala Arg
 260 265 270
 Ile Arg Thr Met Asn Glu Val Ile Thr Gly Ile Arg Ile Ile Lys Met
 275 280 285
 Tyr Ala Trp Glu Lys Ser Phe Ser Asn Leu Ile Thr Asn Leu Arg Lys
 290 295 300
 Lys Glu Ile Ser Lys Ile Leu Arg Ser Ser Cys Leu Arg Gly Met Asn
 305 310 315 320
 Leu Ala Ser Phe Phe Ser Ala Ser Lys Ile Ile Val Phe Val Thr Phe
 325 330 335
 Thr Thr Tyr Val Leu Leu Gly Ser Val Ile Thr Ala Ser Arg Val Phe

340	345	350
Val Ala Val Thr Leu Tyr Gly Ala Val Arg Leu Thr Val Thr Leu Phe		
355	360	365
Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala Ile Val Ser Ile Arg		
370	375	380
Arg Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile Ser Gln Arg Asn Arg		
385	390	395
Gln Leu Pro Ser Asp Gly Lys Lys Met Val His Val Gln Asp Phe Thr		
405	410	415
Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr Leu Gln Gly Leu Ser		
420	425	430
Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val Val Gly Pro Val Gly		
435	440	445
Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu Gly Glu Leu Ala Pro		
450	455	460
Ser His Gly Leu Val Ser Val His Gly Arg Ile Ala Tyr Val Ser Gln		
465	470	475
Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser Asn Ile Leu Phe Gly		
485	490	495
Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val Ile Lys Ala Cys Ala		
500	505	510
Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly Asp Leu Thr Val Ile		
515	520	525
Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln Lys Ala Arg Val Asn		
530	535	540
Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile Tyr Leu Leu Asp Asp		
545	550	555
Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg His Leu Phe Glu Leu		
565	570	575
Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr Ile Leu Val Thr His		
580	585	590
Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile Leu Ile Leu Lys Asp		
595	600	605
Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu Phe Leu Lys Ser Gly		
610	615	620
Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn Glu Glu Ser Glu Gln		
625	630	635
Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn Arg Thr Phe Ser Glu		
645	650	655

Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro Ser Leu Lys Asp Gly
 660 665 670
 Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro Val Thr Leu Ser Glu
 675 680 685
 Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln Ala Tyr Lys Asn Tyr
 690 695 700
 Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile Phe Leu Ile Leu Leu
 705 710 715 720
 Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln Asp Trp Trp Leu Ser
 725 730 735
 Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val Thr Val Asn Gly Gly
 740 745 750
 Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp Tyr Leu Gly Ile Tyr
 755 760 765
 Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly Ile Ala Arg Ser Leu
 770 775 780
 Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln Thr Leu His Asn Lys
 785 790 795 800
 Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu Phe Phe Asp Arg Asn
 805 810 815
 Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys Asp Ile Gly His Leu
 820 825 830
 Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe Ile Gln Thr Leu Leu
 835 840 845
 Gln Val Val Gly Val Val Ser Val Ala Val Ala Val Ile Pro Trp Ile
 850 855 860
 Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe Ile Phe Leu Arg Arg
 865 870 875 880
 Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg Leu Glu Ser Thr Thr
 885 890 895
 Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser Leu Gln Gly Leu Trp
 900 905 910
 Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys Gln Glu Leu Phe Asp
 915 920 925
 Ala His Gln Asp Leu His Ser Glu Ala Trp Phe Leu Phe Leu Thr Thr
 930 935 940
 Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile Cys Ala Met Phe Val
 945 950 955 960

Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala Lys Thr Leu Asp Ala
 965 970 975

Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu Thr Leu Met Gly Met
 980 985 990

Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val Glu Asn Met Met Ile
 995 1000 1005

Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu Glu Lys Glu Ala Pro
 1010 1015 1020

Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp Pro His Glu Gly Val
 1025 1030 1035 1040

Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser Pro Gly Gly Pro Leu
 1045 1050 1055

Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser Gln Glu Lys Val Gly
 1060 1065 1070

Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser Leu Ile Ser Ala Leu
 1075 1080 1085

Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp Ile Asp Lys Ile Leu
 1090 1095 1100

Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys Lys Met Ser Ile Ile
 1105 1110 1115 1120

Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met Arg Lys Asn Leu Asp
 1125 1130 1135

Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp Asn Ala Leu Gln Glu
 1140 1145 1150

Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro Gly Lys Met Asp Thr
 1155 1160 1165

Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val Gly Gln Arg Gln Leu
 1170 1175 1180

Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn Gln Ile Leu Ile Ile
 1185 1190 1195 1200

Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr Asp Glu Leu Ile Gln
 1205 1210 1215

Lys Lys Ser Gly Arg Asn Leu Pro Thr Ala Pro Cys
 1220 1225

<210> 538
 <211> 1261
 <212> PRT
 <213> Homo sapiens

<400> 538
 Met Tyr Ser Val Leu Pro Glu Asp Arg Ser Gln His Leu Gly Glu Glu

194

5					10					15					
Leu	Gln	Gly	Phe	Trp	Asp	Lys	Glu	Val	Leu	Arg	Ala	Glu	Asn	Asp	Ala
			20					25					30		
Gln	Lys	Pro	Ser	Leu	Thr	Arg	Ala	Ile	Ile	Lys	Cys	Tyr	Trp	Lys	Ser
		35					40					45			
Tyr	Leu	Val	Leu	Gly	Ile	Phe	Thr	Leu	Ile	Glu	Glu	Ser	Ala	Lys	Val
	50					55					60				
Ile	Gln	Pro	Ile	Phe	Leu	Gly	Lys	Ile	Ile	Asn	Tyr	Phe	Glu	Asn	Tyr
	65					70					75				80
Asp	Pro	Met	Asp	Ser	Val	Ala	Leu	Asn	Thr	Ala	Tyr	Ala	Tyr	Ala	Thr
				85					90					95	
Val	Leu	Thr	Phe	Cys	Thr	Leu	Ile	Leu	Ala	Ile	Leu	His	His	Leu	Tyr
			100					105					110		
Phe	Tyr	His	Val	Gln	Cys	Ala	Gly	Met	Arg	Leu	Arg	Val	Ala	Met	Cys
		115					120					125			
His	Met	Ile	Tyr	Arg	Lys	Ala	Leu	Arg	Leu	Ser	Asn	Met	Ala	Met	Gly
	130					135					140				
Lys	Thr	Thr	Thr	Gly	Gln	Ile	Val	Asn	Leu	Leu	Ser	Asn	Asp	Val	Asn
	145					150					155				160
Lys	Phe	Asp	Gln	Val	Thr	Val	Phe	Leu	His	Phe	Leu	Trp	Ala	Gly	Pro
			165					170						175	
Leu	Gln	Ala	Ile	Ala	Val	Thr	Ala	Leu	Leu	Trp	Met	Glu	Ile	Gly	Ile
			180					185					190		
Ser	Cys	Leu	Ala	Gly	Met	Ala	Val	Leu	Ile	Ile	Leu	Leu	Pro	Leu	Gln
		195					200					205			
Ser	Cys	Phe	Gly	Lys	Leu	Phe	Ser	Ser	Leu	Arg	Ser	Lys	Thr	Ala	Thr
	210					215					220				
Phe	Thr	Asp	Ala	Arg	Ile	Arg	Thr	Met	Asn	Glu	Val	Ile	Thr	Gly	Ile
	225					230					235				240
Arg	Ile	Ile	Lys	Met	Tyr	Ala	Trp	Glu	Lys	Ser	Phe	Ser	Asn	Leu	Ile
			245						250					255	
Thr	Asn	Leu	Arg	Lys	Lys	Glu	Ile	Ser	Lys	Ile	Leu	Arg	Ser	Ser	Cys
		260						265					270		
Leu	Arg	Gly	Met	Asn	Leu	Ala	Ser	Phe	Phe	Ser	Ala	Ser	Lys	Ile	Ile
		275					280					285			
Val	Phe	Val	Thr	Phe	Thr	Thr	Tyr	Val	Leu	Leu	Gly	Ser	Val	Ile	Thr
	290					295					300				
Ala	Ser	Arg	Val	Phe	Val	Ala	Val	Thr	Leu	Tyr	Gly	Ala	Val	Arg	Leu
	305					310					315				320

Thr Val Thr Leu Phe Phe Pro Ser Ala Ile Glu Arg Val Ser Glu Ala
 325 330 335
 Ile Val Ser Ile Arg Arg Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile
 340 345 350
 Ser Gln Arg Asn Arg Gln Leu Pro Ser Asp Gly Lys Lys Met Val His
 355 360 365
 Val Gln Asp Phe Thr Ala Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr
 370 375 380
 Leu Gln Gly Leu Ser Phe Thr Val Arg Pro Gly Glu Leu Leu Ala Val
 385 390 395 400
 Val Gly Pro Val Gly Ala Gly Lys Ser Ser Leu Leu Ser Ala Val Leu
 405 410 415
 Gly Glu Leu Ala Pro Ser His Gly Leu Val Ser Val His Gly Arg Ile
 420 425 430
 Ala Tyr Val Ser Gln Gln Pro Trp Val Phe Ser Gly Thr Leu Arg Ser
 435 440 445
 Asn Ile Leu Phe Gly Lys Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val
 450 455 460
 Ile Lys Ala Cys Ala Leu Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly
 465 470 475 480
 Asp Leu Thr Val Ile Gly Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln
 485 490 495
 Lys Ala Arg Val Asn Leu Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile
 500 505 510
 Tyr Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala Glu Val Ser Arg
 515 520 525
 His Leu Phe Glu Leu Cys Ile Cys Gln Ile Leu His Glu Lys Ile Thr
 530 535 540
 Ile Leu Val Thr His Gln Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile
 545 550 555 560
 Leu Ile Leu Lys Asp Gly Lys Met Val Gln Lys Gly Thr Tyr Thr Glu
 565 570 575
 Phe Leu Lys Ser Gly Ile Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn
 580 585 590
 Glu Glu Ser Glu Gln Pro Pro Val Pro Gly Thr Pro Thr Leu Arg Asn
 595 600 605
 Arg Thr Phe Ser Glu Ser Ser Val Trp Ser Gln Gln Ser Ser Arg Pro
 610 615 620

Ser Leu Lys Asp Gly Ala Leu Glu Ser Gln Asp Thr Glu Asn Val Pro
 625 630 635 640
 Val Thr Leu Ser Glu Glu Asn Arg Ser Glu Gly Lys Val Gly Phe Gln
 645 650 655
 Ala Tyr Lys Asn Tyr Phe Arg Ala Gly Ala His Trp Ile Val Phe Ile
 660 665 670
 Phe Leu Ile Leu Leu Asn Thr Ala Ala Gln Val Ala Tyr Val Leu Gln
 675 680 685
 Asp Trp Trp Leu Ser Tyr Trp Ala Asn Lys Gln Ser Met Leu Asn Val
 690 695 700
 Thr Val Asn Gly Gly Gly Asn Val Thr Glu Lys Leu Asp Leu Asn Trp
 705 710 715 720
 Tyr Leu Gly Ile Tyr Ser Gly Leu Thr Val Ala Thr Val Leu Phe Gly
 725 730 735
 Ile Ala Arg Ser Leu Leu Val Phe Tyr Val Leu Val Asn Ser Ser Gln
 740 745 750
 Thr Leu His Asn Lys Met Phe Glu Ser Ile Leu Lys Ala Pro Val Leu
 755 760 765
 Phe Phe Asp Arg Asn Pro Ile Gly Arg Ile Leu Asn Arg Phe Ser Lys
 770 775 780
 Asp Ile Gly His Leu Asp Asp Leu Leu Pro Leu Thr Phe Leu Asp Phe
 785 790 795 800
 Ile Gln Thr Leu Leu Gln Val Val Gly Val Val Ser Val Ala Val Ala
 805 810 815
 Val Ile Pro Trp Ile Ala Ile Pro Leu Val Pro Leu Gly Ile Ile Phe
 820 825 830
 Ile Phe Leu Arg Arg Tyr Phe Leu Glu Thr Ser Arg Asp Val Lys Arg
 835 840 845
 Leu Glu Ser Thr Thr Arg Ser Pro Val Phe Ser His Leu Ser Ser Ser
 850 855 860
 Leu Gln Gly Leu Trp Thr Ile Arg Ala Tyr Lys Ala Glu Glu Arg Cys
 865 870 875 880
 Gln Glu Leu Phe Asp Ala His Gln Asp Leu His Ser Glu Ala Trp Phe
 885 890 895
 Leu Phe Leu Thr Thr Ser Arg Trp Phe Ala Val Arg Leu Asp Ala Ile
 900 905 910
 Cys Ala Met Phe Val Ile Ile Val Ala Phe Gly Ser Leu Ile Leu Ala
 915 920 925
 Lys Thr Leu Asp Ala Gly Gln Val Gly Leu Ala Leu Ser Tyr Ala Leu

930	935	940
Thr Leu Met Gly Met Phe Gln Trp Cys Val Arg Gln Ser Ala Glu Val 945 950 955 960		
Glu Asn Met Met Ile Ser Val Glu Arg Val Ile Glu Tyr Thr Asp Leu 965 970 975		
Glu Lys Glu Ala Pro Trp Glu Tyr Gln Lys Arg Pro Pro Pro Ala Trp 980 985 990		
Pro His Glu Gly Val Ile Ile Phe Asp Asn Val Asn Phe Met Tyr Ser 995 1000 1005		
Pro Gly Gly Pro Leu Val Leu Lys His Leu Thr Ala Leu Ile Lys Ser 1010 1015 1020		
Gln Glu Lys Val Gly Ile Val Gly Arg Thr Gly Ala Gly Lys Ser Ser 1025 1030 1035 1040		
Leu Ile Ser Ala Leu Phe Arg Leu Ser Glu Pro Glu Gly Lys Ile Trp 1045 1050 1055		
Ile Asp Lys Ile Leu Thr Thr Glu Ile Gly Leu His Asp Leu Arg Lys 1060 1065 1070		
Lys Met Ser Ile Ile Pro Gln Glu Pro Val Leu Phe Thr Gly Thr Met 1075 1080 1085		
Arg Lys Asn Leu Asp Pro Phe Asn Glu His Thr Asp Glu Glu Leu Trp 1090 1095 1100		
Asn Ala Leu Gln Glu Val Gln Leu Lys Glu Thr Ile Glu Asp Leu Pro 1105 1110 1115 1120		
Gly Lys Met Asp Thr Glu Leu Ala Glu Ser Gly Ser Asn Phe Ser Val 1125 1130 1135		
Gly Gln Arg Gln Leu Val Cys Leu Ala Arg Ala Ile Leu Arg Lys Asn 1140 1145 1150		
Gln Ile Leu Ile Ile Asp Glu Ala Thr Ala Asn Val Asp Pro Arg Thr 1155 1160 1165		
Asp Glu Leu Ile Gln Lys Lys Ile Arg Glu Lys Phe Ala His Cys Thr 1170 1175 1180		
Val Leu Thr Ile Ala His Arg Leu Asn Thr Ile Ile Asp Ser Asp Lys 1185 1190 1195 1200		
Ile Met Val Leu Asp Ser Gly Arg Leu Lys Glu Tyr Asp Glu Pro Tyr 1205 1210 1215		
Val Leu Leu Gln Asn Lys Glu Ser Leu Phe Tyr Lys Met Val Gln Gln 1220 1225 1230		
Leu Gly Lys Ala Glu Ala Ala Ala Leu Thr Glu Thr Ala Lys Gln Arg 1235 1240 1245		

Trp Gly Phe Thr Met Leu Ala Arg Leu Val Ser Asn Ser
1250 1255 1260

<210> 539

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 539

Cys Leu Ser His Ser Val Ala Val Val Thr
1 5 10

<210> 540

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 540

Ala Val Val Thr Ala Ser Ala Ala Leu
1 5

<210> 541

<211> 14

<212> PRT

<213> Homo sapiens

<400> 541

Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu
5 10

<210> 542

<211> 15

<212> PRT

<213> Homo sapiens

<400> 542

Thr Gln Val Val Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala
5 10 15

<210> 543

<211> 12

<212> PRT

<213> Homo sapiens

<400> 543

Phe Met Gly Ser Ile Val Gln Leu Ser Gln Ser Val
5 10

<210> 544
<211> 18
<212> PRT
<213> Homo sapiens

<400> 544
Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val Glu Glu Lys Phe
 5 10 15

Met Thr

<210> 545
<211> 18
<212> PRT
<213> Homo sapiens

<400> 545
Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val Tyr Leu Ala
 5 10 15

Ser Val

<210> 546
<211> 29
<212> PRT
<213> Homo sapiens

<400> 546
Phe Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly
 5 10 15

Thr Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg Met
 20 25

<210> 547
<211> 58
<212> PRT
<213> Homo sapiens

<400> 547
Val Ala Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu
 5 10 15

Ser Ala Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu
 20 25 30

Ala Phe Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys
 35 40 45

Cys Arg Met Pro Arg Thr Leu Arg Arg Leu
 50 55

200

<210> 548
<211> 18
<212> PRT
<213> Homo sapiens

<400> 548
Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu
 5 10 15

Glu Cys

<210> 549
<211> 18
<212> PRT
<213> Homo sapiens

<400> 549
Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg
 5 10 15

Gln Ala

<210> 550
<211> 14
<212> PRT
<213> Homo sapiens

<400> 550
Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe
 5 10

<210> 551
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 551
Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala
 5 10

<210> 552
<211> 2577
<212> DNA
<213> Homo sapiens

<400> 552
agcatatgta acatgacctg tgcttcagtg ttcttttgtg atcaaaaatt ccttactttt 60
agtttttttat ctatggtaga accacccaga gcaggggtcc tcaactocca ggccacagac 120
tcataccagt ccacggacta ttatgaacca caccacacag gaggaggtga gcactaggca 180
agccaaggaa gcttcacctg tacttacagc cacacgccat ggctcatatt acagcctgaa 240

```

ctctgcctcc actcagatca gtgataacat tagaaactca ttggagcacg aaccctgttg 300
tgaactgcct atccgaagga tctaggttgt gtgcttcgta tgagaatcta atgccagatg 360
atctatcatt gtctcacttt gccccagat aagaccatct agttgcagaa aaataagctc 420
agagcttcca ctgattctac attatggata tgtgccgccg aagcaagcac aaagccctac 480
ttttacacat gcctagtgat gcttcatgga caaggcttgg ctctgttgag tccaactaac 540
ctacctgaga ttctgagatt tctcttcaat ggcttcctgt gagctagagt ttgaaaatat 600
cttaaaatct tgagctagag atggaagtag cttggacgat ttctattatc atgtaaactg 660
ggtcactcaa ggggcccaacc acagctggga gccactgctc aggggaaggt tcatatggga 720
ctttctactg cccaagggtt tatacaggat ataaagggtc ctcacagtat agatctggta 780
gcaaagaaga agaaacaaac actgatctct ttctgccacc cctctgacct tttggaactc 840
ctctgaccct ttagaacaag cctaccta atctgctaga gaaaagacca acaacggcct 900
caaaggatct cttaccatga aggtctcagc taattcttgg ctaagatgtg ggttccacat 960
taggttctga atatgggggg aagggtcaat ttgctcattt tgtgtgtgga taaagtccag 1020
atggcccagg gccagagcag ggggctgctg ctttgggaac aatggctgag catataacca 1080
taggtatggg aacaaaaaac atcaaagtca ctgtatcaat tgccatgaag actcgaggga 1140
cctgaatcta ccgattcatc ttaaggcagc aggaccagtt tgagtggcaa caatgcagca 1200
gcagaatcaa tggaaacaac agaattgatt caatgtcctt tttttctcc tcttctgac 1260
ttgataaaag ggacogtctt ccttggattt agtgaacccc tttggttcct gaaaaattca 1320
aggagtatct aggacatagt cccagaaga cagtacaaga ctttctgata aactggacat 1380
ttcaagrcce aaataactaa tcagaaaaat caaagatgtg atactatttt ttatcccatg 1440
cataggtgct acacttggat caaatgaaca atgttgggat ctytatggat aaaggtctta 1500
aaagtctctg gataaagaat cctgcaccca ctggtacttc taacttgtct tgtttttgt 1560
ctgwtttctg gctgatgcag gggactaact cactgccacg cgaaaactac ctgaactgaa 1620
ctatgacatc tcacctgata tgtaagatgt aactgttata attattttaa acctcaattt 1680
agcattaact agccttttaa tgtaaacact tacacattat gaygactaga aacagcatat 1740
tctctggccg tctgtccaga tagatcttga gaagatacat caatgttttg ctcaagtaga 1800
aggctgacta tacttgccga tccacaacat acagcaagta tgagagcagt tctaaaatga 1860
cagagatagg aacagtaata aagttattkt aaaagcta attgatatact ttaccaattt 1920
aacatcttgc ctgtccgtgc agaatacaac atttcatgct actaaaagac ataagcatct 1980
tcagtgtctc agtggttcac tttgtaaaat accaccaagg ttaaaaggaa gggacaaaaa 2040
aaaaaaaccc tcttatctca gtgggggtatt gcatagcaga agctactaat ttgaagtcct 2100
ttgatggaca agaaacaata ttagggccac ttatctgaaa tgaacaaaaga tttaagtga 2160
gatttcatca cagcttccct agactgatat gctgtaatag aaaatcagct agggggtaaa 2220
ataaataaga gctctctgca tgctgaaagc aagtaagatt aataataatg gtaagaatag 2280
tagtcacagg agtttcagtt aatgatgcca ataagcatgt gctaggcact gaattaaatg 2340
ccacatatat ctttcttatg cgcagcaaac tttgaaggat atattctcct acttttcata 2400
tatgacaaca tatttgggtg taaataacgt tcccaagggtc acacacctag caagtaagaa 2460
agtttaggaat taaacccagt attgtgtgaa tctaaagcct aacttttttc tctttatcac 2520
ccacctacgg cttgtottca ttaaaggaaa agtgtatcca cttaaaaaaa aaaaaaa 2577

```

<210> 553

<211> 58

<212> PRT

<213> Homo sapiens

<400> 553

```

Ser Ile Cys Asn Met Thr Cys Ala Ser Val Phe Phe Cys Asp Gln Lys
          5                      10                      15

```

```

Phe Leu Thr Phe Ser Phe Leu Ser Met Val Glu Pro Pro Arg Ala Gly
          20                      25                      30

```

```

Val Leu Asn Ser Gln Ala Thr Asp Ser Tyr Gln Ser Thr Asp Tyr Tyr
          35                      40                      45

```

```

Glu Pro His His Thr Gly Gly Gly Glu His
          50                      55

```

<210> 554
 <211> 59
 <212> PRT
 <213> Homo sapiens

<400> 554
 Leu Gln Lys Asn Lys Leu Arg Ala Ser Thr Asp Ser Thr Leu Trp Ile
 5 10 15
 Cys Ala Ala Glu Ala Ser Thr Lys Pro Tyr Phe Tyr Thr Cys Leu Val
 20 25 30
 Met Leu His Gly Gln Gly Leu Ala Leu Leu Ser Pro Thr Asn Leu Pro
 35 40 45
 Glu Ile Leu Arg Phe Leu Phe Asn Gly Phe Leu
 50 55

<210> 555
 <211> 71
 <212> PRT
 <213> Homo sapiens

<400> 555
 Leu Gly Arg Phe Ser Leu Ser Cys Lys Ser Gly His Ser Arg Gly Gln
 5 10 15
 Pro Gln Leu Gly Ala Thr Ala Gln Gly Lys Val His Met Gly Leu Ser
 20 25 30
 Thr Ala Gln Gly Ser Ile Gln Asp Ile Lys Val Pro His Ser Ile Asp
 35 40 45
 Leu Val Ala Lys Lys Lys Lys Gln Thr Leu Ile Ser Phe Cys His Pro
 50 55 60
 Ser Asp Pro Leu Glu Leu Leu
 65 70

<210> 556
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 556
 Asn His Pro Glu Gln Gly Ser Ser Thr Pro Arg Pro Gln Thr His Thr
 5 10 15
 Ser Pro Arg Thr Ile Met Asn His Thr Thr Gln Glu Glu Val Ser Thr
 20 25 30
 Arg Gln Ala Lys Glu Ala Ser Pro Val Leu Thr Ala Thr Arg His Gly
 35 40 45
 Ser Tyr Tyr Ser Leu Asn Ser Ala Ser Thr Gln Ile Ser Asp Asn Ile

203

50 55 60
 Arg Asn Ser Leu Glu His Glu Pro Cys Cys Glu Leu Pro Ile Arg Arg
 65 70 75 80
 Ile

<210> 557
 <211> 54
 <212> PRT
 <213> Homo sapiens

<400> 557
 Ser Leu Ser Ala Thr Pro Leu Thr Leu Trp Asn Ser Ser Asp Pro Leu
 5 10 15
 Glu Gln Ala Tyr Leu Ile Ser Ala Arg Glu Lys Thr Asn Asn Gly Leu
 20 25 30
 Lys Gly Ser Leu Thr Met Lys Val Ser Ala Asn Ser Trp Leu Arg Cys
 35 40 45
 Gly Phe His Ile Arg Phe
 50

<210> 558
 <211> 77
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> (1)...(77)
 <223> Xaa = Any amino acid

<400> 558
 Asn Asp Arg Asp Arg Asn Ser Asn Lys Val Ile Xaa Lys Ala Asn Leu
 5 10 15
 Ile Tyr Phe Thr Asn Leu Thr Ser Cys Leu Ser Val Gln Asn Gln Thr
 20 25 30
 Phe Thr Cys Thr Lys Arg His Lys His Leu Gln Cys Ser Ser Val His
 35 40 45
 Leu Cys Lys Ile Pro Pro Arg Leu Lys Gly Arg Asp Lys Lys Lys Lys
 50 55 60
 Pro Ser Tyr Leu Ser Gly Val Leu His Ser Arg Ser Tyr
 65 70 75

<210> 559
 <211> 50
 <212> PRT

<213> Homo sapiens

<400> 559

Thr Leu Pro Pro Leu Arg Ser Val Ile Thr Leu Glu Thr His Trp Ser
5 10 15

Thr Asn Pro Val Val Asn Cys Leu Ser Glu Gly Ser Arg Leu Cys Ala
20 25 30

Ser Tyr Glu Asn Leu Met Pro Asp Asp Leu Ser Leu Ser His Phe Ala
35 40 45

Pro Arg
50

<210> 560

<211> 56

<212> PRT

<213> Homo sapiens

<400> 560

Ile Gly Ser Leu Lys Gly Pro Thr Thr Ala Gly Ser His Cys Ser Gly
5 10 15

Glu Gly Ser Tyr Gly Thr Phe Tyr Cys Pro Arg Phe Tyr Thr Gly Tyr
20 25 30

Lys Gly Ala Ser Gln Tyr Arg Ser Gly Ser Lys Glu Glu Glu Thr Asn
35 40 45

Thr Asp Leu Phe Leu Pro Pro Leu
50 55

<210> 561

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(57)

<223> Xaa = Any amino acid

<400> 561

Val Leu His Leu Asp Gln Met Asn Asn Val Gly Ile Xaa Met Asp Lys
5 10 15

Gly Leu Lys Ser Pro Glu Ile Lys Asn Pro Ala Pro Thr Gly Thr Ser
20 25 30

Asn Leu Ser Cys Phe Leu Ser Xaa Phe Trp Leu Met Gln Gly Thr Asn
35 40 45

Ser Leu Pro Arg Glu Asn Tyr Leu Asn
50 55

```
<210> 562
<211> 59
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> VARIANT  
<222> (1)...(59)  
<223> Xaa = Any amino acid
```

```

<400> 562
Asp Leu Tyr Pro Xaa Arg Ser Gln His Cys Ser Phe Asp Pro Ser Val
      5                      10                      15
Ala Pro Met His Gly Ile Lys Asn Ser Ile Thr Ser Leu Ile Phe Leu
      20                      25                      30
Ile Ser Tyr Leu Xaa Leu Glu Met Ser Ser Leu Ser Glu Ser Leu Val
      35                      40                      45
Leu Ser Ser Gly Asp Tyr Val Leu Asp Thr Pro
      50                      55

```

```
<210> 563
<211> 79
<212> PRT
<213> Homo sapiens
```

```
<400> 563  
Cys Phe Leu Phe Pro Tyr Leu Trp Leu Tyr Ala Gln Pro Leu Phe Pro  
          5                      10                      15  
  
Lys Gln Gln Pro Pro Ala Leu Ala Pro Gly His Pro Asp Phe Ile His  
          20                      25                      30  
  
Thr Gln Asn Glu Gln Ile Asp Pro Ser Pro His Ile Gln Asn Leu Met  
          35                      40                      45  
  
Trp Asn Pro His Leu Ser Gln Glu Leu Ala Glu Thr Phe Met Val Arg  
          50                      55                      60  
  
Asp Pro Leu Arg Pro Leu Leu Val Phe Ser Leu Ala Asp Ile Arg  
          65                      70                      75
```

```
<210> 564
<211> 64
<212> PRT
<213> Homo sapiens
```

<400> 564
Ala Cys Ser Lys Gly Ser Glu Glu Phe Gln Arg Val Arg Gly Val Ala
5 10 15
Glu Arg Asp Gln Cys Leu Phe Leu Leu Leu Cys Tyr Gln Ile Tyr Thr
20 25 30

Val Arg His Leu Tyr Ile Leu Tyr Arg Thr Leu Gly Ser Arg Lys Ser
 35 40 45

His Met Asn Leu Pro Leu Ser Ser Gly Ser Gln Leu Trp Leu Ala Pro
 50 55 60

<210> 565

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(57)

<223> Xaa = Any amino acid

<400> 565

Leu Tyr Tyr Cys Ser Tyr Leu Cys His Phe Arg Thr Ala Leu Ile Leu
 5 10 15

Ala Val Cys Cys Gly Ser Ala Ser Ile Val Ser Leu Leu Leu Glu Gln
 20 25 30

Asn Ile Asp Val Ser Ser Gln Asp Leu Ser Gly Gln Thr Ala Arg Glu
 35 40 45

Tyr Ala Val Ser Ser Xaa His Asn Val
 50 55

<210> 566

<211> 55

<212> PRT

<213> Homo sapiens

<400> 566

Ile Leu Leu Glu Phe Phe Arg Asn Gln Arg Gly Ser Leu Asn Pro Arg
 5 10 15

Lys Thr Val Pro Phe Ile Lys Ser Glu Gly Gly Glu Lys Lys Gly His
 20 25 30

Cys Asn His Ser Val Val Ser Ile Asp Ser Ala Ala Ala Leu Leu Pro
 35 40 45

Leu Lys Leu Val Leu Leu Pro
 50 55

<210> 567

<211> 51

<212> PRT

<213> Homo sapiens

<400> 567

Tyr Ser Asp Phe Asp Val Phe Cys Ser His Thr Tyr Gly Tyr Met Leu

5 10 15
 Ser His Cys Ser Gln Ser Ser Ser Pro Leu Leu Trp Pro Leu Gly Ile
 20 25 30
 Leu Thr Leu Ser Thr His Lys Met Ser Lys Leu Thr Leu Pro Pro Ile
 35 40 45
 Phe Arg Thr
 50

<210> 568
 <211> 75
 <212> PRT
 <213> Homo sapiens

<400> 568
 Lys Val Gly Glu Tyr Ile Leu Gln Ser Leu Leu Arg Ile Arg Lys Ile
 5 10 15
 Tyr Val Ala Phe Asn Ser Val Pro Ser Thr Cys Leu Leu Ala Ser Leu
 20 25 30
 Thr Glu Thr Pro Val Thr Thr Ile Leu Thr Ile Ile Ile Asn Leu Thr
 35 40 45
 Cys Phe Gln His Ala Glu Ser Ser Tyr Leu Phe Tyr Pro Leu Ala Asp
 50 55 60
 Phe Leu Leu Gln His Ile Ser Leu Gly Lys Leu
 65 70 75

<210> 569
 <211> 4809
 <212> DNA
 <213> Homo sapiens

<400> 569
 gcatccagag tgggtggactg gttacaggct atgaacctac actgatgcgg caccaccacc 60
 cagagtccac rgggttatgtt gggtcacatt tactcttgct gtggtatggt ctatagggtt 120
 ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtcttgtagg 180
 aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctgt 240
 tttcagttgc ttttctaatt ctctcttata gtttacctca aaatcttcct gaggtctcgc 300
 ttctttttaa aatccttgct tactttgcag catcactctg acactcccat tgattcctca 360
 gcacctactg actacacggt taggagtgcagggttagaat tcatgtttta ttcattcttg 420
 ggtctgtagc acccagcaaa gtgctcagta aatgcgcagt aattgatttg acctctgaac 480
 aaatacacac tgtactaaga atctacacac cgaaagacaa aaacaagaca aatttgagt 540
 ctacagggtg cagcgttggc atcacacatg tgcctgtgta ttcctctagg tggttaccag 600
 gagctctgcc actgcatgct cactagtgcagggttcgctc caccacccca gctgggtagc 660
 cgctgctctc acataagggg tccaattaaa attgccagga ataaattccc cgggactttg 720
 acttctcaag agctaagaag gtttgctgag tattctggca tgatgtttgg tgatcaaaca 780
 actgctggcc aaaaatgatg agtatttccc cctcttgctg aagatgtgct ccatacaata 840
 gtccatcaca ttcattcttc atcagtctgg aagtgtgcag aacaacatgt aatagataat 900
 atgattggct gcacacttcc agactgatga atgatgaatg tgatggacta ttgtatggag 960
 cacatcttca gcaagagggg gaaatactca tcattttatc tattacatgt tgttctggtt 1020

tttttttttt	tccaatgtcc	agcctaaact	ataaagtact	ttgagaacgc	acagtgagcc	1080
ataagcttgc	caataaagag	tcctctgtgg	tatggaactg	gcttatttca	tacacaatct	1140
gcaaacaatg	agggcactat	tggaacata	ctgtgctgca	cagagcattt	acaccgctta	1200
tctttaatct	tcccagcaa	tccttgcttt	gtgcgcattt	atgatccttg	ctctcagaag	1260
tccacatact	tttccccaac	cgtaacaaat	tatttaactc	atctaattga	tgtatgtccg	1320
cgcagtctga	aaacagtaat	tgtccttggt	aagaagttag	tttaagagag	ctctagggca	1380
ctcatcacaa	ctccagccct	gccctccatg	tggtagcagc	tctttggact	ggggctaagt	1440
gcttattctt	gtgcttcatt	cctggtaagc	tcaatttctt	taccttagga	taactttgct	1500
ggaaaagggc	tcagattcag	ccgaccattg	tggcctctgt	ggctgtcaca	gcttgtccct	1560
gacatgctat	gatgttgggt	ccccttctca	tccccttggt	atttcttctg	ctggcccaca	1620
gccagaacaa	ctaggccttt	tactccacca	tccctttggt	ttcttttggt	tcgttggtta	1680
aaatcaatcc	ttctaccatc	catgcatagc	aatttctaaa	aactgaattt	caagagcagt	1740
atctgaagaa	acaaacatga	tttggtcctt	ttagtaaaaa	gaataaattt	taataaatca	1800
actttgaaat	agttgtaaga	gttaagaaaa	agcacaaaa	tgagatcatc	agagcagctt	1860
ggcctcaaag	gacaggcagc	aggattctac	agggtttgag	ccttcctaag	tgaagctggt	1920
tcttcgaggc	tcctgtctcc	aagctcctag	ctaacagccc	cttctccac	gattggcaac	1980
aaagagcaaa	aataaactttg	tacttgatgc	tgagtcagtg	taaaaagcca	taaaaaattc	2040
cctctaaatg	tcaaaatggt	tgccctcctt	gaggcttctc	tccctcctact	gggtctggat	2100
aaattgacac	tggtcttata	ttgagtcaca	gatctggggc	ctgccacaga	gagcttctct	2160
ctagtgtgtg	atgctttttc	tccaaactat	tgatacaaaa	tgcactggaa	tagaaatcaa	2220
cagaaactgg	tcaaaggtgt	ggcatacaca	ttctcatgta	gatgtaaaagc	tgtgcttaga	2280
attcctttgt	ggagtctggt	ttggtcttgg	ttttcttggg	gtttgattca	tttttttacg	2340
taaattacaa	aaaccctcca	catttcttca	tggattgtat	tagtccatgt	tctccagaga	2400
agcagaacga	gttggatgta	tgttttgtaa	gagattatga	ggaaccggct	catgtgatga	2460
aggaggttga	gaggtcctgt	gctctgccat	ctgcaagctg	aagacctgga	aagctgaggg	2520
tgtggctcac	gtctgagctc	gaaggcccaa	gaaccagggg	aaaccaagggt	gtagattcca	2580
ggttgaaggc	aggagaagat	ggatgtccca	gctcagcagg	caggcaggaa	gcaaagggg	2640
taaattcctc	cttctctccac	cttttggttc	attcaggcct	tcaacagatt	ggatgagcgc	2700
ccccccaccc	ccacactagg	gagggccatc	tgctttactg	agtcggctga	gtcaagtgcc	2760
agcctcatcc	caaaacactc	tccagacaca	cgcagaaatg	tttcatctgg	gcaccctgtg	2820
gccagtcag	ctgacacaca	gaactaacca	tgacatggat	tcttcttaaa	gcagtgatag	2880
gagcgaacag	aaacattttc	ataattttca	attattttta	atgaaaacta	tatctgatgg	2940
aattgtttta	acctagtctg	gccacacatt	atttctggg	accgcccctc	cttcaatccc	3000
ttggacactg	atgactttat	gccagatta	cactggaggc	ctgtgctgat	tttctaacac	3060
atacctgcaa	ctgagctggc	aaaaagaaaa	ctaggcaagt	atgacagata	catgatgcac	3120
aggctaagtg	caaaggaaag	aaaaacacca	actgcaggga	tgagggactc	acccctttag	3180
aagtttctac	ttgagcagct	agaagactac	aatgccactc	atcaaaacag	tgactcaggg	3240
ggagtatttg	ggataaaagga	ggaatctgat	gttggaggtc	aaatttgaag	tgtctttaag	3300
acctacaggt	aacgagacag	ctggacaaac	acatggaact	caggacaaag	gctctaagga	3360
cagcacagca	gctgacatcc	tgtgtgacag	ccttgaaagc	agcaggcccg	ccgctcacat	3420
tttggaagg	aaaatgggta	caatgttgtc	tgccactttg	gggccttctt	gggtcacatg	3480
cattttacat	ttatgcagtt	gatataattta	tgtttcttgg	gtcttttata	cattagacac	3540
catgattctc	aatcctttgt	tattttgtat	tacaaaaagc	tgaattatta	tttcaaatat	3600
gggcaaatta	gagccttcca	tattgccaag	gtgtatcaac	cacactgata	ycaygatctc	3660
tcttttgaat	tagttttcca	gttcacacct	accatttatt	tcatgattgg	tttcagactt	3720
gttctctctg	gaaacactcc	ctaacaagca	cccttgagg	aatgaagaca	caccacacac	3780
atctacecca	ttactgcatg	tactcaagag	tcagctttta	tatgatctct	cccaagtgtc	3840
cctataatgg	ggatctttca	ctcaccttaa	agtgaggaca	aaatacttga	aagcatgagc	3900
ccagtgcctg	taggtgtgca	atataacctca	gaccaaggaa	gtgccgaacg	catctggctt	3960
ttagcaaggc	acctgacaaa	gtccttcagg	atgtttttgt	acatgagcta	gagaaatgta	4020
cctggagaa	agcttctact	gccagatgat	cttactcaaa	agatgcagat	taagcaaaat	4080
atcaacccaa	agggtggtcc	ctgatggccc	accagcccct	gtgcctggct	cgtttcttat	4140
gtttcctaga	tttggtttca	gacttgctcc	tcctgcagac	actccctaac	cagcatcctt	4200
gcagaaaaat	ggtgaactag	aaaaggcctg	tgtgggtcac	gtggccaccc	aaacaccacag	4260
cagtgtctaa	ggtatgcgtg	ggagcctgca	cagcaggagc	gggtcttctt	ggagacccgc	4320
atgagatgca	aagggcagtg	gacaaggagc	caaggagggt	ggctctagtc	acgttggtat	4380
ggtgccagct	tgaggatgct	gggcaagtcc	cgagccgtct	gccttcttag	taccacagtt	4440
accactgtct	gttacctcgc	gagttcaagt	gcttcacgtg	agacagctac	gagacaggcc	4500

```

cctggaaact ggaaaaatgcy aagtaaatgt catgcacaat tgttggtcac attttatctc 4560
aatcactttt accaaatcag gctaaaccct gggattcat aacgtcttg gctgtacaaa 4620
ttgttccttg aaatgactca gagacatttt ctgaattggc ttccatcagc caagcatttc 4680
ttcagaactg gaaaaatgct ttaaatttgg ctttgtcatg attattaaaa cactctgtac 4740
attttttatt attgaaatta acacattgcc tactttttta aaattggaaa aagaaaaaaa 4800
aaaaaaaaa                                     4809

```

<210> 570

<211> 951

<212> DNA

<213> Homo sapiens

<400> 570

```

aaaattgaat attgagatac cattcttttag tgttacottt tttaccacaca tgtgtttctg 60
aaaatattgg aatttttattc atcttaaaaa ttggaccggg ccttattttac catctttaat 120
ccatttttagt actatgggtg agtacatgga attgaagtct ggcttaaatac ttcagaaaagt 180
tatatatcta ttttattttta tttttttgag acagagtctc gctgtgtcac ccaggctgga 240
gtgcggtgcc acaatcttgg ctcaactgcaa cctctgagtc ccaggttcaa gcgatactca 300
tgccctggcc tcctgagtag ctgggactac aggcgtgcac caccacatct ggctaattct 360
tttttgtatt tttagtagag acgggggtttc actgtggtct ccatctcctg acctcgtgat 420
ccgcctgcct cccaaagtgc tgggattaca ggcatgagcc accgcacaca gctgggactg 480
ggtaatttat aaagaaaaga ggtttaatga ctcacagttc cgcatggctg gagaggcctc 540
aggaacttta caatcatggt ggaaggcgaa ggggaagcaa ggcacgtctt acatggtggc 600
aggagagaac gagtgaaggg ggagactgcc acaaactttt tttttttgag acaagagtct 660
ggcctgttg cccaggtctg agtgcagtgg catgatctca gctcactgca acctctgcct 720
cacaggttca agcaattctc atgcctcagc ctcccgcata gctgggacca caggatgca 780
ccaccacacc tagctaattt ttgtagtttt agtagagatg gggctcact atgttgctca 840
ggctggtcta aaactcctgg gctccagcaa tccgcctgcc ttggcctccc aaagtgtctg 900
ggttacaggc ataagccacc acatccagcc tgccacatac ttttaaacta t 951

```

<210> 571

<211> 819

<212> DNA

<213> Homo sapiens

<400> 571

```

cagcttaaaa atggtttctt gaaatcagtg attagcattc actcaccagt acccctacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttattttctgc 120
ttattgcttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagagggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaaagatggt tctcagggtt ttcttgacg attttcttct tttctgattc tgacaatggt 300
ttaaatcatt gtactgtggt tatcatttct ctgcatttat tttaccatc ttcttttga 360
acttgtctta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcacggtg gctcacatct 480
gtaatcccag cactttgggg aggcgtgagc gggtagatca cttgaggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatcccg ttactaaaa atacaaaaat taccaggga 600
tggtggcggg cgctgtaat cccaggtact cgggaggtg agggaggaga atcgcttgaa 660
cctgggaggg tgaggaggga gaatcgcttg aaccgggag gcagaggttg cagtgaaccg 720
agatcatggt gctgcactcc agcctggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaaacaaac aaaaacagaga gattttgct 819

```

<210> 572

<211> 203

<212> DNA

<213> Homo sapiens

<400> 572

```

tatagaatac tcaagctatg catcaagctt ggtaccgagc tcgcatccac tatttacggc 60

```

```
<210> 573
<211> 132
<212> PRT
<213> Homo sapiens
```

```
<400> 573
Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
      5                                10                        15
.
Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg
      20                                25                        30
Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu
      35                                40                        45
Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu
      50                                55                        60
Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala
      65                                70                        75                        80
Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly
      85                                90                        95
Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro
      100                               105                       110
Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile
      115                               120                       125
Leu Leu Asn Tyr
      130
```

```
<210> 574
<211> 62
<212> PRT
<213> Homo sapiens
```

```

<400>.574
Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
                    5                      10                      15

His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
                20                      25                      30

Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
                35                      40                      45

Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
    50                      55                      60

```

<210> 575

<211> 76
<212> PRT
<213> Homo sapiens

<400> 575
Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp
 5 10 15

Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu
 20 25 30

Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly
 35 40 45

Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp
 50 55 60

Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys
 65 70 75

<210> 576
<211> 68
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> (1)...(68)
<223> Xaa = Any Amino Acid

<400> 576
Met Leu Gly Lys Ser Arg Ala Val Cys Leu Pro Ser Thr Thr Val Thr
 5 10 15

Thr Val Cys Tyr Leu Ala Ser Ser Ser Ala Ser Arg Glu Thr Ala Thr
 20 25 30

Arg Gln Ala Pro Gly Asn Trp Lys Met Xaa Ser Lys Cys His Ala Gln
 35 40 45

Leu Leu Phe Thr Phe Tyr Leu Asn His Phe Tyr Gln Ile Arg Leu Asn
 50 55 60

Pro Gly Tyr Ser
 65

<210> 577
<211> 57
<212> PRT
<213> Homo sapiens

<400> 577
Met Tyr Leu Glu Asn Ser Phe Tyr Cys Gln Met Ile Leu Leu Lys Arg
 5 10 15

Cys Arg Leu Ser Lys Ile Ser Thr Gln Arg Val Val Pro Asp Gly Pro

20 25 30
 Pro Ala Pro Val Pro Gly Ser Phe Pro Met Phe Pro Arg Phe Gly Phe
 35 40 45
 Arg Leu Ala Pro Pro Ala Asp Thr Pro
 50 55

<210> 578
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 578
 Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu Leu Tyr Ile Arg His
 5 10 15
 His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr Lys Lys Leu Asn Tyr
 20 25 30
 Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His Ile Ala Lys Val Tyr
 35 40 45
 Gln Pro His
 50

<210> 579
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 579
 Met His Phe Thr Phe Met Gln Leu Ile Tyr Leu Cys Phe Leu Gly Leu
 5 10 15
 Leu Tyr Ile Arg His His Asp Ser Gln Ser Phe Val Ile Leu Tyr Tyr
 20 25 30
 Lys Lys Leu Asn Tyr Tyr Phe Lys Tyr Gly Gln Ile Arg Ala Phe His
 35 40 45
 Ile Ala Lys Val Tyr Gln Pro His
 50 55

<210> 580
 <211> 67
 <212> PRT
 <213> Homo sapiens

<400> 580
 Met Glu Leu Arg Thr Lys Ala Leu Arg Thr Ala Gln Gln Leu Thr Ser
 5 10 15
 Cys Val Thr Ala Leu Lys Ala Ala Gly Pro Pro Leu Thr Phe Trp Lys
 20 25 30

213

Gly Lys Trp Val Gln Cys Cys Leu Pro Leu Trp Gly Leu Leu Gly Ser
 35 40 45

His Ala Phe Tyr Ile Tyr Ala Val Asp Ile Phe Met Phe Pro Gly Ser
 50 55 60

Phe Ile His
 65

<210> 581

<211> 77

<212> PRT

<213> Homo sapiens

<400> 581

Met Leu Glu Val Lys Phe Glu Val Ser Leu Arg Pro Thr Gly Asn Glu
 5 10 15

Thr Ala Gly Gln Thr His Gly Thr Gln Asp Lys Gly Ser Lys Asp Ser
 20 25 30

Thr Ala Ala Asp Ile Leu Cys Asp Ser Leu Glu Ser Ser Arg Pro Ala
 35 40 45

Ala His Ile Leu Glu Gly Lys Met Gly Thr Met Leu Ser Ala Thr Leu
 50 55 60

Gly Pro Ser Trp Val Thr Cys Ile Leu His Leu Cys Ser
 65 70 75

<210> 582

<211> 51

<212> PRT

<213> Homo sapiens

<400> 582

Met Leu Phe Leu Gln Thr Ile Asp Thr Lys Cys Thr Gly Ile Glu Ile
 5 10 15

Asn Arg Asn Trp Ser Lys Val Trp His Thr His Ser His Val Asp Val
 20 25 30

Lys Leu Cys Leu Glu Phe Leu Cys Gly Val Trp Phe Gly Leu Gly Phe
 35 40 45

Leu Gly Val
 50

<210> 583

<211> 60

<212> PRT

<213> Homo sapiens

<400> 583

214

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 5 10 15

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 20 25 30

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 35 40 45

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 50 55 60

<210> 584

<211> 76

<212> PRT

<213> Homo sapiens

<400> 584

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
 5 10 15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 20 25 30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 35 40 45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 50 55 60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 65 70 75

<210> 585

<211> 50

<212> PRT

<213> Homo sapiens

<400> 585

Met Val Tyr Arg Phe Gly Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu
 5 10 15

Ala Ser Leu Gly Ser Ser Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp
 20 25 30

Arg Gln Ala Asp Pro Ser Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu
 35 40 45

Leu Phe
 50

<210> 586

<211> 60

<212> PRT

<213> Homo sapiens

Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
5 10 15

Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
20 25 30

Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser
35 40 45

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
50 55 60

<213> Homo sapiens

ctggacactt	tgcgagggct	tttgtgtggt	gctgctgctg	cccgtcatgc	tactcatcgt	60
agcccgcccg	gtgaagctcg	ctgctttccc	tacctcctta	agtgactgcc	aaacgcccac	120
cggctggaat	tgctctgggt	atgatgacag	agaaaatgat	ctcttcctct	gtgacaccaa	180
caactgtaaa	tttgatgggg	aatgtttaag	aattggagac	actgtgactt	gcgtctgtca	240
gttcaagtgc	aaacaatgact	atgtgcctgt	gtgtggctcc	aatggggaga	gctaccagaa	300
tgagtgttat	ctgcgcagact	ctgcatgcaa	acagcagagt	gagatacttg	tggtgtcaga	360
aggatcatgc	gccacagatg	caggatcagg	atctggagat	ggagctccatg	aaggctctgg	420
agaaactagt	caaaaggaga	cattccacctg	tgatatattgc	cagtttggtg	cagaatgtga	480
cgaagatgcc	gaggatgtct	ggtgtgtgtg	taatattgac	tgtttctcaa	ccaacttcaa	540
tcccctctgc	gcttctgatg	ggaaatctta	tgataatgca	tgccaaatca	aagaagcatc	600
gtgtcagaaa	caggagaaaa	ttgaagtcac	gtctttgggt	cgatgtcaag	ataacacaac	660
tacaactact	aagtctgaag	atgggcatta	tgcaagaaca	gattatgcag	agaatgctaa	720
caaattagaa	gaaagtgcc	gagaacacca	cataccttgt	ccggaacatt	acaatggctt	780
ctgcattgat	gggaagtgtg	agcatttctat	caatatgcag	gagccattct	gcaggtgtga	840
tgctggttat	actggacaac	actgtgaaaa	aaaggactac	agtgttctat	acgttgttcc	900
cggctcgtga	cgatttcagt	atgtcttaat	cgcagctgtg	attggaacaa	ttcagattgc	960
tgtcatctgt	gtggtgggtc	tctgcacac	aaggaaatgc	cccgaagca	acagaattca	1020
cagacagaag	caaaatacag	ggcactacag	ttcagacaat	acaacaagag	cgtccacgag	1080
gttaatctaa	agggagcatg	tttcacagtg	gctggactac	cgagagcttg	gactacacaa	1140
tacagtatta	tagacaaaag	aataagacaa	gagatctaca	catgttgctt	tgcattttgtg	1200
gtaattctaca	ccaatgaaaa	catgtactac	agctatattt	gattatgtat	ggatatattt	1260
gaatatgtat	acattgtctt	gatgtttttt	ctgtaatgta	aataaactat	ttatatcaca	1320
caatawagtt	ttttctttcc	catgtatttg	ttatatataa	taaatactca	gtgatgagaa	1380
aaaaaaaaaa	aaaaaaaaaa	rwmqaccc				1408

<213> Homo sapiens

Met Pro Gln Lys Gln Gln Asn Ser Gln Thr Glu Ala Lys Tyr Arg Ala
5 10 15

Leu Gln Phe Arg Gln Tyr Asn Lys Ser Val His Glu Val Asn Leu Lys
20 25 30

216

Gly Ala Cys Phe Thr Val Ala Gly Leu Pro Arg Ala Trp Thr Thr Gln
 35 40 45
 Tyr Ser Ile Ile Asp Lys Arg Ile Arg Gln Glu Ile Tyr Thr Cys Cys
 50 55 60
 Leu Ala Phe Val Val Ile Tyr Thr Asn Glu Asn Met Tyr Tyr Ser Tyr
 65 70 75 80
 Ile

<210> 589
 <211> 157
 <212> PRT
 <213> Homo sapiens

<400> 589
 Met Thr Met Cys Leu Cys Val Ala Pro Met Gly Arg Ala Thr Arg Met
 5 10 15
 Ser Val Thr Cys Asp Arg Leu His Ala Asn Ser Arg Val Arg Tyr Leu
 20 25 30
 Trp Cys Gln Lys Asp His Val Pro Gln Met Gln Asp Gln Asp Leu Glu
 35 40 45
 Met Glu Ser Met Lys Ala Leu Glu Lys Leu Val Lys Arg Arg His Pro
 50 55 60
 Pro Val Ile Phe Ala Ser Leu Val Gln Asn Val Thr Lys Met Pro Arg
 65 70 75 80
 Met Ser Gly Val Cys Val Ile Leu Thr Val Leu Lys Pro Thr Ser Ile
 85 90 95
 Pro Ser Ala Leu Leu Met Gly Asn Leu Met Ile Met His Ala Lys Ser
 100 105 110
 Lys Lys His Arg Val Arg Asn Arg Arg Lys Leu Lys Ser Cys Leu Trp
 115 120 125
 Val Asp Val Lys Ile Thr Gln Leu Gln Leu Leu Ser Leu Lys Met Gly
 130 135 140
 Ile Met Gln Glu Gln Ile Met Gln Arg Met Leu Thr Asn
 145 150 155

<210> 590
 <211> 347
 <212> PRT
 <213> Homo sapiens

<400> 590
 Met Leu Leu Ile Val Ala Arg Pro Val Lys Leu Ala Ala Phe Pro Thr
 5 10 15

Ser Leu Ser Asp Cys Gln Thr Pro Thr Gly Trp Asn Cys Ser Gly Tyr
 20 25 30
 Asp Asp Arg Glu Asn Asp Leu Phe Leu Cys Asp Thr Asn Thr Cys Lys
 35 40 45
 Phe Asp Gly Glu Cys Leu Arg Ile Gly Asp Thr Val Thr Cys Val Cys
 50 55 60
 Gln Phe Lys Cys Asn Asn Asp Tyr Val Pro Val Cys Gly Ser Asn Gly
 65 70 75 80
 Glu Ser Tyr Gln Asn Glu Cys Tyr Leu Arg Gln Ala Ala Cys Lys Gln
 85 90 95
 Gln Ser Glu Ile Leu Val Val Ser Glu Gly Ser Cys Ala Thr Asp Ala
 100 105 110
 Gly Ser Gly Ser Gly Asp Gly Val His Glu Gly Ser Gly Glu Thr Ser
 115 120 125
 Gln Lys Glu Thr Ser Thr Cys Asp Ile Cys Gln Phe Gly Ala Glu Cys
 130 135 140
 Asp Glu Asp Ala Glu Asp Val Trp Cys Val Cys Asn Ile Asp Cys Ser
 145 150 155 160
 Gln Thr Asn Phe Asn Pro Leu Cys Ala Ser Asp Gly Lys Ser Tyr Asp
 165 170 175
 Asn Ala Cys Gln Ile Lys Glu Ala Ser Cys Gln Lys Gln Glu Lys Ile
 180 185 190
 Glu Val Met Ser Leu Gly Arg Cys Gln Asp Asn Thr Thr Thr Thr Thr
 195 200 205
 Lys Ser Glu Asp Gly His Tyr Ala Arg Thr Asp Tyr Ala Glu Asn Ala
 210 215 220
 Asn Lys Leu Glu Glu Ser Ala Arg Glu His His Ile Pro Cys Pro Glu
 225 230 235 240
 His Tyr Asn Gly Phe Cys Met His Gly Lys Cys Glu His Ser Ile Asn
 245 250 255
 Met Gln Glu Pro Ser Cys Arg Cys Asp Ala Gly Tyr Thr Gly Gln His
 260 265 270
 Cys Glu Lys Lys Asp Tyr Ser Val Leu Tyr Val Val Pro Gly Pro Val
 275 280 285
 Arg Phe Gln Tyr Val Leu Ile Ala Ala Val Ile Gly Thr Ile Gln Ile
 290 295 300
 Ala Val Ile Cys Val Val Val Leu Cys Ile Thr Arg Lys Cys Pro Arg
 305 310 315 320

Asp Asn Thr Thr Arg Ala Ser Thr Arg Leu Ile
340 345

```
<210> 591
<211> 565
<212> DNA
<213> Homo sapien
```

<400>	591						
actaaagcaa	atgaacaagc	tgacttgcta	gtatcatctg	cattcattga	agcacaagaa		60
cttcatgcct	tgactcatgt	aaatgcaata	ggattaaaaa	ataaatttga	tatcacatgg		120
aaacagacaa	aaaatattgt	acaacattgc	acccagtgtc	agattctaca	cctggccact		180
caggaagcaa	gagttaatcc	cagaggtcta	tgtcctaata	tgttatggca	aatggatgtc		240
atgcacgtac	cttcatttgg	aaaattgtca	tttgtccatg	tgacagttga	tactatttca		300
catttcatat	gggcaacctg	ccagacagga	gaaagtactt	cccagtgtta	aagacattta		360
ttactcttgt	ttcctgtcat	gggagttcca	gaaaaagtta	aaacagacaa	tgggccagggt		420
tactgtagta	aagcatttca	aaaattctta	aatcagtgga	aaattacaca	tacaatagga		480
attctctata	attcccaagg	acaggcata	attgaaggaa	ctaatagaac	actcaaagct		540
caattgggta	aacaaaaaaa	aaaaa					565

```
<210> 592
<211> 188
<212> PRT
<213> Homo sapien
```

<400>	592															
Thr	Lys	Ala	Asn	Glu	Gln	Ala	Asp	Leu	Leu	Val	Ser	Ser	Ala	Phe	Ile	
1				5					10					15		
Glu	Ala	Gln	Glu	Leu	His	Ala	Leu	Thr	His	Val	Asn	Ala	Ile	Gly	Leu	
			20					25					30			
Lys	Asn	Lys	Phe	Asp	Ile	Thr	Trp	Lys	Gln	Thr	Lys	Asn	Ile	Val	Gln	
		35					40					45				
His	Cys	Thr	Gln	Cys	Gln	Ile	Leu	His	Leu	Ala	Thr	Gln	Glu	Ala	Arg	
	50					55					60					
Val	Asn	Pro	Arg	Gly	Leu	Cys	Pro	Asn	Val	Leu	Trp	Gln	Met	Asp	Val	
65				70						75					80	
Met	His	Val	Pro	Ser	Phe	Gly	Lys	Leu	Ser	Phe	Val	His	Val	Thr	Val	
				85					90					95		
Asp	Thr	Tyr	Ser	His	Phe	Ile	Trp	Ala	Thr	Cys	Gln	Thr	Gly	Glu	Ser	
			100					105					110			
Thr	Ser	His	Val	Lys	Arg	His	Leu	Ser	Cys	Phe	Pro	Val	Met	Gly		
		115					120					125				
Val	Pro	Glu	Lys	Val	Lys	Thr	Asp	Asn	Gly	Pro	Gly	Tyr	Cys	Ser	Lys	
	130					135					140					
Ala	Phe	Gln	Lys	Phe	Leu	Asn	Gln	Trp	Lys	Ile	Thr	His	Thr	Ile	Gly	
145				150						155				160		
Ile	Leu	Tyr	Asn	Ser	Gln	Gly	Gln	Ala	Ile	Ile	Glu	Gly	Thr	Asn	Arg	
			165						170					175		
Thr	Leu	Lys	Ala	Gln	Leu	Val	Lys	Gln	Lys	Lys	Lys					
		180						185								

<210> 593
<211> 271

219

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(271)

<223> n = A,T,C or G

<400> 593

actttatgtt	cnagtgcana	aanccncctg	gattgccacc	ntactctcag	ggctgtgant	60
tgtgcnccca	nagcaacctg	ggcacgcggg	gacagggggg	ccnacaattg	aggagcggt	120
gtccctagct	ggggtctata	catgncnggg	naagggcngc	tgagtnccat	nagcaaagga	180
nctagnatnt	gcgggggtgc	ggcctgggcc	taccctttna	agcatccntn	gatccactcc	240
angaancng	gggtagnacg	gtttnccaac	a			271

<210> 594

<211> 376

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(376)

<223> n = A,T,C or G

<400> 594

cctttggggg	nggggggaac	ctttaccatt	gtncctcttt	atttcatttg	gttngggttc	60
gcgccctcnn	gggccaacaa	agttatcgtn	nttgaagaga	anattttttt	ggnttngncc	120
cgattaagcg	ncaaatgtgt	agcaaaangc	cgtgccactt	gtggcgtagc	tncgtcggt	180
cgattcgacg	acaaggcgtn	gcgcgntanc	gttagtctcn	aatngaccn	gtggcatgag	240
cccacgangg	nttcgtgtcg	tcacatggnc	tctagacata	acgcncnccn	ttttttncag	300
aggggntgc	cgcccttagg	gaggnagggg	tggggacact	agccaancca	nantctnacc	360
ccattgaaga	aaaggn					376

<210> 595

<211> 242

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(242)

<223> n = A,T,C or G

<400> 595

agnctgctgn	tcgtncctn	tatgtggctt	catnntgagg	acaanagtng	cactgaggct	60
tgngnatgcc	aggcaaggnc	aagctggctc	aaaaagcatc	caccacctc	tgnaangggg	120
atgccangag	cangtgcacc	agtcccaact	angagnccn	ggcatgntac	atcttcttcc	180
accctnaaa	ntttgngcta	caangnccat	ttttctttt	ctcttaaggg	ncnctggct	240
tc						242

<210> 596

<211> 535

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(535)

<223> n = A,T,C or G

<400> 596

accagttgga	tactgctaaa	nagatatatta	tgcagcctca	tatgttaagt	cgtatatattt	60
gaaagctttt	ttaaattttt	ctttaagaag	atttttagatg	cttatcactg	agtaccagag	120
ggatgtaggc	tgatgccctt	atcaacaaaag	tcagggactg	tggcacacaa	ggattgacta	180
ctgcagacac	ggccacaatg	ctacctctag	agggcctgaa	tccccctgcc	ctctctggtg	240
gggagaaggg	ctggcagagc	cattagcatg	ggctccggcc	aatcctggcc	actttgacac	300
tcctggtgct	gacccagggg	cctggaggaa	gggatgaggt	gggcagtaga	gatgctcagg	360
gcagtggccc	ctttccatcc	acactggaac	tatttcagta	ttttaccacc	aattcagcca	420
ttcccttggtg	cgctggctga	acatcagccc	tgctccaggt	ctcagtttcc	cctttgtaaa	480
gggaaagctc	tggattcagg	gagtgatgaa	gaggtcatca	tggtcttgag	aattc	535

<210> 597

<211> 257

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(257)

<223> n = A,T,C or G

<400> 597

tttcnatacc	caaaantacc	ccatattang	accanacatt	tgtctnggaa	aaattaccat	60
tntntaacnt	ttgggccacc	tgagannaaa	tggtgtgaat	ncatgataag	atggancagn	120
atttctctta	agatnngatn	agaccccgtt	tttcacggaa	catatccaag	nacccaatag	180
gnaacaagcc	acgggnggag	tcacaaacat	atattcttta	ctctcataat	ccgtnnccaca	240
naactnttgn	acttgac					257

<210> 598

<211> 222

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(222)

<223> n = A,T,C or G

<400> 598

nntggntacc	gtcnaaactt	nncttggtac	ccgagctcgg	atccactagt	ccagtgtggt	60
ggaattccat	tgtgttgggc	tataagctgt	aatagtggag	ncgtgctngg	ttcattgcan	120
nagnccctcc	gcanncacnc	ttgnnacaac	ctgtgagnag	gcnataaatt	attcacataa	180
tcatactgc	atgaanctga	ctcaaacgca	tccacntaca	cc		222

<210> 599

<211> 238

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(238)

<223> n = A,T,C or G

<400> 599

gcatgacatc	ancgatgtnt	ttggnnacct	ganattngct	aaaactngng	natgccgggn	60
atgnaggttt	ggtantgac	tatgcactca	catctcatgg	ggacgtttca	tgtggagtgn	120
tcgacaangt	tgctgnancn	gagaagtgat	gatctcagtt	gaaagggcca	tgtgaataca	180
cnttacactt	gaaaaagaag	cacattggga	atatcacgaa	acgnccacca	acatcctg	238

<210> 600

<211> 232

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(232)

<223> n = A,T,C or G

<400> 600

cgaactat	agactaccta	ggaaaattat	tttagtatca	gaagaatatc	aggggtgtag	60
tactcatcag	agctaaatga	gagcgcttta	aaaatgttag	tttgtcttcc	gccatttcta	120
cagaaagctg	caatttcagg	ttttcaacct	aataggtgat	atttaanaaa	aaaaaaaagc	180
aatcgcaaat	agccccactg	cttttacaaa	tcattttttc	cccaacacaa	tg	232

<210> 601

<211> 547

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(547)

<223> n = A,T,C or G

<400> 601

cattgtgttg	gggaaaaaat	gatttgtata	agcagtgggg	ctatttgcca	ttgctttttt	60
tttttcttaa	atatcaccta	ttaggttgaa	aacctgaaat	tgcagctttc	tgtagaaatg	120
gcggaagaca	aactaacatt	tttaaagcgc	tctcatctag	ctctgatgag	tactacaccc	180
ctnatattct	tctgatacta	aaataatttt	cctagtgtag	tctaaacttt	tttaaaaaga	240
catgtaatcc	gcggagttag	taactcaaaa	cgagtgcac	tnggaagtat	cgcagccggt	300
nctggatnaa	attcccagct	tgctngcttg	ctnagccggg	gggcggtnaa	aaaaacatct	360
gcagccnngg	ggnaaaaacc	ttcgcatgtg	tcttacgtgt	ttacgttatt	ttatttcctt	420
nnagcaaggc	nggganttgg	ggactcgaaa	tggtacagtt	gggctgggga	tcgccttgt	480
tacataaaaag	ncgtccagaa	gagggacggt	tacaggcngg	ganctccaaa	ggtcagtcct	540
tgccatt						547

<210> 602

<211> 826

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(826)

<223> n = A,T,C or G

<400> 602

cgggggggnt	tacgtctctc	tgacgctttt	tattgtacca	gggcgatccc	agcccaactg	60
taccatttga	gtccctactc	ctgccttgct	ctagggaat	aaaataacgt	aaacacgtaa	120
gaacaatgcg	aaagcgtttt	cttccttagg	ctgcagattg	tcttcttcac	cgcccttgct	180
tagctagcta	gctagctggg	aatttaatcc	agaaacggct	tgcgatacct	cctagatgca	240

ctcgttttga	gttacaaact	ccgcggatta	catgtctttt	taaaaaagtt	tagactacac	300
tagggaaaa	tatttttagta	tcagaagaat	atcagggggt	gtagtactca	tcagagctna	360
atgagagcgc	tttaaaaatg	ttagtttgtc	ttccgccatt	tctacagaaa	gctgcaattt	420
cagggttttca	ncctaataagg	tgatatntaa	gaaaaaaaaa	acaatcgcan	atagcccact	480
gctttttacaa	atcatttttc	tcttctaggt	atagcctgtc	aggtggccta	atgtattttt	540
gacatctcta	ggaattttta	tagaccagaa	atgggtgcc	gagatatgcc	tgactaatac	600
ttaagtgggg	atttatgtat	ttctcaanca	agtgattaaa	gcaaaactag	gcacgaatga	660
aatcaagatc	tttaggccag	aatcatgaa	nanttttana	attattttan	gaatctgtgg	720
cttctcttct	taaaatngaa	aaaaaaattg	tttaaaccac	naaggtctga	ataccaagc	780
nccctgaacn	anagaacaan	gccggagcac	cccctcccaa	atcccc		826

<210> 603

<211> 817

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(817)

<223> n = A,T,C or G

<400> 603

nnangacttt	tgtggtnnta	tacaattntt	ttttctat	ctatgaagag	aaagccacag	60
agtccataaa	taattctaaa	actcatcatg	actttcttgc	ctaaaagatc	ttgatttcaa	120
tcgtgcctag	ttttgcttta	atcaacttgc	tgagaaatac	ataaatcccc	acttaagatt	180
agtgcaggca	tatctctggc	acccatttct	ggttctatta	aaattcctag	agatgtcaaa	240
aattacatta	ggccacctga	caggctatac	ctagaagaga	aaaaatgatt	tgtaaaagca	300
gtggggctat	ttgcgattgc	tttttttttt	tcttaaatat	cacctattag	gttgaaaacc	360
tgaaattgca	gctttctgta	gaaatggcgg	aagacaaact	aacattttta	aagcgtcttc	420
atthagctct	gatgagtact	acaccctga	tattcttctg	atactaaaat	aattttccta	480
gtgtagtcta	aactttttta	aaaagacatg	taatccgcgg	agtttgtaac	tcaaaacgag	540
tgcatctagg	aggtatcgca	agccgtttct	ggattaaatt	cccagctagc	ttgcttgctt	600
agcaggggcg	ggnaaanaag	acatctgcag	cctagggaag	aaaacctttc	gcattgttct	660
tacgtgttta	cgttatttta	tttcttanaa	caaggcngaa	ttgggactcg	aatgggtcag	720
ttgggggtgg	ggatcccctg	gtncataaaa	ngtcanaaag	anggtacag	cggaacncca	780
agggctcgcc	tgcatttana	ctcggaattt	tggtgcc			817

<210> 604

<211> 694

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(694)

<223> n = A,T,C or G

<400> 604

cttttcaaat	catttttnct	cttctaggt	tancctgtca	ggtggcctaa	tgtaattttt	60
gacatctcta	ngaattttta	tagaaccaga	aatgggtgcc	agagatatgc	ctgcactaat	120
cttaagtggg	gatttatgta	tttctcaagc	aagtgattaa	agcaaaacta	ggcacgattg	180
aatcaagat	cttttaggca	anaaagtc	gatgagttt	agaattattt	taggactctg	240
tggttttctc	ttcatagaaa	tagaaaaaaa	aattgtataa	aaccacaaaa	ggtcctgaat	300
agccaaagca	acactganca	aaaagaacan	agcagggaag	caacacacta	ccngaattca	360
aattatacta	ccagggtgta	gtaacaaaaa	cagcattcta	ttggcataaa	atagacacca	420
agaccaatgg	ancagaataa	agaacccac	aaataaatcc	atatatntac	cgccanctga	480
ttatcaataa	cnaacaccaa	gaacatatnt	taagggaent	nctattcaat	aantagtgtc	540
ggnaaaaact	gggaaatcca	tatgcagaaa	naatgaaact	agacccttat	ccctcaccat	600

```

acgcaaannt caacttcgga atgggattac aaaacttaag acattccaac ccaagaaact 660
atnaaancta ctattaagaa aacagatcnc nccc 694

```

```

<210> 605
<211> 678
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(678)
<223> n = A,T,C or G

```

```

<400> 605
taaaaaatcta gactacacta ggaaattatt ttantatcag aagaatatca ggggtgtagt 60
actcatcana gctaaatgag agcgctttaa aaatgttagt ttgtcttccg ccatttctac 120
agaaagctgc aatttcaggt tttcaaccta ataggtagata ttttaagaaa aaaaaaagca 180
atcgcaaata gccccactgc ttttacaat cattttttct cttctaggta tagcctgtca 240
ggtggcctaa tgtaattttt gacatctcta ggaattttaa tagaaccaga aatgggtgcc 300
agagatatgc ctgcactaat ctttaagtggg gatttatgta tttctcaagc aagtgattaa 360
agcaaaacta ggcacgattg aaatcaanat cttttaggca agaaagtcac gatgagtttt 420
anaattattt taggactctg tggctttctc ttcatagaaa tagaaaaaaa aaattgtata 480
aaaaccacaa aaggtcctga atagcccaaa gcaacactga acaaaaangaa caaagcagga 540
agcaacacac taccggaatt caattatact accaaggtgt antaaccaaa acagcattct 600
attgggcata aaatagacca aagaccagtg ggaaacagaa taaagaancc caaaataaat 660
cctatattta cngccnc 678

```

```

<210> 606
<211> 263
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1)...(263)
<223> n = A,T,C or G

```

```

<400> 606
gtggggctcng cancagccaa ctacagcttc tttcgggctt tgtagcaga cggatcatcc 60
tctagtccac tgtgntcaaa ttccattgtg tgggggcccnc tcgcctcggc canagatctg 120
agtgancana cntgtcccca ctgaggtgcc ccacagcngn ttgtnttcag cangggctna 180
caactcgacc ggcagcgan ggctggcaga antgngcgcc tnnctcattc ctacgngtn 240
ngccgcagga aggangacag gcc 263

```

```

<210> 607
<211> 22
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Primer

```

```

<400> 607
ccatgtgggt cccggttgtc tt 22

```

```

<210> 608
<211> 22
<212> DNA

```

<213> Artificial Sequence

<220>

<223> Primer

<400> 608

gataggggtg ctcaggggtt gg

22

<210> 609

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 609

gctggacagg gggcaaaagc tggggcagtg aaccatgtgc

40

<210> 610

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 610

ccttgtccag atagcccagt agctgac

27

<210> 611

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 611

gatagagaaa accgtccagg ccagtattgt gggaggctgg gagtgc

46

<210> 612

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 612

gcacatgggt cactgcccga gcttttgccc cctgtccagc

40

<210> 613

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 613

gccgctcgag ttagaattcg gggttgcca cgatggtg

38

<210> 614

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 614

cgcggggcat atgcatcacc atcaccatca catcataaac ggcgaggact gca

53

<210> 615

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 615

gcactccag cctcccacaa tactggcctg gacggttttc totatc

46

<210> 616

<211> 1350

<212> DNA

<213> Homo sapien

<400> 616

atgcatcacc	atcaccatca	catcataaac	ggcgaggact	gcagcccga	ctcgagccc	60
tggcaggcgg	cactggatcat	ggaaaacgaa	ttgttctgct	cgggcgtcct	ggtgcatccg	120
cagtgggtgc	tgtagccgc	acactgtttc	cagaactcct	acaccatcgg	gctgggacctg	180
cacagtcctg	aggccgacca	agagccagg	agccagatgg	tggaggccag	cctctccgta	240
cggcaccacg	agtacaacag	acccttgctc	gtaacgacc	tcatgctcat	caagttggac	300
gaatccgtgt	ccgagtctga	caccatccgg	agcatcagca	ttgcttcgca	gtgccctacc	360
gcggggaact	cttgctcgt	ttctggctgg	ggtctgctgg	cgaacggcag	aatgcctacc	420
gtgctgcagt	gcgtgaacgt	gtcgggtggtg	tctgaggagg	tctgcagtaa	gctctatgac	480
ccgctgtacc	acccagcat	gttctgcgcc	ggcggagggc	aagaccagaa	ggactcctgc	540
aacggtgact	ctggggggcc	cctgatctgc	aacgggtact	tgcagggcct	tgtgtctttc	600
ggaaaagccc	cgtgtggcca	agttggcgtg	ccagggtgtct	acaccaacct	ctgcaaattc	660
actgagtga	tagagaaaac	cgtccaggcc	agtattgtgg	gaggctggga	gtgcgagaag	720
cattcccac	cctggcaggt	gcttgtggcc	tctcgtggca	gggcagtctg	cggcggtgtt	780
ctggtgcacc	ccagtggtg	cctcacagct	gccactgca	tcaggaacaa	aagcgtgatc	840
ttgctgggtc	ggcacagcct	gtttcatcct	gaagacacag	gccaggattt	tcaggtcagc	900
cacagcttcc	cacaccgct	ctacgatatg	agcctcctga	agaatcgatt	cctcaggcca	960
ggtgatgact	ccagccacga	cctcatgctg	ctccgcctgt	cagagcctgc	cgagctcacg	1020
gatgctgtga	aggtcatgga	cctgccacc	caggagccag	cactggggac	cacctgctac	1080
gcctcaggct	ggggcagcat	tgaaccagag	gagttcctga	cccaaagaa	acttcagtgt	1140
gtggacctcc	atgttatctc	caatgacgtg	tgtgcgcaag	ttcaccctca	gaaggtgacc	1200
aagttcatgc	tgtgtgctgg	acgctggaca	gggggcaaaa	gctggggcag	tgaaccatgt	1260
gccctgccc	aaaggccttc	cctgtacacc	aaggtggtgc	attaccggaa	gtggatcaag	1320
gacaccatcg	tggccaaccc	cgaattctaa				1350

<210> 617

<211> 449
 <212> PRT
 <213> Homo sapien

<400> 617

Met	His	His	His	His	His	His	Ile	Ile	Asn	Gly	Glu	Asp	Cys	Ser	Pro
1				5					10					15	
His	Ser	Gln	Pro	Trp	Gln	Ala	Ala	Leu	Val	Met	Glu	Asn	Glu	Leu	Phe
		20						25					30		
Cys	Ser	Gly	Val	Leu	Val	His	Pro	Gln	Trp	Val	Leu	Ser	Ala	Ala	His
		35					40					45			
Cys	Phe	Gln	Asn	Ser	Tyr	Thr	Ile	Gly	Leu	Gly	Leu	His	Ser	Leu	Glu
	50					55					60				
Ala	Asp	Gln	Glu	Pro	Gly	Ser	Gln	Met	Val	Glu	Ala	Ser	Leu	Ser	Val
65					70					75					80
Arg	His	Pro	Glu	Tyr	Asn	Arg	Pro	Leu	Leu	Ala	Asn	Asp	Leu	Met	Leu
				85				90						95	
Ile	Lys	Leu	Asp	Glu	Ser	Val	Ser	Glu	Ser	Asp	Thr	Ile	Arg	Ser	Ile
		100						105					110		
Ser	Ile	Ala	Ser	Gln	Cys	Pro	Thr	Ala	Gly	Asn	Ser	Cys	Leu	Val	Ser
	115					120						125			
Gly	Trp	Gly	Leu	Leu	Ala	Asn	Gly	Arg	Met	Pro	Thr	Val	Leu	Gln	Cys
	130					135					140				
Val	Asn	Val	Ser	Val	Val	Ser	Glu	Glu	Val	Cys	Ser	Lys	Leu	Tyr	Asp
145					150					155					160
Pro	Leu	Tyr	His	Pro	Ser	Met	Phe	Cys	Ala	Gly	Gly	Gly	Gln	Asp	Gln
				165				170						175	
Lys	Asp	Ser	Cys	Asn	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Ile	Cys	Asn	Gly
			180					185					190		
Tyr	Leu	Gln	Gly	Leu	Val	Ser	Phe	Gly	Lys	Ala	Pro	Cys	Gly	Gln	Val
	195						200					205			
Gly	Val	Pro	Gly	Val	Tyr	Thr	Asn	Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile
	210					215						220			
Glu	Lys	Thr	Val	Gln	Ala	Ser	Ile	Val	Gly	Gly	Trp	Glu	Cys	Glu	Lys
225					230					235					240
His	Ser	Gln	Pro	Trp	Gln	Val	Leu	Val	Ala	Ser	Arg	Gly	Arg	Ala	Val
				245					250					255	
Cys	Gly	Gly	Val	Leu	Val	His	Pro	Gln	Trp	Val	Leu	Thr	Ala	Ala	His
			260					265					270		
Cys	Ile	Arg	Asn	Lys	Ser	Val	Ile	Leu	Leu	Gly	Arg	His	Ser	Leu	Phe
	275					280						285			
His	Pro	Glu	Asp	Thr	Gly	Gln	Val	Phe	Gln	Val	Ser	His	Ser	Phe	Pro
	290					295					300				
His	Pro	Leu	Tyr	Asp	Met	Ser	Leu	Leu	Lys	Asn	Arg	Phe	Leu	Arg	Pro
305					310					315					320
Gly	Asp	Asp	Ser	Ser	His	Asp	Leu	Met	Leu	Leu	Arg	Leu	Ser	Glu	Pro
				325					330					335	
Ala	Glu	Leu	Thr	Asp	Ala	Val	Lys	Val	Met	Asp	Leu	Pro	Thr	Gln	Glu
			340					345					350		
Pro	Ala	Leu	Gly	Thr	Thr	Cys	Tyr	Ala	Ser	Gly	Trp	Gly	Ser	Ile	Glu
	355						360					365			
Pro	Glu	Glu	Phe	Leu	Thr	Pro	Lys	Lys	Leu	Gln	Cys	Val	Asp	Leu	His
	370					375					380				
Val	Ile	Ser	Asn	Asp	Val	Cys	Ala	Gln	Val	His	Pro	Gln	Lys	Val	Thr
385					390					395					400
Lys	Phe	Met	Leu	Cys	Ala	Gly	Arg	Trp	Thr	Gly	Gly	Lys	Ser	Trp	Gly
				405					410					415	
Ser	Glu	Pro	Cys	Ala	Leu	Pro	Glu	Arg	Pro	Ser	Leu	Tyr	Thr	Lys	Val

420 425 430
 Val His Tyr Arg Lys Trp Ile Lys Asp Thr Ile Val Ala Asn Pro Glu
 435 440 445
 Phe

<210> 618
 <211> 3923
 <212> DNA
 <213> Homo sapien

<400> 618
 acagaagaaa tagcaagtgc cgagaagctg gcatcagaaa aacagagggg agatttgtgt 60
 ggctgcagcc gagggagacc aggaagatct gcatgggtgg aaggacctga tgatacagag 120
 gaattacaac acatataact agtggtttcaa tgaacaccaa gataaataag tgaagagcta 180
 gtccgctgtg agtctcctca gtgacacagg gctggatcac catcgacggc actttctgag 240
 tactcagtgc agcaaagaaa gactacagac atctcaatgg caggggtgag aaataagaaa 300
 ggctgctgac ttaccatct gaggccacac atctgctgaa atggagataa ttaacatcac 360
 tagaaacagc aagatgacaa tataatgtct aagtagtgac atgtttttgc acatttcag 420
 cccctttaaa tatccacaca cacaggaagc acaaaaggaa gcacagagat ccctgggaga 480
 aatgcccgcc cgccatcttg ggtcatcgtat gagcctcgcc ctgtgcctgg tcccgcttgt 540
 gagggaagga cattagaaaa tgaattgatg tgcttccttaa aggatgggca ggaaaacaga 600
 tctgttgtg gatattttatt tgaacgggat tacagatttg aaatgaagtc acaaagttag 660
 cattaccaat gagaggaaaa cagacgagaa aatcttgatg gcttcacaag acatgcaaca 720
 aacaaaatgg aatactgtga tgacatgagg cagccaagct ggggaggaga taaccacggg 780
 gcagagggtc aggattctgg ccctgctgcc taaactgtgc gttcataacc aaatcatttc 840
 atatttctaa ccctcaaaac aaagctgttg taatatctga tctctacggg tccttctggg 900
 cccaacattc tccatatatc cagccacact catttttaat atttagttcc cagatctgta 960
 ctgtgacctt tctacactgt agaataacat tactctttt gttcaaagac ccttcgtgtt 1020
 gctgcctaata atgtagctga ctgtttttcc taaggagtgt tctggcccag gggatctgtg 1080
 aacaggctgg gaagcatctc aagatcttcc caggggtata cttactagca cacagcatga 1140
 tcattacgga gtgaattatc taatcaacat catcctcagt gtctttgcc atactgaaat 1200
 tcatttccca cttttgtgcc cattctcaag acctcaaaat gtcattccat taatatcaca 1260
 ggattaaact ttttttttaa cctggaagaa ttcaatgtta catgcagcta tgggaattta 1320
 attacataatt ttgttttcca gtgcaaagat gactaagtcc tttatccctc ccctttgttt 1380
 gatttttttt ccagtataaa gttaaaatgc tttagccttg actgaggctg tatcacgac 1440
 agcctctccc catccctcca gccttatctg tcatcaccat caaccctcc cataccacct 1500
 aaacaaaatc taacttgtaa ttccttgaa atgtcaggac atacattatt ccttctgcct 1560
 gagaagctct tcctgtctc ttaaatctag aatgatgtaa agttttgaat aagttgacta 1620
 tcttacttca tgcaaagaag ggacacatat gagattcatc atcacatgag acagcaata 1680
 ctaaaagtgt aatttgatta taagagtta gataaatata tgaaatgcaa gagccacaga 1740
 gggaatgttt atggggcacg tttgtaagcc tgggatgtga agcaaaggca gggaacctca 1800
 tagtatctta tataatatac ttcatctctc tatctctatc acaatatcca acaagctttt 1860
 cacagaattc atgcagtgc aatccccaaa ggtaaccttt atccatttca tgggtgagtgc 1920
 gctttagaat ttgggcaaat catactggtc acttatctca actttgagat gtgtttgtcc 1980
 ttgtagttaa ttgaaagaaa tagggcactc ttgtgagcca ctttaggggt cactcctggc 2040
 aataaagaat ttacaaagag ctactcagga ccagttgtta agagctctgt gtgtgtgtgt 2100
 gtgtgtgtgt gagtgatcat gccaaagtgt gcctctctct cttgacccat tatttcagac 2160
 ttaaaacaag catgttttca aatggcacta tgagctgcca atgatgtatc accaccatat 2220
 ctcatatttc tccagtaaat gtgataataa tgtcatctgt taacataaaa aaagtttgac 2280
 ttcacaaaag cagctggaag tggacaacca caatatgcat aaatctaact cctaccatca 2340
 gctacacact gcttgacata tattgttaga agcacctcgc atttgtgggt tctcttaagc 2400
 aaaatacttg cattaggtct cagctggggc tgtgcatcag gcggtttgag aaatattcaa 2460
 ttctcagcag aagccagaat ttgaattccc tcatctttta ggaatcattt accaggtttg 2520
 gagaggattc agacagctca ggtgctttca ctaatgtctc tgaacttctg tccctctttg 2580
 tgttcatgga tagtccaata aataatgtta tctttgaact gatgtcata ggagagaata 2640
 taagaactct gagtgatatc aacattaggg attcaaagaa atattagatt taagctcaca 2700

ctggtcaaaa	ggaaccaaga	tacaaagaac	tctgagctgt	catcgtcccc	atctctgtga	2760
gccacaacca	acagcaggac	ccaacgcgat	tctgagatcc	ttaaatacaag	gaaaccagtg	2820
tcatgagttg	aattctccta	ttatggatgc	tagcttctgg	ccatctctgg	ctctcctctt	2880
gacacatatt	agcttctagc	ctttgcttcc	acgactttta	tcttttctcc	aacacatcgc	2940
ttaccaatcc	tctctctgct	ctgttgcttt	ggacttcccc	acaagaattt	caacgactct	3000
caagtctttt	cttccatccc	caccaactaac	ctgaatgcct	agacccttat	ttttattaat	3060
ttccaataga	tgtgcctat	gggctatatt	gcttttagatg	aacattagat	atttaaagct	3120
caagaggttc	aaaatccaac	tattatcttt	ctctttcttt	cacctccctg	ctcctctccc	3180
tatattactg	attgcactga	acagcatggt	ccccaatgta	gcatgcaaa	tgagaaaccc	3240
agtggctcct	tgtggtacat	gcatgcaaga	ctgctgaagc	cagaaggatg	actgattacg	3300
cctcatgggt	ggaggggacc	actcctgggc	cttcgtgatt	gtcaggagca	agacctgaga	3360
tgtccctgc	cttcagtgtc	ctctgcatct	cccctttcta	atgaagatcc	atagaatttg	3420
ctacatttga	gaattccaat	taggaactca	catgttttat	ctgccctatc	aattttttaa	3480
acttgctgaa	aattaagttt	tttcaaaatc	tgtccttgta	aattactttt	tcttacagtg	3540
tcttggcata	ctatatcaac	tttgattctt	tgttacaact	tttcttactc	ttttatcacc	3600
aaagtggctt	ttattctctt	tattattatt	attttctttt	actactatat	tacgttggtta	3660
ttattttggt	ctctatagta	tcaatttatt	tgatttagtt	tcaatttatt	tttattgctg	3720
acttttaaaa	taagtgattc	ggggggtggg	agaacagggg	agggagagca	ttaggacaaa	3780
tacctaatgc	atgtgggact	taaaacctag	atgatgggtt	gataggtgca	gcaaacact	3840
atggcacacg	tatacctgtg	taacaaacct	acacattctg	cacatgtatc	ccagaaacgta	3900
aagtaaaatt	taaaaaaaag	tga				3923

<210> 619

<211> 3674

<212> DNA

<213> Homo sapien

<400> 619

agaaagtttc	cttttttttt	tttaatggtg	aaaagatata	cacatattta	gaattagcca	60
gctgggctca	gttttagatta	ttccaatttt	gttggcaaca	tccagagcat	cgtaatcagg	120
agccagttaa	acataattcct	tcttctctcc	atcaggccaa	atcacggtgt	tgaccttgge	180
cacatcaatg	tcttagaact	tcttcacagc	ctgtttgatc	tgggtgcttg	tggctttaac	240
atccacaatg	aacacaagtg	tgttggtgtc	ttctatcttc	ttcgtggtga	ctcagtggtc	300
agcggaaact	tgatgatagc	gtagtgggtc	agcttgatc	tcctgggagc	gctcttccaa	360
agatatttgg	gctgcctcgg	gagttgcagc	gtcttgggcc	gccggaaggt	gggtgacgta	420
cggatcttct	ttttttgtgt	ggctgtggac	acctttcaac	actgtcttct	tggcctttaa	480
atccttcgct	ttggtttcgg	ctataggagg	ggcaggagct	tccttcttca	ctttcggcgc	540
catcttgtag	aaagggaaag	tttcctttct	aataccattt	tcacttctcc	cgaattttgt	600
ggatcgtttc	ttggtatcta	cccagattt	caggagtgtt	ggctggatct	tagggattgt	660
gaagtcttca	tttccctgtg	gtgagatctg	aggcatgatt	ttaaacagtg	tgagggaagg	720
agatctccag	gcactttaat	agaatggaga	agcaggatgg	gatttgagag	gaaatctgat	780
tttgaaaaaa	ggagaactag	agttgagttc	gtaattaaact	agcaccttaa	aggtcattca	840
gcatgcccat	ctgcacagtg	ggtgtaatca	ccctacagaa	caaaaacaaa	aaggcaatgg	900
agaggaagct	gtaaagcact	gtacatgttt	aactcattgt	tatgtaagct	agccgaaggc	960
ttcacagact	tgaattcatc	tccaagttc	tcttctgtga	ctggaaactc	tgcccttaggt	1020
tgcttaaaac	ttgagaaaca	gaatattgct	tcccctgcct	gccttcttga	gtacacttgc	1080
ctacacaaaag	atgcacatcc	ttgtttgtgt	gtgtgtgtcc	atttgctgtg	acattcttgt	1140
gaaagtcaaa	gtttcccagc	tgttgacata	cacaagtttg	tttggtgcaa	cctgtcagat	1200
gcatccctta	gacaggccct	ttgatactct	gggaaagaca	ttggacttac	agtcggaacg	1260
aaaagaaaaga	aatgtgatat	gtatagcgtg	cagttagttg	gagttttacc	tgtattgttt	1320
taatttcaac	aagcctgagg	actagccaca	aatgtaccca	gtttacaaat	gaggaaacag	1380
gtgcaaaaag	gttgttacct	gtcaaaggtc	gtatgtggca	gagccaagat	ttgagccag	1440
ttatgtctga	tgaacttagc	ctatgctctt	taaacttctg	aatgctgacc	attgaggata	1500
tctaacttta	gatcaattgc	attttccctc	caagactatt	tacttatcaa	tacaataata	1560
ccacttttac	caatctattg	ttttgatacg	agactcaaat	atgccagata	tatgtaaaaag	1620
caacctacaa	gctctctaag	catgctcacc	taaaagattc	ccgggatcta	ataggctcaa	1680
agaaacttct	tctagaaata	taaaagagaa	aattggatta	tgcaaaaatt	cattattaat	1740

ttttttcatc	catcctttaa	ttcagcaaac	atztatctgt	tggtgacttt	atgcagtatg	1800
gccttttaag	gattggggga	caggtgaaga	acgggggtgcc	agaatgcatc	ctcctactaa	1860
tgaggtcagt	acacatttgc	attttaaaat	gccctgtcca	gctgggcatg	gtggatcatg	1920
cctgtaatct	caacattgga	aggccaaggc	aggaggattg	cttcagccca	ggagttcaag	1980
accagcctgg	gcaacataga	aagaccccat	ctctcaatca	atcaatcaat	gccctgtcct	2040
tgaataaaaa	actctttaag	aaaggtttaa	tgggcagggt	gtggtagctc	atgcctataa	2100
tacagcactt	tgggaggctg	aggcaggagg	atcactttag	cccagaagtt	caagaccagc	2160
ctgggcaaca	agtgcacact	catctcaatt	ttttaataaa	atgaatacat	acataaggaa	2220
agataaaaaa	aaaagttaaa	tgaagaata	cagtataaaa	caaactctct	ggacctaaaa	2280
gtatttttgt	tcaagccaaa	tattgtgaat	cacctctctg	tggtgaggat	acagaatatc	2340
taagcccagg	aaactgagca	gaaagtcat	gtactaacta	atcaacccga	ggcaaggcaa	2400
aaatgagact	aactaatcaa	tccgaggcaa	ggggcaaat	agacggaacc	tgactctggt	2460
ctattaagcg	acaactttcc	ctctgttgta	ttttctcttt	attcaatgta	aaaggataaa	2520
aactctctaa	aactaaaaac	aatgtttgtc	aggagttaca	aaccatgacc	aactaattat	2580
ggggaatcat	aaaatatgac	tgtatgagat	cttgatggtt	tacaaagtgt	acccactggt	2640
aatcacttta	aacattaatg	aacttaaaaa	tgaatttacg	gagattggaa	tggttctttc	2700
ctgttgattt	agttggctca	ggctgccata	acaaaatacc	acagactggg	aggcttaagt	2760
aacagaaatt	catttctcac	agttctgggg	gctggaagtc	cacgatcaag	gtgcaggaaa	2820
ggcaggcttc	attctgaggc	ccctctcttg	gctcacatgt	ggccaccctc	ccactgcgtg	2880
ctcacatgac	ctctttgtgc	tcctggaaag	agggtgtggg	ggacagaggg	aaagagaagg	2940
agagggaaact	ctctggtgtc	tcgtctttca	aggaccctaa	cctggggccac	tttggcccag	3000
gcaactgtgg	gtgggggggt	gtggctgctc	tgctctgagt	ggccaagata	aagcaacaga	3060
aaaatgtcca	aagctgtgca	gcaaagacaa	gccaccgaac	agggatctgc	tcactcagtgt	3120
ggggacctcc	aagtcggcca	ccctggaggc	aagcccccam	agagcccatg	caaggaggca	3180
gcagcagaag	aagggaattg	tcctgtcctt	tggcacattc	ctcaccgacc	tggtgatgct	3240
ggacactgcg	atgaatggta	atgtggatga	gaatatgatg	gactcccaga	aaaggagacc	3300
cagctgctca	ggtggctgca	aatcattaca	gccttcatcc	tggggaggaa	ctgggggcct	3360
ggttctgggt	cagagagcag	cccagtgagg	gtgagagcta	cagcctgtcc	tgccagctgg	3420
atccccagtc	ccgtcaacc	agtaatcaag	gctgagcaga	tcaggcttcc	cggagctggt	3480
cttggaagc	cgcctctggg	gtgagttggc	tcctgctgtg	gtactgagac	aatattgtca	3540
taaattcaat	gcgccttgt	atcccttttt	cttttttata	tgtctacatc	tataatcact	3600
atgcatacta	gtctttgtta	gtgtttctat	tcmaacttaat	agagatatgt	tataactaaa	3660
aaaaaaaaaa	aaaa					3674

<210> 620

<211> 2051

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(2051)

<223> n = A,T,C or G

<400> 620

ggaccagggg	ctgaagtga	ccccagcac	agcacagctg	ctctataaaa	acgtggccag	60
actttttttt	ttgaagcaag	tcctgttct	tggtcgctct	gactagtccc	atcaggcccc	120
tggatcccaa	gactcagcat	ccaaggctcc	ctccaggaat	cctggcagct	cagcatactt	180
tatcctgttt	catctgagag	caaaaatgta	aaattggatg	cacagaaaag	tgactcaaag	240
tgcttaatat	ctagaagaaa	tctaggagca	gcaagaagag	caggacaaac	aggccaggcg	300
gtgtcaggag	cccagggtct	cagctggang	gaacgtcaac	cctgcagtgg	gagcaggggc	360
cctttgcaca	tcctaggcac	agatggtaat	gtagacacca	caggtaagct	gggcttggtg	420
cctacccttc	cccggattca	gaaagaaacc	aaacaaggag	ctttgtgtgg	aatgaaacct	480
cctttcctcc	cagaagcact	gctgactgtt	tggtggttgc	catttgtggc	agtgagccct	540
tggttggtct	gaggttgggc	tggtttctcc	tcctggccct	gccctacaga	tcataaagga	600
gaacagcaag	acgtccccag	caaacatcca	cagatggcct	tggaaataag	tcaccttctt	660
caccctgcag	gaatgccagt	gaacatattg	ctgacatctt	ggagctcagt	acctcatagt	720
gtaacggcgt	cagtagatct	gcctgtgctg	ggacttctct	tactaccat	tcctgagggg	780

cgatgcttct	gcagggcctg	tgacttgggtg	cacaacttca	gacaccatca	tcttcgagca	840
gcaccgcacc	ctcactagcc	aggggtgttg	tgacttcctc	aaggccaagg	ccacattcaa	900
ggcttcggac	ttcattgatg	cgcttgtgct	gagcaagggtg	gcttctccgg	gatcttaatt	960
caggaggtag	aatggagcct	gagatcaagt	gtctgatcaa	gcctcagtg	atgggcgctg	1020
ttcatcctct	ggtgctgaag	cagccaagag	acccaagtct	gcctggctgc	ctcttaggat	1080
atgacagcag	agccagtggc	ctctactaga	tctgtacaa	cctcacaaaa	caccagaca	1140
tcgggagtg	tgccagcctg	tgatgcaaga	gtcctaatac	tgaagacatt	gaatgacctg	1200
tcgttgtgct	gtttttacca	aaaaggatca	tgaggatcag	agaggaaaag	tcacttgccc	1260
aaagtccac	agctgaacag	tggtggagtt	caactttgac	cgtagggctgt	ctggccccc	1320
aggtgtatgc	ttgcttctct	cccaagagac	tcttttctta	tcaggctcaa	atgaatgaaa	1380
ggaggatgtt	aaagacaacg	ccattattga	cgagatcact	cccaagcgga	ttggagattg	1440
tccaatatt	tagacctata	gcaaggcctt	gggagaaatg	gtggtgcagc	aggagagcag	1500
gaacctaac	attgccatcc	taaggccctc	cattgtgtgg	agcaacgtgg	caccagcttt	1560
tctggggtg	ggttgataat	ctaaatggat	gtagccgact	cattattgcg	gtatgtatag	1620
ggatgaagaa	gtaactgtaa	tgtagtggag	gaatagtaag	aaaattctta	gtgctggctt	1680
agcttaattg	atccaaaaac	ataaatgcta	ctttactatc	aattgaagca	tattattttca	1740
attattctgg	ttataatatg	gaggcaggat	gaaattgttt	ttattctttt	agaatttttt	1800
ttttcagga	aaacagaggt	aaagtgcctat	caattactat	ttaagagttc	tattttgaaa	1860
agtgagaatt	aaggattttt	cttttctttt	taaaaaaaac	ttttttaaaa	attaaaaata	1920
aaagaagcaa	aagtcttagg	aaaatgaagc	aagtagccct	gccactctat	gtacagtaat	1980
aacaatatct	gtcccagtta	ttatgtacaa	tattataaaa	aatgtcgag	acagtaaaaa	2040
aaaaaaaaa	a					2051

<210> 621

<211> 2841

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(2841)

<223> n = A,T,C or G

<400> 621

gcagagcaca	gcatagctgc	tttaccaaat	catggccaga	ctgcttctgt	aagcaggccc	60
ctgatcctgt	tccacctcac	tggaacaggac	ctcccaactg	gggcctccag	ctacccccac	120
cagcatccct	tgccaatgg	aaatttgaaa	tgttcctggg	acagagctcc	tggaagagagg	180
ggcaggccac	cacctttgct	gtttgggtga	ctagccgttc	tgccctgcag	gctttggaga	240
gccaagctg	acaaggggta	gaagagggtgc	ctcagcacag	cacagccacg	ctacgaaaac	300
atggccagac	tcttgtttta	gtcagtcctc	gaacacattt	ctagtcagtg	ggtgaagtct	360
ttcaaccagg	gtctctggct	accttgactg	ctgttctctg	gccgacagag	gtctcaggcc	420
tccctgagtc	agagctccc	gggggaggac	cagattgtca	tctttgctgt	ttgggtgacc	480
cagccatttc	agccttaggg	cttcagagtg	tctgaggtag	ccaggggctg	aagtgaaccc	540
ccagcacagc	acagctgctg	tataaaaaac	tgccagact	ttttcttta	gcaagtccct	600
gttcttattc	ctcctgacta	ggtaagactt	ctcaacttgc	ctccagccac	atcttattgg	660
tgtgttcaga	ttggcaacag	gtttgtacct	cagtgggtaca	gagctcccag	aggaaggggt	720
aggctatcat	cttccctgga	aaatacagag	caattaggga	cttgaggggga	ccccagcat	780
tccacagcag	cccttcagaa	aagtggccag	actctgtact	tgatgggcag	atcctcctgg	840
cctgtgtctc	tagccagccc	accactggag	ctatcaagcc	agtagcaact	cagcagttcc	900
ttggacagtc	cttccaggag	caaatgaaat	cctttctgcc	actgcctttg	cagtgaactg	960
cccttgctat	cctcagaaga	tatatcacgg	gagcaaaagc	cctaagtgcc	atatcaacac	1020
ctccaataag	ctgcagttga	cccaaagaac	aagccaatcc	atctcccaca	ggttccacac	1080
acactccact	actcatcacc	agacagggaa	ccctggcttg	ggccacagc	acagaccctc	1140
catcctgggc	cgattacact	gagtgattgc	taactcacat	gtctctggga	tggaagcacc	1200
aggagacaag	caaagtgggtg	gagcagcaag	tcagggtgatg	tggaagccag	agggcaggga	1260
gagctatctc	tctgggctcc	acttgccctt	gtgagacact	ttgtcccagc	actccttagt	1320
ctgcttgctc	ctcccagggc	cccagcctgg	ccacacctgc	ttacagggca	ctctcagatg	1380
cccataccat	agtttctgtg	ctagtgagacc	gtaccatata	agtggagagc	tgcaagcaag	1440

tggcccentac	ggccacgcac	cagcctgcac	attacctctc	catactgcag	ccctttatat	1500
ggaaacttcc	tacatcactt	tgtgtgtgt	gtttacacag	gtggattttg	ctttacttgc	1560
actgacagca	cacaggaggg	cagcacacac	cccaaccac	atcaactgcc	attaaagaaa	1620
agaaatttca	gcccataatt	tcatgtccag	caaaattagg	catcataagt	gaaggagaaa	1680
taagatcctt	ttcagacaag	caaattgtga	gggaattcaa	tatcaccaga	tctaccttac	1740
aagagctcct	gaaggaagca	ctaaatatgg	aaagaaaaaa	ccatcaccag	ccactacaaa	1800
aatgcagtga	agaacgcagt	gaattacgca	gtccagtgat	gctaaaaacc	aaccacatac	1860
gttaagtctg	caaaataaacc	agctgacagc	atgacgcagc	gataaatcca	cacataccat	1920
tactaacctt	aaatgaaaat	gggctaaatg	ctcccattga	aagacatggg	gcaagctgga	1980
taaagaacca	agaccactg	gagtatgctg	tcttcaagaa	acccatctca	catgcggtgg	2040
catacatagg	ctcaaaaataa	aggaatggag	aaaaatattt	caagcaaattg	gaaaacagaa	2100
aaaagcaggt	gttgcactcc	tactttctga	caaaacagac	tatgcgaata	aagataaaaa	2160
agagaaggac	attacaaagg	tggtcctgac	ctttgatata	tctcattgct	tgataccaac	2220
ctgggctggt	ttaattgccc	aaanccaata	ggataatttg	ctgaggttgt	ggagcttctc	2280
ccctgcagag	agtcctctgat	ctcccaaaat	ttggttgaga	tgtaagggtg	attttgctgt	2340
acaactcctt	ttctgaagtt	ttactcattt	ccaaaaagga	aggcaagttt	tctgtcttcc	2400
atgacgatgg	agagcaggca	tctcctttcc	tgagtttcag	cttgcttctg	acaggggaagg	2460
tgagtgtaa	ttttttccag	cttctaagat	ggcagagaac	gatcaccagc	ctgagcctta	2520
tttccaggta	agtagctgaa	ttagagtttt	gtcttaaaat	ttttccttaa	tgattaaaaat	2580
gtaagattac	ccaccagctg	cttttaattt	ctcccttagc	attagaacac	tcagtaatca	2640
tatgaattgt	gcatttggtt	gttttgctta	actctttctg	tttggttatg	tttggggttt	2700
tattgttgtt	gtttcacttt	tctcccatct	cttctgact	tggtcaaata	caaaggaatg	2760
ttcgaaattg	tggggagcaa	ggcatctgaa	atggctaaaa	ctcctgtggc	tgcaaaaaat	2820
agaaataaaa	aaaaaaaaa	a				2841

<210> 622

<211> 3228

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1)...(3228)

<223> n = A,T,C or G

<400> 622

tccgccccat	tgacgcaa	ggcggtaggc	gtgtacgggtg	ggaggtctat	ataagcagag	60
ctctcnggct	aactagagaa	cccactgctt	actggcttat	cgaaattaat	acgactcact	120
atagggagac	ccaagctggc	tagcgttta	acttaagctt	ggtaccgagc	tcggatccac	180
tagtccagtg	tgggtggaatt	ccattgtgtt	gggcaggaaa	caagcaaagt	ggtggagcag	240
caagtcagggt	gatgtggagc	ccagagggtca	gggatggctg	tctctctagg	gtccacttgc	300
ccttgtaga	cactttatcc	cagcacttta	ggaatactga	ggtcatacca	gccacatctt	360
atatgcaaga	ttgccagca	gagatcaggt	ccgagagttc	ccttttttaa	aaaaggagac	420
ttgcttaata	aaagaagtct	agccacgttt	gtgtagagcg	gctgtgctgt	gctgggggtt	480
cacttttgag	agagttctcc	tctgagacct	gatctctgga	ggctgggcaa	tcttgcaactt	540
gagatggggc	tggctctgatc	tcagcactcc	ttagtctgct	cgcctctccc	atggccccag	600
cctggccaca	cctgcttaag	gggcactctt	agatgccac	accataactt	ccatgctagt	660
ggactgtacc	atatcagtggt	agagctgcag	caaggtggcc	cctagagcca	cgcaccagcc	720
tgacatttgc	ctctccatac	ggcagccctt	tatttggaaa	cttctaaat	cactttgctg	780
tggtgtgtta	cacgggtgtg	ttttgcttta	cttgcctga	gagcacacgg	gagtgcagca	840
cacaccccaa	cccacatcaa	ctgccattaa	agaaaagaaa	tttcagcca	gaatttcatg	900
tccagcaaaa	ttaagcatca	taagtgaagg	agaaataaga	tccttttcag	acaagcaagt	960
gctgagggaa	tttggtatca	ccagatctac	cttacgagag	ctcctgaagg	aagcactaaa	1020
tatggaaaga	aaagatcatc	acctgctact	acaaaaacac	actgaagtac	acagtccaat	1080
gatgctaaaa	agcaagcaca	tatgtaagtc	tgcaaaaata	ccagctgaca	gcatgacgac	1140
aggataaaaat	ccacacatac	cattactaac	cttaaatgta	aatgggctaa	atgctcccat	1200
tgaagacac	ggggcaagct	gggtaaagaa	ccaagaccca	ctggagtatg	ccgtcttcaa	1260
gcaacccatc	tcacgtgcag	tgccatacat	aggctcaaaa	taaaggaatg	gagaaaaata	1320

tttcaagcaa	atggaaaaca	gaaaaaaggt	gttgactcc	cagtttctga	caaaacagac	1380
tctaccaata	aagataaaaa	aagagaagga	cattacaaag	gtggctcctga	cctttgataa	1440
atctcattat	tgcttgatac	caacctgggc	tatttgtatt	gcccacacga	ataggataat	1500
ttgctgaggt	tgtggagctt	ctcccttca	cagagtcctt	gatctccgaa	aatttggttg	1560
agatgtaagg	ttgattttgc	tgtacaactc	cttttttgaa	gttttactca	tttccaacaa	1620
ggaaggcaag	ttttcctgct	tccattgaca	aaggagagca	ggcacctcct	ttcctgagtt	1680
tcagcttgct	tctgacaggg	aaggagcttt	gagatttgaa	tactggcctg	ctgggttttg	1740
gacgtgcatt	gggctgtgg	tcccatttgt	gttattttct	tgggaaattt	cttccctttg	1800
gagtgagaaa	gcttacccaa	tgctgtacc	atcatcgta	cttaaaagaa	ctccatttta	1860
agttcaggga	ctccttggca	gaagagaccg	tagccttgta	tcagatcata	aaggagaaga	1920
gcaagaggtc	cccggaac	atccacagat	ggccttggaa	ataagtcacc	ttgctcacc	1980
tgcaggaatg	ccagtgaact	tattgctgac	atccttgagc	tcagtaccct	catagtgtaa	2040
cggcgtcagc	agatctgcct	gtgctgggac	ttcctgtact	acccattcct	gaggggcgat	2100
gcttctgcag	ggcctgtgac	ttggtgcaca	acttcagaca	ccatcatctt	gcagcagcac	2160
cgcacctca	ctagccaggg	tgttgatgac	ttcctcaagg	ccaaggccac	attcaaggct	2220
tcggacttca	ttgatgcgct	tgtgctgagc	aaggtggctt	ctccgggac	ttaattcagg	2280
agtgagaatg	gagcttgaga	tcaagtgtct	gatcaagcct	cagtgtatgg	gcgctgttca	2340
tcntctgggt	ctgaagcagc	caagagacc	aagctgcct	ggctgcntct	taggatatga	2400
cagcagagcc	agtggcctct	actagatcct	gtacaacctc	acaaaacacc	cagacatcgg	2460
gagtgctgcc	agcctgtgat	gcaagagtc	taatcctgaa	gacattgaat	gacctgtcat	2520
tctgctgttt	ttacacaaaa	ggatcatgag	gatcagagag	gaaaagtac	ttgcccaag	2580
tcacacagct	gaacagtgg	ggagtccaac	tttgaccgtg	ggctgtctga	ccccaagggtg	2640
tatgcttgct	tctctcccaa	gagacaactt	tcttatcagg	ctcaaataaa	tgaaaggagg	2700
atgttaaagg	taggatctct	gaagcctgtg	ccagtggaa	cgcagctcat	ggctggcacc	2760
tgtgttctca	ttcttacctc	attaagagta	aagtttattg	agtttattga	atttaagtat	2820
ctttagttag	atcatatatt	attagtaaga	actgggacca	aacagatttt	ctgactctaa	2880
aagagagatt	ttcacagaaa	cagatatata	cctgtaagta	tacagacacg	catacacaca	2940
tttctttact	gctcataaaa	attagtcctt	attagaatgt	gggatgtata	aatgtaagag	3000
aattttcatg	ttaaaattga	cagatacatt	tttaaattgt	cctaaaataa	atttaattat	3060
ttttntttta	gaattttcca	ttattaatgt	tatttttatg	agaaactata	taactttatt	3120
gataatacat	acaataaccc	tttgtttttc	aaattgaaaa	tacagtgtat	tttgcaaata	3180
actaagtcct	aattttgtat	taaaatttta	aattttcaaa	aaaaaaaa		3228

<210> 623

<211> 4894

<212> DNA

<213> Homo sapiens

<400> 623

ctgcacgcgc	tggtccggg	tgacagccgc	gcgcctcggc	caggatctga	gtgatgagac	60
gtgtccccac	tgaggtgccc	cacagcagca	ggtgttgagc	atgggctgag	aagctggacc	120
ggcaccaaag	ggctggcaga	aatgggcgc	tggtgtattc	ctaggcagtt	ggcggcagca	180
aggaggagag	gcccagctt	ctggagcaga	gcccagacga	agcagttctg	gagtgcctga	240
acggccccct	gagccctacc	cgcctggccc	actatggtcc	agaggctgtg	ggtgagccgc	300
ctgctgcggc	accggaaaagc	ccagctcttg	ctgggtcaacc	tgctaacctt	tggcctggag	360
gtgtgttttg	ccgcaggcat	cacctatgtg	ccgcctctgc	tgtctggaagt	gggggtagag	420
gagaagttca	tgaccatggt	gctgggtgag	tcaactacatc	ctccttcctt	cctgttccag	480
atacatgcc	cctggcatgt	gggacaggag	tacctctgcc	ctgggagctg	cttggaggga	540
gaggtggtct	gctgggaagg	cattgctggg	caggagggtg	accttgggct	gagggggcac	600
accaagagaa	agaagagaat	accaaggaca	tacccagtc	acctctggat	ccctggctct	660
gcacagagcc	tggtcatag	gagacactgg	agaaatgctc	ctaacctttg	gctagccctt	720
ttataattta	tagcgattat	ctcatttaat	gcttacaacc	accatttgag	gtgatccatt	780
ttacagagaa	ggaagcagag	gcttttaaga	ggttaggtaa	gtcttagcca	aagccaaata	840
gcagctgaac	agtagagctg	ggactccatc	aaggtctccc	agccggagct	tgctcctacc	900
cctaggacaa	ggggtggact	cctgactctg	cagataaatt	ctacaaaagc	cacagaaggc	960
aagtagtaac	cattgtgtga	caaccctca	ccccaggaa	gaggggcccc	tgtgaggatt	1020
gcaggctctg	gagtcacact	gcttggtgaa	acgctgcctc	ttacctccc	taggtctgcg	1080

```

cctttgaata agtatcactt cttagtgtgt ccatgcctca gtttgtccat ctgaaaatgg 1140
gggcatctgt aatgcctgtg ttatgaggag taaattacag catccctgtg aagacgtagc 1200
acagtgtcga gtacggaatg ttatttccat ccttctcacg gagcttggtt ccccttcccc 1260
ttgcccttta cttgtcccag ccattgactc atactacttc cettcttgca ggcattggtc 1320
cagtgtcggg cctggctgtg gtcccgtcc taggctcagc cagtaccac tggcgtggac 1380
gctatggcgg ccgcccggcc ttcatctggg cactgtcctt gggcatcctg ctgagccact 1440
ttctcatccc aagggccggc tggctagcag ggctgtgtg cccggatccc aggcccttg 1500
agctggcact gctcatcctg ggcgtggggc tgcctggaatt ctgtggccag gtgtgcttca 1560
ctccactgga ggccctgtc tctgacctct tccgggaccc ggaccactgt cggcaggcct 1620
actctgtcta tgccttcatg atcagtcttg ggggtgcct gggctacctc ctgcctgcca 1680
ttgactggga caccagtgc ctggccccc acctgggcac ccaggaggag tgcctctttg 1740
gcctgtcac cctcatcttc ctcacctgcg tagcagccac actgctggtg gctgaggagg 1800
cagcgtcggg cccaccggag ccagcagaag ggctgtcggc cccctccttg tgcggcct 1860
gctgtccatg ccggggccgc ttggcttcc ggaacctggg cggcctgctt ccccggtgc 1920
accagtgtg ctgcccagc ccccgaccc tgcgcccgt cttcgtggct gagctgtgca 1980
gctggatggc actcatgacc ttacgctgt tttacacgga tttcgtggc gaggggctgt 2040
accaggcgt gccagagct gagccgggca ccgaggccg gagacactat gatgaaggta 2100
aggccttggc agccagcaga ggctgtgtg ggagccccc accagagacg acactcgggg 2160
ctgtgtctgg gctggtgcct ctccatcctg gcccgcactt ctctgtcagg aaagtgggga 2220
tggaccccat ctgcatacac ggcttctcat ggggtgtgga catctctgt tgcggtttca 2280
ggaaggcctc tggctgtctt aggagtctga tcagagtctg tgcggcgtt tgacagaagg 2340
aaaggcggag cttattcaaa gtctagagg agtggaggag ttaaggctg atttcagatc 2400
tgctgggttc cagccgcagt gtgcccctc ctcccccaac gactttccaa ataatctcac 2460
cagcgccttc cagctcaggc gtctagaag cgtcttgaag cctatggcca gctgtctttg 2520
tgttccctct caccgcctg tctcacagc tgagactccc aggaaacct cagactacct 2580
tctctgcct tcagcaagg gcgttgcca cattctctga gggtcagtgg aagaacctag 2640
actcccattg ctagaggtag aaagggaag ggtgctggg agcagggtg gtccacagca 2700
ggtctcgtg agcaggtagc tgtggttccg ccttctcatc tccctgagac tgcctcgacc 2760
cttccctccc aggtctgtc tgatggccc tctcctctg caggcgttcg gatgggcagg 2820
ctgggctgt tctgcagtg cgcctctcc ctggtcttct ctctggtcat ggaccggtg 2880
gtgcagcgat tcggcactg agcagtctat ttggccagt tggcagctt cctgtggct 2940
gccggtgcca catgctgtc ccacagtgt gccgtggtg cagcttcagc cgcctcacc 3000
gggttcacct tctcagcct gcagatcct ccctacacac tggcctccct ctaccaccg 3060
gagaagcagg tgttctctg ccaataccga ggggacact gaggtgctag cagtgaggac 3120
agcctgatga ccagcttct gccaggccct aagcctggag ctccctccc taatggacac 3180
gtgggtggtg gaggcagtg cctgtccca cctccaccg cgtctgcgg ggcctctgcc 3240
tgtatgtct ccgtacgtg ggtggtggg gagccaccg aggccagggt ggttccgggc 3300
cggggcatct gectggaact cgcctcctg gatagtgcct tctgtgtc ccagggtggc 3360
ccatccctgt ttatgggtc cattgtccag ctacagcagt ctgtcactg ctatatgtg 3420
tctgcgcag gcctgggtt ggtcgccatt tactttgcta cacaggtagt atttgacaag 3480
agcgaattg ccaatactc agcgtagaaa acttccagca cattgggtg gagggcctg 3540
ctactgggt cccagctccc tgcctctgt agccccatg ggcgtccgg ctggccgcca 3600
gtttctgtt ctgcaaaagt aatgtggct tctgtgcca ccctgtgtg ctgaggtgct 3660
tagctgcaca gctgggggt ggggcgtccc tctcctctc cccagctc tagggctg 3720
tgactggagg ccttccaagg ggtttcagt ctggacttat acaggaggc cagaagggt 3780
ccatgcactg gaatgcggg actctgcagg tggattacc aggcctcagg ttaacagcta 3840
gcctcctagt tgagacacac ctagagaagg gtttttggg gctgaataaa ctcagtcacc 3900
tggtttcca tctctaagc ccttaacct cagcttcgt taatgtagct cttgcatgg 3960
agtttctagg atgaaacact ccacctggg atttgaacat atgaaagta tttgtaggg 4020
aagagtctg aggggcaaca cacaagaacc aggtccctc agcccacagc actgtcttt 4080
tgcgatcca cccctctt accttttatc aggatgtggc ctgttggtc ttctgttgc 4140
atcacagaga cacaggcatt taaatattta acttatttat ttaacaaaagt agaagggaat 4200
ccattgctag cttttctgtg ttggtgtcta atatttggg aggggtgggg atccccaa 4260
atcaggtccc ctgagatagc tggtcattg gctgatcatt gccagaatct tcttctcct 4320
gggtctggc ccccaaatg cctaaccag gaccttgaa attctactc tcccaaatg 4380
taattcaaaa tgctgttacc caaggttagg gtgttgaag aaggtagagg gtggggctt 4440
aggtctcaac ggcttcccta accaccctc ttctcttgg ccagcctgt tccccca 4500
tccactcccc tctactctc ctaggactg gctgatgaag gcactgcca aaatttccc 4560

```

tacccccaac	tttccctac	ccccaacttt	ccccaccagc	tccacaaccc	tgtttgagc	4620
tactgcagga	ccagaagcac	aaagtgcggg	ttcccaagcc	tttgtccatc	tcagccccc	4680
gagtatatct	gtgcttggg	aatctcacac	agaaactcag	gagcaccccc	tgcttgagct	4740
aagggaggtc	ttatctctca	gggggggttt	aagtgcggtt	tgcaataatg	tcgtcttatt	4800
tatttagcgg	ggtgaatatt	ttatactgta	agtgagcaat	cagagtataa	tgtttatggg	4860
gacaaaatta	aaggctttct	tatatgttta	aaaa			4894

<210> 624

<211> 2904

<212> DNA

<213> Homo sapiens

<400> 624

gtctatgcct	tcatgatcag	tcttgggggc	tgcttgggct	acctcctgcc	tgccattgac	60
tgggacacca	gtgccctggc	ccctacctg	ggcaccacag	aggagtgcct	ctttggcctg	120
ctcacctca	tcttccctac	ctgcgtagca	gccacactgc	tggtggctga	ggaggcagcg	180
ctgggcccga	cagaccagc	agaagggtcg	tcggccccc	ccttgctgcc	ccactgctgt	240
ccatgcggg	cccgttggc	ttccgggaac	ctgggcggcc	tgcttccccg	gctgcaccag	300
ctgtgctgcc	gcatgccccg	caccctgcgc	cggctcttcg	tggtgagct	gtgcagctgg	360
atggcactca	tgaccttcac	gctgttttac	acggatttcg	tgggcgaggg	gctgtaccag	420
ggcgtgcccc	gagctgagcc	gggcaccgag	gcccggagac	actatgatga	aggaaggcct	480
ctgggtgctc	taggagtctg	atcagagtcg	ttgccccagt	ttgacagaag	gaaaggcgga	540
gcttattcaa	agtctagagg	gagtggagga	gttaaggctg	gatttcagat	ctgcctggtt	600
ccagccgcag	tgtgccctct	gctcccccaa	cgactttcca	aataatctca	ccagcgccct	660
ccagctcagg	cgtcctagaa	gcgtcttgaa	gcctatggcc	agctgtcttt	gtgttccctc	720
tcacccgcct	gtcctcacag	ctgagactcc	caggaaacct	tcagactacc	ttcctctgcc	780
ttcagcaagg	ggcgttgccc	acattctctg	agggcgcttc	gatgggcagc	ctggggctgt	840
tctgcagtg	cgccatctcc	ctggtcttct	ctctggtcat	ggaccggctg	gtgcagcgat	900
tcggcactcg	agcagtctat	ttggccagtg	tggcagcttt	ccctgtggct	gccggtgcca	960
catgcctgtc	ccacagtgtg	gccgtggtga	cagcttcagc	cgccctcacc	gggttcacct	1020
tctcagccct	gcagatccct	ccctacacac	tgccctccct	ctaccaccgg	gagaagcagg	1080
tggtctcgcc	caaataccga	ggggacactg	gaggtgctag	cagtgaggac	agcctgatga	1140
ccagcttcct	gccaggecct	aagcctggag	ctcccttccc	taatggacac	gtgggtgctg	1200
gaggcagtg	cctgctccca	cctccacccg	cgtctgcgg	ggcctctgcc	tgtgatgtct	1260
ccgtacgtgt	ggtggtgggt	gagcccaacc	aggccagggt	ggttccgggc	cggggcactct	1320
gcttggaacct	cgccatccct	gatagtgcct	tcctgctgtc	ccaggtggcc	ccatccctgt	1380
ttatgggctc	cattgtccag	ctcagccagt	ctgtcactgc	ctatatgggt	tctgccgcag	1440
gcctgggtct	ggtcgccatt	tactttgcta	cacaggtagt	atttgacaag	agcgacttgg	1500
ccaaatactc	agcgtagaaa	acttccagca	cattgggggt	gagggcctgc	ctcactgggt	1560
ccagctccc	cgctcctgtt	agccccatgg	ggctgcccgg	ctggccgcga	gtttctgttg	1620
ctgccaaaagt	aatgtggctc	tctgctgcca	ccctgtgctg	ctgaggtgcg	tagctgcaca	1680
gctgggggct	ggggcgctcc	tctcctctct	ccccagctct	tagggctgcc	tgactggagg	1740
ccttccaagg	gggtttcagt	ctggacttat	acagggaggg	cagaagggct	ccatgcactg	1800
gaatgcgggg	actctgcagg	tggattaccc	aggctcaggg	ttaacagcta	gcctcctagt	1860
tgagacacac	ctagagaagg	gtttttggga	gctgaataaa	ctcagtcacc	tggtttccca	1920
tctctaagcc	ccttaacctg	cagcttcggt	taatgtagct	cttgcatggg	agtttctagg	1980
atgaaacact	cctccatggg	atgtgaacat	atgaaagtta	tttgtagggg	aagagtccct	2040
aggggcaaca	cacaagaacc	aggtcccctc	agccacagc	actgtctttt	tgctgatcca	2100
ccccctctt	acctttttatc	aggatgtggc	ctggtgggtc	ttctgttgcc	atcacagaga	2160
cacaggcatt	taaatattta	acttatttat	ttacaaaagt	agaagggaat	ccattgctag	2220
cttttctgtg	ttggtgtcta	atatttgggt	agggtggggg	atccccaca	atcaggtccc	2280
ctgagatagc	tggtcattgg	gctgatcatt	gccagaatct	tcttctcctg	gggtctggcc	2340
ccccaaaatg	cctaaccacg	gaccttggaa	attctactca	tccaaaatga	taattccaaa	2400
tgctgttacc	caagggttagg	gtgttgaagg	aaggtagagg	gtggggcttc	aggtctcaac	2460
ggcttcccta	accacccctc	ttctcttggc	ccagcctggt	tccccccact	tccactcccc	2520
tctactctct	ctaggactgg	gctgatgaag	gcaactgcca	aaatttcccc	tacccccaac	2580
tttccctac	cccccaacttt	ccccaccagc	tccacaaccc	tgtttgagc	tactgcagga	2640

```

ccagaagcac aaagtgcggt ttcccaagcc tttgtccatc tcagcccccag gagtatatct 2700
gtgcttgggg aatctcacac agaaactcag gagcaccccc tgccctgagct aagggaggtc 2760
ttatctctca gggggggttt aagtgccgtt tgcaataatg tcgtcttatt tatttagcgg 2820
ggtgaatatt ttatactgta agtgagcaat cagagtataa tgtttatggt gacaaaatta 2880
aaggctttct tatatgttta aaaa 2904

```

<210> 625

<211> 4034

<212> DNA

<213> Homo sapiens

<400> 625

```

aaccagcctg cagcgctgg ctccgggtga cagccgcgcg cctcggccag gatctgagtg 60
atgagacgtg tccccactga ggtgccccac agcagcaggt gttgagcatg ggctgagaag 120
ctggaccggc accaaagggc tggcagaaat gggcgccctg ctgattccta ggcagttggc 180
ggcagcaagg aggagaggcc gcagcttctg gagcagagcc gagacgaagc agttctggag 240
tgccctgaacg gccccctgag ccctaccgcc ctggcccaact atgggtccaga ggctgtgggt 300
gagccgcctg ctgcggcacc ggaaagccca gctcttgctg gtcaacctgc taacctttgg 360
cctggagggtg tgtttggccg caggcatcac ctatgtgccg cctctgctgc tgggaagtggg 420
ggtagaggag aagttcatga ccatgggtct gggcattggt ccagtgtctg gcctggtctg 480
tgtcccgctc ctaggctcag ccagtgaaca ctggcgtgga cgctatggcc gccgcccggc 540
cttcatctgg gcactgtcct tgggcatcct gctgagcctc tttctcatcc caagggccgg 600
ctggctagca gggctgctgt gcccgatcc cagggccctg gagctggcac tgctcatcct 660
gggcgtgggg ctgctggact tctgtggcca ggtgtgcttc actccactgg aggcctgct 720
ctctgacctc ttccgggacc cggaccactg tcgccaggcc tactctgtct atgccttcac 780
gatcagtctt gggggtgcc tgggctacct cctgctgcc attgactggg acaccagtgc 840
cctggccccc tacctgggca ccaggagga gtgcctcttt ggctgtctca ccctcatctt 900
cctcacctgc gttagacca cactgctggt ggctgaggag gcagcgtgg gccccaccga 960
gccagcagaa gggctgtcgg cccctcctt ttgcgccac tgctgtccat gccggggccg 1020
cttggctttc cggaacctgg gcgcctgct tccccggctg caccagctgt gctgccgcat 1080
gcccgcacc ctgcccggc tctctgtggc tgagctgtgc agctggatgg cactcatgac 1140
cttcacgctg ttttacaagg atttctggg cgaggggctg taccaggggc tgcccagagc 1200
tgagccgggc accgaggccc ggagacacta tgatgaaggt aaggccttgg cagccagcag 1260
aggctggtgt gggagccgcc caccagagac gacactcggg gctgtgtctg ggctggtgcc 1320
tctccatcct ggcgccgact tctctgtcag gaaagtgggg atggaccca tctgcataca 1380
cggcttctca tgggtgtgga acatctctgc ttgcggtttc aggaaggcct ctggtgctc 1440
taggagtctg atcagagtgc ttgccccagt ttgacagaag gaaaggcgga gcttattcaa 1500
agtctagagg gagtggagga gtttaaggctg gatttcagat ctgcctggtt ccagccgcag 1560
tgtgccctct gctcccccaa cgactttcca aataatctca ccagcgcctt ccagctcagg 1620
cgtcctagaa gcgtcttgaa gcctatggcc agctgtcttt gtgttccctc tcaccgcct 1680
gtcctcacag ctgagactcc caggaaacct tcagactacc ttctctgcc ttcagcaagg 1740
ggcgttgccc acattctctg aggtcagtg gaagaaccta gactccatt gctagaggta 1800
gaaaggggaa ggtgctggg gagcagggt ggtccacagc aggtctctg cagcaggtag 1860
ctgtggttcc gccttctcat ctccctgaga ctgctccgac ccttccctcc caggctctgt 1920
ctgatggccc ctctccctct gcaggcgttc ggatgggcag cctggggctg ttctgcaagt 1980
gcgccatctc cctggtcttc tctctggtca tggaccggct ggtgcagcga ttccggcactc 2040
gagcagctca tttggccagt gtggcagctt tccctgtggc tgccggtgcc acatgcctgt 2100
cccacagtgt ggccgtggtg acagcttcag ccgcctcac cgggttcacc ttctcagccc 2160
tgcagatcct gccctacaca ctggcctccc tctaccaccg ggagaagcag gtgttctctg 2220
ccaaataccg aggggacact ggaggtgcta gcagtgagga cagcctgatg accagcttcc 2280
tgccaggccc taagcctgga gctcccttcc ctaatggaca cgtgggtgct ggaggcagt 2340
gcctgctccc acctccaccc gcgctctgcg gggcctctgc ctgtgatgtc tccgtacgtg 2400
tgggtggtgg tgagccacc gaggccaggg tggttccggg ccggggcacc tgccaggacc 2460
togccatcct ggatagtgcc ttctgctgt cccagggtgg cccatccctg tttatgggct 2520
ccattgtcca gctcagccag tctgtcactg cctatatggt gtctgcgca ggctgggtc 2580
tggtcgccat ttactttgct acacaggtag tatttgacaa gagcgacttg gccaaatact 2640
cagcgtagaa aacttcacg acattggggt ggagggcctg cctcactggg tcccagctcc 2700

```



```

ccgtctctgt tagcccatg gggctgccc gctggccgcc agtttctgtt gctgccaag 2760
taatgtggct ctctgctgcc accctgtgct gctgaggtgc gtagctgcac agctgggggc 2820
tggggcgtcc ctctcctctc tccccagtct ctagggtgc ctgactggag gccttccaag 2880
ggggtttcag tctggactta tacagggagg ccagaagggc tccatgcaact ggaatgctgg 2940
gactctgcag gtggattacc caggctcagg gttaacagct agcctcctag ttgagacaca 3000
cctagagaag ggtttttggg agctgaataa actcagtcac ctggtttccc atctctaagc 3060
cccttaacct gcagotctgt ttaatgtagc tcttgcatgg gagtttctag gatgaaacac 3120
tctccatgg gatttgaaca tatgaaagtt atttgtaggg gaagagtcct gaggggcaac 3180
acacaagaac caggctccct cagcccacag cactgtcttt ttgctgatcc accccctct 3240
taccttttat caggatgtgc ctgttggtcc ttctgttgcc atcacagaga cacaggcatt 3300
taaataattta acttatttat ttaacaaagt agaagggaat ccattgctag cttttctgtg 3360
ttggtgtcta atatttgggt aggggtgggg atccccaaca atcagggtccc ctgagatagc 3420
tggtcattgg gctgatcatt gccagaatct tcttctctct gggctctggc ccccaaatg 3480
cctaaccag gaccttgaa attctactca tcccaaatga taattccaaa tgctgttacc 3540
caagggttagg gtgttgaagg aaggtagagg gtggggcttc aggtctcaac ggcttcccta 3600
accacccctc ttctcttggc ccagcctggt tcccccaact tccactcccc tctactctct 3660
ctaggactgg gctgatgaag gactgccc aaatttcccc taccocaac ttccccctac 3720
ccccaacttt ccccaccagc tccacaaccc tgtttggagc tactgcagga ccagaagcac 3780
aaagtgcggt ttcccaagcc tttgtccatc tcagccccc gagtatact gtgcttgggg 3840
aatctcacac agaaactcag gagcaccccc tgctgagct aaggagggtc ttatctctca 3900
gggggggttt aagtgcggt tgcaataat tgcgtctatt tatttagcgg ggtgaatatt 3960
ttatactgta agtgagcaat cagagtataa tgtttatggt gacaaaatta aaggctttct 4020
tatatgttta aaaa 4034

```

<210> 626

<211> 6976

<212> DNA

<213> Homo sapiens

<400> 626

```

gaagctggac cggcacaaaa gggctggcag aaatgggcgc ctggctgatt cctaggcagt 60
tgccggcagc aaggaggaga ggccgcagct tctggagcag agccgagacg aagcagttct 120
ggagtgcctg aacggccccc tgagccctac ccgcctggcc cactatggtc cagaggctgt 180
gggtgagccg cctgctgcgg caccggaaag ccagctctt gctggtcaac ctgctaacct 240
ttggcctgga ggtgtgtttg gccgcaggca tcacctatgt gccgcctctg ctgctggaag 300
tgggggtaga ggagaagttc atgaccatgg tgctgggtga gtcaactacat cctccttctc 360
tctgttcca gatacatgcc acctggcatg tgggacagga gtacctctgc cctgggagct 420
gcttggaggg agaggtggtc tgctgggaag gcattgctgg gcaggagggt gaccctgggc 480
tgagggggga caccaagaga aagaagagaa taccaaggac atacccagc cactctgga 540
tccctggtcc tgacacagagc ctggctcata ggagacactg gagaaatgct cctaaccctt 600
ggctagccct tttataattt atagcgatta tctcatttaa tgcttacaac caccatttga 660
ggtgatccat ttacagaga aggaagcaga ggcttttaag aggttaggta agtcttagcc 720
aaagccaaat agcagctgaa cagtagagct gggactccat caaggctctc cagccggagc 780
ttgctcctac ccctaggaca aggggtggac tctgactct gcagataaat tctacaaaag 840
ccacagaagg caagtagtaa ccattgtgtg acaacccctc acccccagga agagggggccc 900
ctgtgaggat tgcaggctct ggagtcacac tgcttgttga aacgctgcct cttaccctcc 960
ctaggtctgc gcctttgaat aagtatcact tmttagttgc tccatgcctc agtttgtcca 1020
tctgaaaatg ggggcactct taatgcctgt gttatgagga gtaaattaca gcatccctgt 1080
gaagacgtag cacagtgtcg agtacggaat gttatttcca tcttctcac ggagcttgg 1140
tccccctccc cttgcccttt acttgtccca gccattgact catactactt cccttcttgc 1200
aggcattggt ccagtgtctg gcctggctct tgctccgctc ctaggctcag ccagtacca 1260
ctggcgtgga cgtatggcc gccgcggcc ctctcatctg gcactgtcct tgggcatcct 1320
gctgagcctc tttctcatcc caagggccgg ctggctagca gggctgctgt gcccgatcc 1380
caggccctc gagctggcac tgctcatcct gggcgtgggg ctgctggact tctgtggcca 1440
ggtgtgcttc actccactgg aggcctgtc ctctgacctc ttccgggacc cggaccactg 1500
tcgccaggcc tactctgtct atgcctcat gatcagctt gggggtgcc tgggctacct 1560
cctgctgccc attgactggg acaccagtgc cctggccccc tacctgggca cccaggagga 1620

```

gtgcctcttt	ggcctgctca	ccctcatctt	cctcacctgc	gtagcagcca	cactgctggt	1680
ggctgaggag	gcagcgctgg	gccccaccga	gccagcagaa	gggctgtogg	ccccctcctt	1740
gtcgccccac	tgtgtgccat	gcggggcccg	cttggtcttc	cggaacctgg	gcgcctgtgt	1800
tccccggctg	caccagctgt	gctgccgcat	gccccgcacc	ctgcgcgggc	tcttcgtggc	1860
tgagctgtgc	agctggatgg	cactcatgac	cttcacgctg	ttttacacgg	atttcgtggg	1920
cgaggggctg	taccagggcg	tgcccagagc	tgagccgggc	accgaggccc	ggagaccata	1980
tgatgaaggt	aaggccttgg	cagccagcag	aggctggtgt	gggagccgcc	caccagagac	2040
gacactcggg	gctgtgtctg	ggctggtgcc	tctccatcct	ggccccgact	tctctgtcag	2100
gaaagtgggg	atggacccca	tctgcataca	cggcttctca	tgggtgtgga	acatctctgc	2160
ttgcggtttc	aggaaggcct	ctggctgtct	taggagtctg	atcagagtcg	ttgccccagt	2220
ttgacagaag	gaaaggcgga	gcttattcaa	agtctagagg	gagtggagga	gttaaggctg	2280
gatttcagat	ctgcctgggt	ccagccgcag	tgtgccctct	gctcccccaa	cgactttcca	2340
aataatctca	ccagcgccct	ccagctcagg	cgctcttaga	gcgtcttgaa	gcctatggcc	2400
agctgtcttt	gtgttccctc	tcacccgcct	gtcctcacag	ctgagactcc	caggaaacct	2460
tcagactacc	ttcctctgcc	ttcagcaagg	ggcgttgccc	acattctctg	agggtcagtg	2520
gaagaacctt	gactccattt	gctagaggta	gaaaggggaa	gggtgctggg	gagcagggct	2580
ggtccacagc	aggtctcgtg	cagcaggtac	ctgtggttcc	gccttctcat	ctccctgaga	2640
ctgctccgac	ccttccctcc	caggtctctg	ctgatggccc	ctctccctct	gcaggcgttc	2700
ggatgggcag	cctggggctg	ttcctgcagt	gcgccatctc	cctggtcttc	tctctggtca	2760
tggaccgggt	ggtgcagcga	ttcggcactc	gagcagctta	tttggccagt	gtggcagctt	2820
tccctgtggc	tgccgggtgc	acatgcctgt	cccacagtgt	ggccgtgggtg	acagcttcag	2880
ccgccctcac	cgggttcacc	ttctcagccc	tgcagatcct	gccctacaca	ctggcctccc	2940
tctaccaccg	ggagaagcag	gtactcattg	gccagtgggt	ggagtccagg	tgggaggggt	3000
ggtctgggtt	tttgggaggc	caactagctc	agaacctggt	atctggcaag	caactttgga	3060
gaatgcttct	ttgaatcaga	gaagaagcct	atcctagccc	cagggccaga	ggcttgggct	3120
gcagaacagt	gtagattaga	ttctgggaat	gacttcctgg	ggtcaggact	gtgtagcact	3180
tgaatggatg	attgcaggaa	atgcaaaata	cgatagtggg	aatcccgaag	ggtcaggcca	3240
gcaggagccc	taggtctcta	ggctggttgt	tctatggaga	ggcagggcgc	tgaatcagat	3300
gacccctggg	ccatttcagc	tcagcagacg	ggagtgggaa	tggtecagcc	ttagcaacac	3360
ctttcttcag	ggagcagcaa	cctgacttag	cctgtatcct	actctggtct	ctgagatggg	3420
gcaggctcct	tcctaccccc	tttctttctg	gcttattttt	cttttctgtc	taattccctt	3480
ttcttttctt	gcctccctcc	tttgccctct	tccttttctc	cttcccttcc	cccttccctt	3540
gtggcagata	tctgagcttg	acacctgacc	cactcacttg	ggcactgtgt	aagttgtggg	3600
gacctccttc	ttggttggcc	ctacactaac	cagccctctc	aggggcccct	ttccttggga	3660
agccacctaa	cccaggtagt	gtggtcatcc	ttgtccctcc	cactgacctc	actgagctac	3720
aaacctgggt	gctggactct	gccttgaggg	gcatgaagtt	ggggtgtccc	aaggaggagg	3780
gagatgcagg	actgctctca	tagagctctc	agactgtagg	gaagacctgc	ccctgcgtct	3840
cgtagcactt	gaggagagga	gtaggttaagt	tcgtagctga	gaggctggtt	aactgagtag	3900
gtagctgcag	gggtgagagg	tatggagggg	aggggctaag	gttttggttg	ggggagcctg	3960
gtccctgaga	cccctgttag	ccactgata	accttcttca	gccttcactc	ttctgcttgc	4020
ctgggctggg	ggcagggggc	tggcatcagc	ggccaggcct	gagtatgtgc	tgtcgtgcca	4080
gggaacgttc	tggggctagc	catcttctcc	agatggagga	gcattgtctgt	cctcggacca	4140
ctccagactc	caacctcagc	ggacattcct	ggggtggcag	gcagggagga	gaagtccctg	4200
gaggccccct	cctaacagca	gctgatggca	gacttggcac	tgcacgctgt	ctgcctgttc	4260
ctttgcccac	ttgttgagct	gcatggtgag	ccgtgggctt	ccctggtgtc	aggtttgagc	4320
tctgccatgg	ctcccacctc	gcaaatgcag	ccaactcaac	tcttctggca	tggggacaat	4380
gttgataaag	acctggcctt	gtccttaaat	aggaggctct	gggccatcaa	gggcaggggt	4440
tggggggatg	gtggtcgacc	agtcactctg	atctaagtca	gacagcagga	aggaagttag	4500
aagccttcaa	cattagcaca	gctggggctg	ggggaggtgg	gaagagggac	attcctcctg	4560
cttggggctt	actggattct	ccctgccccca	aggctgggga	caagggagct	catggcaggg	4620
cagctaccct	agtggcatct	gggaccccag	agaggcagag	cttctctgca	cggggcaatg	4680
aggatttcca	gatgtcggag	tggaggcgag	gcaggaagga	aggttaggag	agcctgcgtg	4740
gggtttgggc	catcaggggc	cctgccttgg	cttttgttcc	tctgttctgt	gcatctctta	4800
ccacgctctt	cattccccct	gtgtcttttc	cttaccttgg	agctctgttc	tctctgatct	4860
gtgatattga	gtttgtctgc	ctcttacctg	ttctaagagg	ctagaggaga	cctagacttc	4920
tgggttcaca	tttgtccccg	ccctaccccc	ttacccttct	cccactcctg	aggaagggtc	4980
ctggttagac	ttggaccaag	tagggctctcc	atcttctctc	ctgctcctga	ttctcatgaa	5040
gtcccatatg	ccctgggatg	gaggcaaggg	tctgtttctca	cagctggggt	ggtgccagtg	5100

```

ctgggtacac acctgtcctc ttccctttt cttcaccct ctgccttagg tgttcctgcc 5160
caaataccga ggggacactg gaggtgctag cagtgaggac agcctgatga ccagcttcct 5220
gccaggccct aagcctggag ctcccttccc taatggacac gtgggtgctg gaggcagtg 5280
cctgtcctca cctccaccgg cgctctgcgg ggctctgcc tgtgatgtct ccgtacgtgt 5340
ggtggtgggt gagccaccg aggccagggt ggttcggggc cggggcatct gcctggacct 5400
cgccatcctg gatagtgcct tctgtctgtc ccagggtggc ccatccctgt ttatgggctc 5460
cattgtccag ctcagccagt ctgtcactgc ctatatggtg tctgccgcag gcctgggtct 5520
ggtcgccatt tactttgcta cacaggtagt atttgacaag agcgacttgg ccaaatactc 5580
agcgtagaaa acttccagca cattgggggt gagggcctgc ctactgggt cccagctccc 5640
cgctcctggt agcccccagg ggctgccggg ctggccgcca gtttctgttg ctgccaaagt 5700
aatgtggctc tctgtgccca cctgtgctg ctgaggtgcg tagctgcaca gctgggggct 5760
ggggcgctcc tctcctctct ccccagtctc tagggctgcc tgactggagg ccttccaagg 5820
gggtttcagt ctggacttat acagggaggg cagaagggt ccatgcactg gaatgcgggg 5880
actctgcagg tggattaccc aggtcaggg ttaacagcta gcctcctagt tgagacacac 5940
ctagagaagg gtttttgga gctgaataaa ctcagtcacc tggtttccca tctctaagcc 6000
ccttaacctg cagcttcggt taatgtagct cttgcatggg agtttctagg atgaaacact 6060
cctccatggg atttgaacat atgaaagtta ttgtagggg aagagtcctg aggggcaaca 6120
cacaagaacc aggtcccctc agcccacagc actgtctttt tgctgatcca ccccccctct 6180
accttttatc aggatgtggc ctgttggtcc ttctgttgcc atcacagaga cacaggcatt 6240
taaataattt acttatttat ttaacaaagt agaagggaat ccattgctag cttttctgtg 6300
ttgggtgtct atatttgggt aggggtgggg atccccaaca atcagggtccc ctgagatagc 6360
tggtcatttg gctgatcatt gccagaatct tcttctcctg gggctctggc ccccaaatg 6420
cctaaccagg gaccttgga attctactca tcccaaatga taattccaaa tgctgttacc 6480
caagggttag gtgttgaagg aaggtagagg gtggggcttc aggtctcaac ggcttcccta 6540
accacccctc ttctcttggc ccagcctggt tcccccact tccactccc tctactctct 6600
ctaggactgg gctgatgaag gcactgccca aaatttcccc taccoccaaac tttccctac 6660
ccccaacttt cccaccagc tccacaaccc tgtttggagc tactgcagga ccagaagcac 6720
aaagtgcggt ttcccaagcc tttgtccatc tcagcccca gagtatact gtgcttgggg 6780
aatctcacac agaaactcag gagcacccc tgctgagct aaggagggtc ttatctctca 6840
gggggggttt aagtgcggt tgcaataatg tctcttatt tatttagcgg ggtgaatatt 6900
ttatactgta agtgagcaat cagagtataa tgtttatggt gacaaaatta aaggctttct 6960
tatatgttta aaaaaa

```

<210> 627

<211> 123

<212> PRT

<213> Homo sapiens

<400> 627

```

Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe
          5                      10                      15

```

```

Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val
          20                      25                      30

```

```

Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys
          35                      40                      45

```

```

Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly
          50                      55                      60

```

```

Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu
          65                      70                      75                      80

```

```

Tyr His Arg Glu Lys Gln Val Leu Ile Gly Gln Trp Val Glu Ser Gly
          85                      90                      95

```

239

Trp Glu Gly Trp Ser Gly Phe Leu Gly Gly Gln Leu Ala Gln Asn Leu
 100 105 110

Val Ser Gly Lys Gln Leu Trp Arg Met Leu Leu
 115 120

<210> 628
 <211> 150
 <212> PRT
 <213> Homo sapiens

<400> 628
 Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
 5 10 15

Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu
 20 25 30

Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val
 35 40 45

Glu Glu Lys Phe Met Thr Met Val Leu Gly Glu Ser Leu His Pro Pro
 50 55 60

Ser Phe Leu Phe Gln Ile His Ala Thr Trp His Val Gly Gln Glu Tyr
 65 70 75 80

Leu Cys Pro Gly Ser Cys Leu Glu Gly Glu Val Val Cys Trp Glu Gly
 85 90 95

Ile Ala Gly Gln Glu Gly Asp Pro Gly Leu Arg Gly His Thr Lys Arg
 100 105 110

Lys Lys Arg Ile Pro Arg Thr Tyr Pro Ser His Leu Trp Ile Pro Gly
 115 120 125

Pro Ala Gln Ser Leu Ala His Arg Arg His Trp Arg Asn Ala Pro Asn
 130 135 140

Leu Trp Leu Ala Leu Leu
 145 150

<210> 629
 <211> 371
 <212> PRT
 <213> Homo sapiens

<400> 629
 Met Leu Phe Pro Ser Phe Ser Arg Ser Leu Val Pro Leu Pro Leu Ala
 5 10 15

Leu Tyr Leu Ser Gln Pro Leu Thr His Thr Thr Ser Leu Leu Ala Gly
 20 25 30

Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser Ala
 35 40 45

240

Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp
 50 55 60
 Ala Leu Ser Leu Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala
 65 70 75 80
 Gly Trp Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu
 85 90 95
 Ala Leu Leu Ile Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val
 100 105 110
 Cys Phe Thr Pro Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro
 115 120 125
 Asp His Cys Arg Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu
 130 135 140
 Gly Gly Cys Leu Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser
 145 150 155 160
 Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu
 165 170 175
 Leu Thr Leu Ile Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala
 180 185 190
 Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala
 195 200 205
 Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe
 210 215 220
 Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg
 225 230 235 240
 Met Pro Arg Thr Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp
 245 250 255
 Met Ala Leu Met Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu
 260 265 270
 Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg
 275 280 285
 Arg His Tyr Asp Glu Gly Lys Ala Leu Ala Ala Ser Arg Gly Trp Cys
 290 295 300
 Gly Ser Arg Pro Pro Glu Thr Thr Leu Gly Ala Val Ser Gly Leu Val
 305 310 315 320
 Pro Leu His Pro Gly Pro Asp Phe Ser Val Arg Lys Val Gly Met Asp
 325 330 335
 Pro Ile Cys Ile His Gly Phe Ser Trp Val Trp Asn Ile Ser Ala Cys
 340 345 350

Gly Phe Arg Lys Ala Ser Gly Cys Ser Arg Ser Leu Ile Arg Val Val
 355 360 365

Ala Pro Val
 370

<210> 630

<211> 2983

<212> DNA

<213> Homo sapiens

<400> 630

```

agagatagag tcttccctgg cattgcagga gagaatctga agggatgatg gatgcatcaa 60
aagagctgca agttctccac attgacttot tgaatcagga caacgocgtt tctcaccaca 120
catgggagtt ccaaacgagc agtccctgtg tccggcgagg acaggtgttt cacctgcggc 180
tggtgctgaa ccagccccta caatccctacc accaactgaa actggaattc agcacagggc 240
cgaatccctag catcgccaaa cacaccctgg tggtgctcga cccgaggacg ccctcagacc 300
actacaactg gcaggcaacc cttcaaaatg agtctggcaa agaggtcaca gtggctgtca 360
ccagttcccc caatgccatc ctgggcaagt accaactaaa cgtgaaaact ggaaaccaca 420
tccttaagtc tgaagaaaac atccctatacc ttctcttcaa cccatggtgt aaagaggaca 480
tggttttcat gcctgatgag gacgagcgca aagagtacat cctcaatgac acgggctgcc 540
attacgtggg ggctgccaga agtatcaaat gcaaacccctg gaactttggt cagtttgaga 600
aaaatgtcct ggactgctgc atttccctgc tgactgagag ctccctcaag cccacagata 660
ggagggaccc cgtgctgggtg tgcagggcca tgtgtgctat gatgagcttt gagaaaggcc 720
agggcgtgct cattgggaat tggactgggg actatgaagg tggcacagcc ccatacaagt 780
ggacaggcag tgccccgatc ctgcagcagt actacaacac gaagcaggct gtgtgctttg 840
gccagtgtct ggtgtttgtc gggatccctga ctacagtgtc gagagcgttg gccatcccag 900
cacgcagtgt gacaggcttc gattcagctc acgacacaga aaggaacctc acggtggaca 960
cctatgtgaa tgagaatggc aagaaaatca ccagtatgac ccacgactct gtctggaatt 1020
tccatgtgtg gacggatgcc tggatgaagc gaccggatct gcccaagggc tacgacggct 1080
ggcaggctgt ggacgcaacg ccgcaggagc gaagccaggg tgtcttctgc tgtgggcat 1140
caccactgac cgctatccgc aaaggtgaca tctttattgt ctatgacacc agattcgtct 1200
tctcagaagt gaatggtgac aggtcatct ggttgggtgaa gatggtgaat gggcaggagg 1260
agttacacgt aatttcaatg gagaccacaa gcatcgggaa aaacatcagc accaaggcag 1320
tgggccaaga caggcggaga gatatacct atgagtacaa gtatccagaa ggctcctctg 1380
aggagaggca ggtcatggat catgccttcc tccttctcag ttctgagagg gagcacagac 1440
gacctgtaaa agagaacttt cttcacatgt cggtaacaat agatgatgtg ctgctgggaa 1500
actctgttaa tttcacctgt attcttaaaa ggaagaccgc tgccctacag aatgtcaaca 1560
tcttgggctc ctttgaacta cagttgtaca ctggcaagaa gatggcaaaa ctgtgtgacc 1620
tcaataagac ctgcagatc caaggtcaag tatcagaagt gactctgacc ttggactcca 1680
agacctacat caacagcctg gctatattag atgatgagcc agttatcaga ggtttcatca 1740
ttgcggaat tgtggagtct aaggaaatca tggcctctga agtattcacg tctttccagt 1800
accctgagtt ctctatagag ttgcctaaca caggcagaat tggccagcta cttgtctgca 1860
attgtatctt caagaatacc ctggccatcc ctttgactga cgtcaagttc tctttggaaa 1920
gcctgggcat ctctcacta cagacctctg accatgggac ggtgcagcct ggtgagacca 1980
tccaatccca aataaaatgc accccaataa aaactggacc caagaaatct atcgtcaagt 2040
taagttccaa acaagtgaag gagattaatg ctccagaagt tgttctcatc accaagtagc 2100
cttgtctgat cgtgtggagc cttagttagc ttctacatt gtgcttagct 2160
ttcagattat ggatgattaa attttagtgc ttatatgagg gcagattcaa gagccagcag 2220
gtcaaaaagg ccaacacac cataagcagc cagaccacaa aggccaggtc ctgtgctatc 2280
acagggtcac ctcttttaca gttagaaaca ccagccgagg ccacagaatc ccatcccttt 2340
cctgagtcac ggcctcaaaa atcagggcca ccattgtctc aattcaaatc catagatttc 2400
gaagccacag agtctctccc tggagcagca gactatgggc agcccagtgc tgccacctgc 2460
tgacgaccct tgagaagctg ccatactctc aggccatggg ttcaccagcc ctgaaggcac 2520
ctgtcaactg gagtgtcttc tcagcactgg gatgggcctg atagaagtgc attctcctcc 2580

```

```

tattgcctcc attctcctct ctctatccct gaaatccagg aagtcctct cctggtgctc 2640
caagcagttt gaagcccaat ctgcaaggac atttctcaag ggccatgtgg ttttgagac 2700
aaccctgtcc tcaggcctga actcaccata gagaccatg tcagcaaacg gtgaccagca 2760
aatcctcttc ccttattcta aagctgcccc ttgggagact ccaggagaaa ggcatgtctt 2820
cctccctggt gtgaactctt tctttggtat tccatccact atcctggcaa ctcaaggctg 2880
cttctgttaa ctgaagcctg ctccttcttg ttctgcctc cagagatttg ctcaaatgat 2940
caataagctt taaattaaac tctacttcaa gaaaaaaaaa ccg 2983

```

<210> 631

<211> 3064

<212> DNA

<213> Homo sapiens

<400> 631

```

aattctaaaa atgcttttgc aagcttgcat gcctgcaggc gcagcgcccg ccagtgtgat 60
ggatatctgc agaattcggc ttgcgctcag ctggaattcc gcagagatag agtcttccct 120
ggcattgcag gagagaatct gaaggatga tggatgcac aaaagagctg caagttctcc 180
acattgactt cttgaatcag gacaaacgag tttctacca cacatgggag ttccaaacga 240
gcagtccgtg gttccggcga ggacagggtt ttcacctgcg gctggtgctg aaccagcccc 300
tacaatccta ccaccaactg aaactggaat tcagcacagg gccgaatcct agcatcgcca 360
aacacaccct ggtggtgctc gaccgagga cgccctcaga ccactacaac tggcaggcaa 420
cccttcaaaa tgagtctggc aaagaggtca cagtggctgt caccagttcc cccaatgcca 480
tcctgggcaa gtaccaacta aacgtgaaaa ctggaaacca catccttaag tctgaagaaa 540
acatcctata ccttctcttc aacctatggt gtaaagagga catggttttc atgctgatg 600
aggacgagcg caaagagtac atcctcaatg acacgggctg ccattacgtg ggggctgcca 660
gaagtatcaa atgcaaaccc tggaaacttg gtcagttaga gaaaaatgtc ctggactgct 720
gcatttccct gctgactgag agtccctca agcccacaga taggagggac cccgtgctgg 780
tgtgcagggc catgtgtgct atgatgagct ttgagaaagg ccaggcgctg ctcatggga 840
attggactgg ggactacgaa ggtggcacag cccatacaa gtggacaggc agtgccccga 900
tcctgcagca gtactacaac acgaagcagg ctgtgtgctt tggccagtgc tgggtgtttg 960
ctgggatcct gactacagtg ctgagagcgt tgggcatccc agcacgcagt gtgacaggct 1020
tcgattcagc tcacgacaca gaaaggaacc tcacggtgga cacctatgtg aatgagaatg 1080
cgcagaaaat caccagtatg acccagcact ctgtctggaa tttccatgtg tggacgggat 1140
cctggatgaa gcgaccctac gacggctggc aggcgtgga cgcaacgcg caggagcgaa 1200
gccagggtgt cttctgctgt gggccatcac cactgaccgc catccgaaa ggtgacatct 1260
ttattgtcta tgacaccaga ttctctctc cagaagtga tgggtgacagg ctcatctggt 1320
tggtagaat ggtgaatggg caggaggagt tacacgtaat ttcaatggag accacaagca 1380
tcgggaaaaa catcagcacc aaggcagtgg gccaaagacag gcggagagat atcacctatg 1440
agtacaagta tccagaaggc tcctctgagg agaggcagg catggtatcat gccttctcc 1500
ttctcagttc tgagagggag cacagacagc ctgtaaaaga gaactttctt cacatgtcgg 1560
tacaatcaga tgatgtgctg ctgggaaact ctgttaattt caccgtgatt cttaaaagga 1620
agaccgctgc cctacagaat gtcaacatct tgggctcctt tgaactacag ttgtacactg 1680
gcaagaagat ggcaaaaactg tgtgacctca ataagacctc gcagatccaa ggtcaagtat 1740
cagaagtga tctgaccttg gactccaaga cctacatcaa cagcctggct atattagatg 1800
atgagccagt tatcagagg ttcatcattg cggaaattgt ggagtctaag gaaatcatgg 1860
cctctgaagt attcaggtca aaccagtacc ctgagttctc tatagagtgt cctaacacag 1920
gcagaattgg ccagctactt gtctgcaatt gtatcttcaa gaataccctg gccatccctt 1980
tgactgacgt caagtctctt ttggaaagcc tgggcatctc ctactacag acctctgacc 2040
atgggacggg gacgctggt gagaccatcc aatcccaaat aaaatgcacc ccaataaaaa 2100
ctggacccaa gaaatttata gtcaagttaa gttccaaaca agtgaaagag attaatgtct 2160
agaagattgt tctcatcacc aagtagcctt gtctgatgct gtggagcctt agttgagatt 2220
tcagcatttc ctaccttggt cttagctttc agattatgga tgattaaatt tgatgactta 2280
tatgagggca gattcaagag ccagcaggtc aaaaaggcca acacaaccat aagcagccag 2340
acccacaagg ccaggtcctg tgctatcaca gggtcacctc ttttacagtt agaaacacca 2400
gccgaggcca cagaatccca tcccttctct gagtcatggc ctcaaaaatc agggccacca 2460
ttgtctcaat tcaaatccat agatttcgaa gccacagagc tcttccctgg agcagcagac 2520
tatgggcagc ccagtgtgc caccgtgtga cgaccctga gaagctgcca tatcttcagg 2580
ccatgggttc accagccctg aaggcacctg tcaactggag tgctctctca gcactgggat 2640

```

```

gggcctgata gaagtgcatt ctctctctat tgcctccatt ctctctctc tatccctgaa 2700
atccaggaag tccctctcct ggtgctccaa gcagtttgaa gcccaatctg caaggacatt 2760
tctcaagggc catgtggttt tgcagacaac cctgtcctca ggctgaaact caccatagag 2820
acccatgtca gcaaacggtg accagcaaatt cctcttcctt tattctaaag ctgccccttg 2880
ggagactoca gggagaaggc attgcttctt ccctgggtgtg aactctttct ttggtattcc 2940
atccactatc ctggcaactc aaggctgctt ctgttaactg aagcctgctc cttcttggtc 3000
tggcctccag agatttgctc aaatgatcaa taagctttaa attaaaccgg aatccgcgga 3060
attc
3064

```

<210> 632

<211> 684

<212> PRT

<213> Homo sapiens

<400> 632

```

Met Met Asp Ala Ser Lys Glu Leu Gln Val Leu His Ile Asp Phe Leu
      5                                10                                15

Asn Gln Asp Asn Ala Val Ser His His Thr Trp Glu Phe Gln Thr Ser
      20                                25                                30

Ser Pro Val Phe Arg Arg Gly Gln Val Phe His Leu Arg Leu Val Leu
      35                                40                                45

Asn Gln Pro Leu Gln Ser Tyr His Gln Leu Lys Leu Glu Phe Ser Thr
      50                                55                                60

Gly Pro Asn Pro Ser Ile Ala Lys His Thr Leu Val Val Leu Asp Pro
      65                                70                                75                                80

Arg Thr Pro Ser Asp His Tyr Asn Trp Gln Ala Thr Leu Gln Asn Glu
      85                                90                                95

Ser Gly Lys Glu Val Thr Val Ala Val Thr Ser Ser Pro Asn Ala Ile
      100                                105                                110

Leu Gly Lys Tyr Gln Leu Asn Val Lys Thr Gly Asn His Ile Leu Lys
      115                                120                                125

Ser Glu Glu Asn Ile Leu Tyr Leu Leu Phe Asn Pro Trp Cys Lys Glu
      130                                135                                140

Asp Met Val Phe Met Pro Asp Glu Asp Glu Arg Lys Glu Tyr Ile Leu
      145                                150                                155                                160

Asn Asp Thr Gly Cys His Tyr Val Gly Ala Ala Arg Ser Ile Lys Cys
      165                                170                                175

Lys Pro Trp Asn Phe Gly Gln Phe Glu Lys Asn Val Leu Asp Cys Cys
      180                                185                                190

Ile Ser Leu Leu Thr Glu Ser Ser Leu Lys Pro Thr Asp Arg Arg Asp
      195                                200                                205

Pro Val Leu Val Cys Arg Ala Met Cys Ala Met Met Ser Phe Glu Lys
      210                                215                                220

Gly Gln Gly Val Leu Ile Gly Asn Trp Thr Gly Asp Tyr Glu Gly Gly

```


244

225		230		235		240
Thr Ala Pro Tyr Lys Trp Thr Gly Ser Ala Pro Ile Leu Gln Gln Tyr	245		250		255	
Tyr Asn Thr Lys Gln Ala Val Cys Phe Gly Gln Cys Trp Val Phe Ala	260		265		270	
Gly Ile Leu Thr Thr Val Leu Arg Ala Leu Gly Ile Pro Ala Arg Ser	275		280		285	
Val Thr Gly Phe Asp Ser Ala His Asp Thr Glu Arg Asn Leu Thr Val	290		295		300	
Asp Thr Tyr Val Asn Glu Asn Gly Lys Lys Ile Thr Ser Met Thr His	305		310		315	320
Asp Ser Val Trp Asn Phe His Val Trp Thr Asp Ala Trp Met Lys Arg	325		330		335	
Pro Asp Leu Pro Lys Gly Tyr Asp Gly Trp Gln Ala Val Asp Ala Thr	340		345		350	
Pro Gln Glu Arg Ser Gln Gly Val Phe Cys Cys Gly Pro Ser Pro Leu	355		360		365	
Thr Ala Ile Arg Lys Gly Asp Ile Phe Ile Val Tyr Asp Thr Arg Phe	370		375		380	
Val Phe Ser Glu Val Asn Gly Asp Arg Leu Ile Trp Leu Val Lys Met	385		390		395	400
Val Asn Gly Gln Glu Glu Leu His Val Ile Ser Met Glu Thr Thr Ser	405		410		415	
Ile Gly Lys Asn Ile Ser Thr Lys Ala Val Gly Gln Asp Arg Arg Arg	420		425		430	
Asp Ile Thr Tyr Glu Tyr Lys Tyr Pro Glu Gly Ser Ser Glu Glu Arg	435		440		445	
Gln Val Met Asp His Ala Phe Leu Leu Leu Ser Ser Glu Arg Glu His	450		455		460	
Arg Arg Pro Val Lys Glu Asn Phe Leu His Met Ser Val Gln Ser Asp	465		470		475	480
Asp Val Leu Leu Gly Asn Ser Val Asn Phe Thr Val Ile Leu Lys Arg	485		490		495	
Lys Thr Ala Ala Leu Gln Asn Val Asn Ile Leu Gly Ser Phe Glu Leu	500		505		510	
Gln Leu Tyr Thr Gly Lys Lys Met Ala Lys Leu Cys Asp Leu Asn Lys	515		520		525	
Thr Ser Gln Ile Gln Gly Gln Val Ser Glu Val Thr Leu Thr Leu Asp	530		535		540	

245

Ser Lys Thr Tyr Ile Asn Ser Leu Ala Ile Leu Asp Asp Glu Pro Val
 545 550 555 560
 Ile Arg Gly Phe Ile Ile Ala Glu Ile Val Glu Ser Lys Glu Ile Met
 565 570 575

Ala Ser Glu Val Phe Thr Ser Phe Gln Tyr Pro Glu Phe Ser Ile Glu
 580 585 590

Leu Pro Asn Thr Gly Arg Ile Gly Gln Leu Leu Val Cys Asn Cys Ile
 595 600 605

Phe Lys Asn Thr Leu Ala Ile Pro Leu Thr Asp Val Lys Phe Ser Leu
 610 615 620

Glu Ser Leu Gly Ile Ser Ser Leu Gln Thr Ser Asp His Gly Thr Val
 625 630 635 640

Gln Pro Gly Glu Thr Ile Gln Ser Gln Ile Lys Cys Thr Pro Ile Lys
 645 650 655

Thr Gly Pro Lys Lys Phe Ile Val Lys Leu Ser Ser Lys Gln Val Lys
 660 665 670

Glu Ile Asn Ala Gln Lys Ile Val Leu Ile Thr Lys
 675 680

<210> 633

<211> 679

<212> PRT

<213> Homo sapiens

<400> 633

Met Met Asp Ala Ser Lys Glu Leu Gln Val Leu His Ile Asp Phe Leu
 5 10 15

Asn Gln Asp Asn Ala Val Ser His His Thr Trp Glu Phe Gln Thr Ser
 20 25 30

Ser Pro Val Phe Arg Arg Gly Gln Val Phe His Leu Arg Leu Val Leu
 35 40 45

Asn Gln Pro Leu Gln Ser Tyr His Gln Leu Lys Leu Glu Phe Ser Thr
 50 55 60

Gly Pro Asn Pro Ser Ile Ala Lys His Thr Leu Val Val Leu Asp Pro
 65 70 75 80

Arg Thr Pro Ser Asp His Tyr Asn Trp Gln Ala Thr Leu Gln Asn Glu
 85 90 95

Ser Gly Lys Glu Val Thr Val Ala Val Thr Ser Ser Pro Asn Ala Ile
 100 105 110

Leu Gly Lys Tyr Gln Leu Asn Val Lys Thr Gly Asn His Ile Leu Lys
 115 120 125

Ser Glu Glu Asn Ile Leu Tyr Leu Leu Phe Asn Pro Trp Cys Lys Glu
 130 135 140
 Asp Met Val Phe Met Pro Asp Glu Asp Glu Arg Lys Glu Tyr Ile Leu
 145 150 155 160
 Asn Asp Thr Gly Cys His Tyr Val Gly Ala Ala Arg Ser Ile Lys Cys
 165 170 175
 Lys Pro Trp Asn Phe Gly Gln Phe Glu Lys Asn Val Leu Asp Cys Cys
 180 185 190
 Ile Ser Leu Leu Thr Glu Ser Ser Leu Lys Pro Thr Asp Arg Arg Asp
 195 200 205
 Pro Val Leu Val Cys Arg Ala Met Cys Ala Met Met Ser Phe Glu Lys
 210 215 220
 Gly Gln Gly Val Leu Ile Gly Asn Trp Thr Gly Asp Tyr Glu Gly Gly
 225 230 235 240
 Thr Ala Pro Tyr Lys Trp Thr Gly Ser Ala Pro Ile Leu Gln Gln Tyr
 245 250 255
 Tyr Asn Thr Lys Gln Ala Val Cys Phe Gly Gln Cys Trp Val Phe Ala
 260 265 270
 Gly Ile Leu Thr Thr Val Leu Arg Ala Leu Gly Ile Pro Ala Arg Ser
 275 280 285
 Val Thr Gly Phe Asp Ser Ala His Asp Thr Glu Arg Asn Leu Thr Val
 290 295 300
 Asp Thr Tyr Val Asn Glu Asn Gly Glu Lys Ile Thr Ser Met Thr His
 305 310 315 320
 Asp Ser Val Trp Asn Phe His Val Trp Thr Asp Ala Trp Met Lys Arg
 325 330 335
 Pro Tyr Asp Gly Trp Gln Ala Val Asp Ala Thr Pro Gln Glu Arg Ser
 340 345 350
 Gln Gly Val Phe Cys Cys Gly Pro Ser Pro Leu Thr Ala Ile Arg Lys
 355 360 365
 Gly Asp Ile Phe Ile Val Tyr Asp Thr Arg Phe Val Phe Ser Glu Val
 370 375 380
 Asn Gly Asp Arg Leu Ile Trp Leu Val Lys Met Val Asn Gly Gln Glu
 385 390 395 400
 Glu Leu His Val Ile Ser Met Glu Thr Thr Ser Ile Gly Lys Asn Ile
 405 410 415
 Ser Thr Lys Ala Val Gly Gln Asp Arg Arg Arg Asp Ile Thr Tyr Glu
 420 425 430
 Tyr Lys Tyr Pro Glu Gly Ser Ser Glu Glu Arg Gln Val Met Asp His

247

435	440	445
Ala Phe Leu Leu Leu Ser Ser Glu Arg Glu His Arg Gln Pro Val Lys		
450	455	460
Glu Asn Phe Leu His Met Ser Val Gln Ser Asp Asp Val Leu Leu Gly		
465	470	475
Asn Ser Val Asn Phe Thr Val Ile Leu Lys Arg Lys Thr Ala Ala Leu		
	485	490
Gln Asn Val Asn Ile Leu Gly Ser Phe Glu Leu Gln Leu Tyr Thr Gly		
	500	510
Lys Lys Met Ala Lys Leu Cys Asp Leu Asn Lys Thr Ser Gln Ile Gln		
	515	520
Gly Gln Val Ser Glu Val Thr Leu Thr Leu Asp Ser Lys Thr Tyr Ile		
	530	540
Asn Ser Leu Ala Ile Leu Asp Asp Glu Pro Val Ile Arg Gly Phe Ile		
545	550	555
Ile Ala Glu Ile Val Glu Ser Lys Glu Ile Met Ala Ser Glu Val Phe		
	565	570
Thr Ser Asn Gln Tyr Pro Glu Phe Ser Ile Glu Leu Pro Asn Thr Gly		
	580	585
Arg Ile Gly Gln Leu Leu Val Cys Asn Cys Ile Phe Lys Asn Thr Leu		
	595	600
Ala Ile Pro Leu Thr Asp Val Lys Phe Ser Leu Glu Ser Leu Gly Ile		
	610	615
Ser Ser Leu Gln Thr Ser Asp His Gly Thr Val Gln Pro Gly Glu Thr		
625	630	635
Ile Gln Ser Gln Ile Lys Cys Thr Pro Ile Lys Thr Gly Pro Lys Lys		
	645	650
Phe Ile Val Lys Leu Ser Ser Lys Gln Val Lys Glu Ile Asn Ala Gln		
	660	665
Lys Ile Val Leu Ile Thr Lys		
	675	

<210> 634

<211> 5668

<212> DNA

<213> Homo sapiens

<400> 634

gtcacttagg aaaaggtgtc ctttcgggca gccgggctca gcatgaggaa cagaaggaat 60
gacactctgg acagcaccgg gacctgtac tccagcgcgt ctcggagcac agacttgtct 120
tacagtgaag gcgacttggt gaattttatt caagcaaatt ttaagaaacg agaatgtgtc 180

ttctttacca	aagattccaa	ggccacggag	aatgtgtgca	agtgtggcta	tgcccagagc	240
cagcacatgg	aaggcacc	gatcaaccaa	agtgagaaat	ggaactacaa	gaaacacacc	300
aaggaatttc	ctaccgacgc	ctttggggat	attcagtttg	agacactggg	gaagaaaggg	360
aagtatatac	gtctgtcctg	cgacacggac	gcggaaatcc	tttacgagct	gctgacccag	420
cactggcacc	tgaaaacacc	caacctggtc	atttctgtga	ccgggggccc	caagaacttc	480
gccctgaagc	cgcgcatgcg	caagatcttc	agccggctca	tctacatcgc	gcagtccaaa	540
ggtgcttgga	ttctcacggg	aggcaccat	tatggcctga	cgaagtacat	cggggaggtg	600
gtgagagata	acaccatcag	caggagtcca	gaggagaata	ttgtggccat	tggtcatagca	660
gcttggggca	tggtctccaa	ccgggacacc	ctcatcagga	attgcatgac	tgagggttat	720
tttttagccc	agtaccttat	ggatgacttc	acaagggatc	cactgtatat	cctggacaac	780
aaccacacac	atttgcctgt	cgtagacaat	ggctgtcatg	gacatccac	tgctgaagca	840
aagctccgga	atcagctaga	gaagcatatc	tctgagcgca	ctattcaaga	ttccaactat	900
ggtggcaaga	tccccattgt	gtgttttgcc	caaggaggtg	gaaaagagac	tttgaaagcc	960
atcaatacct	ccatcaaaaa	taaaattcct	tgtgtgggtg	tggaaggctc	gggccggatc	1020
gctgatgtga	tcgctagcct	ggtggaggtg	gaggatgccc	cgacatcttc	tgccgtcaag	1080
gagaagctgg	tgcgcttttt	accccgacag	gtgtcccggc	tgtctgagga	ggagactgag	1140
agttggatca	aatggctcaa	agaaattctc	gaatgttctc	acctattaac	agttattaaa	1200
atggaagaag	ctggggatga	aattgtgagc	aatgccatct	cctacgctct	atacaagcc	1260
ttcagcacca	gtgagcaaga	caaggataac	tggaaatggc	agctgaagct	tctgctggag	1320
tggaaaccagc	tggacttagc	caatgatgag	attttcacca	atgaccgccg	atgggagtct	1380
gctgaccttc	aagaagtcat	gtttacggct	ctcataaagg	acagacccaa	gtttgtccgc	1440
ctctttctgg	agaatggctt	gaacctacgg	aagtttctca	cccatgatgt	cctcactgaa	1500
ctcttctcca	accacttcag	cacgcttgtg	taccggaatc	tgcagatcgc	caagaattcc	1560
tataatgatg	ccctcctcac	gtttgtctgg	aaactggttg	cgaacttcog	aagaggcttc	1620
cggaaaggaag	acagaaatgg	ccgggacgag	atggacatag	aactccacga	cgtgtctcct	1680
attactcggc	accccttgca	agctctcttc	atctgggcca	ttcttcagaa	taagaaggaa	1740
ctctccaaag	tcatttggga	gcagaccagg	ggctgcaactc	tggcagccct	gggagccagc	1800
aagcttctga	agactctggc	caaagtgaag	aacgacatca	atgctgctgg	ggagtccgag	1860
gagctggcta	atgagtagca	gacccgggct	gttgagctgt	tactgagtg	ttacagcagc	1920
gatgaagact	tggcagaaca	gctgctggtc	tattcctgtg	aagcttgggg	tggaaagcaac	1980
tgtctggagc	tggcgggtga	ggccacagac	cagcatttca	ccgcccagcc	tgggggtccag	2040
aattttcttt	ctaagcaatg	gtatggagag	atttcccag	acaccaagaa	ctggaagatt	2100
atcctgtgtc	tggttattat	acccttggtg	ggctgtggct	ttgtatcatt	taggaagaaa	2160
cctgtcgaca	agcaacaaga	gctgcttgg	tactatgtgg	cgttcttcac	ctccccctc	2220
gtggtcttct	cctggaatgt	ggtcttctac	atcgcttcc	tcctgctgtt	tgcctacgtg	2280
ctgctcatgg	atttccattc	ggtgccacac	ccccccgagc	tggctcctga	ctcgctggtc	2340
tttgctctct	tctgtgatga	agttagacag	tggtagtaaa	atggggtgaa	ttattttact	2400
gacctgtgga	atgtgatgga	cacgctgggg	cttttttact	tcatagcagg	aattgtattt	2460
cggctccact	cttctaataa	aagctctttg	tattctggac	gagtcatttt	ctgtctggac	2520
tacattattt	tcactctaag	attgatccac	atttttactg	taagcagaaa	cttaggaccc	2580
aagattataa	tgctgcagag	gatgtgatc	gatgtgttct	tcttctgtt	cctctttgag	2640
gtgtggatgg	tggccttttg	cgtggccagg	caagggatcc	ttaggcagaa	tgagcagcgc	2700
tggaggtgga	tattccgttc	ggtcatctac	gagccctacc	tggccatgtt	cgccaggtg	2760
cccagtgacg	tggatggtac	cacgtatgac	tttgcccaact	gcaccttcac	tgggaatgag	2820
tccaagccac	tgtgtgtgga	gctggatgag	cacaacctgc	cccgttccc	cgagtggatc	2880
accatcccc	tgggtgtgat	ctacatgtta	tccaccaaca	tcctgctggt	caacctgctg	2940
gtcgccatgt	ttggctacac	ggtgggcacc	gtccaggaga	acaatgacca	ggtctggaag	3000
ttccagaggt	acttccctggt	gcaggagtac	tgcagccgcc	tcaatatccc	cttccccttc	3060
atcgtcttcg	cttacttcta	catggtgggt	aaaaagtgtc	tcaagtgttg	ctgcaaggag	3120
aaaaacatgg	agtcttctgt	ctgctgtttc	aaaaatgaag	acaatgagac	tctggcatgg	3180
gaggggtgtca	tgaaggaaaa	ctacctgtgc	aagatcaaca	caaaagccaa	cgacacctca	3240
gaggaaatga	ggcatcgatt	tagacaactg	gatacaaagc	ttaatgatct	caagggtctt	3300
ctgaaagaga	ttgctaataa	aatcaaataa	aactgtatga	aactctaata	gagaaaaatc	3360
taattatagc	aagatcatat	taaggaatgc	tgatgaacaa	ttttgctatc	gactactaaa	3420
tgagagattt	tcagaccctt	gggtacatgg	tggatgattt	ttaatcacc	tagtgtgtctg	3480
agaccttgag	aataaagtgt	gtgattgggt	tcatacttga	agacggatat	aaaggaagaa	3540
tatttctctt	atgtgtttct	ccagaatggt	gcctgtttct	ctctgtgtct	caatgcctgg	3600
gactggaggt	tgatagttta	agtgtgttct	taccgcctcc	tttttctctt	aatcttattt	3660

```

ttgatgaaca catatatagg agaacatcta tcctatgaat aagaacctgg tcatgcttta 3720
ctcctgtatt gttatTTTTgt tcatttccaa ttgattctct acttttccct tttttgtatt 3780
atgtgactaa ttagtTggca tattgttaaa agtctctcaa attaggccag attctaaaaac 3840
atgctgcagc aagaggaccc cgctctcttc aggaaaagtg ttttcatttc tcaggatgct 3900
tcttacctgt cagaggaggt gacaaggcag tctcttgctc tcttggaactc accaggctcc 3960
tattgaagga accaccccca ttcttaataa tgtgaaaagt cgcccaaat gcaaccttga 4020
aaggcactac tgactttgtt cttattggat actcctctta tttattattt ttccattaaa 4080
aataatagct ggctattata gaaaatttag accatacaga gatgtagaaa gaacataaat 4140
tgtccccatt accttaaggt aatcactgct aacaatttct ggatggtttt tcaagtctat 4200
tttttttcta tgtatgtctc aattctcttt caaaatttta cagaatgtta tcatactaca 4260
tatatacttt ttatgtaagc tttttcactt agtattttat caaatatgtt tttattatat 4320
tcatagcctt cttaaacatt atatcaataa ttgcataata ggcaacctct agcgattacc 4380
ataattttgc tcattgaagg ctatctccag ttgatcattg ggatgagcat ctttTgtcat 4440
gaatcctatt gctgtatttg ggaaaatttt ccaagggttag attccaataa atatctattt 4500
attattaaat attaaaatat cgatttatta ttaaaaccat ttataaggct ttttcataaa 4560
tgtatagcaa ataggaatta ttaacttgag cataagatat gagatacatg aacctgaact 4620
attaaaataa aatattatat ttaaccctag tttagaaga agtcaatatg cttattttaa 4680
tattatggat ggtgggcaga tcaactgagg tcaggagttc gagaccagcc tggccaacat 4740
ggcaaaacca catctctact aaaaataaaa aaattagctg ggtgtggtgg tgcactcctg 4800
taatcccagc tactcagaag gctgaggtac aagaattgct ggaacctggg aggcggaggt 4860
tgcagtgaac caagattgca ccactgcact ccagccgggg tgacagagtg agactccgac 4920
tgaaaataaa taaataaata aataaataaa taaataaata aatattatgg atggtgaagg 4980
gaatggtata gaattggaga gattatctta ctgaacacct gtagtcccag ctttctctgg 5040
aagtgggtgg atttgagcag gatgtgcaca aggcaattga aatgcccata attagtttct 5100
cagctttgaa tacactataa actcagtggc tgaaggagga aattttagaa ggaagctact 5160
aaaagatcta atttgaaaaa ctacaaaagc attaactaaa aaagtttatt ttccttttgt 5220
ctgggcagta gtgaaaataa ctactcacia cattcactat gtttgcaagg aattaacaca 5280
aataaaagat gcctttttac ttaaaccgca agacagaaaa cttgcccaat actgagaagc 5340
aacttgcatc agagagggaa ctgttaaatg ttttcaacc agttcatctg gtggatgttt 5400
ttgcaggtta ctctgagaat tttgcttatg aaaaatcatt atttttagtg tagttcaca 5460
taatgtattg aacatacttc taatcaaagg tgctatgtcc ttgtgtatgg tactaaatgt 5520
gtcctgtgta cttttgcaca actgagaatc ctgcggcttg gtttaatgag tgtgttcâtg 5580
aaataaataa tggaggaatt gtcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 5640
aaaaaaaaaa aaaaaaaaaa aaaaaaaa 5668

```

<210> 635

<211> 1095

<212> PRT

<213> Homo sapiens

<400> 635

```

Met Arg Asn Arg Arg Asn Asp Thr Leu Asp Ser Thr Arg Thr Leu Tyr
      5              10              15

Ser Ser Ala Ser Arg Ser Thr Asp Leu Ser Tyr Ser Glu Ser Asp Leu
      20              25              30

Val Asn Phe Ile Gln Ala Asn Phe Lys Lys Arg Glu Cys Val Phe Phe
      35              40              45

Thr Lys Asp Ser Lys Ala Thr Glu Asn Val Cys Lys Cys Gly Tyr Ala
      50              55              60

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp
      65              70              75              80

Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp
      85              90              95

```

Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser
 100 105 110
 Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp
 115 120 125
 His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys
 130 135 140
 Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile
 145 150 155 160
 Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His
 165 170 175
 Tyr Gly Leu Thr Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile
 180 185 190
 Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp
 195 200 205
 Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu
 210 215 220
 Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro
 225 230 235 240
 Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn
 245 250 255
 Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu
 260 265 270
 Glu Lys His Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly
 275 280 285
 Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu
 290 295 300
 Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val
 305 310 315 320
 Glu Gly Ser Gly Arg Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val
 325 330 335
 Glu Asp Ala Pro Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe
 340 345 350
 Leu Pro Arg Thr Val Ser Arg Leu Ser Glu Glu Glu Thr Glu Ser Trp
 355 360 365
 Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val
 370 375 380
 Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser
 385 390 395 400

Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu Gln Asp Lys Asp Asn
 405 410 415
 Trp Asn Gly Gln Leu Lys Leu Leu Glu Trp Asn Gln Leu Asp Leu
 420 425 430
 Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp
 435 440 445
 Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe
 450 455 460
 Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr
 465 470 475 480
 His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val
 485 490 495
 Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu
 500 505 510
 Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys
 515 520 525
 Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val
 530 535 540
 Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile
 545 550 555 560
 Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg
 565 570 575
 Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu
 580 585 590
 Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu
 595 600 605
 Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr
 610 615 620
 Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu
 625 630 635 640
 Ala Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr Asp
 645 650 655
 Gln His Phe Thr Ala Gln Pro Gly Val Gln Asn Phe Leu Ser Lys Gln
 660 665 670
 Trp Tyr Gly Glu Ile Ser Arg Asp Thr Lys Asn Trp Lys Ile Ile Leu
 675 680 685
 Cys Leu Phe Ile Ile Pro Leu Val Gly Cys Gly Phe Val Ser Phe Arg
 690 695 700
 Lys Lys Pro Val Asp Lys His Lys Lys Leu Leu Trp Tyr Tyr Val Ala

705		710		715		720
Phe Phe Thr Ser	Pro Phe Val Val Phe	Ser Trp Asn Val Val	Phe Tyr			
	725		730			735
Ile Ala Phe Leu	Leu Leu Phe Ala Tyr	Val Leu Leu Met Asp	Phe His			
	740		745			750
Ser Val Pro His	Pro Pro Glu Leu	Val Leu Tyr Ser	Leu Val Phe	Val		
	755		760			765
Leu Phe Cys Asp	Glu Val Arg Gln	Trp Tyr Val Asn	Gly Val Asn	Tyr		
	770		775			780
Phe Thr Asp Leu	Trp Asn Val Met Asp	Thr Leu Gly Leu	Phe Tyr Phe			
	785		790			800
Ile Ala Gly Ile	Val Phe Arg Leu	His Ser Ser Asn	Lys Ser Ser	Leu		
	805		810			815
Tyr Ser Gly Arg	Val Ile Phe Cys	Leu Asp Tyr Ile	Ile Phe Thr	Leu		
	820		825			830
Arg Leu Ile His	Ile Phe Thr Val	Ser Arg Asn Leu	Gly Pro Lys	Ile		
	835		840			845
Ile Met Leu Gln	Arg Met Leu Ile	Asp Val Phe Phe	Phe Leu Phe	Leu		
	850		855			860
Phe Ala Val Trp	Met Val Ala Phe	Gly Val Ala Arg	Gln Gly Ile	Leu		
	865		870			880
Arg Gln Asn Glu	Gln Arg Trp Arg	Trp Ile Phe Arg	Ser Val Ile	Tyr		
	885		890			895
Glu Pro Tyr Leu	Ala Met Phe Gly	Gln Val Pro Ser	Asp Val Asp	Gly		
	900		905			910
Thr Thr Tyr Asp	Phe Ala His Cys	Thr Phe Thr Gly	Asn Glu Ser	Lys		
	915		920			925
Pro Leu Cys Val	Glu Leu Asp Glu	His Asn Leu Pro	Arg Phe Pro	Glu		
	930		935			940
Trp Ile Thr Ile	Pro Leu Val Cys	Ile Tyr Met Leu	Ser Thr Asn	Ile		
	945		950			960
Leu Leu Val Asn	Leu Leu Val Ala	Met Phe Gly Tyr	Thr Val Gly	Thr		
	965		970			975
Val Gln Glu Asn	Asn Asp Gln Val	Trp Lys Phe Gln	Arg Tyr Phe	Leu		
	980		985			990
Val Gln Glu Tyr	Cys Ser Arg Leu	Asn Ile Pro Phe	Pro Phe Ile	Val		
	995		1000			1005
Phe Ala Tyr Phe	Tyr Met Val Val	Lys Lys Cys Phe	Lys Cys Cys	Cys		
	1010		1015			1020

Lys Glu Lys Asn Met Glu Ser Ser Val Cys Cys Phe Lys Asn Glu Asp
 1025 1030 1035 1040

Asn Glu Thr Leu Ala Trp Glu Gly Val Met Lys Glu Asn Tyr Leu Val
 1045 1050 1055

Lys Ile Asn Thr Lys Ala Asn Asp Thr Ser Glu Glu Met Arg His Arg
 1060 1065 1070

Phe Arg Gln Leu Asp Thr Lys Leu Asn Asp Leu Lys Gly Leu Leu Lys
 1075 1080 1085

Glu Ile Ala Asn Lys Ile Lys
 1090 1095

<210> 636

<211> 3639

<212> DNA

<213> Homo sapiens

<400> 636

```

gattacgcaa gctathtagg tgacactata gaatwctcag cttgcatcaa gcttggtacc 60
gagctcgga ccttagtaac ggccgccagt gtgctggaat tcgcccttgc agccgggctc 120
agcatgagga acagaaggaa tgacactctg gacagcacc ggacctgta ctccagcgcg 180
tctcggagca cagacttgct ttacagtga agcgacttgg tgaattttat tcaagcaaat 240
ttaaagaaac gagaatgtgt cttctttacc aaagattcca aggccacgga gaatgtgtgc 300
aagtgtggct atgccagag ccagcacatg gaaggcacc agatcaacca aagtgagaaa 360
tggaactaca agaaacacac caaggaattt cctaccgacg cctttgggga tattcagttt 420
gagacactgg ggaagaaagg gaagtatata cgtctgtcct gcgacacgga cgcggaaatc 480
ctttacgagc tgtgaccca gactggcac ctgaaaacac ccaacctggt catttctgtg 540
accgggggag ccaagaactt cgccctgaag ccgcgcattg gcaagatctt cagccggctc 600
atctacatcg cgcagtccaa aggtgcttgg attctcacgg gaggcaccca ttatggcctg 660
atgaagtaca tcggggaggt ggtgagagat aacaccatca gcaggagttc agaggagaat 720
attgtggcca ttggcatagc agcttggggc atggtctcca accgggacac cctcatcagg 780
aattgcgatg ctgagggcta ttttttagcc cagtacctta tggatgactt cacaagagat 840
ccactgtata tcttgacaa caaccacaca catttgctgc tcgtggacaa tggtgtcat 900
ggacatccca ctgtogaagc aaagctccgg aatcagctag agaagtatat ctctgagcgc 960
actattcaag attccaacta tggtggaag atccccattg tgtgttttgc ccaaggagggt 1020
ggaaaagaga ctttgaaagc catcaatacc tccatcaaaa ataaaattcc ttgtgtggtg 1080
gtggaaggct cgggccagat cgctgatgtg atcgtagcc tgggtggagggt ggaggatgcc 1140
ctgacatctt ctgccgtcaa ggagaagctg gtgcgctttt taccocgcac ggtgtcccg 1200
ctgcctgagg aggagactga gagttggatc aaatggctca aagaaattct cgaatgttct 1260
cacctattaa cagttattaa aatggaagaa gctggggatg aaattgtgag caatgccatc 1320
tctacgctc tatacaaagc ctccagcacc agtgagcaag acaaggataa ctggaatggg 1380
cagctgaagc ttctgctgga gtggaaccag ctggacttag ccaatgatga gattttcacc 1440
aatgaccgcc gatgggagtc tgtgacctt caagaagtea tgtttacggc tctcataaag 1500
gacagaccca agtttgtccg cctctttctg gagaatggct tgaacctacg gaagtttctc 1560
accatgatg tctcactga actcttctcc aaccacttca gcacgcttgt gtaccggaat 1620
ctgcagatcg ccaagaattc ctataatgat gccctcctca cgtttgtctg gaaactgggt 1680
gcgaacttcc gaagaggctt ccggaaggaa gacagaaatg gccgggacga gatggacata 1740
gaactccacg acgtgtctcc tattactcgg caccocctgc aagctctctt catctgggcc 1800
attcttcaga ataagaagga actctocaaa gtcatgtggg agcagaccag gggctgcact 1860
ctggcagccc tgggagccag caagcttctg aagactctgg ccaaagtga gaaacgacatc 1920
aatgctgctg gggagtccga ggagctggct aatgagtacg agaccggggc tgttgagctg 1980
ttcactgagt gttacagcag cgatgaagac ttggcagaac agctgctggt ctattcctgt 2040

```

```

gaagcttggg gtggaagcaa ctgtctggag ctggcgggtg aggccacaga ccagcatttc 2100
atcgcccagc ctgggggtcca gaattttctt tctaagcaat ggtatggaga gatttcccga 2160
gacaccaaga actggaagat tatcctgtgt ctgtttatta tacccttggg gggctgtggc 2220
tttgtatcat ttaggaagaa acctgtcgac aagcacaaga agctgctttg gtactatgtg 2280
gcgttcttca cctccccctt cgtggtcttc tcctggaatg tggctctcta catcgccctc 2340
ctcctgctgt ttgcctacgt gctgctcatg gatttccatt cggtgccaca ccccccgag 2400
ctggctctgt actcgctggg ctttgcctc ttctgtgatg aagtggagac gtggtagcta 2460
aatggggtga attattttac tgacctgtgg aatgtgatgg acacgctggg gcttttttac 2520
ttcatagcag gaattgtatt tcggctccac tcttctaata aaagctcttt gtattctgga 2580
cgagtcatth tctgtctgga ctacattatt ttactctaa gattgatcca cttttttact 2640
gtaagcagaa acttaggacc caagattata atgctgcaga ggatgctgat cgatgtgttc 2700
ttcttctgtt tctcttttgc ggwtgggatg gtggcctttg gcgtggccag gcaagggatc 2760
cttaggcaga atgagcagcg ctggaggtgg atattccgtt cggtcaccta cgagccctac 2820
ctggccatgt tcggccaggt gccacgtgac gtggatggta ccacgtatga ctttgccac 2880
tgcaccttca ctgggaatga gtccaagcca ctgtgtgtgg agctggatga gcacaacctg 2940
ccccggttcc cagagtggat caccatcccc ctggtgtgca tctacatgtt atccaccaac 3000
atcctgtctg tcaacctgct ggtcgccatg tttggctaca cgggtgggac cgtccaggag 3060
aacaatgacc aggtctggaa gttccagagg tacttctctg tgcaggagta ctgcagccgc 3120
ctcaatatcc ccttccccct catcgtcttc gcttacttct acatggtggt gaagaagtgc 3180
ttcaagtgtt gctgcaagga gaaaaacatg gactcttctg tctgctgttt caaaaatgaa 3240
gacaatgaga ctctggcatg ggaggtgtgc atgaaggaaa actaccttgt caagatcaac 3300
acaaaagcca acgacacctc agaggaaatg aggcacgat ttagacaact ggatacaaa 3360
cttaatgatc tcaagggtct tctgaaagag attgctaata aaatcaaata aaactgtatg 3420
aactctaag gagaaaaatc taattatagc aagatcatat taaggaatgc tgatgaacaa 3480
tttgctatc gactactaaa tgagagattt tcagaccctt gggtagatgg tggatgattt 3540
taaatacccc tagtgtgtg agaccttgag aataaagtgt gaagggcgaa ttctgcagat 3600
atccatcaca ctggcggccg ctcgagcatg catctagag 3639

```

<210> 637

<211> 1095

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(1095)

<223> Xaa = Any Amino Acid

<400> 637

```

Met Arg Asn Arg Arg Asn Asp Thr Leu Asp Ser Thr Arg Thr Leu Tyr
          5                      10                      15

```

```

Ser Ser Ala Ser Arg Ser Thr Asp Leu Ser Tyr Ser Glu Ser Asp Leu
          20                      25                      30

```

```

Val Asn Phe Ile Gln Ala Asn Phe Lys Lys Arg Glu Cys Val Phe Phe
          35                      40                      45

```

```

Thr Lys Asp Ser Lys Ala Thr Glu Asn Val Cys Lys Cys Gly Tyr Ala
          50                      55                      60

```

```

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp
          65                      70                      75                      80

```

```

Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp
          85                      90                      95

```

```

Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser

```

255

100	105	110
Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp 115 120 125		
His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys 130 135 140		
Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile 145 150 155 160		
Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His 165 170 175		
Tyr Gly Leu Met Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile 180 185 190		
Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp 195 200 205		
Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu 210 215 220		
Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro 225 230 235 240		
Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn 245 250 255		
Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu 260 265 270		
Glu Lys Tyr Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly 275 280 285		
Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu 290 295 300		
Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val 305 310 315 320		
Glu Gly Ser Gly Gln Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val 325 330 335		
Glu Asp Ala Leu Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe 340 345 350		
Leu Pro Arg Thr Val Ser Arg Leu Pro Glu Glu Glu Thr Glu Ser Trp 355 360 365		
Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val 370 375 380		
Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser 385 390 395 400		
Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu Gln Asp Lys Asp Asn 405 410 415		

Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp Asn Gln Leu Asp Leu
 420 425 430
 Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp
 435 440 445
 Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe
 450 455 460
 Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr
 465 470 475 480
 His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val
 485 490 495
 Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu
 500 505 510
 Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys
 515 520 525
 Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val
 530 535 540
 Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile
 545 550 555 560
 Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg
 565 570 575
 Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu
 580 585 590
 Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu
 595 600 605
 Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr
 610 615 620
 Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu
 625 630 635 640
 Ala Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr Asp
 645 650 655
 Gln His Phe Ile Ala Gln Pro Gly Val Gln Asn Phe Leu Ser Lys Gln
 660 665 670
 Trp Tyr Gly Glu Ile Ser Arg Asp Thr Lys Asn Trp Lys Ile Ile Leu
 675 680 685
 Cys Leu Phe Ile Ile Pro Leu Val Gly Cys Gly Phe Val Ser Phe Arg
 690 695 700
 Lys Lys Pro Val Asp Lys His Lys Lys Leu Leu Trp Tyr Tyr Val Ala
 705 710 715 720

Phe Phe Thr Ser Pro Phe Val Val Phe Ser Trp Asn Val Val Phe Tyr
 725 730 735
 Ile Ala Phe Leu Leu Leu Phe Ala Tyr Val Leu Leu Met Asp Phe His
 740 745 750
 Ser Val Pro His Pro Pro Glu Leu Val Leu Tyr Ser Leu Val Phe Val
 755 760 765
 Leu Phe Cys Asp Glu Val Arg Gln Trp Tyr Val Asn Gly Val Asn Tyr
 770 775 780
 Phe Thr Asp Leu Trp Asn Val Met Asp Thr Leu Gly Leu Phe Tyr Phe
 785 790 795 800
 Ile Ala Gly Ile Val Phe Arg Leu His Ser Ser Asn Lys Ser Ser Leu
 805 810 815
 Tyr Ser Gly Arg Val Ile Phe Cys Leu Asp Tyr Ile Ile Phe Thr Leu
 820 825 830
 Arg Leu Ile His Ile Phe Thr Val Ser Arg Asn Leu Gly Pro Lys Ile
 835 840 845
 Ile Met Leu Gln Arg Met Leu Ile Asp Val Phe Phe Phe Leu Phe Leu
 850 855 860
 Phe Ala Xaa Trp Met Val Ala Phe Gly Val Ala Arg Gln Gly Ile Leu
 865 870 875 880
 Arg Gln Asn Glu Gln Arg Trp Arg Trp Ile Phe Arg Ser Val Ile Tyr
 885 890 895
 Glu Pro Tyr Leu Ala Met Phe Gly Gln Val Pro Ser Asp Val Asp Gly
 900 905 910
 Thr Thr Tyr Asp Phe Ala His Cys Thr Phe Thr Gly Asn Glu Ser Lys
 915 920 925
 Pro Leu Cys Val Glu Leu Asp Glu His Asn Leu Pro Arg Phe Pro Glu
 930 935 940
 Trp Ile Thr Ile Pro Leu Val Cys Ile Tyr Met Leu Ser Thr Asn Ile
 945 950 955 960
 Leu Leu Val Asn Leu Leu Val Ala Met Phe Gly Tyr Thr Val Gly Thr
 965 970 975
 Val Gln Glu Asn Asn Asp Gln Val Trp Lys Phe Gln Arg Tyr Phe Leu
 980 985 990
 Val Gln Glu Tyr Cys Ser Arg Leu Asn Ile Pro Phe Pro Phe Ile Val
 995 1000 1005
 Phe Ala Tyr Phe Tyr Met Val Val Lys Lys Cys Phe Lys Cys Cys Cys
 1010 1015 1020
 Lys Glu Lys Asn Met Glu Ser Ser Val Cys Cys Phe Lys Asn Glu Asp

1025 1030 1035 1040
 Asn Glu Thr Leu Ala Trp Glu Gly Val Met Lys Glu Asn Tyr Leu Val
 1045 1050 1055
 Lys Ile Asn Thr Lys Ala Asn Asp Thr Ser Glu Glu Met Arg His Arg
 1060 1065 1070
 Phe Arg Gln Leu Asp Thr Lys Leu Asn Asp Leu Lys Gly Leu Leu Lys
 1075 1080 1085
 Glu Ile Ala Asn Lys Ile Lys
 1090 1095

<210> 638
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 638
 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser
 5 10 15

<210> 639
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 639
 agaatgccta ccgtgctgca gtgcgtgaac gtgtcgggtgg tgtct 45

<210> 640
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 640
 gagccagggga gccagatggt ggaggccagc ctctccgtac ggcac 45

<210> 641
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 641
 gaggccgacc aagagccagg gagccagatg gtggaggcca gcctc 45

<210> 642
 <211> 45
 <212> DNA
 <213> Homo sapiens

<400> 642
 ggctgcaca gtcttgaggc cgaccaagag ccaggagacc agatg 45

<210> 643
<211> 45
<212> DNA
<213> Homo sapiens

<400> 643
tacaccatcg ggctgggcct gcacagtctt gagggccgacc aagag

45

<210> 644
<211> 42
<212> DNA
<213> Homo sapiens

<400> 644
ttccagaact cctacaccat cgggctgggc ctgcacagtc tt

42

<210> 645
<211> 45
<212> DNA
<213> Homo sapiens

<400> 645
ctgtcagccg cacactgttt ccagaactcc tacaccatcg ggctg

45

<210> 646
<211> 45
<212> DNA
<213> Homo sapiens

<400> 646
catccgcagt ggggtgctgtc agccgcacac tgtttccaga actcc

45

<210> 647
<211> 45
<212> DNA
<213> Homo sapiens

<400> 647
tcgggcgtcc tgggtgcatcc gcagtgggtg ctgtcagccg cacac

45

<210> 648
<211> 45
<212> DNA
<213> Homo sapiens

<400> 648
aacgaattgt tctgctcggg cgtcctgggtg catccgcagt ggggtg

45

<210> 649
<211> 45
<212> DNA
<213> Homo sapiens

<400> 649
gcactggtca tggaaaacga attgttctgc tcgggcgtcc tgggtg

45

<210> 650
<211> 51

<212> DNA

<213> Homo sapiens

<400> 650

tcgcagccct ggcaggcggc actggtcatg gaaaacgaat tgttctgctc g 51

<210> 651

<211> 45

<212> DNA

<213> Homo sapiens

<400> 651

atcagcattg cttgcagtg ccctaccgcg gggaactctt gcctc 45

<210> 652

<211> 45

<212> DNA

<213> Homo sapiens

<400> 652

tccgtgtccg agtctgacac catccggagc atcagcattg cttcg 45

<210> 653

<211> 45

<212> DNA

<213> Homo sapiens

<400> 653

atcaagttgg acgaatccgt gtccgagtct gacaccatcc ggagc 45

<210> 654

<211> 45

<212> DNA

<213> Homo sapiens

<400> 654

aacgacctca tgctcatcaa gttggacgaa tccgtgtccg agtct 45

<210> 655

<211> 45

<212> DNA

<213> Homo sapiens

<400> 655

agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaa 45

<210> 656

<211> 15

<212> PRT

<213> Homo sapiens

<400> 656

Glu	Pro	Gly	Ser	Gln	Met	Val	Glu	Ala	Ser	Leu	Ser	Val	Arg	His
				5					10					15

<210> 657

<211> 15

<212> PRT

<213> Homo sapiens

<400> 657

Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu Ala Ser Leu
5 10 15

<210> 658

<211> 15

<212> PRT

<213> Homo sapiens

<400> 658

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met
5 10 15

<210> 659

<211> 15

<212> PRT

<213> Homo sapiens

<400> 659

Tyr Thr Ile Gly Leu Gly Leu His Ser Leu Glu Ala Asp Gln Glu
5 10 15

<210> 660

<211> 14

<212> PRT

<213> Homo sapiens

<400> 660

Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly Leu His Ser Leu
5 10

<210> 661

<211> 15

<212> PRT

<213> Homo sapiens

<400> 661

Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
5 10 15

<210> 662

<211> 15

<212> PRT

<213> Homo sapiens

<400> 662

His Pro Gln Trp Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser
5 10 15

<210> 663
<211> 15
<212> PRT
<213> Homo sapiens

<400> 663
Ser Gly Val Leu Val His Pro Gln Trp Val Leu Ser Ala Ala His
5 10 15

<210> 664
<211> 15
<212> PRT
<213> Homo sapiens

<400> 664
Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val
5 10 15

<210> 665
<211> 15
<212> PRT
<213> Homo sapiens

<400> 665
Ala Leu Val Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val
5 10 15

<210> 666
<211> 17
<212> PRT
<213> Homo sapiens

<400> 666
Ser Gln Pro Trp Gln Ala Ala Leu Val Met Glu Asn Glu Leu Phe Cys
5 10 15

Ser

<210> 667
<211> 15
<212> PRT
<213> Homo sapiens

<400> 667
Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn Ser Cys Leu
5 10 15

<210> 668
<211> 15
<212> PRT
<213> Homo sapiens

<400> 668

Ser Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser
5 10 15

<210> 669

<211> 15

<212> PRT

<213> Homo sapiens

<400> 669

Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp Thr Ile Arg Ser
5 10 15

<210> 670

<211> 15

<212> PRT

<213> Homo sapiens

<400> 670

Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
5 10 15

<210> 671

<211> 15

<212> PRT

<213> Homo sapiens

<400> 671

Arg Pro Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu
5 10 15

<210> 672

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 672

ggaccagcat atgaggaaca gaaggaatga cactc 35

<210> 673

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 673

ccgctcgagt ccacccaag cttcacagg 29

atgaggaaca	gaaggaatga	cactctggac	agcacccgga	ccctgtactc	cagcgcgtct	60
cggagcacag	acttgtctta	cagtgaagc	gacttggtga	attttattca	agcaaathtt	120
aagaaacgag	aatgtgtctt	ctttaccaa	gattccaagg	ccacggagaa	tgtgtgcaag	180
tgtggctatg	cccagagcca	gcacatggaa	ggcaccaga	tcaaccaaag	tgagaaatgg	240
aactacaaga	aacacaccaa	ggaatttcct	accgacgcct	ttggggatat	tcagtttgag	300
acactgggga	agaaagggaa	gtatatacgt	ctgtcctgcg	acacggacgc	ggaaatcctt	360
tacgagctgc	tgaccacgca	ctggcacctg	aaaacaccca	acctgggtcat	ttctgtgacc	420
ggggggccca	agaactctgc	cctgaagccg	cgcattcgca	agatcttcag	ccggctcatc	480
tactcgcgc	agtccaaagg	tgtgtggatt	ctcacgggag	gcaccatta	tggcctgatg	540
aagtacatcg	gggaggtggt	gagagataac	accatcagca	ggagttcaga	gggaaatatt	600
gtggccattg	gcatagcagc	ttggggcatg	gtctccaacc	gggacaccct	catcaggaat	660
tgcgatgctg	agggctatht	tttagcccag	taccttatgg	atgacttcac	aagagatcca	720
ctgtatatcc	tggacaacaa	ccacacacat	ttgctgctcg	tggacaatgg	ctgtcatgga	780
catcccactg	tcgaagcaaa	gctccggaat	cagctagaga	agtatatctc	tgagcgcact	840
attcaagatt	ccaactatgg	tggcaagatc	cccatttgtt	gttttgccca	aggaggtgga	900
aaagagactt	tgaaaagccat	caatacctcc	atcaaaaata	aaattctctg	tgtggtggtg	960
gaaggctcgg	ccgagatcgc	tcatgtgatc	cgtagcctgg	tggagggtga	gggtgcctgt	1020
acatcttctg	ccgtcaagga	gaagctggtg	cgctttttac	ccgcacgggt	gtcccggtg	1080
cctgaggagg	agactgagag	ttggatcaaa	tggctcaaag	aaattctcga	atgttctcac	1140
ctattaacag	ttattaaaat	ggaagaagct	ggggatgaaa	ttgtgagcaa	tgccatctcc	1200
tacgctctat	acaaagcctt	cagcaccagt	gagcaagaca	aggataactg	gaatgggcag	1260
ctgaagcttc	tgctggagtg	gaaccagctg	gacttagcca	atgatgagat	tttcaccaat	1320
gaccgccagt	gggagctctgc	tgaccttgag	gaagtcattg	ttacggctct	cataaaaggc	1380
agaccceaag	ttgtccgcct	ctttcttcaa	aatggcttga	acctacggaa	gtttctcacc	1440
catgatgtcc	tcactgaact	cttctccaac	cacttcagca	cgcttggtta	ccggaatctg	1500
cagatcgcca	agaattccta	taatgatgcc	ctcctcacgt	ttgtctggaa	actggttgcg	1560
aacttccgaa	gaggcttccg	gaaggaagac	agaaatggcc	gggacgagat	ggacatagaa	1620
ctocacgacg	tgtctcctat	tactcggcac	cccctgcaag	ctctcttcac	ctgggccatt	1680
cttcagaata	agaaggaact	ctccaaagtc	atttgggagc	agaccagggg	ctgcaactctg	1740
gcagccctgg	gagccagcaa	gcttctgaag	actctggcca	aagtgaagaa	cgacatcaat	1800
gctgctgggg	agtccgagga	tgtggctaag	gagtacgaga	cccgggctgt	tgagctgttc	1860
actgagtgtt	acagcagca	tgaagacttg	gcagaacagc	tgtgtgtcta	ttcctgtgaa	1920
gcttgggggtg	gactcgagca	ccaccaccac	caccactga			1959

```
<210> 675
<211> 652
<212> PRT
<213> Homo sapiens
```

Met	Arg	Asn	Arg	Arg	Asn	Asp	Thr	Leu	Asp	Ser	Thr	Arg	Thr	Leu	Tyr
				5					10					15	
Ser	Ser	Ala	Ser	Arg	Ser	Thr	Asp	Leu	Ser	Tyr	Ser	Glu	Ser	Asp	Leu
			20					25					30		
Val	Asn	Phe	Ile	Gln	Ala	Asn	Phe	Lys	Lys	Arg	Glu	Cys	Val	Phe	Phe
		35					40					45			
Thr	Lys	Asp	Ser	Lys	Ala	Thr	Glu	Asn	Val	Cys	Lys	Cys	Gly	Tyr	Ala
	50					55					60				

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp
 65 70 75 80
 Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp
 85 90 95
 Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser
 100 105 110
 Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp
 115 120 125
 His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys
 130 135 140
 Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile
 145 150 155 160
 Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His
 165 170 175
 Tyr Gly Leu Met Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile
 180 185 190
 Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp
 195 200 205
 Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu
 210 215 220
 Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro
 225 230 235 240
 Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn
 245 250 255
 Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu
 260 265 270
 Glu Lys Tyr Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly
 275 280 285
 Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu
 290 295 300
 Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val
 305 310 315 320
 Glu Gly Ser Gly Gln Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val
 325 330 335
 Glu Asp Ala Leu Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe
 340 345 350
 Leu Pro Arg Thr Val Ser Arg Leu Pro Glu Glu Glu Thr Glu Ser Trp
 355 360 365
 Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val

370		375		380
Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser				
385		390		395
Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu Gln Asp Lys Asp Asn				
	405		410	415
Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp Asn Gln Leu Asp Leu				
	420		425	430
Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp				
	435		440	445
Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe				
	450		455	460
Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr				
	465		470	475
His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val				
	485		490	495
Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu				
	500		505	510
Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys				
	515		520	525
Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val				
	530		535	540
Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile				
	545		550	555
Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg				
	565		570	575
Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu				
	580		585	590
Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu				
	595		600	605
Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr				
	610		615	620
Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu				
	625		630	635
Ala Trp Gly Gly Leu Glu His His His His His His				
	645		650	

<210> 676

<211> 132

<212> PRT

<213> Homo sapien

<400> 676

```

Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
1          5          10          15
Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser
20          25          30
Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly
35          40          45
Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val
50          55          60
Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val
65          70          75          80
Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala
85          90          95
Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Trp
100         105         110
Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu
115         120         125
Gly Pro Pro Ala
130

```

<210> 677

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 677

ggggaattca tgatccggga gaaatttgcc cactgc

36

<210> 678

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 678

gggctcgagt caggagtttg agaccagcct ggc

33

<210> 679

<211> 675

<212> DNA

<213> Homo sapiens

<400> 679

atgcatacc atcaccatca cacggcgcgc tccgataact tccagctgtc ccagggtggg 60
 cagggattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120


```

accgttcata tcgggcctac cgccttcctc ggcttggtg ttgtcgacaa caacggcaac 180
ggcgcacgag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcatcatcc cggtgacgtc atctcgggtga cctggcaaac caagtccggc 360
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catgatccgg 420
gagaaatttg cccactgcac cgtgctaacc attgcacaca gattgaacac cattattgac 480
agcgacaaga taatggtttt agattcagga agactgaaag aatatgatga gccgtatggt 540
ttgctgcaaa ataaagagag cctattttac aagatggtgc aacaactggg caaggcagaa 600
gccgctgcc tcaactgaaac agcaaaacag agatgggggt tcaccatggt ggccaggctg 660
gtctcaaaact cctga 675

```

<210> 680

<211> 291

<212> DNA

<213> Homo sapiens

<400> 680

```

atggggatcc gggagaaatt tgccactgc accgtgctaa ccattgcaca cagattgaac 60
accattattg acagcgacaa gataatggtt ttagattcag gaagactgaa agaatatgat 120
gagccgtatg ttttgctgca aaataaagag agcctatttt acaagatggt gcaacaactg 180
ggcaaggcag aagccgctgc cctcactgaa acagcaaaac agagatgggg ttccaccatg 240
ttggccaggc tgggtctcaa ctccctcgag caccaccacc accaccactg a 291

```

<210> 681

<211> 1074

<212> DNA

<213> Homo sapiens

<400> 681

```

atgtcagcca ttgagagggt gtcagaggca atcgtcagca tccgaagaat ccagaccttt 60
ttgtactttg atgagatata acagcgcaac cgtcagctgc cgtcagatgg taaaaagatg 120
gtcatgtgac aggattttac tgctttttgg gataaggcat cagagacccc aactctacaa 180
ggcctttcct ttaactgtcag acctggcgaa ttgttagctg tggtcggccc cgtgggagca 240
gggaagtcat cactgttaag tgccgtgctc ggggaattgg cccaagtca cgggctggtc 300
agcgtgcatg gaagaattgc ctatgtgtct cagcagccct ggggtgttctc gggaactctg 360
aggagtaata ttttattttg gaagaaatac gaaaaggaaac gatatgaaa agtcataaag 420
gcttgtgctc tgaaaaagga tttacagctg ttggaggatg gtgatctgac tgtgatagga 480
gatcggggaa ccacgctgag tggaggcgag aaagcacggg taaaccttgc aagagcagtg 540
tatcaagatg ctgacatcta tctcctggac gatcctctca gtgcagtaga tgcggaagtt 600
agcagacact tgttcgaact gtgtatttgt caaattttgc atgagaagat cacaatttta 660
gtgactcatc agttgcagta cctcaaagct gcaagtcaga ttctgatatt gaaagatggt 720
aaaatggtgc agaaggggac ttacactgag ttctctaaat ctggtataga ttttggctcc 780
cttttaaga aggataatga ggaaagtga caacctccag ttccaggaac tcccacacta 840
aggaatcgta ccttctcaga gtcttcgggt tgggtctcaac aatcttctag accctccttg 900
aaagatggtg ctctggagag ccaagataca gagaatgtcc cagttacact atcagaggag 960
aaccgttctg aaggaaaagt tggttttcag gcctataaga attacttcag agctggtgct 1020
cactggattg tcttcatttt ccttattctc gagcaccacc accaccacca ctga 1074

```

<210> 682

<211> 224

<212> PRT

<213> Homo sapiens

<400> 682

```

Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
      5                                10                                15

```

```

Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala

```

20 25 30
 Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
 35 40 45
 Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
 50 55 60
 Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
 65 70 75 80
 Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
 85 90 95
 Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser
 100 105 110
 Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr
 115 120 125
 Leu Ala Glu Gly Pro Pro Ala Glu Phe Met Ile Arg Glu Lys Phe Ala
 130 135 140
 His Cys Thr Val Leu Thr Ile Ala His Arg Leu Asn Thr Ile Ile Asp
 145 150 155 160
 Ser Asp Lys Ile Met Val Leu Asp Ser Gly Arg Leu Lys Glu Tyr Asp
 165 170 175
 Glu Pro Tyr Val Leu Leu Gln Asn Lys Glu Ser Leu Phe Tyr Lys Met
 180 185 190
 Val Gln Gln Leu Gly Lys Ala Glu Ala Ala Ala Leu Thr Glu Thr Ala
 195 200 205
 Lys Gln Arg Trp Gly Phe Thr Met Leu Ala Arg Leu Val Ser Asn Ser
 210 215 220

<210> 683

<211> 357

<212> PRT

<213> Homo sapiens

<400> 683

Met Ser Ala Ile Glu Arg Val Ser Glu Ala Ile Val Ser Ile Arg Arg
 5 10 15
 Ile Gln Thr Phe Leu Leu Leu Asp Glu Ile Ser Gln Arg Asn Arg Gln
 20 25 30
 Leu Pro Ser Asp Gly Lys Lys Met Val His Val Gln Asp Phe Thr Ala
 35 40 45
 Phe Trp Asp Lys Ala Ser Glu Thr Pro Thr Leu Gln Gly Leu Ser Phe

270

50	55	60
Thr Val Arg Pro Gly Glu Leu Leu Ala Val Val Gly Pro Val Gly Ala		
65	70	75 80
Gly Lys Ser Ser Leu Leu Ser Ala Val Leu Gly Glu Leu Ala Pro Ser		
	85	90 95
His Gly Leu Val Ser Val His Gly Arg Ile Ala Tyr Val Ser Gln Gln		
	100	105 110
Pro Trp Val Phe Ser Gly Thr Leu Arg Ser Asn Ile Leu Phe Gly Lys		
	115	120 125
Lys Tyr Glu Lys Glu Arg Tyr Glu Lys Val Ile Lys Ala Cys Ala Leu		
	130	135 140
Lys Lys Asp Leu Gln Leu Leu Glu Asp Gly Asp Leu Thr Val Ile Gly		
	145	150 155 160
Asp Arg Gly Thr Thr Leu Ser Gly Gly Gln Lys Ala Arg Val Asn Leu		
	165	170 175
Ala Arg Ala Val Tyr Gln Asp Ala Asp Ile Tyr Leu Leu Asp Asp Pro		
	180	185 190
Leu Ser Ala Val Asp Ala Glu Val Ser Arg His Leu Phe Glu Leu Cys		
	195	200 205
Ile Cys Gln Ile Leu His Glu Lys Ile Thr Ile Leu Val Thr His Gln		
	210	215 220
Leu Gln Tyr Leu Lys Ala Ala Ser Gln Ile Leu Ile Leu Lys Asp Gly		
	225	230 235 240
Lys Met Val Gln Lys Gly Thr Tyr Thr Glu Phe Leu Lys Ser Gly Ile		
	245	250 255
Asp Phe Gly Ser Leu Leu Lys Lys Asp Asn Glu Glu Ser Glu Gln Pro		
	260	265 270
Pro Val Pro Gly Thr Pro Thr Leu Arg Asn Arg Thr Phe Ser Glu Ser		
	275	280 285
Ser Val Trp Ser Gln Gln Ser Ser Arg Pro Ser Leu Lys Asp Gly Ala		
	290	295 300
Leu Glu Ser Gln Asp Thr Glu Asn Val Pro Val Thr Leu Ser Glu Glu		
	305	310 315 320
Asn Arg Ser Glu Gly Lys Val Gly Phe Gln Ala Tyr Lys Asn Tyr Phe		
	325	330 335
Arg Ala Gly Ala His Trp Ile Val Phe Ile Phe Leu Ile Leu Glu His		
	340	345 350
His His His His His		
	355	

271

<210> 684
<211> 96
<212> PRT
<213> Homo sapiens

<400> 684
Met Gly Ile Arg Glu Lys Phe Ala His Cys Thr Val Leu Thr Ile Ala
 5 10 15
His Arg Leu Asn Thr Ile Ile Asp Ser Asp Lys Ile Met Val Leu Asp
 20 25 30
Ser Gly Arg Leu Lys Glu Tyr Asp Glu Pro Tyr Val Leu Leu Gln Asn
 35 40 45
Lys Glu Ser Leu Phe Tyr Lys Met Val Gln Gln Leu Gly Lys Ala Glu
 50 55 60
Ala Ala Ala Leu Thr Glu Thr Ala Lys Gln Arg Trp Gly Phe Thr Met
 65 70 75 80
Leu Ala Arg Leu Val Ser Asn Ser Leu Glu His His His His His His
 85 90 95

<210> 685
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 685
cgcccatggg gatccgggag aaatttgccc actgc 35

<210> 686
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 686
cgctcggagg gagtttgaga ccagcctggc caaca 35

<210> 687
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 687

gcatggacca tatgtcagcc attgagaggg tgtcagag

38

<210> 688

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 688

ccgctcgaga ataaggaaaa tgaagacaat ccag

34

<210> 689

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 689

gttgaattca tgcacggggc ccagggtg

27

<210> 690

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 690

cccctcgagt cactatgggtc tgcctcttga

30

<210> 691

<211> 915

<212> DNA

<213> Homo sapiens

<400> 691

atgcatcacc atcaccatca cacggccgag tccgataact tccagctgtc ccagggtggg 60
cagggtattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120
accgttcata tcgggcctac cgccttcctc ggcttggtg ttgtcgaaa caacggcaac 180
ggcgacagag tccaacgcgt ggtcgggagc gctccggcgg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggg cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcacatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catgcacggg 420
cccagggtgc tggcacgctg ctccgagtg gcttgctcctg ccttggtcgc cacctctgcg 480
ggggtgcgtc tggagggggt ggaccggcca ccaaccttac ccagtcaagg aagtggatgg 540
ccatgttccc acagcctgag tggctgccac ctgatggctg atggagcaaa ggccttagga 600
aaagcagatg gcccttggcc ctaccttttt gttagaagaa ctgatgttcc atgtcctgca 660
gcgagtgagg ttggtggctg tgccccagc tcctggcgcg ccctcgcaga ggtgactggt 720

```
<210> 692
<211> 304
<212> PRT
<213> Homo sapiens
```

<400> 692

Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
5 10 15

Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala
20 25 30

Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
35 40 45

Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
50 55 60

Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
65 70 75 80

Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
85 90 95

Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser
100 105 110

Val Thr Trp Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr
115 120 125

Leu Ala Glu Gly Pro Pro Ala Glu Phe Met His Gly Pro Gln Val Leu
130 135 140

Ala Arg Cys Ser Glu Cys Ala Cys Pro Ala Leu Ala Ala Thr Ser Ala
145 150 155 160

Gly Val Arg Leu Glu Gly Val Asp Arg Pro Pro Thr Leu Pro Ser Gln
165 170 175

Gly Ser Gly Trp Pro Cys Ser His Ser Leu Ser Gly Cys His Leu Met
180 . 185 190

Ala Asp Gly Ala Lys Ala Leu Gly Lys Ala Asp Gly Pro Trp Pro Tyr
195 200 205

Leu Phe Val Arg Arg Thr Asp Val Pro Cys Pro Ala Ala Ser Glu Val
210 215 220

Gly Gly Cys Ala Pro Ser Ser Trp Arg Ala Leu Ala Glu Val Thr Gly
225 230 235 240

Cys Ser Leu Gly Pro Leu Gly Leu Ala Gln His Ala Gln Ala Ser Val
245 250 255

274

Leu Leu Leu Cys Tyr Lys Trp Ser His Ile Gly Glu Thr Ser Ser His
 260 265 270

Leu Arg Ser Lys Val Tyr Ala Ala Phe Gly Gly Ser Ser Pro Cys Leu
 275 280 285

Lys Gly Leu Met Ser Leu Trp Ala Ser Trp Leu Ser Arg Gly Arg Pro
 290 295 300

<210> 693

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 693

cgaagtcacg tggaggccag cctc

24

<210> 694

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer

<400> 694

cctgaccgaa ttcattaact ggctggac

29

<210> 695

<211> 166

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(166)

<223> Xaa = Any Amino Acid

<400> 695

Met Gly His His His His His Val Glu Ala Ser Leu Ser Val Arg
 1 5 10 15
 His Pro Glu Tyr Asn Arg Pro Leu Leu Ala Asn Asp Leu Met Leu Ile
 20 25 30
 Lys Leu Asp Glu Ser Val Ser Glu Ser Asp Thr Ile Arg Ser Ile Ser
 35 40 45
 Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn Ser Cys Leu Val Ser Gly
 50 55 60
 Trp Gly Leu Leu Ala Asn Gly Arg Met Pro Thr Val Leu Gln Cys Val
 65 70 75 80
 Asn Val Ser Val Val Ser Glu Glu Val Cys Ser Lys Leu Tyr Asp Pro

85										90					95				
Leu	Tyr	His	Pro	Ser	Met	Phe	Cys	Ala	Gly	Gly	Gly	Gln	Xaa	Gln	Xaa				
100								105					110						
Asp	Ser	Cys	Asn	Gly	Asp	Ser	Gly	Gly	Pro	Leu	Ile	Cys	Asn	Gly	Tyr				
115								120					125						
Leu	Gln	Gly	Leu	Val	Ser	Phe	Gly	Lys	Ala	Pro	Cys	Gly	Gln	Val	Gly				
130								135					140						
Val	Pro	Gly	Val	Tyr	Thr	Asn	Leu	Cys	Lys	Phe	Thr	Glu	Trp	Ile	Glu				
145								150					155			160			
Lys	Thr	Val	Gln	Ala	Ser														
165																			

```
<210> 696
<211> 504
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<222> (1)...(504)  
<223> n = A,T,C or G
```

<400>	696						
atgggccatc	atcatcatca	tacgtggag	gccagcctct	cgtacggca	cccagagtac		60
aacagaccct	tgctcgctaa	cgacctcatg	ctcatcaagt	tggacgaatc	cgtgtccgag		120
tctgacacca	tccggagcat	cagcattgct	tgcagtgcc	ctaccgcg	gaactcttgc		180
ctcgtttctg	gctggggctct	gctggcgaac	ggcagaatgc	ctaccgtgct	gcagtgcggtg		240
aacgtgtcgg	tggtgtctga	ggaggctctgc	agtaagctct	atgaccgcgt	gtaccacccc		300
agcatgttct	gcgccggcgg	agggcaanac	cagaangact	cctgcaacgg	tgactctggg		360
ggggccccctga	tctgcaaccg	gtacttgcag	ggccttgtgt	ctttcgaaa	agccccgtgt		420
ggccaagtgtg	gcgtgcacgg	tgtctacacc	aacctctgca	aattcactga	gtggatatagag		480
aaaaccgtcc	aqgccagtta	atga					504

```
<210> 697
<211> 21
<212> DNA
<213> Artificial Sequence
```

<220>
<223> PCR primer

<400> 697
ctcagggttc cggagccgcg g 21

```
<210> 698
<211> 35
<212> DNA
<213> Artificial Sequence
```

<220>
<223> PCR primer

<400> 698
ctatagaatt cattaccaa aagctgggct ccagc 35

<210> 699

<211> 241
 <212> PRT
 <213> Homo sapiens

<400> 699

```

Met Gln His His His His His His Leu Arg Val Pro Glu Pro Arg Pro
 1           5           10           15
Gly Glu Ala Lys Ala Glu Gly Ala Ala Pro Pro Thr Pro Ser Lys Pro
          20           25           30
Leu Thr Ser Phe Leu Ile Gln Asp Ile Leu Arg Asp Gly Ala Gln Arg
          35           40           45
Gln Gly Gly Arg Thr Ser Ser Gln Arg Gln Arg Asp Pro Glu Pro Glu
          50           55           60
Pro Glu Pro Glu Pro Glu Gly Gly Arg Ser Arg Ala Gly Ala Gln Asn
 65           70           75           80
Asp Gln Leu Ser Thr Gly Pro Arg Ala Ala Pro Glu Glu Ala Glu Thr
          85           90           95
Leu Ala Glu Thr Glu Pro Glu Arg His Leu Gly Ser Tyr Leu Leu Asp
          100          105          110
Ser Glu Asn Thr Ser Gly Ala Leu Pro Arg Leu Pro Gln Thr Pro Lys
          115          120          125
Gln Pro Gln Lys Arg Ser Arg Ala Ala Phe Ser His Thr Gln Val Ile
          130          135          140
Glu Leu Glu Arg Lys Phe Ser His Gln Lys Tyr Leu Ser Ala Pro Glu
145          150          155          160
Arg Ala His Leu Ala Lys Asn Leu Lys Leu Thr Glu Thr Gln Val Lys
          165          170          175
Ile Trp Phe Gln Asn Arg Arg Tyr Lys Thr Lys Arg Lys Gln Leu Ser
          180          185          190
Ser Glu Leu Gly Asp Leu Glu Lys His Ser Ser Leu Pro Ala Leu Lys
          195          200          205
Glu Glu Ala Phe Ser Arg Ala Ser Leu Val Ser Val Tyr Asn Ser Tyr
          210          215          220
Pro Tyr Tyr Pro Tyr Leu Tyr Cys Val Gly Ser Trp Ser Pro Ala Phe
225          230          235          240
Trp

```

<210> 700
 <211> 729
 <212> DNA
 <213> Homo sapiens

<400> 700

```

atgcagcatc accaccatca ccacctcagg gttccggagc cgcgccccgg ggaggcgaaa      60
gcggaggggg ccgcgccgcc gaccccgctc aagccgctca cgtccttcct catccaggac      120
atcctgcggg acggcgcgca gcggcaaggc ggccgcacga gcagccagag acagcgcgac      180
ccggagcccg agccagagcc agagccagag ggaggacgca gccgcgccgg ggcgcagaac      240
gaccagctga gcaccgggcc ccgcgccgcg ccggatgagg ccgagacgct ggcagagacc      300
gagccagaaa ggcacttggg gtcttatctg ttggactctg aaaacacttc aggcgccctt      360
ccaaggcttc cccaaacccc taagcagccg cagaagcgct cccgagctgc cttctccac      420
actcaggtga tcgagttgga gaggaagttc agccatcaga agtacctgtc ggcccctgaa      480
cgggcccacc tggccaagaa cctcaagctc acggagaccc aagtgaagat atggttccag      540
aacagacgct ataagactaa gcgaaagcag ctctcctcgg agctgggaga cttggagaag      600
cactcctttt tgccggccct gaaagaggag gccttctccc gggcctccct ggtctccgtg      660
tataacagct atccttacta cccatacctg cactgcgtgg gcagctggag cccagctttt      720
tggtaatga                                     729

```

277

<210> 701
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 701
 ctactaagcg ctggagtgag ggatcag

27

<210> 702
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 702
 catcgagaat tcactactct ctgactagat gtc

33

<210> 703
 <211> 161
 <212> PRT
 <213> Homo sapiens

<400> 703
 Met Gln His His His His His His Ala Gly Val Arg Asp Gln Gly Gln
 1 5 10 15
 Gly Ala Arg Trp Pro His Thr Gly Lys Arg Gly Pro Leu Leu Gln Gly
 20 25 30
 Leu Thr Trp Ala Thr Gly Gly His Cys Phe Ser Ser Glu Glu Ser Gly
 35 40 45
 Ala Val Asp Gly Ala Gly Gln Lys Lys Asp Arg Ala Trp Leu Arg Cys
 50 55 60
 Pro Glu Ala Val Ala Gly Phe Pro Leu Gly Ser Asp Cys Arg Glu Gly
 65 70 75 80
 Gly Arg Gln Gly Cys Gly Gly Ser Asp Asp Glu Asp Asp Leu Gly Val
 85 90 95
 Ala Pro Gly Leu Ala Pro Ala Trp Ala Leu Thr Gln Pro Pro Ser Gln
 100 105 110
 Ser Pro Gly Pro Gln Ser Leu Pro Ser Thr Pro Ser Ser Ile Trp Pro
 115 120 125
 Gln Trp Val Ile Leu Ile Thr Glu Leu Thr Ile Pro Ser Pro Ala His
 130 135 140
 Gly Pro Pro Trp Leu Pro Asn Ala Leu Glu Arg Gly His Leu Val Arg
 145 150 155 160
 Glu

<210> 704
 <211> 489
 <212> DNA
 <213> Homo sapiens

<400> 704
 atgcagcatc accaccatca ccacgctgga gtgagggatc aggggcaggg cgcgagatgg 60
 cctcacacag ggaagagagg gcccctcctg cagggcctca cctgggccac aggaggacac 120
 tgcttttctc ctgaggagtc aggagctgtg gatggtgctg gacagaagaa ggacagggcc 180
 tggctcaggt gtccagaggc tgtcgctggc ttccctttgg gatcagactg cagggagggg 240
 gggcggcagg gttgtggggg gagtgcgat gaggatgacc tgggggtggc tccaggcctt 300
 gccctgcct gggccctcac ccagcctccc tcacagtctc ctggccctca gtctctcccc 360
 tccactccat cctccatctg gcctcagtgg gtcattctga tcaactgaact gaccataccc 420
 agccctgccc acggccctcc atggctcccc aatgccctgg agaggggaca tctagtca 480
 gagtagtga 489

<210> 705
 <211> 132
 <212> PRT
 <213> Homo sapiens

<400> 705
 Thr Ala Ala Ser Asp Asn Phe Gln Leu Ser Gln Gly Gly Gln Gly Phe
 1 5 10 15
 Ala Ile Pro Ile Gly Gln Ala Met Ala Ile Ala Gly Gln Ile Arg Ser
 20 25 30
 Gly Gly Gly Ser Pro Thr Val His Ile Gly Pro Thr Ala Phe Leu Gly
 35 40 45
 Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val Gln Arg Val
 50 55 60
 Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr Gly Asp Val
 65 70 75 80
 Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr Ala Met Ala
 85 90 95
 Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser Val Asn Trp
 100 105 110
 Gln Thr Lys Ser Gly Gly Thr Arg Thr Gly Asn Val Thr Leu Ala Glu
 115 120 125
 Gly Pro Pro Ala
 130

<210> 706
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 706
 ggggaattca tcacctatgt gccgcctctg c

31

<210> 707
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 707
gggctcgagt cactcgccca cgaaatccgt gtaaaacagc

40

<210> 708
<211> 1203
<212> DNA
<213> Homo sapiens

<400> 708
atgcatcacc atcaccatca cacggccgcg tccgataact tccagctgtc ccagggtggg 60
cagggtattcg ccattccgat cgggcaggcg atggcgatcg cgggccagat caagcttccc 120
accgttcata tcgggcctac cgccttcctc ggcttgggtg ttgtcgacaa caacggcaac 180
ggcgcacgag tccaacgctg ggtcgggagc gctccggcgg caagtctcgg catctccacc 240
ggcgacgtga tcaccgcggt cgacggcgct ccgatcaact cggccaccgc gatggcggac 300
gcgcttaacg ggcacatcc cggtgacgtc atctcggtga cctggcaaac caagtcgggc 360
ggcacgcgta cagggaacgt gacattggcc gagggacccc cggccgaatt catcacctat 420
gtgcgcgctc tgctgctgga agtgggggta gaggagaagt tcatgacat ggtgctgggc 480
attggtccag tgctgggcct ggtctgtgtc ccgctcctag gctcagccag tgaccactgg 540
cgtggacgct atggccgccc cgggcccttc atctgggcac tgtccttggg catcctgctg 600
agcctctttc tcatcccaag ggccggctgg ctacgaggc tgctgtgcc ggatcccagg 660
cccctggagc tggcactgct catcctgggc gtggggctgc tggacttctg tggccaggag 720
tgcttcactc cactggaggc cctgctctct gacctcttc gggaccggga ccactgtgc 780
caggcctact ctgtctatgc cttcatgac agtcttgggg gctgcctggg ctacctctg 840
cctgccattg actgggacac cagtgcctg gcccctacc tgggcacca ggaggagtgc 900
ctctttggcc tgctcaccct catcttcctc acctgcgtag cagccacact gctggtggct 960
gaggaggcag cgctgggccc caccgagcca gcagaagggc tgtcggcccc ctccctgtcg 1020
cccactgct gtccatgccg ggcccgttg gctttccgga acctgggcgc cctgcttccc 1080
cggctgcacc agctgtgctg ccgcatgccc cgcacctgc gccggtctt cgtggctgag 1140
ctgtgcagct ggatggcact catgacctc acgctgtttt acacggattt cgtgggcgag 1200
tga 1203

<210> 709
<211> 400
<212> PRT
<213> Homo sapiens

<400> 709
Met His His His His His His Thr Ala Ala Ser Asp Asn Phe Gln Leu
5 10 15
Ser Gln Gly Gly Gln Gly Phe Ala Ile Pro Ile Gly Gln Ala Met Ala
20 25 30
Ile Ala Gly Gln Ile Lys Leu Pro Thr Val His Ile Gly Pro Thr Ala
35 40 45
Phe Leu Gly Leu Gly Val Val Asp Asn Asn Gly Asn Gly Ala Arg Val
50 55 60
Gln Arg Val Val Gly Ser Ala Pro Ala Ala Ser Leu Gly Ile Ser Thr
65 70 75 80
Gly Asp Val Ile Thr Ala Val Asp Gly Ala Pro Ile Asn Ser Ala Thr
85 90 95
Ala Met Ala Asp Ala Leu Asn Gly His His Pro Gly Asp Val Ile Ser

100				105				110							
Val	Thr	Trp	Gln	Thr	Lys	Ser	Gly	Gly	Thr	Arg	Thr	Gly	Asn	Val	Thr
		115					120					125			
Leu	Ala	Glu	Gly	Pro	Pro	Ala	Glu	Phe	Ile	Thr	Tyr	Val	Pro	Pro	Leu
	130					135					140				
Leu	Leu	Glu	Val	Gly	Val	Glu	Glu	Lys	Phe	Met	Thr	Met	Val	Leu	Gly
145					150					155					160
Ile	Gly	Pro	Val	Leu	Gly	Leu	Val	Cys	Val	Pro	Leu	Leu	Gly	Ser	Ala
				165					170					175	
Ser	Asp	His	Trp	Arg	Gly	Arg	Tyr	Gly	Arg	Arg	Arg	Pro	Phe	Ile	Trp
			180					185					190		
Ala	Leu	Ser	Leu	Gly	Ile	Leu	Leu	Ser	Leu	Phe	Leu	Ile	Pro	Arg	Ala
		195					200					205			
Gly	Trp	Leu	Ala	Gly	Leu	Leu	Cys	Pro	Asp	Pro	Arg	Pro	Leu	Glu	Leu
	210					215					220				
Ala	Leu	Leu	Ile	Leu	Gly	Val	Gly	Leu	Leu	Asp	Phe	Cys	Gly	Gln	Val
225					230					235					240
Cys	Phe	Thr	Pro	Leu	Glu	Ala	Leu	Leu	Ser	Asp	Leu	Phe	Arg	Asp	Pro
				245					250					255	
Asp	His	Cys	Arg	Gln	Ala	Tyr	Ser	Val	Tyr	Ala	Phe	Met	Ile	Ser	Leu
			260					265					270		
Gly	Gly	Cys	Leu	Gly	Tyr	Leu	Leu	Pro	Ala	Ile	Asp	Trp	Asp	Thr	Ser
		275					280					285			
Ala	Leu	Ala	Pro	Tyr	Leu	Gly	Thr	Gln	Glu	Glu	Cys	Leu	Phe	Gly	Leu
		290				295					300				
Leu	Thr	Leu	Ile	Phe	Leu	Thr	Cys	Val	Ala	Ala	Thr	Leu	Leu	Val	Ala
305					310					315					320
Glu	Glu	Ala	Ala	Leu	Gly	Pro	Thr	Glu	Pro	Ala	Glu	Gly	Leu	Ser	Ala
				325					330					335	
Pro	Ser	Leu	Ser	Pro	His	Cys	Cys	Pro	Cys	Arg	Ala	Arg	Leu	Ala	Phe
			340					345					350		
Arg	Asn	Leu	Gly	Ala	Leu	Leu	Pro	Arg	Leu	His	Gln	Leu	Cys	Cys	Arg
		355					360					365			
Met	Pro	Arg	Thr	Leu	Arg	Arg	Leu	Phe	Val	Ala	Glu	Leu	Cys	Ser	Trp
						375					380				
Met	Ala	Leu	Met	Thr	Phe	Thr	Leu	Phe	Tyr	Thr	Asp	Phe	Val	Gly	Glu
385					390					395					400

281

<210> 710
<211> 20
<212> PRT
<213> Homo sapiens

<400> 710
Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys Asp Val
 5 10 15

Ser Val Arg Val
 20

<210> 711
<211> 60
<212> DNA
<213> Homo sapiens

<400> 711
ctgctccac ctccaccgc gctctgcggg gcctctgcct gtgatgtctc cgtacgtgtg 60

<210> 712
<211> 10
<212> PRT
<213> Homo sapiens

<400> 712
Ala Ser Ala Cys Asp Val Ser Val Arg Val
 5 10

<210> 713
<211> 30
<212> DNA
<213> Homo sapiens

<400> 713
gcctctgcct gtgatgtctc cgtacgtgtg 30

<210> 714
<211> 9
<212> PRT
<213> Homo sapiens

<400> 714
Ala Ser Ala Cys Asp Val Ser Val Arg
 1 5

<210> 715
<211> 9
<212> PRT
<213> Homo sapiens

<400> 715
Ser Ala Cys Asp Val Ser Val Arg Val
 5

<210> 716
<211> 27

<212> DNA

<213> Homo sapiens

<400> 716

tctgcctgtg atgtctccgt acgtgtg

27

<210> 717

<211> 19

<212> PRT

<213> Homo sapiens

<400> 717

Gly Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser
5 10 15

Ala Ser Asp

<210> 718

<211> 19

<212> PRT

<213> Homo sapiens

<400> 718

Val Pro Pro Leu Leu Leu Glu Val Gly Val Glu Glu Lys Phe Met Thr
5 10 15

Met Val Leu

<210> 719

<211> 19

<212> PRT

<213> Homo sapiens

<400> 719

Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
5 10 15

Gln Leu Leu

<210> 720

<211> 57

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(57)

<223> n = A,T,C or G

<400> 720

ggcnathggnc cngtnytngg nytngtntgy gtnccnytny tnggnwsngc nwsngay 57

<210> 721
<211> 57
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(57)
<223> n = A,T,C or G

<400> 721
gtncncncny tnytnytnga rgtnggngtn gargaraart tyatgacnat ggtnytn 57

<210> 722
<211> 57
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(57)
<223> n = A,T,C or G

<400> 722
atggtncarm gnynttgggt nwsnmgnytn ytnmgncaym gnaargcnca rytnytn 57

<210> 723
<211> 9
<212> PRT
<213> Homo sapiens

<400> 723
Val Leu Gln Cys Val Asn Val Ser Val
1 5

<210> 724
<211> 9
<212> PRT
<213> Homo sapiens

<400> 724
Arg Met Pro Thr Val Leu Gln Cys Val
1 5

<210> 725
<211> 9
<212> PRT
<213> Homo sapiens

<400> 725
Asn Leu Cys Lys Phe Thr Glu Trp Ile
1 5

<210> 726
<211> 9
<212> PRT

<213> Homo sapiens

<400> 726

Met Leu Ile Lys Leu Asp Glu Ser Val
1 5

<210> 727

<211> 9

<212> PRT

<213> Homo sapiens

<400> 727

Leu Leu Ala Asn Asp Leu Met Leu Ile
1 5

<210> 728

<211> 10

<212> PRT

<213> Homo sapiens

<400> 728

Leu Leu Ala Asn Gly Arg Met Pro Thr Val
1 5 10

<210> 729

<211> 10

<212> PRT

<213> Homo sapiens

<400> 729

Leu Met Leu Ile Lys Leu Asp Glu Ser Val
1 5 10

<210> 730

<211> 10

<212> PRT

<213> Homo sapiens

<400> 730

Val Leu Gln Cys Val Asn Val Ser Val Val
1 5 10

<210> 731

<211> 10

<212> PRT

<213> Homo sapiens

<400> 731

Gly Leu Leu Ala Asn Gly Arg Met Pro Thr
1 5 10

<210> 732

<211> 10

<212> PRT

<213> Homo sapiens

<400> 732

Thr Val Leu Gln Cys Val Asn Val Ser Val

285

1 5 10

<210> 733

<211> 9

<212> PRT

<213> Homo sapiens

<400> 733

Gly Val Leu Val His Pro Gln Trp Val

1

5

<210> 734

<211> 9

<212> PRT

<213> Homo sapiens

<400> 734

Val Leu Val His Pro Gln Trp Val Leu

1

5

<210> 735

<211> 1195

<212> DNA

<213> Homo sapiens

<400> 735

```
ccgagactca cggccaagct aaggcgaaga gtgggtggct gaagccatac tattttatag 60
aattaatgga aagcagaaaa gacatcacaa accaagaaga actttggaaa atgaagccta 120
ggagaaatatt agaagaagac gattatttgc ataaggacac gggagagacc agcatgctaa 180
aaagacctgt gcttttgcat ttgcacaaaa cagcccatgc tgatgaattt gactgccctt 240
cagaacttca gcacacacag gaactctttc cacagtggca cttgccaatt aaaatagctg 300
ctattatagc atctctgact tttctttaca ctcttctgag ggaagtaatt caccctttag 360
caacttccca tcaacaatat tttataaaaa ttccaatcct ggcatcaaac aaagtcttgc 420
caatggtttc catcactctc ttggcattgg tttacctgcc aggtgtgata gcagcaattg 480
tccaacttca taatggaacc aagtataaga agtttccaca ttggttggat aagtggatgt 540
taacaagaaa gcagtttggg cttctcagtt tcttttttgc tgtactgcat gcaatttata 600
gtctgtctta cccaatgagg cgatcctaca gatacaagtt gctaaactgg gcatatcaac 660
aggtccaaca aaataaagaa gatgcctgga ttgagcatga tgtttggaga atggagattt 720
atgtgtctct gggaattgtg ggattggcaa tactggctct gttggctgtg acatctattc 780
catctgtgag tgactctttg acatggagag aatttcacta tattcagagc aagctaggaa 840
ttgtttccct tctactgggc acaatacacg cattgatttt tgccctggaat aagtggatag 900
atataaaaca atttgtatgg tatacacctc caacttttat gatagctgtt ttccttccaa 960
ttgttgtcct gatattttaa agcatactat tcctgccatg cttgaggaag aagatactga 1020
agattagaca tggttgggaa gacgtcacca aaattaacaa aactgagata tgttccagat 1080
tgtagaatta ctgtttacac acatttttgt tcaatattga tatattttat caccaacatt 1140
tcaagtttgt atttgttaat aaaatgatta ttcaaggaaa aaaaaaaaaa aaaaaa 1195
```

<210> 736

<211> 339

<212> PRT

<213> Homo sapiens

<400> 736

Met Glu Ser Arg Lys Asp Ile Thr Asn Gln Glu Glu Leu Trp Lys Met

5

10

15

Lys Pro Arg Arg Asn Leu Glu Glu Asp Asp Tyr Leu His Lys Asp Thr
 20 25 30
 Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Leu His Leu His Gln
 35 40 45
 Thr Ala His Ala Asp Glu Phe Asp Cys Pro Ser Glu Leu Gln His Thr
 50 55 60
 Gln Glu Leu Phe Pro Gln Trp His Leu Pro Ile Lys Ile Ala Ala Ile
 65 70 75 80
 Ile Ala Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu Val Ile His
 85 90 95
 Pro Leu Ala Thr Ser His Gln Gln Tyr Phe Tyr Lys Ile Pro Ile Leu
 100 105 110
 Val Ile Asn Lys Val Leu Pro Met Val Ser Ile Thr Leu Leu Ala Leu
 115 120 125
 Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Val Gln Leu His Asn Gly
 130 135 140
 Thr Lys Tyr Lys Lys Phe Pro His Trp Leu Asp Lys Trp Met Leu Thr
 145 150 155 160
 Arg Lys Gln Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala
 165 170 175
 Ile Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu
 180 185 190
 Leu Asn Trp Ala Tyr Gln Gln Val Gln Gln Asn Lys Glu Asp Ala Trp
 195 200 205
 Ile Glu His Asp Val Trp Arg Met Glu Ile Tyr Val Ser Leu Gly Ile
 210 215 220
 Val Gly Leu Ala Ile Leu Ala Leu Leu Ala Val Thr Ser Ile Pro Ser
 225 230 235 240
 Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr Ile Gln Ser Lys
 245 250 255
 Leu Gly Ile Val Ser Leu Leu Leu Gly Thr Ile His Ala Leu Ile Phe
 260 265 270
 Ala Trp Asn Lys Trp Ile Asp Ile Lys Gln Phe Val Trp Tyr Thr Pro
 275 280 285
 Pro Thr Phe Met Ile Ala Val Phe Leu Pro Ile Val Val Leu Ile Phe
 290 295 300
 Lys Ser Ile Leu Phe Leu Pro Cys Leu Arg Lys Lys Ile Leu Lys Ile
 305 310 315 320
 Arg His Gly Trp Glu Asp Val Thr Lys Ile Asn Lys Thr Glu Ile Cys

287

325

330

335

Ser Gln Leu

<210> 737

<211> 2172

<212> DNA

<213> Homo sapiens

<400> 737

```

aaaattgaat attgagatac cattctttag tgttaccttt ttaccacaca tgtgtttctg 60
aaaatattgg aattttattc atcttaaaaa ttggaccggt ccttatttac catctttaat 120
ccatttttagt actatgggtg agtacatgga attgaaagtct ggcttaaata ttacagaaagt 180
tatatatcta ttttatttta tttttttgag acagagtctc gctgtgtcac ccaggctgga 240
gtgcggtgcc acaatcttgg ctactgcaa cctctgagtc ccagggtcaa gcgataactca 300
tgcctcggcc tcctgagtag ctgggactac aggcgtgcac caccacatct ggctaactctt 360
tttttgtatt ttttagtagag acgggggttt actgtggtct ccactctctg acctcgtgat 420
ccgcctgcct cccaaagtgc tgggattaca ggcattgagcc accgcacaca gctgggactg 480
ggtaatttat aaagaaaaga ggtttaatga ctacacagttc cgcattggctg gagaggcctc 540
aggaaactta caatcatggt ggaaggcgaa ggggaagcaa ggcacgtctt acatgggtggc 600
aggagagaac gagtgggggg ggagactgcc acaaaacttt tttttttgag acaagagtct 660
ggccctgttg cccaggctgg agtgagtggt catgatctca gctcactgca acctctgcct 720
cacaggttca agcaattctc atgcctcagc ctcccgcata gctgggacca caggtatgca 780
ccaccacacc tagctaattt ttgtagtttt agtagagatg gggctcact atgttgctca 840
ggctggtcta aaactcctgg gctccagcaa tccgctgcc ttggcctccc aaagtgcctg 900
ggttacagggc ataagccacc acatccagcc tgccacatac ttttaaaacta tcaggtctca 960
tgagaactca tgcactatca caagaatagc atggggaaaa tccccccat aatccaatca 1020
cctcccacca ggtctcctcc gacacgtggg attgggtggg gacacagagc caaacctat 1080
cagatgctgc aggggctggg gacactgaga ccactcagac ctggtgtctc tgtcactctt 1140
ctgggctctg tctgtctcca ggacctccct cccctccat ggtatagaag gaaagtgcctg 1200
taaggtgcaa attgcacagg aactccttaa gacatacatc atccactcag cagttttagg 1260
ttcgcagcaa aatggagtgg aaggaacaga aatttcctgt gcacccctcc ccgctgtctc 1320
cgccatatcg gcatcctgca tccagagtgg tggactggtt acaggctatg aacctacact 1380
gatgcggcac caccacccag agtccacggg ttatgttggg tcacatttac tcttgctgtg 1440
gtatggtcta taggtttgga cagatgtccg ataactcctt ttacattttg gcatccttgg 1500
gtagctcgtc ttgtaggaat ggacttgctt caaagtggag gcaggcagat ccttcagacg 1560
ggtatatgga gccctgtttt cagttgcttt tctaattctc tcttatcgtt tacctcaaaa 1620
tcttcctgag gtctcgtctc cttttaaaat ccttgtctac tttgcagcat cactctgaca 1680
ctccattgat tcctcagcac ctactgacta cacggttagg agtgcaaggg tagaattcat 1740
gttttattca tctttgggtc tgtagcacc agcaaagtgc tcagtaaag cgcagtaatt 1800
gatttgacct ctgaacaaat acacactgta ctaagaatct acacaccgaa agacaaaaac 1860
aagacaaatt tgagtgtac aggtgtcacg cttggcatca cacatgtgcc tgtgtattcc 1920
tctaggtggt taccaggagc tctgccactg catgtccact agtgacgggt tcgctccacc 1980
accccgctg ggtagccgct gctctcacat aaggggtcca attaaaattg ccaggaataa 2040
attccccgg actttgactt ctcaagagct aagaaggttt gctgagtatt ctggcatgat 2100
gtttggtgat caaacaactg ctggccaaaa atgatgagta tttcccctc ttgctgaaga 2160
tgtgtccat ac
2172

```

<210> 738

<211> 2455

<212> DNA

<213> Homo sapiens

<400> 738

```

cagcttaaaa atggtttctt gaaatcagtg attagcattc actcaccagt acccctacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttatttctgc 120

```

```

ttattgcttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagaggggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaaagatggt tctcagggtt ttcttgacg attttcttct tttctgattc tgacaatggt 300
ttaaatcatt gtactgtggt tatcatttct ctgcatttat tttacccatc ttcctttgta 360
actgtccta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcaagggtg gctcacatct 480
gtaatcccag cactttgggg aggctgagac ggggtgatca cttgagggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatcccg ttcactaaaa atacaaaaat taccaggga 600
tggtggcggg cgctgtaat cccagggtact cgggaggctg agggaggaga atcgcttgaa 660
cctgggaggc tgaggaggga gaatcgcttg aaccgggag gcagagggtg cagtgaaccg 720
agatcatggt gctgcaactc agcctggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaacaaac aaaaacagaga gattttgctg caatgtacaa ggagcaattt 840
gctcctttta aaaaataatt tttggccagg cacagtggct cacacctgta atcccagcac 900
tttggaagc caaggtgggt ggatcatttg aggtcaggag tttgagatca gcctggccaa 960
catggtgaaa cactatctct attaaaaata caaaaatgtg ctcagtgtgg tgggtgcacat 1020
ctgtaatctc agcctccgc atagctggga ccacagggtat gcaccaccac acctagctaa 1080
tttttgtagt tttagtagag atggggtctc actatgttgc tcaggctggt ctaaaactcc 1140
tgggctccag caatccgcct gccttggcct cccaaagtgc tggggttaca ggcataagcc 1200
accacatcca gcctgccaca tacttttaaa ctatcaggtc tcatgagaac tcatgacta 1260
tcacaagaat agcatgggga aaatcccccc cataatccaa tcacctcca ccaggtctcc 1320
tccgacacgt gggattgggt ggggacacag agccaaaccg tatcagatgc tgcaggggct 1380
ggggacactg agaccactca gacctggtgt ctctgtcact cttctgggct ctgtctgtct 1440
ccaggacctc cctccccttc catggtatag aaggaaagt ctgtaagggt caaattgcac 1500
aggaaactct taagacatac atcatccact cagcagtttt aggttcgcag caaatggag 1560
tggaaggaac agaaatttcc tgtgcacccc tcccgcctgt ctccgccata tccgcatcct 1620
gcatccagag tgggtggactg gttacaggct atgaacctac actgatgcgg caccaccacc 1680
cagagtccac aggttatggt ggttcacatt tactcttgct gtggtatggt ctataggttt 1740
ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtctttagag 1800
aatggacttg cttaaaagt gaggcaggca gatccttcag acgggtatat ggagccctgt 1860
tttcagttgc ttttctaatt ctctcttctc gtttacctca aaatcttctc gaggtctcgc 1920
ttccttttaa taactttgac tactttgcag catcactctg acactccatt gattcctcag 1980
cacctactga ctacacggtt aggagtgcga gggtagaatt catgttttat tcatctttgg 2040
gtctgtagca cccagcaaag tgcctagtaa atgcgcagta attgatttga cctctgaaca 2100
aatacacact gtactaagaa tctacacacc gaaagacaaa aacaagacaa atttgagtgc 2160
tacagggtgc acgcttgga tcaacatgt gcctgtgtat tcccttaggt ggttaccagg 2220
agctctgcca ctgcatgtcc actagtgcg ggttcgctcc accaccccag ctgggtagcc 2280
gctgctctca cataaggggt ccaattaaaa ttgccaggaa taaattcccc cggactttga 2340
cttctcaaga gctaagaagg tttgctgagt attctggcat gatgtttggt gatcaaaaa 2400
ctgctggcca aaaatgatga gtatttcccc ctcttgctga agatgtgctc catac 2455

```

<210> 739

<211> 2455

<212> DNA

<213> Homo sapiens

<400> 739

```

cagcttaaaa atggtttctt gaaatcagt attagcattc actcaccagt acccctacta 60
aggggtaggc actggtttgt actcctggga atacaggagt acaccagaat ttatttctgc 120
ttattgcttt tgttgcaaat gccgtggctt catctgagga attctagaat tcagaggggtg 180
tagccctcca ctctgctgtc ttgctatctg ctctcattgc atccgtttta cctgcattct 240
gaaagatggt tctcagggtt ttcttgacg attttcttct tttctgattc tgacaatggt 300
ttaaatcatt gtactgtggt tatcatttct ctgcatttat tttacccatc ttcctttgta 360
actgtccta ttgtctttta atttctgcct gttctttatg gctttcaact tcataaataa 420
catgttttct caaatctctt tgtgaattcc agagagggcc aggcaagggtg gctcacatct 480
gtaatcccag cactttgggg aggctgagac ggggtgatca cttgagggtca ggagtttgag 540
accagcctgg ccaacatggt gaaatcccg ttcactaaaa atacaaaaat taccaggga 600
tggtggcggg cgctgtaat cccagggtact cgggaggctg agggaggaga atcgcttgaa 660
cctgggaggc tgaggaggga gaatcgcttg aaccgggag gcagagggtg cagtgaaccg 720

```

```

agatcatgtt gctgcactcc agcctgggtca acagagcaag actctgcctc aaaaacaaac 780
aaataaacia acaaaacaaac aaaacagaga gattttgctg caatgtacaa ggagcaattt 840
gctcctttta aaaaataatt tttggccagg cacagtggct cacacctgta atcccagcac 900
tttggaagc caaggtgggt ggatcatttg aggtcaggag tttgagatca gcctggccaa 960
catggtgaaa cactatctct attaaaaata caaaaatgtg ctgagtgtgg tgggtgacat 1020
ctgtaatctc agcctcccgc atagctggga ccacaggtat gcaccaccac acctagctaa 1080
ttttttagt tttagtagag atggggctc actatgttg tcaggctgggt ctaaaactcc 1140
tgggctccag caatccgcct gccttggcct cccaaagtgc tggggttaca ggcataagcc 1200
accacatcca gcctgccaca tacttttaaa ctatcaggtc tcatgagaac tcatgacta 1260
tcacaagaat agcatgggga aaatccccc cataatcaa tcacctcca ccaggtctcc 1320
tccgacacgt gggattgggt ggggacacag agccaaaccg tatcagatgc tgcaggggct 1380
ggggacactg agaccactca gacctgggtg ctctgtcact cttctgggct ctgtctgtct 1440
ccaggacctc cctccccttc catggtatag aaggaaagtg ctgtaagggtg caaattgcac 1500
aggaactctc taagacatac atcatccact cagcagtttt aggttcgcag caaaatggag 1560
tggaagggaac agaaatttcc tgtgcacccc tcccgcgtgt ctccgccata tcggcatcct 1620
gcatccagag tgggtggactg gttacagggt atgaacctac actgatgcgg caccaccacc 1680
cagagtcacac aggttatgtt ggttcacatt tactcttgct gtggtatggt ctataggttt 1740
ggacagatgt ccgataatcc tttttacatt ttggcatcct tgggtagctc gtctttagg 1800
aatggacttg cttcaaagtg gaggcaggca gatccttcag acgggtatat ggagccctgt 1860
tttcagttgc ttttctaatt ctctcttate gtttacctca aaatcttct gaggtctcgc 1920
ttccttttaa aatccttgct tactttgcag catcactctg aactccatt gattcctcag 1980
cacctactga ctacacggtt aggagtgcac gggtagaatt catgttttat tcatctttg 2040
gtctgtagca cccagcaaag tgctcagtaa atgcgcagta attgatttga cctctgaaca 2100
aatacacact gtactaagaa tctacacacc gaaagacaaa aacaagacaa atttgagtgc 2160
tacaggtgtc acgcttggtc tcacacatgt gcctgtgtat tcctctaggt ggttaccagg 2220
agctctgcca ctgcatgtcc actagtacg ggttcgctcc accaccccag ctgggtagcc 2280
gctgctctca cataaggggt ccaattaaaa ttgccaggaa taaattcccc cggactttga 2340
cttctcaaga gctaagaagg tttgctgagt attctggcat gatgtttggt gatcaacaa 2400
ctgctggcca aaaatgatga gtatttcccc ctcttgctga agatgtgctc catac 2455

```

<210> 740

<211> 62

<212> PRT

<213> Homo sapiens

<400> 740

```

Met Thr His Ser Ser Ala Trp Leu Glu Arg Pro Gln Glu Thr Tyr Asn
          5                      10                      15

```

```

His Gly Gly Arg Arg Arg Gly Ser Lys Ala Arg Leu Thr Trp Trp Gln
          20                      25                      30

```

```

Glu Arg Thr Ser Glu Gly Gly Asp Cys His Lys Leu Phe Phe Phe Glu
          35                      40                      45

```

```

Thr Arg Val Trp Pro Cys Cys Pro Gly Trp Ser Ala Val Ala
          50                      55                      60

```

<210> 741

<211> 135

<212> PRT

<213> Homo sapiens

<400> 741

```

Met Val Glu Gly Glu Gly Glu Ala Arg His Val Leu His Gly Gly Arg
          5                      10                      15

```

290

Arg Glu Arg Val Arg Gly Glu Thr Ala Thr Asn Phe Phe Phe Leu Arg
 20 25 30
 Gln Glu Ser Gly Pro Val Ala Gln Ala Gly Val Gln Trp His Asp Leu
 35 40 45
 Ser Ser Leu Gln Pro Leu Pro His Arg Phe Lys Gln Phe Ser Cys Leu
 50 55 60
 Ser Leu Pro His Ser Trp Asp His Arg Tyr Ala Pro Pro His Leu Ala
 65 70 75 80
 Asn Phe Cys Ser Phe Ser Arg Asp Gly Val Ser Leu Cys Cys Ser Gly
 85 90 95
 Trp Ser Lys Thr Pro Gly Leu Gln Gln Ser Ala Cys Leu Gly Leu Pro
 100 105 110
 Lys Cys Trp Gly Tyr Arg His Lys Pro Pro His Pro Ala Cys His Ile
 115 120 125
 Leu Leu Asn Tyr Gln Val Ser
 130 135

<210> 742
 <211> 77
 <212> PRT
 <213> Homo sapiens

<400> 742
 Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro Ile Ile Gln
 5 10 15
 Ser Pro Pro Thr Arg Ser Pro Pro Thr Arg Gly Ile Gly Trp Gly His
 20 25 30
 Arg Ala Lys Pro Tyr Gln Met Leu Gln Gly Leu Gly Thr Leu Arg Pro
 35 40 45
 Leu Arg Pro Gly Val Ser Val Thr Leu Leu Gly Ser Val Cys Leu Gln
 50 55 60
 Asp Leu Pro Pro Leu Pro Trp Tyr Arg Arg Lys Val Leu
 65 70 75

<210> 743
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 743
 Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
 5 10 15
 Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
 20 25 30

291

Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser
 35 40 45

Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
 50 55 60

<210> 744

<211> 76

<212> PRT

<213> Homo sapiens

<400> 744

Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
 5 10 15

Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 20 25 30

Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 35 40 45

Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 50 55 60

Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 65 70 75

<210> 745

<211> 76

<212> PRT

<213> Homo sapiens

<400> 745

Met Val Lys Ser Arg Phe Thr Lys Asn Thr Lys Ile Thr Gln Ala Trp
 5 10 15

Trp Arg Ala Pro Val Ile Pro Gly Thr Arg Glu Ala Glu Gly Gly Glu
 20 25 30

Ser Leu Glu Pro Gly Arg Leu Arg Glu Glu Asn Arg Leu Asn Pro Gly
 35 40 45

Gly Arg Gly Cys Ser Glu Pro Arg Ser Cys Cys Cys Thr Pro Ala Trp
 50 55 60

Ser Thr Glu Gln Asp Ser Ala Ser Lys Thr Asn Lys
 65 70 75

<210> 746

<211> 80

<212> PRT

<213> Homo sapiens

<400> 746

Met Leu Leu His Ser Ser Leu Val Asn Arg Ala Arg Leu Cys Leu Lys


```

<400> 748
Met His Tyr His Lys Asn Ser Met Gly Lys Ile Pro Pro Ile Ile Gln
          5                      10                      15

Ser Pro Pro Thr Arg Ser Pro Pro Thr Arg Gly Ile Gly Trp Gly His
          20                      25                      30

Arg Ala Lys Pro Tyr Gln Met Leu Gln Gly Leu Gly Thr Leu Arg Pro
          35                      40                      45

Leu Arg Pro Gly Val Ser Val Thr Leu Leu Gly Ser Val Cys Leu Gln
          50                      55                      60

Asp Leu Pro Pro Leu Pro Trp Tyr Arg Arg Lys Val Leu
          65                      70                      75

```

293

<210> 749
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 749
 Met Leu Val His Ile Tyr Ser Cys Cys Gly Met Val Tyr Arg Phe Gly
 5 10 15
 Gln Met Ser Asp Asn Pro Phe Tyr Ile Leu Ala Ser Leu Gly Ser Ser
 20 25 30
 Ser Cys Arg Asn Gly Leu Ala Ser Lys Trp Arg Gln Ala Asp Pro Ser
 35 40 45
 Asp Gly Tyr Met Glu Pro Cys Phe Gln Leu Leu Phe
 50 55 60

<210> 750
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 750
 Met Cys Leu Cys Ile Pro Leu Gly Gly Tyr Gln Glu Leu Cys His Cys
 5 10 15
 Met Ser Thr Ser Asp Gly Phe Ala Pro Pro Pro Gln Leu Gly Ser Arg
 20 25 30
 Cys Ser His Ile Arg Gly Pro Ile Lys Ile Ala Arg Asn Lys Phe Pro
 35 40 45
 Arg Thr Leu Thr Ser Gln Glu Leu Arg Arg Phe Ala Glu Tyr Ser Gly
 50 55 60
 Met Met Phe Gly Asp Gln Thr Thr Ala Gly Gln Lys
 65 70 75

<210> 751
 <211> 2479
 <212> DNA
 <213> Homo sapiens

<400> 751
 gtcattattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
 ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaaccat ggataccaac 120
 cggaaaaccc ctatcccgca cagccactg tgggtcccccac tgtctacgag gtgcatccgg 180
 ctcaagtacta cccgtccccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
 accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
 agaaagcact gtgcatcacc ttgaccctgg ggaccttcct cgtgggagct gcgctggccg 360
 ctggcctact ctggaagttc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
 cctcaggtac ctgcatcaac cctctaaact ggtgtgatgg cgtgtcacac tgccccggcg 480
 gggaggacga gaatcgggtgt gttgcctct acggaccaa cttcatcctt cagatgtact 540
 catctcagag gaagtctctg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600

```

gggcggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
atgacagcgg atccaccagc ttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
ataaaaaact gtaccacagt gatgcctgtt ctcaaaaagc agtggtttct ttacgctgtt 780
tagcctgagg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840
cgctcccggg ggctggccc tggcaggcca gcctgcacgt ccagaacgtc cacgtgtgcg 900
gaggctccat catcaccccc gagtggatcg tgacagccgc ccactgcgtg gaaaaacctc 960
ttaacaatcc atggcatttg acggcatttg cggggatttt gagacaatct ttcattgttct 1020
atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080
agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140
aaccagtgtg tctgcccacc ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200
ccgggtgggg ggccaccgag gagaaaggga agacctcaga agtgctgaac gctgccaagg 1260
tgcttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320
cagccatgat ctgtgccggc ttctgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380
gagggcctct ggtcacttcg aacaacaata tctgggtggc gataggggat acaagctggg 1440
gttctggctg tgccaaagct tacagaccag gagtgtacgg gaatgtgatg gtattcacgg 1500
actggattta tcgacaaatg aaggcaaacg gctaattcac atggtcttcg tccttgacgt 1560
cgttttacaa gaaaacaatg gggctgggtt tgcttcccgc tgcatgattt actcttagag 1620
atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680
tgccatactg tgcaggctgc agtggctccc ctgccagcc tgctctccct aaccttctgt 1740
ccgcaagggg tgatggccgg ctgggtgtgg gcactggcgg tcaattgtgg aaggaagagg 1800
gttggaggct gccccattg agatcttcct gctgagtcct ttccaggggc caattttgga 1860
tgagcatgga gctgtcactt ctcagctgct ggatgacttg agatgaaaaa ggagagacat 1920
ggaaaggagg acagccaggt ggcacctgca ggggctgccc tctggggcca cttggtagt 1980
tcccagcct acttcacaag gggattttgc tgatgggtt ttagagcctt agcagccctg 2040
gatggtggcc agaaataaag ggaccagccc ttcattgggtg gtgacgtgtt agtcacttgt 2100
aagggaaca gaaacatttt tgttcttatg ggggtgagaat atagacagtg cccttggtgc 2160
gaggaagca attgaaaagg aacttgcctt gagcactcct ggtgcaggtc tccacctgca 2220
cattgggtgg ggctcctggg agggagactc agccttcctc ctcatcctcc ctgacctgc 2280
tcctagcacc ctggagagtg aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340
atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400
atgctcagtt taaggtacac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460
ctgagttcaa agccatctt
2479

```

<210> 752

<211> 492

<212> PRT

<213> Homo sapiens

<400> 752

```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
      5                      10                      15

```

```

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
      20                      25                      30

```

```

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
      35                      40                      45

```

```

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
      50                      55                      60

```

```

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
      65                      70                      75                      80

```

```

Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
      85                      90                      95

```

```

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys

```

295

100					105					110					
Cys	Ser	Asn	Ser	Gly	Ile	Glu	Cys	Asp	Ser	Ser	Gly	Thr	Cys	Ile	Asn
		115					120					125			
Pro	Ser	Asn	Trp	Cys	Asp	Gly	Val	Ser	His	Cys	Pro	Gly	Gly	Glu	Asp
		130				135					140				
Glu	Asn	Arg	Cys	Val	Arg	Leu	Tyr	Gly	Pro	Asn	Phe	Ile	Leu	Gln	Met
145						150					155				160
Tyr	Ser	Ser	Gln	Arg	Lys	Ser	Trp	His	Pro	Val	Cys	Gln	Asp	Asp	Trp
				165					170					175	
Asn	Glu	Asn	Tyr	Gly	Arg	Ala	Ala	Cys	Arg	Asp	Met	Gly	Tyr	Lys	Asn
			180					185					190		
Asn	Phe	Tyr	Ser	Ser	Gln	Gly	Ile	Val	Asp	Asp	Ser	Gly	Ser	Thr	Ser
		195					200					205			
Phe	Met	Lys	Leu	Asn	Thr	Ser	Ala	Gly	Asn	Val	Asp	Ile	Tyr	Lys	Lys
	210						215				220				
Leu	Tyr	His	Ser	Asp	Ala	Cys	Ser	Ser	Lys	Ala	Val	Val	Ser	Leu	Arg
225						230					235				240
Cys	Leu	Ala	Cys	Gly	Val	Asn	Leu	Asn	Ser	Ser	Arg	Gln	Ser	Arg	Ile
				245					250					255	
Val	Gly	Gly	Glu	Ser	Ala	Leu	Pro	Gly	Ala	Trp	Pro	Trp	Gln	Val	Ser
			260					265					270		
Leu	His	Val	Gln	Asn	Val	His	Val	Cys	Gly	Gly	Ser	Ile	Ile	Thr	Pro
		275					280					285			
Glu	Trp	Ile	Val	Thr	Ala	Ala	His	Cys	Val	Glu	Lys	Pro	Leu	Asn	Asn
	290					295					300				
Pro	Trp	His	Trp	Thr	Ala	Phe	Ala	Gly	Ile	Leu	Arg	Gln	Ser	Phe	Met
305						310					315				320
Phe	Tyr	Gly	Ala	Gly	Tyr	Gln	Val	Gln	Lys	Val	Ile	Ser	His	Pro	Asn
				325					330					335	
Tyr	Asp	Ser	Lys	Thr	Lys	Asn	Asn	Asp	Ile	Ala	Leu	Met	Lys	Leu	Gln
			340					345					350		
Lys	Pro	Leu	Thr	Phe	Asn	Asp	Leu	Val	Lys	Pro	Val	Cys	Leu	Pro	Asn
		355					360					365			
Pro	Gly	Met	Met	Leu	Gln	Pro	Glu	Gln	Leu	Cys	Trp	Ile	Ser	Gly	Trp
	370					375					380				
Gly	Ala	Thr	Glu	Glu	Lys	Gly	Lys	Thr	Ser	Glu	Val	Leu	Asn	Ala	Ala
385						390					395				400
Lys	Val	Leu	Leu	Ile	Glu	Thr	Gln	Arg	Cys	Asn	Ser	Arg	Tyr	Val	Tyr
				405					410					415	

Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
 420 425 430

Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
 435 440 445

Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
 450 455 460

Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
 465 470 475 480

Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly
 485 490

<210> 753
 <211> 683
 <212> DNA
 <213> Homo sapiens

<400> 753
 gtcataattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
 ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaaccat ggataccaac 120
 cggaaaaccc ctatcccgca cagccactg tggccccac tgtctacgag gtgcatccgg 180
 ctcagtacta cccgtcccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
 accccgctcg ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
 agaaagcact gtgcatcacc ttgaccctgg ggaccttct cgtgggagct gcgctggccg 360
 ctggcctact ctggaagtto atgggcagca agtgctccaa ctctgggata gagtgcgact 420
 cctcaggtac ctgcatcaac ccctctaact ggtgtgatgg cgtgtcacac tgccccggcg 480
 gggaggacga gaatcggtgt gttcgcctct acggacaaaa cttcatcctt cagatgtact 540
 catctcagag gaagtcttgg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600
 gggcggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
 atgacagcgg atccaccagc ttt 683

<210> 754
 <211> 209
 <212> PRT
 <213> Homo sapiens

<400> 754
 Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
 1 5 10 15
 Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
 20 25 30
 Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
 35 40 45
 Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
 50 55 60
 Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
 65 70 75 80
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
 85 90 95

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
 100 105 110
 Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
 115 120 125
 Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
 130 135 140
 Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met
 145 150 155 160
 Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
 165 170 175
 Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
 180 185 190
 Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
 195 200 205
 Phe

<210> 755
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 755
 Val Gly Glu Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr
 1 5 10 15
 Glu Ala Arg Arg His Tyr Asp Glu Gly Val Arg
 20 25

<210> 756
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 756
 ggatccgccg ccaccatgtc actttctagc ctgct

35

<210> 757
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 757
 gtcgactcag ctggaccaca gccgcag

27

<210> 758
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 758
ggatccgccg ccaccatggg ctgcaggctg ctct

34

<210> 759
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 759
gtcgactcag aaatcctttc tcttgac

27

<210> 760
<211> 936
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...()
<223> n = A,T,C or G

<400> 760
atgggctgca ggctgntctg ctgtgcggtt ctctgtctcc tgggagcggc ccccatggaa 60
acgggagtta cgcagacacc aagacacctg gtcattggaa tgacaaataa gaagtctttg 120
aaatgtgaac aacatctggg tcataacgct atgtattggt acaagcaaag tgctaagaag 180
ccactggagc tcatgtttgt ctacagtctt gaagaacggg ttgaaaacaa cagtgtgcca 240
agtcgtttct cacctgaatg ccccaacagc tctcacttat tccttcacct acacacctg 300
cagccagaag actcggccct gtatctctgc gccagcagcc aagaccggac aagcagctcc 360
tacgagcagt acttcgggcc gggcaccagg ctccaggtca cagaggacct gaaaaacgtg 420
ttcccacccg aggtcgtctg gtttgagcca tcagaagcag agatctccca caccctaaag 480
gccacactgg tgtgcctggc cacaggcttc taccctgacc acgtggagct gagctggtgg 540
gtgaatggga aggaggtgca cagtggggtc agcacagacc cgcagccctc caaggagcag 600
cccgcctca atgactccag atactgcctg agcagccgcc tgagggtctc ggccaccttc 660
tggcagaacc ccgcgaacca cttccgctgt caagtcagc tctacgggct ctcgagaaat 720
gacgagtggg cccaggatag ggccaaacct gtcacccaga tcgtcagcgc cgaggcctgg 780
ggtagagcag actgtggctt cacctccgag tcttaccagc aaggggtcct gtctgccacc 840
atcctctatg agatcttgct agggaaggcc acctgtgatg ccgtgctggt cagtgccttc 900
gtgctgatgg ccattggtcaa gagaaaggat ttctga 936

<210> 761
<211> 834
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...()
<223> n = A,T,C or G

<400> 761
atgtcacttt ctgacctgct naagggtggtc acagcttcac tgtggctagg acctggcatt 60
gcccagaaga taactcaaac ccaaccagga atgttcgtgc aggaaaagga ggctgtgact 120
ctggactgca catatgacac cagtgatcaa agttatggtc tcttctggta caagcagccc 180

```

agcagtgggg aaatgatttt ttttatttat caggggtctt atgacgagca aaatgcaaca 240
gaaggtcgct actcattgaa tttccagaag gcaagaaaat cgcgcaacct tgtcatctcc 300
gcttcacaac tgggggactc agcaatgtat ttctgtgcaa tgagagaggg cgcgggagga 360
ggaaacaaac tcacctttgg gacaggcact cagctaaaag tggaactcaa tatccagaac 420
cctgaccctg ccgtgtacca gctgagagac tctaaatcca gtgacaagtc tgtctgccta 480
ttcaccgatt ttgattctca aacaaatgtg tcacaaagta aggattctga tgtgtatatc 540
acagacaaaa ctgtgctaga catgaggtct atggacttca agagcaacag tgctgtggcc 600
tggagcaaca aatctgactt tgcattgtgca aacgccttca acaacagcat tattccagaa 660
gacaccttct tccccagccc agaaagttcc tgtgatgtca agctggtcga gaaaagcttt 720
gaaacagata cgaacctaaa ctttcaaaac ctgtcagtga ttgggttccg aatcctcctc 780
ctgaaagtgg ccgggtttta tctgctcatg acgctgcggc tgtggtccag ctga      834

```

<210> 762

<211> 311

<212> PRT

<213> Homo sapiens

<220>

<221> variant

<222> (1)...(311)

<223> Xaa = Any amino acid

<400> 762

```

Met Gly Cys Arg Leu Xaa Cys Cys Ala Val Leu Cys Leu Leu Gly Ala
                    5                      10                      15

```

```

Val Pro Met Glu Thr Gly Val Thr Gln Thr Pro Arg His Leu Val Met
                    20                      25                      30

```

```

Gly Met Thr Asn Lys Lys Ser Leu Lys Cys Glu Gln His Leu Gly His
                    35                      40                      45

```

```

Asn Ala Met Tyr Trp Tyr Lys Gln Ser Ala Lys Lys Pro Leu Glu Leu
                    50                      55                      60

```

```

Met Phe Val Tyr Ser Leu Glu Glu Arg Val Glu Asn Asn Ser Val Pro
                    65                      70                      75                      80

```

```

Ser Arg Phe Ser Pro Glu Cys Pro Asn Ser Ser His Leu Phe Leu His
                    85                      90                      95

```

```

Leu His Thr Leu Gln Pro Glu Asp Ser Ala Leu Tyr Leu Cys Ala Ser
                    100                     105                     110

```

```

Ser Gln Asp Arg Thr Ser Ser Ser Tyr Glu Gln Tyr Phe Gly Pro Gly
                    115                     120                     125

```

```

Thr Arg Leu Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu
                    130                     135                     140

```

```

Val Ala Val Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys
                    145                     150                     155                     160

```

```

Ala Thr Leu Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu
                    165                     170                     175

```

```

Leu Ser Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr
                    180                     185                     190

```


300

Asp Pro Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr
 195 200 205
 Cys Leu Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro
 210 215 220
 Arg Asn His Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn
 225 230 235 240
 Asp Glu Trp Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser
 245 250 255
 Ala Glu Ala Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr
 260 265 270
 Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly
 275 280 285
 Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala
 290 295 300
 Met Val Lys Arg Lys Asp Phe
 305 310

<210> 763
 <211> 277
 <212> PRT
 <213> Homo sapiens

<400> 763

Met Ser Leu Ser Ser Leu Leu Lys Val Val Thr Ala Ser Leu Trp Leu
 5 10 15
 Gly Pro Gly Ile Ala Gln Lys Ile Thr Gln Thr Gln Pro Gly Met Phe
 20 25 30
 Val Gln Glu Lys Glu Ala Val Thr Leu Asp Cys Thr Tyr Asp Thr Ser
 35 40 45
 Asp Gln Ser Tyr Gly Leu Phe Trp Tyr Lys Gln Pro Ser Ser Gly Glu
 50 55 60
 Met Ile Phe Leu Ile Tyr Gln Gly Ser Tyr Asp Glu Gln Asn Ala Thr
 65 70 75 80
 Glu Gly Arg Tyr Ser Leu Asn Phe Gln Lys Ala Arg Lys Ser Ala Asn
 85 90 95
 Leu Val Ile Ser Ala Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe Cys
 100 105 110
 Ala Met Arg Glu Gly Ala Gly Gly Gly Asn Lys Leu Thr Phe Gly Thr
 115 120 125
 Gly Thr Gln Leu Lys Val Glu Leu Asn Ile Gln Asn Pro Asp Pro Ala
 130 135 140

Val Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu
145 150 155 160

Phe Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser
165 170 175

Asp Val Tyr Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp
180 185 190

Phe Lys Ser Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala
195 200 205

Cys Ala Asn Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe
210 215 220

Pro Ser Pro Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe
225 230 235 240

Glu Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe
245 250 255

Arg Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu
260 265 270

Arg Leu Trp Ser Ser
275

<210> 764

<211> 1536

<212> DNA

<213> Homo sapiens

<400> 764

atgtacaacc tgttgctgtc ctacgacaga catggggacc acctgcagcc cctggacctc 60
gtgcccacatc accaggggtct cacccttttc aagctggctg gaggaggagg taacactgtg 120
atgtttcagc acctgatgca gaagcgaag cacaccagtg ggacgtatgg accactgacc 180
tcgactctct atgacctcac agagatcgac tcctcagggg atgagcagtc cctgctggaa 240
cttatcatca ccaccaagaa gcgggaggct cgccagatcc tggaccagac gccggtgaag 300
gagctggtga gcctcaagtg gaagcgttac gggcgccgt acttctgcat gctgggtgcc 360
atatatctgc tgtacatcat ctgcttcacc atgtgctgca tctaccgcc cctcaagccc 420
aggaccaata accgcacgag ccccgggac aacaccctct tacagcagaa gctacttcag 480
gaagcctaca tgacccttaa ggacgatata cggctggtcg gggagctggt gactgtcatt 540
ggggctatca tcctcctgct ggtagaggtt ccagacatct tcagaatggg ggtcactcgc 600
ttctttggac agaccatcct tggggggcca ttccatgtcc tcatcatcac ctatgccttc 660
atggtgctgg tgaccatggt gatgcggctc atcagtgccca gcggggagggt ggtacccatg 720
tcctttgcac tcgtgctggg ctggtgcaac gtcattgtact tcgcccgagg attccagatg 780
ctaggccctc tcaccatcat gattcagaag atgatttttg gcgacctgat gcgattctgc 840
tggctgatgg ctgtggtcat cctgggcttt gcttcagcct tctatatcat cttccagaca 900
gaggaccccg aggagctagg ccacttctac gactacccca tggccctggt cagcaccttc 960
gagctgttcc ttaccatcat cgatggccca gccaaactaca acgtggacct gcccttcatt 1020
tacagcatca cctatgctgc ctttgccatc atcgccacac tgctcatgct caacctcctc 1080
attgccatga tgggcgacac tcactggcga gtggcccatg agcgggatga gctgtggagg 1140
gccagattg tggccaccac ggtgatgctg gagcgggaag tgccctcgtg cctgtggcct 1200
cgctccggga tctgcggacg ggagtatggc ctgggagacc gctggttctt gcgggtggaa 1260
gacaggcaag atctcaaccg gcagcggatc caacgctacg cacaggcctt ccacaccgg 1320
ggctctgagg atttgacaa agactcagtg gaaaaactag agctgggctg tcccttcagc 1380

```
<210> 765
<211> 1533
<212> DNA
<213> Homo sapiens
```

<400>	765						
atgtacaacc	tgttgctgtc	ctacgcacaga	catggggacc	acctgcagcc	cctggacctc	60	
gtgccaatc	accagggtct	cacccctttc	aagctggctg	gagtgagg	taacactgtg	120	
atgtttcagc	acctgatgca	gaagcggaag	cacaccag	ggacgtatgg	accactgacc	180	
tgcactctct	atgacctcac	agagatcgac	tcctcagggg	atgagcagtc	cctgctggaa	240	
cttatcatca	ccaccaagaa	gcgggaggct	cgccagatcc	tggaccagac	gcgggtgaag	300	
gagctgggtga	gacctcaagt	gaagcgggtac	ggggcgccgt	acttctgcat	gctgggtgcc	360	
atatctctgc	tgtacatcat	ctgcttcacc	atgtgctgca	tctaccgccc	cctcaagccc	420	
aggaccaata	accgcacgag	cccccgggac	aacacctct	tacagcagaa	gctacttcag	480	
gaagcctaca	tgacccctaa	ggacgatatc	cgctggtctg	gggagctgg	gactgtcatt	540	
ggggctatca	tcactctgct	ggtagagggt	ccagacatct	tcagaatggg	ggtcactcgc	600	
ttctttggac	agaccatcct	tgggggcca	ttccatgtcc	tcatcatcac	ctatgccttc	660	
atggtgctgg	tgaccatggt	gatgcggctc	atcagtcca	gcggggaggt	ggtaccatg	720	
tcctttgcac	tcgtgctggg	ctggtgcaac	gtcatgtact	tcgcccagg	attccagatg	780	
ctaggccctc	tcaccatcat	gattcagaag	atgatttttg	gcgacctgat	gcgattctgc	840	
tggctgatgg	ctgtggtcat	ctctggcttt	gcttcagcct	tctatatcat	cttcagaca	900	
gaggaccocg	aggagctagg	ccacttctac	gactaccca	tggccctgtt	cagcaccttc	960	
gagctgttcc	ttaccatcat	cgatggcca	gccaaactaca	acgtggacct	gcccttcag	1020	
tacagcatca	cctatgctgc	ctttgccatc	atcgccacac	tgtctatgct	caacctcctc	1080	
attgccatga	tgggcgacac	tcactggcga	gtggcccatg	agcgggatga	gctgtggagg	1140	
gccagattg	tggccaccac	ggtgatgctg	gagcggaagc	tgctctgctg	cctgtggcct	1200	
cgctccggga	tctgcggacg	ggagtatggc	ctgggagacc	gctggttct	gcgggtggaa	1260	
gacagccaag	atctcaaccg	gcagcggatc	caacgctacg	cacaggcctt	ccacaccocg	1320	
ggctctgagg	atttgacaa	agactcagtg	gaaaaactag	agctgggctg	tccttcaagc	1380	
ccccacctgt	cccttccat	gccctcagtg	tctcgaaagta	cctcccgag	cagtgccaat	1440	
tgggaaaggc	ttcggaagg	gacctgagg	agagacctgc	gtgggataat	caacagggg	1500	
ctggaggacg	gggagagctg	ggaatatcag	atc			1533	

```
<210> 766
<211> 511
<212> PRT
<213> Homo sapiens
```

```

<400> 766
Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg His Gly Asp His Leu Gln
      5                      10                      15

Pro Leu Asp Leu Val Pro Asn His Gln Gly Leu Thr Pro Phe Lys Leu
      20                      25                      30

Ala Gly Val Glu Gly Asn Thr Val Met Phe Gln His Leu Met Gln Lys
      35                      40                      45

Arg Lys His Thr Gln Trp Thr Tyr Gly Pro Leu Thr Ser Thr Leu Tyr
      50                      55                      60

Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp Glu Gln Ser Leu Leu Glu
      65                      70                      75                      80

```


385 390 395 400
 Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly Leu Gly Asp Arg Trp Phe
 405 410 415
 Leu Arg Val Glu Asp Arg Gln Asp Leu Asn Arg Gln Arg Ile Gln Arg
 420 425 430
 Tyr Ala Gln Ala Phe His Thr Arg Gly Ser Glu Asp Leu Asp Lys Asp
 435 440 445
 Ser Val Glu Lys Leu Glu Leu Gly Cys Pro Phe Ser Pro His Leu Ser
 450 455 460
 Leu Pro Met Pro Ser Val Ser Arg Ser Thr Ser Arg Ser Ser Ala Asn
 465 470 475 480
 Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg Arg Asp Leu Arg Gly Ile
 485 490 495
 Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser Trp Glu Tyr Gln Ile
 500 505 510

 <210> 767
 <211> 134
 <212> PRT
 <213> Homo sapiens

 <400> 767
 Met Tyr Asn Leu Leu Leu Ser Tyr Asp Arg His Gly Asp His Leu Gln
 5 10 15
 Pro Leu Asp Leu Val Pro Asn His Gln Gly Leu Thr Pro Phe Lys Leu
 20 25 30
 Ala Gly Val Glu Gly Asn Thr Val Met Phe Gln His Leu Met Gln Lys
 35 40 45
 Arg Lys His Thr Gln Trp Thr Tyr Gly Pro Leu Thr Ser Thr Leu Tyr
 50 55 60
 Asp Leu Thr Glu Ile Asp Ser Ser Gly Asp Glu Gln Ser Leu Leu Glu
 65 70 75 80
 Leu Ile Ile Thr Thr Lys Lys Arg Glu Ala Arg Gln Ile Leu Asp Gln
 85 90 95
 Thr Pro Val Lys Glu Leu Val Ser Leu Lys Trp Lys Arg Tyr Gly Arg
 100 105 110
 Pro Tyr Phe Cys Met Leu Gly Ala Ile Tyr Leu Leu Tyr Ile Ile Cys
 115 120 125
 Phe Thr Met Cys Cys Ile
 130

305

<210> 768
<211> 55
<212> PRT
<213> Homo sapiens

<400> 768
Ala Tyr Arg Pro Leu Lys Pro Arg Thr Asn Asn Arg Thr Ser Pro Arg
 5 10 15

Asp Asn Thr Leu Leu Gln Gln Lys Leu Leu Gln Glu Ala Tyr Met Thr
 20 25 30

Pro Lys Asp Asp Ile Arg Leu Val Gly Glu Leu Val Thr Val Ile Gly
 35 40 45

Ala Ile Ile Ile Leu Leu Val
 50 55

<210> 769
<211> 39
<212> PRT
<213> Homo sapiens

<400> 769
Glu Val Pro Asp Ile Phe Arg Met Gly Val Thr Arg Phe Phe Gly Gln
 5 10 15

Thr Ile Leu Gly Gly Pro Phe His Val Leu Ile Ile Thr Tyr Ala Phe
 20 25 30

Met Val Leu Val Thr Met Val
 35

<210> 770
<211> 19
<212> PRT
<213> Homo sapiens

<400> 770
Met Arg Leu Ile Ser Ala Ser Gly Glu Val Val Pro Met Ser Phe Ala
 5 10 15

Leu Val Leu

<210> 771
<211> 52
<212> PRT
<213> Homo sapiens

<400> 771
Gly Trp Cys Asn Val Met Tyr Phe Ala Arg Gly Phe Gln Met Leu Gly
 5 10 15

Pro Phe Thr Ile Met Ile Gln Lys Met Ile Phe Gly Asp Leu Met Arg

306

20 25 30
 Phe Cys Trp Leu Met Ala Val Val Ile Leu Gly Phe Ala Ser Ala Phe
 35 40 45
 Tyr Ile Ile Phe
 50

 <210> 772
 <211> 213
 <212> PRT
 <213> Homo sapiens

 <400> 772
 Gln Thr Glu Asp Pro Glu Glu Leu Gly His Phe Tyr Asp Tyr Pro Met
 5 10 15
 Ala Leu Phe Ser Thr Phe Glu Leu Phe Leu Thr Ile Ile Asp Gly Pro
 20 25 30
 Ala Asn Tyr Asn Val Asp Leu Pro Phe Met Tyr Ser Ile Thr Tyr Ala
 35 40 45
 Ala Phe Ala Ile Ile Ala Thr Leu Leu Met Leu Asn Leu Leu Ile Ala
 50 55 60
 Met Met Gly Asp Thr His Trp Arg Val Ala His Glu Arg Asp Glu Leu
 65 70 75 80
 Trp Arg Ala Gln Ile Val Ala Thr Thr Val Met Leu Glu Arg Lys Leu
 85 90 95
 Pro Arg Cys Leu Trp Pro Arg Ser Gly Ile Cys Gly Arg Glu Tyr Gly
 100 105 110
 Leu Gly Asp Arg Trp Phe Leu Arg Val Glu Asp Arg Gln Asp Leu Asn
 115 120 125
 Arg Gln Arg Ile Gln Arg Tyr Ala Gln Ala Phe His Thr Arg Gly Ser
 130 135 140
 Glu Asp Leu Asp Lys Asp Ser Val Glu Lys Leu Glu Leu Gly Cys Pro
 145 150 155 160
 Phe Ser Pro His Leu Ser Leu Pro Met Pro Ser Val Ser Arg Ser Thr
 165 170 175
 Ser Arg Ser Ser Ala Asn Trp Glu Arg Leu Arg Gln Gly Thr Leu Arg
 180 185 190
 Arg Asp Leu Arg Gly Ile Ile Asn Arg Gly Leu Glu Asp Gly Glu Ser
 195 200 205
 Trp Glu Tyr Gln Ile
 210

<210> 773
 <211> 1302
 <212> DNA
 <213> Homo sapiens

<400> 773

```

tggacaaaagg ggggtcacaca ttccttccat acggttgagc ctctacctgc ctgggtgctgg 60
tcacagttca gcttcttcat gatggtggat cccaatggca atgaatccag tgctacatac 120
ttcatcctaa taggcctccc tggtttagaa gaggctcagt tctgggtggc cttcccattg 180
tgctccctct accttattgc tgtgctaggt aacttgacaa tcatctacat tgtgcggact 240
gagcacagcc tgcattgagcc catgtatata tttctttgca tgctttcagg cattgacatc 300
ctcatctcca cctcatccat gcccaaaatg ctggccatct tctggttcaa ttccactacc 360
atccagtttg atgcttgtct gctacagatg tttgccatcc actccttate tggcatggaa 420
tcacacagtc tgctggccat ggcttttgac cgctatgtgg ccatctgtca cccactgcgc 480
catgccacag tacttacgtt gcctcgtgtc accaaaattg gtgtggctgc tgtggtgcgg 540
ggggctgcac tgatggcacc ccttcctgtc ttcacaaagc agctgccctt ctgccgctcc 600
aatatccttt cccattccta ctgcctacac caagatgtca tgaagctggc ctgtgatgat 660
atccgggtca atgtcgtcta tggccttate gtcacatctc ccgccattgg cctggactca 720
cttctcatct ccttctcata tctgcttatt ctttaagactg tgttgggctt gacacgtgaa 780
gccaggcca aggcatttgg cacttgcgtc tctcatgtgt gtgctgtgtt catattctat 840
gtacctttca ttggattgtc catggtgcat cgcttttagc agcggcgtga ctctccgctg 900
cccgctcatc tggccaatat ctatctgctg gttcctcctg tgctcaacc aattgtctat 960
ggagtgaaga caaaggagat tgcacagcgc atccttcgac ttttccatgt ggccacacac 1020
gcttcagagc cctaggtgtc agtgatcaaa cttcttttcc attcagagtc ctctgattca 1080
gatttttaag ttaacatttt ggaagacagt attcagaaaa aaaatttcct taataaaaaat 1140
acaactcaga tccttcaaatt atgaaactgg ttggggaatc tccatttttt caatattatt 1200
ttcttctttg ttttcttgtc acatataatt attaataccc tgactagggt gtggttttag 1260
ggttattact tttcatttta ccatgcagtc caaatctaaa ct 1302

```

<210> 774
 <211> 2061
 <212> DNA
 <213> Homo sapiens

<400> 774

```

acgattcgac agcgcacatc tgcacttttc catgtggcca cacacgcttc agagccctag 60
gtgtcagtgat tcaaaacttct tttccattca gagtcctctg attcagattt taatgttaac 120
attttggaag acagtattca gaaaaaaaat ttccttaata aaaatacaac tcagatcctt 180
caaatatgaa actggttggg gaatctccat tttttcaata ttattttctt ctttgttttc 240
ttgctacata taattattaa taccctgact aggttgtggt tggagggtta ttacttttca 300
ttttaccatg cagtccaaat ctaaaactgct tctactgatg gtttacagca ttctgagata 360
agaatggtac atctagagaa catttgccaa aggcctaagc acggcaaagg aaaataaaca 420
cagaatataa taaaatgaga taatctagct taaaactata acttcctctt cagaactccc 480
aaccacattg gatctcagaa aaatgctgtc ttcaaaatga cttctacaga gaagaaataa 540
tttttctctt ggacactagc acttaagggg aagattggaa gtaaagcctt gaaaagagta 600
catttaccta cgttaatgaa agttgacaca ctgttctgag agttttcaca gcatatggac 660
cctgtttttc ctatttaatt ttcttatcaa ccctttaatt aggcaaagat attattagta 720
ccctcattgt agccatggga aaattgatgt tcagtgggga tcagtgaatt aaatggggtc 780
atacaagtat aaaaattaaa aaaaaaggac ttcattgcca atctcatatg atgtggaaga 840
actgttagag taaccaacag ggtagtgggt tagagatttc cagagtctta catttctag 900
aggaggtatt taattcttct tcactcatcc atgtgtgtat ttaggaaatt cctggcaaca 960
gaactcatgg ctttaatccc actagctatt gcttattgtc ctgggtccaat tgccaattac 1020
ctgtgtcttg gaagaagtga tttctagggt caccattatg gaagattctt attcagaaag 1080
tctgcatagg gcttatagca agttatttat ttttaaaagt tccatagggt attctgatag 1140
gcagtgaagg tagggagcca ccagttatga tgggaagtat ggaatggcag gtcttgaaga 1200
taacattggc cttttgagtg tgactcgtag ctggaaagtg agggaatctt caggaccatg 1260
ctttatttgg ggcttctgtc agtatggaac agggactttg agaccaggaa agcaatctga 1320

```



```

cttaggcatg ggaatcaggc atttttgctt ctgaggggct attaccaagg gttaataggt 1380
ttcatcttca acaggatatg acaacagtgt taaccaagaa actcaaatta caaatactaa 1440
aacatgtgat catatatgtg gtaagtttca ttttcttttt caatcctcag gttccctgat 1500
atggattcct ataacatgct ttcatccctt tttgtaatgg atatcatatt tggaaatgcc 1560
tatttaatac ttgtatttgc tgctggactg taagcccatg agggcactgt ttattattga 1620
atgtcatctc tgttcatcat tgactgctct ttgtcatca ttgaatcccc cagcaaagtg 1680
cctagaacat aatagtgtt atgcttgaca ccggttattt ttcatcaaac ctgattcctt 1740
ctgtcctgaa cacatagcca ggcaattttc cagccttctt tgagttgggt attattaaat 1800
tctggccatt acttccaatg tgagtggag tgacatgtgc aatttctata cctggctcat 1860
aaaaccctcc catgtgcagc ctttcatgtt gacattaaat gtgacttggg aagctatgtg 1920
ttacacagag taaatcacca gaagcctgga tttctgaaaa aactgtgcag agccaaacct 1980
ctgtcatttg caactccac ttgtatttgt acgaggcagt tggataagtg aaaaataaag 2040
tactattgtg tcaagtctct g
2061

```

<210> 775

<211> 957

<212> DNA

<213> Homo sapiens

<400> 775

```

atgatggtgg atcccaatgg caatgaatcc agtgctacat acttcatcct aataggcctc 60
cctggtttag aagaggctca gttctggttg gccttcccat tgtgctccct ctaccttatt 120
gctgtgctag gtaacttgac aatcatctac attgtgcgga ctgagcacag cctgcatgag 180
cccatgtata ttttctttg catgctttca ggcattgaca tctcatctc cacctcatcc 240
atgccccaaa tgctggccat cttctggttc aattccacta ccatccagtt tgatgcttgt 300
ctgtacaga tgtttgccat ccactcctta tctggcatgg aatccacagt gctgctggcc 360
atggcttttg accgctatgt ggccatctgt caccactgc gccatgccac agtacttacg 420
ttgcctcgtg tcacaaaaat tgggtgtggct gctgtggtgc ggggggctgc actgatggca 480
ccccttcttg tcttcatcaa gcagctgcc cttctgccgt ccaatatcct ttcccattcc 540
tactgcctac accaagatgt catgaagctg gcctgtgatg atatccgggt caatgtcgtc 600
tatggcctta tcttcatcat ctccgccatt ggcttgact cacttctcat ctcttctca 660
tatctgctta ttcttaagac tgtgttgggc ttgacacgtg aagcccaggc caaggcattt 720
ggcacttgcg tctctcatgt gtgtgctgtg ttcatattct atgtacctt cattggattg 780
tccatggtgc atcgctttag caagcggcgt gactctccgc tgcccgctcat cttggccaat 840
atctatctgc tggttcctcc tgtgctcaac ccaattgtct atggagtga gacaaaggag 900
attcgacagc gcacctctcg acttttccat gtggccacac acgcttcaga gccctag 957

```

<210> 776

<211> 954

<212> DNA

<213> Homo sapiens

<400> 776

```

atgatggtgg atcccaatgg caatgaatcc agtgctacat acttcatcct aataggcctc 60
cctggtttag aagaggctca gttctggttg gccttcccat tgtgctccct ctaccttatt 120
gctgtgctag gtaacttgac aatcatctac attgtgcgga ctgagcacag cctgcatgag 180
cccatgtata ttttctttg catgctttca ggcattgaca tctcatctc cacctcatcc 240
atgccccaaa tgctggccat cttctggttc aattccacta ccatccagtt tgatgcttgt 300
ctgtacaga tgtttgccat ccactcctta tctggcatgg aatccacagt gctgctggcc 360
atggcttttg accgctatgt ggccatctgt caccactgc gccatgccac agtacttacg 420
ttgcctcgtg tcacaaaaat tgggtgtggct gctgtggtgc ggggggctgc actgatggca 480
ccccttcttg tcttcatcaa gcagctgcc cttctgccgt ccaatatcct ttcccattcc 540
tactgcctac accaagatgt catgaagctg gcctgtgatg atatccgggt caatgtcgtc 600
tatggcctta tcttcatcat ctccgccatt ggcttgact cacttctcat ctcttctca 660
tatctgctta ttcttaagac tgtgttgggc ttgacacgtg aagcccaggc caaggcattt 720
ggcacttgcg tctctcatgt gtgtgctgtg ttcatattct atgtacctt cattggattg 780
tccatggtgc atcgctttag caagcggcgt gactctccgc tgcccgctcat cttggccaat 840

```

<400> 777																
Met	Met	Val	Asp	Pro	Asn	Gly	Asn	Glu	Ser	Ser	Ala	Thr	Tyr	Phe	Ile	
				5					10					15		
Leu	Ile	Gly	Leu	Pro	Gly	Leu	Glu	Glu	Ala	Gln	Phe	Trp	Leu	Ala	Phe	
			20					25					30			
Pro	Leu	Cys	Ser	Leu	Tyr	Leu	Ile	Ala	Val	Leu	Gly	Asn	Leu	Thr	Ile	
		35					40					45				
Ile	Tyr	Ile	Val	Arg	Thr	Glu	His	Ser	Leu	His	Glu	Pro	Met	Tyr	Ile	
	50					55					60					
Phe	Leu	Cys	Met	Leu	Ser	Gly	Ile	Asp	Ile	Leu	Ile	Ser	Thr	Ser	Ser	
65					70					75					80	
Met	Pro	Lys	Met	Leu	Ala	Ile	Phe	Trp	Phe	Asn	Ser	Thr	Thr	Ile	Gln	
				85					90					95		
Phe	Asp	Ala	Cys	Leu	Leu	Gln	Met	Phe	Ala	Ile	His	Ser	Leu	Ser	Gly	
			100					105					110			
Met	Glu	Ser	Thr	Val	Leu	Leu	Ala	Met	Ala	Phe	Asp	Arg	Tyr	Val	Ala	
		115					120					125				
Ile	Cys	His	Pro	Leu	Arg	His	Ala	Thr	Val	Leu	Thr	Leu	Pro	Arg	Val	
	130					135					140					
Thr	Lys	Ile	Gly	Val	Ala	Ala	Val	Val	Arg	Gly	Ala	Ala	Leu	Met	Ala	
145					150					155					160	
Pro	Leu	Pro	Val	Phe	Ile	Lys	Gln	Leu	Pro	Phe	Cys	Arg	Ser	Asn	Ile	
				165					170					175		
Leu	Ser	His	Ser	Tyr	Cys	Leu	His	Gln	Asp	Val	Met	Lys	Leu	Ala	Cys	
			180					185					190			
Asp	Asp	Ile	Arg	Val	Asn	Val	Val	Tyr	Gly	Leu	Ile	Val	Ile	Ile	Ser	
		195					200					205				
Ala	Ile	Gly	Leu	Asp	Ser	Leu	Leu	Ile	Ser	Phe	Ser	Tyr	Leu	Leu	Ile	
	210					215					220					
Leu	Lys	Thr	Val	Leu	Gly	Leu	Thr	Arg	Glu	Ala	Gln	Ala	Lys	Ala	Phe	
225					230					235					240	
Gly	Thr	Cys	Val	Ser	His	Val	Cys	Ala	Val	Phe	Ile	Phe	Tyr	Val	Pro	
				245					250					255		

310

Ile Leu Arg Leu Phe His Val Ala Thr His Ala Ser Glu Pro
305 310 315

Asp Arg Tyr Val Ala Ile Cys His Pro Leu Arg His Ala Thr Val Leu
5 10 15

Thr Leu Pro Arg
20

<210> 782
<211> 37
<212> PRT
<213> Homo sapiens

<400> 782
Phe Ile Lys Gln Leu Pro Phe Cys Arg Ser Asn Ile Leu Ser His Ser
5 10 15
Tyr Cys Leu His Gln Asp Val Met Lys Leu Ala Cys Asp Asp Ile Arg
20 25 30

Val Asn Val Val Tyr
35

<210> 783
<211> 13
<212> PRT
<213> Homo sapiens

<400> 783
Lys Thr Val Leu Gly Leu Thr Arg Glu Ala Gln Ala Lys
5 10

<210> 784
<211> 10
<212> PRT
<213> Homo sapiens

<400> 784
Val His Arg Phe Ser Lys Arg Arg Asp Ser
5 10

<210> 785
<211> 22
<212> PRT
<213> Homo sapiens

<400> 785
Lys Thr Lys Glu Ile Arg Gln Arg Ile Leu Arg Leu Phe His Val Ala
5 10 15

Thr His Ala Ser Glu Pro
20

<210> 786
<211> 3245
<212> DNA
<213> Homo sapiens

<400> 786

```

gtcgacccac gcgtccgcgc gagctaagca ggaggcggag gcggaggcgg agggcgaggg 60
gcgggggagcg ccgcctggag cgcgcgaggt cataattgaac attccagata cctatcatta 120
ctcgatgctg ttgataacag caagatggct ttgaaactcag ggtcaccacc agctatttga 180
ccttactatg aaaaccatgg ataccaaccg gaaaaccctt atcccgaca gccactgtg 240
gtccccactg tctacgaggt gcatccggct cagtactacc cgtccccctg gccccagtac 300
gccccgaggg tcttgacgca ggctccaac ccgtcgtct gcacgcagcc caaatcccca 360
tccgggacag tgtgcacctc aaagactaag aaagcactgt gcatcacctt gaccctgggg 420
accttcctcg tgggagctgc gctggccgct ggctactct ggaagtcat gggcagcaag 480
tgctccaact ctgggataga gtgcgactcc cagggtacct gcatcaacc ctctaactgg 540
tgtgatggcg tgtcacactg ccccgcgggg gaggacgaga atcggtgtgt tcgctctac 600
ggatcaaact tcatccttca ggtgtactca tctcagagga agtcctggca ccctgtgtgc 660
caagacgact ggaacgagaa ctacgggagg gcggcctgca gggacatggg ctataagaat 720
aatttttact ctacccaagg aatagtggat gacagcggat ccaccagctt tatgaaactg 780
aacacaagtg ccggcaatgt cgatatctat aaaaaactgt accacagtga tgcctgttct 840
tcaaaagcag tggtttcttt acgctgtata gcctgcgggg tcaacttgaa ctcaagccgc 900
cagagcagga ttgtgggagg cgaagcgcgc ctcggggggg cctggccctg gcaggtcagc 960
ctgcacgtcc agaacgtcca cgtgtgcgga ggcctcatca tcaccccgga gtggatctgt 1020
acagccgccc actgcgtgga aaaacctctt aacaatccat ggcatgtgac ggcatttgcg 1080
gggattttga gacaatcttt catgttctat ggagccggat accaagtaga aaaagtgtt 1140
tctcatccaa attatgactc caagaccaag aacaatgaca ttgcgctgat gaagctgcag 1200
aagcctctga ctttcaacga cctagtgaag ccagtgtgtc tgcccaacc aggcattgat 1260
ctgcagccag aacagctctg ctggatttcc ggggtggggg ccaccgagga gaaagggag 1320
acctcagaag tgcgaacgc tgccaagggt cttctcattg agacacagag atgcaacagc 1380
agatatgtct ctgacaacct tgacagtgga gggcctctgg tcacttcgaa gaacaatgc 1440
aacgtcgatt cttgccaggg tgacagtgga gggcctctgg tcacttcgaa gaacaatgc 1500
tggtggctga taggggatac aagctggggg tctggctgtg ccaaagctta cagaccagga 1560
gtgtacggga atgtgatgtt attcacggac tggatttatc gacaaatgag ggcagacggc 1620
taatccacat ggtcttcgtc cttgacgtcg ttttacaaga aaacaatggg gctggttttg 1680
cttccccgtg catgatttac tcttagagat gattcagagg tcacttcatt tttattaac 1740
agtgaacttg tctggctttg gcactctctg ccattctgtg caggctgcag tggctccct 1800
gcccagcctg cctccctaa cccctgtcc gcaaggggtg atggccggct ggttgtgggc 1860
actggcggtc aagtgtggag gagaggggtg gaggctgccc cattgagatc ttcctgtctg 1920
gtcctttcca ggggccaatt ttggatgagc atggagctgt cacctctcag ctgctggatg 1980
acttgagatg aaaaaggaga gacatgaaa gggagacagc caggtggcac ctgcagcggc 2040
tgccctctgg ggccacttg tagtgtcccc agcctacctc tccacaaggg gattttgctg 2100
atgggttctt agagccttag cagccctgga tgggtggcag aaataaagg accagccct 2160
catgggtggt gacgtggtag tcacttgtaa ggggaacaga aacatttttg ttcctatggg 2220
gtgagaatat agacagtgc cttggtgcga ggaagcaat tgaaaaggaa cttgccctga 2280
gcactcctgg tgcaggtctc cacctgcaca ttgggtggg ctctctggag ggagactcag 2340
ccttcctcct cactcctcct gaccctgctc ctgacacct ggagagtga catgcccct 2400
ggtcctggca gggcgccaag tctggcaca tgttggcctc ttcaggcctg ctagtcaact 2460
gaaattgagg tccatggggg aaatcaagga tgctcagttt aaggtacact gtttccatgt 2520
tatgtttcta cacattgcta cctcagtgtc cctggaaact tagcttttga tgtctccaag 2580
tagtccacct tcatttaact ctttgaaact gtatcatott tgccaagtaa gagtgggtgc 2640
ctatttcagc tgctttgaca aaatgactgg ctctgactt aacgttctat aaatgaatgt 2700
gctgaagcaa agtggccatg gtggcgcgca agaagagaaa gatgtgtttt gttttggact 2760
ctctgtggtc cttccaatg ctgtgggttt ccaaccaggg gaaggggtccc ttttgacttg 2820
ccaagtcca taaccatgag cactactcta ccatgtttct gcctcctggc caagcaggct 2880
ggtttgcaag aatgaaatga atgattctac agctaggact taaccttgaa atggaaagtc 2940
ttgcaatccc atttgagga tccgtctgtg cacatgcctc tgtagagagc agcattccca 3000
gggaccttg aaacagtttg cactgtaagg tgcttgctcc ccaagacaca tctaaaagg 3060
tggtgtaagt gtgaaaacgt cttccttctt tattgcccct tottatttat gtgaacaact 3120
gtttgtcttt tttgtatct tttttaaact gtaaagttca attgtgaaaa tgaatatcat 3180
gcaataaat tatgcgattt ttttttcaaa gtaaaaaaaa aaaaaaaaaa aaaaaggcgc 3240
gccgc 3245

```

<210> 787
<211> 1479
<212> DNA
<213> Homo sapiens

<400> 787
atggccttga actcagggtc accaccagct attggacctt actatgaaaa ccatggatac 60
caaccggaaa acccctatcc cgcacagccc actgtggtcc ccactgtcta cgaggtgcat 120
ccggtcagc actaccgctc ccccggtgcc cagtacgccc cgagggtcct gacgcaggct 180
tccaaccccg tcgtctgcac gcagcccaaa tcccatccg ggacagtgtg cacctcaaaag 240
actaagaaag cactgtgcat caccttgacc ctggggacct tcctcgtggg agctgcgctg 300
gccgtggcc tactctggaa gttcatgggc agcaagtgtc ccaactctgg gatagagtgc 360
gactcctcag gtacctgcat caaccctct aactggtgtg atggcgtgtc aactgcccc 420
ggcggggagg acgagaatcg gtgtgttcgc ctctacggat caaacttcat ccttcagggtg 480
tactcatctc agaggaagtc ctggcaccct gtgtgccaag acgactggaa cgagaactac 540
gggcggggcgg cctgcaggga catgggctat aagaataatt ttactctag ccaaggaata 600
gtggatgaca gcggatccac cagctttatg aaactgaaca caagtgccgg caatgtcgat 660
atctataaaa aactgtacca cagtgtgcc tgttcttcaa aagcagtggg ttctttacgc 720
tgtatagcct gcggggtcaa cttgaactca agccgccaga gcaggattgt gggcggcgag 780
agcgcgctcc cgggggcctg gccctggcag gtcagcctgc acgtccagaa cgtccacgtg 840
tgcggaggct ccatcatcac ccccgagtgg atcgtgacag ccgcccactg cgtggaaaaa 900
cctcttaaca atccatggca ttggacggca tttgcgggga ttttgagaca atctttcatg 960
ttctatggag ccggatacca agtagaaaaa gtgatttctc atccaaatta tgactccaag 1020
accaagaaca atgacattgc gctgatgaag ctgcagaagc ctctgacttt caacgacctt 1080
gtgaaaccag tgtgtctgcc caaccaggc atgatgctgc agccagaaca gctctgctgg 1140
atttcggggt ggggggccac cgaggagaaa ggaagacct cagaagtgtc gaacgctgcc 1200
aaggtgcttc tcattgagac acagagatgc aacagcagat atgtctatga caactgatc 1260
acaccagcca tgatctgtgc cggttctctg cagggaacg tcgattcttg ccagggtgac 1320
agtggagggc ctctggtcac ttogaagaac aatatctggt ggctgatagg ggatacaagc 1380
tggggttctg gctgtgccaa agcttacaga ccaggagtgt acgggaatgt gatggtattc 1440
acggactgga tttatcgaca aatgagggca gacggctaa 1479

<210> 788
<211> 1476
<212> DNA
<213> Homo sapiens

<400> 788
atggccttga actcagggtc accaccagct attggacctt actatgaaaa ccatggatac 60
caaccggaaa acccctatcc cgcacagccc actgtggtcc ccactgtcta cgaggtgcat 120
ccggtcagc actaccgctc ccccggtgcc cagtacgccc cgagggtcct gacgcaggct 180
tccaaccccg tcgtctgcac gcagcccaaa tcccatccg ggacagtgtg cacctcaaaag 240
actaagaaag cactgtgcat caccttgacc ctggggacct tcctcgtggg agctgcgctg 300
gccgtggcc tactctggaa gttcatgggc agcaagtgtc ccaactctgg gatagagtgc 360
gactcctcag gtacctgcat caaccctct aactggtgtg atggcgtgtc aactgcccc 420
ggcggggagg acgagaatcg gtgtgttcgc ctctacggat caaacttcat ccttcagggtg 480
tactcatctc agaggaagtc ctggcaccct gtgtgccaag acgactggaa cgagaactac 540
ggcggggcgg cctgcaggga catgggctat aagaataatt ttactctag ccaaggaata 600
gtggatgaca gcggatccac cagctttatg aaactgaaca caagtgccgg caatgtcgat 660
atctataaaa aactgtacca cagtgtgcc tgttcttcaa aagcagtggg ttctttacgc 720
tgtatagcct gcggggtcaa cttgaactca agccgccaga gcaggattgt gggcggcgag 780
agcgcgctcc cgggggcctg gccctggcag gtcagcctgc acgtccagaa cgtccacgtg 840
tgcggaggct ccatcatcac ccccgagtgg atcgtgacag ccgcccactg cgtggaaaaa 900
cctcttaaca atccatggca ttggacggca tttgcgggga ttttgagaca atctttcatg 960
ttctatggag ccggatacca agtagaaaaa gtgatttctc atccaaatta tgactccaag 1020
accaagaaca atgacattgc gctgatgaag ctgcagaagc ctctgacttt caacgacctt 1080
gtgaaaccag tgtgtctgcc caaccaggc atgatgctgc agccagaaca gctctgctgg 1140

```
<210> 789
<211> 492
<212> PRT
<213> Homo sapiens
```

<400> 789

Met	Ala	Leu	Asn	Ser	Gly	Ser	Pro	Pro	Ala	Ile	Gly	Pro	Tyr	Tyr	Glu
				5					10					15	
Asn	His	Gly	Tyr	Gln	Pro	Glu	Asn	Pro	Tyr	Pro	Ala	Gln	Pro	Thr	Val
		20						25					30		
Val	Pro	Thr	Val	Tyr	Glu	Val	His	Pro	Ala	Gln	Tyr	Tyr	Pro	Ser	Pro
		35					40					45			
Val	Pro	Gln	Tyr	Ala	Pro	Arg	Val	Leu	Thr	Gln	Ala	Ser	Asn	Pro	Val
	50					55					60				
Val	Cys	Thr	Gln	Pro	Lys	Ser	Pro	Ser	Gly	Thr	Val	Cys	Thr	Ser	Lys
	65				70					75					80
Thr	Lys	Lys	Ala	Leu	Cys	Ile	Thr	Leu	Thr	Leu	Gly	Thr	Phe	Leu	Val
				85					90					95	
Gly	Ala	Ala	Leu	Ala	Ala	Gly	Leu	Leu	Trp	Lys	Phe	Met	Gly	Ser	Lys
			100					105					110		
Cys	Ser	Asn	Ser	Gly	Ile	Glu	Cys	Asp	Ser	Ser	Gly	Thr	Cys	Ile	Asn
		115					120					125			
Pro	Ser	Asp	Trp	Cys	Asp	Gly	Val	Ser	His	Cys	Pro	Gly	Gly	Glu	Asp
		130				135					140				
Glu	Asn	Arg	Cys	Val	Arg	Leu	Tyr	Gly	Ser	Asn	Phe	Ile	Leu	Gln	Val
	145				150					155					160
Tyr	Ser	Ser	Gln	Arg	Lys	Ser	Trp	His	Pro	Val	Cys	Gln	Asp	Asp	Trp
			165						170				175		
Asn	Glu	Asn	Tyr	Gly	Arg	Ala	Ala	Cys	Arg	Asp	Met	Gly	Tyr	Lys	Asn
			180					185					190		
Asn	Phe	Tyr	Ser	Ser	Gln	Gly	Ile	Val	Asp	Asp	Ser	Gly	Ser	Thr	Ser
		195					200					205			
Phe	Met	Lys	Leu	Asn	Thr	Ser	Ala	Gly	Asn	Val	Asp	Ile	Tyr	Lys	Lys
		210					215				220				
Leu	Tyr	His	Ser	Asp	Ala	Cys	Ser	Ser	Lys	Ala	Val	Val	Ser	Leu	Arg
	225				230					235					240
Cys	Ile	Ala	Cys	Gly	Val	Asn	Leu	Asn	Ser	Ser	Arg	Gln	Ser	Arg	Ile
				245					250					255	
Val	Gly	Gly	Glu	Ser	Ala	Leu	Pro	Gly	Ala	Trp	Pro	Trp	Gln	Val	Ser
			260					265					270		
Leu	His	Val	Gln	Asn	Val	His	Val	Cys	Gly	Gly	Ser	Ile	Ile	Thr	Pro
		275					280					285			
Glu	Trp	Ile	Val	Thr	Ala	Ala	His	Cys	Val	Glu	Lys	Pro	Leu	Asn	Asn
		290				295					300				
Pro	Trp	His	Trp	Thr	Ala	Phe	Ala	Gly	Ile	Leu	Arg	Gln	Ser	Phe	Met
					310					315					320
Phe	Tyr	Gly	Ala	Gly	Tyr	Gln	Val	Glu	Lys	Val	Ile	Ser	His	Pro	Asn
				325					330					335	
Tyr	Asp	Ser	Lys	Thr	Lys	Asn	Asn	Asp	Ile	Ala	Leu	Met	Lys	Leu	Gln
			340					345					350		

Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn
 355 360 365
 Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp
 370 375 380
 Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala
 385 390 395 400
 Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr
 405 410 415
 Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
 420 425 430
 Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
 435 440 445
 Lys Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
 450 455 460
 Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
 465 470 475 480
 Thr Asp Trp Ile Tyr Arg Gln Met Arg Ala Asp Gly
 485 490

<210> 790

<211> 100

<212> PRT

<213> Homo sapiens

<400> 790

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
 5 10 15
 Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
 20 25 30
 Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
 35 40 45
 Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
 50 55 60
 Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
 65 70 75 80
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
 85 90 95
 Gly Ala Ala Leu
 100

<210> 791

<211> 393

<212> PRT

<213> Homo sapiens

<400> 791

Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys Cys Ser Asn
 5 10 15
 Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn Pro Ser Asn
 20 25 30
 Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp Glu Asn Arg
 35 40 45
 Cys Val Arg Leu Tyr Gly Ser Asn Phe Ile Leu Gln Val Tyr Ser Ser
 50 55 60
 Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp Asn Glu Asn
 65 70 75 80

316

Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn Asn Phe Tyr
 85 90 95
 Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser Phe Met Lys
 100 105 110
 Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys Leu Tyr His
 115 120 125
 Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg Cys Ile Ala
 130 135 140
 Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile Val Gly Gly
 145 150 155 160
 Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser Leu His Val
 165 170 175
 Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro Glu Trp Ile
 180 185 190
 Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn Pro Trp His
 195 200 205
 Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met Phe Tyr Gly
 210 215 220
 Ala Gly Tyr Gln Val Glu Lys Val Ile Ser His Pro Asn Tyr Asp Ser
 225 230 235 240
 Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln Lys Pro Leu
 245 250 255
 Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn Pro Gly Met
 260 265 270
 Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp Gly Ala Thr
 275 280 285
 Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala Lys Val Leu
 290 295 300
 Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr Asp Asn Leu
 305 310 315 320
 Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly Asn Val Asp
 325 330 335
 Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser Lys Asn Asn
 340 345 350
 Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly Cys Ala Lys
 355 360 365
 Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe Thr Asp Trp
 370 375 380
 Ile Tyr Arg Gln Met Arg Ala Asp Gly
 385 390

<210> 792

<211> 595

<212> PRT

<213> Homo sapiens

<400> 792

Met Ser Phe Leu Asn Phe Thr Ala Val Leu Phe Ala Ala Ser Ser Ala
 1 5 10 15
 Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile
 20 25 30
 Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe Asp
 35 40 45
 Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe
 50 55 60
 Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser
 65 70 75 80

Leu Glu Lys Arg Glu Ala Glu Ala Met Val Leu Gly Ile Gly Pro Val
 85 90 95
 Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp
 100 105 110
 Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu
 115 120 125
 Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala
 130 135 140
 Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile
 145 150 155 160
 Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro
 165 170 175
 Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg
 180 185 190
 Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu
 195 200 205
 Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro
 210 215 220
 Tyr Leu Gly Thr Gln Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile
 225 230 235 240
 Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala
 245 250 255
 Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser
 260 265 270
 Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly
 275 280 285
 Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr
 290 295 300
 Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met
 305 310 315 320
 Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln
 325 330 335
 Gly Val Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp
 340 345 350
 Glu Gly Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile
 355 360 365
 Ser Leu Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly
 370 375 380
 Thr Arg Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala
 385 390 395 400
 Gly Ala Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala
 405 410 415
 Ala Leu Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr
 420 425 430
 Leu Ala Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr
 435 440 445
 Arg Gly Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser
 450 455 460
 Phe Leu Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val
 465 470 475 480
 Gly Ala Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly
 485 490 495
 Ala Ser Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr
 500 505 510
 Glu Ala Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile
 515 520 525
 Leu Asp Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met
 530 535 540

Gly Ser Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser
545 550 555 560
Ala Ala Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val
565 570 575
Phe Asp Lys Ser Asp Leu Ala Lys Tyr Ser Ala Gly Gly His His His
580 585 590
His His His
595

